0000792977-20-000090.txt : 20200915 0000792977-20-000090.hdr.sgml : 20200915 20200915160554 ACCESSION NUMBER: 0000792977-20-000090 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 134 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200915 DATE AS OF CHANGE: 20200915 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000792977 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042742593 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-10865 FILM NUMBER: 201176067 BUSINESS ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 6174983300 MAIL ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: AMAG PHARMACEUTICALS INC. DATE OF NAME CHANGE: 20070724 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MAGNETICS INC DATE OF NAME CHANGE: 19920703 10-K/A 1 a201910-ka.htm 10-K/A Document
0.250.33P3YP3YP1YP6YAMAG Pharmaceuticals, Inc (the “Company” or “we”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to amend and restate certain items in its Annual Report on Form 10-K for the year ended December 31, 2019, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 6, 2020 (the “Original 10-K”). The Company identified immaterial errors in its previously reported revenue over the impacted annual periods of 2016 through 2019 and, in connection therewith, the Company’s management identified a material weakness in our internal control over financial reporting (“ICFR”) related to ensuring the timely recognition of our gross-to-net adjustments for certain governmental rebates and the related accruals. Accordingly, this Amendment is being filed to amend Item 6, Selected Financial Data, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, Item 8, Financial Statements and Supplementary Data, and Item 9A, Controls and Procedures, of Part II of the Original 10-K and restate the financial statements and related notes to reflect the immaterial errors identified, Management’s Annual Report on Internal Control Over Financial Reporting, management’s assessment of the effectiveness of our disclosure controls and procedures and PwC’s Report of Independent Registered Public Accounting Firm on the Company’s internal control over financial reporting.true--12-31FY20190000792977us-gaap:AccountingStandardsUpdate201609Memberus-gaap:AccountingStandardsUpdate201609Memberus-gaap:AccountingStandardsUpdate201409Memberus-gaap:AccountingStandardsUpdate20140900.010.01117500000117500000346067603399908134606760339990810.100.100.03690790.0365464P5YP1Y14400000P1Y000.010.012000000200000000500000P3YP4YP3Y000000P10YP10YP10Yus-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember 0000792977 2019-01-01 2019-12-31 0000792977 2019-06-28 0000792977 2020-03-02 0000792977 2018-12-31 0000792977 2019-12-31 0000792977 2017-01-01 2017-12-31 0000792977 2018-01-01 2018-12-31 0000792977 us-gaap:ProductMember 2017-01-01 2017-12-31 0000792977 us-gaap:ServiceMember 2018-01-01 2018-12-31 0000792977 us-gaap:ProductMember 2018-01-01 2018-12-31 0000792977 us-gaap:ProductMember 2019-01-01 2019-12-31 0000792977 us-gaap:ProductAndServiceOtherMember 2018-01-01 2018-12-31 0000792977 us-gaap:ServiceMember 2019-01-01 2019-12-31 0000792977 us-gaap:ServiceMember 2017-01-01 2017-12-31 0000792977 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0000792977 us-gaap:ProductAndServiceOtherMember 2017-01-01 2017-12-31 0000792977 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000792977 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000792977 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000792977 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2016-12-31 0000792977 us-gaap:CommonStockMember 2018-12-31 0000792977 us-gaap:RetainedEarningsMember 2019-12-31 0000792977 us-gaap:RetainedEarningsMember 2017-12-31 0000792977 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000792977 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000792977 us-gaap:CommonStockMember 2016-12-31 0000792977 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2017-12-31 0000792977 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000792977 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000792977 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000792977 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2017-12-31 0000792977 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000792977 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000792977 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000792977 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000792977 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000792977 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000792977 us-gaap:CommonStockMember 2017-12-31 0000792977 us-gaap:RetainedEarningsMember 2018-12-31 0000792977 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000792977 2016-12-31 0000792977 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000792977 us-gaap:CommonStockMember 2019-12-31 0000792977 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000792977 2017-12-31 0000792977 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000792977 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000792977 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000792977 us-gaap:RetainedEarningsMember 2016-12-31 0000792977 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2016-12-31 0000792977 2016-01-01 2016-12-31 0000792977 amag:IntrarosaMember 2017-01-01 2017-12-31 0000792977 amag:VyleesiProductsMember 2018-01-01 2018-12-31 0000792977 amag:VyleesiProductsMember 2019-01-01 2019-12-31 0000792977 amag:IntrarosaMember 2019-01-01 2019-12-31 0000792977 amag:VyleesiProductsMember 2017-01-01 2017-12-31 0000792977 amag:IntrarosaMember 2018-01-01 2018-12-31 0000792977 amag:EndoceuticsInc.Member 2017-01-01 2017-12-31 0000792977 amag:EndoceuticsInc.Member 2018-12-31 0000792977 amag:EndoceuticsInc.Member 2018-01-01 2018-12-31 0000792977 amag:EndoceuticsInc.Member 2019-01-01 2019-12-31 0000792977 amag:EndoceuticsInc.Member 2019-12-31 0000792977 amag:EndoceuticsInc.Member 2017-12-31 0000792977 amag:AmerisourceBergenDrugCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0000792977 amag:AmerisourceBergenDrugCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000792977 amag:McKessonCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0000792977 amag:McKessonCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000792977 amag:McKessonCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000792977 amag:AmerisourceBergenDrugCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000792977 amag:CardinalHealthInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000792977 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000792977 us-gaap:ConvertibleDebtSecuritiesMember amag:ConvertibleNotesDue2019Member 2017-01-01 2017-12-31 0000792977 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000792977 us-gaap:ConvertibleDebtSecuritiesMember amag:ConvertibleNotesDue2022Member 2019-01-01 2019-12-31 0000792977 us-gaap:EmployeeStockMember 2017-01-01 2017-12-31 0000792977 us-gaap:WarrantMember 2019-01-01 2019-12-31 0000792977 us-gaap:ConvertibleDebtSecuritiesMember amag:ConvertibleNotesDue2022Member 2017-01-01 2017-12-31 0000792977 us-gaap:ConvertibleDebtSecuritiesMember amag:ConvertibleNotesDue2019Member 2019-01-01 2019-12-31 0000792977 us-gaap:ConvertibleDebtSecuritiesMember amag:ConvertibleNotesDue2022Member 2018-01-01 2018-12-31 0000792977 us-gaap:ConvertibleDebtSecuritiesMember amag:ConvertibleNotesDue2019Member 2018-01-01 2018-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000792977 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0000792977 us-gaap:WarrantMember 2018-01-01 2018-12-31 0000792977 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000792977 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0000792977 us-gaap:WarrantMember 2017-01-01 2017-12-31 0000792977 amag:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000792977 srt:MinimumMember 2019-01-01 2019-12-31 0000792977 srt:MaximumMember 2019-01-01 2019-12-31 0000792977 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-01-01 0000792977 amag:TwoCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2019-12-31 0000792977 amag:FerahemeMember 2019-01-01 2019-12-31 0000792977 us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0000792977 us-gaap:EquipmentMember 2019-01-01 2019-12-31 0000792977 amag:ComputerEquipmentAndSoftwareMember 2019-01-01 2019-12-31 0000792977 amag:CardinalHealthInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0000792977 amag:CardinalHealthInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000792977 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember amag:CBRBusinessMember 2018-01-01 2018-12-31 0000792977 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember amag:CBRBusinessMember 2017-01-01 2017-12-31 0000792977 amag:MakenaMember 2017-01-01 2017-12-31 0000792977 amag:MakenaMember 2018-01-01 2018-12-31 0000792977 amag:MakenaMember 2019-01-01 2019-12-31 0000792977 amag:FerahemeMember 2017-01-01 2017-12-31 0000792977 amag:FerahemeMember 2018-01-01 2018-12-31 0000792977 amag:MugardMember 2018-01-01 2018-12-31 0000792977 amag:MugardMember 2019-01-01 2019-12-31 0000792977 amag:MugardMember 2017-01-01 2017-12-31 0000792977 2019-03-31 0000792977 2019-10-01 2019-12-31 0000792977 us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000792977 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000792977 us-gaap:CertificatesOfDepositMember 2018-12-31 0000792977 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2018-12-31 0000792977 us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000792977 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000792977 us-gaap:CertificatesOfDepositMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000792977 amag:MugardMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000792977 amag:MugardMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 amag:MugardMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0000792977 amag:MugardMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000792977 amag:MugardMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000792977 amag:MugardMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 amag:MugardMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000792977 amag:MugardMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 amag:ContingentConsiderationMember 2018-01-01 2018-12-31 0000792977 amag:EndoceuticsLicenseAgreementMember 2019-12-31 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2018-12-31 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2018-12-31 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2019-12-31 0000792977 amag:EndoceuticsLicenseAgreementMember 2018-12-31 0000792977 us-gaap:FurnitureAndFixturesMember 2018-12-31 0000792977 us-gaap:LeaseholdImprovementsMember 2018-12-31 0000792977 amag:ComputerEquipmentAndSoftwareMember 2018-12-31 0000792977 us-gaap:ConstructionInProgressMember 2019-12-31 0000792977 us-gaap:EquipmentMember 2018-12-31 0000792977 us-gaap:LeaseholdImprovementsMember 2019-12-31 0000792977 us-gaap:FurnitureAndFixturesMember 2019-12-31 0000792977 us-gaap:EquipmentMember 2019-12-31 0000792977 us-gaap:ConstructionInProgressMember 2018-12-31 0000792977 amag:ComputerEquipmentAndSoftwareMember 2019-12-31 0000792977 2018-11-05 2018-11-05 0000792977 amag:MakenaAutoInjectorMember us-gaap:DevelopedTechnologyRightsMember 2019-10-01 2019-12-31 0000792977 2018-12-31 2018-12-31 0000792977 amag:IntrarosaMember us-gaap:DevelopedTechnologyRightsMember 2019-10-01 2019-12-31 0000792977 2018-10-31 0000792977 2019-10-31 2019-10-31 0000792977 2018-10-31 2018-10-31 0000792977 amag:MakenaMember us-gaap:DevelopedTechnologyRightsMember 2019-04-01 2019-06-30 0000792977 2019-06-30 0000792977 2018-11-01 2018-12-31 0000792977 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-12-31 0000792977 us-gaap:MeasurementInputControlPremiumMember 2019-12-31 0000792977 2019-10-31 0000792977 amag:MakenaMember us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000792977 us-gaap:MeasurementInputControlPremiumMember 2018-09-30 0000792977 srt:MinimumMember us-gaap:MeasurementInputControlPremiumMember 2018-09-30 0000792977 2018-01-01 2018-06-30 0000792977 srt:MinimumMember us-gaap:MeasurementInputControlPremiumMember 2019-12-31 0000792977 amag:VyleesiProductsMember us-gaap:DevelopedTechnologyRightsMember 2019-10-01 2019-12-31 0000792977 srt:MaximumMember us-gaap:MeasurementInputControlPremiumMember 2018-09-30 0000792977 srt:MaximumMember us-gaap:MeasurementInputControlPremiumMember 2019-12-31 0000792977 amag:IntrarosaMember us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000792977 amag:MakenaAutoInjectorMember us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000792977 amag:MakenaMember us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000792977 amag:VyleesiProductsMember us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000792977 amag:IntrarosaMember us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000792977 amag:MakenaAutoInjectorMember us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000792977 amag:VyleesiProductsMember us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000792977 amag:LumaraHealthInc.Member us-gaap:DomesticCountryMember 2019-12-31 0000792977 amag:PerospherePharmaceuticalsInc.Member us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0000792977 us-gaap:DomesticCountryMember 2019-12-31 0000792977 amag:LumaraHealthInc.Member us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0000792977 amag:PerospherePharmaceuticalsInc.Member us-gaap:DomesticCountryMember 2019-12-31 0000792977 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0000792977 amag:InterestExpenseCarryforwardMember 2019-12-31 0000792977 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember amag:CBRBusinessMember us-gaap:CapitalLossCarryforwardMember 2019-12-31 0000792977 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0000792977 us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000792977 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000792977 us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0000792977 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0000792977 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0000792977 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0000792977 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0000792977 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:EquityIncentivePlan2007Member 2019-01-01 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:LumaraHealth2013PlanMember 2019-01-01 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:EquityIncentivePlan2007Member 2018-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:EquityIncentivePlan2019Member 2019-01-01 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:InducementGrantsMember 2019-01-01 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:EquityIncentivePlan2019Member 2018-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:InducementGrantsMember 2018-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:LumaraHealth2013PlanMember 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:InducementGrantsMember 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:EquityIncentivePlan2019Member 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:LumaraHealth2013PlanMember 2018-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:EquityIncentivePlan2007Member 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0000792977 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000792977 amag:NonEmployeeDirectorStockOptionMember 2017-01-01 2017-12-31 0000792977 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000792977 amag:NonEmployeeDirectorStockOptionMember 2019-01-01 2019-12-31 0000792977 amag:NonEmployeeDirectorStockOptionMember 2018-01-01 2018-12-31 0000792977 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000792977 amag:InducementGrantsMember 2019-12-31 0000792977 amag:EquityIncentivePlan2019Member 2019-01-01 2019-12-31 0000792977 amag:EquityIncentivePlan2019Member 2019-12-31 0000792977 amag:EquityIncentivePlan2019Member 2018-12-31 0000792977 amag:InducementGrantsMember 2019-01-01 2019-12-31 0000792977 amag:LumaraHealth2013PlanMember 2018-12-31 0000792977 amag:InducementGrantsMember 2018-12-31 0000792977 amag:EquityIncentivePlan2007Member 2019-01-01 2019-12-31 0000792977 amag:EquityIncentivePlan2007Member 2018-12-31 0000792977 amag:LumaraHealth2013PlanMember 2019-12-31 0000792977 amag:EquityIncentivePlan2007Member 2019-12-31 0000792977 amag:LumaraHealth2013PlanMember 2019-01-01 2019-12-31 0000792977 amag:February2019Member amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2019-01-01 2019-12-31 0000792977 amag:EmployeeAndNonEmployeeDirectorStockOptionMember 2019-01-01 2019-12-31 0000792977 amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2017-02-01 2017-02-28 0000792977 amag:LumaraHealth2013PlanMember 2014-11-30 0000792977 amag:EmployeeStockPurchasePlan2015Member 2019-01-01 2019-12-31 0000792977 amag:February2017Member amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2019-12-31 0000792977 amag:PerformanceRestrictedStockUnitsRSUsMember 2019-12-31 0000792977 amag:March2018Member amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2019-01-01 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000792977 amag:EmployeeStockPurchasePlan2015Member 2018-06-01 2018-06-30 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000792977 amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2019-01-01 2019-12-31 0000792977 amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2019-02-01 2019-02-28 0000792977 amag:March2018Member amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2019-12-31 0000792977 amag:EmployeeStockPurchasePlan2015Member 2015-05-01 2015-05-31 0000792977 amag:February2019Member amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2019-12-31 0000792977 amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2018-03-01 2018-03-31 0000792977 amag:PerformanceRestrictedStockUnitsRSUsMember 2019-01-01 2019-12-31 0000792977 amag:EmployeeStockPurchasePlan2015Member 2015-05-31 0000792977 us-gaap:RestructuringChargesMember 2019-01-01 2019-03-31 0000792977 us-gaap:EmployeeStockOptionMember amag:InducementGrantsMember 2019-01-01 2019-12-31 0000792977 2019-01-01 0000792977 2016-01-31 0000792977 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000792977 amag:CivilCaseInSaginawChippewaIndianTribeV.PurduePharmaEtAlMember us-gaap:PendingLitigationMember 2019-11-06 2019-11-06 0000792977 us-gaap:AccountingStandardsUpdate201602Member 2019-12-31 0000792977 amag:LunarRepresentativeLLCV.AMAGPharmaceuticalsInc.Member us-gaap:PendingLitigationMember 2019-09-25 2019-09-25 0000792977 us-gaap:PendingLitigationMember us-gaap:SubsequentEventMember 2019-11-04 2020-01-13 0000792977 srt:MaximumMember 2019-12-31 0000792977 srt:MinimumMember 2019-12-31 0000792977 amag:PerospherePharmaceuticalsInc.Member amag:MilestoneAchievementApprovalByEuropeanMedicinesAgencyMember 2019-01-31 0000792977 amag:PalatinTechnologiesInc.Member amag:VyleesiProductsMember amag:FirstSalesMilestoneAchievementMember 2017-02-28 0000792977 amag:EndoceuticsInc.Member amag:IntrarosaMember amag:FirstSalesMilestoneAchievementMember 2017-04-03 2017-04-03 0000792977 amag:PalatinTechnologiesInc.Member amag:VyleesiProductsMember amag:RegulatoryMilestoneAchievementAcceptanceByU.S.FoodAndDrugAdministrationOfNewDrugApplicationMember 2019-01-01 2019-06-30 0000792977 amag:PerospherePharmaceuticalsInc.Member 2019-01-16 2019-01-16 0000792977 amag:EndoceuticsInc.Member amag:IntrarosaMember amag:FirstAnniversaryOfClosingMember 2019-12-31 0000792977 amag:EndoceuticsInc.Member 2017-06-30 0000792977 amag:PerospherePharmaceuticalsInc.Member amag:PerosphereTermLoanMember us-gaap:LineOfCreditMember 2019-01-16 2019-01-16 0000792977 amag:PerospherePharmaceuticalsInc.Member 2019-01-31 0000792977 amag:PerospherePharmaceuticalsInc.Member amag:RegulatoryMilestoneAchievementMember 2019-01-31 0000792977 amag:VeloBioLLCMember 2018-09-01 2018-09-30 0000792977 amag:PerospherePharmaceuticalsInc.Member amag:FirstSalesMilestoneAchievementMember 2019-01-01 2019-01-31 0000792977 amag:PalatinTechnologiesInc.Member 2017-02-01 2017-02-28 0000792977 amag:PerospherePharmaceuticalsInc.Member amag:PerosphereConvertibleNoteMember us-gaap:ConvertibleDebtMember 2019-01-16 0000792977 amag:VeloBioLLCMember amag:RegulatoryMilestoneAchievementU.S.FoodAndDrugAdministrationApprovalMember 2018-09-30 0000792977 amag:EndoceuticsInc.Member 2017-04-03 2017-04-03 0000792977 amag:VeloBioLLCMember amag:AnnualSalesMilestoneAchievementsMember 2018-09-30 0000792977 amag:VeloBioLLCMember srt:MinimumMember amag:AnnualSalesMilestoneAchievementsMember 2018-09-01 2018-09-30 0000792977 amag:EndoceuticsInc.Member 2017-04-01 2017-06-30 0000792977 amag:PalatinTechnologiesInc.Member amag:VyleesiProductsMember amag:FirstSalesMilestoneAchievementMember 2017-02-01 2017-02-28 0000792977 amag:EndoceuticsInc.Member amag:IntrarosaMember amag:FirstSalesMilestoneAchievementMember 2017-04-03 0000792977 amag:VeloBioLLCMember amag:CommercialMilestonePaymentsMember 2018-09-30 0000792977 amag:PalatinTechnologiesInc.Member 2017-02-28 0000792977 amag:PalatinTechnologiesInc.Member amag:VyleesiProductsMember amag:RegulatoryMilestoneAchievementAcceptanceByU.S.FoodAndDrugAdministrationOfNewDrugApplicationMember 2018-04-01 2018-06-30 0000792977 amag:EndoceuticsInc.Member amag:IntrarosaMember us-gaap:DevelopedTechnologyRightsMember 2017-06-30 0000792977 amag:EndoceuticsInc.Member amag:IntrarosaMember amag:SalesMilestonesAchievementMember 2017-04-03 0000792977 amag:PrascoLLCMember amag:FailureToSupplyACertainPercentageOfProductMember 2019-01-01 2019-12-31 0000792977 amag:PalatinTechnologiesInc.Member amag:VyleesiProductsMember amag:AchievementOfCertainAnnualSalesMilestonesOverCourseOfLicenseAgreementMember 2017-02-28 0000792977 amag:VeloBioLLCMember srt:MaximumMember amag:AnnualSalesMilestoneAchievementsMember 2018-09-01 2018-09-30 0000792977 amag:EndoceuticsInc.Member amag:IntrarosaMember amag:DeliveryOfIntrarosaLaunchQuantitiesMember 2017-07-01 2017-09-30 0000792977 amag:VeloBioLLCMember amag:RegulatoryMilestoneAchievementMember 2018-09-30 0000792977 amag:PerospherePharmaceuticalsInc.Member amag:SalesMilestonesAchievementMember 2019-01-31 0000792977 amag:EndoceuticsInc.Member amag:IntrarosaMember amag:TieredRoyaltiesMember 2017-04-03 2017-04-03 0000792977 amag:DebtInstrumentConversionPeriodTwoMember amag:ConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2017-04-01 2017-06-30 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2017-06-30 0000792977 amag:SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2018-09-30 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2014-02-28 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2017-04-01 2017-06-30 0000792977 amag:SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2015-08-31 0000792977 amag:SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2018-09-01 2018-09-30 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2014-02-01 2014-02-28 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2019-02-15 2019-02-15 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2017-05-31 0000792977 amag:TermLoanFacility2015Member us-gaap:LineOfCreditMember 2017-05-01 2017-05-31 0000792977 amag:DebtInstrumentConversionPeriodOneMember amag:ConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2017-04-01 2017-06-30 0000792977 amag:SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2017-10-31 0000792977 amag:SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2017-10-01 2017-10-31 0000792977 us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0000792977 amag:TermLoanFacility2015Member us-gaap:LineOfCreditMember 2015-08-31 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2017-05-01 2017-05-31 0000792977 us-gaap:ConvertibleDebtMember 2017-01-01 2017-12-31 0000792977 us-gaap:ConvertibleDebtMember 2018-01-01 2018-12-31 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2018-12-31 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2018-12-31 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2019-12-31 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0000792977 2019-02-01 2019-02-28 0000792977 us-gaap:ContractTerminationMember 2019-12-31 0000792977 us-gaap:OtherRestructuringMember 2019-01-01 2019-12-31 0000792977 us-gaap:ContractTerminationMember 2019-01-01 2019-12-31 0000792977 us-gaap:EmployeeSeveranceMember 2019-12-31 0000792977 us-gaap:EmployeeSeveranceMember 2018-12-31 0000792977 us-gaap:OtherRestructuringMember 2019-12-31 0000792977 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-12-31 0000792977 us-gaap:OtherRestructuringMember 2018-12-31 0000792977 us-gaap:ContractTerminationMember 2018-12-31 0000792977 srt:ScenarioPreviouslyReportedMember 2019-01-01 2019-03-31 0000792977 2019-04-01 2019-06-30 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2019-01-01 2019-03-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-01-01 2019-03-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-04-01 2019-06-30 0000792977 srt:ScenarioPreviouslyReportedMember 2019-04-01 2019-06-30 0000792977 2019-01-01 2019-03-31 0000792977 us-gaap:ProductMember 2019-01-01 2019-03-31 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2019-04-01 2019-06-30 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-01-01 2019-03-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-04-01 2019-06-30 0000792977 us-gaap:ProductMember 2019-04-01 2019-06-30 0000792977 2019-07-01 2019-09-30 0000792977 amag:MakenaAutoInjectorIntrarosaAndVyleesiProductsMember us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-12-31 0000792977 amag:MakenaMember us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-06-30 0000792977 amag:ContingentConsiderationMember 2018-04-01 2018-06-30 0000792977 amag:PerospherePharmaceuticalsInc.Member 2019-01-01 2019-03-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-01-01 2018-03-31 0000792977 2018-04-01 2018-06-30 0000792977 us-gaap:ProductMember 2018-01-01 2018-03-31 0000792977 srt:ScenarioPreviouslyReportedMember 2018-01-01 2018-03-31 0000792977 2018-01-01 2018-03-31 0000792977 srt:ScenarioPreviouslyReportedMember 2018-04-01 2018-06-30 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-01-01 2018-03-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-04-01 2018-06-30 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2018-01-01 2018-03-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-04-01 2018-06-30 0000792977 us-gaap:ProductMember 2018-04-01 2018-06-30 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2018-04-01 2018-06-30 0000792977 2018-10-01 2018-12-31 0000792977 srt:ScenarioPreviouslyReportedMember 2018-10-01 2018-12-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-07-01 2018-09-30 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-07-01 2018-09-30 0000792977 srt:ScenarioPreviouslyReportedMember 2018-07-01 2018-09-30 0000792977 us-gaap:ProductMember 2018-10-01 2018-12-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-10-01 2018-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-10-01 2018-12-31 0000792977 us-gaap:ProductMember 2018-07-01 2018-09-30 0000792977 2018-07-01 2018-09-30 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2018-07-01 2018-09-30 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2018-10-01 2018-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-07-01 2019-09-30 0000792977 us-gaap:ProductMember 2019-10-01 2019-12-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-07-01 2019-09-30 0000792977 srt:ScenarioPreviouslyReportedMember 2019-07-01 2019-09-30 0000792977 srt:ScenarioPreviouslyReportedMember 2019-10-01 2019-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-10-01 2019-12-31 0000792977 us-gaap:ProductMember 2019-07-01 2019-09-30 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2019-07-01 2019-09-30 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2019-10-01 2019-12-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-10-01 2019-12-31 0000792977 amag:AllowanceForPromotions1Member 2018-12-31 0000792977 amag:AllowanceForSalesReturns1Member 2018-12-31 0000792977 amag:AllowanceForSalesReturns1Member 2019-01-01 2019-12-31 0000792977 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0000792977 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-01-01 2017-12-31 0000792977 amag:AllowanceForSalesReturns1Member 2017-12-31 0000792977 amag:AllowanceForPromotions1Member 2017-12-31 0000792977 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-01-01 2019-12-31 0000792977 amag:AllowanceForPromotions1Member 2018-01-01 2018-12-31 0000792977 amag:AllowanceForPromotions1Member 2017-01-01 2017-12-31 0000792977 amag:AllowanceForPromotions1Member 2019-12-31 0000792977 amag:AllowanceForSalesReturns1Member 2018-01-01 2018-12-31 0000792977 amag:AllowanceForPromotions1Member 2019-01-01 2019-12-31 0000792977 amag:AllowanceForPromotions1Member 2016-12-31 0000792977 amag:AllowanceForSalesReturns1Member 2019-12-31 0000792977 amag:AllowanceForSalesReturns1Member 2016-12-31 0000792977 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 0000792977 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-12-31 0000792977 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0000792977 amag:AllowanceForSalesReturns1Member 2017-01-01 2017-12-31 0000792977 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-01-01 2018-12-31 0000792977 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2017-01-01 0000792977 2017-01-01 2017-03-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-12-31 0000792977 srt:ScenarioPreviouslyReportedMember 2019-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2017-01-01 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2016-01-01 2019-12-31 0000792977 srt:ScenarioPreviouslyReportedMember 2018-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2017-01-01 2017-12-31 0000792977 srt:ScenarioPreviouslyReportedMember 2017-01-01 2017-12-31 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2017-01-01 2017-12-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2017-01-01 2017-12-31 0000792977 srt:ScenarioPreviouslyReportedMember 2018-01-01 2018-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-01-01 2018-12-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-01-01 2018-12-31 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2018-01-01 2018-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-01-01 2019-12-31 0000792977 srt:ScenarioPreviouslyReportedMember 2019-01-01 2019-12-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-01-01 2019-12-31 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2019-01-01 2019-12-31 0000792977 amag:MillicentPharmaLimitedMember amag:IntrarosaMember us-gaap:SubsequentEventMember 2020-04-01 2020-06-30 0000792977 amag:MillicentPharmaLimitedMember amag:IntrarosaMember amag:FirstTimeNetSalesDuringThresholdPeriodExceeds175MillionMember us-gaap:SubsequentEventMember 2020-05-21 2020-05-21 0000792977 amag:MillicentPharmaLimitedMember amag:IntrarosaMember amag:FirstTimeNetSalesDuringThresholdPeriodExceeds65MillionMember us-gaap:SubsequentEventMember 2020-05-21 2020-05-21 0000792977 us-gaap:SubsequentEventMember 2020-08-06 2020-08-06 0000792977 amag:NorgineB.V.Member amag:CiraparantagMember srt:MaximumMember amag:SalesMilestonesAchievementMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-31 0000792977 amag:MillicentPharmaLimitedMember amag:IntrarosaMember srt:MaximumMember us-gaap:SubsequentEventMember 2020-05-21 2020-05-21 0000792977 amag:MillicentPharmaLimitedMember amag:IntrarosaMember us-gaap:SubsequentEventMember 2020-05-21 2020-05-21 0000792977 amag:NorgineB.V.Member amag:CiraparantagMember srt:MaximumMember amag:RegulatoryMilestoneAchievementMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-31 0000792977 amag:NorgineB.V.Member amag:CiraparantagMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-31 0000792977 amag:MillicentPharmaLimitedMember amag:IntrarosaMember amag:FirstTimeNetSalesDuringThresholdPeriodExceeds115MillionMember us-gaap:SubsequentEventMember 2020-05-21 2020-05-21 0000792977 amag:PalatinTechnologiesInc.Member amag:VyleesiProductsMember srt:ScenarioForecastMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-31 0000792977 us-gaap:SubsequentEventMember 2020-07-14 2020-07-14 0000792977 us-gaap:SubsequentEventMember 2020-04-01 2020-06-30 0000792977 us-gaap:SubsequentEventMember 2020-05-01 2020-05-31 0000792977 amag:PalatinTechnologiesInc.Member amag:VyleesiProductsMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-31 0000792977 amag:CiraparantagMember us-gaap:SubsequentEventMember 2020-07-31 0000792977 amag:MillicentPharmaLimitedMember amag:IntrarosaMember us-gaap:SubsequentEventMember 2020-01-01 2020-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares amag:product_candidate amag:business_segment amag:facility xbrli:pure amag:employee amag:plan amag:lawsuit amag:defendant amag:day amag:month
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________ ______
FORM 10-K/A
Amendment No. 1
(Mark One)
 
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended December 31, 2019
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 001-10865
amag_rgba03.jpg
AMAG PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
04-2742593
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification No.)
1100 Winter Street,
Waltham,
Massachusetts
02451
(Address of Principal Executive Offices)
(Zip Code)
(617) 498-3300
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
 
 
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per share
Preferred Share Purchase Rights
AMAG
NASDAQ Global Select Market
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒ 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
 
Accelerated filer
☒
Non-accelerated filer
☐
 
Smaller reporting company
☐
 
 
 
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒ 
The aggregate market value of the registrant’s voting stock held by non-affiliates as of June 28, 2019 was approximately $335.0 million based on the closing price of $9.99 of the Common Stock of the registrant as reported on the NASDAQ Global Select Market on such date. As of March 2, 2020, there were 34,265,738 shares of the registrant’s Common Stock, par value $0.01 per share, outstanding.




EXPLANATORY NOTE

AMAG Pharmaceuticals, Inc (the “Company” or “we”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to amend and restate certain items in its Annual Report on Form 10-K for the year ended December 31, 2019, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 6, 2020 (the “Original 10-K”).

As previously disclosed, including in the Company’s Current Report on Form 8-K filed with the SEC on August 17, 2020, the Company identified immaterial errors in its previously reported revenue for Makena® (hydroxyprogesterone caproate injection) that overstated revenues by approximately $6.3 million in the aggregate over the impacted annual periods of 2016 through 2019 and understated revenue as previously reported in the three month period ended March 31, 2020 by approximately $1.8 million and, in connection therewith, the Company’s management identified a material weakness in its internal control over financial reporting (“ICFR”) related to ensuring the timely recognition of its gross-to-net adjustments for certain governmental rebates and the related accruals. Specifically, the Company did not design and maintain controls to allow for an effective review of disputed claims related to certain government rebate arrangements, where the decision had been made to initially not record and accrue for such items, to assess whether and when the need to record an accrual is required for such claims. Also, as previously disclosed, management determined that its report regarding the effectiveness of the Company’s ICFR contained in the Original 10-K, and PricewaterhouseCoopers LLP (“PwC”), the Company’s independent registered accounting firm as of December 31, 2019, have determined its opinion relating to the effectiveness of the Company’s ICFR as of December 31, 2019 included in the Original 10-K, should not be relied upon.

Accordingly, this Amendment is being filed to amend Item 6, Selected Financial Data, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, Item 8, Financial Statements and Supplementary Data, and Item 9A, Controls and Procedures, of Part II of the Original 10-K and to revise the financial statements and related notes to reflect the correction of the immaterial errors identified, and to restate Management’s Annual Report on Internal Control Over Financial Reporting, management’s assessment of the effectiveness of our disclosure controls and procedures and PwC’s Report of Independent Registered Public Accounting Firm on the Company’s internal control over financial reporting. Additionally, in accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the Company is including with this Amendment currently dated certifications as Exhibits 31.1, 31.2, 32.1 and 32.2 and Item 15 of Part IV of the Original 10-K is accordingly replaced with the Item 15 included herein.

Except as described above, this Amendment does not amend, update or change any other disclosures in the Original Form 10-K. In addition, the information contained in this Amendment does not reflect events occurring after the filing of the Original 10-K and does not modify or update the disclosures therein, except as specifically identified above. Significant developments with respect to those disclosures, as well as other changes in and risks to our business, have occurred and are described in filings we have made with the SEC subsequent to filing the Original 10-K, including our Quarterly Report on Form 10-Q for the three and six months ended June 30, 2020, which further describes the impact of the material weakness. Accordingly, this Amendment should be read in conjunction with the Company’s filings made with the SEC subsequent to the filing of the Original 10-K, including the information contained under the heading “Risk Factors,” or otherwise identified as risks to the Company and its operations, in such filings.



AMAG PHARMACEUTICALS, INC.
FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, 2019
TABLE OF CONTENTS



PART II
 
ITEM 6. SELECTED FINANCIAL DATA:
The following table sets forth selected financial data as of and for the years ended December 31, 2019, 2018, 2017, 2016 and 2015. The selected financial data set forth below has been derived from our audited financial statements. This information should be read in conjunction with the financial statements and the related notes thereto included in Part II, Item 8 of this Annual Report on Form 10-K/A and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Part II, Item 7 of this Annual Report on Form 10-K/A. Our consolidated financial statements as of December 31, 2019 and 2018, and for the years ended December 31, 2019, 2018 and 2017, have been revised to correct prior period errors as discussed in Note X, “Revision of Prior Period Financial Statements” to our consolidated financial statements included in this Annual Report on Form 10-K/A. Accordingly, this selected financial data reflects the impact of those revisions. The tables below are also revised to reflect the correction of the related immaterial prior period errors as of and for the year ended December 31, 2016. There was no impact to 2015 as a result of these prior period errors.
 
Years Ended December 31,
 
2019
 
2018
 
2017
 
2016
 
2015
 
(in thousands, except per share data)
Statements of Operations Data
 
 
 
 
 
 
 
 
 
Continuing Operations:
 
 
 
 
 
 
 
 
 
Revenues:
 
 
 
 
 
 
 
 
 
Product sales, net
$
309,985

 
$
471,898

 
$
493,843

 
$
430,828

 
$
341,816

Collaboration revenue (1)
16,400

 
—

 
—

 
—

 
51,050

Other revenues
161

 
150

 
124

 
317

 
1,278

Total revenues
326,546

 
472,048

 
493,967

 
431,145

 
394,144

Costs and expenses:
 
 
 
 
 
 
 
 
 
Cost of product sales (2)
107,193

 
215,892

 
161,349

 
96,314

 
78,509

Research and development expenses
64,853

 
44,846

 
75,017

 
65,561

 
42,710

Acquired in-process research and development (3)
74,856

 
32,500

 
65,845

 
—

 
—

Selling, general and administrative expenses (4)
286,600

 
227,810

 
178,151

 
169,468

 
131,127

Impairment of assets (5)
232,336

 
—

 
319,246

 
15,724

 
—

Acquisition-related costs
—

 
—

 
—

 
—

 
11,232

Restructuring expenses
7,420

 
—

 
—

 
341

 
2,274

Total costs and expenses
773,258

 
521,048

 
799,608

 
347,408

 
265,852

Operating (loss) income
(446,712
)
 
(49,000
)
 
(305,641
)
 
83,737

 
128,292

Other income (expense):
 
 
 
 
 
 
 
 
 
Interest expense
(25,709
)
 
(51,971
)
 
(68,382
)
 
(73,153
)
 
(53,251
)
Loss on debt extinguishment (6)
—

 
(35,922
)
 
(10,926
)
 
—

 
(10,449
)
Interest and dividend income
4,285

 
5,328

 
2,810

 
3,149

 
1,501

Other income (expense)
428

 
(74
)
 
(70
)
 
189

 
(9,173
)
Total other expense
(20,996
)
 
(82,639
)
 
(76,568
)
 
(69,815
)
 
(71,372
)
(Loss) income from continuing operations before income taxes
(467,708
)
 
(131,639
)
 
(382,209
)
 
13,922

 
56,920

Income tax (benefit) expense (7)
(47
)
 
40,436

 
(175,521
)
 
12,656

 
12,764

Net (loss) income from continuing operations
$
(467,661
)
 
$
(172,075
)
 
$
(206,688
)
 
$
1,266

 
$
44,156

 
 
 
 
 
 
 
 
 
 
Discontinued operations:
 
 
 
 
 
 
 
 
 
Income (loss) from discontinued operations
$
—

 
$
18,873

 
$
10,313

 
$
(6,209
)
 
$
(17,076
)
Gain on sale of CBR business
—

 
87,076

 
—

 
—

 
—

Income tax expense (benefit)
—

 
2,371

 
4,388

 
(1,633
)
 
(5,699
)
Net income (loss) from discontinued operations
$
—

 
$
103,578

 
$
5,925

 
$
(4,576
)
 
$
(11,377
)

4



 
 
 
 
 
 
 
 
 
 
Net (loss) income
$
(467,661
)
 
$
(68,497
)
 
$
(200,763
)
 
$
(3,310
)
 
$
32,779

 
 
 
 
 
 
 
 
 
 
Basic earnings per share:
 

 
 

 
 

 
 
 
 
(Loss) income from continuing operations
$
(13.74
)
 
$
(5.00
)
 
$
(5.92
)
 
$
0.04

 
$
1.40

Income (loss) from discontinued operations
—

 
3.01

 
0.17

 
(0.13
)
 
(0.36
)
Total
$
(13.74
)
 
$
(1.99
)
 
$
(5.75
)
 
$
(0.09
)
 
$
1.04

 
 
 
 
 
 
 
 
 
 
Diluted earnings per share:
 
 
 
 
 
 
 
 
 
(Loss) income from continuing operations
$
(13.74
)
 
$
(5.00
)
 
$
(5.92
)
 
$
0.04

 
$
1.25

Income (loss) from discontinued operations
—

 
3.01

 
0.17

 
(0.13
)
 
(0.32
)
Total
$
(13.74
)
 
$
(1.99
)
 
$
(5.75
)
 
$
(0.09
)
 
$
0.93

 
 
 
 
 
 
 
 
 
 
Weighted average shares outstanding used to compute earnings per share:
 

 
 

 
 

 
 

 
 

Basic
34,030

 
34,394

 
34,907

 
34,346

 
31,471

Diluted
34,030

 
34,394

 
34,907

 
34,833

 
35,308

 
December 31,
 
2019
 
2018
 
2017
 
2016
 
2015
Balance Sheet Data
    
    
    
    
    
    
    
    
    
Cash, cash equivalents and marketable securities
$
171,751

 
$
394,171

 
$
299,448

 
$
527,130

 
$
456,359

Working capital (current assets less current liabilities)
$
102,070

 
$
354,628

 
$
201,006

 
$
404,339

 
$
360,753

Total assets (8)
$
791,227

 
$
1,175,459

 
$
1,901,138

 
$
2,478,426

 
$
2,476,210

Long-term liabilities (9)
$
296,914

 
$
263,360

 
$
832,394

 
$
1,230,645

 
$
1,298,025

Stockholders’ equity
$
279,816

 
$
741,557

 
$
787,882

 
$
933,562

 
$
932,264

________________________

(1) 
In 2019, we recognized $16.4 million in collaboration revenue associated with the termination of a clinical trial collaboration agreement with a pharmaceutical company that we acquired in connection with the Perosphere transaction. In 2015, we recognized $44.4 million in revenues associated with the amortization of the then remaining deferred revenue balance as a result of the termination of a license, development and commercialization agreement (the “Takeda Termination Agreement”) with Takeda Pharmaceutical Company Limited (“Takeda”) and $6.7 million of additional revenues related to payments made by Takeda upon the final termination date under the terms of the Takeda Termination Agreement.

(2) 
Cost of product sales in 2019, 2018, 2017, 2016, and 2015 included approximately $24.8 million, $158.4 million, $130.4 million, $77.8 million, and $63.3 million, respectively, of non-cash expense related to the amortization of intangible assets and the step-up of Lumara Health’s inventories at the acquisition date.

(3) 
2019 reflects $74.9 million related to our acquisition of Perosphere. 2018 reflects $12.5 million paid in connection with our acquisition of AMAG-423 and $20.0 million paid to Palatin upon FDA acceptance of the Vyleesi NDA. 2017 reflects $65.8 million related to a $60.0 million one-time upfront payment under the terms of the Palatin License Agreement and $5.8 million, which represented a portion of the consideration recorded in 2017 under the terms of the Endoceutics License Agreement.

(4) 
2019, 2018 and 2017 reflect increases driven by organizational growth associated with significant launch activities for multiple products and costs related to the commercialization of Intrarosa and Vyleesi. 2016 reflects an increase in the Makena-related contingent consideration based on the expected timing of milestone payments.

(5) 
In 2019, we recognized $232.3 million of charges related to the impairments of the asset groups containing the Makena base technology, Makena auto-injector developed technology, Intrarosa developed technology and Vyleesi developed technology driven by (i) the discontinuation of the Makena IM products, (ii) the unfavorable FDA Advisory Committee

5



recommendation for Makena and (iii) our intention to divest Intrarosa and Vyleesi based on the strategic review that we conducted. In 2017, we recognized a $319.2 million impairment charge related to the Makena base technology intangible asset. In 2016, we recognized $15.7 million of charges related to the impairment of the remaining net intangible asset related to MuGard.

(6) 
Reflects $35.9 million, $10.9 million and $10.4 million loss on debt extinguishment in 2018, 2017 and 2015, respectively, due to the early redemption of a $500.0 million aggregate principal amount of 7.875% Senior Notes due 2023 (the “2023 Senior Notes”), the early repayment of a 2015 term loan facility and the early repayment of a 2014 term loan facility, respectively.

(7) 
The $175.5 million income tax benefit in 2017 was primarily driven by the deferred tax benefit related to the Makena base technology intangible asset impairment and amortization.

(8) 
Reflects the impact of aggregate asset impairment charges of $232.3 million in 2019, the sale of the Cord Blood Registry business in 2018 and the $319.2 million impairment charge related to the Makena base technology intangible asset in 2017.

(9) 
Long-term liabilities decreased in 2018 and 2017 primarily due to the repayment of our 2023 Senior Notes and 2015 term loan facility, respectively.

ITEM 7.  
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS:

Overview

AMAG Pharmaceuticals, Inc., a Delaware corporation, was founded in 1981. We are a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs by leveraging our development and commercial expertise to invest in and grow our pharmaceutical products and product candidates across a range of therapeutic areas. Our currently marketed products support the health of patients in the areas of hematology and maternal and women’s health, including Feraheme® (ferumoxytol injection) for intravenous (“IV”) use, Makena® (hydroxyprogesterone caproate injection) auto-injector, Intrarosa® (prasterone) vaginal inserts and Vyleesi®(bremelanotide injection). In addition to our approved products, our portfolio includes two product candidates, AMAG-423 (digoxin immune fab (ovine)), which is being studied for the treatment of severe preeclampsia, and ciraparantag, which is being studied as an anticoagulant reversal agent.

In January 2020, we announced that we had recently completed a review of our product portfolio and strategy with the objective of driving near- and long-term profitability and enhancing shareholder value. Based on this strategic review, we are currently pursuing options to divest Intrarosa and Vyleesi. In addition, we announced that William Heiden will be stepping down as our President and Chief Executive Officer. We expect that Mr. Heiden will remain at the company until the Board of Directors (the “Board”) appoints a new Chief Executive Officer.

We intend to continue to expand the impact of our current and future products for patients by delivering on our growth strategy, which includes collaborating on and acquiring promising therapies at various stages of development, and advancing them through the clinical and regulatory process to deliver new treatment options to patients. Our primary sources of revenue in 2019 were from sales of Feraheme, Makena and Intrarosa. Except as otherwise stated below, the following discussions of our results of operations reflect the results of our continuing operations, excluding the results related to the Cord Blood Registry (the “CBR business”), which we sold in August 2018. The CBR business has been separated from continuing operations and reflected as a discontinued operation. See Note C, “Discontinued Operations,” to our consolidated financial statements included in this Annual Report on Form 10-K.

The consolidated financial statements as of December 31, 2019 and 2018, and for the years ended December 31, 2019, 2018 and 2017 have been revised to correct prior period errors as discussed in Note X, “Revision of Prior Period Financial Statements” to our consolidated financial statements included in this Annual Report on Form 10-K/A. Accordingly, Management’s Discussion and Analysis reflects the impact of those revisions.

AMAG’s Portfolio of Products and Product Candidates

Feraheme

Feraheme received approval from the U.S. Food and Drug Administration (the “FDA”) in June 2009 for use as an IV iron replacement therapy for the treatment of iron deficiency anemia (“IDA”) in adult patients with chronic kidney disease (“CKD”). In February 2018, the FDA approved the supplemental New Drug Application to expand the Feraheme label to

6



include all eligible adult IDA patients who have intolerance to oral iron or have had unsatisfactory response to oral iron in addition to patients who have CKD. IDA is prevalent in many different patient populations, such as patients with CKD, gastrointestinal diseases or disorders, inflammatory diseases, and chemotherapy-induced anemia. For many of these patients, treatment with oral iron is unsatisfactory or is not tolerated. It is estimated that approximately five million people in the U.S. have IDA and we estimate that a small fraction of the patients who are diagnosed with IDA regardless of the underlying cause are currently being treated with IV iron.

The expanded Feraheme label was supported by two positive pivotal Phase 3 trials, which evaluated Feraheme versus iron sucrose or placebo in a broad population of patients with IDA and positive results from a third Phase 3 randomized, double-blind non-inferiority trial that evaluated the incidence of moderate-to-severe hypersensitivity reactions (including anaphylaxis) and moderate-to-severe hypotension with Feraheme compared to Injectafer® (ferric carboxymaltose injection) (the “Feraheme comparator trial”). The Feraheme comparator trial demonstrated comparability to Injectafer® based on the primary composite endpoint of the incidence of moderate-to-severe hypersensitivity reactions (including anaphylaxis) and moderate-to-severe hypotension (Feraheme incidence 0.6%; Injectafer® incidence 0.7%). Adverse event rates were similar across both treatment groups; however, the incidence of severe hypophosphatemia (defined by blood phosphorous of <0.2 mg/dl at week 2) was less in the patients receiving Feraheme (0.4% of patients) compared to those receiving Injectafer® (38.7% of patients).

Makena

We acquired the rights to Makena in connection with our acquisition of Lumara Health Inc. (“Lumara Health”) in November 2014. Makena is indicated to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth.

Makena was approved by the FDA in February 2011 as an intramuscular (“IM”) injection (the “Makena IM product”) packaged in a multi-dose vial and in February 2016 as a single-dose preservative-free vial. In February 2018, the Makena auto-injector was approved by the FDA for administration via a pre-filled subcutaneous auto-injector, a drug-device combination product (the “Makena auto-injector”). In mid-2018, we launched our own authorized generic of both the single- and multi-dose vials (the “Makena authorized generic”) through Prasco, LLC (“Prasco”). As previously disclosed, based on manufacturing challenges and increased generic competition we no longer offer a branded IM product of Makena and in August 2019 we and Prasco determined it was not commercially viable to continue the relationship and mutually terminated our distribution and supply agreement, such that we no longer offer the Makena authorized generic. Further, as a result of the loss of substantial market share for the Makena IM product, in the second quarter of 2019 we revised our long-term Makena IM products forecast resulting in the recording of significant impairment charges related to the Makena IM products, as discussed in Note I, “Goodwill and Intangible Assets, Net” to the consolidated financial statements included in this annual report on Form 10-K.

In March 2019, we announced topline results from the Progestin’s Role in Optimizing Neonatal Gestation clinical trial (“PROLONG” or “Trial 003”), a randomized, double-blinded, placebo-controlled clinical trial evaluating Makena in patients with a history of a prior spontaneous singleton preterm delivery. The PROLONG trial was conducted under the FDA’s “Subpart H” accelerated approval process. The approval of Makena was based primarily on the Meis trial (“Trial 002”), which was conducted by the Maternal-Fetal Medicine Units Network, sponsored by the National Institute of Child Health and Human Development. In contrast to the Meis trial, the PROLONG trial did not demonstrate a statistically significant difference between the treatment and placebo arms for the co-primary endpoints: the incidence of preterm delivery at less than 35 weeks (Makena treated group 11.0% vs. placebo 11.5%) and the percentage of patients who met criteria for the pre-specified neonatal morbidity and mortality composite index (Makena treated group 5.6% vs. placebo 5.0%). The adverse event profile between the two arms was comparable. Adverse events of special interest, including miscarriage and stillbirth, were infrequent and similar between the treatment and placebo groups. The PROLONG trial enrolled 1,708 pregnant women, over 75% of whom were enrolled outside the U.S.

On October 29, 2019, the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee (the “Advisory Committee”) met to discuss the results of the PROLONG trial to inform the FDA’s regulatory decision for Makena. Following various presentations by experts and discussions at the meeting, the Advisory Committee voted as follows: (a) in response to the question “Do the findings from Trial 003 verify the clinical benefits of Makena on neonatal outcomes?”, 16 members voted “No” and no members voted “Yes”; (b) in response to the question “Based on the findings from Trial 002 and Trial 003, is there substantial evidence of effectiveness of Makena in reducing the risk of recurrent preterm birth?”, 13 members voted “No” and three members voted “Yes”; and (c) in response to the question, “Should the FDA (A) pursue withdrawal of approval for Makena, (B) leave Makena on the market under accelerated approval and require a new confirmatory trial, or (C) leave Makena on the market without requiring a new confirmatory trial?”, nine members voted for (A), seven members voted for (B) and no members voted for (C). The FDA is not required to follow the recommendations of its Advisory Committees but will take them into consideration in deciding what regulatory steps to take with respect to Makena. During the fourth quarter of 2019, we

7



reassessed the fair value of assets related to the Makena auto-injector following the Advisory Committee meeting and recorded significant impairment charges, as discussed in Note I, “Goodwill and Intangible Assets, Net” to the consolidated financial statements included in this annual report on Form 10-K.

This complex and unique situation has no clear precedent and it is therefore difficult to predict outcomes or timing of any FDA actions with respect to Makena. We remain committed to working collaboratively with the FDA to seek a path forward to ensure eligible pregnant women continue to have access to Makena and the currently approved generics that rely on Makena as the innovator drug.

AMAG-423

In September 2018, we acquired the global rights to AMAG-423 for the treatment of preeclampsia and eclampsia in antepartum and postpartum women pursuant to an option agreement entered into in July 2015 (the “Velo Agreement”) with Velo Bio, LLC, a privately-held life sciences company (“Velo”). AMAG-423 is an antibody fragment currently in development for the treatment of severe preeclampsia in pregnant women and has been granted both orphan drug and Fast Track designations by the FDA. AMAG-423 is intended to bind to endogenous digitalis-like factors (“EDLFs”) and remove them from the circulation. EDLFs appear to be elevated in preeclampsia and may play an important role in the pathogenesis of preeclampsia though their inhibitory actions on Na+/K+-ATPase (the sodium pump). By decreasing circulating EDLFs, AMAG-423 is believed to improve vascular endothelial function and lead to better post-delivery outcomes in affected mothers and their babies.

We are currently conducting a multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase 2b/3a study in which we expect to enroll approximately 200 antepartum women with severe preeclampsia between 23 weeks and 0 days and 31 weeks and six days gestation. The study is enrolling at sites both within the U.S. and outside of the U.S. Participants in the study receive either AMAG-423 or placebo intravenously four times a day over a maximum of four days. The study’s primary endpoint is to demonstrate a reduction in the percentage of babies who develop severe intraventricular hemorrhage (bleeding in the brain), necrotizing enterocolitis (severe inflammation of the infant bowels) or death by 36 weeks corrected gestational age between the AMAG-423 and placebo arms. Secondary endpoints include the change from baseline in maternal creatinine clearance, maternal incidence of pulmonary edema during treatment and the period of time between treatment and delivery. In addition to these endpoints, information on both maternal as well as neonatal outcomes and complications related to preeclampsia and/or prematurity will be collected and analyzed. Severe preeclampsia presents challenges to enrollment as it is an extremely complex and dynamic condition; oftentimes, the patient needs be scheduled for immediate delivery. While we continue to work to obtain the necessary country approvals, opening new sites as well as implementing and optimizing strategies to enhance enrollment, the serious nature of the condition under study and the characteristics of the patient population make it difficult for us to predict the timing of enrollment completion.
 
Ciraparantag
 
In January 2019, we acquired ciraparantag with our acquisition of Perosphere Pharmaceuticals Inc. (“Perosphere”), a privately-held biopharmaceutical company pursuant to an Agreement and Plan of Merger (the “Perosphere Agreement”). Ciraparantag is a small molecule anticoagulant reversal agent in development as a single dose solution that is delivered intravenously to reverse the effects of certain novel oral anticoagulants (“NOACs”) (Xarelto®(rivaroxaban), Eliquis®(apixaban), and Savaysa®(edoxaban)) as well as Lovenox® (enoxaparin sodium injection), a low molecular weight heparin (“LMWH”) when reversal of the anticoagulant effect of these products is needed for emergency surgery, urgent procedures or due to life-threatening or uncontrolled bleeding. Ciraparantag has been granted Fast Track designation by the FDA.

Ciraparantag has been evaluated in more than 250 healthy volunteers across seven clinical trials. A first in human Phase 1 study evaluated the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of ciraparantag alone and following a single dose of Savaysa®, and another Phase 1 study evaluated the overall metabolism of the drug. Two Phase 2a studies evaluated the safety, tolerability, pharmacokinetic, and pharmacodynamic effects related to the reversal of unfractionated heparin and Lovenox® and three Phase 2b randomized, single-blind, placebo-controlled dose-ranging studies evaluated the reversal of Savaysa®, Eliquis®, and Xarelto® to assess the safety and efficacy of ciraparantag, each of which included 12 subjects dosed with ciraparantag. In these Phase 2b clinical trials, ciraparantag or placebo was administered to healthy volunteers in a blinded fashion after achieving steady blood concentrations of the respective anticoagulant. Pharmacodynamic assessments of whole blood clotting time (“WBCT”), an important laboratory measure of clotting capacity, were sampled frequently for the first hour post study drug dose, and then periodically thereafter out to 24 hours post administration of study drug. Key endpoints in the Phase 2 trials included mean change from baseline in WBCT and the proportion of subjects that returned to within 10% of their baseline WBCT. Subjects in these studies experienced a rapid and statistically significant (p<0.001) reduction in WBCT compared to placebo as early as 15 minutes after the administration of ciraparantag in each of

8



the four studies and the effect was sustained for 24 hours. Moreover, in both the Eliquis® and Xarelto® studies, 100% of subjects in the highest dose cohorts (180 mg of ciraparantag) were responders, as defined by a return to within 10% of baseline WBCT within 30 minutes and sustained for at least six hours. Ciraparantag has been well tolerated in clinical trials, with the most common related adverse events to date being mild sensations of coolness, warmth or tingling, skin flushing, and alterations in taste. There have been no drug-related serious adverse events to date.

We are planning to conduct a clinical study in healthy volunteers to confirm the proposed dose of ciraparantag to be used in the Phase 3 program, after reaching peak steady state blood concentrations of certain NOAC drugs. This proposed study will utilize an automated coagulometer developed by Perosphere Technologies, Inc. (“Perosphere Technologies”), an independent company, to measure WBCT. An investigational device exemption, which Perosphere Technologies will submit once the design of the healthy volunteer study is finalized, is required for use of the coagulometer in clinical studies. Over the past several months, Perosphere Technologies has completed additional analytic studies and we have continued to work with the FDA on the design of this next clinical study. Following the completion of this study, we plan to schedule an End of Phase 2 meeting with the FDA to discuss the design of the Phase 3 program to evaluate the safety and efficacy of ciraparantag in the target patient population. We currently expect enrollment in the healthy volunteer study to be completed by the end of 2020, assuming our proposed protocol is acceptable to the FDA and that additional dose exploration is not needed.

In December 2019, we entered into a termination and settlement agreement with Daiichi Sankyo, Inc. to terminate a clinical trial collaboration agreement we acquired in connection with the Perosphere transaction. Under the terms of the settlement agreement, we received $10.0 million in December 2019 as a termination payment from Daiichi Sankyo, Inc. In 2019, we also recognized $6.4 million of deferred revenue that we acquired from Perosphere related to the original agreement.

Products to be Divested

In January 2020, following a review of our product portfolio and strategy, we announced that we would be pursuing options to divest Intrarosa and Vyleesi from our product portfolio.

Intrarosa

In February 2017, we entered into a license agreement (the “Endoceutics License Agreement”) with Endoceutics, Inc. (“Endoceutics”) pursuant to which Endoceutics granted us the U.S. rights to Intrarosa, an FDA-approved product for the treatment of moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy (“VVA”), due to menopause. Intrarosa was approved by the FDA in November 2016 and was launched commercially in July 2017. Intrarosa is the only FDA-approved vaginal non-estrogen treatment indicated for the treatment of moderate to severe dyspareunia, a symptom of VVA, due to menopause. Intrarosa contains prasterone, a synthetic form of dehydroepiandrosterone, which is an inactive endogenous (i.e. occurring in the body) sex steroid. The mechanism of action of Intrarosa is not fully established. Intrarosa is contraindicated in women with undiagnosed abnormal genital bleeding and its label contains a precaution that it has not been studied in women with a history of breast cancer.

Vyleesi

We acquired the exclusive rights to commercialize Vyleesi in certain territories in January 2017 pursuant to a license agreement (the “Palatin License Agreement”) entered into with Palatin Technologies, Inc. (“Palatin”). On June 21, 2019, the FDA approved Vyleesi for the treatment of acquired, generalized HSDD in premenopausal women, and Vyleesi became commercially available in the U.S. in September 2019 through specialty pharmacies. Based on the June 2019 approval, we made a $60.0 million milestone payment to Palatin in July 2019, which we recorded as an intangible asset.

Vyleesi, a melanocortin receptor agonist, is an “as needed” therapy used in anticipation of sexual activity and self-administered by premenopausal women with HSDD in the thigh or abdomen via a single-use subcutaneous auto-injector. The most common adverse events are nausea, flushing, injection site reactions, headache and vomiting. Vyleesi is contraindicated in women with uncontrolled hypertension or known cardiovascular disease. In addition, the Vyleesi label includes precautions that it may cause (i) small, transient increases in blood pressure with a corresponding decrease in heart rate; (ii) focal hyperpigmentation (darkening of the skin on certain parts of the body), including the face, gums (gingiva) and breasts; and (iii) nausea.

Critical Accounting Policies

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). The preparation of these financial statements requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenues and expenses, and the related disclosure of contingent liabilities. Actual results could differ materially from those estimates. Management employs the following critical accounting policies affecting our most significant estimates and assumptions: revenue recognition and related sales allowances and accruals; valuation of marketable securities; valuation of inventory; business combinations and asset acquisitions, including acquisition-related contingent consideration; goodwill; intangible assets; equity-based compensation; and income taxes.

9




Revenue Recognition

Product revenues
On January 1, 2018, we adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), by applying the modified retrospective transition method to all contracts that were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for prior periods. There was no impact to our product revenue as a result of adoption.

Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:

a.Identify the contract(s) with a customer;
b.Identify the performance obligations in the contract;
c.Determine the transaction price;
d.Allocate the transaction price to the performance obligations in the contract; and
e.Recognize revenue when (or as) the performance obligations are satisfied.

We only apply the five step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, if the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Our major sources of revenue during the reporting periods were product revenues from Makena, Feraheme and Intrarosa. The adoption of ASC 606 in 2018 did not have an impact on the pattern or timing of recognition of our product revenue, as the majority of our product revenue continues to be recognized when the customer takes control of our product.

We receive payments from customers based upon contractual billing schedules; accounts receivable are recorded when the right to consideration becomes unconditional.

Performance Obligations

At contract inception, we assess the goods promised in our contracts with customers and identify a performance obligation for each promise to transfer to the customer a good (or bundle of goods) that is distinct. To identify the performance obligations, we consider all of the goods promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. We determined that the following distinct goods represent separate performance obligations:

•Supply of Makena product
•Supply of Feraheme product
•Supply of Intrarosa product
•Supply of Vyleesi product

We principally sell our products to wholesalers, specialty distributors, specialty pharmacies and other customers (collectively, “Customers”), who purchase products directly from us. Our Customers subsequently resell the products to healthcare providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payers that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products.

For the majority of our Customers, we transfer control at the point in time when the goods are delivered. In instances when we perform shipping and handling activities, these are considered fulfillment activities, and accordingly, the costs are accrued when the related revenue is recognized. Taxes collected from Customers and remitted to governmental authorities are excluded from revenues.


10



Variable Consideration
Under ASC 606, we are required to make estimates of the net sales price, including estimates of variable consideration (such as rebates, chargebacks, discounts, copay assistance and other deductions), and recognize the estimated amount as revenue, when we transfer control of the product to our customers. Variable consideration must be determined using either an “expected value” or a “most likely amount” method.

We record product revenues net of certain allowances and accruals in our consolidated statements of operations. Product sales allowances and accruals are primarily comprised of both direct and indirect fees, discounts and rebates and provisions for estimated product returns. Direct fees, discounts and rebates are contractual fees and price adjustments payable to Customers that purchase products directly from us. Indirect fees, discounts and rebates are contractual price adjustments payable to healthcare providers and organizations, such as certain physicians, clinics, hospitals, group purchasing organizations (“GPOs”), and dialysis organizations that typically do not purchase products directly from us but rather from wholesalers and specialty distributors. Consideration payable to a Customer, or other parties that purchase goods from a Customer, are considered to be a reduction of the transaction price, and therefore, of revenue.

Product sales allowances and accruals are based on definitive contractual agreements or legal requirements (such as laws and regulations to provide mandatory discounts for sales to government entities) related to the purchase and/or utilization of the product by these entities and are recorded in the same period that the related revenue is recognized. We use the expected value method for estimating variable consideration. We estimate product sales allowances and accruals using either historical, actual and/or other data, including estimated patient usage, applicable contractual rebate rates, contract performance by the benefit providers, other current contractual and statutory requirements, historical market data based upon experience of our products and other products similar to them, specific known market events and trends such as competitive pricing and new product introductions, current and forecasted Customer buying patterns and inventory levels, and the shelf life of our products. As part of this evaluation, we also review changes to federal and other legislation, changes to rebate contracts, changes in the level of discounts, and changes in product sales trends. Although allowances and accruals are recorded at the time of product sale, rebates are typically paid out in arrears, one to three months after the sale. 

The estimate of variable consideration, which is included in the transaction price, may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved in a future period. Estimating variable consideration and the related constraint requires the use of significant management judgment and actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.

Discounts

We typically offer a 2% prompt payment discount to certain customers as an incentive to remit payment in accordance with the stated terms of the invoice, generally between 30 to 60 days. Because we anticipate that those customers who are offered this discount will take advantage of the discount, 100% of the prompt payment discount at the time of sale is accrued for eligible customers, based on the gross amount of each invoice. We adjust the accrual quarterly to reflect actual experience.

Chargebacks

Chargeback reserves represent the estimated obligations resulting from the difference between the prices at which we sell our products to wholesalers and the sales price ultimately paid to wholesalers under fixed price contracts by third-party payers, including governmental agencies. The chargeback estimates are determined based on actual product sales data and forecasted customer buying patterns. Actual chargeback amounts are determined at the time of resale to the qualified healthcare provider, and we generally issue credits for such amounts within several weeks of receiving notification from the wholesaler. Estimated chargeback amounts are recorded at the time of sale and adjusted quarterly to reflect actual experience.

Distributor/Wholesaler and Group Purchasing Organization Fees

Fees under arrangements with distributors and wholesalers are usually based upon units of product purchased during the prior month or quarter and are usually paid by us within several weeks of the receipt of an invoice from the wholesaler or distributor. Fees under arrangements with GPOs are usually based upon member purchases during the prior quarter and are generally billed by the GPO within 30 days after period end. In accordance with ASC 606, since the consideration given to the Customer is not for a distinct good or service, the consideration is a reduction of the transaction price of the vendor’s products

11



or services. We have included these fees in contractual adjustments in the table above. We generally pay such amounts within several weeks of the receipt of an invoice from the distributor, wholesaler or GPO. Accordingly, we accrue the estimated fee due at the time of sale, based on the contracted price invoiced to the Customer. We adjust the accrual quarterly to reflect actual experience.

Product Returns

Consistent with industry practice, we generally offer wholesalers, specialty distributors and other customers a limited right to return our products based on the product’s expiration date. The current shelf-lives or time between manufacture and expiration for products in our portfolio range from three to five years. Product returns are estimated based on the historical return patterns and known or expected changes in the marketplace. We track actual returns by individual production lots. Returns on lots eligible for credits under our returned goods policy are monitored and compared with historical return trends and rates. We expect that wholesalers and healthcare providers will not stock significant inventory due to the cost of the product, the expense to store our products, and/or that our products are readily available for distribution. We record an estimate of returns at the time of sale. If necessary, our estimated rate of returns may be adjusted for actual return experience as it becomes available and for known or expected changes in the marketplace. There were no material adjustments to our reserve for product returns during the years ended December 31, 2019, 2018 or 2017. To date, our product returns have been relatively limited; however, returns experience may change over time. We may be required to make future adjustments to our product returns estimate, which would result in a corresponding change to our net product sales in the period of adjustment and could be significant.

Sales Rebates

We contract with various private payer organizations, primarily pharmacy benefit managers, for the payment of rebates with respect to utilization of our products. We determine our estimates for rebates, if applicable, based on actual product sales data and our historical product claims experience. Rebate amounts generally are invoiced quarterly and are paid in arrears, and we expect to pay such amounts within several weeks of notification by the provider. We regularly assess our reserve balance and the rate at which we accrue for claims against product sales. If we determine in future periods that our actual rebate experience is not indicative of expected claims, if actual claims experience changes, or if other factors affect estimated claims rates, we may be required to adjust our current accumulated reserve estimate, which would affect net product sales in the period of the adjustment and could be significant.

Governmental Rebates

Governmental rebates relate to our reimbursement arrangements with state Medicaid programs. We determine our estimates for Medicaid rebates, if applicable, based on actual product sales data and our historical product claims experience. In estimating these reserves, we provide for a Medicaid rebate associated with both those expected instances where Medicaid will act as the primary insurer as well as in those instances where we expect Medicaid will act as the secondary insurer. Rebate amounts generally are invoiced quarterly and are paid in arrears, and we expect to pay such amounts within several weeks of notification by the Medicaid or provider entity. We regularly assess our Medicaid reserve balance and the rate at which we accrue for claims against product sales. If we determine in future periods that our actual rebate experience is not indicative of expected claims, if actual claims experience changes, or if other factors affect estimated claims rates, we may be required to adjust our current Medicaid accumulated reserve estimate, which would affect net product sales in the period of the adjustment and could be significant.

Other Discounts
Other discounts which we offer include voluntary patient assistance programs, such as copay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug copayments required by payers. The calculation of the accrual for copay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with product that has been recognized as revenue.

Collaboration Revenues

When we enter into collaboration agreements, we assess whether the agreements fall within the scope of ASC Topic 808, Collaborative Arrangements (“ASC 808”) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent

12



consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606. However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the related underlying expense.

Marketable Securities

We account for and classify our marketable securities as either “available-for-sale,” “held-to-maturity,” or “trading debt securities,” in accordance with the accounting guidance related to the accounting and classification of certain investments in marketable securities. The determination of the appropriate classification by us is based primarily on management’s ability and intent to sell the debt security at the time of purchase. As of December 31, 2019 and 2018, all of our marketable securities were classified as available-for-sale.

Available-for-sale securities are those securities which we view as available for use in current operations, if needed. We generally classify our available-for-sale securities as short-term investments, even though the stated maturity date may be one year or more beyond the current balance sheet date. Available-for-sale marketable securities are stated at fair value with their unrealized gains and losses included in accumulated other comprehensive income (loss) within the consolidated statements of stockholders’ equity, until such gains and losses are realized in other income (expense) within the consolidated statements of operations or until an unrealized loss is considered other-than-temporary.

We recognize other-than-temporary impairments of our marketable securities when there is a decline in fair value below the amortized cost basis and if (a) we have the intent to sell the security or (b) it is more likely than not that we will be required to sell the security prior to recovery of its amortized cost basis. If either of these conditions is met, we recognize the difference between the amortized cost basis of the security and its fair value at the impairment measurement date in our consolidated statements of operations. If neither of these conditions is met, we must perform additional analysis to evaluate whether the unrealized loss is associated with the creditworthiness of the issuer of the security rather than other factors, such as interest rates or market factors. If we determine from this analysis that we do not expect to receive cash flows sufficient to recover the entire amortized cost of the security, a credit loss exists, the impairment is considered other-than-temporary and is recognized in our consolidated statements of operations.

Inventory

Inventory is stated at the lower of cost or net realizable value, with approximate cost being determined on a first-in, first-out basis. Prior to initial approval from the FDA or other regulatory agencies, we expense costs relating to the production of inventory in the period incurred, unless we believe regulatory approval and subsequent commercialization of the product candidate is probable and we expect the future economic benefit from sales of the product to be realized, at which point we capitalize the costs as inventory. We assess any costs capitalized prior to regulatory approval each quarter for indicators of impairment, such as a reduced likelihood of approval. We expense costs associated with clinical trial material as research and development expense.

On a quarterly basis, we analyze our inventory levels to determine whether we have any obsolete, expired, or excess inventory. If any inventory is expected to expire prior to being sold, has a cost basis in excess of its net realizable value, is in excess of expected sales requirements as determined by internal sales forecasts, or fails to meet commercial sale specifications, the inventory is written-down through a charge to cost of product sales. The determination of whether inventory costs will be realizable requires estimates by management of future expected inventory requirements, based on sales forecasts. Once packaged, our products have a shelf-life ranging from three to five years. As a result of comparison to internal sales forecasts, we expect to fully realize the carrying value of our finished goods inventory. If actual market conditions are less favorable than those projected by management or in the event of an adverse FDA action, inventory write-downs may be required. Charges for inventory write-downs are not reversed if it is later determined that the product is saleable.

Business Combinations and Asset Acquisitions

The purchase price allocation for business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values. Under Accounting Standards Update (“ASU”) No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business (“2017-01”), we first determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the single asset or group of assets, as applicable, is not a business.

13




We account for business combinations using the acquisition method of accounting, under which the total purchase price of an acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. Acquisition-related costs are expensed as incurred. Any excess of the consideration transferred over the estimated fair values of the identifiable net assets acquired is recorded as goodwill.

The purchase price allocations for business combinations are initially prepared on a preliminary basis and are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. Any adjustments to the purchase price allocations are made as soon as practicable but no later than one year from the acquisition date.

Acquired inventory is recorded at its fair value, which may require a step-up adjustment to recognize the inventory at its expected net realizable value. The inventory step-up is recorded to cost of product sales in our consolidated statements of operations when related inventory is sold, and we record step-up costs associated with clinical trial material as research and development expense.

Acquisition-Related Contingent Consideration

Contingent consideration arising from a business combination is included as part of the purchase price and is recognized at its estimated fair value as of the acquisition date. Subsequent to the acquisition date, we measure contingent consideration arrangements at fair value for each period until the contingency is resolved. These changes in fair value are recognized in selling, general and administrative expenses in our consolidated statements of operations. Changes in fair values reflect new information about the likelihood of the payment of the contingent consideration and the passage of time. For asset acquisitions, we record contingent consideration for obligations we consider to be probable and estimable and these liabilities are not adjusted to fair value.

Goodwill
We test goodwill at the reporting unit level for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that could indicate impairment and trigger an interim impairment assessment include, but are not limited to, an adverse change in current economic and market conditions, including a significant prolonged decline in market capitalization, a significant adverse change in legal factors, unexpected adverse business conditions, and an adverse action or assessment by a regulator. Our annual impairment test date is October 31. We have determined that we operate in a single operating segment and have a single reporting unit.
In performing our goodwill impairment tests, we utilize the approach prescribed under ASC 350, as amended by ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”), which requires that an entity perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value.
When we perform any goodwill impairment test, the estimated fair value of our reporting unit is determined using either an income approach (utilizing a discounted cash flow (“DCF”) model) or a market approach, when appropriate, which assesses our market capitalization as adjusted for a control premium, or a combination thereof. Under the market approach, when our carrying value exceeds our market capitalization, we consider a control premium for purposes of estimating the fair value of our reporting unit, as we believe that a market participant buyer would be required to pay a control premium for our business. As described in the accounting guidance for evaluating long-lived assets for impairment, an entity’s fair value may include a control premium in addition to the quoted market price to determine the fair value of a single reporting unit entity, as an acquiring entity is often willing to pay more for equity securities that give it a controlling interest than an investor would pay for a number of equity securities representing less than a controlling interest. This accounting guidance also indicates that the quoted market price of an individual security need not be the sole measurement basis of the fair value of a single reporting unit. When our market capitalization exceeds our carrying value, we utilize our market capitalization as the indicator of fair value in our impairment test.
When utilizing an income approach, the DCF model is based upon expected future after-tax operating cash flows of the reporting unit discounted to a present value using a risk-adjusted discount rate. Estimates of future cash flows require management to make significant assumptions concerning (i) future operating performance, including future sales, long-term growth rates, operating margins, variations in the amount and timing of cash flows and the probability of achieving the

14



estimated cash flows (ii) the probability of regulatory approvals, and (iii) future economic conditions, all of which may differ from actual future cash flows. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rate, which is intended to reflect the risks inherent in future cash flow projections, used in the DCF model, is based on estimates of the weighted average cost of capital (“WACC”) of market participants relative to our reporting unit. Financial and credit market volatility can directly impact certain inputs and assumptions used to develop the WACC. Any changes in these assumptions may affect our fair value estimate and the result of an impairment test. The discount rates and other inputs and assumptions are consistent with those that a market participant would use. In addition, in order to assess the reasonableness of the fair value of our reporting unit as calculated under the DCF model, we also compare the reporting unit’s fair value to our market capitalization and calculate an implied control premium. We evaluate the implied control premium by comparing it to control premiums of recent comparable market transactions, as applicable. For additional information, see Note I, “Goodwill and Intangible Assets, Net” to our consolidated financial statements included in this Annual Report on Form 10-K.

Intangible Assets

We amortize our intangible assets that have finite lives based on either the straight-line method, or if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be utilized.

If we acquire an asset or a group of assets that do not meet the definition of a business, the acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.

Impairment of Long-Lived Assets

We review our long-lived assets, which includes property and equipment and identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. To evaluate recoverability, management compares the projected undiscounted future cash flows associated with the asset or asset group, including proceeds from its eventual disposition over its estimated useful life against its carrying amount. If the undiscounted cash flows are not sufficient to recover the carrying value of the asset or asset group, the asset or asset group is considered impaired. The impairment loss, if any, is measured as the excess of the carrying amount of the asset or asset group over its estimated fair value, which is typically calculated utilizing a DCF model following the same methodology as described in the preceding section.

Equity-Based Compensation

Equity-based compensation cost is generally measured at the estimated grant date fair value and recorded to expense over the requisite service period, which is generally the vesting period. Because equity-based compensation expense is based on awards ultimately expected to vest, we must make certain judgments about whether employees, officers, directors, consultants and advisers will complete the requisite service period, and reduce the compensation expense being recognized for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based upon historical experience and adjusted for unusual events such as corporate restructurings, which can result in higher than expected turnover and forfeitures. If factors change and we employ different assumptions in future periods, the compensation expense that we record in the future may differ significantly from what we have recorded in the current period.

We estimate the fair value of equity-based compensation involving stock options based on the Black-Scholes option pricing model. This model requires the input of several factors such as the expected option term, the expected risk-free interest rate over the expected option term, the expected volatility of our stock price over the expected option term and the expected dividend yield over the expected option term and are subject to various assumptions. The fair value of awards calculated using the Black-Scholes option pricing model is generally amortized on a straight-line basis over the requisite service period, and is recognized based on the proportionate amount of the requisite service period that has been rendered during each reporting period.

We estimate the fair value of our restricted stock units (“RSUs”) whose vesting is contingent upon market conditions, such as total shareholder return, using the Monte-Carlo simulation model. The fair value of RSUs where vesting is contingent upon market conditions is amortized based upon the estimated derived service period. The fair value of RSUs granted to our employees and directors whose vesting is dependent on future service is determined based upon the quoted closing market price per share on the date of grant, adjusted for estimated forfeitures.


15



We believe our valuation methodologies are appropriate for estimating the fair value of the equity awards we grant to our employees and directors. Our equity award valuations are estimates and may not be reflective of actual future results or amounts ultimately realized by recipients of these grants. These amounts are subject to future quarterly adjustments based upon a variety of factors, which include, but are not limited to, changes in estimated forfeiture rates and the issuance of new equity-based awards.

Income Taxes

We use the asset and liability method of accounting for deferred income taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A deferred tax asset is established for the expected future benefit of net operating loss (“NOL”) and credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance against net deferred tax assets is required if, based on available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Significant judgments, estimates and assumptions regarding future events, such as the amount, timing and character of income, deductions and tax credits, are required in the determination of our provision for income taxes and whether valuation allowances are required against deferred tax assets. In evaluating our ability to recover our deferred tax assets, we consider all available evidence, both positive and negative, including the existence of taxable temporary differences, our past operating results, the existence of cumulative income in the most recent fiscal years, changes in the business in which we operate and our forecast of future taxable income. In determining future taxable income, we are responsible for assumptions utilized including the amount of state and federal operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income. As of December 31, 2019, we have established a valuation allowance on our net deferred tax assets other than refundable alternative minimum tax (“AMT”) credits to the extent that our existing taxable temporary differences would not be available as a source of income to realize the benefits of those deferred tax assets.

We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position. We evaluate uncertain tax positions on a quarterly basis and adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could impact our income tax provision in future periods. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as a provision for income tax in our consolidated statement of operations.

Impact of Recently Issued and Proposed Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. For further discussion on recent accounting pronouncements, please see Note V, “Recently Issued and Proposed Accounting Pronouncements,” to our consolidated financial statements included in this Annual Report on Form 10-K for additional information.
Results of Operations - 2019 as compared to 2018
 

16



Revenues
 
Total revenues for 2019 and 2018 consisted of the following (in thousands except for percentages):
 
Years Ended December 31,
 
2019 to 2018
 
2019
 
2018
 
$ Change
 
% Change
Product sales, net
 
 
 
 
 
 
 
Feraheme
$
167,947

 
$
135,001

 
$
32,946

 
24
 %
Makena
120,859

 
320,311

 
(199,452
)
 
(62
)%
Intrarosa
21,417

 
16,218

 
5,199

 
32
 %
Other
(238
)
 
368

 
(606
)
 
<(100 %)

Total
309,985

 
471,898

 
(161,913
)
 
(34
)%
Other revenues
16,561

 
150

 
16,411

 
>100 %

Total revenues
$
326,546

 
$
472,048

 
$
(145,502
)
 
(31
)%
 
Our total revenues for 2019 decreased by $145.5 million as compared to 2018, due primarily to a $260.0 million decrease in Makena IM net sales driven by supply disruptions, generic competition, changes in estimates to prior period liabilities and our withdrawal from the IM market during 2019, partially offset by an increase in Makena auto-injector net sales. Also offsetting the decrease in Makena revenues was a $32.9 million increase in Feraheme net sales in 2019, as compared to 2018.
In addition, during the fourth quarter of 2019, we entered into a termination and settlement agreement (the “Termination Agreement”) with Daiichi Sankyo, Inc. to terminate a clinical trial collaboration agreement we acquired in connection with the Perosphere transaction. Under the terms of the settlement agreement we received $10.0 million in December 2019. As more fully described in Note D “Revenue Recognition” to the consolidated financial statements included in this Annual Report on Form 10-K, the $10.0 million termination payment and $6.4 million of deferred revenue that we acquired from Perosphere were recognized as collaboration revenue in our consolidated statements of operations for the year ended December 31, 2019.

We expect that total net product sales for 2020 will decrease compared to 2019 due to an expected decline in Makena net product sales and our intention to divest Intrarosa and Vyleesi during the first half of 2020. We expect these declines to be partially offset by increases in Feraheme net sales.

The following table sets forth customers who represented 10% or more of our total revenues for 2019 and 2018:
 
Years Ended December 31,
 
2019
 
2018
McKesson Corporation
36
%
 
26
%
AmerisourceBergen Drug Corporation
28
%
 
27
%
Cardinal Health
13
%
 
< 10%


17



Product Sales Allowances and Accruals

Total gross product sales were offset by product sales allowances and accruals for 2019 and 2018 as follows (in thousands except for percentages): 
 
Years Ended December 31,
 
2019 to 2018
 
2019
 
Percent of
gross
product sales
 
2018
 
Percent of
gross
product sales
 
$ Change
 
% Change
Gross product sales
$
955,693

 
 
 
$
974,330

 
 
 
$
(18,637
)
 
(2
)%
Provision for product sales allowances and accruals:
 
 
 
 
 
 
 
 
 
 
 
Contractual adjustments
530,645

 
56
%
 
387,540

 
40
%
 
143,105

 
37
 %
Governmental rebates
115,063

 
12
%
 
114,892

 
12
%
 
171

 
1
 %
Total
645,708

 
68
%
 
502,432

 
52
%
 
143,276

 
29
 %
Product sales, net
$
309,985

 
 
 
$
471,898

 
 
 
$
(161,913
)
 
(34
)%
 
The increase in contractual adjustments as a percentage of gross product sales primarily related to an increase in rebates offered to commercial purchasers and payers.

We record product revenue net of certain allowances and accruals on our consolidated statements of operations. Our contractual adjustments include provisions for returns, pricing and prompt payment discounts, as well as wholesaler distribution fees, rebates to hospitals that qualify for 340B pricing, and volume-based and other commercial rebates and other discounts. Governmental rebates relate to our reimbursement arrangements with state Medicaid programs.

We may refine our estimated revenue reserves as we continue to obtain additional experience or as our customer mix changes. If we determine in future periods that our actual experience is not indicative of our expectations, if our actual experience changes, or if other factors affect our estimates, we may be required to adjust our allowances and accruals estimates, which would affect our net product sales in the period of the adjustment and could be significant.

An analysis of the amount of our product reserves for 2019 and 2018, is as follows (in thousands):
 
Contractual Adjustments
 
Governmental Rebates
 
Total
Balance at January 1, 2018
$
62,164

 
$
53,742

 
$
115,906

Current provisions relating to sales in current year
389,861

 
106,988

 
496,849

Adjustments relating to sales in prior years
(2,330
)
 
7,903

 
5,573

Payments/returns relating to sales in current year
(333,694
)
 
(75,920
)
 
(409,614
)
Payments/returns relating to sales in prior years
(58,802
)
 
(58,501
)
 
(117,303
)
Balance at December 31, 2018
$
57,199

 
$
34,212

 
$
91,411

Current provisions relating to sales in current year
521,916

 
100,926

 
622,842

Adjustments relating to sales in prior years
8,774

 
14,137

 
22,911

Payments/returns relating to sales in current year
(431,014
)
 
(60,218
)
 
(491,232
)
Payments/returns relating to sales in prior years
(61,654
)
 
(41,435
)
 
(103,089
)
Balance at December 31, 2019
$
95,221

 
$
47,622

 
$
142,843



18



Costs and Expenses
Cost of Product Sales
Cost of product sales for 2019 and 2018 were as follows (in thousands except for percentages):
 
Years Ended December 31,
 
2019 to 2018
 
2019
 
2018
 
$ Change
 
% Change
Direct cost of product sales
$
82,393

 
$
57,492

 
$
24,901

 
43
 %
Amortization of intangible assets
$
24,800

 
$
158,400

 
$
(133,600
)
 
(84
)%
 
$
107,193

 
$
215,892

 
$
(108,699
)
 
(50
)%
Direct cost of product sales as a percentage of net product sales
27
%
 
12
%
 
 
 
 
Our cost of product sales are primarily comprised of manufacturing costs, costs of managing our contract manufacturers, costs for quality assurance and quality control associated with our product sales, royalty obligations and the amortization of product-related intangible assets. Direct cost of product sales as a percentage of net product sales increased from 12% during the year ended December 31, 2018 to 27% during the year ended December 31, 2019, driven by a shift in revenue mix from products with a lower cost of product sales, such as the Makena IM product, to products with a higher cost of product sales, such as the Makena auto-injector and inventory write downs recorded in conjunction with the impairments of the Makena base technology and Makena auto-injector asset groups. We expect direct cost of product sales as a percentage of net product sales to decline in 2020 based on our expectation that a higher proportion of our revenue will be from Feraheme.

Amortization of intangible assets decreased by $133.6 million from December 31, 2018 to December 31, 2019, primarily due to a decrease in amortization of the Makena base technology intangible asset, which related to our Makena IM products and was fully impaired during the second quarter of 2019.
  
Research and Development Expenses
 
Research and development expenses include both external and internal expenses. External expenses primarily include costs of clinical trials and fees paid to contract research organizations (“CROs”), clinical supply and manufacturing expenses, regulatory filing fees, consulting and professional fees as well as other general costs related to the execution of research and development activities. Internal expenses primarily include compensation of employees engaged in research and development activities. Research and development expenses are expensed as incurred. Where possible, we track our external costs by major project. To the extent that external costs are not attributable to a specific project or activity, they are included in other external costs. Prior to the initial regulatory approval of our products or development of new manufacturing processes, costs associated with manufacturing process development and the manufacture of drug product are recorded as research and development expenses, unless we believe regulatory approval and subsequent commercialization of the product candidate is probable and we expect the future economic benefit from sales of the product to be realized, at which point we capitalize the costs as inventory.

Research and development expenses for 2019 and 2018 consisted of the following (in thousands except for percentages):
 
Years Ended December 31,
 
2019 to 2018
 
2019
 
2018
 
$ Change
 
% Change
External research and development expenses
$
41,654

 
27,898

 
13,756

 
49
%
Internal research and development expenses
23,199

 
16,948

 
6,251

 
37
%
Total research and development expenses
$
64,853

 
$
44,846

 
$
20,007

 
45
%
 
Total research and development expenses incurred in 2019 increased by $20.0 million, or 45%, as compared to 2018 primarily related to our development program for AMAG-423 and increases in internal costs related headcount to support our development programs.
We have a number of ongoing research and development programs that we are conducting independently or in collaboration with third parties. We expect our research and development expenses to remain consistent in 2020 as compared to 2019 as we continue to invest in AMAG-423 and ciraparantag. We cannot determine with certainty the duration and completion costs of our current or future clinical trials of our products or product candidates as the duration, costs and timing of clinical trials depends on a variety of factors including the uncertainties of future clinical and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation.


19



Acquired In-Process Research and Development

During 2019, we recorded $74.9 million for acquired in-process research and development (“IPR&D”) related to the acquisition of ciraparantag from Perosphere.

During 2018, we recorded $32.5 million for acquired IPR&D related to a $20.0 million milestone obligation to Palatin associated with the FDA acceptance of the Vyleesi New Drug Application (“NDA”) and $12.5 million as an upfront option exercise fee in connection with our acquisition of AMAG-423.
 
Selling, General and Administrative Expenses
 
Our selling, general and administrative expenses include costs related to our commercial personnel, including our specialty sales forces, medical education professionals, pharmacovigilance, safety monitoring and commercial support personnel, costs related to our administrative personnel, including our legal, finance, business development and executive personnel, external and facilities costs required to support the marketing and sale of our products, and other costs associated with our corporate activities.

Selling, general and administrative expenses for 2019 and 2018 consisted of the following (in thousands except for percentages):
 
Years Ended December 31,
 
2019 to 2018
 
2019
 
2018
 
$ Change
 
% Change
Compensation, payroll taxes and benefits
$
107,362

 
$
126,754

 
$
(19,392
)
 
(15
)%
Professional, consulting and other outside services
164,690

 
134,049

 
30,641

 
23
 %
Fair value of contingent consideration liability
(270
)
 
(49,607
)
 
49,337

 
(99
)%
Equity-based compensation expense
14,818

 
16,614

 
(1,796
)
 
(11
)%
Total selling, general and administrative expenses
$
286,600

 
$
227,810

 
$
58,790

 
26
 %
 
Total selling, general and administrative expenses in 2018 included a $49.6 million decrease to the fair value of contingent consideration liability expense based on actual Makena net sales and our expectations for future performance. Excluding this decrease, selling, general and administrative expenses increased by $9.2 million as compared to 2018. This increase was driven primarily by higher external costs to support the September 2019 launch of Vyleesi, partially offset by a decrease in costs as a result of our February 2019 restructuring to combine our women’s health and maternal health sales forces.

We expect that total selling, general and administrative expenses will decrease substantially in 2020 as compared to 2019 with the planned divestiture of Intrarosa and Vyleesi.

Impairment of Assets

As more fully described in Note I, “Goodwill and Intangible Assets, Net” to the consolidated financial statements included in this Annual Report on Form 10-K, we recorded $232.3 million of impairment charges during 2019 related to the asset groups containing the Makena base technology, the Makena auto-injector developed technology, the Intrarosa developed technology and Vyleesi developed technology.

There were no asset impairments during the year ended December 31, 2018.

Restructuring Expense

In February 2019, we completed a restructuring to combine our women’s health and maternal health sales forces into one integrated sales team. Approximately 110 employees were displaced through this workforce reduction. We recorded a one-time restructuring charge of $7.4 million primarily related to severance and related benefits in the first quarter of 2019 and expect these charges to be substantially paid in cash by the end of the first quarter of 2020. Estimated total savings from the restructuring in 2019 were approximately $15.2 million of selling, general and administrative expense, specifically related to compensation, payroll taxes and benefits. Estimated savings were partially offset by planned increases in selling, general and administrative expenses related to professional, consulting and other outside services associated with the launch of Vyleesi and continued investment in the growth of our commercial products. For additional information on restructuring expenses, see Note S, “Restructuring Expenses” to our consolidated financial statements included in this Annual Report on Form 10-K.


20



Other Expense, Net
Other expense, net for 2019 and 2018 consisted of the following (in thousands except for percentages):
 
Years Ended December 31,
 
2019 to 2018
 
2019
 
2018
 
$ Change
 
% Change
Interest expense
$
(25,709
)
 
$
(51,971
)
 
$
26,262

 
(51
)%
Loss on debt extinguishment
—

 
(35,922
)
 
35,922

 
(100
)%
Interest and dividend income
4,285

 
5,328

 
(1,043
)
 
(20
)%
Other expense
428

 
(74
)
 
502

 
>(100 %)

Total other expense, net
$
(20,996
)
 
$
(82,639
)
 
$
61,643

 
(75
)%

Other expense, net for 2019 decreased by $61.6 million compared to 2018, primarily due to (i) a $35.9 million loss on extinguishment of debt (including a $28.1 million redemption premium), incurred during 2018 as a result of the early redemption of the 2023 Senior Notes, and (ii) a $26.3 million reduction in interest expense in 2019 as a result of this redemption and the repayment of the 2019 Convertible Notes in February 2019.

We expect our other expense, net to remain consistent in 2020 as compared to 2019.
Income Tax (Benefit) Expense
The following table summarizes our effective tax rate and income tax (benefit) expense for 2019 and 2018 (in thousands except for percentages):
 
Years Ended December 31,
 
2019
 
2018
Effective tax rate
—
%
 
(31
)%
Income tax expense (benefit)
$
(47
)
 
$
40,436

For 2019, we recognized an immaterial income tax benefit, representing an effective tax rate of 0%. The difference between the expected statutory federal tax rate of 21% and the 0% effective tax rate for 2019 was primarily attributable to the valuation allowance established against our current period losses generated and the non-deductible IPR&D expense related to the Perosphere acquisition. We have established a valuation allowance on our deferred tax assets other than refundable AMT credits to the extent that our existing taxable temporary differences would not be available as a source of income to realize the benefits of those deferred tax assets. The income tax benefit for the year ended December 31, 2019 primarily related to the offset of the recognition of the income tax expense recorded in other comprehensive loss associated with the increase in the value of available-for-sale securities that we carried at fair market value during the period, partially offset by state income taxes.

For 2018, we recognized income tax expense of $40.4 million, representing an effective tax rate of (31)%. The difference between the expected statutory federal tax rate of 21% and the (31)% effective tax rate for 2018 was primarily attributable to the establishment of a valuation allowance on net deferred tax assets other than refundable AMT credits, the impact of non-deductible stock compensation and other non-deductible expenses, partially offset by a benefit from contingent consideration associated with Lumara Health, state income taxes and orphan drug tax credits. Our valuation allowance on our deferred tax assets, other than refundable AMT credits, increased during the year ended December 31, 2018 primarily because the deferred tax liabilities associated with the CBR business, which was reclassified to discontinued operations and sold during 2018, are no longer available as a source of income to realize the benefits of the net deferred tax assets.

Net Income from Discontinued Operations

Net income from discontinued operations was $103.6 million in 2018. Of the $103.6 million net income from discontinued operations, $87.1 million represented a gain on the sale of the CBR business, which closed on August 6, 2018. For additional information, see Note C, “Discontinued Operations,” to our consolidated financial statements included in this Annual Report on Form 10-K.


21



Results of Operations - 2018 as compared to 2017
 
Management’s discussion and analysis of our results of operations for the year ended December 31, 2018 compared to the year ended December 31, 2017 may be found in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations - 2018 as compared to 2017 section of our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 1, 2019 (the “2018 Annual Report”), which discussion is incorporated herein by reference. Our results of operations for the years ended December 31, 2018 and 2017 as presented in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations - 2018 as compared to 2017” section of our 2018 Annual Report were not revised to reflect the correction of the immaterial errors disclosed in Note X, “Revision of Prior Period Financial Statements”. Due to the immaterial nature of these errors, they had no impact on management’s discussion contained in our 2018 Annual Report.

Liquidity and Capital Resources
 
General
 
We currently finance our operations primarily from cash generated from our operating activities, including sales of our commercialized products. Cash, cash equivalents, marketable securities and certain financial obligations as of December 31, 2019 and 2018 consisted of the following (in thousands except for percentages):
 
December 31,
 
 
 
 
 
2019
 
2018
 
$ Change
 
% Change
Cash and cash equivalents
$
113,009

 
$
253,256

 
$
(140,247
)
 
(55
)%
Marketable Securities
58,742

 
140,915

 
(82,173
)
 
(58
)%
Total
$
171,751

 
$
394,171

 
$
(222,420
)
 
(56
)%
 
 
 
 
 
 
 
 
Outstanding principal on 2022 Convertible Notes
$
320,000

 
$
320,000

 
$
—

 
—
 %
Outstanding principal on 2019 Convertible Notes
—

 
21,417

 
(21,417
)
 
(100
)%
Total
$
320,000

 
$
341,417

 
$
(21,417
)
 
(6
)%
 
Cash Flows
The following table presents a summary of the primary sources and uses of cash for the years ended December 31, 2019, 2018 and 2017 (in thousands):
 
For the Years Ended December 31
 
2019 compared to 2018
 
2018 compared to 2017
(In thousands, except percentages)
2019
 
2018
 
2017
 
 
Net cash (used in) provided by operating activities
$
(125,696
)
 
$
60,800

 
$
106,596

 
$
(186,496
)
 
$
(45,796
)
Net cash provided by investing activities
20,962

 
502,155

 
102,920

 
(481,193
)
 
399,235

Net cash used in financing activities
(35,513
)
 
(501,974
)
 
(293,644
)
 
466,461

 
(208,330
)
Net (decrease) increase in cash, cash equivalents and restricted cash
$
(140,247
)
 
$
60,981

 
$
(84,128
)
 
$
(201,228
)
 
$
145,109


Operating Activities

Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We have historically financed our operating and capital expenditures primarily through cash flows earned through our operations. We expect cash provided by operating activities in addition to our cash, cash equivalents and marketable securities will continue to be a primary source of funds to finance operating needs and capital expenditures.
Operating cash flow is derived by adjusting our net income (loss) for:
•
Non-cash operating items, such as depreciation and amortization, impairment of long-lived assets and equity-based compensation; and

•
Changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations.

For 2019 compared to 2018, net cash flows provided by operating activities decreased by $186.5 million, driven primarily by a decrease in net income as adjusted for non-cash charges of $205.5 million and a $19.0 million increase due to changes in operating assets and liabilities. Included within net loss for 2019 was $74.9 million of acquired IPR&D expense related to the Perosphere asset acquisition, of which $60.8 million was paid in cash during the first quarter of 2019. The cash flows from

22



operating activities for 2018 include cash flows from the operating activities of the CBR business, which are included in discontinued operations. Subsequent to the closing of the CBR transaction on August 6, 2018, we no longer generated cash flows from that business. See Note C, “Discontinued Operations,” to our consolidated financial statements included in this Annual Report on Form 10-K for further detail regarding our discontinued operations.

For 2018 compared to 2017, net cash flows provided by operations decreased by $45.8 million, driven primarily by a decrease in net income as adjusted for non-cash charges of $29.8 million and a $15.9 million decrease due to changes in operating assets and liabilities.

Investing Activities

Cash flows provided by investing activities was $21.0 million in 2019 due primarily to net proceeds from the sale of marketable securities of $83.5 million, partially offset by a $60.0 million milestone payment triggered by the FDA approval of Vyleesi and capital expenditures of $2.5 million.

Cash flows provided by investing activities in 2018 was $502.2 million due to $519.3 million in proceeds from the sale of CBR, partially offset by net purchases of marketable securities of $4.6 million and capital expenditures of $2.5 million.

Cash flows provided by investing activities in 2017 was $102.9 million due to net proceeds from the sale of marketable securities of $167.7 million, partially offset by $55.8 million of cash used to purchase the Intrarosa asset and capital expenditures of $9.0 million.

Financing Activities

Cash used in financing activities was $35.5 million in 2019 due to the $21.4 million repayment of our 2019 Convertible Notes, $13.7 million for the repurchase of common stock and $1.8 million for payments of employee tax withholdings related to equity-based compensation offset by $1.5 million of proceeds from the issuance of common stock under the Employee Stock Purchase Plan.

Cash used in financing activities was $502.0 million in 2018 due to the repayment of the $475.0 million balance of our 2023 Senior Notes and a related redemption premium of $28.1 million.

Cash used in financing activities in 2017 was $293.6 million driven by $353.1 million of principal payments made during 2017, including the full repayment of the remaining balance of a 2015 term loan facility, $191.7 million used for the repurchase of a portion of our 2019 Convertible Notes, $39.8 million of contingent consideration payments and the repurchase of common stock of $19.5 million, partially offset by $320.0 million net proceeds related to the issuance of our 2022 Convertible Notes.

Future Liquidity Considerations
We believe that our cash, cash equivalents and marketable securities as of December 31, 2019, and the cash we expect to receive from sales of our products, will be sufficient to fund our current operating plans and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements.

We generated negative cash flows from operations during the year ended December 31, 2019 and while we expect to generate positive cash flows from continuing operations during 2020, these cash flows and our cash on hand as of December 31, 2019 in the aggregate will be insufficient to settle our 2022 Convertible Notes. We therefore expect that we will need to issue new securities, in the form of debt, equity or equity-linked, or some combination thereof. We may also utilize proceeds from a potential strategic collaboration or other transaction to manage our existing obligations.

For a detailed discussion regarding the risks and uncertainties related to our liquidity and capital resources, please refer to our Risk Factors in Part I, Item 1A of this Annual Report on Form 10-K.

Borrowings and Other Liabilities
In the second quarter of 2017, we issued $320.0 million aggregate principal amount of convertible senior notes due 2022 (the “2022 Convertible Notes”). We received net proceeds of $310.4 million from the sale of the 2022 Convertible Notes, after deducting fees and expenses of $9.6 million. The 2022 Convertible Notes are senior unsecured obligations and bear interest at a rate of 3.25% per year, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2017. The 2022 Convertible Notes will mature on June 1, 2022, unless earlier repurchased or converted. Upon conversion of

23



the 2022 Convertible Notes, such 2022 Convertible Notes will be convertible into, at our election, cash, shares of our common stock, or a combination thereof, at a conversion rate of 36.5464 shares of common stock per $1,000 principal amount of the 2022 Convertible Notes, which corresponds to an initial conversion price of approximately $27.36 per share of our common stock. The conversion rate is subject to adjustment from time to time. The 2022 Convertible Notes were not convertible by the note holders as of December 31, 2019.

Share Repurchase Program
 
As of January 1, 2019, we had $20.5 million available under our previously approved share repurchase program to repurchase up to $60.0 million in shares of our common stock. In March 2019, our Board authorized additional repurchases of shares in an amount up to $20.0 million under this program. During the first quarter of 2019, we repurchased and retired 1,074,800 shares of common stock for $13.7 million. As of December 31, 2019, $26.8 million remained available for future repurchases under this program.
 
Contractual Obligations

Our long-term contractual obligations include commitments and estimated purchase obligations entered into in the normal course of business. These include commitments related to our operating leases, purchases of inventory and debt obligations (including interest payments). Future contractual obligations, as of December 31, 2019, are as follows (in thousands):
 
Payment due by period
 
Total
 
Less than 1 year
 
1-3 years
 
3-5 years
 
More than 5 years
Lease obligations
$
29,686

 
$
4,077

 
$
6,941

 
$
6,476

 
$
12,192

Purchase commitments
105,903

 
31,373

 
39,009

 
29,829

 
5,692

2022 Convertible Notes
346,000

 
10,400

 
335,600

 
—

 
—

Total
$
481,589

 
$
45,850

 
$
381,550

 
$
36,305

 
$
17,884


Lease Obligations
We are a party to operating leases for real estate, including our lease for use as our principal executive offices, vehicles and office equipment. Refer to Note P, “Commitments and Contingencies” to our consolidated financial statements included in this Annual Report on Form 10-K for more information on our lease obligations.
Purchase Obligations
Purchase obligations primarily represent minimum purchase commitments for inventory. As of December 31, 2019, our minimum purchase commitments totaled $105.9 million.

Contingent Regulatory and Commercial Milestone Payments

We are required to make payments contingent on the achievement of certain regulatory and/or commercial milestones under the terms of our collaboration, license and other strategic agreements. Please refer to Note Q, “Collaboration, License and Other Strategic Agreements” to our consolidated financial statements included in this Annual Report on Form 10-K for more information regarding these contingent payments.
Employment Arrangements

We have entered into employment agreements or other arrangements with most of our executive officers and certain other employees, which provide for the continuation of salary and certain benefits and, in certain instances, the acceleration of the vesting of certain equity awards to such individuals in the event that the individual is terminated other than for cause, as defined in the applicable employment agreements or arrangements.

Indemnification Obligations

In the course of operating our business, we have entered into a number of indemnification arrangements under which we may be required to make payments to or on behalf of certain third parties including our directors, officers, and certain employees as well as certain other third parties with whom we enter into agreements. For further discussion of how this may

24



affect our business, see Note P, “Commitments and Contingencies,” to our consolidated financial statements included in this Annual Report on Form 10-K.

Legal Proceedings

For detailed information on our legal proceedings, see Note P, “Commitments and Contingencies,” to our consolidated financial statements included in this Annual Report on Form 10-K. 

Off-Balance Sheet Arrangements
As of December 31, 2019, we did not have any off-balance sheet arrangements as defined in Regulation S-K, Item 303(a)(4)(ii).
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA:

Index To Consolidated Financial Statements





25



MANAGEMENT’S ANNUAL REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING (RESTATED)
Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities and Exchange Act of 1934, as amended. Our internal control over financial reporting is a process designed under the supervision of our principal executive officer and principal financial officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our management, including our principal executive officer and principal financial officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2019. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. The Company did not design and maintain effective internal controls related to ensuring the timely recognition of our gross-to-net (“GTN”) adjustments for certain governmental rebates and the related accruals. Specifically, we did not design and maintain controls to allow for an effective review of disputed claims related to certain government rebate arrangements, where the decision has been made to initially not record and accrue for such items, to assess whether and when the need to record an accrual is required for such claims. This control deficiency resulted in a misstatement of the Company’s product sales, net, and accrued expenses, and the revision of the Company’s previously issued annual and interim consolidated financial statements as of and for the years ended December 31, 2019, 2018 and 2017 and for each of the interim periods in 2019 and 2018. Additionally, this control deficiency could result in a misstatement of the aforementioned account balances or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected. Therefore, management has concluded that this control deficiency constitutes a material weakness.
In Management’s Annual Report on Internal Control over Financial Reporting included in the Original 10-K, our management previously concluded that the Company maintained effective internal control over financial reporting as of December 31, 2019. Subsequent to the filing date of the Original 10-K, management has concluded that the material weakness described above existed as of December 31, 2019. As a result, we have concluded that we did not maintain effective internal control over financial reporting as of December 31, 2019 based on the criteria set forth by COSO in Internal Control -Integrated Framework (2013). Accordingly, management has restated its annual report on internal control over financial reporting.
The effectiveness of the Company’s internal control over financial reporting as of December 31, 2019, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which is included in “Item 8. Financial Statements and Supplementary Data” of this Amendment.

26



Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of AMAG Pharmaceuticals, Inc.

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of AMAG Pharmaceuticals, Inc. and its subsidiaries (the “Company”) as of December 31, 2019 and 2018, and the related consolidated statements of operations, comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2019, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company did not maintain, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO because a material weakness in internal control over financial reporting existed as of that date related to the timely recognition of the Company’s gross-to-net adjustments for certain governmental rebates and the related accruals. Specifically, the Company did not design and maintain controls to allow for an effective review of disputed claims related to certain government rebate arrangements, where the decision has been made to initially not record and accrue for such items, to assess whether and when the need to record an accrual is required for such claims.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness referred to above is described in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. We considered this material weakness in determining the nature, timing, and extent of audit tests applied in our audit of the 2019 consolidated financial statements, and our opinion regarding the effectiveness of the Company’s internal control over financial reporting does not affect our opinion on those consolidated financial statements.

Restatement of Management’s Conclusion Regarding Internal Control over Financial Reporting

Management and we previously concluded that the Company maintained effective internal control over financial reporting as of December 31, 2019. However, management has subsequently determined that a material weakness in internal control over financial reporting existed as of that date related to the timely recognition of the Company’s gross-to-net adjustments for certain governmental rebates and the related accruals as discussed above. Accordingly, management’s report has been restated and our present opinion on internal control over financial reporting, as presented herein, is different from that expressed in our previous report.

Changes in Accounting Principles

As discussed in Note W to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019 and the manner in which it accounts for share-based compensation in 2017.

Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in management’s report referred to above. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement,

27



whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.


/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts
March 6, 2020, except for the effects of the revision discussed in Note X to the consolidated financial statements and the matter discussed in the second paragraph of Management’s Annual Report on Internal Control over Financial Reporting, as to which the date is September 15, 2020


We served as the Company’s auditor from 1982 to 2020.


28




AMAG PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
 
As of December 31,
 
2019
 
2018
ASSETS
 
 
 
Current assets:
 

 
 

Cash and cash equivalents
$
113,009

 
$
253,256

Marketable securities
58,742

 
140,915

Accounts receivable, net
94,163

 
75,347

Inventories
31,553

 
26,691

Prepaid and other current assets
19,100

 
18,961

Note receivable
—

 
10,000

Total current assets
316,567

 
525,170

Property and equipment, net
4,116

 
7,521

Goodwill
422,513

 
422,513

Intangible assets, net
23,620

 
217,033

Operating lease right-of-use asset
23,286

 
—

Deferred tax assets
630

 
1,260

Restricted cash
495

 
495

Other long-term assets
—

 
1,467

Total assets
$
791,227

 
$
1,175,459

LIABILITIES AND STOCKHOLDERS’ EQUITY
 

 
 

Current liabilities:
 

 
 

Accounts payable
$
27,021

 
$
14,487

Accrued expenses
183,382

 
134,635

Current portion of convertible notes, net
—

 
21,276

Current portion of operating lease liability
4,077

 
—

Current portion of acquisition-related contingent consideration
17

 
144

Total current liabilities
214,497

 
170,542

Long-term liabilities:
 

 
 

Convertible notes, net
277,034

 
261,933

Long-term operating lease liability
19,791

 
—

Long-term acquisition-related contingent consideration
—

 
215

Other long-term liabilities
89

 
1,212

Total liabilities
511,411

 
433,902

Commitments and Contingencies (Note P)


 


Stockholders’ equity:
 

 
 

Preferred stock, par value $0.01 per share, 2,000,000 shares authorized; none issued
—

 
—

Common stock, par value $0.01 per share, 117,500,000 shares authorized; 33,999,081 and 34,606,760 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively
339

 
346

Additional paid-in capital
1,297,917

 
1,292,736

Accumulated other comprehensive loss
(3,239
)
 
(3,985
)
Accumulated deficit
(1,015,201
)
 
(547,540
)
Total stockholders’ equity
279,816

 
741,557

Total liabilities and stockholders’ equity
$
791,227

 
$
1,175,459

The accompanying notes are an integral part of these consolidated financial statements.

29



AMAG PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
 
Years Ended December 31,
 
2019
 
2018
 
2017
Revenues:
 
 
 
 
 
Product sales, net
$
309,985

 
$
471,898

 
$
493,843

Collaboration revenue
16,400

 
—

 
—

Other revenues
161

 
150

 
124

Total revenues
326,546

 
472,048

 
493,967

Costs and expenses:
 
 
 
 
 
Cost of product sales
107,193

 
215,892

 
161,349

Research and development expenses
64,853

 
44,846

 
75,017

Acquired in-process research and development
74,856

 
32,500

 
65,845

Selling, general and administrative expenses
286,600

 
227,810

 
178,151

Impairment of assets
232,336

 
—

 
319,246

Restructuring expenses
7,420

 
—

 
—

Total costs and expenses
773,258

 
521,048

 
799,608

Operating loss
(446,712
)
 
(49,000
)
 
(305,641
)
Other income (expense):
 
 
 
 
 
Interest expense
(25,709
)
 
(51,971
)
 
(68,382
)
Loss on debt extinguishment
—

 
(35,922
)
 
(10,926
)
Interest and dividend income
4,285

 
5,328

 
2,810

Other income (expense)
428

 
(74
)
 
(70
)
Total other expense, net
(20,996
)
 
(82,639
)
 
(76,568
)
Loss from continuing operations before income taxes
(467,708
)
 
(131,639
)
 
(382,209
)
Income tax (benefit) expense
(47
)
 
40,436

 
(175,521
)
Net loss from continuing operations
$
(467,661
)
 
$
(172,075
)
 
$
(206,688
)
 
 
 
 
 
 
Discontinued operations:
 
 
 
 
 
Income from discontinued operations
$
—

 
$
18,873

 
$
10,313

Gain on sale of CBR business
—

 
87,076

 
—

Income tax expense
—

 
2,371

 
4,388

Net income from discontinued operations
$
—

 
$
103,578

 
$
5,925

 
 
 
 
 
 
Net loss
$
(467,661
)
 
$
(68,497
)
 
$
(200,763
)
 
 
 
 
 
 
Basic and diluted earnings per share:
 
 
 
 
 
Loss from continuing operations
$
(13.74
)
 
$
(5.00
)
 
$
(5.92
)
Income from discontinued operations
—

 
3.01

 
0.17

Total
$
(13.74
)
 
$
(1.99
)
 
$
(5.75
)
 
 
 
 
 
 
Weighted average shares outstanding used to compute earnings per share (basic and diluted):
34,030

 
34,394

 
34,907

The accompanying notes are an integral part of these consolidated financial statements.

30



AMAG PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(IN THOUSANDS)

 
Years Ended December 31,
 
2019
 
2018
 
2017
Net loss
$
(467,661
)
 
$
(68,497
)
 
$
(200,763
)
Other comprehensive income (loss)
 
 
 
 
 
Holding gains (losses) arising during period, net of tax
746

 
(77
)
 
(70
)
Total comprehensive loss
$
(466,915
)
 
$
(68,574
)
 
$
(200,833
)

The accompanying notes are an integral part of these consolidated financial statements.


31



AMAG PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(IN THOUSANDS, EXCEPT SHARES)

 
Common Stock
 
Additional Paid-in Capital
 
Accumulated Other Comprehensive Income (Loss)
 
Accumulated Deficit
 
Total Stockholders’ Equity
 
Shares
 
Amount
Balance at December 31, 2016
34,336,147

 
$
343

 
$
1,238,031

 
$
(3,838
)
 
$
(300,974
)
 
$
933,562

Settlement of warrants
—

 
—

 
323

 
—

 
—

 
323

Equity component of the 2022 Convertible Notes, net of issuance costs and taxes
—

 
—

 
43,236

 
—

 
—

 
43,236

Cumulative effect of previously unrecognized excess tax benefits related to stock compensation
—

 
—

 
—

 
—

 
21,558

 
21,558

Equity component of debt repurchase
—

 
—

 
(27,988
)
 
—

 
—

 
(27,988
)
Shares issued in connection with Endoceutics License Agreement
600,000

 
6

 
13,494

 
—

 
—

 
13,500

Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program
(1,366,266
)
 
(14
)
 
(19,453
)
 
—

 
—

 
(19,467
)
Issuance of common stock under employee stock purchase plan
120,580

 
1

 
1,593

 
—

 
—

 
1,594

Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings
392,651

 
5

 
(1,272
)
 
—

 
—

 
(1,267
)
Non-cash equity based compensation
—

 
—

 
23,664

 
—

 
—

 
23,664

Unrealized losses on securities, net of tax
—

 
—

 
—

 
(70
)
 
—

 
(70
)
Net loss
—

 
—

 
—

 
—

 
(200,763
)
 
(200,763
)
Balance at December 31, 2017
34,083,112

 
341

 
1,271,628

 
(3,908
)
 
(480,179
)
 
787,882

ASC 606 adoption adjustment, net of tax
—

 
—

 
—

 
—

 
1,136

 
1,136

Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings
463,776

 
4

 
275

 
—

 
—

 
279

Issuance of common stock under employee stock purchase plan
59,872

 
1

 
917

 
—

 
—

 
918

Non-cash equity based compensation
—

 
—

 
19,916

 
—

 
—

 
19,916

Unrealized losses on securities, net of tax
—

 
—

 
—

 
(77
)
 
—

 
(77
)
Net loss
—

 
—

 
—

 
—

 
(68,497
)
 
(68,497
)
Balance at December 31, 2018
34,606,760

 
346

 
1,292,736

 
(3,985
)
 
(547,540
)
 
741,557

Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings
281,184

 
3

 
(1,803
)
 
—

 
—

 
(1,800
)
Issuance of common stock under employee stock purchase plan
185,937

 
1

 
1,505

 
—

 
—

 
1,506

Repurchase of common stock pursuant to the share repurchase program
(1,074,800
)
 
(11
)
 
(13,719
)
 
—

 
—

 
(13,730
)
Non-cash equity based compensation
—

 
—

 
19,198

 
—

 
—

 
19,198

Unrealized gains on securities, net of tax
—

 
—

 
—

 
746

 
—

 
746

Net loss
—

 
—

 
—

 
—

 
(467,661
)
 
(467,661
)
Balance at December 31, 2019
33,999,081

 
$
339

 
$
1,297,917

 
$
(3,239
)
 
$
(1,015,201
)
 
$
279,816


The accompanying notes are an integral part of these consolidated financial statements.
 

32



AMAG PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
 
Years Ended December 31,
 
2019
 
2018
 
2017
Cash flows from operating activities:
 
 
 
 
 
Net loss
$
(467,661
)
 
$
(68,497
)
 
$
(200,763
)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
 
 
 
 
 
Depreciation and amortization
27,324

 
172,223

 
155,538

Impairment of long-lived assets
232,336

 
—

 
319,246

Provision for bad debt expense
—

 
678

 
3,852

Amortization of premium/discount on purchased securities
(95
)
 
87

 
302

Write-down of inventory
19,767

 
5,176

 
—

(Gain) loss on disposal of fixed assets
—

 
(99
)
 
265

Non-cash equity-based compensation expense 
19,198

 
19,916

 
23,664

Non-cash IPR&D expense
18,029

 
—

 
945

Loss on debt extinguishment
—

 
35,922

 
10,926

Amortization of debt discount and debt issuance costs
15,242

 
15,658

 
14,395

(Gain) loss on sale of marketable securities, net
(265
)
 
(1
)
 
70

Change in fair value of contingent consideration
(270
)
 
(49,607
)
 
(47,686
)
Deferred income taxes
404

 
41,948

 
(178,688
)
Non-cash lease expense
2,725

 
—

 
—

Gain on sale of the CBR business
—

 
(87,076
)
 
—

Transaction costs
—

 
(14,111
)
 
—

Changes in operating assets and liabilities:
 
 
 
 
 
Accounts receivable, net
(18,816
)
 
16,995

 
(14,978
)
Inventories
(19,253
)
 
(454
)
 
(2,331
)
Prepaid and other current assets
(113
)
 
(6,097
)
 
(2,222
)
Accounts payable and accrued expenses
53,952

 
(30,614
)
 
18,636

Deferred revenues
(6,400
)
 
8,658

 
17,080

Payment of contingent consideration in excess of acquisition date fair value
—

 
—

 
(10,432
)
Other assets and liabilities
(1,800
)
 
95

 
(1,223
)
Net cash (used in) provided by operating activities
(125,696
)
 
60,800

 
106,596

Cash flows from investing activities:
 
 
 
 
 
Proceeds from sales or maturities of marketable securities
98,321

 
85,342

 
294,957

Purchases of marketable securities
(14,815
)
 
(89,956
)
 
(127,249
)
Milestone payment for Vyleesi developed technology
(60,000
)
 
—

 
—

Acquisition of Intrarosa intangible asset
—

 
—

 
(55,800
)
Proceeds from the sale of the CBR business
—

 
519,303

 
—

Note receivable
—

 
(10,000
)
 
—

Capital expenditures
(2,544
)
 
(2,534
)
 
(8,988
)
Net cash provided by investing activities
20,962

 
502,155

 
102,920


The accompanying notes are an integral part of these consolidated financial statements.



33



AMAG PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)
(IN THOUSANDS)
 
Years Ended December 31,
 
2019
 
2018
 
2017
Cash flows from financing activities:
 
 
 
 
 
Long-term debt principal payments
—

 
(475,000
)
 
(353,125
)
Proceeds from 2022 Convertible Notes
—

 
—

 
320,000

Payments to repurchase 2019 Convertible Notes
(21,417
)
 
—

 
(191,730
)
Payment of premium on debt extinguishment
—

 
(28,054
)
 
(625
)
Proceeds to settle warrants
—

 
—

 
323

Payment of convertible debt issuance costs
—

 
—

 
(9,553
)
Payment of contingent consideration
(72
)
 
(119
)
 
(39,793
)
Payments for repurchases of common stock
(13,730
)
 
—

 
(19,466
)
Proceeds from the issuance of common stock under the ESPP
1,506

 
—

 
—

Proceeds from the exercise of common stock options
30

 
3,881

 
3,021

Payments of employee tax withholding related to equity-based compensation
(1,830
)
 
(2,682
)
 
(2,696
)
Net cash used in financing activities
(35,513
)
 
(501,974
)
 
(293,644
)
Net (decrease) increase in cash, cash equivalents and restricted cash
(140,247
)
 
60,981

 
(84,128
)
Cash, cash equivalents and restricted cash at beginning of the year
253,751

 
192,770

 
276,898

Cash, cash equivalents and restricted cash at end of the year
$
113,504

 
$
253,751

 
$
192,770

Supplemental data of cash flow information:
 
 
 
 
 
Cash (refunded) paid for taxes
$
(202
)
 
$
5,345

 
$
5,296

Cash paid for interest
$
10,667

 
$
48,757

 
$
56,959

Non-cash investing and financing activities:
 
 
 
 
 
Right-of-use assets obtained in exchange for lease obligations
$
18,455

 
$
—

 
$
—

Settlement of note receivable in connection with Perosphere acquisition
$
10,000

 
$
—

 
$
—

Fair value of common stock issued in connection with the acquisition of the Intrarosa intangible asset
$
—

 
$
—

 
$
12,555

Contingent consideration accrued for the acquisition of the Intrarosa intangible asset
$
—

 
$
—

 
$
9,300


The accompanying notes are an integral part of these consolidated financial statements.


34



AMAG PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

A.     DESCRIPTION OF BUSINESS
AMAG Pharmaceuticals, Inc., a Delaware corporation, was founded in 1981. We are a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs by leveraging our development and commercial expertise to invest in and grow our pharmaceutical products across a range of therapeutic areas. Our currently marketed products support the health of patients in the areas of hematology and maternal and women’s health, including Feraheme® (ferumoxytol injection) for intravenous use, Makena® (hydroxyprogesterone caproate injection) auto-injector, Intrarosa® (prasterone) vaginal inserts and Vyleesi®(bremelanotide injection). In addition to our marketed products, our portfolio includes two product candidates, AMAG-423 (digoxin immune fab (ovine)), which is being studied for the treatment of severe preeclampsia, and ciraparantag, which is being studied as an anticoagulant reversal agent.

In March 2019, we announced topline results from the Progestin’s Role in Optimizing Neonatal Gestation clinical trial (“PROLONG” or “Trial 003”), a randomized, double-blinded, placebo-controlled clinical trial evaluating Makena in patients with a history of a prior spontaneous singleton preterm delivery. The PROLONG trial was conducted under the U.S. Food and Drug Administration’s (the “FDA”) “Subpart H” accelerated approval process. The approval of Makena was based primarily on the Meis trial (“Trial 002”), which was conducted by the Maternal-Fetal Medicine Units Network, sponsored by the National Institute of Child Health and Human Development. In contrast to the Meis trial, the PROLONG trial did not demonstrate a statistically significant difference between the treatment and placebo arms for the co-primary endpoints. On October 29, 2019, the Advisory Committee met to discuss the results of the PROLONG trial to inform the FDA’s regulatory decision for Makena. Following various presentations by experts and discussions at the meeting, the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee (the “Advisory Committee”) voted as follows: (a) in response to the question “Do the findings from Trial 003 verify the clinical benefits of Makena on neonatal outcomes?”, 16 members voted “No” and no members voted “Yes”; (b) in response to the question “Based on the findings from Trial 002 and Trial 003, is there substantial evidence of effectiveness of Makena in reducing the risk of recurrent preterm birth?”, 13 members voted “No” and three members voted “Yes”; and (c) in response to the question, “Should the FDA (A) pursue withdrawal of approval for Makena, (B) leave Makena on the market under accelerated approval and require a new confirmatory trial, or (C) leave Makena on the market without requiring a new confirmatory trial?”, nine members voted for (A), seven members voted for (B) and no members voted for (C). The FDA is not required to follow the recommendations of its Advisory Committees, but will take them into consideration in deciding what regulatory steps to take with respect to Makena. We are unable to predict the outcome or timing of any FDA action with respect to Makena.

In December 2019 we completed a review of our product portfolio and strategy. This strategic review resulted in our intention to divest Intrarosa® (prasterone) and Vyleesi® (bremelanotide), as announced in January 2020. We determined that these anticipated actions did not result in the related assets meeting the criteria to be recorded as held of sale at December 31, 2019.
We are subject to risks common to companies in the pharmaceutical industry including, but not limited to (as such risks pertain to our business) the impact of any action by the FDA with respect to Makena, including the potential of the removal of Makena’s approval, our ability to successfully divest Intrarosa and Vyleesi, our ability to successfully commercialize our products, intense competition, including from generic products; maintaining and defending the proprietary nature of our technology, including in the event that Sandoz launches a generic version of Feraheme in accordance with the 2018 settlement agreement; our dependence upon third-party manufacturers and our potential inability to obtain raw or other materials and impacts of supply shortages; our reliance on and the extent of reimbursement from third parties for the use of our products, including the impact of generic competitors, Makena’s high Medicaid reimbursement concentration; our ability to expand our product portfolio through business development transactions; the approval of our product candidates and our ability to commercialize such products, if approved; potential litigation, including securities and product liability suits; our ability to work effectively and collaboratively with our licensors and partners; our reliance on other third parties in our business, including to conduct our clinical trials and undertake our product and distribution; our ability to maintain, attract and retain key employees; our potential failure to comply with federal and state healthcare fraud and abuse laws, marketing disclosure laws, or other federal and state laws and regulations and potential civil or criminal penalties as a result thereof; uncertainties regarding reporting and payment obligations under government pricing programs; post-approval commitments for Feraheme; our ability to comply with data protection laws and regulations; the impact of disruptions to our information technology systems; our level of and ability to repay our indebtedness; our access to sufficient capital; the availability of net operating loss carryforwards and other tax assets; potential differences between actual future results and the estimates or assumptions used by us in preparation of our consolidated financial statements, including goodwill and intangible assets; the volatility of our stock price; the potential

35



fluctuation of our operating results; and provisions in our charter, by-laws and certain contracts that discourage an acquisition of our company.

Throughout this Annual Report on Form 10-K, AMAG Pharmaceuticals, Inc. and our consolidated subsidiaries are collectively referred to as “the Company,” “AMAG,” “we,” “us,” or “our.”

B.     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“GAAP”) and include the accounts of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

As of June 30, 2018, our CBR business met the criteria to be classified as a discontinued operation. All historical operating results for CBR are reflected within discontinued operations in the consolidated statements of operations for the years ended December 31, 2018 and 2017. For additional information, see Note C, “Discontinued Operations.”

Use of Estimates and Assumptions

The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent liabilities. The most significant estimates and assumptions are used to determine amounts and values of, but are not limited to: revenue recognition related to product sales revenue; product sales allowances and accruals; allowance for doubtful accounts; marketable securities; inventory; acquisition date fair value and subsequent fair value estimates used to assess impairment of long-lived assets, including goodwill and other intangible assets; debt obligations; certain accrued liabilities, including clinical trial accruals; equity-based compensation expense, and income taxes, inclusive of valuation allowances. Actual results could differ materially from those estimates.

Revenue Recognition

Product revenues
On January 1, 2018, we adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”) applying the modified retrospective transition method to all contracts that were not completed as of January 1, 2018 as an adjustment of $1.1 million to the opening balance of stockholders’ equity at the beginning of 2018. The adjustment recorded was for incremental contract acquisition costs related to the CBR business. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for prior periods. There was no impact to our product revenue as a result of adoption.

Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:

a.Identify the contract(s) with a customer;
b.Identify the performance obligations in the contract;
c.Determine the transaction price;
d.Allocate the transaction price to the performance obligations in the contract; and
e.Recognize revenue when (or as) the performance obligations are satisfied.

We only apply the five step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, if the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.


36



Our major sources of revenue during the reporting periods were product revenues from Makena, Feraheme and Intrarosa. The adoption of ASC 606 in 2018 did not have an impact on the pattern or timing of recognition of our product revenue, as the majority of our product revenue continues to be recognized when the customer takes control of our product.

We receive payments from customers based upon contractual billing schedules; accounts receivable are recorded when the right to consideration becomes unconditional.

Performance Obligations

At contract inception, we assess the goods promised in our contracts with customers and identify a performance obligation for each promise to transfer to the customer a good (or bundle of goods) that is distinct. To identify the performance obligations, we consider all of the goods promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. We determined that the following distinct goods represent separate performance obligations:

•Supply of Makena product
•Supply of Feraheme product
•Supply of Intrarosa product
•Supply of Vyleesi product

We principally sell our products to wholesalers, specialty distributors, specialty pharmacies and other customers (collectively, “Customers”), who purchase products directly from us. Our Customers subsequently resell the products to healthcare providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payers that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products.

For the majority of our Customers, we transfer control at the point in time when the goods are delivered. In instances when we perform shipping and handling activities, these are considered fulfillment activities, and accordingly, the costs are accrued when the related revenue is recognized. Taxes collected from Customers and remitted to governmental authorities are excluded from revenues.

Variable Consideration
Under ASC 606, we are required to make estimates of the net sales price, including estimates of variable consideration (such as rebates, chargebacks, discounts, copay assistance and other deductions), and recognize the estimated amount as revenue, when we transfer control of the product to our customers. Variable consideration must be determined using either an “expected value” or a “most likely amount” method.

We record product revenues net of certain allowances and accruals in our consolidated statements of operations. Product sales allowances and accruals are primarily comprised of both direct and indirect fees, discounts and rebates and provisions for estimated product returns. Direct fees, discounts and rebates are contractual fees and price adjustments payable to Customers that purchase products directly from us. Indirect fees, discounts and rebates are contractual price adjustments payable to healthcare providers and organizations, such as certain physicians, clinics, hospitals, group purchasing organizations (“GPOs”), and dialysis organizations that typically do not purchase products directly from us but rather from wholesalers and specialty distributors. Consideration payable to a Customer, or other parties that purchase goods from a Customer, are considered to be a reduction of the transaction price, and therefore, of revenue.

Product sales allowances and accruals are based on definitive contractual agreements or legal requirements (such as laws and regulations to provide mandatory discounts for sales to government entities) related to the purchase and/or utilization of the product by these entities and are recorded in the same period that the related revenue is recognized. We use the expected value method for estimating variable consideration. We estimate product sales allowances and accruals using either historical, actual and/or other data, including estimated patient usage, applicable contractual rebate rates, contract performance by the benefit providers, other current contractual and statutory requirements, historical market data based upon experience of our products and other products similar to them, specific known market events and trends such as competitive pricing and new product introductions, current and forecasted Customer buying patterns and inventory levels, and the shelf life of our products. As part of this evaluation, we also review changes to federal and other legislation, changes to rebate contracts, changes in the level of discounts, and changes in product sales trends. Although allowances and accruals are recorded at the time of product sale, rebates are typically paid out in arrears, one to three months after the sale. 


37



The estimate of variable consideration, which is included in the transaction price, may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved in a future period. Estimating variable consideration and the related constraint requires the use of significant management judgment and actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. No amounts were constrained as of December 31, 2019.

Discounts

We typically offer a 2% prompt payment discount to certain customers as an incentive to remit payment in accordance with the stated terms of the invoice, generally between 30 to 60 days. Because we anticipate that those customers who are offered this discount will take advantage of the discount, 100% of the prompt payment discount at the time of sale is accrued for eligible customers, based on the gross amount of each invoice. We adjust the accrual quarterly to reflect actual experience.

Chargebacks

Chargeback reserves represent the estimated obligations resulting from the difference between the prices at which we sell our products to wholesalers and the sales price ultimately paid to wholesalers under fixed price contracts by third-party payers, including governmental agencies. The chargeback estimates are determined based on actual product sales data and forecasted customer buying patterns. Actual chargeback amounts are determined at the time of resale to the qualified healthcare provider, and we generally issue credits for such amounts within several weeks of receiving notification from the wholesaler. Estimated chargeback amounts are recorded at the time of sale and adjusted quarterly to reflect actual experience.

Distributor/Wholesaler and Group Purchasing Organization Fees

Fees under arrangements with distributors and wholesalers are usually based upon units of product purchased during the prior month or quarter and are usually paid by us within several weeks of the receipt of an invoice from the wholesaler or distributor. Fees under arrangements with GPOs are usually based upon member purchases during the prior quarter and are generally billed by the GPO within 30 days after period end. In accordance with ASC 606, since the consideration given to the Customer is not for a distinct good or service, the consideration is a reduction of the transaction price of the vendor’s products or services. We have included these fees in contractual adjustments in the table above. We generally pay such amounts within several weeks of the receipt of an invoice from the distributor, wholesaler or GPO. Accordingly, we accrue the estimated fee due at the time of sale, based on the contracted price invoiced to the Customer. We adjust the accrual quarterly to reflect actual experience.

Product Returns

Consistent with industry practice, we generally offer wholesalers, specialty distributors and other customers a limited right to return our products based on the product’s expiration date. The current shelf-lives or time between manufacture and expiration for products in our portfolio range from three to five years. Product returns are estimated based on the historical return patterns and known or expected changes in the marketplace. We track actual returns by individual production lots. Returns on lots eligible for credits under our returned goods policy are monitored and compared with historical return trends and rates. We expect that wholesalers and healthcare providers will not stock significant inventory due to the cost of the product, the expense to store our products, and/or that our products are readily available for distribution. We record an estimate of returns at the time of sale. If necessary, our estimated rate of returns may be adjusted for actual return experience as it becomes available and for known or expected changes in the marketplace. There were no material adjustments to our reserve for product returns during the years ended December 31, 2019, 2018 or 2017. To date, our product returns have been relatively limited; however, returns experience may change over time. We may be required to make future adjustments to our product returns estimate, which would result in a corresponding change to our net product sales in the period of adjustment and could be significant.

Sales Rebates

We contract with various private payer organizations, primarily pharmacy benefit managers, for the payment of rebates with respect to utilization of our products. We determine our estimates for rebates, if applicable, based on actual product sales data and our historical product claims experience. Rebate amounts generally are invoiced quarterly and are paid in arrears, and we expect to pay such amounts within several weeks of notification by the provider. We regularly assess our reserve balance and the rate at which we accrue for claims against product sales. If we determine in future periods that our actual rebate

38



experience is not indicative of expected claims, if actual claims experience changes, or if other factors affect estimated claims rates, we may be required to adjust our current accumulated reserve estimate, which would affect net product sales in the period of the adjustment and could be significant.

Governmental Rebates

Governmental rebates relate to our reimbursement arrangements with state Medicaid programs. We determine our estimates for Medicaid rebates, if applicable, based on actual product sales data and our historical product claims experience. In estimating these reserves, we provide for a Medicaid rebate associated with both those expected instances where Medicaid will act as the primary insurer as well as in those instances where we expect Medicaid will act as the secondary insurer. Rebate amounts generally are invoiced quarterly and are paid in arrears, and we expect to pay such amounts within several weeks of notification by the Medicaid or provider entity. We regularly assess our Medicaid reserve balance and the rate at which we accrue for claims against product sales. If we determine in future periods that our actual rebate experience is not indicative of expected claims, if actual claims experience changes, or if other factors affect estimated claims rates, we may be required to adjust our current Medicaid accumulated reserve estimate, which would affect net product sales in the period of the adjustment and could be significant.

Other Discounts
Other discounts which we offer include voluntary patient assistance programs, such as copay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug copayments required by payers. The calculation of the accrual for copay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with product that has been recognized as revenue.

Collaboration Revenues

When we enter into collaboration agreements, we assess whether the agreements fall within the scope of ASC Topic 808, Collaborative Arrangements (“ASC 808”) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606. However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the related underlying expense.

Cash and Cash Equivalents

Cash and cash equivalents consist principally of cash held in commercial bank accounts, money market funds and U.S. treasury securities having an original maturity of less than three months at the date of acquisition. We consider all highly liquid marketable securities with a maturity of three months or less as of the acquisition date to be cash equivalents. At December 31, 2019 and 2018, substantially all of our cash and cash equivalents were held in either commercial bank accounts or money market funds.

Concentrations and Significant Customer Information

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and cash equivalents, marketable securities, and accounts receivable. We currently hold our excess cash primarily in institutional money market funds, corporate debt securities, U.S. treasury and government agency securities and certificates of deposit. As of December 31, 2019, we did not have a material concentration in any single investment.


39



Our operations are located entirely within the U.S. We focus primarily on developing, manufacturing, and commercializing our products and product candidates. The following table sets forth customers who represented 10% or more of our total revenues for 2019, 2018 and 2017:
 
Years Ended December 31,
 
2019
 
2018
 
2017
McKesson Corporation
36%
 
26%
 
24%
AmerisourceBergen Drug Corporation
28%
 
27%
 
26%
Cardinal Health
13%
 
< 10%
 
< 10%

 
Our net accounts receivable primarily represent amounts due for products sold directly to wholesalers, distributors and specialty pharmacies. Accounts receivable for our products are recorded net of reserves for estimated chargeback obligations, prompt payment discounts and any allowance for doubtful accounts.
As part of our credit management policy, we perform ongoing credit evaluations of our customers, and we generally do not require collateral. If the financial condition of any of our significant product sales customers was to deteriorate and result in an impairment of its ability to make payments owed to us, an allowance for doubtful accounts may be required which could have a material effect on earnings in the period of any such adjustment. We did not experience any significant bad debts and have not established an allowance for doubtful accounts as of December 31, 2019 and 2018.
At December 31, 2019 and 2018, three customers accounted for 10% or more of our accounts receivable balance, representing approximately 85% and 73% in the aggregate of our total accounts receivable, respectively.
 
We are currently dependent on a single supplier for certain of our manufacturing processes, including Feraheme drug substance (produced in two separate facilities) and a single supplier for our Makena auto-injector product. We have been and may continue to be exposed to a significant loss of revenue from the sale of our products in the event that our suppliers and/or manufacturers are not able to fulfill demand for any reason.
Fair Value Measurements

We apply the provisions of ASC Topic 820, Fair Value Measurements (“ASC 820”) for our financial assets and liabilities that are re-measured and reported at fair value each reporting period and our nonfinancial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis, including property and equipment and identifiable intangible assets. Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, we consider the principal or most advantageous market in which it would transact and consider assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. Financial assets and liabilities are categorized within the valuation hierarchy based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•
Level 1- Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•
Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•
Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Marketable Securities

We account for and classify our marketable securities as either “available-for-sale,” “held-to-maturity,” or “trading debt securities,” in accordance with the accounting guidance related to the accounting and classification of certain investments in marketable securities. The determination of the appropriate classification by us is based primarily on management’s ability and intent to sell the debt security at the time of purchase. As of December 31, 2019 and 2018, all of our marketable securities were classified as available-for-sale.

Available-for-sale securities are those securities which we view as available for use in current operations, if needed. We generally classify our available-for-sale securities as short-term investments, even though the stated maturity date may be one year or more beyond the current balance sheet date. Available-for-sale marketable securities are stated at fair value with their

40



unrealized gains and losses included in accumulated other comprehensive income (loss) within the consolidated statements of stockholders’ equity, until such gains and losses are realized in other income (expense) within the consolidated statements of operations or until an unrealized loss is considered other-than-temporary.

We recognize other-than-temporary impairments of our marketable securities when there is a decline in fair value below the amortized cost basis and if (a) we have the intent to sell the security or (b) it is more likely than not that we will be required to sell the security prior to recovery of its amortized cost basis. If either of these conditions is met, we recognize the difference between the amortized cost basis of the security and its fair value at the impairment measurement date in our consolidated statements of operations. If neither of these conditions is met, we must perform additional analysis to evaluate whether the unrealized loss is associated with the creditworthiness of the issuer of the security rather than other factors, such as interest rates or market factors. If we determine from this analysis that we do not expect to receive cash flows sufficient to recover the entire amortized cost of the security, a credit loss exists, the impairment is considered other-than-temporary and is recognized in our consolidated statements of operations.

Inventory

Inventory is stated at the lower of cost or net realizable value, with approximate cost being determined on a first-in, first-out basis. Prior to initial approval from the FDA or other regulatory agencies, we expense costs relating to the production of inventory in the period incurred, unless we believe regulatory approval and subsequent commercialization of the product candidate is probable and we expect the future economic benefit from sales of the product to be realized, at which point we capitalize the costs as inventory. We assess any costs capitalized prior to regulatory approval each quarter for indicators of impairment, such as a reduced likelihood of approval. We expense costs associated with clinical trial material as research and development expense.

On a quarterly basis, we analyze our inventory levels to determine whether we have any obsolete, expired, or excess inventory. If any inventory is expected to expire prior to being sold, has a cost basis in excess of its net realizable value, is in excess of expected sales requirements as determined by internal sales forecasts, or fails to meet commercial sale specifications, the inventory is written-down through a charge to cost of product sales. The determination of whether inventory costs will be realizable requires estimates by management of future expected inventory requirements, based on sales forecasts. Once packaged, our products have a shelf-life ranging from three to five years. As a result of comparison to internal sales forecasts, we expect to fully realize the carrying value of our finished goods inventory. If actual market conditions are less favorable than those projected by management, inventory write-downs may be required. Charges for inventory write-downs are not reversed if it is later determined that the product is saleable.

Property and Equipment, Net

Property and equipment are recorded at cost and depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:
 
Useful Life
Computer equipment and software
5 Years
Furniture and fixtures
5 Years
Leasehold improvements
Lesser of Lease or Asset Life
Laboratory and production equipment
5 Years


Costs for capital assets not yet placed in service are capitalized on our balance sheets and will be depreciated in accordance with the above guidelines once placed into service. Costs for maintenance and repairs are expensed as incurred. Upon sale or other disposition of property and equipment, the cost and related depreciation are removed from the accounts and any resulting gain or loss is charged to our consolidated statements of operations. Assets classified as held for sale are no longer subject to depreciation and are recorded at the lower of carrying value or estimated net realizable value.

Intangible Assets

We amortize our intangible assets that have finite lives based on either the straight-line method, or if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be utilized.

If we acquire an asset or a group of assets that do not meet the definition of a business, the acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.

41




Impairment of Long-Lived Assets

We review our long-lived assets, which includes property and equipment and identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. To evaluate recoverability, management compares the projected undiscounted future cash flows associated with the asset or asset group, including proceeds from its eventual disposition over its estimated useful life against its carrying amount. If the undiscounted cash flows are not sufficient to recover the carrying value of the asset or asset group, the asset or asset group is considered impaired. The impairment loss, if any, is measured as the excess of the carrying amount of the asset or asset group over its estimated fair value, which is typically calculated utilizing a discounted cash flow (“DCF”) model following the same methodology as described in the following section.

Goodwill
We test goodwill at the reporting unit level for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that could indicate impairment and trigger an interim impairment assessment include, but are not limited to, an adverse change in current economic and market conditions, including a significant prolonged decline in market capitalization, a significant adverse change in legal factors, unexpected adverse business conditions, and an adverse action or assessment by a regulator. Our annual impairment test date is October 31. We have determined that we operate in a single operating segment and have a single reporting unit.
In performing our goodwill impairment tests, we utilize the approach prescribed under Accounting Standards Codification (“ASC”) 350, as amended by Accounting Standards Update (“ASU”) 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”), which requires that an entity perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value.
When we perform any goodwill impairment test, the estimated fair value of our reporting unit is determined using an income approach that utilizes a DCF model or a market approach, when appropriate, which assesses our market capitalization as adjusted for a control premium, or a combination thereof.
Under the market approach, when our carrying value exceeds our market capitalization, we consider a control premium for purposes of estimating the fair value of our reporting unit, as we believe that a market participant buyer would be required to pay a control premium for our business. The control premium utilized is based on control premiums observed in recent comparable market transactions. As described in the accounting guidance for evaluating long-lived assets for impairment, an entity’s fair value may include a control premium in addition to the quoted market price to determine the fair value of a single reporting unit entity, as an acquiring entity is often willing to pay more for equity securities that give it a controlling interest than an investor would pay for a number of equity securities representing less than a controlling interest. This accounting guidance also indicates that the quoted market price of an individual security need not be the sole measurement basis of the fair value of a single reporting unit. When our market capitalization exceeds our carrying value, we utilize our market capitalization as the indicator of fair value in our impairment test.
Under the income approach, the DCF model is based upon expected future after-tax operating cash flows of the reporting unit discounted to a present value using a risk-adjusted discount rate. Estimates of future cash flows require management to make significant assumptions concerning (i) future operating performance, including future sales, long-term growth rates, operating margins, variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows (ii) the probability of regulatory approvals, and (iii) future economic conditions, all of which may differ from actual future cash flows. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rate, which is intended to reflect the risks inherent in future cash flow projections, used in the DCF model, is based on estimates of the weighted average cost of capital (“WACC”) of market participants relative to our reporting unit. Financial and credit market volatility can directly impact certain inputs and assumptions used to develop the WACC. Any changes in these assumptions may affect our fair value estimate and the result of an impairment test. The discount rates and other inputs and assumptions are consistent with those that a market participant would use. In addition, in order to assess the reasonableness of the fair value of our reporting unit as calculated under the DCF model, we also compare the reporting unit’s fair value to our market capitalization and calculate an implied control premium (the excess sum of the reporting unit’s fair value over its market capitalization). We evaluate the implied control premium by comparing it to control premiums of recent comparable market transactions, as applicable.

42




Business Combinations and Asset Acquisitions

The purchase price allocation for business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values. Under ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business (“2017-01”), we first determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the single asset or group of assets, as applicable, is not a business.

We account for acquired businesses using the acquisition method of accounting, under which the total purchase price of an acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. Acquisition-related costs are expensed as incurred. Any excess of the consideration transferred over the estimated fair values of the identifiable net assets acquired is recorded as goodwill.

The purchase price allocations for business combinations are initially prepared on a preliminary basis and are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. Any adjustments to the purchase price allocations are made as soon as practicable but no later than one year from the acquisition date.

Acquired inventory is recorded at its fair value, which may require a step-up adjustment to recognize the inventory at its expected net realizable value. The inventory step-up is recorded to cost of product sales in our consolidated statements of operations when related inventory is sold, and we record step-up costs associated with clinical trial material as research and development expense.

Acquisition-Related Contingent Consideration

Contingent consideration arising from a business combination is included as part of the purchase price and is recognized at its estimated fair value as of the acquisition date. Subsequent to the acquisition date, we measure contingent consideration arrangements at fair value for each period until the contingency is resolved. These changes in fair value are recognized in selling, general and administrative expenses in our consolidated statements of operations. Changes in fair values reflect new information about the likelihood of the payment of the contingent consideration and the passage of time. For asset acquisitions, we record contingent consideration for obligations we consider to be probable and estimable and these liabilities are not adjusted to fair value.

Leases

Effective January 1, 2019, we adopted ASC Topic 842, Leases (“ASC 842”), and chose to apply the provisions of ASC 842 as of the effective date with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected to utilize the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also made accounting policy elections to not separate lease and non-lease components for our real estate lease and to not recognize leases with an initial term of twelve months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis on our consolidated statements of income over the lease term. We did not have any material short-term leases accounted for under this policy during the year ended December 31, 2019.
We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liability, and long-term operating lease liability on our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease.
ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Our incremental borrowing rate is determined based on an evaluation of our creditworthiness and the prevailing market rates for collateralized debt with maturity dates commensurate with the term of each lease. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option. Lease expense for operating leases is recognized on a straight-line basis over the lease term.

43



The lease payments used to determine our ROU assets may include lease incentives, stated rent increases, and escalation clauses linked to rates of inflation when determinable and are recognized in our ROU assets on our consolidated balance sheet. In addition, certain lease agreements contain lease and non-lease components. With the exception of our real estate leases, we separate lease payments for the identified assets from any non-lease payments included in the agreement. For our real estate leases, we account for the lease and non-lease components as a single lease component. Additionally, for vehicle and certain equipment leases, we apply a portfolio approach to effectively account for the related ROU assets and operating lease liabilities.

Restricted Cash

We classified $0.5 million of our cash as restricted cash, a non-current asset on the balance sheet, as of December 31, 2019 and 2018. This amount represented the security deposit delivered to the landlord of our Waltham, Massachusetts headquarters.

Research and Development Expenses

Research and development expenses include both external and internal expenses. External expenses primarily include costs of clinical trials and fees paid to contract research organizations (“CROs”), clinical supply and manufacturing expenses, regulatory filing fees, consulting and professional fees as well as other general costs related to the execution of research and development activities. Internal expenses primarily include compensation of employees engaged in research and development activities. Research and development expenses are expensed as incurred. Manufacturing costs are generally expensed as incurred until a product has received the necessary initial regulatory approval.

Patents

We expense all patent-related costs in selling, general and administrative expenses as incurred.

Advertising Costs

Advertising costs are expensed as incurred and included in selling, general and administrative expenses in our consolidated statements of operations. Advertising costs, including promotional expenses, costs related to digital marketing and print media advertising space were $53.3 million, $29.8 million and $9.1 million for the years ended December 31, 2019, 2018 and 2017, respectively.

Equity-Based Compensation

Equity-based compensation cost is generally measured at the estimated grant date fair value and recorded to expense over the requisite service period, which is generally the vesting period. Because equity-based compensation expense is based on awards ultimately expected to vest, we must make certain judgments about whether employees, officers, directors, consultants and advisers will complete the requisite service period, and reduce the compensation expense being recognized for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based upon historical experience and adjusted for unusual events such as corporate restructurings, which can result in higher than expected turnover and forfeitures. If factors change and we employ different assumptions in future periods, the compensation expense that we record in the future may differ significantly from what we have recorded in the current period.

We estimate the fair value of equity-based compensation involving stock options based on the Black-Scholes option pricing model. This model requires the input of several factors such as the expected option term, the expected risk-free interest rate over the expected option term, the expected volatility of our stock price over the expected option term and the expected dividend yield over the expected option term and are subject to various assumptions. The fair value of awards calculated using the Black-Scholes option pricing model is generally amortized on a straight-line basis over the requisite service period, and is recognized based on the proportionate amount of the requisite service period that has been rendered during each reporting period.

We estimate the fair value of our restricted stock units (“RSUs”) whose vesting is contingent upon market conditions, such as total shareholder return, using the Monte-Carlo simulation model. The fair value of RSUs where vesting is contingent upon market conditions is amortized based upon the estimated derived service period. The fair value of RSUs granted to our employees and directors whose vesting is dependent on future service is determined based upon the quoted closing market price per share on the date of grant, adjusted for estimated forfeitures.


44



We believe our valuation methodologies are appropriate for estimating the fair value of the equity awards we grant to our employees and directors. Our equity award valuations are estimates and may not be reflective of actual future results or amounts ultimately realized by recipients of these grants. These amounts are subject to future quarterly adjustments based upon a variety of factors, which include, but are not limited to, changes in estimated forfeiture rates and the issuance of new equity-based awards.

Income Taxes

We use the asset and liability method of accounting for deferred income taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A deferred tax asset is established for the expected future benefit of net operating loss (“NOL”) and credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance against net deferred tax assets is required if, based on available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Significant judgments, estimates and assumptions regarding future events, such as the amount, timing and character of income, deductions and tax credits, are required in the determination of our provision for income taxes and whether valuation allowances are required against deferred tax assets. In evaluating our ability to recover our deferred tax assets, we consider all available evidence, both positive and negative, including the existence of taxable temporary differences, our past operating results, the existence of cumulative income in the most recent fiscal years, changes in the business in which we operate and our forecast of future taxable income. In determining future taxable income, we are responsible for assumptions utilized including the amount of state and federal operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income. As of December 31, 2019, we have established a valuation allowance on our net deferred tax assets other than refundable alternative minimum tax (“AMT”) credits to the extent that our existing taxable temporary differences would not be available as a source of income to realize the benefits of those deferred tax assets.

We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position. We evaluate uncertain tax positions on a quarterly basis and adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could impact our income tax provision in future periods. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as a provision for income tax in our consolidated statement of operations.

Comprehensive Loss

Our comprehensive loss consists of net loss and other comprehensive loss. Other comprehensive loss includes changes in equity that are excluded from net loss, which for all periods presented in these consolidated financial statements related to unrealized holding gains and losses on available-for-sale marketable securities, net of tax.

Basic and Diluted Earnings per Share

We compute basic earnings per share by dividing earnings by the weighted average number of common shares outstanding during the relevant period. Diluted earnings per share is computed by dividing earnings by the diluted number of common shares outstanding during the period. Except where the result would be antidilutive, diluted earnings per common share would be computed assuming the impact of the conversion of the 3.25% convertible senior notes due in 2022 (the “2022 Convertible Notes”), the exercise of outstanding stock options and the vesting of RSUs.
We have a choice to settle the conversion obligation of our 2022 Convertible Notes (the “2022 Convertible Notes”) in cash, shares or any combination of the two. Our policy is to settle the principal balance of the 2022 Convertible Notes in cash. As such, we apply the treasury stock method to these securities and the dilution related to the conversion premium, if any, of the 2022 Convertible Notes is included in the calculation of diluted weighted-average shares outstanding to the extent the issuance is dilutive based on the average stock price during each reporting period being greater than the conversion price of the 2022 Convertible Notes.

45



The components of basic and diluted earnings per share for 2019, 2018 and 2017 were as follows (in thousands, except per share data):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Net loss from continuing operations
$
(467,661
)
 
$
(172,075
)
 
$
(206,688
)
Net income from discontinued operations
—

 
103,578

 
5,925

 
 

 
 

 
 

Weighted average common shares outstanding
34,030

 
34,394

 
34,907

Effect of dilutive securities:
 

 
 

 
 

Stock options and RSUs
—

 
—

 
—

Shares used in calculating dilutive net loss per share
34,030

 
34,394

 
34,907

 
 

 
 

 
 

Basic and diluted earnings per share:
 

 
 

 
 

Loss from continuing operations
$
(13.74
)
 
$
(5.00
)
 
$
(5.92
)
Income from discontinued operations
—

 
3.01

 
0.17

Total
$
(13.74
)
 
$
(1.99
)
 
$
(5.75
)

 
The following table sets forth the potential common shares issuable upon the exercise of outstanding options, the vesting of RSUs and the conversion of the Convertible Notes (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Options to purchase shares of common stock
3,976

 
3,797

 
3,531

Shares of common stock issuable upon the vesting of RSUs
1,579

 
1,129

 
1,070

Warrants
—

 
1,008

 
1,008

2022 Convertible Notes
11,695

 
11,695

 
11,695

2019 Convertible Notes
—

 
790

 
790

Shares of common stock under employee stock purchase plan
—

 
81

—
—

Total
17,250

 
18,500

 
18,094


 In connection with the issuance of the 2019 Convertible Notes, in February 2014, we entered into convertible bond hedges with certain financial institutions. The convertible bond hedges were not included for purposes of calculating the number of diluted shares outstanding, as their effect would be anti-dilutive. The convertible bond hedges and warrants expired in February 2019 in conjunction with the settlement of the 2019 Convertible Notes.

Business Segments
We have determined that we conduct our operations in one business segment: the manufacture, development and commercialization of products for use in treating various conditions, with a focus on maternal and women’s health and anemia management. Long-lived assets consist entirely of intangible assets, property and equipment and are located in the U.S. for all periods presented.  
Immaterial Revision of Prior Period Financial Information
Prior period amounts, specifically net product sales and accrued expenses have been revised to correct a prior period error related to gross-to-net (“GTN”) adjustments for governmental rebates and the related accrual for a certain state program. Refer to Note X, “Revision of Prior Period Financial Statements” for further detail.
C.    DISCONTINUED OPERATIONS
On August 6, 2018, we completed the sale of our CBR business to GI Partners pursuant to the CBR Purchase Agreement. We determined that the sale of CBR represented a strategic shift that would have a major effect on our business and therefore met the criteria for classification as discontinued operations at June 30, 2018. All historical operating results for CBR were reflected within discontinued operations in the consolidated statements of operations for the years ended December 31, 2018 and 2017.

46



The following is a summary of net income from discontinued operations for the years ended December 31, 2018 and 2017:    
 
Years Ended December 31,
 
2018
 
2017
Service revenues, net
$
71,217

 
$
114,177

Costs and expenses:
 
 
 
Cost of services
12,559

 
21,817

Selling, general and administrative expenses
39,899

 
81,782

Total costs and expenses
52,458

 
103,599

Operating income
18,759

 
10,578

Other income (expense)
114

 
(265
)
Income from discontinued operations
18,873

 
10,313

Gain on sale of CBR business
87,076

 
—

Income tax expense
2,371

 
4,388

Net income from discontinued operations
$
103,578

 
$
5,925



The cash flows related to discontinued operations have not been segregated and are included in the consolidated statements of cash flows for the years ended December 31, 2018 and 2017. For the years ended December 31, 2018 and 2017, capital expenditures related to the CBR business were $1.6 million and $4.9 million, respectively. Depreciation and amortization expense related to the CBR business for the same periods was $8.4 million and $21.7 million, respectively. Excluding the gain of $87.1 million recognized on the sale of the CBR business and the related transaction expenses of $14.1 million presented in the consolidated statements of cash flows for the year ended December 31, 2018, there were no other significant operating or investing non-cash items related to the CBR business for any period presented.

D.    REVENUE RECOGNITION
Product Revenue

The following table provides information about disaggregated revenue by product for the years ended December 31, 2019, 2018 and 2017 (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Product sales, net
 
 
 
 
 
Makena
$
120,859

 
$
320,311

 
$
385,356

Feraheme
167,947

 
135,001

 
105,930

Intrarosa
21,417

 
16,218

 
1,816

Other
(238
)
 
368

 
741

Total
$
309,985

 
$
471,898

 
$
493,843


Total gross product sales were offset by product sales allowances and accruals for the years ended December 31, 2019, 2018 and 2017 as follows (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Gross product sales
$
955,693

 
$
974,330

 
$
920,061

Provision for product sales allowances and accruals:
 
 
 
 
 
Contractual adjustments
530,645

 
387,540

 
310,588

Governmental rebates
115,063

 
114,892

 
115,630

Total
645,708

 
502,432

 
426,218

Product sales, net
$
309,985

 
$
471,898

 
$
493,843



47




The following table summarizes the product revenue allowance and accrual activity for the years ended December 31, 2019, 2018 and 2017 (in thousands):
 
Contractual
 
Governmental
 
 
 
Adjustments
 
Rebates
 
Total
Balance at January 1, 2017
$
47,600

 
$
52,741

 
$
100,341

Current provisions relating to sales in current year
314,537

 
113,969

 
428,506

Adjustments relating to sales in prior years
(3,949
)
 
1,661

 
(2,288
)
Payments/returns relating to sales in current year
(253,545
)
 
(61,569
)
 
(315,114
)
Payments/returns relating to sales in prior years
(42,479
)
 
(53,060
)
 
(95,539
)
Balance at December 31, 2017
62,164

 
53,742

 
115,906

Current provisions relating to sales in current year
389,861

 
106,988

 
496,849

Adjustments relating to sales in prior years
(2,330
)
 
7,903

 
5,573

Payments/returns relating to sales in current year
(333,694
)
 
(75,920
)
 
(409,614
)
Payments/returns relating to sales in prior years
(58,802
)
 
(58,501
)
 
(117,303
)
Balance at December 31, 2018
57,199

 
34,212

 
91,411

Provisions related to current period sales
521,916

 
100,926

 
622,842

Adjustments related to prior period sales
8,774

 
14,137

 
22,911

Payments/returns relating to current period sales
(431,014
)
 
(60,218
)
 
(491,232
)
Payments/returns relating to prior period sales
(61,654
)
 
(41,435
)
 
(103,089
)
Balance at December 31, 2019
$
95,221

 
$
47,622

 
$
142,843



During the year ended December 31, 2019, we recorded adjustments of $14.1 million for Medicaid rebate claims received that related to prior period sales and $8.8 million for contractual adjustments related to prior period sales. We concluded that these adjustments represented changes in estimate during the year ended December 31, 2019 due to higher Medicaid and payer utilization and subsequent rebate obligations than anticipated based on our historical experience.

Collaboration Revenue

During the first quarter of 2019, in conjunction with the Perosphere transaction, we assumed responsibility for a clinical trial collaboration agreement with a pharmaceutical company. This agreement provided for milestone payments to us, provided we met certain clinical obligations in connection with our ciraparantag program. We also acquired $6.4 million of deferred revenue related to this agreement, which represented the fair value of our remaining performance obligations associated with upfront milestone payments received by Perosphere under this agreement prior to acquisition. We accounted for this agreement under ASC 606.

During the fourth quarter of 2019, we entered into a termination and settlement agreement (the “Termination Agreement”) with the pharmaceutical company which provided for a $10.0 million termination payment to us and stated that no party had any remaining performance obligations effective as of the termination date. The $10.0 million termination payment was received during the fourth quarter of 2019. Under ASC 606, the Termination Agreement met the definition of a contract modification and was accounted for as a cumulative catch-up adjustment at the time of modification.
During the year ended December 31, 2019, the $10.0 million termination payment and $6.4 million of deferred revenue were recognized as collaboration revenue in our consolidated statements of operations.

E.    MARKETABLE SECURITIES
As of December 31, 2019 and 2018, our marketable securities consisted of securities classified as available-for-sale in accordance with accounting standards which provide guidance related to accounting and classification of certain investments in marketable securities.

48



The following is a summary of our marketable securities as of December 31, 2019 and 2018 (in thousands):
 
December 31, 2019
 
 
 
Gross
 
Gross
 
Estimated
 
Amortized
 
Unrealized
 
Unrealized
 
Fair
Description of Securities:
Cost
 
Gains
 
Losses
 
Value
Short-term investments:*
 
 
 
 
 
 
 
Corporate debt securities
$
46,186

 
$
140

 
$
(2
)
 
$
46,324

U.S. treasury and government agency securities
2,750

 
—

 
—

 
2,750

Certificates of deposit
1,500

 
—

 
—

 
1,500

Total short-term investments
50,436

 
140

 
(2
)
 
50,574

Long-term investments:**
 
 
 
 
 
 
 
Corporate debt securities
8,016

 
152

 
—

 
8,168

Total long-term investments
8,016

 
152

 
—

 
8,168

Total investments
$
58,452

 
$
292

 
$
(2
)
 
$
58,742

 
 
December 31, 2018
 
 
 
Gross
 
Gross
 
Estimated
 
Amortized
 
Unrealized
 
Unrealized
 
Fair
Description of Securities:
Cost
 
Gains
 
Losses
 
Value
Short-term investments:*
 
 
 
 
 
 
 
Corporate debt securities
$
51,184

 
$
—

 
$
(236
)
 
$
50,948

U.S. treasury and government agency securities
7,647

 
—

 
(34
)
 
7,613

Commercial paper
3,995

 
—

 
—

 
3,995

Certificates of deposit
12,000

 
—

 
—

 
12,000

Total short-term investments
74,826

 
—

 
(270
)
 
74,556

Long-term investments:**
 
 
 
 
 
 
 
Corporate debt securities
62,530

 
52

 
(433
)
 
62,149

U.S. treasury and government agency securities
2,742

 
—

 
(32
)
 
2,710

Certificates of deposit
1,500

 
—

 
—

 
1,500

Total long-term investments
66,772

 
52

 
(465
)
 
66,359

Total investments
$
141,598

 
$
52

 
$
(735
)
 
$
140,915



* Represents marketable securities with a remaining maturity of less than one year.
** Represents marketable securities with a remaining maturity of one to three years classified as short-term on our consolidated balance sheets.
 
Impairments and Unrealized Gains and Losses on Marketable Securities
We did not recognize any other-than-temporary impairment losses in our consolidated statements of operations related to our marketable securities during 2019, 2018 or 2017. We considered various factors, including the length of time that each security was in an unrealized loss position and our ability and intent to hold these securities until recovery of their amortized cost basis occurs. As of December 31, 2019, we have no material losses in an unrealized loss position for more than one year. Future events may occur, or additional information may become available, which may cause us to identify credit losses where we do not expect to receive cash flows sufficient to recover the entire amortized cost basis of a security and may necessitate the recording of future realized losses on securities in our portfolio. Significant losses in the estimated fair values of our marketable securities could have a material adverse effect on our earnings in future periods.


49



F.     FAIR VALUE MEASUREMENTS
The following tables present information about our assets and liabilities that we measure at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques utilized to determine such fair value as of December 31, 2019 and 2018 (in thousands):
 
Fair Value Measurements at December 31, 2019 Using:
 
Total
 
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Cash equivalents
$
13,732

 
$
13,732

 
$
—

 
$
—

Corporate debt securities
54,492

 
—

 
54,492

 
—

U.S. treasury and government agency securities
2,750

 
—

 
2,750

 
—

Certificates of deposit
1,500

 
—

 
1,500

 
—

Total Assets
$
72,474

 
$
13,732

 
$
58,742

 
$
—

Liabilities:
 

 
 

 
 

 
 

Contingent consideration
17

 
—

 
—

 
17

Total Liabilities
$
17

 
$
—

 
$
—

 
$
17

 
Fair Value Measurements at December 31, 2018 Using:
 
Total
 
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Cash equivalents
$
71,568

 
$
71,568

 
$
—

 
$
—

Corporate debt securities
113,097

 
—

 
113,097

 
—

U.S. treasury and government agency securities
10,323

 
—

 
10,323

 
—

Commercial paper
3,995

 
—

 
3,995

 
—

Certificates of deposit
13,500

 
—

 
13,500

 
—

Total Assets
$
212,483

 
$
71,568

 
$
140,915

 
$
—

Liabilities:
 
 
 
 
 
 
 
Contingent consideration
359

 
—

 
—

 
359

Total Liabilities
$
359

 
$
—

 
$
—

 
$
359


Cash equivalents

Our cash equivalents are classified as Level 1 assets under the fair value hierarchy as these assets have been valued using quoted market prices in active markets and do not have any restrictions on redemption. As of December 31, 2019 and 2018, cash equivalents were comprised of funds in money market accounts.
Marketable securities
Our marketable securities are classified as Level 2 assets under the fair value hierarchy as these assets were primarily determined from independent pricing services, which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based upon other significant observable market transactions. At the end of each reporting period, we perform quantitative and qualitative analysis of prices received from third parties to determine whether prices are reasonable estimates of fair value. After completing our analysis, we did not adjust or override any fair value measurements provided by our pricing services as of December 31, 2019 or 2018. In addition, there were no transfers or reclassifications of any securities between Level 1 and Level 2 during 2019 or 2018.

50



Contingent consideration
In accordance with GAAP, for asset acquisitions, we record contingent consideration for obligations we consider to be probable and estimable and these liabilities are not adjusted to fair value. As of December 31, 2019 and December 31, 2018, no contingent consideration was recorded in accrued expenses.
We recorded contingent consideration related to the November 2014 acquisition of Lumara Health Inc. (“Lumara Health”) for our Makena product and related to our June 2013 license agreement for MuGard® Mucoadhesive Oral Wound Rinse (the “MuGard License Agreement”) with Abeona Therapeutics, Inc. (“Abeona”), under which we acquired the U.S. commercial rights for the management of oral mucositis and stomatitis (the “MuGard Rights”).
The fair value measurements of contingent consideration obligations and the related intangible assets arising from business combinations are classified as Level 3 under the fair value hierarchy as they have been valued using unobservable inputs. These inputs include: (a) the estimated amount and timing of projected cash flows; (b) the probability of the achievement of the factors on which the contingency is based; and (c) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement.
During 2018, we reduced the fair value of our contingent consideration liability by approximately $49.6 million, primarily based on actual Makena net sales to date and our expectations for future performance, which indicated that achievement of future milestones is not probable. This adjustment was based on our estimates, which are reliant on a number of external factors as well as the exercise of judgment.
We believe the estimated fair values of the contingent payments associated with Lumara Health and the MuGard Rights are based on reasonable assumptions, however, our actual results may vary significantly from the estimated results.
Debt

We estimate the fair value of our debt obligations by using quoted market prices obtained from third-party pricing services, which is classified as a Level 2 input. As of December 31, 2019, the estimated fair value of the 2022 Convertible Notes was $274.8 million, which differed from its carrying value. As of December 31, 2018, the estimated fair value of the 2022 Convertible Notes and the 2019 Convertible Notes was $294.8 million and $20.9 million, respectively, which differed from their carrying values. See Note R, “Debt,” for additional information on our debt obligations.

Nonrecurring Fair Value Measurements

During the year ended December 31, 2019, we measured the Makena base technology, Makena auto-injector developed technology, Intrarosa developed technology and Vyleesi developed technology intangible assets at fair value based on indicators of impairment identified for the Makena, Intrarosa and Vyleesi products. The aggregate fair values of our intangible assets at December 31, 2019 was $23.6 million and we recorded total impairment charges of $232.3 million in our consolidated statements of operations for the year ended December 31, 2019. The fair value measurement related to the Makena base technology intangible asset was recorded during the second quarter of 2019. The Makena auto-injector developed technology intangible asset was measured at fair value as of October 29, 2019 and the Intrarosa developed technology and Vyleesi developed technology intangible assets were measured at fair value as of December 31, 2019. See Note I, “Goodwill and Intangible Assets, Net” for additional information regarding our intangible asset impairment assessments.

G.     INVENTORIES

Our major classes of inventories were as follows as of December 31, 2019 and 2018 (in thousands):
 
December 31,
 
2019
 
2018
Raw materials
$
5,211

 
$
9,388

Work in process
6,248

 
5,932

Finished goods
20,094

 
11,371

Total inventories
$
31,553

 
$
26,691



During the year ended December 31, 2019, we recorded inventory write-downs of $19.8 million in conjunction with the impairments of the asset groups related to the Makena intramuscular (“IM”) products and the Makena auto-injector product.


51



H.     PROPERTY AND EQUIPMENT, NET
Property and equipment, net consisted of the following as of December 31, 2019 and 2018 (in thousands):
 
December 31,
 
2019
 
2018
Computer equipment and software
$
1,568

 
$
1,637

Furniture and fixtures
1,714

 
1,737

Leasehold improvements
4,984

 
2,938

Laboratory and production equipment
6,570

 
6,000

Construction in progress
656

 
420

 
15,492

 
12,732

Less: accumulated depreciation
(11,376
)
 
(5,211
)
Property and equipment, net
$
4,116

 
$
7,521



During 2019, 2018 and 2017, depreciation expense was $2.6 million, $1.6 million, and $1.2 million, respectively.

I.     GOODWILL AND INTANGIBLE ASSETS, NET
Goodwill
Our $422.5 million goodwill balance represents goodwill of the continuing business following the goodwill allocation performed in 2018 in connection with the CBR transaction discussed in Note C, “Discontinued Operations.” As of December 31, 2019, we had no accumulated impairment losses related to goodwill. 
2019 Impairment Testing Results
On October 31, 2019 (the “2019 measurement date”), we conducted our 2019 annual goodwill impairment test using a market approach to estimate the fair value of our reporting unit as of the 2019 measurement date. We considered our market capitalization, as adjusted for a control premium, to be one indicator of the fair value of our reporting unit. On October 31, 2019, our stock price closed at $9.71 per share, resulting in a market capitalization of approximately $329 million, which was below the carrying amount of our reporting unit as of the 2019 measurement date, resulting in an implied control premium of 6%. During the fourth quarter of 2019, we obtained a control premium analysis that benchmarked average control premiums paid in prior merger and acquisition transactions among biotechnology and pharmaceutical companies. The analysis indicated that control premiums vary depending on facts and circumstances for each transaction. The range of control premiums observed was between 37% and 84%, with a median of 65%. Management believes that using this market approach of assessing reasonable control premiums provided a sufficient basis to assess whether the fair value of our reporting unit, including a range of reasonable control premiums, was above its carrying amount. Incorporating control premiums in this range to our October 31, 2019 market capitalization of $329 million resulted in a fair value which was at least 29% greater (at the low end of the range) than the carrying amount of our net assets as of October 31, 2019. As a result of this review, we determined that there was no impairment of our goodwill at October 31, 2019.
Between October 31, 2019 and December 31, 2019, in accordance with ASC 350, we evaluated business factors, including the business decision to divest Intrarosa and Vyleesi, to determine whether there were indicators that the fair value of our reporting unit was less than its carrying value. We determine that it was not more likely than not that the fair value of the reporting unit was less than its carrying value and accordingly, determined that there was no impairment of goodwill at December 31, 2019.

Based on our assessment, we determined that there was no goodwill impairment at October 31, 2019 or December 31, 2019. However, the future occurrence of events including, but are not limited to, an adverse change in current economic and market conditions, including a significant prolonged decline in market capitalization, a significant adverse change in legal factors, unexpected adverse business conditions and an adverse action or assessment by a regulator could indicate potential impairment and trigger an interim impairment assessment of goodwill. As a result of the significance of goodwill, our results of operations and financial position in a future period could be negatively impacted should an impairment test be triggered that results in an impairment of goodwill.


52



2018 Impairment Testing Results

During the second quarter of 2018, in conjunction with the goodwill allocation required by the CBR transaction and in accordance with ASC 350, we performed a goodwill impairment test to assess whether there were indicators that its fair value was less than its carrying value. As a result of this evaluation, we determined that there was no impairment of goodwill at June 30, 2018.

On October 31, 2018 (the “2018 measurement date”), we conducted our 2018 annual goodwill impairment test using a market approach to estimate the fair value of our reporting unit as of the 2018 measurement date. We considered our market capitalization, as adjusted for a control premium, to be one indicator of the fair value of our reporting unit. On October 31, 2018, our stock price closed at $21.50 per share, resulting in a market capitalization of approximately $742 million, which was below the carrying amount of our reporting unit as of the 2018 measurement date, resulting in an implied control premium of 2%. In the days following our October 31, 2018 annual testing date, our stock price declined, largely in response to our November 1, 2018 earnings release and Company update. This decline resulted in a market capitalization of approximately $633 million on November 5, 2018, resulting in an implied control premium of 20%. During the third quarter of 2018, we obtained an updated control premium analysis that benchmarked average control premiums paid in prior merger and acquisition transactions among biotechnology and pharmaceutical companies. The analysis indicated that control premiums vary depending on facts and circumstances for each transaction. The range of control premiums observed was between 39% and 96%, with a median of 71%. Management believes that using this market approach of assessing reasonable control premiums provided a sufficient basis to assess whether the fair value of our reporting unit, including a range of reasonable control premiums, was above its carrying amount. Incorporating control premiums in this range to our October 31, 2018 market capitalization of $742 million resulted in a fair value which was at least 36% greater (at the low end of the range) than the carrying amount of our net assets as of October 31, 2018. As a result of this review, we determined that there was no impairment of our goodwill at October 31, 2018.
Between October 31, 2018 and December 31, 2018, our stock price continued to fluctuate, with a median closing stock price of $17.84 per share for the period from November 1, 2018 through December 31, 2018. The median closing stock price of $17.84 per share resulted in a market capitalization of approximately $617 million, which as compared to the $747 million carrying amount of our reporting unit at December 31, 2018 resulted in an implied control premium of 21%. Incorporating the range of control premiums obtained from the control premium study used in our annual goodwill impairment test at October 31, 2018 to the calculated market capitalization of $617 million resulted in a fair value which was at least 15% greater (at the low end of the range) than the carrying amount of our net assets as of December 31, 2018. Using the closing stock price of $15.19 per share on December 31, 2018 results in an implied control premium of 41%. This implied control premium is within the range of control premiums observed. As a result of this review, we determined that there was no impairment of our goodwill between our annual goodwill impairment test date and December 31, 2018. In addition, we determined that there were no other indicators of impairment through December 31, 2018 requiring further assessment.
Intangible Assets
 
December 31, 2019
 
December 31, 2018
 
Original Cost
 
Life to Date Accumulated Amortization
 
Life to Date Impairments
 
Net Book Value
 
Original Cost
 
Life to Date Accumulated Amortization
 
Life to Date Impairments
 
Net Book Value
Amortizable intangible assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Makena base technology
$
797,100

 
$
400,496

 
$
396,604

 
$
—

 
$
797,100

 
$
400,495

 
$
319,246

 
$
77,359

Makena auto-injector developed technology
79,100

 
15,782

 
55,426

 
7,892

 
79,100

 
6,952

 
—

 
72,148

Intrarosa developed technology
77,655

 
16,798

 
56,881

 
3,976

 
77,655

 
10,129

 
—

 
67,526

Vyleesi developed technology
60,000

 
9,264

 
38,984

 
11,752

 
—

 
—

 
—

 
—

Total intangible assets
$
1,013,855

 
$
442,340

 
$
547,895

 
$
23,620

 
$
953,855

 
$
417,576

 
$
319,246

 
$
217,033


During the second quarter of 2019, Vyleesi received FDA approval, which triggered a $60.0 million milestone payment, which was capitalized as developed technology.

Late in the second quarter of 2019, we were notified that an additional manufacturing site for the Makena IM products, which relates to the Makena base technology intangible asset, received FDA approval. However, the approval was received later than expected and the extended period of the stock-out caused our authorized generic partner to lose additional customers and market share, resulting in no shipments of IM to our authorized generic partner during that quarter. As a result of this loss of market share, we deemed it probable as of the end of the second quarter of 2019 that we would terminate the Distribution and Supply Agreement with our authorized generic partner. We do not expect to generate any future revenues from shipments

53



of the IM products. Accordingly, we eliminated the Makena IM products from our long-term revenue forecast during the second quarter of 2019. These business factors were considered indicators of impairment for the Makena base technology intangible asset during the second quarter of 2019. We determined that the fair value of the Makena base technology intangible asset was zero at June 30, 2019, and as a result, we recorded an impairment charge for the full remaining value of the asset of $77.4 million, which was recorded within a separate operating expense line item on our consolidated statements of operations. The Distribution and Supply Agreement with our authorized generic partner was terminated in August 2019 and we have not sold any Makena IM in the second half of 2019.

During the fourth quarter of 2019, we identified indicators of impairment for the Makena auto-injector developed technology, Intrarosa developed technology and Vyleesi developed technology intangible assets (each part of its own asset group) related to (i) the October 29, 2019 unfavorable FDA Advisory Committee recommendation for Makena as described in Note A, “Description of Business”, and (ii) the December 2019 decision to divest Intrarosa and Vyleesi based on the strategic review that we conducted. We determined that the Intrarosa and Vyleesi asset groups did not meet the criteria to be classified as held for sale as of December 31, 2019 and as a result, assessed these assets for potential impairment under the held and used guidance. For each asset group, we estimated the sum of the undiscounted projected cash flows and found that the sum of the projected, probability-weighted undiscounted cash flows were less than the carrying value of each corresponding asset group. Therefore, we reassessed the fair value of each asset group using an income approach, a Level 3 measurement technique, which included probability weighting a range of potential outcomes as impacted by multiple significant and inter-related business factors. For all three asset groups, these significant assumptions included an estimated probability of a negative FDA action with respect to Makena and the expected timing of any such FDA action. In addition, for the Intrarosa and Vyleesi asset groups, management’s assessment also included assumptions regarding the probability of completing a sale of these assets and the expected timing of a sale, should one occur. We derived these estimates based on management’s judgment as informed by externally available information. We believe the assumptions we used to determine the estimated fair value of the asset groups are reasonable. Based on our consideration of these probability-weighted assumptions evaluated in the aggregate, we recorded impairment charges of $55.4 million, $56.9 million and $39.0 million to reduce the carrying values of the Makena auto-injector developed technology, Intrarosa developed technology and Vyleesi developed technology intangible assets to their respective estimated fair values. Total impairment charges of $155.0 million were recorded within a separate operating expense line item in our consolidated statements of operations during the fourth quarter of 2019, of which $151.3 million were allocated to the intangible assets in each asset group. In addition, we reassessed and prospectively adjusted the estimated remaining useful lives of the Makena auto-injector developed technology, Intrarosa developed technology and Vyleesi developed technology intangible assets and other long-lived assets within each asset group. As such, we accelerated amortization of these intangible assets resulting in an additional $7.1 million of expense recorded in 2019. As described in more detail above, our assessment was based on our estimates and assumptions, a number of which are based on external factors and the exercise of management judgment. Actual results may differ significantly from our estimates.

As of December 31, 2019, the weighted average estimated remaining amortization period for our finite-lived intangible assets was approximately one year. Total amortization expense for 2019, 2018 and 2017, was $24.8 million, $158.4 million and $130.4 million, respectively. Amortization expense is recorded in cost of product sales in our consolidated statements of operations. We expect amortization expense related to our finite-lived intangible assets to be $23.6 million during the year ended December 31, 2020.

J.     CURRENT AND LONG-TERM LIABILITIES
Accrued Expenses
Accrued expenses consisted of the following as of December 31, 2019 and 2018 (in thousands):
 
December 31,
 
2019
 
2018
Commercial rebates, fees and returns
$
124,730

 
$
85,618

Accrued manufacturing
21,364

 
9,282

Salaries, bonuses, and other compensation
18,693

 
22,482

Professional, license, and other fees and expenses
13,392

 
13,960

Accrued research and development
3,539

 
2,226

Interest expense
867

 
1,067

Restructuring expense
797

 
—

Total accrued expenses
$
183,382

 
$
134,635



54




K.     INCOME TAXES
For the years ended December 31, 2019, 2018, and 2017, all of our profit or loss before income taxes was from U.S. operations. The income tax (benefit) expense consisted of the following (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Current:
 
 
 
 
 
Federal
$
(630
)
 
$
(1,136
)
 
$
2,162

State
179

 
1,469

 
5,358

Total current
$
(451
)
 
$
333

 
$
7,520

Deferred:
 
 
 
 
 
Federal
$
432

 
$
43,546

 
$
(172,238
)
State
(28
)
 
(3,443
)
 
(10,803
)
Total deferred
$
404

 
$
40,103

 
$
(183,041
)
Total income tax (benefit) expense
$
(47
)
 
$
40,436

 
$
(175,521
)


The reconciliation of the statutory U.S. federal income tax rate to our effective income tax rate from continuing operations was as follows:
 
Years Ended December 31,
 
2019
 
2018
 
2017
Statutory U.S. federal tax rate
21.0
 %
 
21.0
 %
 
35.0
 %
State taxes, net of federal benefit
2.6

 
4.7

 
3.3

Impact of 2017 tax reform on deferred tax balance
—

 
—

 
4.5

Equity-based compensation expense
(0.4
)
 
(1.5
)
 
(0.8
)
Contingent consideration
—

 
7.1

 
4.4

In-process research and development
(3.4
)
 
—

 
—

Other permanent items, net
(0.4
)
 
(1.4
)
 
(0.5
)
Tax credits
0.4

 
6.2

 
0.7

Valuation allowance
(19.8
)
 
(67.4
)
 
(0.8
)
Other, net
—

 
0.6

 
0.1

Effective tax rate
—
 %
 
(30.7
)%
 
45.9
 %


For the year ended December 31, 2019, we recognized an immaterial income tax benefit, representing an effective tax rate of 0.0%. The difference between the expected statutory federal tax rate of 21.0% and the effective tax rate of 0.0% for the year ended December 31, 2019, was primarily attributable to the valuation allowance established against our current period losses generated and the non-deductible IPR&D expense related to the Perosphere acquisition.We have established a valuation allowance on our deferred tax assets other than refundable AMT credits to the extent that our existing taxable temporary differences would not be available as a source of income to realize the benefits of those deferred tax assets. The income tax benefit for the year ended December 31, 2019 primarily related to the offset of the recognition of the income tax expense recorded in other comprehensive loss associated with the increase in the value of available-for-sale securities that we carried at fair market value during the period, partially offset by state income taxes.
For the year ended December 31, 2018, we recognized income tax expense of $40.4 million representing an effective tax rate of (30.7)%. The difference between the expected statutory federal tax rate of 21.0% and the (30.7)% effective tax rate for 2018 was primarily attributable to the establishment of a valuation allowance on net deferred tax assets other than refundable AMT credits, the impact of non-deductible stock compensation and other non-deductible expenses, partially offset by a benefit from contingent consideration associated with Lumara Health, state income taxes and orphan drug tax credits. The valuation allowance on our deferred tax assets, other than refundable AMT credits, increased during the year ended December 31, 2018 primarily because the deferred tax liabilities associated with the CBR business, which was reclassified to discontinued operations and sold during the year ended December 31, 2018, are no longer available as a source of income to realize the benefits of the net deferred tax assets.

55




For the year ended December 31, 2017, we recognized an income tax benefit of $175.5 million representing an effective tax rate of 45.9%. The difference between the expected statutory federal tax rate of 35.0% and the 45.9% effective tax rate for 2017 was primarily attributable to the impact of the 2017 federal tax reform legislation, as discussed below, contingent consideration associated with Lumara Health, federal research and orphan drug tax credits generated during the year, and the impact of state income taxes, partially offset by equity-based compensation expenses and an increase to our valuation allowance.

On December 22, 2017, the Tax Cuts and Jobs Act (the “2017 Tax Act”), was enacted. The 2017 Tax Act includes significant changes to the U.S. corporate income tax system, including a reduction of the federal corporate income tax rate from 35.0% to 21.0%, effective January 1, 2018. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which those temporary differences are expected to be recovered or settled. As a result of the reduction in the federal tax rate from 35.0% to 21.0%, we revalued our ending net deferred tax liabilities at December 31, 2017 and recognized a $17.1 million tax benefit.

Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future enacted rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. The components of our deferred tax assets and liabilities were as follows (in thousands):
 
December 31,
 
2019
 
2018
Assets
 
 
 
Net operating loss carryforwards
$
79,679

 
$
46,888

Tax credit carryforwards
28,641

 
24,290

Capital loss carryforwards
20,659

 
20,896

Interest expense carryforwards
5,746

 
4,318

Equity-based compensation expense
6,106

 
5,931

Capitalized research & development
2,347

 
4,635

Intangible assets
67,847

 
12,565

Reserves
5,721

 
2,683

Lease liability
5,739

 
—

Property, plant and equipment
391

 
—

Contingent consideration
4

 
87

Other
10,846

 
6,627

Valuation allowance
(218,291
)
 
(114,516
)
Liabilities
 
 
 
Property, plant and equipment depreciation
—

 
(614
)
Debt instruments
(9,195
)
 
(12,489
)
Right of use asset
(5,599
)
 
—

Other
(11
)
 
(41
)
Net deferred tax assets
$
630

 
$
1,260



The valuation allowance increased by approximately $103.8 million for the year ended December 31, 2019. We have established a valuation allowance on our deferred tax assets other than refundable AMT credits to the extent that our existing taxable temporary differences would not be available as a source of income to realize the benefits of those deferred tax assets. Our valuation allowance on our deferred tax assets, other than refundable AMT credits, increased during the year ended December 31, 2019, primarily due to our current period losses generated.
At December 31, 2019, we had federal and state NOL carryforwards of approximately $332.8 million and $184.6 million, respectively, of which $123.1 million and $16.6 million federal and state NOL carryforwards, were acquired as part of the Lumara Health transaction, respectively, and $21.4 million and $14.6 million federal and state NOL carryforwards were acquired as part of the Perosphere transaction, respectively. The majority of the federal and state NOLs expire at various dates

56



through 2039. We have $127.4 million of federal NOLs generated after 2017 which will not expire. We have federal tax credits of approximately $26.1 million to offset future tax liabilities of which $2.3 million were acquired as part of the Lumara Health transaction and $2.3 million of which were acquired as part of the Perosphere transaction. We have state tax credits of $2.5 million to offset future tax liabilities of which $1.2 million were acquired as part of the Perosphere transaction. These federal and state tax credits will expire periodically through 2039 if not utilized. We have a capital loss carryforward of $90.4 million from the sale of the CBR business that can only be used to offset future capital gains and expires in 2023. Our interest expense carryforward is $23.6 million, which may be carried forward indefinitely.
Utilization of our NOLs, interest expense carryforwards, and research and development (“R&D”) credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section 382 of the Internal Revenue Code of 1986 (“Section 382”) as well as similar state provisions. These ownership changes may limit the amount of NOLs and interest expense carryforwards that can be utilized annually to offset future taxable income and may limit the amounts of R&D credit carryforwards that can be utilized annually to offset taxes. In general, an ownership change as defined by Section 382 results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. Since our formation, we have raised capital through the issuance of capital stock on several occasions. These financings, combined with the purchasing shareholders’ subsequent disposition of those shares, could result in a change of control, as defined by Section 382. We conducted an analysis under Section 382 to determine if historical changes in ownership through December 31, 2019, based upon publicly available information as of December 31, 2019, would limit or otherwise restrict our ability to utilize these NOLs, interest expense, and R&D credit carryforwards. As a result of this analysis, we do not believe there are any significant limitations on our ability to utilize these carryforwards. The NOLs and tax credits acquired from Lumara Health and Perosphere are subject to restrictions under Section 382. These restricted NOLs and credits may be utilized subject to an annual limitation. We identified ownership changes associated with the attributes acquired as part of the Lumara Health and Perosphere transactions and determined these attributes are subject to annual limitations. Future changes in ownership after December 31, 2019 could affect the limitation in future years and any limitation may result in expiration of a portion of the NOL or R&D credit carryforwards before utilization.
Unrecognized tax benefits represent uncertain tax positions for which reserves have been established. A reconciliation of our changes in unrecognized tax benefits is as follows (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Unrecognized tax benefits at the beginning of the year
$
11,180

 
$
10,560

 
$
13,020

Additions based on tax positions related to the current year
521

 
12

 
574

Additions for tax positions from prior years
2,173

 
608

 
340

Subtractions for federal tax reform
—

 
—

 
(3,296
)
Subtractions for tax positions from prior years
(336
)
 
—

 
(78
)
Unrecognized tax benefits at the end of the year
$
13,538

 
$
11,180

 
$
10,560


The amount of unrecognized tax benefits that would impact the effective tax rate if recognized is immaterial, as the majority of our uncertain tax positions relate to NOL and credit carryforwards, which, if recognized, are currently expected to require a full valuation allowance.

Our unrecognized tax benefits as of December 31, 2019 increased by $2.4 million as compared to December 31, 2018 primarily due to tax reserves associated with NOLs and R&D credit carryforwards acquired in connection with the Perosphere transaction.

Our unrecognized tax benefits as of December 31, 2018 increased by $0.6 million as compared to December 31, 2017 primarily due to tax reserves established on R&D tax credits.

Our unrecognized tax benefits as of December 31, 2017 decreased by $2.5 million as compared to December 31, 2016 primarily due to the change in the federal tax rate, which reduced the future value of our federal NOLs and the corresponding value of the unrecognized tax benefits related to those NOLs. This decrease was partially offset by tax reserves established on R&D tax credits.

We have recorded minimal interest or penalties on unrecognized tax benefits since inception. We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We do not expect our unrecognized tax benefits to change significantly in the next 12 months.

57



The statute of limitations for assessment by the Internal Revenue Service (the “IRS”) and most state tax authorities is closed for tax years prior to December 31, 2016, although carryforward attributes that were generated prior to tax year 2016 may still be adjusted upon examination by the IRS or state tax authorities if they either have been or will be used in a future period. We file income tax returns in the U.S. federal and various state jurisdictions. There are currently no federal or state audits in progress.

L.     ACCUMULATED OTHER COMPREHENSIVE LOSS

The following table summarizes the changes in the accumulated balances of other comprehensive loss associated with unrealized (losses) gains on securities during 2019, 2018 and 2017 (in thousands):
 
December 31,
 
2019
 
2018
 
2017
Beginning balance
$
(3,985
)
 
$
(3,908
)
 
$
(3,838
)
Other comprehensive income (loss) before reclassifications
746

 
(77
)
 
(70
)
Ending balance
$
(3,239
)
 
$
(3,985
)
 
$
(3,908
)

M.     EQUITY-BASED COMPENSATION
We currently maintain three equity compensation plans, namely our 2019 Equity Incentive Plan (the “2019 Plan”), which was approved by our stockholders at our 2019 annual meeting and replaced our Fourth Amended and Restated 2007 Equity Incentive Plan, as amended (the “2007 Plan”), the Lumara Health Inc. Amended and Restated 2013 Incentive Compensation Plan (the “Lumara Health 2013 Plan”) and our 2015 Employee Stock Purchase Plan (“2015 ESPP”). All outstanding stock options granted under each of our equity compensation plans other than our 2015 ESPP (discussed below) have an exercise price equal to the closing price of a share of our common stock on the grant date.
Our 2019 Plan succeeded our 2007 Plan, which has expired and under which no further grants may be made. The number of shares available for future grants under the 2019 Plan consists of the sum of (i) the number of shares that remained available for issuance under the 2007 Plan as of the date of adoption of the 2019 Plan and (ii) an additional 2,161,000 shares. All outstanding awards granted under the 2007 Plan will remain subject to the terms of the 2007 Plan. In addition, any shares subject to outstanding awards granted under the 2007 Plan that expire or terminate for any reason prior to exercise will be added to the total number of shares of our stock available for issuance under the 2019 Plan. The allotted number of shares available for issuance under the 2019 Plan was 3,519,304 as of December 31, 2019 and there were 2,828,030 shares remaining available for future issuance under the 2019 Plan. As of December 31, 2019, all outstanding options under both the 2019 Plan and 2007 Plan have a ten-year term.
In November 2014, we assumed the Lumara Health 2013 Plan in connection with the acquisition of Lumara Health. The total number of shares issuable pursuant to awards under this plan as of the effective date of the acquisition and after taking into account any adjustments as a result of the acquisition, was 200,000 shares. As of December 31, 2019, there were 9,817 shares remaining available for issuance under the Lumara Health 2013 Plan, which are available for grants to certain employees, officers, directors, consultants, and advisers of AMAG and our subsidiaries who are newly-hired or who previously performed services for Lumara Health. All outstanding options under the Lumara Health 2013 Plan have a ten-year term.
The 2019 Plan, 2007 Plan and the Lumara Health 2013 Plan provide for the grant of stock options, RSUs, restricted stock, stock, stock appreciation rights and other equity interests in our company. We generally issue common stock from previously authorized but unissued shares to satisfy option exercises and RSU awards. The terms and conditions of each award are determined by our Board of Directors (the “Board”) or the Compensation Committee of our Board. The terms and conditions of each award assumed in the acquisition of Lumara Health were previously determined by Lumara Health prior to being assumed in connection with the acquisition, subject to applicable adjustments made in connection with such acquisition.

In May 2015, our stockholders approved our 2015 ESPP, which authorizes the issuance of up to 200,000 shares of our common stock to eligible employees. In June 2018, at our annual meeting of stockholders, our stockholders approved an amendment to our 2015 ESPP to increase the maximum number of shares of our common stock that will be made available for sale thereunder by 500,000 shares. The terms of the 2015 ESPP permit eligible employees to purchase shares (subject to certain plan and tax limitations) in semi-annual offerings through payroll deductions of up to an annual maximum of 10% of the employee’s “compensation” as defined in the 2015 ESPP. Shares are purchased at a price equal to 85% of the fair market value of our common stock on either the first or last business day of the offering period, whichever is lower. Plan periods consist of six-month periods typically commencing June 1 and ending November 30 and commencing December 1 and ending May 31. As of December 31, 2019, 445,713 shares have been issued under our 2015 ESPP.

58




During 2019, we also granted equity through inducement grants outside of our equity compensation plans to certain employees to induce them to accept employment with us (collectively, “Inducement Grants”). The options were granted at an exercise price equal to the fair market value of a share of our common stock on the respective grant dates and will be exercisable in four equal annual installments beginning on the first anniversary of the respective grant dates. The RSU grants will vest in three equal annual installments beginning on the first anniversary of the respective grant dates. The foregoing grants were made pursuant to inducement grants outside of our stockholder approved equity plans as permitted under the NASDAQ Stock Market listing rules. We assessed the terms of these awards and determined there was no possibility that we would have to settle these awards in cash and therefore, equity accounting was applied.
Stock Options
The following table summarizes stock option activity during 2019:
 
2019 Equity
 
2007 Equity
 
2013 Lumara
 
Inducement
 
 
 
Plan
 
Plan
 
Equity Plan
 
Grants
 
Total
Outstanding at December 31, 2018
—

 
2,781,786

 
124,450

 
810,343

 
3,716,579

Granted
479,212

 
465,009

 
37,000

 
80,366

 
1,061,587

Exercised
—

 
(2,025
)
 
—

 
—

 
(2,025
)
Expired or terminated
(6,800
)
 
(659,304
)
 
(29,675
)
 
(194,545
)
 
(890,324
)
Outstanding at December 31, 2019
472,412

 
2,585,466

 
131,775

 
696,164

 
3,885,817


 
Restricted Stock Units
The following table summarizes RSU activity during 2019:
 
2019 Equity
 
2007 Equity
 
2013 Lumara
 
Inducement
 
 
 
Plan
 
Plan
 
Equity Plan
 
Grants
 
Total
Outstanding at December 31, 2018
—

 
1,041,141

 
2,101

 
85,293

 
1,128,535

Granted
132,542

 
1,023,847

 
1,100

 
29,385

 
1,186,874

Vested
—

 
(358,362
)
 
(1,034
)
 
(44,909
)
 
(404,305
)
Expired or terminated
(3,800
)
 
(299,321
)
 
—

 
(28,546
)
 
(331,667
)
Outstanding at December 31, 2019
128,742

 
1,407,305

 
2,167

 
41,223

 
1,579,437


 
In February 2019, March 2018 and February 2017, we granted RSUs under our 2007 Plan to certain members of our senior management covering a maximum of 365,591, 206,250 and 191,250 shares of common stock, respectively. These performance-based RSUs will vest, if at all, on February 24, 2022, March 1, 2021 and February 22, 2020, respectively, based on our total shareholder return (“TSR”) performance measured against the median TSR of a defined group of companies over a three-year period. As of December 31, 2019, the maximum shares of common stock that may be issued under these awards was 325,091, 155,250 and 131,250, respectively. The maximum aggregate total fair value of these RSUs at December 31, 2019 was $4.2 million, $2.9 million and $2.6 million, respectively, which is being recognized as expense over a period of three years from the date of grant, net of any estimated and actual forfeitures.

Equity-based compensation expense
Equity-based compensation expense for 2019, 2018 and 2017 consisted of the following (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Cost of product sales
$
871

 
$
802

 
$
884

Research and development
2,844

 
2,533

 
3,225

Selling, general and administrative
14,818

 
16,614

 
16,187

Total equity-based compensation expense
18,533

 
19,949

 
20,296

Income tax effect
—

 
—

 
(6,188
)
After-tax effect of equity-based compensation expense
$
18,533

 
$
19,949

 
$
14,108


 

59



In addition to the equity-based compensation expense presented in the table above, we incurred $0.7 million of equity-based compensation expense related to the restructuring activities during the first quarter of 2019, which is classified within restructuring expense on our consolidated statements of operations for the year ended December 31, 2019.
The following table summarizes the weighted average assumptions we utilized for purposes of valuing grants of options to our employees and non-employee directors:
 
Years Ended December 31,
 
2019
 
2018
 
2017
 
 
 
Non-Employee
 
 
 
Non-Employee
 
 
 
Non-Employee
 
Employees
 
Directors
 
Employees
 
Directors
 
Employees
 
Directors
Risk free interest rate (%)
2.12
 
2.04
 
2.75
 
2.70
 
1.86
 
1.61
Expected volatility (%)
57
 
59
 
57
 
59
 
53
 
57
Expected option term (years)
5.0
 
4.0
 
5.0
 
4.0
 
5.0
 
4.0
Dividend yield
none
 
none
 
none
 
none
 
none
 
none


Risk free interest rates utilized are based upon published U.S. Treasury yields at the date of the grant for the expected option term. During 2019, 2018 and 2017, we estimated our expected stock price volatility by using the historical volatility of our own common stock price over the prior period equivalent to our expected option term, in order to better reflect expected future volatility. To compute the expected option term, we analyze historical exercise experience as well as expected stock option exercise patterns.

The following table summarizes details regarding stock options granted under our equity incentive plans for the year ended December 31, 2019:
 
December 31, 2019
 
Options
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term
 
Aggregate Intrinsic Value
($ in thousands)
Outstanding at beginning of year
3,716,579

 
$
24.81

 
7.3

 
$
—

Granted
1,061,587

 
12.71

 
—

 
—

Exercised
(2,025
)
 
14.56

 
—

 
—

Expired and/or forfeited
(890,324
)
 
22.93

 
—

 
—

Outstanding at end of year
3,885,817

 
$
21.94

 
6.8

 
$
776

Outstanding at end of year - vested and unvested expected to vest
3,799,575

 
$
22.12

 
6.8

 
$
701

Exercisable at end of year
2,242,727

 
$
25.76

 
5.5

 
$
116



The weighted average grant date fair value of stock options granted during 2019, 2018 and 2017 was $6.33, $10.76 and $9.52, respectively. A total of 728,758 stock options vested during 2019. The aggregate intrinsic value of options exercised during 2019, 2018 and 2017, excluding purchases made pursuant to our 2015 ESPP, measured as of the exercise date, was approximately $0.0 million, $0.6 million and $0.4 million, respectively. The intrinsic value of a stock option is the amount by which the fair market value of the underlying stock on a specific date exceeds the exercise price of the common stock option.

60




The following table summarizes details regarding RSUs granted under our equity incentive plans for the year ended December 31, 2019:
 
December 31, 2019
 
Restricted Stock Units
 
Weighted Average Grant Date Fair Value
Outstanding at beginning of year
1,128,535

 
$
23.42

Granted
1,186,874

 
15.65

Vested
(404,305
)
 
22.49

Forfeited
(331,667
)
 
19.71

Outstanding at end of year
1,579,437

 
$
18.60

Outstanding at end of year and expected to vest
1,462,952

 
$
18.88



The weighted average grant date fair value of RSUs granted during 2019, 2018 and 2017 was $15.65, $22.32 and $24.18, respectively. The total fair value of RSUs that vested during 2019, 2018 and 2017 was $9.1 million, $12.4 million and $12.3 million, respectively.

At December 31, 2019, the amount of unrecorded equity-based compensation expense for both option and RSU awards, attributable to future periods was approximately $28.1 million. Of this amount, $11.5 million was associated with stock options and is expected to be amortized on a straight-line basis to expense over a weighted average period of approximately 2.5 years, $12.3 million was associated with RSUs and is expected to be amortized on a straight-line basis to expense over a weighted average period of approximately 1.7 years, and $4.3 million was associated with performance-based RSUs and is expected to be amortized on a straight-line basis to expense over a weighted average period of approximately 1.5 years. Such amounts will be amortized primarily to research and development or selling, general and administrative expense. These future estimates are subject to change based upon a variety of future events, which include, but are not limited to, changes in estimated forfeiture rates, employee turnover, and the issuance of new stock options and other equity-based awards.

N.    EMPLOYEE SAVINGS PLAN
We provide a 401(k) Plan to our employees by which they may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code. Each employee may elect to defer a percentage of his or her salary up to a specified maximum. As of December 31, 2019 our 401(k) Plan provided, among other things, for a company contribution of 4% of each employee’s combined salary and certain other compensation for the plan year. Contributions by us to the 401(k) Plan are not taxable to employees until withdrawn from the 401(k) Plan and contributions are deductible by us when made. The amount of our company contribution for the 401(k) Plan was $3.7 million, $4.0 million and $2.3 million for 2019, 2018 and 2017, respectively.
O.     STOCKHOLDERS’ EQUITY

As of January 1, 2019, we had $20.5 million available under our previously approved program to repurchase up to $60.0 million in shares of our common stock. In March 2019, our Board authorized additional repurchases of shares in an amount up to $20.0 million under this program. The repurchase program does not have an expiration date and may be suspended for periods or discontinued at any time. Under the program, we may purchase our stock from time to time at the discretion of management in the open market or in privately negotiated transactions. The number of shares repurchased and the timing of the purchases will depend on a number of factors, including share price, trading volume and general market conditions, along with working capital requirements, general business conditions and other factors. We may also from time to time establish a trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934 to facilitate purchases of our shares under this program. During 2019, we repurchased and retired 1,074,800 shares of common stock under this repurchase program for $13.7 million. During 2018, we did not repurchase shares of common stock under this program. As of December 31, 2019, $26.8 million remains available for the repurchase of shares under the program. 

61



P.     COMMITMENTS AND CONTINGENCIES
Commitments
Our long-term contractual obligations include commitments and estimated purchase obligations entered into in the normal course of business. These include commitments related to our facility and vehicle leases, purchases of inventory, debt obligations, and other purchase obligations.
Operating Lease Obligations
During 2019, we had operating leases for real estate, including our lease for use as our principal executive offices, vehicles and office equipment. As of January 1, 2019, we recorded operating lease liabilities of $8.5 million and related ROU assets of $7.6 million in connection with our adoption of ASC 842. During the fourth quarter of 2019, we modified the operating lease for our principal executive offices to extend the term through July 2028. As of December 31, 2019, we had operating lease liabilities of $23.9 million and related ROU assets of $23.3 million. As of December 31, 2019, our leases have remaining terms of one to 8.5 years. The weighted average remaining lease term and discount rate for our operating leases was 7.95 years and 5.1% at December 31, 2019, respectively.

Lease costs for our operating leases were $5.1 million, $5.1 million and $3.0 million for the years ended December 31, 2019, 2018 and 2017, respectively. Operating cash outflows for operating leases were $5.2 million for the year ended December 31, 2019.

Future minimum payments under our non-cancelable operating leases as of December 31, 2019 are as follows (in thousands):
Period
 
Future Minimum Lease Payments
Year Ending December 31, 2020
 
$
4,077

Year Ending December 31, 2021
 
3,207

Year Ending December 31, 2022
 
3,734

Year Ending December 31, 2023
 
3,230

Year Ending December 31, 2024
 
3,246

Thereafter
 
12,192

Total
 
$
29,686

Less: Interest
 
$
5,818

Operating lease liability
 
$
23,868



Purchase Obligations

Purchase obligations primarily represent minimum purchase commitments for inventory. As of December 31, 2019, our minimum purchase commitments totaled $105.9 million.

Contingent Regulatory and Commercial Milestone Payments

We are required to make payments contingent on the achievement of certain regulatory and/or commercial milestones under the terms of our collaboration, license and other strategic agreements. Please refer to Note Q, “Collaboration, License and Other Strategic Agreements” for additional details regarding these contingent payments.
Employment Arrangements

We have entered into employment agreements or other arrangements with most of our executive officers and certain other employees, which provide for the continuation of salary and certain benefits and, in certain instances, the acceleration of the vesting of certain equity awards to such individuals in the event that the individual is terminated other than for cause, as defined in the applicable employment agreements or arrangements.


62



Indemnification Obligations

As permitted under Delaware law, pursuant to our certificate of incorporation, by-laws and agreements with all of our current directors, executive officers, and certain of our employees, we are obligated to indemnify such individuals for certain events or occurrences while the officer, director or employee is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification obligations is not capped. Our director and officer insurance policy limits our initial exposure and our policy provides significant coverage. As a result, we believe the estimated fair value of these indemnification obligations is likely to be immaterial.

We are also a party to a number of other agreements entered into in the ordinary course of business, typically with business partners, contract manufacturers, clinical sites and customers, which contain typical provisions and which obligate us to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. Our aggregate maximum potential future liability under such indemnification provisions is uncertain. We have not incurred any expenses as a result of such indemnification provisions during the years ended December 31, 2019, 2018 or 2017. Accordingly, we have determined that the estimated aggregate fair value of our potential liabilities under such indemnification provisions is not significant, and we have not recorded any liability related to such indemnification.

Contingencies

Legal Proceedings

We accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss. We review these accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. For certain matters referenced below, the liability is not probable or the amount cannot be reasonably estimated and, therefore, accruals have not been made. In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, we will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, we will provide disclosure to that effect. We expense legal costs as they are incurred.
On November 6, 2019, we were served with a summons in a case filed in the U.S. District Court, Northern District of Ohio, captioned Civil Case in Saginaw Chippewa Indian Tribe v. Purdue Pharma et al (Case No. 1-19-op-45841). The complaint names K-V Pharmaceutical Company (“KV”) (Lumara Health’s predecessor company), certain of its successor entities, subsidiaries and affiliate entities as defendants, along with over forty other pharmaceutical companies. We acquired Lumara Health in November 2014, a year after KV emerged from bankruptcy protection, at which time it and its then-existing subsidiaries became our wholly-owned subsidiaries. The plaintiff in this action alleges that KV’s subsidiary, Ethex Corporation (as well as the other pharmaceutical companies named in the complaint), manufactured, promoted, sold, and distributed opioids, including a generic version of morphine. We are in discussions with the plaintiff’s counsel to dismiss all claims in the Chippewa case. At this time, based on available information, we are currently unable to predict the outcome or reasonably estimate the range of potential loss associated with this matter, if any.

On November 1, 2019, we were named as a defendant in a class action lawsuit filed in the United States District Court for the Western District of Missouri, captioned Barnes v. AMAG Pharmaceuticals, Inc., Case No. 3:19-cv-05088-RK (W.D. Mo.).  Subsequently, other plaintiffs represented by the same law firm have filed four similar class action lawsuits in other jurisdictions, captioned Gill v. AMAG Pharmaceuticals, Inc., Case No. 2:19-cv-02681-DDC-JPO (D. Kan., filed Nov. 4, 2019), Faughnan, et al. v. AMAG Pharmaceuticals, Inc., Case No. 3:19-cv-01394-FJS-ML (N.D.N.Y, filed Nov. 12, 2019), Zamifrova v. AMAG Pharmaceuticals, Inc., Case No. 2:20-cv-00152-JMV-SCM (D.N.J., filed Jan. 3, 2020) and Nelson v. AMAG Pharmaceuticals, Inc., Case No. 2:20-cv-00089-WBS-DMC (E.D. Cal., filed Jan. 13, 2020). The plaintiffs in these actions, on behalf of themselves and purported state-wide classes of similarly situated consumers, assert claims for violation of state consumer protection laws and unjust enrichment based on allegations that we and/or our predecessor companies made misrepresentations and omissions regarding the effectiveness of Makena in connection with the sale and marketing of that product from 2011 through the present. Because these cases are in the earliest stages, we are currently unable to predict the outcome or reasonably estimate the range of potential loss associated with this matter, if any.

On August 29, 2019, Lunar Representative, LLC (“Plaintiff”), on behalf of the former equityholders of Lumara Health Inc. (“Lumara”), filed a complaint against us in the Delaware Court of Chancery, captioned Lunar Representative, LLC v. AMAG Pharmaceuticals, Inc. (No. 2019-0688-JTL). On September 25, 2019, we filed a motion to dismiss the complaint. On January 9,

63



2020, Plaintiff filed an amended complaint. Plaintiff alleges that we did not exercise commercially reasonable efforts to market and sell the drug product Makena, and failed to achieve sales milestones for Makena, in breach of certain provisions of the September 28, 2014 Agreement and Plan of Merger between, among other parties, us and Lumara. On January 24, 2020, we filed a motion to dismiss the amended complaint. Plaintiff is seeking damages of $50.0 million, together with pre- and post-judgment interest, as well as attorneys’ fees and costs. At this time, based on available information, we are unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses. We believe this lawsuit is without merit and intend to vigorously defend against the allegations.  

On or about April 6, 2016, we received Notice of a Lawsuit and Request to Waive Service of a Summons in a case entitled Plumbers’ Local Union No. 690 Health Plan v. Actavis Group et. al. (“Plumbers’ Union”), which was filed in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania and, after removal to federal court, is now pending in the United States District Court for the Eastern District of Pennsylvania (Civ. Action No. 16-65-AB). Thereafter, we were also made aware of a related complaint entitled Delaware Valley Health Care Coalition v. Actavis Group et. al. (“Delaware Valley”), which was filed with the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania District Court of Pennsylvania (Case ID: 160200806). The complaints name K-V Pharmaceutical Company (“KV”) (Lumara Health’s predecessor company), certain of its successor entities, subsidiaries and affiliate entities (the “Subsidiaries”), along with a number of other pharmaceutical companies. We acquired Lumara Health in November 2014, a year after KV emerged from bankruptcy protection, at which time it, along with its then existing subsidiaries, became our wholly-owned subsidiary. We have not been served with process or waived service of summons in either case. The actions are being brought alleging unfair and deceptive trade practices with regard to certain pricing practices that allegedly resulted in certain payers overpaying for certain of KV’s generic products. On July 21, 2016, the Plaintiff in the Plumbers’ Union case dismissed KV with prejudice to refiling and on October 6, 2016, all claims against the Subsidiaries were dismissed without prejudice. We are in discussions with Plaintiff’s counsel to similarly dismiss all claims in the Delaware Valley case. Because we have not been served with process in the Delaware Valley case, we are currently unable to predict the outcome or reasonably estimate the range of potential loss associated with this matter, if any.

On July 20, 2015, the Federal Trade Commission (the “FTC”) notified us that it is conducting an investigation into whether Lumara Health or its predecessor engaged in unfair methods of competition with respect to Makena or any hydroxyprogesterone caproate product. The FTC noted in its letter that the existence of the investigation does not indicate that the FTC has concluded that Lumara Health or its predecessor has violated the law and we believe that our contracts and practices comply with relevant law and policy, including the federal Drug Quality and Security Act (the “DQSA”), which was enacted in November 2013, and public statements from and enforcement actions by the FDA regarding its implementation of the DQSA. We have provided the FTC with a response providing a brief overview of the DQSA for context, which we believe was helpful, including: (a) how the statute outlined that large-scale compounding of products that are copies or near-copies of FDA-approved drugs (like Makena) is not in the interests of public safety; (b) our belief that the DQSA has had a significant impact on the compounding of hydroxyprogesterone caproate; and (c) how our contracts with former compounders allow those compounders to continue to serve physicians and patients with respect to supplying medically necessary alternative/altered forms of hydroxyprogesterone caproate. We believe we have fully cooperated with the FTC and we have had no further interactions with the FTC on this matter since we provided our response to the FTC in August 2015.
We may periodically become subject to other legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which we are focused. Other than the above actions, we are not aware of any material claims against us as of December 31, 2019 or 2018.

Q.     COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS
During 2019, we were a party to the following collaboration, license or other strategic agreements:
Perosphere

On January 16, 2019, we acquired Perosphere Pharmaceuticals Inc. (“Perosphere”) pursuant to the Agreement and Plan of Merger (the “Perosphere Agreement”), dated as of December 12, 2018 between AMAG and Perosphere. Pursuant to the Perosphere Agreement, in January 2019, we paid approximately $50.0 million (the “Upfront Merger Consideration”). Of the Upfront Merger Consideration, approximately $40.0 million was funded from our available cash and approximately $10.0 million was deemed paid in connection with the cancellation of a convertible note in the principal amount of $10.0 million issued to us by Perosphere in October 2018. In addition to the Upfront Merger Consideration, we used available cash to repay $12.0 million of Perosphere’s term loan indebtedness and approximately $6.2 million of Perosphere’s other liabilities. We are also required to pay regulatory and sales milestone payments to Perosphere as described in more detail below. Further, we were

64



a party to a clinical trial collaboration agreement with a pharmaceutical company, which we acquired through the Perosphere transaction, which provided for partial funding of the Phase 3 program for ciraparantag if certain clinical milestones were met. In December 2019, the clinical trial collaboration agreement with the pharmaceutical company was terminated as described in more detail in Note D, “Revenue Recognition.”

Substantially all of the fair value of the assets acquired in conjunction with the Perosphere transaction was concentrated in the IPR&D asset. As a result, we accounted for this transaction as an asset acquisition under ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”). The acquired IPR&D was charged to expense at acquisition, as it relates to a development stage compound with no alternative future use. A summary of the assets and liabilities acquired in exchange for cash consideration of $60.8 million and $10.0 million that was deemed paid in connection with the cancellation of the convertible note, described above, is presented in the following table (in millions):
Assets:
 
Cash
$
2.6

Operating lease right-of-use asset
0.8

Property and equipment
1.4

IPR&D
74.9

 
$
79.7

Liabilities:
 
Accrued severance liabilities
$
(1.7
)
Deferred revenue
(6.4
)
Operating lease liability
(0.8
)
 
$
(8.9
)


Excluded from the table above are contingent payments associated with achievement of potential regulatory and sales milestones as described below, which were not deemed probable at the date of acquisition. The fair values of certain of the assets and liabilities acquired are classified as Level 3 estimates under the fair value hierarchy as they have been valued using unobservable inputs. These inputs include: (a) the estimated amount and timing of projected cash flows; (b) the probability of the achievement of key development and regulatory objectives; and (c) the risk-adjusted discount rate used to present value the probability-weighted cash flows. The fair values of the assets and liabilities acquired were initially valued and recorded based on various market factors, including an analysis of estimated sales using a discount rate of approximately 34%.

Under and subject to the terms and conditions set forth in the Perosphere Agreement, we are obligated to pay future contingent consideration of up to an aggregate of $365.0 million (the “Milestone Payments”), including (a) up to an aggregate of $140.0 million that becomes payable upon the achievement of specified regulatory milestones for ciraparantag (the “Regulatory Milestone Payments”), including a $40.0 million milestone payment upon approval of ciraparantag by the European Medicines Agency and (b) up to an aggregate of $225.0 million that becomes payable conditioned upon the achievement of specified sales milestones (the “Sales Milestone Payments”). If the final label approved for ciraparantag in the U.S. includes a boxed warning, the Regulatory Milestone Payments shall no longer be payable, and any previously paid Regulatory Milestone Payments shall be credited against 50% of any future Milestone Payments that otherwise becomes payable. The first sales milestone payment of $20.0 million will be payable upon annual net sales of ciraparantag of at least $100.0 million.
Velo

In September 2018, we exercised our option to acquire the global rights to AMAG-423 pursuant to an option agreement entered into in July 2015 with Velo Bio, LLC (“Velo”), the terms of which were amended at the time of exercise. Under the terms of the agreement, we paid Velo an upfront option exercise fee of $12.5 million and are obligated to pay Velo a $30.0 million milestone payment upon FDA approval of AMAG-423. In addition, we are obligated to pay sales milestone payments to Velo of up to $240.0 million in the aggregate, triggered at various annual net sales thresholds between $300.0 million and $900.0 million and low-single digit royalties based on net sales. Further, we have assumed additional obligations under a previous agreement entered into by Velo with a third-party, including a $5.0 million milestone payment upon regulatory approval and $10.0 million following the first commercial sale of AMAG-423, payable in quarterly installments as a percentage of quarterly gross commercial sales until the obligation is met. We are also obligated to pay the third-party low-single digit royalties based on net sales. We accounted for this transaction as an asset acquisition under ASU 2017-01.

65



Prasco

In December 2017, we entered into a Distribution and Supply Agreement (the “Prasco Agreement”) with Prasco, LLC (“Prasco”), under which Prasco was granted an exclusive, non-sublicensable, nontransferable license to purchase, distribute and sell a generic version of Makena in the U.S. (the “Makena authorized generic”). In July 2018, Prasco launched the Makena authorized generic of both the single-dose and multi-dose IM injections and in August 2019, we and Prasco terminated the Prasco Agreement based on our determination that it was not commercially viable to continue the relationship. Under the Prasco Agreement, we were responsible for the manufacture and supply of the Makena authorized generic to be sold to Prasco at a predetermined supply price. Prasco was also required to pay us a certain percentage of the net distributable profits from the sale of the Makena authorized generic. We accounted for revenue recognized under the Prasco Agreement in accordance with ASC 606. Pursuant to the terms of the Prasco Agreement, in certain circumstances we have reimbursed Prasco as a result of our failure to supply a certain percentage of product ordered by Prasco in a prespecified timeframe. During the year ended December 31, 2019, we incurred $3.5 million of failure to supply penalties, the majority of which were incurred in the first quarter of 2019.
Antares

We are party to a development and license agreement (the “Antares License Agreement”) with Antares Pharma, Inc. (“Antares”), which grants us an exclusive, worldwide, royalty-bearing license, with the right to sublicense, to certain intellectual property rights, including know-how, patents and trademarks, to develop, use, sell, offer for sale and import and export the Makena auto-injector. Under the terms of the Antares License Agreement, as amended in March 2018, we are responsible for the clinical development and preparation, submission and maintenance of all regulatory applications in each country where we desire to market and sell the Makena auto-injector, including the U.S. We are required to pay royalties to Antares on net sales of the Makena auto-injector until the Antares License Agreement is terminated (the “Antares Royalty Term”). The royalty rates range from high single digit to low double digits and are tiered based on levels of net sales of the Makena auto-injector and decrease after the expiration of licensed patents or where there are generic equivalents to the Makena auto-injector being sold in a particular country. In addition, we are required to pay Antares sales milestone payments upon the achievement of certain annual net sales. The Antares License Agreement terminates at the end of the Antares Royalty Term, but is subject to early termination by us for convenience and by either party upon an uncured breach by or bankruptcy of the other party. In March 2018, the Antares License Agreement was amended to, among other things, transfer the agreement to AMAG from our subsidiary, amend certain confidentiality provisions, and to provide for co-termination with the Antares Manufacturing Agreement (described below).

We are also party to a Manufacturing Agreement with Antares (the “Antares Manufacturing Agreement”) that sets forth the terms and conditions pursuant to which Antares agreed to sell to us on an exclusive basis, and we agreed to purchase, the fully packaged Makena auto-injector for commercial distribution. Antares remains responsible for the manufacture and supply of the device components and assembly of the Makena auto-injector. We are responsible for the supply of the drug to be used in the assembly of the finished auto-injector product. The Antares Manufacturing Agreement terminates at the expiration or earlier termination of the Antares License Agreement, but is subject to early termination by us for certain supply failure situations, and by either party upon an uncured breach by or bankruptcy of the other party or our permanent cessation of commercialization of the Makena auto-injector for efficacy or safety reasons.

Endoceutics

In February 2017, we entered into the Endoceutics License Agreement with Endoceutics, Inc. (“Endoceutics”) to obtain an exclusive right to commercialize Intrarosa for the treatment of vulvar and vaginal atrophy (“VVA”) and FSD in the United States. We have agreed to use commercially reasonable efforts to market, promote and otherwise commercialize Intrarosa for the treatment of VVA. The transactions contemplated by the Endoceutics License Agreement closed on April 3, 2017. We accounted for the Endoceutics License Agreement as an asset acquisition under ASU 2017-01.
Upon the closing of the Endoceutics License Agreement, we made an upfront payment of $50.0 million and issued 600,000 shares of unregistered common stock to Endoceutics, which had a value of $13.5 million, as measured on April 3, 2017, the date of closing. In addition, we paid Endoceutics $10.0 million in the third quarter of 2017 upon the delivery by Endoceutics of Intrarosa launch quantities and $10.0 million in 2018 following the first anniversary of the closing. In the second quarter of 2017, we recorded a total of $83.5 million of consideration, of which $77.7 million was allocated to the Intrarosa developed technology intangible asset and $5.8 million was recorded as IPR&D expense based on their relative fair values.
Under the terms of the Endoceutics License Agreement, we pay tiered royalties to Endoceutics equal to a percentage of net sales of Intrarosa in the U.S. ranging from mid-teens to mid twenty percent. Endoceutics is also eligible to receive certain sales

66



milestone payments up to an aggregate of $895.0 million, including a first sales milestone payment of $15.0 million, which would be triggered when Intrarosa annual net U.S. sales exceed $150.0 million.

In April 2017, we entered into an exclusive commercial supply agreement with Endoceutics pursuant to which Endoceutics, itself or through affiliates or contract manufacturers, agreed to manufacture and supply Intrarosa to us (the “Endoceutics Supply Agreement”) and is our exclusive supplier of Intrarosa in the U.S., subject to certain rights for us to manufacture and supply Intrarosa in the event of a cessation notice or supply failure (as such terms are defined in the Endoceutics Supply Agreement). The Endoceutics Supply Agreement will generally remain in effect until the termination of the Endoceutics License Agreement.
The Endoceutics License Agreement expires on the date of expiration of all royalty obligations due thereunder unless earlier terminated in accordance with the Endoceutics License Agreement.
Palatin
In January 2017, we entered into a license agreement with Palatin Technologies, Inc. (“Palatin”) under which we acquired (a) an exclusive license in all countries of North America (the “Palatin Territory”), with the right to grant sub-licenses, to research, develop and commercialize the Vyleesi Products, (b) a worldwide non-exclusive license, with the right to grant sub-licenses, to manufacture the Vyleesi Products, and (c) a non-exclusive license in all countries outside the Palatin Territory, with the right to grant sub-licenses, to research and develop (but not commercialize) the Vyleesi Products (the “Palatin License Agreement”). The transaction closed in February 2017 and was accounted for as an asset acquisition under ASU 2017-01.
Under the terms of the Palatin License Agreement, in February 2017 we paid Palatin $60.0 million as a one-time upfront payment and subject to agreed-upon deductions reimbursed Palatin approximately $25.0 million for reasonable, documented, out-of-pocket expenses incurred by Palatin in connection with the development and regulatory activities necessary to submit the Vyleesi New Drug Application (“NDA”) in the U.S. The $60.0 million upfront payment made in February 2017 to Palatin was recorded as IPR&D expense as the product candidate had not received regulatory approval. In June 2018, our NDA submission to the FDA for Vyleesi was accepted, which triggered a $20.0 million milestone payment, which we paid in the second quarter of 2018 and recorded as an IPR&D expense in the first quarter of 2018 when acceptance was deemed probable. In June 2019, the FDA approval of Vyleesi triggered a $60.0 million milestone payment to Palatin, which we paid in July 2019 and recorded as a developed technology intangible asset in the second quarter of 2019.
In addition, the Palatin License Agreement requires us to make contingent payments of up to $300.0 million of aggregate sales milestone payments upon the achievement of certain annual net sales milestones over the course of the license. The first sales milestone payment of $25.0 million will be triggered when Vyleesi annual net sales exceed $250.0 million. We are also obligated to pay Palatin tiered royalties on annual net sales of the Vyleesi Products, on a product-by-product basis, in the Palatin Territory ranging from the high-single digits to the low double-digits. After the expiration of the applicable royalties for any Vyleesi Product in a given country, the license for such Vyleesi Product in such country would become a fully paid-up, royalty-free, perpetual and irrevocable license. The Palatin License Agreement expires on the date of expiration of all royalty obligations due thereunder, unless earlier terminated in accordance with the Palatin License Agreement.
Abeona
We acquired the U.S. commercial rights to MuGard, a prescription oral mucoadhesive, under a June 2013 license agreement with Abeona (the “MuGard Rights”). We ceased selling MuGard at the end of 2019.

R.     DEBT

Our outstanding debt obligations as of December 31, 2019 and December 31, 2018 consisted of the following (in thousands):
 
December 31,
 
2019
 
2018
2022 Convertible Notes
$
277,034

 
$
261,933

2019 Convertible Notes
—

 
21,276

Total long-term debt
277,034

 
283,209

Less: current maturities
—

 
21,276

Long-term debt, net of current maturities
$
277,034

 
$
261,933


 

67



Convertible Notes
The outstanding balances of our Convertible Notes as of December 31, 2019 consisted of the following (in thousands):
 
 
2022 Convertible Notes
Liability component:
 
 

Principal
 
$
320,000

Less: debt discount and issuance costs, net
 
42,966

Net carrying amount
 
$
277,034

Gross equity component
 
$
72,576



In accordance with accounting guidance for debt with conversion and other options, we separately account for the liability and equity components of our Convertible Notes by allocating the proceeds between the liability component and the embedded conversion option (the “Equity Component”) due to our ability to settle the Convertible Notes in cash, common stock or a combination of cash and common stock, at our option. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The allocation was performed in a manner that reflected our non-convertible debt borrowing rate for similar debt. The Equity Component of the Convertible Notes was recognized as a debt discount and represents the difference between the proceeds from the issuance of the Convertible Notes and the fair value of the liability of the Convertible Notes on their respective dates of issuance. The excess of the principal amount of the liability component over its carrying amount (the “Debt Discount”) is amortized to interest expense using the effective interest method over five years. The Equity Component is not remeasured as long as it continues to meet the conditions for equity classification.
2022 Convertible Notes
In the second quarter of 2017, we issued $320.0 million aggregate principal amount of convertible senior notes due in 2022 and received net proceeds of $310.4 million from the sale of the 2022 Convertible Notes, after deducting fees and expenses of $9.6 million. The approximately $9.6 million of debt issuance costs primarily consisted of underwriting, legal and other professional fees, and allocated these costs to the liability and equity components based on the allocation of the proceeds. Of the total $9.6 million of debt issuance costs, $2.2 million was allocated to the Equity Component and recorded as a reduction to additional paid-in capital and $7.4 million was allocated to the liability component and is now recorded as a reduction of the 2022 Convertible Notes in our consolidated balance sheet. The portion allocated to the liability component is amortized to interest expense using the effective interest method over five years.
The 2022 Convertible Notes are governed by the terms of an indenture between us, as issuer, and Wilmington Trust, National Association, as the trustee. The 2022 Convertible Notes are senior unsecured obligations and bear interest at a rate of 3.25% per year, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2017. The 2022 Convertible Notes will mature on June 1, 2022, unless earlier repurchased or converted. Upon conversion of the 2022 Convertible Notes, such 2022 Convertible Notes will be convertible into, at our election, cash, shares of our common stock, or a combination thereof, at a conversion rate of 36.5464 shares of common stock per $1,000 principal amount of the 2022 Convertible Notes, which corresponds to an initial conversion price of approximately $27.36 per share of our common stock.
The conversion rate is subject to adjustment from time to time upon the occurrence of certain events, including, but not limited to, the issuance of stock dividends and payment of cash dividends. At any time prior to the close of business on the business day immediately preceding March 1, 2022, holders may convert their 2022 Convertible Notes at their option only under the following circumstances:
1)
during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending September 30, 2017, if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
2)
during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of the 2022 Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or
3)
upon the occurrence of specified corporate events.

68



On or after March 1, 2022, until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their 2022 Convertible Notes, in multiples of $1,000 principal amount, at the option of the holder regardless of the foregoing circumstances. The 2022 Convertible Notes were not convertible as of December 31, 2019.
We determined the expected life of the debt was equal to the five-year term on the 2022 Convertible Notes. The effective interest rate on the liability component was 9.49% for the period from the date of issuance through December 31, 2019. As of December 31, 2019, the “if-converted value” did not exceed the remaining principal amount of the 2022 Convertible Notes.
2019 Convertible Notes
In February 2014, we issued $200.0 million aggregate principal amount of 2019 Convertible Notes. We received net proceeds of $193.3 million from the sale of the 2019 Convertible Notes, after deducting fees and expenses of $6.7 million. We used $14.1 million of the net proceeds from the sale of the 2019 Convertible Notes to pay the cost of the convertible bond hedges, as described below (after such cost was partially offset by the proceeds to us from the sale of warrants in the warrant transactions described below). The 2019 Convertible Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on February 15 and August 15 of each year.
In 2017, we entered into two privately negotiated transactions with certain investors to repurchase approximately $178.5 million aggregate principal amount of the 2019 Convertible Notes for an aggregate repurchase price of approximately $192.7 million, including accrued interest. Pursuant to ASC Topic 470, Debt (“ASC 470”), we concluded that the 2017 repurchases of 2019 Convertible Notes should be accounted for as extinguishments and we recorded a net debt extinguishment loss of $0.1 million related to the difference between the consideration paid, the fair value of the liability component and carrying values at the repurchase date. The remaining $21.4 million of 2019 Convertible Notes matured on February 15, 2019 and were settled with cash.
Convertible Notes Interest Expense
The following table sets forth total interest expense recognized related to the 2022 Convertible Notes and 2019 Convertible Notes during 2019, 2018, and 2017 (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Contractual interest expense
$
10,467

 
$
10,935

 
$
8,961

Amortization of debt issuance costs
1,412

 
1,403

 
1,275

Amortization of debt discount
13,830

 
13,414

 
11,071

Total interest expense
$
25,709

 
$
25,752

 
$
21,307


Convertible Bond Hedge and Warrant Transactions
In February 2014 we entered into convertible bond hedge transactions and separate warrant transactions of our common stock underlying the aggregate principal amount of the 2019 Convertible Notes with certain financial institutions (the “call spread counterparties”). In connection with our 2017 repurchases of the 2019 Convertible Notes, as discussed above, we entered into agreements with the call spread counterparties to terminate a portion of the then existing convertible bond hedge transactions in an amount corresponding to the amount of such 2019 Convertible Notes repurchased and to terminate a portion of the then-existing warrant transactions. In February 2019, the 2019 Convertible Notes were settled with cash and the remaining bond hedge and warrant transactions expired.
2023 Senior Notes
In August 2015, in connection with the CBR acquisition, we completed a private placement of $500 million aggregate principal amount of 7.875% Senior Notes due 2023 (the “2023 Senior Notes”). The 2023 Senior Notes were issued pursuant to an Indenture, dated as of August 17, 2015 (the “Indenture”), by and among us, certain of our subsidiaries acting as guarantors of the 2023 Senior Notes and Wilmington Trust, National Association, as trustee. In October 2017, we repurchased $25.0 million of the 2023 Senior Notes in a privately negotiated transaction, resulting in a loss on extinguishment of debt of $1.1 million. In September 2018, we repurchased the remaining $475.0 million of the 2023 Senior Notes at a premium of $28.1 million using the proceeds from the CBR sale, which resulted in a loss on extinguishment of debt of $35.9 million, inclusive of the premium paid.
2015 Term Loan Facility
In August 2015, we entered into a credit agreement with a group of lenders, including Jefferies Finance LLC as administrative and collateral agent, that provided us with, among other things, a six-year $350.0 million term loan facility,

69



under which we borrowed the full amount (the “2015 Term Loan Facility”). In May 2017, we repaid the remaining outstanding borrowings and accrued interest of the 2015 Term Loan Facility and, in accordance with ASC 470, recognized a $9.7 million loss on debt extinguishment.
Future Payments
Future annual principal payments on our long-term debt as of December 31, 2019 include $320.0 million due during the year ended December 31, 2022.

S.     RESTRUCTURING EXPENSES
In February 2019, we completed a restructuring to combine our women’s health and maternal health sales forces into one integrated sales team. Approximately 110 employees were displaced through this workforce reduction. We recorded one-time restructuring charges of $7.4 million primarily related to severance and related benefits on our consolidated statement of operations for the year ended December 31, 2019. We expect the restructuring charges incurred to date under this program to be substantially paid in cash by the end of the first quarter of 2020.
The following table displays charges taken related to restructuring activities during the year ended December 31, 2019 and a rollforward of the changes to the accrued balances as of December 31, 2019 (in thousands): 
 
Workforce reduction
 
Contract termination
 
Other
 
Total
Balance accrued at December 31, 2018
$
—

 
$
—

 
$
—

 
$
—

2019 restructuring charges
7,034

 
229

 
157

 
7,420

Payments
(6,237
)
 
(229
)
 
(157
)
 
(6,623
)
Balance accrued at December 31, 2019
$
797

 
$
—

 
$
—

 
$
797




70



T.    CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED
The following tables provide unaudited consolidated quarterly financial data for 2019 and 2018, which have been revised to correct for immaterial errors in prior periods as detailed below and further described in Note X, “Revision of Prior Period Financial Statements” (in thousands, except per share data):
 
March 31, 2019
 
June 30, 2019
 
September 30, 2019
 
December 31, 2019
Total revenues
$
75,488

 
$
77,767

 
$
83,808

 
$
89,483

Gross profit
57,011

 
53,477

 
62,703

 
46,162

Operating expenses (1)
175,024

 
169,662

 
81,050

 
240,329

Net loss from continuing operations
$
(122,400
)
 
$
(121,169
)
 
$
(23,940
)
 
$
(200,152
)
Net income (loss) from discontinued operations
$
—

 
$
—

 
$
—

 
$
—

Net loss
$
(122,400
)
 
$
(121,169
)
 
$
(23,940
)
 
$
(200,152
)
 
 
 
 
 
 
 
 
Basic and diluted earnings per share:
 
 
 
 
 
 
 
Loss from continuing operations
$
(3.55
)
 
$
(3.58
)
 
$
(0.71
)
 
$
(5.90
)
Income (loss) from discontinued operations
—

 
—

 
—

 
—

Total
$
(3.55
)
 
$
(3.58
)
 
$
(0.71
)
 
$
(5.90
)
 
March 31, 2018
 
June 30, 2018
 
September 30, 2018
 
December 31, 2018
Total revenues
$
116,867

 
$
145,663

 
$
121,646

 
$
87,871

Gross profit
52,955

 
68,887

 
75,157

 
59,155

Operating expenses (2)
104,239

 
27,591

 
95,084

 
78,241

Net loss from continuing operations
$
(58,994
)
 
$
(26,795
)
 
$
(65,282
)
 
$
(21,004
)
Net income (loss) from discontinued operations
$
3,856

 
$
5,736

 
$
95,517

 
$
(1,531
)
Net (loss) income
$
(55,138
)
 
$
(21,059
)
 
$
30,235

 
$
(22,535
)
 
 
 
 
 
 
 
 
Basic and diluted earnings per share:
 
 
 
 
 
 
 
Loss from continuing operations
$
(1.72
)
 
$
(0.78
)
 
$
(1.89
)
 
$
(0.61
)
Income (loss) from discontinued operations
0.11

 
0.17

 
2.77

 
(0.04
)
Total
$
(1.61
)
 
$
(0.61
)
 
$
0.88

 
$
(0.65
)
The sum of quarterly earnings per share totals differ from annual earnings per share totals due to rounding.

(1) 
Operating expenses for the first quarter of 2019 include $74.9 million relating to IPR&D acquired through the Perosphere acquisition and $7.4 million relating to the restructuring expenses for the consolidation of the women’s health and maternal health sales forces. Operating expenses for the second quarter of 2019 include $77.4 million of impairment charges relating to the Makena base technology intangible asset. Operating expenses for the fourth quarter of 2019 include $155.0 million of impairment charges relating to the Makena auto-injector, Intrarosa and Vyleesi asset groups.

(2) 
Operating expenses for the second quarter of 2018 include the reversal of $49.8 million relating to the fair value of a contingent consideration liability that was no longer expected to be paid.


71



The following tables present the effect of the revisions to our unaudited condensed consolidated statements of operations for the three months ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 to correct for immaterial errors in prior periods as further described in Note X, “Revision of Prior Period Financial Statements” (in thousands, except per share amounts):

 
Three Months Ended March 31, 2019
 
Three Months Ended June 30, 2019
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
75,729

 
$
(316
)
 
$
75,413

 
$
77,976

 
$
(342
)
 
$
77,634

Total revenues
75,804

 
(316
)
 
75,488

 
78,109

 
(342
)
 
77,767

Income tax (benefit) expense
(137
)
 
—

 
(137
)
 
(120
)
 
—

 
(120
)
Net loss
$
(122,084
)
 
$
(316
)
 
$
(122,400
)
 
$
(120,827
)
 
$
(342
)
 
$
(121,169
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
(3.54
)
 
$
(0.01
)
 
$
(3.55
)
 
$
(3.57
)
 
$
(0.01
)
 
$
(3.58
)

 
Three Months Ended September 30, 2019
 
Three Months Ended December 31, 2019
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
84,107

 
$
(323
)
 
$
83,784

 
$
73,378

 
$
(224
)
 
$
73,154

Total revenues
84,131

 
(323
)
 
83,808

 
89,707

 
(224
)
 
89,483

Income tax (benefit) expense
232

 
—

 
232

 
(21
)
 
—

 
(21
)
Net loss
$
(23,617
)
 
$
(323
)
 
$
(23,940
)
 
$
(199,928
)
 
$
(224
)
 
$
(200,152
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
(0.70
)
 
$
(0.01
)
 
$
(0.71
)
 
$
(5.89
)
 
$
(0.01
)
 
$
(5.90
)


The following tables present the effect of the revisions to our unaudited condensed consolidated statements of operations for the three months ended March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018 to correct for immaterial errors in prior periods as further described in Note X, “Revision of Prior Period Financial Statements” (in thousands, except per share amounts):

 
Three Months Ended March 31, 2018
 
Three Months Ended June 30, 2018
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
117,348

 
$
(520
)
 
$
116,828

 
$
146,219

 
$
(591
)
 
$
145,628

Total revenues
117,387

 
(520
)
 
116,867

 
146,254

 
(591
)
 
145,663

Income tax (benefit) expense
(8,000
)
 
376

 
(7,624
)
 
52,556

 
387

 
52,943

Net loss
$
(54,242
)
 
$
(896
)
 
$
(55,138
)
 
$
(20,081
)
 
$
(978
)
 
$
(21,059
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
(1.59
)
 
$
(0.02
)
 
$
(1.61
)
 
$
(0.58
)
 
$
(0.03
)
 
$
(0.61
)


72



 
Three Months Ended September 30, 2018
 
Three Months Ended December 31, 2018
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
122,238

 
$
(592
)
 
$
121,646

 
$
88,047

 
$
(251
)
 
$
87,796

Total revenues
122,238

 
(592
)
 
121,646

 
88,122

 
(251
)
 
87,871

Income tax (benefit) expense
(2,352
)
 
12

 
(2,340
)
 
(2,550
)
 
7

 
(2,543
)
Net loss
$
30,839

 
$
(604
)
 
$
30,235

 
$
(22,277
)
 
$
(258
)
 
$
(22,535
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
0.89

 
$
(0.01
)
 
$
0.88

 
$
(0.64
)
 
$
(0.01
)
 
$
(0.65
)




73



U.
VALUATION AND QUALIFYING ACCOUNTS (IN THOUSANDS)
 
Balance at Beginning of Period
 
Additions (2)
 
Deductions Charged to Reserves
 
Balance at End of Period
Year ended December 31, 2019:
 
 
 
 
 
 
 
Accounts receivable allowances(1)
$
9,543

 
$
324,542

 
$
(310,668
)
 
$
23,417

Rebates, fees and returns reserves(2)
$
81,868

 
$
321,210

 
$
(283,653
)
 
$
119,425

Valuation allowance for deferred tax assets (3)
$
114,516

 
$
104,858

 
$
(1,083
)
 
$
218,291

Year ended December 31, 2018:
 
 
 
 
 
 
 
Accounts receivable allowances(1)
$
12,060

 
$
229,509

 
$
(232,026
)
 
$
9,543

Rebates, fees and returns reserves(2)
$
103,846

 
$
272,913

 
$
(294,891
)
 
$
81,868

Valuation allowance for deferred tax assets (3)
$
4,740

 
$
109,800

 
$
(24
)
 
$
114,516

Year ended December 31, 2017:
 
 
 
 
 
 
 
Accounts receivable allowances(1)
$
9,533

 
$
168,945

 
$
(166,418
)
 
$
12,060

Rebates, fees and returns reserves(2)
$
90,809

 
$
257,273

 
$
(244,236
)
 
$
103,846

Valuation allowance for deferred tax assets (3)
$
1,429

 
$
3,875

 
$
(564
)
 
$
4,740

________________________

(1) 
Accounts receivable allowances represent discounts and other chargebacks related to the provision of our product sales.

(2) 
Additions to rebates, fees and returns reserves are recorded as a reduction of revenues.

(3) 
As of December 31, 2019 and 2018, we have established a valuation allowance on our net deferred tax assets other than refundable AMT credits. At December 31, 2017, our valuation allowance related primarily to certain of our state NOL and credit carryforwards.

V.     RECENTLY ISSUED AND PROPOSED ACCOUNTING PRONOUNCEMENTS
From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by us as of the specified effective date.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. We adopted ASU 2016-13 effective January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on our consolidated financial statements.
W.     RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASC 842”). This standard requires an entity to recognize on its balance sheet assets and liabilities associated with the rights and obligations created by leases with terms greater than twelve months. We adopted the standard effective January 1, 2019. We chose to apply the provisions of ASC 842 as of the effective date with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected to utilize the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also made accounting policy elections to not separate lease and non-lease components for our real estate lease and to not recognize leases with an initial term of twelve months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis on our condensed consolidated statements of income over the lease term.
In preparation for adoption of the standard, we implemented internal controls to enable the preparation of the related financial information. The adoption of this standard resulted in the recognition of operating lease liabilities of $8.5 million and related ROU assets of $7.6 million on our condensed consolidated balance sheets as of January 1, 2019, but did not have an impact on our consolidated statements of operations.
In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 (“ASU 2018-18”). This standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In

74



addition, ASU 2018-18 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. We adopted ASU 2018-18 during the first quarter of 2019 and applied the provisions of this update retrospectively to all contracts that were not completed as of the date of our initial adoption of ASC 606. The adoption of ASU 2018-18 did not have a material impact on our financial position or results of operations.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. We adopted ASU 2016-09 during the first quarter of 2017 and will now record all excess tax benefits and deficiencies related to share-based compensation in our condensed consolidated statements of operations as discrete events in the interim reporting period in which the benefit or deficiency occurs. Such benefits and deficiencies will not be considered in the calculation of our annual estimated effective tax rate. Any excess tax benefits that were not previously recognized because the related tax deduction had not reduced current taxes payable (i.e. was not realized) are to be recorded using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings as of the beginning of the period in which the new guidance is adopted. We recorded a cumulative-effect adjustment to our accumulated deficit from previously unrecognized excess tax benefits of $21.6 million during the first quarter of 2017. Lastly, we will continue to use the current method of estimated forfeitures each period rather than accounting for forfeitures as they occur.

X.     REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS
Subsequent to the issuance of our Form 10-K for the year ended December 31, 2019, management identified certain individually immaterial errors aggregating to $6.3 million related to governmental rebate accruals associated with Makena sales from 2016 through 2019.

From 2016 through 2019, we understated our GTN adjustments for governmental rebates and the related accrual for a certain state program. We concluded that the errors were not material to any prior annual or interim period; however, we determined that correcting the aggregate error would be material to the three and six months ended June 30, 2020. As a result, we have revised our historical financial statements to properly reflect GTN adjustments and the related accrual in the appropriate periods.

The effect of the corrections to our consolidated balance sheet for the years ended December 31, 2019 and 2018 were as follows (in thousands):

 
December 31, 2019
 
As reported
 
Adjustment
 
As adjusted
Accrued expenses
177,079

 
6,303

 
183,382

Accumulated deficit
$
(1,008,898
)
 
$
(6,303
)
 
$
(1,015,201
)

 
December 31, 2018
 
As reported
 
Adjustment
 
As adjusted
Accrued expenses
129,537

 
5,098

 
134,635

Accumulated deficit
$
(542,442
)
 
$
(5,098
)
 
$
(547,540
)


75



The effect of the corrections to our consolidated statements of operations for the years ended December 31, 2019, 2018 and 2017 are as follows (in thousands, except per share amounts):

 
Year Ended December 31, 2019
 
As reported
 
Adjustment
 
As adjusted
Product sales, net
$
311,190

 
$
(1,205
)
 
$
309,985

Total revenues
327,751

 
(1,205
)
 
326,546

Income tax (benefit) expense
(47
)
 
—

 
(47
)
Net loss from continuing operations
(466,456
)
 
(1,205
)
 
(467,661
)
Net loss
$
(466,456
)
 
$
(1,205
)
 
$
(467,661
)
 
 
 
 
 
 
Basic and diluted net loss per share
$
(13.71
)
 
$
(0.03
)
 
$
(13.74
)

 
Year Ended December 31, 2018
 
As reported
 
Adjustment
 
As adjusted
Product sales, net
$
473,852

 
$
(1,954
)
 
$
471,898

Total revenues
474,002

 
(1,954
)
 
472,048

Income tax (benefit) expense
39,654

 
782

 
40,436

Net loss from continuing operations
(169,339
)
 
(2,736
)
 
(172,075
)
Net loss
$
(65,761
)
 
$
(2,736
)
 
$
(68,497
)
 
 
 
 
 
 
Basic and diluted net loss per share
$
(1.91
)
 
$
(0.08
)
 
$
(1.99
)

 
Year Ended December 31, 2017
 
As reported
 
Adjustment
 
As adjusted
Product sales, net
$
495,645

 
$
(1,802
)
 
$
493,843

Total revenues
495,769

 
(1,802
)
 
493,967

Income tax (benefit) expense
(175,254
)
 
(267
)
 
(175,521
)
Net loss from continuing operations
(205,153
)
 
(1,535
)
 
(206,688
)
Net loss
$
(199,228
)
 
$
(1,535
)
 
$
(200,763
)
 
 
 
 
 
 
Basic and diluted net loss per share
$
(5.71
)
 
$
(0.04
)
 
$
(5.75
)


The consolidated statements of other comprehensive loss for the years ended December 31, 2019, 2018 and 2017 have been revised to include the changes to “net loss” summarized above.

The consolidated statements of stockholders’ equity for the years ended December 31, 2019, 2018 and 2017 have been revised to include the changes to “net loss” summarized above as well as an increase of $0.8 million to the beginning “accumulated deficit” as of January 1, 2017, representing the accumulated error through that date.

The impact on our consolidated statements of cash flows for the years ended December 31, 2019, 2018 and 2017, was limited to the offsetting corrections between “net loss” and changes in “accounts payable and accrued expenses” and “deferred income taxes” presented within “net cash used in operating activities” in each year, as summarized in the above tables.

Y.     SUBSEQUENT EVENTS (unaudited)
In connection with the amendment of our financial statements, we have evaluated subsequent events through the date the financial statements were available to be reissued.

May 2020 Restructuring

In May 2020, we completed a restructuring to reduce the size of our organization in conjunction with the planned divestiture of Intrarosa and Vyleesi and expected declines in our revenue due to the COVID-19 pandemic. Approximately 110 employees were displaced through this workforce reduction. We recorded a one-time restructuring charge of $8.2 million primarily related to severance and related benefits on our condensed consolidated statement of operations during the second quarter of 2020 and expect the restructuring charges incurred to date under this program to be substantially paid in cash by the end of the second quarter of 2021.

Sale of Intrarosa

On May 21, 2020, we sold our rights to commercialize and have manufactured Intrarosa in the United States to Millicent Pharma Limited (“Millicent”) pursuant to an Asset Purchase Agreement between the Company and Millicent, dated May 21, 2020. Under the terms of the Asset Purchase Agreement, we received an upfront payment of $20.9 million in cash, subject to customary purchase price adjustments, including in connection with the transfer of certain inventory. We are eligible to receive up to $105.0 million in aggregate milestone payments upon the achievement of certain sales milestones, namely: (a) $25.0 million the first time net sales during any consecutive twelve month period exceeds $65.0 million, (b) $35.0 million the first time net sales during any consecutive twelve month period exceeds $115.0 million and (c) $45.0 million the first time net sales during any consecutive twelve month period exceeds $175.0 million. We recognized a Gain on Sale of Assets of $14.4 million on our condensed consolidated statements of operations for the three and six months ended June 30, 2020 related to this transaction.

Cessation of the AMAG-423 Study

In July 2020, we decided to stop the AMAG-423 Phase 2b/3a study. This decision was based primarily on the independent Data Safety Monitoring Board’s (the “DSMB”) unanimous recommendation to stop the study following an interim analysis of the data collected to date in the study, which analysis we asked the DSMB to conduct due to extended and ongoing delays in enrollment of the trial (based primarily on the effect of COVID-19 on clinical trial research and the nature of the patient population). There were no safety concerns raised during this study and safety was not a contributing factor to our decision to terminate the study. We are currently focused on ensuring an appropriate closeout of the study in partnership with investigators and other relevant stakeholders. In connection with the cessation of the AMAG-423 Phase 2b/3a study, on August 6, 2020, we terminated our supply agreement (including termination of significant minimum purchase obligations) with our third party supplier in exchange for a one-time payment by us of $12.5 million and our grant to our third party supplier of a 9-month option (subject to extension under certain situations) to acquire the AMAG-423 program rights and assume our related obligations, including our obligations under the Velo Option Agreement.

License to Develop and Commercialize ciraparantag in Europe, Australia and New Zealand

In July 2020, we entered into a License and Commercialization Agreement with Norgine B.V. (“Norgine”, and such agreement, the “Norgine Agreement”), pursuant to which we granted Norgine an exclusive license to develop and commercialize ciraparantag in certain countries in Europe, Australia and New Zealand. We received a $30.0 million upfront payment upon signing. In addition, pursuant to the terms and conditions of the Norgine Agreement (a) Norgine will pay us one-

76



third of the actual and reasonable out-of-pocket costs of the Phase 3 program, pursuant to a mutually agreed upon budget, (b) we are eligible to receive up to $70.0 million upon the achievement of certain regulatory milestones (of which we will pay $40.0 million to the former equity holders of Perosphere pursuant to the terms of the Perosphere Agreement), (c) we are eligible to receive up to $190.0 million contingent upon meeting certain sales milestones, and (d) Norgine will pay us tiered double-digit royalties on net sales in the licensed territory. We will be responsible for manufacturing and supplying Norgine with its requirements of clinical and commercial product pursuant to supply agreement(s) to be entered into by the parties.

Settlement

On July 14, 2020, we entered into a Confidential Settlement Agreement and Release with a third-party manufacturer to resolve outstanding disputes. Pursuant to this agreement, we were paid a sum of $17.4 million, and the parties exchanged mutual releases to resolve all disputes between them.

Termination of the Palatin Agreement

In July 2020, we entered into a termination agreement with Palatin detailing the terms and conditions for the termination of our rights and obligations to develop and commercialize Vyleesi under the Palatin License Agreement and for the transfer of full ownership of Vyleesi to Palatin (the “Termination Agreement”). In accordance with the terms of the Termination Agreement, we transferred and assigned to Palatin the regulatory approval for Vyleesi, inventory, certain third party contracts, intellectual property rights and regulatory files and commercial materials of AMAG related to Vyleesi in the AMAG Territory. In consideration for the early termination of the License Agreement, the assumption of certain liabilities by Palatin (including significant minimum purchase obligations), and in lieu of any future milestone payments, royalties and other payments by AMAG to Palatin contemplated by the Palatin License Agreement, we paid Palatin $12.0 million following the termination, and we will pay an additional $4.3 million on March 31, 2021. In addition, we agreed to provide certain transitional services to Palatin for a period of time following the closing pursuant to a transition services agreement.

ITEM 9A. CONTROLS AND PROCEDURES:
Managements’ Evaluation of our Disclosure Controls and Procedures
Our principal executive officer and principal financial officer, with the participation of our management, have each evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of December 31, 2019. At the time we filed the Original 10-K, our principal executive officer and principal financial officer had concluded that as of December 31, 2019 our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Subsequent to that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of December 31, 2019 because of the material weakness in our internal control over financial reporting, as described in Management’s Annual Report on Internal Control Over Financial Reporting (Restated).
Management’s Annual Report on Internal Control Over Financial Reporting (Restated)
Management’s Annual Report on Internal Control Over Financial Reporting (Restated) is contained in Part II, Item 8 “Financial Statements and Supplementary Data” of this Amended Annual Report on Form 10-K/A for the year ended December 31, 2019 and is incorporated herein by reference.
Plan for Remediation of Material Weakness

We have already taken certain steps and will take additional steps to remediate this material weakness, including the development of enhanced controls governing our GTN adjustments for governmental rebates and accruals.
Our remediation efforts are intended to address the identified material weakness. Management is committed to continuous improvement of our internal control over financial reporting and will continue to diligently review our internal control over financial reporting.

77




Changes in Internal Control Over Financial Reporting
 
There were no changes in our internal control over financial reporting (as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during the three months ended December 31, 2019 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting. 
 
PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES:
(a) The following documents are filed as part of this Annual Report on Form 10-K/A:

(1)
Financial Statements:
The financial statements are filed as part of this Annual Report on Form 10-K/A under “Item 8. Financial Statements and Supplementary Data.”


78



(2)
Financial Statement Schedules:
The financial statement schedules are omitted as they are either not applicable or the information required is presented in the financial statements and notes thereto under “Item 8. Financial Statements and Supplementary Data.”

(3)
Exhibits:
See Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K/A.

EXHIBIT INDEX
 
 
 
Exhibit
Number
    
Description
2.1
 
2.2
 
3.1, 4.1
 
3.2, 4.2
 
3.3, 4.3
 
4.4
 
4.5
 
4.6
 
4.7
 
4.8
 
10.1*
 
10.2*
 
10.3*
 
10.4*
 
10.5*
 
10.6*
 

79



10.7*
 
10.8*
 
10.9*
 
10.10*
 
10.11*
 
10.12*
 
10.13*
 
10.14*
 
10.15*
 
10.16*
 
10.17*
 
10.18*
 
10.19*
 
10.20*
 
10.21*
 
10.22*
 
10.23*
 
10.24
 
10.25
 
10.26
 
10.27
 

80



10.28
 
10.29
 
10.30
 
10.31
 
10.32
 
10.33
 
10.34
 
10.35
 
10.36
 
10.37
 
10.38
 
10.39
 
10.40
 
10.41
 
10.42
 
10.43
 

81



10.44
 
10.45
 
21.1
 
23.1+
 
24.1
 
Power of Attorney (included on the signature page(s) hereto)
31.1+
 
31.2+
 
32.1++
 
32.2++
 
101.SCH+
 
Inline XBRL Taxonomy Extension Schema Document
101.CAL+
 
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF+
 
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB+
 
Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE+
 
Inline XBRL Taxonomy Extension Presentation Linkbase Document
104+
 
Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)

+
 
Exhibits marked with a plus sign (“+”) are filed herewith.
++
 
Exhibits marked with a double plus sign (“++”) are furnished herewith.
*
 
Exhibits marked with a single asterisk reference management contracts, compensatory plans or arrangements, filed in response to Item 15(a)(3) of the instructions to Form 10‑K.
 
 
The other exhibits listed and not marked with a “+” or “++” have previously been filed with the SEC and are incorporated herein by reference, as indicated.

82



SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
AMAG PHARMACEUTICALS, INC.
 
 
 
By:
/s/ Scott D. Myers
 
 
Scott D. Myers
President and Chief Executive Officer
 
Date:
September 15, 2020

We, the undersigned officers and directors of AMAG Pharmaceuticals, Inc., hereby severally constitute and appoint Scott D. Myers and Brian Piekos, and each of them singly, our true and lawful attorneys, with full power to them and each of them singly, to sign for us in our names in the capacities indicated below, all amendments to this report, and generally to do all things in our names and on our behalf in such capacities to enable AMAG Pharmaceuticals, Inc. to comply with the provisions of the Securities Exchange Act of 1934, as amended, and all requirements of the Securities and Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Name
 
Title
 
Date
 
 
 
 
 
/s/ Scott D. Myers
 
President and Chief Executive Officer (Principal Executive Officer) and Director
 
September 15, 2020
Scott D. Myers
 
 
 
 
 
 
 
 
 
/s/ Brian Piekos
 
Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)
 
September 15, 2020
Brian Piekos
 
 
 
 
 
 
 
 
 
/s/ John Fallon, M.D.
 
Director
 
September 15, 2020
John Fallon, M.D.
 
 
 
 
 
 
 
 
 
/s/ Paul Fonteyne
 
Director
 
September 15, 2020
Paul Fonteyne
 
 
 
 
 
 
 
 
 
/s/ David E. Johnson
 
Director
 
September 15, 2020
David E. Johnson
 
 
 
 
 
 
 
 
 
/s/ Kathrine O’Brien
 
Director
 
September 15, 2020
Kathrine O’Brien
 
 
 
 
 
 
 
 
 
/s/ Anne M. Phillips, M.D., FRCPC
 
Director
 
September 15, 2020
Anne M. Phillips, M.D., FRCPC
 
 
 
 
 
 
 
 
 
/s/ Gino Santini
 
Director
 
September 15, 2020
Gino Santini
 
 
 
 
 
 
 
 
 
/s/ Davey S. Scoon
 
Director
 
September 15, 2020
Davey S. Scoon
 
 
 
 
 
 
 
 
 
/s/ James Sulat
 
Director
 
September 15, 2020
James Sulat
 
 
 
 

83


 EX-23.1 2 ex2312019a.htm EXHIBIT 23.1 Exhibit
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S‑3 (File No.  333-225604) and on Forms S‑8 (File Nos. 333‑148682, 333‑159938, 333‑168786, 333-182821, 333‑190435, 333‑197873, 333-203924, 333-211277, 333-218911, 333-226548 and 333-231542) of AMAG Pharmaceuticals, Inc. of our report dated March 6, 2020, except for the effects of the revision discussed in Note X to the consolidated financial statements and the matter discussed in the second paragraph of Management's Annual Report on Internal Control over Financial Reporting, as to which the date is September 15, 2020 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Amendment No. 1 on Form 10‑K/A.

/s/ PricewaterhouseCoopers LLP
 
Boston, Massachusetts
 
September 15, 2020
 



 EX-31.1 3 ex3112019a.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
 
CERTIFICATIONS
 
I, Scott D. Myers, certify that:

1.
I have reviewed this Annual Report on Form 10‑K/A of AMAG Pharmaceuticals, Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a‑15(f) and 15d‑15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
 
Date:
September 15, 2020
 
 
 
 
 
 
/s/ Scott D. Myers
 
 
Scott D. Myers
 
 
President and Chief Executive Officer
(Principal Executive Officer)


 EX-31.2 4 ex3122019a.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2

CERTIFICATIONS

I, Brian Piekos, certify that:

1.
I have reviewed this Annual Report on Form 10‑K/A of AMAG Pharmaceuticals, Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a‑15(f) and 15d‑15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
 
 
Date:
September 15, 2020
 
 
 
/s/ Brian Piekos
 
 
Brian Piekos
 
 
Executive Vice President, Chief Financial Officer and Treasurer
(Principal Financial Officer)


 EX-32.1 5 ex3212019a.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002

In connection with the Annual Report of AMAG Pharmaceuticals, Inc. (the “Company”) on Form 10-K/A for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Scott D. Myers, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
 
 
 
/s/ Scott D. Myers
 
Scott D. Myers
 
President and Chief Executive Officer
 
(Principal Executive Officer)
 
 
 
 
September 15, 2020
 



 EX-32.2 6 ex3222019a.htm EXHIBIT 32.2 Exhibit
Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002

In connection with the Annual Report of AMAG Pharmaceuticals, Inc. (the “Company”) on Form 10-K/A for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian Piekos, Executive Vice President, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


 
 
 
/s/ Brian Piekos
 
Brian Piekos
 
Executive Vice President, Chief Financial Officer and
 
Treasurer (Principal Financial Officer)
 
 
 
 
September 15, 2020
 






 EX-101.SCH 7 amag-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2112100 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS - Assets Acquired and Liabilities Assumed Related to the Asset Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - COMMITMENTS AND CONTINGENCIES - Operating Leases, Fiscal Year Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - COMMITMENTS AND CONTINGENCIES - Operating Leases, Fiscal Year Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED - Schedule of Effects of Corrections and Prior Period Ajustments (Details) link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED - Schedule of Unaudited Consolidated Quartely Financial Data (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED (Tables) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - CURRENT AND LONG-TERM LIABILITIES link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - CURRENT AND LONG-TERM LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - CURRENT AND LONG-TERM LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 2418407 - Disclosure - DEBT - 2015 Term Loan Facility (Details) link:presentationLink link:calculationLink link:definitionLink 2418406 - Disclosure - DEBT - 2023 Senior Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2418404 - Disclosure - DEBT - Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2418408 - Disclosure - DEBT - Future Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - DEBT - Outstanding Convertible Note Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - DEBT - Schedule of Outstanding Debt Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2418405 - Disclosure - DEBT - Schedule of Total Interest Expense Recognized Related to the Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - DESCRIPTION OF BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - DISCONTINUED OPERATIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - DISCONTINUED OPERATIONS - Summary of Net Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - EMPLOYEE SAVINGS PLAN link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - EMPLOYEE SAVINGS PLAN (Details) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - EQUITY-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - EQUITY-BASED COMPENSATION - Activity Related to Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - EQUITY-BASED COMPENSATION - Equity-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - EQUITY-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2413407 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of RSUs Granted (Details) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Stock-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - EQUITY-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - EQUITY-BASED COMPENSATION - Weighted-Average Fair Value Assumptions, Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - FAIR VALUE MEASUREMENTS - Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - FAIR VALUE MEASUREMENTS - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - FAIR VALUE MEASUREMENTS - Nonrecurring Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET - Goodwill - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET - Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - INCOME TAXES - Deferred Tax Components (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - INCOME TAXES - Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - INCOME TAXES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - INCOME TAXES - Reconciliation of Uncertain Tax Positions (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - INCOME TAXES - Schedule of Income Tax Expense (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - MARKETABLE SECURITIES link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - MARKETABLE SECURITIES (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - MARKETABLE SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - PROPERTY AND EQUIPMENT, NET link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 2423401 - Disclosure - RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - RECENTLY ISSUED AND PROPOSED ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - RESTRUCTURING EXPENSES link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - RESTRUCTURING EXPENSES - Components of Restructuring Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - RESTRUCTURING EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - RESTRUCTURING EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - REVENUE RECOGNITION link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - REVENUE RECOGNITION - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - REVENUE RECOGNITION - Disaggregated Revenue By Major Products (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - REVENUE RECOGNITION - Product Revenue Allowance and Accrual Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - REVENUE RECOGNITION (Tables) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - REVENUE RECOGNITION - Total Gross Product (Details) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS link:presentationLink link:calculationLink link:definitionLink 2424403 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Condensed Consolidated Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 2424404 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Condensed Consolidated Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2424402 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2324301 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - STOCKHOLDERS’ EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - SUBSEQUENT EVENTS (unaudited) link:presentationLink link:calculationLink link:definitionLink 2425401 - Disclosure - SUBSEQUENT EVENTS (unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2402409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2402410 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basic and Diluted Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2402412 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Business Segments (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customers Who Represent 10% or More of Total Revenues or Accounts Receivable Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2402407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2402408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2402411 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Anti-dilutive Securities excluded from Computation of Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS link:presentationLink link:calculationLink link:definitionLink 2421402 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS (Details) link:presentationLink link:calculationLink link:definitionLink 2321301 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 amag-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 amag-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 amag-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Notes Senior Notes [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 2023 Senior Notes Senior Notes Due 2023 [Member] Senior Notes Due 2023 [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Principal amount of debt at time of issuance Debt Instrument, Face Amount Interest rate Debt Instrument, Interest Rate, Stated Percentage Repurchased amount Debt Instrument, Repurchased Face Amount Loss on debt extinguishment Gain (Loss) on Extinguishment of Debt Payment of premium on debt extinguishment Payment for Debt Extinguishment or Debt Prepayment Cost Revenue from Contract with Customer [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Product sales, net Product [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Gross product sales Revenue from Contract with Customer, Excluding Assessed Tax, Gross Revenue from Contract with Customer, Excluding Assessed Tax, Gross Provision for product sales allowances and accruals: Provision For Product Sales Allowances And Accruals [Abstract] Provision For Product Sales Allowances And Accruals Contractual adjustments Revenue From Contract With Customer, Contractual Adjustments Revenue From Contract With Customer, Contractual Adjustments Governmental rebates Revenue Adjustment, Governmental Rebates Revenue Adjustment, Governmental Rebates Total Provision For Product Sales Allowances And Accruals Provision For Product Sales Allowances And Accruals Product sales, net Revenue from Contract with Customer, Excluding Assessed Tax Contractual Adjustments Revenue From Contract From Customer, Allowance [Roll Forward] Revenue From Contract From Customer, Allowance [Roll Forward] Balance at Beginning of Period Revenue From Contract From Customer, Allowance Revenue From Contract From Customer, Allowance Provisions related to current period sales Revenue from Contract with Customer, Contractual Adjustments, Current Period Sales Revenue from Contract with Customer, Contractual Adjustments, Current Period Sales Adjustments related to prior period sales Revenue from Contract with Customer, Contractual Adjustments, Prior Period Sales Revenue from Contract with Customer, Contractual Adjustments, Prior Period Sales Payments/returns relating to current period sales Revenue From Contract With Customer, Payments And Returns, Current Period Sales Revenue From Contract With Customer, Payments And Returns, Current Period Sales Payments/returns relating to prior period sales Revenue From Contract With Customer, Payments And Returns, Prior Period Sales Revenue From Contract With Customer, Payments And Returns, Prior Period Sales Balance at End of Period Governmental Rebates Revenue Adjustment, Governmental Rebates, Allowance [Roll Forward] Revenue Adjustment, Governmental Rebates, Allowance [Roll Forward] Balance at Beginning of Period Revenue Adjustment, Governmental Rebates, Allowance Revenue Adjustment, Governmental Rebates, Allowance Provisions related to current period sales Revenue Adjustment, Governmental Rebates, Current Period Sales Revenue Adjustment, Governmental Rebates, Current Period Sales Adjustments related to prior period sales Revenue Adjustment, Governmental Rebates, Prior Period Sales Revenue Adjustment, Governmental Rebates, Prior Period Sales Payments/returns relating to current period sales Revenue Adjustment, Governmental Rebates, Payments And Returns, Current Period Sales Revenue Adjustment, Governmental Rebates, Payments And Returns, Current Period Sales Payments/returns relating to prior period sales Revenue Adjustment, Governmental Rebates, Payments And Returns, Prior Period Sales Revenue Adjustment, Governmental Rebates, Payments And Returns, Prior Period Sales Balance at End of Period Revenue, Allowance [Roll Forward] Revenue, Allowance [Roll Forward] Revenue, Allowance [Roll Forward] Balance at Beginning of Period Revenue, Allowance Revenue, Allowance Provisions related to current period sales Revenue Adjustments, Current Period Sales Revenue Adjustments, Current Period Sales Adjustments related to prior period sales Revenue Adjustment, Prior Period Sales Revenue Adjustment, Prior Period Sales Payments/returns relating to current period sales Revenue, Payments and Returns, Current Period Sales Revenue, Payments and Returns, Current Period Sales Payments/returns relating to prior period sales Revenue, Payments and Returns, Prior Period Sales Revenue, Payments and Returns, Prior Period Sales Balance at End of Period Accounting Policies [Abstract] Inventory, Current [Table] Inventory, Current [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Inventory [Line Items] Inventory [Line Items] Shelf-life Inventory, Finished Goods, Shelf Life Inventory, Finished Goods, Shelf Life Restructuring and Related Activities [Abstract] Employees displaced through workforce reduction Restructuring and Related Cost, Number of Positions Eliminated Restructuring expenses Restructuring Charges Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Scenario [Axis] Scenario [Axis] Scenario [Domain] Scenario [Domain] Forecast Forecast [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] First Time Net Sales During Threshold Period Exceeds $65 Million First Time Net Sales During Threshold Period Exceeds $65 Million [Member] First Time Net Sales During Threshold Period Exceeds $65 Million [Member] First Time Net Sales During Threshold Period Exceeds $115 Million First Time Net Sales During Threshold Period Exceeds $115 Million [Member] First Time Net Sales During Threshold Period Exceeds $115 Million [Member] First Time Net Sales During Threshold Period Exceeds $175 Million First Time Net Sales During Threshold Period Exceeds $175 Million [Member] First Time Net Sales During Threshold Period Exceeds $175 Million [Member] Regulatory Milestone Achievement Regulatory Milestone Achievement [Member] Regulatory Milestone Achievement [Member] Sales Milestones Achievement Sales Milestones Achievement [Member] Sales Milestones Achievement [Member] Intrarosa Intrarosa [Member] Intrarosa [Member] Ciraparantag Ciraparantag [Member] Ciraparantag [Member] Vyleesi Products Vyleesi Products [Member] Vyleesi Products [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Millicent Pharma Limited Millicent Pharma Limited [Member] Millicent Pharma Limited [Member] Norgine B.V. Norgine B.V. [Member] Norgine B.V. [Member] Palatin Technologies, Inc. Palatin Technologies, Inc. [Member] Palatin Technologies, Inc. [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Restructuring charges Proceeds related to collaborative arrangement Proceeds Related To Collaborative Arrangement Proceeds Related To Collaborative Arrangement Potential milestone proceeds from collaborative arrangement Collaborative Arrangement, Potential Milestone Proceeds Collaborative Arrangement, Potential Milestone Proceeds Potential milestone proceeds, triggering event, sales Collaborative Arrangement, Potential Milestone Proceeds, Triggering Event, Threshold Amount Collaborative Arrangement, Potential Milestone Proceeds, Triggering Event, Threshold Amount Consecutive period for sales to exceed threshold amount for potential milestone proceeds (in months) Collaborative Arrangement, Potential Milestone Proceeds, Triggering Event, Threshold Period Collaborative Arrangement, Potential Milestone Proceeds, Triggering Event, Threshold Period Gain on sale of assets Gain (Loss) on Disposition of Intangible Assets Agreement termination payment Purchase Commitment, Termination Payment Purchase Commitment, Termination Payment Option period to third party supplier to acquire study Purchase Commitment, Option To Third Party To Acquire Study, Period Purchase Commitment, Option To Third Party To Acquire Study, Period Recovery of direct costs Collaborative Arrangement, Recovery Of Direct Costs, Percentage Collaborative Arrangement, Recovery Of Direct Costs, Percentage Potential milestone proceeds from collaborative arrangement payable to equity holders Collaborative Arrangement, Potential Milestone Proceeds, Payable To Equity Holders Collaborative Arrangement, Potential Milestone Proceeds, Payable To Equity Holders Settlement awarded to other party Litigation Settlement, Amount Awarded to Other Party Early contract termination fees Asset Acquisition, Early Contract Termination Fees Asset Acquisition, Early Contract Termination Fees Share-based Payment Arrangement [Abstract] Summary of details regarding stock options granted under equity incentive plans Share-based Payment Arrangement, Option, Activity [Table Text Block] Summary of details regarding restricted stock units granted under equity incentive plans Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Schedule of equity-based compensation expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of share-based payment award, stock options, valuation assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Statement of Comprehensive Income [Abstract] Net loss Net Income (Loss) Attributable to Parent Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Unrealized (losses) gains on marketable securities: Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract] Holding gains (losses) arising during period, net of tax Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Discontinued Operations and Disposal Groups [Abstract] DISCONTINUED OPERATIONS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Equity [Abstract] ACCUMULATED OTHER COMPREHENSIVE LOSS Comprehensive Income (Loss) Note [Text Block] Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Concentration Risk [Table] Concentration Risk [Table] Feraheme Feraheme [Member] Feraheme [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Revenue from Contract with Customer Revenue from Contract with Customer Benchmark [Member] Accounts Receivable Accounts Receivable [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] McKesson Corporation McKesson Corporation [Member] Represents McKesson Corporation. AmerisourceBergen Drug Corporation Amerisource Bergen Drug Corporation [Member] Represents AmerisourceBergen Drug Corporation, a major customer of the entity. Cardinal Health Cardinal Health, Inc. [Member] Cardinal Health, Inc. [Member] Three Customers Three Customers [Member] Three Customers [Member] Two Customers Two Customers [Member] Two Customers [Member] Concentrations and Significant Customer Information Concentration Risk [Line Items] Concentration risk, including less than and more than 10% (percent) Concentration Risk, Percentage Number of production facilities Number Of Production Facilities Number Of Production Facilities SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] VALUATION AND QUALIFYING ACCOUNTS SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Rebate payment term Rebate, Payment Term Rebate, Payment Term Discount percentage Revenue Discount Percentage Revenue Discount Percentage Standard payment term Revenue, Standard Payment Term Revenue, Standard Payment Term Percentage of discount accrued at time of sale Revenue Discount, Percentage Accrued At Time Of Sale Revenue Discount, Percentage Accrued At Time Of Sale GPO billing period Group Purchasing Organization, Billing Period Group Purchasing Organization, Billing Period Product return term Contract With Customer, Refund Liability, Term Contract With Customer, Refund Liability, Term SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Accounts receivable allowances Allowance For Promotions1 [Member] Allowance For Promotions1 [Member] Rebates, fees and returns reserves Allowance For Sales Returns1 [Member] Allowance For Sales Returns1 [Member] Valuation allowance for deferred tax assets SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Valuation Allowance for Impairment of Recognized Servicing Assets [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Balance at Beginning of Period SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Additions SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Deductions Charged to Reserves SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Balance at End of Period Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Beginning balance (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Expired and/or forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Ending balance (shares) Outstanding at end of year - vested and unvested expected to vest (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Exercisable at end of year (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Beginning balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Expired and/or forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Ending balance (in dollars per share) Outstanding at end of year - vested and unvested expected to vest (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Exercisable at end of year (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Stock Option Activity, Additional Disclosures Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Remaining Contractual Term, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Outstanding at end of year - vested and unvested expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Exercisable at end of year Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value, Outstanding at end of year Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding at end of year, vested and unvested expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Aggregate Intrinsic Value, Exercisable at end of year Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Attributable to Parent, Net of Tax AOCI Attributable to Parent, Net of Tax [Roll Forward] Beginning balance Stockholders' Equity Attributable to Parent Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Ending balance Property, Plant and Equipment [Abstract] Schedule of property equipment, net Property, Plant and Equipment [Table Text Block] Fair Value Disclosures [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Convertible Debt Convertible Debt [Member] 2022 Convertible Notes Convertible Notes Due 2022 [Member] Convertible Notes due 2022 [Member] 2019 Convertible Notes Convertible Notes Due 2019 [Member] Convertible Notes due 2019 [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Debt Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair value of debt Debt Instrument, Fair Value Disclosure Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Computer equipment and software Computer Equipment And Software [Member] Computer Equipment and Software [Member] Furniture and fixtures Furniture and Fixtures [Member] Laboratory and production equipment Equipment [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Estimated useful lives Property, Plant and Equipment, Useful Life Cover [Abstract] Document Type Document Type Document Annual Report Document Annual Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Public Float Entity Public Float Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Amendment Description Amendment Description Schedule of changes in accumulated other comprehensive loss associated with unrealized (losses) gains on securities Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Measurement Input Type [Axis] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Measurement Input, Control Premium Measurement Input, Control Premium [Member] Goodwill [Line Items] Goodwill [Line Items] Goodwill Goodwill Accumulated impairment losses Goodwill, Impaired, Accumulated Impairment Loss Share price (in dollars per share) Share Price Market capitalization Market Capitalization Market Capitalization Fair value percentage below carrying amount, reporting unit Reporting Unit, Percentage Of Fair Value Below Carrying Amount Reporting Unit, Percentage Of Fair Value Below Carrying Amount Reporting unit, measurement input Reporting Unit, Measurement Input Reporting Unit, Measurement Input Reporting unit, measurement input, median Reporting Unit, Measurement Input, Median Reporting Unit, Measurement Input, Median Fair value percentage above carrying amount, net assets Net Assets, Percentage Of Fair Value In Excess Of Carrying Amount Net Assets, Percentage Of Fair Value In Excess Of Carrying Amount Goodwill, impairment Goodwill, Impairment Loss Share price, median (in dollars per share) Share Price, Median Share Price, Median Reporting unit, carrying amount Reporting Unit, Carrying Amount Reporting Unit, Carrying Amount Impairment of intangible assets Impairment of Intangible Assets, Finite-lived Organization, Consolidation and Presentation of Financial Statements [Abstract] Summary of assets acquired and liabilities assumed related to the asset acquisition Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Payables and Accruals [Abstract] Schedule of accrued expenses Schedule of Accrued Liabilities [Table Text Block] Fair value of intangible assets Finite-lived Intangible Assets, Fair Value Disclosure Impairment of assets Asset Impairment Charges DESCRIPTION OF BUSINESS Nature of Operations [Text Block] COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS Collaborative Arrangement Disclosure [Text Block] Contractual interest expense Interest Expense, Debt, Excluding Amortization Amortization of debt issuance costs Amortization of Debt Issuance Costs Amortization of debt discount Amortization of Debt Discount (Premium) Total interest expense Interest Expense, Debt Income Tax Disclosure [Abstract] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) Total current Current Income Tax Expense (Benefit) Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) Total deferred Deferred Income Tax Expense (Benefit) Total income tax (benefit) expense Income Tax Expense (Benefit) EQUITY-BASED COMPENSATION Share-based Payment Arrangement [Text Block] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] RSUs Restricted Stock Units (RSUs) [Member] Equity compensation plans Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Restricted Stock Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding at beginning of year (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Outstanding at end of year (shares) Outstanding at end of year and expected to vest (shares) Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Beginning balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeitures (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Ending balance (in dollars per share) Outstanding at end of year and expected to vest (in dollars per share) Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Exercise Price Award Date [Axis] Award Date [Axis] Award Date [Domain] Award Date [Domain] February 2019 February 2019 [Member] February 2019 March 2018 March 2018 [Member] March 2018 [Member] February 2017 February 2017 [Member] February 2017 [Member] Performance Restricted Stock Units (RSUs) Performance Restricted Stock Units (RSUs) [Member] Performance Restricted Stock Units (RSUs) [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2019 Equity Plan Equity Incentive Plan 2019 [Member] Equity Incentive Plan 2019 [Member] 2007 Equity Plan Equity Incentive Plan 2007 [Member] This element represents the 2007 Equity Incentive Plan also referred as the 2007 Plan. 2013 Lumara Equity Plan Lumara Health 2013 Plan [Member] Represents information relating to the Lumara Health 2013 Plan. Inducement Grants Inducement Grants [Member] Represents the other equity compensation grants such as inducement grants used for certain employees to induce them to accept employment with the company. Stock Options Expired or terminated (shares) Restricted Stock Units Expired or terminated (in shares) Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Remaining number of shares available for future grants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Fair value, performance- based RSUs Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Compensation expense, period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition STOCKHOLDERS’ EQUITY Stockholders' Equity Note Disclosure [Text Block] Furniture and fixtures Leasehold improvements Leasehold Improvements [Member] Laboratory and production equipment Construction in progress Construction in Progress [Member] Property and equipment, gross Property, Plant and Equipment, Gross Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net Depreciation expense Depreciation Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Unrecognized tax benefits at the beginning of the year Unrecognized Tax Benefits Additions based on tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Additions for tax positions from prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Subtractions for federal tax reform Unrecognized Tax Benefits, Decrease Resulting From Tax Cuts And Jobs Act Unrecognized Tax Benefits, Decrease Resulting From Tax Cuts And Jobs Act Subtractions for tax positions from prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Unrecognized tax benefits at the end of the year Statement of Cash Flows [Abstract] Statement [Table] Statement [Table] Endoceutics, Inc. Endoceutics, Inc. [Member] Endoceutics, Inc. [Member] Statement [Line Items] Statement [Line Items] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Impairment of long-lived assets Provision for bad debt expense Accounts Receivable, Credit Loss Expense (Reversal) Amortization of premium/discount on purchased securities Accretion (Amortization) of Discounts and Premiums, Investments Write-down of inventory Inventory Write-down (Gain) loss on disposal of fixed assets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Non-cash equity-based compensation expense Share-based Payment Arrangement, Noncash Expense Non-cash IPR&D expense Noncash Research And Development In Process Expense Noncash Research and Development in Process Expense Loss on debt extinguishment Amortization of debt discount and debt issuance costs Amortization of Debt Issuance Costs and Discounts (Gain) loss on sale of marketable securities, net Marketable Securities, Gain (Loss) Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Deferred income taxes Deferred Income Taxes and Tax Credits Non-cash lease expense Non-cash Lease Expense Non-cash Lease Expense Gain on sale of the CBR business Gain (Loss) on Disposition of Business Transaction costs Increase (Decrease) In Transaction Costs Increase (Decrease) In Transaction Costs Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Deferred revenues Increase (Decrease) in Contract with Customer, Liability Payment of contingent consideration in excess of acquisition date fair value Payment for Contingent Consideration Liability, Operating Activities Other assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Proceeds from sales or maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Purchases of marketable securities Payments to Acquire Marketable Securities Acquisition of intangible asset Payments to Acquire Intangible Assets Proceeds from the sale of the CBR business Proceeds from Divestiture of Businesses Note receivable Payments to Acquire Notes Receivable Capital expenditures Payments to Acquire Property, Plant, and Equipment Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Long-term debt principal payments Repayments of Medium-term Notes Proceeds from 2022 Convertible Notes Proceeds from Convertible Debt Payments to repurchase 2019 Convertible Notes Repayments of Convertible Debt Payment of premium on debt extinguishment Proceeds to settle warrants Proceeds From Termination Of Bond Hedge And Warrants Proceeds from Termination of Bond Hedge and Warrants Payment of convertible debt issuance costs Payments of Debt Issuance Costs Payment of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Payments for repurchases of common stock Payments for Repurchase of Common Stock Proceeds from the issuance of common stock under the ESPP Proceeds from Stock Plans Proceeds from the exercise of common stock options Proceeds from Stock Options Exercised Payments of employee tax withholding related to equity-based compensation Payment, Tax Withholding, Share-based Payment Arrangement Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of the year Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of the year Supplemental data of cash flow information: Supplemental Cash Flow Information [Abstract] Cash (refunded) paid for taxes Income Taxes Paid, Net Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Non-cash investing and financing activities: Other Noncash Investing and Financing Items [Abstract] Right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Settlement of note receivable in connection with Perosphere acquisition Noncash or Part Noncash Acquisition, Receivable Settled Noncash or Part Noncash Acquisition, Receivable Settled Fair value of common stock issued in connection with the acquisition of the Intrarosa intangible asset Stock Issued During Period, Value, Purchase of Assets Contingent consideration accrued for the acquisition of the Intrarosa intangible asset Asset Acquisition, Contingent Consideration, Liability Asset Acquisition, Contingent Consideration, Liability Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Workforce reduction Employee Severance [Member] Contract termination Contract Termination [Member] Other Other Restructuring [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Balance accrued at December 31, 2018 Restructuring Reserve Payments Payments for Restructuring Balance accrued at December 31, 2019 Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Civil Case In Saginaw Chippewa Indian Tribe V. Purdue Pharma Et Al Civil Case In Saginaw Chippewa Indian Tribe V. Purdue Pharma Et Al [Member] Civil Case In Saginaw Chippewa Indian Tribe V. Purdue Pharma Et Al [Member] Lunar Representative, LLC V. AMAG Pharmaceuticals, Inc. Lunar Representative, LLC V. AMAG Pharmaceuticals, Inc. [Member] Lunar Representative, LLC V. AMAG Pharmaceuticals, Inc. [Member] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Pending Litigation Pending Litigation [Member] Accounting Standards Update [Axis] Accounting Standards Update [Axis] Accounting Standards Update [Domain] Accounting Standards Update [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Commitments Loss Contingencies [Line Items] Operating lease liability Operating Lease, Liability Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Remaining operating lease term Lessee, Operating Lease, Remaining Lease Term Weighted average operating lease remaining lease term Operating Lease, Weighted Average Remaining Lease Term Weighted average operating lease discount rate Operating Lease, Weighted Average Discount Rate, Percent Lease cost for operating leases Lease, Cost Lease cost for operating leases Operating Leases, Rent Expense, Net Operating cash outflows from operating leases Operating Lease, Payments Remaining minimum purchase commitments Purchase Commitment, Remaining Minimum Amount Committed Number of other pharmaceutical companies named as defendants Loss Contingency, Number of Defendants Number of class action lawsuits filed Loss Contingency, New Claims Filed, Number Damages sought by plaintiff Loss Contingency, Damages Sought, Value Schedule of outstanding debt obligations Schedule of Debt [Table Text Block] Schedule of outstanding convertible debt Convertible Debt [Table Text Block] Schedule of total interest expense recognized related to the convertible notes Interest Income and Interest Expense Disclosure [Table Text Block] Convertible Notes Due 2019 Net loss from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Net income from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Effect of dilutive securities: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Stock options and RSUs (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Shares used in calculating dilutive net loss per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Basic and diluted earnings per share: Earnings Per Share, Basic and Diluted [Abstract] Loss from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic and Diluted Share Income from discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share Total (in dollars per share) Earnings Per Share, Basic and Diluted Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] CBR business CBR Business [Member] CBR Business [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Discontinued Operations, Held-for-sale or Disposed of by Sale Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Service revenues, net Disposal Group, Including Discontinued Operation, Revenue Costs and expenses: Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract] Cost of services Disposal Group, Including Discontinued Operation, Costs of Goods Sold Selling, general and administrative expenses Disposal Group, Including Discontinued Operation, General and Administrative Expense Total costs and expenses Discontinued Operation, Provision for Loss (Gain) on Disposal, before Income Tax Operating income Disposal Group, Including Discontinued Operation, Operating Income (Loss) Other income (expense) Disposal Group, Including Discontinued Operation, Other Income (Expense) Disposal Group, Including Discontinued Operation, Other Income (Expense) Income from discontinued operations Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Gain on sale of CBR business Income tax expense Discontinued Operation, Tax Effect of Discontinued Operation RESTRUCTURING EXPENSES Restructuring and Related Activities Disclosure [Text Block] Future annual principal payments on long-term debt due year ended December 31, 2022 Long-Term Debt, Maturity, Year Three Accounting Changes and Error Corrections [Abstract] REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS Accounting Changes and Error Corrections [Text Block] Statutory U.S. federal tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent State taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Impact of 2017 tax reform on deferred tax balance Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Equity-based compensation expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent Contingent consideration Effective Income Tax Rate Reconciliation, Nondeductible Expense, Contingent Consideration, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Contingent Consideration, Percent In-process research and development Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent Other permanent items, net Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Percent Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Other, net Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent Effective tax rate Effective Income Tax Rate Reconciliation, Percent Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities Debt Securities, Available-for-sale, Current Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Inventories Inventory, Net Prepaid and other current assets Prepaid Expense and Other Assets, Current Note receivable Financing Receivable, before Allowance for Credit Loss, Current Total current assets Assets, Current Property and equipment, net Goodwill Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Deferred tax assets Deferred Income Tax Assets, Net Restricted cash Restricted Cash, Noncurrent Other long-term assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Current portion of convertible notes, net Long-term Debt, Current Maturities Current portion of operating lease liability Operating Lease, Liability, Current Current portion of acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability, Current Total current liabilities Liabilities, Current Long-term liabilities: Liabilities, Noncurrent [Abstract] Convertible notes, net Convertible Debt, Noncurrent Long-term operating lease liability Operating Lease, Liability, Noncurrent Long-term acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and Contingencies (Note P) Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, par value $0.01 per share, 2,000,000 shares authorized; none issued Preferred Stock, Value, Issued Common stock, par value $0.01 per share, 117,500,000 shares authorized; 33,999,081 and 34,606,760 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ equity Total liabilities and stockholders’ equity Liabilities and Equity Condensed Financial Information Disclosure [Abstract] Total revenues Gross profit Gross Profit Operating expenses Operating Expenses Net income (loss) from discontinued operations Net loss Basic and diluted earnings per share: Earnings Per Share, Basic [Abstract] Income (loss) from discontinued operations (in dollars per share) Condensed Financial Statements [Table] Condensed Financial Statements [Table] Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] [Domain] for Asset Acquisition [Axis] Perosphere Pharmaceuticals Inc. Perosphere Pharmaceuticals Inc. [Member] Perosphere Pharmaceuticals Inc. [Member] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Contingent Consideration Contingent Consideration [Member] Contingent Consideration [Member] Makena Makena [Member] Makena Makena Auto-Injector, Intrarosa And Vyleesi Products Makena Auto-Injector, Intrarosa And Vyleesi Products [Member] Makena Auto-Injector, Intrarosa And Vyleesi Products [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Developed technology rights Developed Technology Rights [Member] Condensed Financial Statements, Captions [Line Items] Condensed Financial Statements, Captions [Line Items] In process research and development acquired Indefinite-lived Intangible Assets Acquired Adjustments to fair value of contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Assets Deferred Tax Assets, Gross [Abstract] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Capital loss carryforwards Deferred Tax Assets, Capital Loss Carryforwards Interest expense carryforwards Deferred Tax Asset, Interest Carryforward Equity-based compensation expense Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Capitalized research & development Deferred Tax Assets, Deferred Expense, Capitalized Research And Development Costs Deferred Tax Assets, Deferred Expense, Capitalized Research And Development Costs Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves Lease liability Deferred Tax Assets, Operating Lease Liability Deferred Tax Assets, Operating Lease Liability Property, plant and equipment Deferred Tax Assets, Property, Plant and Equipment Contingent consideration Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Other Deferred Tax Assets, Other Valuation allowance Deferred Tax Assets, Valuation Allowance Liabilities Deferred Tax Liabilities, Gross [Abstract] Property, plant and equipment depreciation Deferred Tax Liabilities, Property, Plant and Equipment Debt instruments Deferred Tax Liabilities, Financing Arrangements Right of use asset Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset Other Deferred Tax Liabilities, Other Net deferred tax assets Deferred Tax Assets, Net Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Use of Estimates and Assumptions Use of Estimates, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Concentrations and Significant Customer Information Concentration Risk, Credit Risk, Policy [Policy Text Block] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Marketable Securities Marketable Securities, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Property and Equipment, Net Property, Plant and Equipment, Policy [Policy Text Block] Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Business Combinations, Asset Acquisitions and Acquisition-Related Contingent Consideration Business Combinations Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Patents Patent Cost Policy [Policy Text Block] Patent Cost Policy [Policy Text Block] Advertising Costs Advertising Cost [Policy Text Block] Equity-Based Compensation Share-based Payment Arrangement [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Basic and Diluted Earnings per Share Earnings Per Share, Policy [Policy Text Block] Business Segments Segment Reporting, Policy [Policy Text Block] Recently Issued and Proposed Accounting Pronouncements and Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] SUBSEQUENT EVENTS (unaudited) Subsequent Events [Text Block] GOODWILL AND INTANGIBLE ASSETS, NET Goodwill and Intangible Assets Disclosure [Text Block] CURRENT AND LONG-TERM LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] DEBT Debt Disclosure [Text Block] Schedule of customers representing greater than 10% of revenues/accounts receivable balances Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of property and equipment estimated useful lives Schedule of components of basic and diluted net income (loss) per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of anti-dilutive securities from computation of diluted net (loss) income per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Mugard [Member] Represents information pertaining to the Mugard product line. Revenues Schedule of components of restructuring expenses and current liabilities Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Line of Credit Line of Credit [Member] 2015 Term Loan Facility Term Loan Facility 2015 [Member] Represents information relating to the 2015 Term Loan Facility. Debt term Debt Instrument, Term Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity REVENUE RECOGNITION Revenue from Contract with Customer [Text Block] PROPERTY AND EQUIPMENT, NET Property, Plant and Equipment Disclosure [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of product sales Cost of Sales [Member] Research and development Research and Development Expense [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Restructuring Charges Restructuring Charges [Member] Equity-based compensation expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total equity-based compensation expense Share-based Payment Arrangement, Expense Income tax effect Share-based Payment Arrangement, Expense, Tax Benefit After-tax effect of equity-based compensation expense Share-based Payment Arrangement, Expense, after Tax Schedule of income tax (benefit) expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of reconciliation of the statutory U.S. federal income tax rate to the entity's effective income tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of components of the entity's deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Summary of income tax contingencies Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Accrued Expenses Accrued Liabilities, Current [Abstract] Commercial rebates, fees and returns Accrued Commercial Rebates, Fees And Returns, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for commercial rebates, fees and returns. Used to reflect the current portion of liabilities (due within one year or within the normal operating cycle if longer). Accrued manufacturing Accrued Manufacturing Costs, Current Accrued Manufacturing Costs, Current Salaries, bonuses, and other compensation Employee-related Liabilities, Current Professional, license, and other fees and expenses Accrued Professional License and Other Fees and Expenses, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional, license, and other fees and expenses. Used to reflect the current portion of liabilities (due within one year or within the normal operating cycle if longer). Accrued research and development Research And Development Payable, Current Research and Development Payable, Current Interest expense Interest Payable, Current Restructuring expense Restructuring Reserve, Current Total accrued expenses Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Failure To Supply A Certain Percentage Of Product Failure To Supply A Certain Percentage Of Product [Member] Failure To Supply A Certain Percentage Of Product [Member] Perosphere Convertible Note Perosphere Convertible Note [Member] Perosphere Convertible Note [Member] Perosphere Term Loan Perosphere Term Loan [Member] Perosphere Term Loan [Member] Velo Bio, LLC Velo Bio, LLC [Member] Velo Bio, LLC [Member] Prasco, LLC Prasco, LLC [Member] Prasco, LLC [Member] Milestone Achievement, Approval By European Medicines Agency Milestone Achievement, Approval By European Medicines Agency [Member] Milestone Achievement, Approval By European Medicines Agency [Member] First Sales Milestone Achievement First Sales Milestone Achievement [Member] First Sales Milestone Achievement [Member] Regulatory Milestone Achievement, U.S.Food and Drug Administration Approval Regulatory Milestone Achievement, U.S. Food And Drug Administration Approval [Member] Regulatory Milestone Achievement, Acceptance By U.S.Food And Drug Administration Approval [Member] Annual Sales Milestone Achievements Annual Sales Milestone Achievements [Member] Annual Sales Milestone Achievements [Member] Commercial Milestone Payments Commercial Milestone Payments [Member] Commercial Milestone Payments [Member] Delivery of Intrarosa Launch Quantities Delivery Of Intrarosa Launch Quantities [Member] Delivery Of Intrarosa Launch Quantities [Member] First Anniversary of Closing First Anniversary Of Closing [Member] First Anniversary Of Closing [Member] Tiered Royalties Tiered Royalties [Member] Tiered Royalties [Member] Regulatory Milestone Achievement, Acceptance by U.S.Food And Drug Administration of New Drug Application Regulatory Milestone Achievement, Acceptance By U.S.Food And Drug Administration Of New Drug Application [Member] Regulatory Milestone Achievement, Acceptance By U.S.Food And Drug Administration Of New Drug Application [Member] Achievement of Certain Annual Sales Milestones Over Course of License Agreement Achievement Of Certain Annual Sales Milestones Over Course Of License Agreement [Member] Achievement Of Certain Annual Sales Milestones Over Course Of License Agreement [Member] Collaborative Agreements Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Consideration recorded Asset Acquisition, Consideration Transferred, Net Asset Acquisition, Consideration Transferred, Net Payments of asset acquisitions Payments For Asset Acquisitions Payments For Asset Acquisitions Cancellation of convertible note Asset Acquisition, Consideration Transferred, Cancellation Of Liabilities Asset Acquisition, Consideration Transferred, Cancellation Of Liabilities Payment for debt extinguishment Other liabilities Asset Acquisitions, Liabilities, Other Asset Acquisitions, Liabilities, Other Cash consideration Asset Acquisition, Consideration Transferred, Gross Asset Acquisition, Consideration Transferred, Gross Discount rate Asset Acquisition, Discount Rate Asset Acquisition, Discount Rate Contingent consideration (up to) Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Value, High Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Value, High Credited percentage Asset Acquisition, Contingent Consideration Terms, Credited Percentage Asset Acquisition, Contingent Consideration Terms, Credited Percentage Contingent consideration, milestone payment Asset Acquisition, Contingent Consideration, Milestone Payment Asset Acquisition, Contingent Consideration, Milestone Payment Potential milestone payment, triggering event, sales Asset Acquisition, Potential Milestone Payment, Triggering Event, Threshold Amount Asset Acquisition, Potential Milestone Payment, Triggering Event, Threshold Amount Payments related to collaborative arrangement Payments Related To Collaborative Arrangement Payments Related to Collaborative Arrangement Milestone payments Option Agreement, Contingent Consideration, Liability Option Agreement, Contingent Consideration, Liability Sales milestone targets Option Agreement, Potential Sales Milestone Payment, Triggering Event, Threshold Amount Option Agreement, Potential Sales Milestone Payment, Triggering Event, Threshold Amount Failure to supply, penalties Loss Contingency, Loss in Period Number of shares issued under arrangement Stock Issued During Period, Shares, Purchase of Assets Shares issued in connection with Endoceutics License Agreement Future contingent payments (up to) Finite-lived intangible assets Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangibles Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangibles IPR&D expense Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Indefinite-Lived Intangibles Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Indefinite-Lived Intangibles Royalty percentage, maximum Asset Acquisition, Contingent Consideration Terms, Royalty Percentage Asset Acquisition, Contingent Consideration Terms, Royalty Percentage Out-of-pocket expenses (up to) Other Commitment Schedule of amortizable intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Inventory Disclosure [Abstract] Schedule of major classes of inventories Schedule of Inventory, Current [Table Text Block] Income Statement [Abstract] Collaboration revenue Service [Member] Other revenues Product and Service, Other [Member] Revenues: Costs and expenses: Costs and Expenses [Abstract] Cost of product sales Cost of Goods and Services Sold Cost, Product and Service [Extensible List] Cost, Product and Service [Extensible List] Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Acquired in-process research and development Research and Development in Process Selling, general and administrative expenses Selling, General and Administrative Expense Total costs and expenses Costs and Expenses Operating loss Operating Income (Loss) Other income (expense): Nonoperating Income (Expense) [Abstract] Interest expense Interest Expense Loss on debt extinguishment Interest and dividend income Investment Income, Interest and Dividend Other income (expense) Other Nonoperating Income (Expense) Total other expense, net Nonoperating Income (Expense) Loss from continuing operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax (benefit) expense Net loss from continuing operations Discontinued operations: Income from discontinued operations Net income from discontinued operations Weighted average shares outstanding used to compute earnings per share (basic and diluted) (in shares) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Options to purchase shares of common stock Share-based Payment Arrangement, Option [Member] Shares of common stock issuable upon the vesting of RSUs Warrants Warrant [Member] Convertible Debt Securities Convertible Debt Securities [Member] Shares of common stock under employee stock purchase plan Employee Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive securities (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Retirement Benefits [Abstract] EMPLOYEE SAVINGS PLAN Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block] Number of product candidates Number Of Product Candidates Number Of Product Candidates Schedule of effects of corrections and prior period adjustments Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Schedule of unaudited consolidated quartely financial data Quarterly Financial Information [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Makena auto-injector developed technology Makena Auto-Injector [Member] Makena Auto-Injector [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Milestone payment accrued for FDA approval of Vyleesi Accrued Milestone Payment, Current Accrued Milestone Payment, Current Fair value of intangible asset Finite-Lived Intangible Assets, Net Amortization of intangible assets Amortization of Intangible Assets Expected useful life Finite-Lived Intangible Asset, Useful Life Expect amortization expense related to finite-lived intangible assets during the next 12 months Finite-Lived Intangible Asset, Expected Amortization, Year One Employer matching contribution (percent) Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Cost recognized Defined Contribution Plan, Cost Schedule of valuation and qualifying accounts Schedule Of Valuation And Qualifying Accounts [Table Text Block] Schedule of Valuation and Qualifying Accounts [Table Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS Accounting Standards Update and Change in Accounting Principle [Text Block] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Revision of Prior Period [Axis] Revision of Prior Period [Axis] Revision of Prior Period [Domain] Revision of Prior Period [Domain] As reported Previously Reported [Member] Adjustment Revision of Prior Period, Error Correction, Adjustment [Member] Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Basic and diluted net loss per share (in dollars per share) RECENTLY ISSUED AND PROPOSED ACCOUNTING PRONOUNCEMENTS Description of New Accounting Pronouncements Not yet Adopted [Text Block] Share repurchase program, authorized amount (in shares) Stock Repurchase Program, Authorized Amount Common stock repurchased and retired (in shares) Stock Repurchased and Retired During Period, Shares Stock repurchased and retired during period, value Stock Repurchased and Retired During Period, Value Available for repurchase of shares Stock Repurchase Program, Remaining Authorized Repurchase Amount Adj Statement of Stockholders' Equity [Abstract] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Deficit Retained Earnings [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (in shares) Common Stock, Shares, Outstanding Settlement of warrants Adjustments to Additional Paid in Capital, Warrant Issued Equity component of the 2022 Convertible Notes, net of issuance costs and taxes Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Equity component of debt repurchase Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments Shares issued in connection with Endoceutics License Agreement (in shares) Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program (in shares) Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Repurchase of common stock pursuant to the share repurchase program (in shares) Stock Repurchased During Period, Shares Repurchase of common stock pursuant to the share repurchase program Stock Repurchased During Period, Value Non-cash equity based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Unrealized gains (losses) on securities, net of tax Ending balance (in shares) Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible List] INCOME TAXES Income Tax Disclosure [Text Block] Disaggregated revenue Disaggregation of Revenue [Table Text Block] Product revenue allowance and accrual activity Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Adjustments related to prior period sales. Medicaid rebates Adjustments related to prior period sales, contractual adjustments Deferred revenue Contract with Customer, Liability Termination payment received Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract 2015 ESPP Employee Stock Purchase Plan 2015 [Member] Employee Stock Purchase Plan 2015 [Member] Employee Stock Option Employee and Non Employee Director Stock Option Employee And Non Employee Director Stock Option [Member] Employee And Non Employee Director Stock Option [Member] Number of equity compensation plans Share-Based Compensation Arrangements By Share-Based Payment Award, Number Of Plans Share-Based Compensation Arrangements By Share-Based Payment Award, Number Of Plans Additional common stock for issuance (shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Shares authorized for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Offering period term Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Annual maximum percentage of employee compensation available for ESPP share purchases Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Employee Compensation Maximum Represents the maximum percentage of an employee's compensation that can be deducted and used to purchase shares under an Employee Stock Purchase Plan. Purchase price per share as a percentage of fair market value of common stock on the first or last day of the plan period Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Stock offering period Share-based Compensation Arrangement By Share-based Payment Award, Stock Offering Period Share-based Compensation Arrangement By Share-based Payment Award, Stock Offering Period Shares issued (in shares) Options granted in period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Options vested in period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Value of options exercised in period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value RSUs granted (in dollars per share) Value of RSUs vested during period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Compensation cost not yet recognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Compensation cost not yet recognized, associated with stock options Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Number of business segments Number of Operating Segments Net carrying amount Long-term Debt Less: current maturities Long-term debt, net of current maturities Long-term Debt, Excluding Current Maturities INVENTORIES Inventory Disclosure [Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Endoceutics License Agreement Endoceutics License Agreement [Member] Endoceutics License Agreement [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Accrued expenses Governmental rebates Increase to accumulated deficit Investments, Debt and Equity Securities [Abstract] Summary of marketable securities Debt Securities, Available-for-sale [Table Text Block] Tax Credit Carryforward [Table] Tax Credit Carryforward [Table] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Capital Loss Carryforward Capital Loss Carryforward [Member] Interest Expense Carryforward Interest Expense Carryforward [Member] Interest Expense Carryforward [Member] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Domestic Tax Authority Domestic Tax Authority [Member] State and Local Jurisdiction State and Local Jurisdiction [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Lumara Health Inc. Lumara Health Inc. [Member] Lumara Health Inc. [Member] Tax Credit Carryforward [Line Items] Tax Credit Carryforward [Line Items] Effective tax rate Tax cuts and jobs act, provisional tax benefit Tax Cuts And Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit) Tax Cuts And Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit) Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Operating loss carryforwards Operating Loss Carryforwards Operating loss carryforwards, not subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Tax credit carryforward, amount Tax Credit Carryforward, Amount Increase (decrease) in unrecognized tax benefits Unrecognized Tax Benefits, Period Increase (Decrease) Capital expenditures Capital Expenditure, Discontinued Operations Depreciation and amortization expense Depreciation and Amortization, Discontinued Operations Transaction expenses Schedule Of Asset Acquisitions [Table] Schedule Of Asset Acquisitions [Table] Schedule Of Asset Acquisitions [Table] Schedule Of Asset Acquisitions [Line Items] Schedule Of Asset Acquisitions [Line Items] [Line Items] for Schedule Of Asset Acquisitions [Table] Assets: Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets [Abstract] Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets [Abstract] Cash Asset Acquisition, Cash Asset Acquisition, Cash Operating lease right-of-use asset Finite-lived Intangible Assets Acquired Property and equipment Property, Plant and Equipment, Additions IPR&D Total Assets Asset Acquisition, Assets Acquired And Liabilities Assumed, Assets Asset Acquisition, Assets Acquired And Liabilities Assumed, Assets Liabilities: Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities [Abstract] Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities [Abstract] Accrued severance liabilities Asset Acquisition, Severance Asset Acquisition, Severance Deferred revenue Asset Acquisition, Deferred Revenue Asset Acquisition, Deferred Revenue Operating lease liability Asset Acquisition, Operating Lease Obligation Asset Acquisition, Operating Lease Obligation Total Liabilities Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities Discontinued operations held for sale Disposal Groups, Including Discontinued Operations [Table Text Block] Developed technology rights Cost Finite-Lived Intangible Assets, Gross Life to Date Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Impairments Finite-Lived Intangible Assets, Accumulated Impairment Loss Amount of accumulated impairment loss for assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Total Total intangible assets Intangible Assets, Net (Excluding Goodwill) [Abstract] Cost Intangible Assets, Gross (Excluding Goodwill) Life to Date Accumulated Amortization Impairments Intangible Assets, Net (Excluding Goodwill), Accumulated Impairment Loss Intangible Assets, Net (Excluding Goodwill), Accumulated Impairment Loss Total Liability component: Long-term Debt, Unclassified [Abstract] Principal Long-term Debt, Gross Less: debt discount and issuance costs, net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Gross equity component Debt Instrument, Convertible, Carrying Amount of Equity Component Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Non Employee Directors Non Employee Director Stock Option [Member] Non Employee Director Stock Option [Member] Risk free interest rate (%) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected volatility (%) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected option term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Raw materials Inventory, Raw Materials, Net of Reserves Work in process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total inventories Maturity schedule by fiscal year, operating leases Lessee, Operating Lease, Liability, Maturity [Table Text Block] Accounting Standards Update and Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Cumulative effect of new accounting principle in period of adoption Year Ending December 31, 2020 Lessee, Operating Lease, Liability, to be Paid, Year One Year Ending December 31, 2021 Lessee, Operating Lease, Liability, to be Paid, Year Two Year Ending December 31, 2022 Lessee, Operating Lease, Liability, to be Paid, Year Three Year Ending December 31, 2023 Lessee, Operating Lease, Liability, to be Paid, Year Four Year Ending December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Year Five Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Total Lessee, Operating Lease, Liability, to be Paid Less: Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED Quarterly Financial Information [Text Block] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Corporate debt securities Corporate Debt Securities [Member] U.S. treasury and government agency securities US Treasury and Government [Member] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Certificates of deposit Certificates of Deposit [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Short-term investments: Short-term Investments [Abstract] Amortized Cost, short-term investments Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost Gross Unrealized Gains, short-term investments Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Within One Year, Gross Unrealized Gain Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Within One Year, Gross Unrealized Gain Gross Unrealized Losses, short-term investments Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Within One Year, Gross Unrealized Loss Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Within One Year, Gross Unrealized Loss Estimated Fair Value, short-term investments Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value Long-term investments: Long-term Investments [Abstract] Amortized Cost, long-term investments Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Amortized Cost Basis Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Amortized Cost Basis Gross Unrealized Gains, long-term investments Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Gross Unrealized Gain Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Gross Unrealized Gain Gross Unrealized Losses, long-term investments Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Gross Unrealized Loss Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Gross Unrealized Loss Estimated Fair Value, long-term investments Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Fair Value Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Fair Value Total investments Investments [Abstract] Amortized Cost, total Debt Securities, Available-for-sale, Amortized Cost Gross Unrealized Gains, total Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses, total Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Estimated Fair Value, total Other-than-temporary impairment losses Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings Schedule of assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Commercial paper Commercial Paper [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Fair value, measurements, recurring Fair Value, Recurring [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Fair value of assets and liabilities measured on a recurring basis Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets: Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Available-for-sale securities Debt Securities, Available-for-sale Total Assets Assets, Fair Value Disclosure Liabilities: Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract] Contingent consideration Business Combination, Contingent Consideration, Liability Total Liabilities Nonfinancial Liabilities Fair Value Disclosure Advertising costs Advertising Expense MARKETABLE SECURITIES Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Debt Instrument, Conversion, Period [Axis] Debt Instrument, Conversion, Period [Axis] Debt Instrument, Conversion, Period [Axis] Debt Instrument, Conversion, Period [Domain] Debt Instrument, Conversion, Period [Domain] [Domain] for Debt Instrument, Conversion, Period [Axis] Debt Instrument, Conversion, Period One Debt Instrument, Conversion, Period One [Member] Debt Instrument, Conversion, Period One [Member] Debt Instrument, Conversion, Period Two Debt Instrument, Conversion, Period Two [Member] Debt Instrument, Conversion, Period Two [Member] Period of amortization of debt discount to interest expense using effective interest method (years) Debt Instrument, Convertible, Remaining Discount Amortization Period Net proceeds from issuance of convertible debt Payment of convertible debt issuance costs Debt issuance costs Debt Issuance Costs, Net Debt issuance costs allocated to equity component Adjustments To Additional Paid In Capital, Equity Component Of Convertible Debt, Debt Issuance Costs Adjustments To Additional Paid In Capital, Equity Component Of Convertible Debt, Debt Issuance Costs Debt issuance costs allocated to the liability component Adjustments To Debt Instrument Carrying Amount, Liability Component Of Convertible Debt, Debt Issuance Costs Adjustments To Debt Instrument Carrying Amount, Liability Component Of Convertible Debt, Debt Issuance Costs Debt conversion ratio Debt Instrument, Convertible, Conversion Ratio Initial conversion price of convertible notes into common stock (USD per share) Debt Instrument, Convertible, Conversion Price Trading period Debt Instrument, Convertible, Threshold Trading Days Consecutive trading period Debt Instrument, Convertible, Threshold Consecutive Trading Days Closing sales price of the entity's common stock that the conversion price must exceed or be equal in order for the notes to be convertible Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Number of consecutive business days after any five consecutive trading day period during the note measurement period Debt Instrument, Convertible, Threshold Business Days Debt Instrument, Convertible, Threshold Business Days Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Proceeds used to pay the cost of the bond hedges (after such cost was partially offset by proceeds from the sale of warrants) Payments for Hedge, Financing Activities Repurchase price Debt Instrument, Repurchase Amount Gain (loss) on debt extinguishment Repayments of convertible debt EX-101.PRE 11 amag-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 amag_rgba03.jpg begin 644 amag_rgba03.jpg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end XML 13 a201910-ka_htm.xml IDEA: XBRL DOCUMENT 0000792977 2019-01-01 2019-12-31 0000792977 2019-06-28 0000792977 2020-03-02 0000792977 2018-12-31 0000792977 2019-12-31 0000792977 2017-01-01 2017-12-31 0000792977 2018-01-01 2018-12-31 0000792977 us-gaap:ProductMember 2017-01-01 2017-12-31 0000792977 us-gaap:ServiceMember 2018-01-01 2018-12-31 0000792977 us-gaap:ProductMember 2018-01-01 2018-12-31 0000792977 us-gaap:ProductMember 2019-01-01 2019-12-31 0000792977 us-gaap:ProductAndServiceOtherMember 2018-01-01 2018-12-31 0000792977 us-gaap:ServiceMember 2019-01-01 2019-12-31 0000792977 us-gaap:ServiceMember 2017-01-01 2017-12-31 0000792977 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0000792977 us-gaap:ProductAndServiceOtherMember 2017-01-01 2017-12-31 0000792977 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000792977 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000792977 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000792977 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2016-12-31 0000792977 us-gaap:CommonStockMember 2018-12-31 0000792977 us-gaap:RetainedEarningsMember 2019-12-31 0000792977 us-gaap:RetainedEarningsMember 2017-12-31 0000792977 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000792977 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000792977 us-gaap:CommonStockMember 2016-12-31 0000792977 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2017-12-31 0000792977 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000792977 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000792977 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000792977 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2017-12-31 0000792977 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000792977 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000792977 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000792977 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000792977 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000792977 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000792977 us-gaap:CommonStockMember 2017-12-31 0000792977 us-gaap:RetainedEarningsMember 2018-12-31 0000792977 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000792977 2016-12-31 0000792977 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000792977 us-gaap:CommonStockMember 2019-12-31 0000792977 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000792977 2017-12-31 0000792977 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000792977 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000792977 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000792977 us-gaap:RetainedEarningsMember 2016-12-31 0000792977 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2016-12-31 0000792977 2016-01-01 2016-12-31 0000792977 amag:IntrarosaMember 2017-01-01 2017-12-31 0000792977 amag:VyleesiProductsMember 2018-01-01 2018-12-31 0000792977 amag:VyleesiProductsMember 2019-01-01 2019-12-31 0000792977 amag:IntrarosaMember 2019-01-01 2019-12-31 0000792977 amag:VyleesiProductsMember 2017-01-01 2017-12-31 0000792977 amag:IntrarosaMember 2018-01-01 2018-12-31 0000792977 amag:EndoceuticsInc.Member 2017-01-01 2017-12-31 0000792977 amag:EndoceuticsInc.Member 2018-12-31 0000792977 amag:EndoceuticsInc.Member 2018-01-01 2018-12-31 0000792977 amag:EndoceuticsInc.Member 2019-01-01 2019-12-31 0000792977 amag:EndoceuticsInc.Member 2019-12-31 0000792977 amag:EndoceuticsInc.Member 2017-12-31 0000792977 amag:AmerisourceBergenDrugCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0000792977 amag:AmerisourceBergenDrugCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000792977 amag:McKessonCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0000792977 amag:McKessonCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000792977 amag:McKessonCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000792977 amag:AmerisourceBergenDrugCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000792977 amag:CardinalHealthInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000792977 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000792977 us-gaap:ConvertibleDebtSecuritiesMember amag:ConvertibleNotesDue2019Member 2017-01-01 2017-12-31 0000792977 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000792977 us-gaap:ConvertibleDebtSecuritiesMember amag:ConvertibleNotesDue2022Member 2019-01-01 2019-12-31 0000792977 us-gaap:EmployeeStockMember 2017-01-01 2017-12-31 0000792977 us-gaap:WarrantMember 2019-01-01 2019-12-31 0000792977 us-gaap:ConvertibleDebtSecuritiesMember amag:ConvertibleNotesDue2022Member 2017-01-01 2017-12-31 0000792977 us-gaap:ConvertibleDebtSecuritiesMember amag:ConvertibleNotesDue2019Member 2019-01-01 2019-12-31 0000792977 us-gaap:ConvertibleDebtSecuritiesMember amag:ConvertibleNotesDue2022Member 2018-01-01 2018-12-31 0000792977 us-gaap:ConvertibleDebtSecuritiesMember amag:ConvertibleNotesDue2019Member 2018-01-01 2018-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000792977 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0000792977 us-gaap:WarrantMember 2018-01-01 2018-12-31 0000792977 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000792977 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0000792977 us-gaap:WarrantMember 2017-01-01 2017-12-31 0000792977 amag:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000792977 srt:MinimumMember 2019-01-01 2019-12-31 0000792977 srt:MaximumMember 2019-01-01 2019-12-31 0000792977 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-01-01 0000792977 amag:TwoCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2019-12-31 0000792977 amag:FerahemeMember 2019-01-01 2019-12-31 0000792977 us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0000792977 us-gaap:EquipmentMember 2019-01-01 2019-12-31 0000792977 amag:ComputerEquipmentAndSoftwareMember 2019-01-01 2019-12-31 0000792977 amag:CardinalHealthInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0000792977 amag:CardinalHealthInc.Member us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000792977 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember amag:CBRBusinessMember 2018-01-01 2018-12-31 0000792977 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember amag:CBRBusinessMember 2017-01-01 2017-12-31 0000792977 amag:MakenaMember 2017-01-01 2017-12-31 0000792977 amag:MakenaMember 2018-01-01 2018-12-31 0000792977 amag:MakenaMember 2019-01-01 2019-12-31 0000792977 amag:FerahemeMember 2017-01-01 2017-12-31 0000792977 amag:FerahemeMember 2018-01-01 2018-12-31 0000792977 amag:MugardMember 2018-01-01 2018-12-31 0000792977 amag:MugardMember 2019-01-01 2019-12-31 0000792977 amag:MugardMember 2017-01-01 2017-12-31 0000792977 2019-03-31 0000792977 2019-10-01 2019-12-31 0000792977 us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000792977 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000792977 us-gaap:CertificatesOfDepositMember 2018-12-31 0000792977 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2018-12-31 0000792977 us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000792977 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000792977 us-gaap:CertificatesOfDepositMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000792977 amag:MugardMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000792977 amag:MugardMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 amag:MugardMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0000792977 amag:MugardMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000792977 amag:MugardMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000792977 amag:MugardMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 amag:MugardMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000792977 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000792977 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000792977 amag:MugardMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000792977 amag:ContingentConsiderationMember 2018-01-01 2018-12-31 0000792977 amag:EndoceuticsLicenseAgreementMember 2019-12-31 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2018-12-31 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2018-12-31 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2019-12-31 0000792977 amag:EndoceuticsLicenseAgreementMember 2018-12-31 0000792977 us-gaap:FurnitureAndFixturesMember 2018-12-31 0000792977 us-gaap:LeaseholdImprovementsMember 2018-12-31 0000792977 amag:ComputerEquipmentAndSoftwareMember 2018-12-31 0000792977 us-gaap:ConstructionInProgressMember 2019-12-31 0000792977 us-gaap:EquipmentMember 2018-12-31 0000792977 us-gaap:LeaseholdImprovementsMember 2019-12-31 0000792977 us-gaap:FurnitureAndFixturesMember 2019-12-31 0000792977 us-gaap:EquipmentMember 2019-12-31 0000792977 us-gaap:ConstructionInProgressMember 2018-12-31 0000792977 amag:ComputerEquipmentAndSoftwareMember 2019-12-31 0000792977 2018-11-05 2018-11-05 0000792977 amag:MakenaAutoInjectorMember us-gaap:DevelopedTechnologyRightsMember 2019-10-01 2019-12-31 0000792977 2018-12-31 2018-12-31 0000792977 amag:IntrarosaMember us-gaap:DevelopedTechnologyRightsMember 2019-10-01 2019-12-31 0000792977 2018-10-31 0000792977 2019-10-31 2019-10-31 0000792977 2018-10-31 2018-10-31 0000792977 amag:MakenaMember us-gaap:DevelopedTechnologyRightsMember 2019-04-01 2019-06-30 0000792977 2019-06-30 0000792977 2018-11-01 2018-12-31 0000792977 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-12-31 0000792977 us-gaap:MeasurementInputControlPremiumMember 2019-12-31 0000792977 2019-10-31 0000792977 amag:MakenaMember us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000792977 us-gaap:MeasurementInputControlPremiumMember 2018-09-30 0000792977 srt:MinimumMember us-gaap:MeasurementInputControlPremiumMember 2018-09-30 0000792977 2018-01-01 2018-06-30 0000792977 srt:MinimumMember us-gaap:MeasurementInputControlPremiumMember 2019-12-31 0000792977 amag:VyleesiProductsMember us-gaap:DevelopedTechnologyRightsMember 2019-10-01 2019-12-31 0000792977 srt:MaximumMember us-gaap:MeasurementInputControlPremiumMember 2018-09-30 0000792977 srt:MaximumMember us-gaap:MeasurementInputControlPremiumMember 2019-12-31 0000792977 amag:IntrarosaMember us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000792977 amag:MakenaAutoInjectorMember us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000792977 amag:MakenaMember us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000792977 amag:VyleesiProductsMember us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000792977 amag:IntrarosaMember us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000792977 amag:MakenaAutoInjectorMember us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000792977 amag:VyleesiProductsMember us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000792977 amag:LumaraHealthInc.Member us-gaap:DomesticCountryMember 2019-12-31 0000792977 us-gaap:StateAndLocalJurisdictionMember amag:PerospherePharmaceuticalsInc.Member 2019-12-31 0000792977 us-gaap:DomesticCountryMember 2019-12-31 0000792977 amag:LumaraHealthInc.Member us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0000792977 us-gaap:DomesticCountryMember amag:PerospherePharmaceuticalsInc.Member 2019-12-31 0000792977 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0000792977 amag:InterestExpenseCarryforwardMember 2019-12-31 0000792977 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember amag:CBRBusinessMember us-gaap:CapitalLossCarryforwardMember 2019-12-31 0000792977 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0000792977 us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000792977 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000792977 us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0000792977 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0000792977 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0000792977 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0000792977 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0000792977 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:EquityIncentivePlan2007Member 2019-01-01 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:LumaraHealth2013PlanMember 2019-01-01 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:EquityIncentivePlan2007Member 2018-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:EquityIncentivePlan2019Member 2019-01-01 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:InducementGrantsMember 2019-01-01 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:EquityIncentivePlan2019Member 2018-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:InducementGrantsMember 2018-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:LumaraHealth2013PlanMember 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:InducementGrantsMember 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:EquityIncentivePlan2019Member 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:LumaraHealth2013PlanMember 2018-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember amag:EquityIncentivePlan2007Member 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0000792977 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000792977 amag:NonEmployeeDirectorStockOptionMember 2017-01-01 2017-12-31 0000792977 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000792977 amag:NonEmployeeDirectorStockOptionMember 2019-01-01 2019-12-31 0000792977 amag:NonEmployeeDirectorStockOptionMember 2018-01-01 2018-12-31 0000792977 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000792977 amag:InducementGrantsMember 2019-12-31 0000792977 amag:EquityIncentivePlan2019Member 2019-01-01 2019-12-31 0000792977 amag:EquityIncentivePlan2019Member 2019-12-31 0000792977 amag:EquityIncentivePlan2019Member 2018-12-31 0000792977 amag:InducementGrantsMember 2019-01-01 2019-12-31 0000792977 amag:LumaraHealth2013PlanMember 2018-12-31 0000792977 amag:InducementGrantsMember 2018-12-31 0000792977 amag:EquityIncentivePlan2007Member 2019-01-01 2019-12-31 0000792977 amag:EquityIncentivePlan2007Member 2018-12-31 0000792977 amag:LumaraHealth2013PlanMember 2019-12-31 0000792977 amag:EquityIncentivePlan2007Member 2019-12-31 0000792977 amag:LumaraHealth2013PlanMember 2019-01-01 2019-12-31 0000792977 amag:February2019Member amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2019-01-01 2019-12-31 0000792977 amag:EmployeeAndNonEmployeeDirectorStockOptionMember 2019-01-01 2019-12-31 0000792977 amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2017-02-01 2017-02-28 0000792977 amag:LumaraHealth2013PlanMember 2014-11-30 0000792977 amag:EmployeeStockPurchasePlan2015Member 2019-01-01 2019-12-31 0000792977 amag:February2017Member amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2019-12-31 0000792977 amag:PerformanceRestrictedStockUnitsRSUsMember 2019-12-31 0000792977 amag:March2018Member amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2019-01-01 2019-12-31 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000792977 amag:EmployeeStockPurchasePlan2015Member 2018-06-01 2018-06-30 0000792977 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000792977 amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2019-01-01 2019-12-31 0000792977 amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2019-02-01 2019-02-28 0000792977 amag:March2018Member amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2019-12-31 0000792977 amag:EmployeeStockPurchasePlan2015Member 2015-05-01 2015-05-31 0000792977 amag:February2019Member amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2019-12-31 0000792977 amag:PerformanceRestrictedStockUnitsRSUsMember amag:EquityIncentivePlan2007Member 2018-03-01 2018-03-31 0000792977 amag:PerformanceRestrictedStockUnitsRSUsMember 2019-01-01 2019-12-31 0000792977 amag:EmployeeStockPurchasePlan2015Member 2015-05-31 0000792977 us-gaap:RestructuringChargesMember 2019-01-01 2019-03-31 0000792977 us-gaap:EmployeeStockOptionMember amag:InducementGrantsMember 2019-01-01 2019-12-31 0000792977 2019-01-01 0000792977 2016-01-31 0000792977 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000792977 amag:CivilCaseInSaginawChippewaIndianTribeV.PurduePharmaEtAlMember us-gaap:PendingLitigationMember 2019-11-06 2019-11-06 0000792977 us-gaap:AccountingStandardsUpdate201602Member 2019-12-31 0000792977 amag:LunarRepresentativeLLCV.AMAGPharmaceuticalsInc.Member us-gaap:PendingLitigationMember 2019-09-25 2019-09-25 0000792977 us-gaap:PendingLitigationMember us-gaap:SubsequentEventMember 2019-11-04 2020-01-13 0000792977 srt:MaximumMember 2019-12-31 0000792977 srt:MinimumMember 2019-12-31 0000792977 amag:MilestoneAchievementApprovalByEuropeanMedicinesAgencyMember amag:PerospherePharmaceuticalsInc.Member 2019-01-31 0000792977 amag:PalatinTechnologiesInc.Member amag:VyleesiProductsMember amag:FirstSalesMilestoneAchievementMember 2017-02-28 0000792977 amag:EndoceuticsInc.Member amag:IntrarosaMember amag:FirstSalesMilestoneAchievementMember 2017-04-03 2017-04-03 0000792977 amag:PalatinTechnologiesInc.Member amag:VyleesiProductsMember amag:RegulatoryMilestoneAchievementAcceptanceByU.S.FoodAndDrugAdministrationOfNewDrugApplicationMember 2019-01-01 2019-06-30 0000792977 amag:PerospherePharmaceuticalsInc.Member 2019-01-16 2019-01-16 0000792977 amag:EndoceuticsInc.Member amag:IntrarosaMember amag:FirstAnniversaryOfClosingMember 2019-12-31 0000792977 amag:EndoceuticsInc.Member 2017-06-30 0000792977 amag:PerosphereTermLoanMember us-gaap:LineOfCreditMember amag:PerospherePharmaceuticalsInc.Member 2019-01-16 2019-01-16 0000792977 amag:PerospherePharmaceuticalsInc.Member 2019-01-31 0000792977 amag:RegulatoryMilestoneAchievementMember amag:PerospherePharmaceuticalsInc.Member 2019-01-31 0000792977 amag:VeloBioLLCMember 2018-09-01 2018-09-30 0000792977 amag:FirstSalesMilestoneAchievementMember amag:PerospherePharmaceuticalsInc.Member 2019-01-01 2019-01-31 0000792977 amag:PalatinTechnologiesInc.Member 2017-02-01 2017-02-28 0000792977 amag:PerosphereConvertibleNoteMember us-gaap:ConvertibleDebtMember amag:PerospherePharmaceuticalsInc.Member 2019-01-16 0000792977 amag:VeloBioLLCMember amag:RegulatoryMilestoneAchievementU.S.FoodAndDrugAdministrationApprovalMember 2018-09-30 0000792977 amag:EndoceuticsInc.Member 2017-04-03 2017-04-03 0000792977 amag:VeloBioLLCMember amag:AnnualSalesMilestoneAchievementsMember 2018-09-30 0000792977 amag:VeloBioLLCMember srt:MinimumMember amag:AnnualSalesMilestoneAchievementsMember 2018-09-01 2018-09-30 0000792977 amag:EndoceuticsInc.Member 2017-04-01 2017-06-30 0000792977 amag:PalatinTechnologiesInc.Member amag:VyleesiProductsMember amag:FirstSalesMilestoneAchievementMember 2017-02-01 2017-02-28 0000792977 amag:EndoceuticsInc.Member amag:IntrarosaMember amag:FirstSalesMilestoneAchievementMember 2017-04-03 0000792977 amag:VeloBioLLCMember amag:CommercialMilestonePaymentsMember 2018-09-30 0000792977 amag:PalatinTechnologiesInc.Member 2017-02-28 0000792977 amag:PalatinTechnologiesInc.Member amag:VyleesiProductsMember amag:RegulatoryMilestoneAchievementAcceptanceByU.S.FoodAndDrugAdministrationOfNewDrugApplicationMember 2018-04-01 2018-06-30 0000792977 amag:EndoceuticsInc.Member amag:IntrarosaMember us-gaap:DevelopedTechnologyRightsMember 2017-06-30 0000792977 amag:EndoceuticsInc.Member amag:IntrarosaMember amag:SalesMilestonesAchievementMember 2017-04-03 0000792977 amag:PrascoLLCMember amag:FailureToSupplyACertainPercentageOfProductMember 2019-01-01 2019-12-31 0000792977 amag:PalatinTechnologiesInc.Member amag:VyleesiProductsMember amag:AchievementOfCertainAnnualSalesMilestonesOverCourseOfLicenseAgreementMember 2017-02-28 0000792977 amag:VeloBioLLCMember srt:MaximumMember amag:AnnualSalesMilestoneAchievementsMember 2018-09-01 2018-09-30 0000792977 amag:EndoceuticsInc.Member amag:IntrarosaMember amag:DeliveryOfIntrarosaLaunchQuantitiesMember 2017-07-01 2017-09-30 0000792977 amag:VeloBioLLCMember amag:RegulatoryMilestoneAchievementMember 2018-09-30 0000792977 amag:SalesMilestonesAchievementMember amag:PerospherePharmaceuticalsInc.Member 2019-01-31 0000792977 amag:EndoceuticsInc.Member amag:IntrarosaMember amag:TieredRoyaltiesMember 2017-04-03 2017-04-03 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember amag:DebtInstrumentConversionPeriodTwoMember 2017-04-01 2017-06-30 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2017-06-30 0000792977 amag:SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2018-09-30 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2014-02-28 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2017-04-01 2017-06-30 0000792977 amag:SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2015-08-31 0000792977 amag:SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2018-09-01 2018-09-30 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2014-02-01 2014-02-28 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2019-02-15 2019-02-15 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2017-05-31 0000792977 amag:TermLoanFacility2015Member us-gaap:LineOfCreditMember 2017-05-01 2017-05-31 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember amag:DebtInstrumentConversionPeriodOneMember 2017-04-01 2017-06-30 0000792977 amag:SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2017-10-31 0000792977 amag:SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2017-10-01 2017-10-31 0000792977 us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0000792977 amag:TermLoanFacility2015Member us-gaap:LineOfCreditMember 2015-08-31 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2017-05-01 2017-05-31 0000792977 us-gaap:ConvertibleDebtMember 2017-01-01 2017-12-31 0000792977 us-gaap:ConvertibleDebtMember 2018-01-01 2018-12-31 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2018-12-31 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2018-12-31 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2019-12-31 0000792977 amag:ConvertibleNotesDue2022Member us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0000792977 amag:ConvertibleNotesDue2019Member us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0000792977 2019-02-01 2019-02-28 0000792977 us-gaap:ContractTerminationMember 2019-12-31 0000792977 us-gaap:OtherRestructuringMember 2019-01-01 2019-12-31 0000792977 us-gaap:ContractTerminationMember 2019-01-01 2019-12-31 0000792977 us-gaap:EmployeeSeveranceMember 2019-12-31 0000792977 us-gaap:EmployeeSeveranceMember 2018-12-31 0000792977 us-gaap:OtherRestructuringMember 2019-12-31 0000792977 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-12-31 0000792977 us-gaap:OtherRestructuringMember 2018-12-31 0000792977 us-gaap:ContractTerminationMember 2018-12-31 0000792977 srt:ScenarioPreviouslyReportedMember 2019-01-01 2019-03-31 0000792977 2019-04-01 2019-06-30 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2019-01-01 2019-03-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-01-01 2019-03-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-04-01 2019-06-30 0000792977 srt:ScenarioPreviouslyReportedMember 2019-04-01 2019-06-30 0000792977 2019-01-01 2019-03-31 0000792977 us-gaap:ProductMember 2019-01-01 2019-03-31 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2019-04-01 2019-06-30 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-01-01 2019-03-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-04-01 2019-06-30 0000792977 us-gaap:ProductMember 2019-04-01 2019-06-30 0000792977 2019-07-01 2019-09-30 0000792977 amag:MakenaAutoInjectorIntrarosaAndVyleesiProductsMember us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-12-31 0000792977 amag:MakenaMember us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-06-30 0000792977 amag:ContingentConsiderationMember 2018-04-01 2018-06-30 0000792977 amag:PerospherePharmaceuticalsInc.Member 2019-01-01 2019-03-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-01-01 2018-03-31 0000792977 2018-04-01 2018-06-30 0000792977 us-gaap:ProductMember 2018-01-01 2018-03-31 0000792977 srt:ScenarioPreviouslyReportedMember 2018-01-01 2018-03-31 0000792977 2018-01-01 2018-03-31 0000792977 srt:ScenarioPreviouslyReportedMember 2018-04-01 2018-06-30 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-01-01 2018-03-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-04-01 2018-06-30 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2018-01-01 2018-03-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-04-01 2018-06-30 0000792977 us-gaap:ProductMember 2018-04-01 2018-06-30 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2018-04-01 2018-06-30 0000792977 2018-10-01 2018-12-31 0000792977 srt:ScenarioPreviouslyReportedMember 2018-10-01 2018-12-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-07-01 2018-09-30 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-07-01 2018-09-30 0000792977 srt:ScenarioPreviouslyReportedMember 2018-07-01 2018-09-30 0000792977 us-gaap:ProductMember 2018-10-01 2018-12-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-10-01 2018-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-10-01 2018-12-31 0000792977 us-gaap:ProductMember 2018-07-01 2018-09-30 0000792977 2018-07-01 2018-09-30 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2018-07-01 2018-09-30 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2018-10-01 2018-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-07-01 2019-09-30 0000792977 us-gaap:ProductMember 2019-10-01 2019-12-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-07-01 2019-09-30 0000792977 srt:ScenarioPreviouslyReportedMember 2019-07-01 2019-09-30 0000792977 srt:ScenarioPreviouslyReportedMember 2019-10-01 2019-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-10-01 2019-12-31 0000792977 us-gaap:ProductMember 2019-07-01 2019-09-30 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2019-07-01 2019-09-30 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2019-10-01 2019-12-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-10-01 2019-12-31 0000792977 amag:AllowanceForPromotions1Member 2018-12-31 0000792977 amag:AllowanceForSalesReturns1Member 2018-12-31 0000792977 amag:AllowanceForSalesReturns1Member 2019-01-01 2019-12-31 0000792977 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0000792977 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-01-01 2017-12-31 0000792977 amag:AllowanceForSalesReturns1Member 2017-12-31 0000792977 amag:AllowanceForPromotions1Member 2017-12-31 0000792977 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-01-01 2019-12-31 0000792977 amag:AllowanceForPromotions1Member 2018-01-01 2018-12-31 0000792977 amag:AllowanceForPromotions1Member 2017-01-01 2017-12-31 0000792977 amag:AllowanceForPromotions1Member 2019-12-31 0000792977 amag:AllowanceForSalesReturns1Member 2018-01-01 2018-12-31 0000792977 amag:AllowanceForPromotions1Member 2019-01-01 2019-12-31 0000792977 amag:AllowanceForPromotions1Member 2016-12-31 0000792977 amag:AllowanceForSalesReturns1Member 2019-12-31 0000792977 amag:AllowanceForSalesReturns1Member 2016-12-31 0000792977 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 0000792977 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-12-31 0000792977 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0000792977 amag:AllowanceForSalesReturns1Member 2017-01-01 2017-12-31 0000792977 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-01-01 2018-12-31 0000792977 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2017-01-01 0000792977 2017-01-01 2017-03-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-12-31 0000792977 srt:ScenarioPreviouslyReportedMember 2019-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2017-01-01 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2016-01-01 2019-12-31 0000792977 srt:ScenarioPreviouslyReportedMember 2018-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2017-01-01 2017-12-31 0000792977 srt:ScenarioPreviouslyReportedMember 2017-01-01 2017-12-31 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2017-01-01 2017-12-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2017-01-01 2017-12-31 0000792977 srt:ScenarioPreviouslyReportedMember 2018-01-01 2018-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-01-01 2018-12-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2018-01-01 2018-12-31 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2018-01-01 2018-12-31 0000792977 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-01-01 2019-12-31 0000792977 srt:ScenarioPreviouslyReportedMember 2019-01-01 2019-12-31 0000792977 us-gaap:ProductMember srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-01-01 2019-12-31 0000792977 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2019-01-01 2019-12-31 0000792977 amag:MillicentPharmaLimitedMember amag:IntrarosaMember us-gaap:SubsequentEventMember 2020-04-01 2020-06-30 0000792977 amag:MillicentPharmaLimitedMember amag:IntrarosaMember amag:FirstTimeNetSalesDuringThresholdPeriodExceeds175MillionMember us-gaap:SubsequentEventMember 2020-05-21 2020-05-21 0000792977 amag:MillicentPharmaLimitedMember amag:IntrarosaMember amag:FirstTimeNetSalesDuringThresholdPeriodExceeds65MillionMember us-gaap:SubsequentEventMember 2020-05-21 2020-05-21 0000792977 us-gaap:SubsequentEventMember 2020-08-06 2020-08-06 0000792977 amag:NorgineB.V.Member amag:CiraparantagMember srt:MaximumMember amag:SalesMilestonesAchievementMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-31 0000792977 amag:MillicentPharmaLimitedMember amag:IntrarosaMember srt:MaximumMember us-gaap:SubsequentEventMember 2020-05-21 2020-05-21 0000792977 amag:MillicentPharmaLimitedMember amag:IntrarosaMember us-gaap:SubsequentEventMember 2020-05-21 2020-05-21 0000792977 amag:NorgineB.V.Member amag:CiraparantagMember srt:MaximumMember amag:RegulatoryMilestoneAchievementMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-31 0000792977 amag:NorgineB.V.Member amag:CiraparantagMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-31 0000792977 amag:MillicentPharmaLimitedMember amag:IntrarosaMember amag:FirstTimeNetSalesDuringThresholdPeriodExceeds115MillionMember us-gaap:SubsequentEventMember 2020-05-21 2020-05-21 0000792977 amag:PalatinTechnologiesInc.Member amag:VyleesiProductsMember srt:ScenarioForecastMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-31 0000792977 us-gaap:SubsequentEventMember 2020-07-14 2020-07-14 0000792977 us-gaap:SubsequentEventMember 2020-04-01 2020-06-30 0000792977 us-gaap:SubsequentEventMember 2020-05-01 2020-05-31 0000792977 amag:PalatinTechnologiesInc.Member amag:VyleesiProductsMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-31 0000792977 amag:CiraparantagMember us-gaap:SubsequentEventMember 2020-07-31 0000792977 amag:MillicentPharmaLimitedMember amag:IntrarosaMember us-gaap:SubsequentEventMember 2020-01-01 2020-06-30 iso4217:USD shares iso4217:USD shares amag:product_candidate amag:business_segment amag:facility pure amag:employee amag:plan amag:lawsuit amag:defendant amag:day amag:month 0.25 0.33 P3Y P3Y P1Y P6Y AMAG Pharmaceuticals, Inc (the “Company” or “we”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to amend and restate certain items in its Annual Report on Form 10-K for the year ended December 31, 2019, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 6, 2020 (the “Original 10-K”). The Company identified immaterial errors in its previously reported revenue over the impacted annual periods of 2016 through 2019 and, in connection therewith, the Company’s management identified a material weakness in our internal control over financial reporting (“ICFR”) related to ensuring the timely recognition of our gross-to-net adjustments for certain governmental rebates and the related accruals. Accordingly, this Amendment is being filed to amend Item 6, Selected Financial Data, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, Item 8, Financial Statements and Supplementary Data, and Item 9A, Controls and Procedures, of Part II of the Original 10-K and restate the financial statements and related notes to reflect the immaterial errors identified, Management’s Annual Report on Internal Control Over Financial Reporting, management’s assessment of the effectiveness of our disclosure controls and procedures and PwC’s Report of Independent Registered Public Accounting Firm on the Company’s internal control over financial reporting. true --12-31 FY 2019 0000792977 us-gaap:AccountingStandardsUpdate201609Member us-gaap:AccountingStandardsUpdate201609Member us-gaap:AccountingStandardsUpdate201409Member us-gaap:AccountingStandardsUpdate201409 0 0.01 0.01 117500000 117500000 34606760 33999081 34606760 33999081 0.10 0.10 0.0369079 0.0365464 P5Y P1Y 14400000 P1Y 0 0 0.01 0.01 2000000 2000000 0 0 500000 P3Y P4Y P3Y 0 0 0 0 0 0 P10Y P10Y P10Y us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember 10-K/A true 2019-12-31 false 001-10865 AMAG PHARMACEUTICALS, INC. DE 04-2742593 1100 Winter Street, Waltham, MA 02451 617 498-3300 Common Stock, par value $0.01 per sharePreferred Share Purchase Rights AMAG NASDAQ No No Yes Yes Accelerated Filer false false false 335000000.0 34265738 113009000 253256000 58742000 140915000 94163000 75347000 31553000 26691000 19100000 18961000 0 10000000 316567000 525170000 4116000 7521000 422513000 422513000 23620000 217033000 23286000 630000 1260000 495000 495000 0 1467000 791227000 1175459000 27021000 14487000 183382000 134635000 0 21276000 4077000 17000 144000 214497000 170542000 277034000 261933000 19791000 0 215000 89000 1212000 511411000 433902000 0 0 339000 346000 1297917000 1292736000 -3239000 -3985000 -1015201000 -547540000 279816000 741557000 791227000 1175459000 309985000 471898000 493843000 16400000 0 0 161000 150000 124000 326546000 472048000 493967000 107193000 215892000 161349000 64853000 44846000 75017000 74856000 32500000 65845000 286600000 227810000 178151000 232336000 0 319246000 7420000 0 0 773258000 521048000 799608000 -446712000 -49000000 -305641000 25709000 51971000 68382000 0 -35922000 -10926000 4285000 5328000 2810000 428000 -74000 -70000 -20996000 -82639000 -76568000 -467708000 -131639000 -382209000 -47000 40436000 -175521000 -467661000 -172075000 -206688000 0 18873000 10313000 0 87076000 0 0 2371000 4388000 0 103578000 5925000 -467661000 -68497000 -200763000 -13.74 -5.00 -5.92 0 3.01 0.17 -13.74 -1.99 -5.75 34030000 34394000 34907000 -467661000 -68497000 -200763000 746000 -77000 -70000 -466915000 -68574000 -200833000 34336147 343000 1238031000 -3838000 -300974000 933562000 323000 323000 43236000 43236000 21558000 21558000 27988000 27988000 600000 6000 13494000 13500000 1366266 14000 19453000 19467000 120580 1000 1593000 1594000 392651 5000 -1272000 -1267000 23664000 23664000 -70000 -70000 -200763000 -200763000 34083112 341000 1271628000 -3908000 -480179000 787882000 1136000 1136000 463776 4000 275000 279000 59872 1000 917000 918000 19916000 19916000 -77000 -77000 -68497000 -68497000 34606760 346000 1292736000 -3985000 -547540000 741557000 281184 3000 -1803000 -1800000 185937 1000 1505000 1506000 1074800 11000 13719000 13730000 19198000 19198000 746000 746000 -467661000 -467661000 33999081 339000 1297917000 -3239000 -1015201000 279816000 -467661000 -68497000 -200763000 27324000 172223000 155538000 232336000 0 319246000 0 678000 3852000 95000 -87000 -302000 19767000 5176000 0 0 99000 -265000 19198000 19916000 23664000 18029000 0 945000 0 -35922000 -10926000 15242000 15658000 14395000 265000 1000 -70000 -270000 -49607000 -47686000 404000 41948000 -178688000 2725000 0 0 0 87076000 0 0 14111000 0 18816000 -16995000 14978000 19253000 454000 2331000 113000 6097000 2222000 53952000 -30614000 18636000 -6400000 8658000 17080000 0 0 10432000 1800000 -95000 1223000 -125696000 60800000 106596000 98321000 85342000 294957000 14815000 89956000 127249000 60000000 0 0 0 0 55800000 0 519303000 0 0 10000000 0 2544000 2534000 8988000 20962000 502155000 102920000 0 475000000 353125000 0 0 320000000 21417000 0 191730000 0 28054000 625000 0 0 323000 0 0 9553000 72000 119000 39793000 13730000 0 19466000 1506000 0 0 30000 3881000 3021000 1830000 2682000 2696000 -35513000 -501974000 -293644000 -140247000 60981000 -84128000 253751000 192770000 276898000 113504000 253751000 192770000 -202000 5345000 5296000 10667000 48757000 56959000 18455000 10000000 0 0 0 0 12555000 0 0 9300000 DESCRIPTION OF BUSINESS<div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AMAG Pharmaceuticals, Inc., a Delaware corporation, was founded in 1981. We are a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs by leveraging our development and commercial expertise to invest in and grow our pharmaceutical products across a range of therapeutic areas. Our currently marketed products support the health of patients in the areas of hematology and maternal and women’s health, including Feraheme</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(ferumoxytol injection) for intravenous use, Makena</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(hydroxyprogesterone caproate injection) auto-injector, Intrarosa</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(prasterone) vaginal inserts and Vyleesi</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">(bremelanotide injection). In addition to our marketed products, our portfolio includes </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> product candidates, AMAG-423 (digoxin immune fab (ovine)), which is being studied for the treatment of severe preeclampsia, and ciraparantag, which is being studied as an anticoagulant reversal agent. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2019, we announced topline results from the Progestin’s Role in Optimizing Neonatal Gestation clinical trial (“PROLONG” or “Trial 003”), a randomized, double-blinded, placebo-controlled clinical trial evaluating Makena in patients with a history of a prior spontaneous singleton preterm delivery. The PROLONG trial was conducted under the U.S. Food and Drug Administration’s (the “FDA”) “Subpart H” accelerated approval process. The approval of Makena was based primarily on the Meis trial (“Trial 002”), which was conducted by the Maternal-Fetal Medicine Units Network, sponsored by the National Institute of Child Health and Human Development. In contrast to the Meis trial, the PROLONG trial did not demonstrate a statistically significant difference between the treatment and placebo arms for the co-primary endpoints. On October 29, 2019, the Advisory Committee met to discuss the results of the PROLONG trial to inform the FDA’s regulatory decision for Makena. Following various presentations by experts and discussions at the meeting, the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee (the “Advisory Committee”) voted as follows: (a) in response to the question “Do the findings from Trial 003 verify the clinical benefits of Makena on neonatal outcomes?”, 16 members voted “No” and no members voted “Yes”; (b) in response to the question “Based on the findings from Trial 002 and Trial 003, is there substantial evidence of effectiveness of Makena in reducing the risk of recurrent preterm birth?”, 13 members voted “No” and three members voted “Yes”; and (c) in response to the question, “Should the FDA (A) pursue withdrawal of approval for Makena, (B) leave Makena on the market under accelerated approval and require a new confirmatory trial, or (C) leave Makena on the market without requiring a new confirmatory trial?”, nine members voted for (A), seven members voted for (B) and no members voted for (C). The FDA is not required to follow the recommendations of its Advisory Committees, but will take them into consideration in deciding what regulatory steps to take with respect to Makena. We are unable to predict the outcome or timing of any FDA action with respect to Makena.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019 we completed a review of our product portfolio and strategy. This strategic review resulted in our intention to divest Intrarosa</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> (prasterone) and Vyleesi</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> (bremelanotide), as announced in January 2020. We determined that these anticipated actions did not result in the related assets meeting the criteria to be recorded as held of sale at December 31, 2019. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to risks common to companies in the pharmaceutical industry including, but not limited to (as such risks pertain to our business) the impact of any action by the FDA with respect to Makena, including the potential of the removal of Makena’s approval, our ability to successfully divest Intrarosa and Vyleesi, our ability to successfully commercialize our products, intense competition, including from generic products; maintaining and defending the proprietary nature of our technology, including in the event that Sandoz launches a generic version of Feraheme in accordance with the 2018 settlement agreement; our dependence upon third-party manufacturers and our potential inability to obtain raw or other materials and impacts of supply shortages; our reliance on and the extent of reimbursement from third parties for the use of our products, including the impact of generic competitors, Makena’s high Medicaid reimbursement concentration; our ability to expand our product portfolio through business development transactions; the approval of our product candidates and our ability to commercialize such products, if approved; potential litigation, including securities and product liability suits; our ability to work effectively and collaboratively with our licensors and partners; our reliance on other third parties in our business, including to conduct our clinical trials and undertake our product and distribution; our ability to maintain, attract and retain key employees; our potential failure to comply with federal and state healthcare fraud and abuse laws, marketing disclosure laws, or other federal and state laws and regulations and potential civil or criminal penalties as a result thereof; uncertainties regarding reporting and payment obligations under government pricing programs; post-approval commitments for Feraheme; our ability to comply with data protection laws and regulations; the impact of disruptions to our information technology systems; our level of and ability to repay our indebtedness; our access to sufficient capital; the availability of net operating loss carryforwards and other tax assets; potential differences between actual future results and the estimates or assumptions used by us in preparation of our consolidated financial statements, including goodwill and intangible assets; the volatility of our stock price; the potential </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fluctuation of our operating results; and provisions in our charter, by-laws and certain contracts that discourage an acquisition of our company. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Throughout this Annual Report on Form 10-K, AMAG Pharmaceuticals, Inc. and our consolidated subsidiaries are collectively referred to as “the Company,” “AMAG,” “we,” “us,” or “our.” 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Principles of Consolidation</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“GAAP”) and include the accounts of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of June 30, 2018, our CBR business met the criteria to be classified as a discontinued operation. All historical operating results for CBR are reflected within discontinued operations in the consolidated statements of operations for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. For additional information, see Note C, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Discontinued Operations.</span><span style="font-family:inherit;font-size:10pt;">”</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates and Assumptions</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent liabilities. The most significant estimates and assumptions are used to determine amounts and values of, but are not limited to: revenue recognition related to product sales revenue; product sales allowances and accruals; allowance for doubtful accounts; marketable securities; inventory; acquisition date fair value and subsequent fair value estimates used to assess impairment of long-lived assets, including goodwill and other intangible assets; debt obligations; certain accrued liabilities, including clinical trial accruals; equity-based compensation expense, and income taxes, inclusive of valuation allowances. Actual results could differ materially from those estimates.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product revenues</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2018, we adopted Accounting Standards Codification (“ASC”) Topic 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> (“ASC 606”) applying the modified retrospective transition method to all contracts that were not completed as of January 1, 2018 as an adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the opening balance of stockholders’ equity at the beginning of 2018. The adjustment recorded was for incremental contract acquisition costs related to the CBR business. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for prior periods. There was no impact to our product revenue as a result of adoption.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">a.</span><span style="font-family:inherit;font-size:10pt;">Identify the contract(s) with a customer; </span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">b.</span><span style="font-family:inherit;font-size:10pt;">Identify the performance obligations in the contract; </span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">c.</span><span style="font-family:inherit;font-size:10pt;">Determine the transaction price; </span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">d.</span><span style="font-family:inherit;font-size:10pt;">Allocate the transaction price to the performance obligations in the contract; and </span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">e.</span><span style="font-family:inherit;font-size:10pt;">Recognize revenue when (or as) the performance obligations are satisfied. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We only apply the five step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, if the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our major sources of revenue during the reporting periods were product revenues from Makena, Feraheme and Intrarosa. The adoption of ASC 606 in 2018 did not have an impact on the pattern or timing of recognition of our product revenue, as the majority of our product revenue continues to be recognized when the customer takes control of our product.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We receive payments from customers based upon contractual billing schedules; accounts receivable are recorded when the right to consideration becomes unconditional.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Performance Obligations</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At contract inception, we assess the goods promised in our contracts with customers and identify a performance obligation for each promise to transfer to the customer a good (or bundle of goods) that is distinct. To identify the performance obligations, we consider all of the goods promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. We determined that the following distinct goods represent separate performance obligations: </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">•</span><span style="font-family:inherit;font-size:10pt;">Supply of Makena product </span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">•</span><span style="font-family:inherit;font-size:10pt;">Supply of Feraheme product </span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">•</span><span style="font-family:inherit;font-size:10pt;">Supply of Intrarosa product</span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">•</span><span style="font-family:inherit;font-size:10pt;">Supply of Vyleesi product</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We principally sell our products to wholesalers, specialty distributors, specialty pharmacies and other customers (collectively, “Customers”), who purchase products directly from us. Our Customers subsequently resell the products to healthcare providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payers that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the majority of our Customers, we transfer control at the point in time when the goods are delivered. In instances when we perform shipping and handling activities, these are considered fulfillment activities, and accordingly, the costs are accrued when the related revenue is recognized. Taxes collected from Customers and remitted to governmental authorities are excluded from revenues. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Consideration</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 606, we are required to make estimates of the net sales price, including estimates of variable consideration (such as rebates, chargebacks, discounts, copay assistance and other deductions), and recognize the estimated amount as revenue, when we transfer control of the product to our customers. Variable consideration must be determined using either an “expected value” or a “most likely amount” method. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record product revenues net of certain allowances and accruals in our consolidated statements of operations. Product sales allowances and accruals are primarily comprised of both direct and indirect fees, discounts and rebates and provisions for estimated product returns. Direct fees, discounts and rebates are contractual fees and price adjustments payable to Customers that purchase products directly from us. Indirect fees, discounts and rebates are contractual price adjustments payable to healthcare providers and organizations, such as certain physicians, clinics, hospitals, group purchasing organizations (“GPOs”), and dialysis organizations that typically do not purchase products directly from us but rather from wholesalers and specialty distributors. Consideration payable to a Customer, or other parties that purchase goods from a Customer, are considered to be a reduction of the transaction price, and therefore, of revenue. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales allowances and accruals are based on definitive contractual agreements or legal requirements (such as laws and regulations to provide mandatory discounts for sales to government entities) related to the purchase and/or utilization of the product by these entities and are recorded in the same period that the related revenue is recognized. We use the expected value method for estimating variable consideration. We estimate product sales allowances and accruals using either historical, actual and/or other data, including estimated patient usage, applicable contractual rebate rates, contract performance by the benefit providers, other current contractual and statutory requirements, historical market data based upon experience of our products and other products similar to them, specific known market events and trends such as competitive pricing and new product introductions, current and forecasted Customer buying patterns and inventory levels, and the shelf life of our products. As part of this evaluation, we also review changes to federal and other legislation, changes to rebate contracts, changes in the level of discounts, and changes in product sales trends. Although allowances and accruals are recorded at the time of product sale, rebates are typically paid out in arrears, </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>three months</span></span><span style="font-family:inherit;font-size:10pt;"> after the sale.  </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimate of variable consideration, which is included in the transaction price, may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved in a future period. Estimating variable consideration and the related constraint requires the use of significant management judgment and actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. </span><span style="font-family:inherit;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;"> amounts were constrained as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Discounts</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We typically offer a </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> prompt payment discount to certain customers as an incentive to remit payment in accordance with the stated terms of the invoice, generally between </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>60 days</span></span><span style="font-family:inherit;font-size:10pt;">. Because we anticipate that those customers who are offered this discount will take advantage of the discount, </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the prompt payment discount at the time of sale is accrued for eligible customers, based on the gross amount of each invoice. We adjust the accrual quarterly to reflect actual experience. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Chargebacks</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chargeback reserves represent the estimated obligations resulting from the difference between the prices at which we sell our products to wholesalers and the sales price ultimately paid to wholesalers under fixed price contracts by third-party payers, including governmental agencies. The chargeback estimates are determined based on actual product sales data and forecasted customer buying patterns. Actual chargeback amounts are determined at the time of resale to the qualified healthcare provider, and we generally issue credits for such amounts within several weeks of receiving notification from the wholesaler. Estimated chargeback amounts are recorded at the time of sale and adjusted quarterly to reflect actual experience. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Distributor/Wholesaler and Group Purchasing Organization Fees</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fees under arrangements with distributors and wholesalers are usually based upon units of product purchased during the prior month or quarter and are usually paid by us within several weeks of the receipt of an invoice from the wholesaler or distributor. Fees under arrangements with GPOs are usually based upon member purchases during the prior quarter and are generally billed by the GPO within </span><span style="font-family:inherit;font-size:10pt;"><span>30 days</span></span><span style="font-family:inherit;font-size:10pt;"> after period end. In accordance with ASC 606, since the consideration given to the Customer is not for a distinct good or service, the consideration is a reduction of the transaction price of the vendor’s products or services. We have included these fees in contractual adjustments in the table above. We generally pay such amounts within several weeks of the receipt of an invoice from the distributor, wholesaler or GPO. Accordingly, we accrue the estimated fee due at the time of sale, based on the contracted price invoiced to the Customer. We adjust the accrual quarterly to reflect actual experience.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Returns</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consistent with industry practice, we generally offer wholesalers, specialty distributors and other customers a limited right to return our products based on the product’s expiration date. The current shelf-lives or time between manufacture and expiration for products in our portfolio range from </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">. Product returns are estimated based on the historical return patterns and known or expected changes in the marketplace. We track actual returns by individual production lots. Returns on lots eligible for credits under our returned goods policy are monitored and compared with historical return trends and rates. We expect that wholesalers and healthcare providers will not stock significant inventory due to the cost of the product, the expense to store our products, and/or that our products are readily available for distribution. We record an estimate of returns at the time of sale. If necessary, our estimated rate of returns may be adjusted for actual return experience as it becomes available and for known or expected changes in the marketplace. There were no material adjustments to our reserve for product returns during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. To date, our product returns have been relatively limited; however, returns experience may change over time. We may be required to make future adjustments to our product returns estimate, which would result in a corresponding change to our net product sales in the period of adjustment and could be significant. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales Rebates</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We contract with various private payer organizations, primarily pharmacy benefit managers, for the payment of rebates with respect to utilization of our products. We determine our estimates for rebates, if applicable, based on actual product sales data and our historical product claims experience. Rebate amounts generally are invoiced quarterly and are paid in arrears, and we expect to pay such amounts within several weeks of notification by the provider. We regularly assess our reserve balance and the rate at which we accrue for claims against product sales. If we determine in future periods that our actual rebate </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">experience is not indicative of expected claims, if actual claims experience changes, or if other factors affect estimated claims rates, we may be required to adjust our current accumulated reserve estimate, which would affect net product sales in the period of the adjustment and could be significant.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Governmental Rebates</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Governmental rebates relate to our reimbursement arrangements with state Medicaid programs. We determine our estimates for Medicaid rebates, if applicable, based on actual product sales data and our historical product claims experience. In estimating these reserves, we provide for a Medicaid rebate associated with both those expected instances where Medicaid will act as the primary insurer as well as in those instances where we expect Medicaid will act as the secondary insurer. Rebate amounts generally are invoiced quarterly and are paid in arrears, and we expect to pay such amounts within several weeks of notification by the Medicaid or provider entity. We regularly assess our Medicaid reserve balance and the rate at which we accrue for claims against product sales. If we determine in future periods that our actual rebate experience is not indicative of expected claims, if actual claims experience changes, or if other factors affect estimated claims rates, we may be required to adjust our current Medicaid accumulated reserve estimate, which would affect net product sales in the period of the adjustment and could be significant. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Discounts</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other discounts which we offer include voluntary patient assistance programs, such as copay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug copayments required by payers. The calculation of the accrual for copay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with product that has been recognized as revenue.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration Revenues</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When we enter into collaboration agreements, we assess whether the agreements fall within the scope of ASC Topic 808, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:inherit;font-size:10pt;"> (“ASC 808”) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606. However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the related underlying expense.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents consist principally of cash held in commercial bank accounts, money market funds and U.S. treasury securities having an original maturity of less than three months at the date of acquisition. We consider all highly liquid marketable securities with a maturity of three months or less as of the acquisition date to be cash equivalents. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, substantially all of our cash and cash equivalents were held in either commercial bank accounts or money market funds.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations and Significant Customer Information</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and cash equivalents, marketable securities, and accounts receivable. We currently hold our excess cash primarily in institutional money market funds, corporate debt securities, U.S. treasury and government agency securities and certificates of deposit. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we did not have a material concentration in any single investment.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations are located entirely within the U.S. We focus primarily on developing, manufacturing, and commercializing our products and product candidates. The following table sets forth customers who represented </span><span style="font-family:inherit;font-size:10pt;">10%</span><span style="font-family:inherit;font-size:10pt;"> or more of our total revenues for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:59%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">McKesson Corporation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AmerisourceBergen Drug Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardinal Health</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt; 10%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt; 10%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our net accounts receivable primarily represent amounts due for products sold directly to wholesalers, distributors and specialty pharmacies. Accounts receivable for our products are recorded net of reserves for estimated chargeback obligations, prompt payment discounts and any allowance for doubtful accounts.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of our credit management policy, we perform ongoing credit evaluations of our customers, and we generally do not require collateral. If the financial condition of any of our significant product sales customers was to deteriorate and result in an impairment of its ability to make payments owed to us, an allowance for doubtful accounts may be required which could have a material effect on earnings in the period of any such adjustment. We did not experience any significant bad debts and have not established an allowance for doubtful accounts as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, three customers accounted for </span><span style="font-family:inherit;font-size:10pt;">10%</span><span style="font-family:inherit;font-size:10pt;"> or more of our accounts receivable balance, representing approximately </span><span style="font-family:inherit;font-size:10pt;"><span>85%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>73%</span></span><span style="font-family:inherit;font-size:10pt;"> in the aggregate of our total accounts receivable, respectively.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are currently dependent on a single supplier for certain of our manufacturing processes, including Feraheme drug substance (produced in </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> separate facilities) and a single supplier for our Makena auto-injector product. We have been and may continue to be exposed to a significant loss of revenue from the sale of our products in the event that our suppliers and/or manufacturers are not able to fulfill demand for any reason.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We apply the provisions of ASC Topic 820, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:inherit;font-size:10pt;"> (“ASC 820”) for our financial assets and liabilities that are re-measured and reported at fair value each reporting period and our nonfinancial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis, including property and equipment and identifiable intangible assets. Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, we consider the principal or most advantageous market in which it would transact and consider assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. Financial assets and liabilities are categorized within the valuation hierarchy based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1- Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for and classify our marketable securities as either “available-for-sale,” “held-to-maturity,” or “trading debt securities,” in accordance with the accounting guidance related to the accounting and classification of certain investments in marketable securities. The determination of the appropriate classification by us is based primarily on management’s ability and intent to sell the debt security at the time of purchase. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, all of our marketable securities were classified as available-for-sale.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale securities are those securities which we view as available for use in current operations, if needed. We generally classify our available-for-sale securities as short-term investments, even though the stated maturity date may be one year or more beyond the current balance sheet date. Available-for-sale marketable securities are stated at fair value with their </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unrealized gains and losses included in accumulated other comprehensive income (loss) within the consolidated statements of stockholders’ equity, until such gains and losses are realized in other income (expense) within the consolidated statements of operations or until an unrealized loss is considered other-than-temporary.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize other-than-temporary impairments of our marketable securities when there is a decline in fair value below the amortized cost basis and if (a) we have the intent to sell the security or (b) it is more likely than not that we will be required to sell the security prior to recovery of its amortized cost basis. If either of these conditions is met, we recognize the difference between the amortized cost basis of the security and its fair value at the impairment measurement date in our consolidated statements of operations. If neither of these conditions is met, we must perform additional analysis to evaluate whether the unrealized loss is associated with the creditworthiness of the issuer of the security rather than other factors, such as interest rates or market factors. If we determine from this analysis that we do not expect to receive cash flows sufficient to recover the entire amortized cost of the security, a credit loss exists, the impairment is considered other-than-temporary and is recognized in our consolidated statements of operations.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory is stated at the lower of cost or net realizable value, with approximate cost being determined on a first-in, first-out basis. Prior to initial approval from the FDA or other regulatory agencies, we expense costs relating to the production of inventory in the period incurred, unless we believe regulatory approval and subsequent commercialization of the product candidate is probable and we expect the future economic benefit from sales of the product to be realized, at which point we capitalize the costs as inventory. We assess any costs capitalized prior to regulatory approval each quarter for indicators of impairment, such as a reduced likelihood of approval. We expense costs associated with clinical trial material as research and development expense. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On a quarterly basis, we analyze our inventory levels to determine whether we have any obsolete, expired, or excess inventory. If any inventory is expected to expire prior to being sold, has a cost basis in excess of its net realizable value, is in excess of expected sales requirements as determined by internal sales forecasts, or fails to meet commercial sale specifications, the inventory is written-down through a charge to cost of product sales. The determination of whether inventory costs will be realizable requires estimates by management of future expected inventory requirements, based on sales forecasts. Once packaged, our products have a shelf-life ranging from </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">. As a result of comparison to internal sales forecasts, we expect to fully realize the carrying value of our finished goods inventory. If actual market conditions are less favorable than those projected by management, inventory write-downs may be required. Charges for inventory write-downs are not reversed if it is later determined that the product is saleable. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment, Net</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost and depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:73%;"/><td style="width:27%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer equipment and software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5 Years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5 Years</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lesser of Lease or Asset Life</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory and production equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5 Years</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs for capital assets not yet placed in service are capitalized on our balance sheets and will be depreciated in accordance with the above guidelines once placed into service. Costs for maintenance and repairs are expensed as incurred. Upon sale or other disposition of property and equipment, the cost and related depreciation are removed from the accounts and any resulting gain or loss is charged to our consolidated statements of operations. Assets classified as held for sale are no longer subject to depreciation and are recorded at the lower of carrying value or estimated net realizable value. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We amortize our intangible assets that have finite lives based on either the straight-line method, or if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be utilized. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we acquire an asset or a group of assets that do not meet the definition of a business, the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Impairment of Long-Lived Assets</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We review our long-lived assets, which includes property and equipment and identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. To evaluate recoverability, management compares the projected undiscounted future cash flows associated with the asset or asset group, including proceeds from its eventual disposition over its estimated useful life against its carrying amount. If the undiscounted cash flows are not sufficient to recover the carrying value of the asset or asset group, the asset or asset group is considered impaired. The impairment loss, if any, is measured as the excess of the carrying amount of the asset or asset group over its estimated fair value, which is typically calculated utilizing a discounted cash flow (“DCF”) model following the same methodology as described in the following section.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We test goodwill at the reporting unit level for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that could indicate impairment and trigger an interim impairment assessment include, but are not limited to, an adverse change in current economic and market conditions, including a significant prolonged decline in market capitalization, a significant adverse change in legal factors, unexpected adverse business conditions, and an adverse action or assessment by a regulator. Our annual impairment test date is October 31. We have determined that we operate in a single operating segment and have a single reporting unit. </span></div><div style="line-height:120%;padding-top:17px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In performing our goodwill impairment tests, we utilize the approach prescribed under Accounting Standards Codification (“ASC”) 350, as amended by Accounting Standards Update (“ASU”) 2017-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:inherit;font-size:10pt;"> (“ASU 2017-04”), which requires that an entity perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. </span></div><div style="line-height:120%;padding-top:17px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When we perform any goodwill impairment test, the estimated fair value of our reporting unit is determined using an income approach that utilizes a DCF model or a market approach, when appropriate, which assesses our market capitalization as adjusted for a control premium, or a combination thereof. </span></div><div style="line-height:120%;padding-top:17px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the market approach, when our carrying value exceeds our market capitalization, we consider a control premium for purposes of estimating the fair value of our reporting unit, as we believe that a market participant buyer would be required to pay a control premium for our business. The control premium utilized is based on control premiums observed in recent comparable market transactions. As described in the accounting guidance for evaluating long-lived assets for impairment, an entity’s fair value may include a control premium in addition to the quoted market price to determine the fair value of a single reporting unit entity, as an acquiring entity is often willing to pay more for equity securities that give it a controlling interest than an investor would pay for a number of equity securities representing less than a controlling interest. This accounting guidance also indicates that the quoted market price of an individual security need not be the sole measurement basis of the fair value of a single reporting unit. When our market capitalization exceeds our carrying value, we utilize our market capitalization as the indicator of fair value in our impairment test. </span></div><div style="line-height:120%;padding-top:17px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Under the income approach, the DCF model is based upon expected future after-tax operating cash flows of the reporting unit discounted to a present value using a risk-adjusted discount rate. Estimates of future cash flows require management to make significant assumptions concerning (i) future operating performance, including future sales, long-term growth rates, operating margins, variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows (ii) the probability of regulatory approvals, and (iii) future economic conditions, all of which may differ from actual future cash flows. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rate, which is intended to reflect the risks inherent in future cash flow projections, used in the DCF model, is based on estimates of the weighted average cost of capital (“WACC”) of market participants relative to our reporting unit. Financial and credit market volatility can directly impact certain inputs and assumptions used to develop the WACC. Any changes in these assumptions may affect our fair value estimate and the result of an impairment test. The discount rates and other inputs and assumptions are consistent with those that a market participant would use. In addition, in order to assess the reasonableness of the fair value of our reporting unit as calculated under the DCF model, we also compare the reporting unit’s fair value to our market capitalization and calculate an implied control premium (the excess sum of the reporting unit’s fair value over its market capitalization). We evaluate the implied control premium by comparing it to control premiums of recent comparable market transactions, as applicable. </span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Combinations and Asset Acquisitions</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The purchase price allocation for business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values. Under ASU No. 2017-01, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</span><span style="font-family:inherit;font-size:10pt;"> (“2017-01”), we first determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the single asset or group of assets, as applicable, is not a business.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for acquired businesses using the acquisition method of accounting, under which the total purchase price of an acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. Acquisition-related costs are expensed as incurred. Any excess of the consideration transferred over the estimated fair values of the identifiable net assets acquired is recorded as goodwill. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The purchase price allocations for business combinations are initially prepared on a preliminary basis and are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. Any adjustments to the purchase price allocations are made as soon as practicable but no later than one year from the acquisition date.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired inventory is recorded at its fair value, which may require a step-up adjustment to recognize the inventory at its expected net realizable value. The inventory step-up is recorded to cost of product sales in our consolidated statements of operations when related inventory is sold, and we record step-up costs associated with clinical trial material as research and development expense.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition-Related Contingent Consideration</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration arising from a business combination is included as part of the purchase price and is recognized at its estimated fair value as of the acquisition date. Subsequent to the acquisition date, we measure contingent consideration arrangements at fair value for each period until the contingency is resolved. These changes in fair value are recognized in selling, general and administrative expenses in our consolidated statements of operations. Changes in fair values reflect new information about the likelihood of the payment of the contingent consideration and the passage of time. For asset acquisitions, we record contingent consideration for obligations we consider to be probable and estimable and these liabilities are not adjusted to fair value.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January 1, 2019, we adopted ASC Topic 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (“ASC 842”), and chose to apply the provisions of ASC 842 as of the effective date with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected to utilize the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also made accounting policy elections to not separate lease and non-lease components for our real estate lease and to not recognize leases with an initial term of twelve months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis on our consolidated statements of income over the lease term. We did not have any material short-term leases accounted for under this policy during the </span><span style="font-family:inherit;font-size:10pt;">year ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liability, and long-term operating lease liability on our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Our incremental borrowing rate is determined based on an evaluation of our creditworthiness and the prevailing market rates for collateralized debt with maturity dates commensurate with the term of each lease. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option. Lease expense for operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The lease payments used to determine our ROU assets may include lease incentives, stated rent increases, and escalation clauses linked to rates of inflation when determinable and are recognized in our ROU assets on our consolidated balance sheet. In addition, certain lease agreements contain lease and non-lease components. With the exception of our real estate leases, we separate lease payments for the identified assets from any non-lease payments included in the agreement. For our real estate leases, we account for the lease and non-lease components as a single lease component. Additionally, for vehicle and certain equipment leases, we apply a portfolio approach to effectively account for the related ROU assets and operating lease liabilities.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Cash </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We classified </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of our cash as restricted cash, a non-current asset on the balance sheet, as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. This amount represented the security deposit delivered to the landlord of our Waltham, Massachusetts headquarters.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Expenses</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses include both external and internal expenses. External expenses primarily include costs of clinical trials and fees paid to contract research organizations (“CROs”), clinical supply and manufacturing expenses, regulatory filing fees, consulting and professional fees as well as other general costs related to the execution of research and development activities. Internal expenses primarily include compensation of employees engaged in research and development activities. Research and development expenses are expensed as incurred. Manufacturing costs are generally expensed as incurred until a product has received the necessary initial regulatory approval. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Patents</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expense all patent-related costs in selling, general and administrative expenses as incurred.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advertising Costs </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Advertising costs are expensed as incurred and included in selling, general and administrative expenses in our consolidated statements of operations. Advertising costs, including promotional expenses, costs related to digital marketing and print media advertising space were </span><span style="font-family:inherit;font-size:10pt;"><span>$53.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$29.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$9.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity-Based Compensation</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity-based compensation cost is generally measured at the estimated grant date fair value and recorded to expense over the requisite service period, which is generally the vesting period. Because equity-based compensation expense is based on awards ultimately expected to vest, we must make certain judgments about whether employees, officers, directors, consultants and advisers will complete the requisite service period, and reduce the compensation expense being recognized for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based upon historical experience and adjusted for unusual events such as corporate restructurings, which can result in higher than expected turnover and forfeitures. If factors change and we employ different assumptions in future periods, the compensation expense that we record in the future may differ significantly from what we have recorded in the current period. </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate the fair value of equity-based compensation involving stock options based on the Black-Scholes option pricing model. This model requires the input of several factors such as the expected option term, the expected risk-free interest rate over the expected option term, the expected volatility of our stock price over the expected option term and the expected dividend yield over the expected option term and are subject to various assumptions. The fair value of awards calculated using the Black-Scholes option pricing model is generally amortized on a straight-line basis over the requisite service period, and is recognized based on the proportionate amount of the requisite service period that has been rendered during each reporting period. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate the fair value of our restricted stock units (“RSUs”) whose vesting is contingent upon market conditions, such as total shareholder return, using the Monte-Carlo simulation model. The fair value of RSUs where vesting is contingent upon market conditions is amortized based upon the estimated derived service period. The fair value of RSUs granted to our employees and directors whose vesting is dependent on future service is determined based upon the quoted closing market price per share on the date of grant, adjusted for estimated forfeitures. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe our valuation methodologies are appropriate for estimating the fair value of the equity awards we grant to our employees and directors. Our equity award valuations are estimates and may not be reflective of actual future results or amounts ultimately realized by recipients of these grants. These amounts are subject to future quarterly adjustments based upon a variety of factors, which include, but are not limited to, changes in estimated forfeiture rates and the issuance of new equity-based awards. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use the asset and liability method of accounting for deferred income taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A deferred tax asset is established for the expected future benefit of net operating loss (“NOL”) and credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance against net deferred tax assets is required if, based on available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Significant judgments, estimates and assumptions regarding future events, such as the amount, timing and character of income, deductions and tax credits, are required in the determination of our provision for income taxes and whether valuation allowances are required against deferred tax assets. In evaluating our ability to recover our deferred tax assets, we consider all available evidence, both positive and negative, including the existence of taxable temporary differences, our past operating results, the existence of cumulative income in the most recent fiscal years, changes in the business in which we operate and our forecast of future taxable income. In determining future taxable income, we are responsible for assumptions utilized including the amount of state and federal operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have established a valuation allowance on our net deferred tax assets other than refundable alternative minimum tax (“AMT”) credits to the extent that our existing taxable temporary differences would not be available as a source of income to realize the benefits of those deferred tax assets.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position. We evaluate uncertain tax positions on a quarterly basis and adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could impact our income tax provision in future periods. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as a provision for income tax in our consolidated statement of operations. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Comprehensive Loss</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our comprehensive loss consists of net loss and other comprehensive loss. Other comprehensive loss includes changes in equity that are excluded from net loss, which for all periods presented in these consolidated financial statements related to unrealized holding gains and losses on available-for-sale marketable securities, net of tax.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic and Diluted Earnings per Share </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We compute basic earnings per share by dividing earnings by the weighted average number of common shares outstanding during the relevant period. Diluted earnings per share is computed by dividing earnings by the diluted number of common shares outstanding during the period. Except where the result would be antidilutive, diluted earnings per common share would be computed assuming the impact of the conversion of the </span><span style="font-family:inherit;font-size:10pt;"><span>3.25%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible senior notes due in 2022 (the “2022 Convertible Notes”), the exercise of outstanding stock options and the vesting of RSUs.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have a choice to settle the conversion obligation of our 2022 Convertible Notes (the “2022 Convertible Notes”) in cash, shares or any combination of the two. Our policy is to settle the principal balance of the 2022 Convertible Notes in cash. As such, we apply the treasury stock method to these securities and the dilution related to the conversion premium, if any, of the 2022 Convertible Notes is included in the calculation of diluted weighted-average shares outstanding to the extent the issuance is dilutive based on the average stock price during each reporting period being greater than the conversion price of the 2022 Convertible Notes.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of basic and diluted earnings per share for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands, except per share data):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(467,661</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(172,075</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(206,688</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income from discontinued operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,578</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,925</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,030</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,394</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options and RSUs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used in calculating dilutive net loss per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,030</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,394</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,907</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted earnings per share:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13.74</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.00</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.92</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from discontinued operations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13.74</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.99</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the potential common shares issuable upon the exercise of outstanding options, the vesting of RSUs and the conversion of the Convertible Notes (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options to purchase shares of common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,797</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock issuable upon the vesting of RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,579</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022 Convertible Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,695</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,695</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,695</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 Convertible Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>790</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>790</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock under employee stock purchase plan</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,094</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;">In connection with the issuance of the 2019 Convertible Notes, in February 2014, we entered into convertible bond hedges with certain financial institutions. The convertible bond hedges were not included for purposes of calculating the number of diluted shares outstanding, as their effect would be anti-dilutive. The convertible bond hedges and warrants expired in February 2019 in conjunction with the settlement of the 2019 Convertible Notes. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Segments</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have determined that we conduct our operations in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> business segment: the manufacture, development and commercialization of products for use in treating various conditions, with a focus on maternal and women’s health and anemia management. Long-lived assets consist entirely of intangible assets, property and equipment and are located in the U.S. for all periods presented.  </span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Immaterial Revision of Prior Period Financial Information</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior period amounts, specifically net product sales and accrued expenses have been revised to correct a prior period error related to gross-to-net (“GTN”) adjustments for governmental rebates and the related accrual for a certain state program. Refer to Note X, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">“Revision of Prior Period Financial Statements” </span><span style="font-family:inherit;font-size:10pt;">for further detail.</span></div> The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“GAAP”) and include the accounts of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates and Assumptions</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent liabilities. The most significant estimates and assumptions are used to determine amounts and values of, but are not limited to: revenue recognition related to product sales revenue; product sales allowances and accruals; allowance for doubtful accounts; marketable securities; inventory; acquisition date fair value and subsequent fair value estimates used to assess impairment of long-lived assets, including goodwill and other intangible assets; debt obligations; certain accrued liabilities, including clinical trial accruals; equity-based compensation expense, and income taxes, inclusive of valuation allowances. Actual results could differ materially from those estimates.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product revenues</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2018, we adopted Accounting Standards Codification (“ASC”) Topic 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> (“ASC 606”) applying the modified retrospective transition method to all contracts that were not completed as of January 1, 2018 as an adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the opening balance of stockholders’ equity at the beginning of 2018. The adjustment recorded was for incremental contract acquisition costs related to the CBR business. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for prior periods. There was no impact to our product revenue as a result of adoption.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">a.</span><span style="font-family:inherit;font-size:10pt;">Identify the contract(s) with a customer; </span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">b.</span><span style="font-family:inherit;font-size:10pt;">Identify the performance obligations in the contract; </span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">c.</span><span style="font-family:inherit;font-size:10pt;">Determine the transaction price; </span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">d.</span><span style="font-family:inherit;font-size:10pt;">Allocate the transaction price to the performance obligations in the contract; and </span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">e.</span><span style="font-family:inherit;font-size:10pt;">Recognize revenue when (or as) the performance obligations are satisfied. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We only apply the five step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, if the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our major sources of revenue during the reporting periods were product revenues from Makena, Feraheme and Intrarosa. The adoption of ASC 606 in 2018 did not have an impact on the pattern or timing of recognition of our product revenue, as the majority of our product revenue continues to be recognized when the customer takes control of our product.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We receive payments from customers based upon contractual billing schedules; accounts receivable are recorded when the right to consideration becomes unconditional.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Performance Obligations</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At contract inception, we assess the goods promised in our contracts with customers and identify a performance obligation for each promise to transfer to the customer a good (or bundle of goods) that is distinct. To identify the performance obligations, we consider all of the goods promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. We determined that the following distinct goods represent separate performance obligations: </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">•</span><span style="font-family:inherit;font-size:10pt;">Supply of Makena product </span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">•</span><span style="font-family:inherit;font-size:10pt;">Supply of Feraheme product </span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">•</span><span style="font-family:inherit;font-size:10pt;">Supply of Intrarosa product</span></div><div style="line-height:120%;padding-left:0px;text-indent:24px;"><span style="font-family:inherit;font-size:10pt;padding-right:24px;">•</span><span style="font-family:inherit;font-size:10pt;">Supply of Vyleesi product</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We principally sell our products to wholesalers, specialty distributors, specialty pharmacies and other customers (collectively, “Customers”), who purchase products directly from us. Our Customers subsequently resell the products to healthcare providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payers that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the majority of our Customers, we transfer control at the point in time when the goods are delivered. In instances when we perform shipping and handling activities, these are considered fulfillment activities, and accordingly, the costs are accrued when the related revenue is recognized. Taxes collected from Customers and remitted to governmental authorities are excluded from revenues. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Consideration</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 606, we are required to make estimates of the net sales price, including estimates of variable consideration (such as rebates, chargebacks, discounts, copay assistance and other deductions), and recognize the estimated amount as revenue, when we transfer control of the product to our customers. Variable consideration must be determined using either an “expected value” or a “most likely amount” method. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record product revenues net of certain allowances and accruals in our consolidated statements of operations. Product sales allowances and accruals are primarily comprised of both direct and indirect fees, discounts and rebates and provisions for estimated product returns. Direct fees, discounts and rebates are contractual fees and price adjustments payable to Customers that purchase products directly from us. Indirect fees, discounts and rebates are contractual price adjustments payable to healthcare providers and organizations, such as certain physicians, clinics, hospitals, group purchasing organizations (“GPOs”), and dialysis organizations that typically do not purchase products directly from us but rather from wholesalers and specialty distributors. Consideration payable to a Customer, or other parties that purchase goods from a Customer, are considered to be a reduction of the transaction price, and therefore, of revenue. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales allowances and accruals are based on definitive contractual agreements or legal requirements (such as laws and regulations to provide mandatory discounts for sales to government entities) related to the purchase and/or utilization of the product by these entities and are recorded in the same period that the related revenue is recognized. We use the expected value method for estimating variable consideration. We estimate product sales allowances and accruals using either historical, actual and/or other data, including estimated patient usage, applicable contractual rebate rates, contract performance by the benefit providers, other current contractual and statutory requirements, historical market data based upon experience of our products and other products similar to them, specific known market events and trends such as competitive pricing and new product introductions, current and forecasted Customer buying patterns and inventory levels, and the shelf life of our products. As part of this evaluation, we also review changes to federal and other legislation, changes to rebate contracts, changes in the level of discounts, and changes in product sales trends. Although allowances and accruals are recorded at the time of product sale, rebates are typically paid out in arrears, </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>three months</span></span><span style="font-family:inherit;font-size:10pt;"> after the sale.  </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimate of variable consideration, which is included in the transaction price, may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved in a future period. Estimating variable consideration and the related constraint requires the use of significant management judgment and actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. </span><span style="font-family:inherit;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;"> amounts were constrained as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Discounts</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We typically offer a </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> prompt payment discount to certain customers as an incentive to remit payment in accordance with the stated terms of the invoice, generally between </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>60 days</span></span><span style="font-family:inherit;font-size:10pt;">. Because we anticipate that those customers who are offered this discount will take advantage of the discount, </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the prompt payment discount at the time of sale is accrued for eligible customers, based on the gross amount of each invoice. We adjust the accrual quarterly to reflect actual experience. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Chargebacks</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chargeback reserves represent the estimated obligations resulting from the difference between the prices at which we sell our products to wholesalers and the sales price ultimately paid to wholesalers under fixed price contracts by third-party payers, including governmental agencies. The chargeback estimates are determined based on actual product sales data and forecasted customer buying patterns. Actual chargeback amounts are determined at the time of resale to the qualified healthcare provider, and we generally issue credits for such amounts within several weeks of receiving notification from the wholesaler. Estimated chargeback amounts are recorded at the time of sale and adjusted quarterly to reflect actual experience. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Distributor/Wholesaler and Group Purchasing Organization Fees</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fees under arrangements with distributors and wholesalers are usually based upon units of product purchased during the prior month or quarter and are usually paid by us within several weeks of the receipt of an invoice from the wholesaler or distributor. Fees under arrangements with GPOs are usually based upon member purchases during the prior quarter and are generally billed by the GPO within </span><span style="font-family:inherit;font-size:10pt;"><span>30 days</span></span><span style="font-family:inherit;font-size:10pt;"> after period end. In accordance with ASC 606, since the consideration given to the Customer is not for a distinct good or service, the consideration is a reduction of the transaction price of the vendor’s products or services. We have included these fees in contractual adjustments in the table above. We generally pay such amounts within several weeks of the receipt of an invoice from the distributor, wholesaler or GPO. Accordingly, we accrue the estimated fee due at the time of sale, based on the contracted price invoiced to the Customer. We adjust the accrual quarterly to reflect actual experience.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Returns</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consistent with industry practice, we generally offer wholesalers, specialty distributors and other customers a limited right to return our products based on the product’s expiration date. The current shelf-lives or time between manufacture and expiration for products in our portfolio range from </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">. Product returns are estimated based on the historical return patterns and known or expected changes in the marketplace. We track actual returns by individual production lots. Returns on lots eligible for credits under our returned goods policy are monitored and compared with historical return trends and rates. We expect that wholesalers and healthcare providers will not stock significant inventory due to the cost of the product, the expense to store our products, and/or that our products are readily available for distribution. We record an estimate of returns at the time of sale. If necessary, our estimated rate of returns may be adjusted for actual return experience as it becomes available and for known or expected changes in the marketplace. There were no material adjustments to our reserve for product returns during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. To date, our product returns have been relatively limited; however, returns experience may change over time. We may be required to make future adjustments to our product returns estimate, which would result in a corresponding change to our net product sales in the period of adjustment and could be significant. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales Rebates</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We contract with various private payer organizations, primarily pharmacy benefit managers, for the payment of rebates with respect to utilization of our products. We determine our estimates for rebates, if applicable, based on actual product sales data and our historical product claims experience. Rebate amounts generally are invoiced quarterly and are paid in arrears, and we expect to pay such amounts within several weeks of notification by the provider. We regularly assess our reserve balance and the rate at which we accrue for claims against product sales. If we determine in future periods that our actual rebate </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">experience is not indicative of expected claims, if actual claims experience changes, or if other factors affect estimated claims rates, we may be required to adjust our current accumulated reserve estimate, which would affect net product sales in the period of the adjustment and could be significant.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Governmental Rebates</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Governmental rebates relate to our reimbursement arrangements with state Medicaid programs. We determine our estimates for Medicaid rebates, if applicable, based on actual product sales data and our historical product claims experience. In estimating these reserves, we provide for a Medicaid rebate associated with both those expected instances where Medicaid will act as the primary insurer as well as in those instances where we expect Medicaid will act as the secondary insurer. Rebate amounts generally are invoiced quarterly and are paid in arrears, and we expect to pay such amounts within several weeks of notification by the Medicaid or provider entity. We regularly assess our Medicaid reserve balance and the rate at which we accrue for claims against product sales. If we determine in future periods that our actual rebate experience is not indicative of expected claims, if actual claims experience changes, or if other factors affect estimated claims rates, we may be required to adjust our current Medicaid accumulated reserve estimate, which would affect net product sales in the period of the adjustment and could be significant. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Discounts</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other discounts which we offer include voluntary patient assistance programs, such as copay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug copayments required by payers. The calculation of the accrual for copay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with product that has been recognized as revenue.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration Revenues</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When we enter into collaboration agreements, we assess whether the agreements fall within the scope of ASC Topic 808, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:inherit;font-size:10pt;"> (“ASC 808”) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606. However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the related underlying expense.</span></div> 1100000 P3M 0.02 P30D P60D 1 P30D P5Y <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Cash and cash equivalents consist principally of cash held in commercial bank accounts, money market funds and U.S. treasury securities having an original maturity of less than three months at the date of acquisition. We consider all highly liquid marketable securities with a maturity of three months or less as of the acquisition date to be cash equivalents. The following table sets forth customers who represented <span style="font-family:inherit;font-size:10pt;">10%</span><span style="font-family:inherit;font-size:10pt;"> or more of our total revenues for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:59%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">McKesson Corporation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AmerisourceBergen Drug Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardinal Health</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt; 10%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt; 10%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.36 0.26 0.24 0.28 0.27 0.26 0.13 0.85 0.73 <div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are currently dependent on a single supplier for certain of our manufacturing processes, including Feraheme drug substance (produced in </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> separate facilities) and a single supplier for our Makena auto-injector product. We have been and may continue to be exposed to a significant loss of revenue from the sale of our products in the event that our suppliers and/or manufacturers are not able to fulfill demand for any reason.</span></div>Our operations are located entirely within the U.S. We focus primarily on developing, manufacturing, and commercializing our products and product candidates.<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations and Significant Customer Information</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and cash equivalents, marketable securities, and accounts receivable. We currently hold our excess cash primarily in institutional money market funds, corporate debt securities, U.S. treasury and government agency securities and certificates of deposit.<div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our net accounts receivable primarily represent amounts due for products sold directly to wholesalers, distributors and specialty pharmacies. Accounts receivable for our products are recorded net of reserves for estimated chargeback obligations, prompt payment discounts and any allowance for doubtful accounts.</span></div>As part of our credit management policy, we perform ongoing credit evaluations of our customers, and we generally do not require collateral. If the financial condition of any of our significant product sales customers was to deteriorate and result in an impairment of its ability to make payments owed to us, an allowance for doubtful accounts may be required which could have a material effect on earnings in the period of any such adjustment. 2 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We apply the provisions of ASC Topic 820, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:inherit;font-size:10pt;"> (“ASC 820”) for our financial assets and liabilities that are re-measured and reported at fair value each reporting period and our nonfinancial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis, including property and equipment and identifiable intangible assets. Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, we consider the principal or most advantageous market in which it would transact and consider assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. Financial assets and liabilities are categorized within the valuation hierarchy based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1- Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for and classify our marketable securities as either “available-for-sale,” “held-to-maturity,” or “trading debt securities,” in accordance with the accounting guidance related to the accounting and classification of certain investments in marketable securities. The determination of the appropriate classification by us is based primarily on management’s ability and intent to sell the debt security at the time of purchase. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, all of our marketable securities were classified as available-for-sale.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale securities are those securities which we view as available for use in current operations, if needed. We generally classify our available-for-sale securities as short-term investments, even though the stated maturity date may be one year or more beyond the current balance sheet date. Available-for-sale marketable securities are stated at fair value with their </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unrealized gains and losses included in accumulated other comprehensive income (loss) within the consolidated statements of stockholders’ equity, until such gains and losses are realized in other income (expense) within the consolidated statements of operations or until an unrealized loss is considered other-than-temporary.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize other-than-temporary impairments of our marketable securities when there is a decline in fair value below the amortized cost basis and if (a) we have the intent to sell the security or (b) it is more likely than not that we will be required to sell the security prior to recovery of its amortized cost basis. If either of these conditions is met, we recognize the difference between the amortized cost basis of the security and its fair value at the impairment measurement date in our consolidated statements of operations. If neither of these conditions is met, we must perform additional analysis to evaluate whether the unrealized loss is associated with the creditworthiness of the issuer of the security rather than other factors, such as interest rates or market factors. If we determine from this analysis that we do not expect to receive cash flows sufficient to recover the entire amortized cost of the security, a credit loss exists, the impairment is considered other-than-temporary and is recognized in our consolidated statements of operations.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory is stated at the lower of cost or net realizable value, with approximate cost being determined on a first-in, first-out basis. Prior to initial approval from the FDA or other regulatory agencies, we expense costs relating to the production of inventory in the period incurred, unless we believe regulatory approval and subsequent commercialization of the product candidate is probable and we expect the future economic benefit from sales of the product to be realized, at which point we capitalize the costs as inventory. We assess any costs capitalized prior to regulatory approval each quarter for indicators of impairment, such as a reduced likelihood of approval. We expense costs associated with clinical trial material as research and development expense. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">On a quarterly basis, we analyze our inventory levels to determine whether we have any obsolete, expired, or excess inventory. If any inventory is expected to expire prior to being sold, has a cost basis in excess of its net realizable value, is in excess of expected sales requirements as determined by internal sales forecasts, or fails to meet commercial sale specifications, the inventory is written-down through a charge to cost of product sales. The determination of whether inventory costs will be realizable requires estimates by management of future expected inventory requirements, based on sales forecasts. Once packaged, our products have a shelf-life ranging from </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span>. As a result of comparison to internal sales forecasts, we expect to fully realize the carrying value of our finished goods inventory. If actual market conditions are less favorable than those projected by management, inventory write-downs may be required. Charges for inventory write-downs are not reversed if it is later determined that the product is saleable. P5Y <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment, Net</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost and depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:73%;"/><td style="width:27%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer equipment and software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5 Years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5 Years</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lesser of Lease or Asset Life</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory and production equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5 Years</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs for capital assets not yet placed in service are capitalized on our balance sheets and will be depreciated in accordance with the above guidelines once placed into service. Costs for maintenance and repairs are expensed as incurred. Upon sale or other disposition of property and equipment, the cost and related depreciation are removed from the accounts and any resulting gain or loss is charged to our consolidated statements of operations. Assets classified as held for sale are no longer subject to depreciation and are recorded at the lower of carrying value or estimated net realizable value. </span></div> <div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost and depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:73%;"/><td style="width:27%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer equipment and software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5 Years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5 Years</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lesser of Lease or Asset Life</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory and production equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5 Years</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer equipment and software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,637</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,714</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,737</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,984</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory and production equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,570</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>656</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,492</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,732</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,116</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,521</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P5Y P5Y P5Y <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We amortize our intangible assets that have finite lives based on either the straight-line method, or if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be utilized. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we acquire an asset or a group of assets that do not meet the definition of a business, the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Impairment of Long-Lived Assets</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We review our long-lived assets, which includes property and equipment and identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. To evaluate recoverability, management compares the projected undiscounted future cash flows associated with the asset or asset group, including proceeds from its eventual disposition over its estimated useful life against its carrying amount. If the undiscounted cash flows are not sufficient to recover the carrying value of the asset or asset group, the asset or asset group is considered impaired. The impairment loss, if any, is measured as the excess of the carrying amount of the asset or asset group over its estimated fair value, which is typically calculated utilizing a discounted cash flow (“DCF”) model following the same methodology as described in the following section.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We test goodwill at the reporting unit level for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that could indicate impairment and trigger an interim impairment assessment include, but are not limited to, an adverse change in current economic and market conditions, including a significant prolonged decline in market capitalization, a significant adverse change in legal factors, unexpected adverse business conditions, and an adverse action or assessment by a regulator. Our annual impairment test date is October 31. We have determined that we operate in a single operating segment and have a single reporting unit. </span></div><div style="line-height:120%;padding-top:17px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In performing our goodwill impairment tests, we utilize the approach prescribed under Accounting Standards Codification (“ASC”) 350, as amended by Accounting Standards Update (“ASU”) 2017-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:inherit;font-size:10pt;"> (“ASU 2017-04”), which requires that an entity perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. </span></div><div style="line-height:120%;padding-top:17px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When we perform any goodwill impairment test, the estimated fair value of our reporting unit is determined using an income approach that utilizes a DCF model or a market approach, when appropriate, which assesses our market capitalization as adjusted for a control premium, or a combination thereof. </span></div><div style="line-height:120%;padding-top:17px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the market approach, when our carrying value exceeds our market capitalization, we consider a control premium for purposes of estimating the fair value of our reporting unit, as we believe that a market participant buyer would be required to pay a control premium for our business. The control premium utilized is based on control premiums observed in recent comparable market transactions. As described in the accounting guidance for evaluating long-lived assets for impairment, an entity’s fair value may include a control premium in addition to the quoted market price to determine the fair value of a single reporting unit entity, as an acquiring entity is often willing to pay more for equity securities that give it a controlling interest than an investor would pay for a number of equity securities representing less than a controlling interest. This accounting guidance also indicates that the quoted market price of an individual security need not be the sole measurement basis of the fair value of a single reporting unit. When our market capitalization exceeds our carrying value, we utilize our market capitalization as the indicator of fair value in our impairment test. </span></div><div style="line-height:120%;padding-top:17px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Under the income approach, the DCF model is based upon expected future after-tax operating cash flows of the reporting unit discounted to a present value using a risk-adjusted discount rate. Estimates of future cash flows require management to make significant assumptions concerning (i) future operating performance, including future sales, long-term growth rates, operating margins, variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows (ii) the probability of regulatory approvals, and (iii) future economic conditions, all of which may differ from actual future cash flows. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rate, which is intended to reflect the risks inherent in future cash flow projections, used in the DCF model, is based on estimates of the weighted average cost of capital (“WACC”) of market participants relative to our reporting unit. Financial and credit market volatility can directly impact certain inputs and assumptions used to develop the WACC. Any changes in these assumptions may affect our fair value estimate and the result of an impairment test. The discount rates and other inputs and assumptions are consistent with those that a market participant would use. In addition, in order to assess the reasonableness of the fair value of our reporting unit as calculated under the DCF model, we also compare the reporting unit’s fair value to our market capitalization and calculate an implied control premium (the excess sum of the reporting unit’s fair value over its market capitalization). We evaluate the implied control premium by comparing it to control premiums of recent comparable market transactions, as applicable. </span></div> <div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Combinations and Asset Acquisitions</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The purchase price allocation for business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values. Under ASU No. 2017-01, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</span><span style="font-family:inherit;font-size:10pt;"> (“2017-01”), we first determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the single asset or group of assets, as applicable, is not a business.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for acquired businesses using the acquisition method of accounting, under which the total purchase price of an acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. Acquisition-related costs are expensed as incurred. Any excess of the consideration transferred over the estimated fair values of the identifiable net assets acquired is recorded as goodwill. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The purchase price allocations for business combinations are initially prepared on a preliminary basis and are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. Any adjustments to the purchase price allocations are made as soon as practicable but no later than one year from the acquisition date.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired inventory is recorded at its fair value, which may require a step-up adjustment to recognize the inventory at its expected net realizable value. The inventory step-up is recorded to cost of product sales in our consolidated statements of operations when related inventory is sold, and we record step-up costs associated with clinical trial material as research and development expense.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition-Related Contingent Consideration</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration arising from a business combination is included as part of the purchase price and is recognized at its estimated fair value as of the acquisition date. Subsequent to the acquisition date, we measure contingent consideration arrangements at fair value for each period until the contingency is resolved. These changes in fair value are recognized in selling, general and administrative expenses in our consolidated statements of operations. Changes in fair values reflect new information about the likelihood of the payment of the contingent consideration and the passage of time. For asset acquisitions, we record contingent consideration for obligations we consider to be probable and estimable and these liabilities are not adjusted to fair value.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January 1, 2019, we adopted ASC Topic 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (“ASC 842”), and chose to apply the provisions of ASC 842 as of the effective date with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected to utilize the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also made accounting policy elections to not separate lease and non-lease components for our real estate lease and to not recognize leases with an initial term of twelve months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis on our consolidated statements of income over the lease term. We did not have any material short-term leases accounted for under this policy during the </span><span style="font-family:inherit;font-size:10pt;">year ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liability, and long-term operating lease liability on our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Our incremental borrowing rate is determined based on an evaluation of our creditworthiness and the prevailing market rates for collateralized debt with maturity dates commensurate with the term of each lease. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option. Lease expense for operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The lease payments used to determine our ROU assets may include lease incentives, stated rent increases, and escalation clauses linked to rates of inflation when determinable and are recognized in our ROU assets on our consolidated balance sheet. In addition, certain lease agreements contain lease and non-lease components. With the exception of our real estate leases, we separate lease payments for the identified assets from any non-lease payments included in the agreement. For our real estate leases, we account for the lease and non-lease components as a single lease component. Additionally, for vehicle and certain equipment leases, we apply a portfolio approach to effectively account for the related ROU assets and operating lease liabilities.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Cash </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We classified </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of our cash as restricted cash, a non-current asset on the balance sheet, as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. This amount represented the security deposit delivered to the landlord of our Waltham, Massachusetts headquarters.</span></div> 500000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Expenses</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Research and development expenses include both external and internal expenses. External expenses primarily include costs of clinical trials and fees paid to contract research organizations (“CROs”), clinical supply and manufacturing expenses, regulatory filing fees, consulting and professional fees as well as other general costs related to the execution of research and development activities. Internal expenses primarily include compensation of employees engaged in research and development activities. Research and development expenses are expensed as incurred. Manufacturing costs are generally expensed as incurred until a product has received the necessary initial regulatory approval. <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Patents</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expense all patent-related costs in selling, general and administrative expenses as incurred.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advertising Costs </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Advertising costs are expensed as incurred and included in selling, general and administrative expenses in our consolidated statements of operations. 53300000 29800000 9100000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity-Based Compensation</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity-based compensation cost is generally measured at the estimated grant date fair value and recorded to expense over the requisite service period, which is generally the vesting period. Because equity-based compensation expense is based on awards ultimately expected to vest, we must make certain judgments about whether employees, officers, directors, consultants and advisers will complete the requisite service period, and reduce the compensation expense being recognized for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based upon historical experience and adjusted for unusual events such as corporate restructurings, which can result in higher than expected turnover and forfeitures. If factors change and we employ different assumptions in future periods, the compensation expense that we record in the future may differ significantly from what we have recorded in the current period. </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate the fair value of equity-based compensation involving stock options based on the Black-Scholes option pricing model. This model requires the input of several factors such as the expected option term, the expected risk-free interest rate over the expected option term, the expected volatility of our stock price over the expected option term and the expected dividend yield over the expected option term and are subject to various assumptions. The fair value of awards calculated using the Black-Scholes option pricing model is generally amortized on a straight-line basis over the requisite service period, and is recognized based on the proportionate amount of the requisite service period that has been rendered during each reporting period. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate the fair value of our restricted stock units (“RSUs”) whose vesting is contingent upon market conditions, such as total shareholder return, using the Monte-Carlo simulation model. The fair value of RSUs where vesting is contingent upon market conditions is amortized based upon the estimated derived service period. The fair value of RSUs granted to our employees and directors whose vesting is dependent on future service is determined based upon the quoted closing market price per share on the date of grant, adjusted for estimated forfeitures. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We believe our valuation methodologies are appropriate for estimating the fair value of the equity awards we grant to our employees and directors. Our equity award valuations are estimates and may not be reflective of actual future results or amounts ultimately realized by recipients of these grants. These amounts are subject to future quarterly adjustments based upon a variety of factors, which include, but are not limited to, changes in estimated forfeiture rates and the issuance of new equity-based awards. <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use the asset and liability method of accounting for deferred income taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A deferred tax asset is established for the expected future benefit of net operating loss (“NOL”) and credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance against net deferred tax assets is required if, based on available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Significant judgments, estimates and assumptions regarding future events, such as the amount, timing and character of income, deductions and tax credits, are required in the determination of our provision for income taxes and whether valuation allowances are required against deferred tax assets. In evaluating our ability to recover our deferred tax assets, we consider all available evidence, both positive and negative, including the existence of taxable temporary differences, our past operating results, the existence of cumulative income in the most recent fiscal years, changes in the business in which we operate and our forecast of future taxable income. In determining future taxable income, we are responsible for assumptions utilized including the amount of state and federal operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have established a valuation allowance on our net deferred tax assets other than refundable alternative minimum tax (“AMT”) credits to the extent that our existing taxable temporary differences would not be available as a source of income to realize the benefits of those deferred tax assets.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position. We evaluate uncertain tax positions on a quarterly basis and adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could impact our income tax provision in future periods. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as a provision for income tax in our consolidated statement of operations. </span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Comprehensive Loss</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our comprehensive loss consists of net loss and other comprehensive loss. Other comprehensive loss includes changes in equity that are excluded from net loss, which for all periods presented in these consolidated financial statements related to unrealized holding gains and losses on available-for-sale marketable securities, net of tax.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic and Diluted Earnings per Share </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We compute basic earnings per share by dividing earnings by the weighted average number of common shares outstanding during the relevant period. Diluted earnings per share is computed by dividing earnings by the diluted number of common shares outstanding during the period. Except where the result would be antidilutive, diluted earnings per common share would be computed assuming the impact of the conversion of the </span><span style="font-family:inherit;font-size:10pt;"><span>3.25%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible senior notes due in 2022 (the “2022 Convertible Notes”), the exercise of outstanding stock options and the vesting of RSUs.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have a choice to settle the conversion obligation of our 2022 Convertible Notes (the “2022 Convertible Notes”) in cash, shares or any combination of the two. Our policy is to settle the principal balance of the 2022 Convertible Notes in cash. As such, we apply the treasury stock method to these securities and the dilution related to the conversion premium, if any, of the 2022 Convertible Notes is included in the calculation of diluted weighted-average shares outstanding to the extent the issuance is dilutive based on the average stock price during each reporting period being greater than the conversion price of the 2022 Convertible Notes.</span></div> 0.0325 <div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of basic and diluted earnings per share for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands, except per share data):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(467,661</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(172,075</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(206,688</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income from discontinued operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,578</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,925</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,030</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,394</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options and RSUs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used in calculating dilutive net loss per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,030</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,394</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,907</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted earnings per share:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13.74</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.00</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.92</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from discontinued operations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13.74</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.99</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -467661000 -172075000 -206688000 0 103578000 5925000 34030000 34394000 34907000 0 0 0 34030000 34394000 34907000 -13.74 -5.00 -5.92 0 3.01 0.17 -13.74 -1.99 -5.75 <div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the potential common shares issuable upon the exercise of outstanding options, the vesting of RSUs and the conversion of the Convertible Notes (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options to purchase shares of common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,797</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock issuable upon the vesting of RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,579</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022 Convertible Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,695</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,695</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,695</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 Convertible Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>790</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>790</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock under employee stock purchase plan</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,094</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3976000 3797000 3531000 1579000 1129000 1070000 0 1008000 1008000 11695000 11695000 11695000 0 790000 790000 0 81000 0 17250000 18500000 18094000 <div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Segments</span></div><span style="font-family:inherit;font-size:10pt;">We have determined that we conduct our operations in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span> business segment: the manufacture, development and commercialization of products for use in treating various conditions, with a focus on maternal and women’s health and anemia management. Long-lived assets consist entirely of intangible assets, property and equipment and are located in the U.S. for all periods presented. 1 DISCONTINUED OPERATIONS<div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 6, 2018, we completed the sale of our CBR business to GI Partners pursuant to the CBR Purchase Agreement. We determined that the sale of CBR represented a strategic shift that would have a major effect on our business and therefore met the criteria for classification as discontinued operations at June 30, 2018. All historical operating results for CBR were reflected within discontinued operations in the consolidated statements of operations for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of net income from discontinued operations for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:    </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,177</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs and expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,559</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,817</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,899</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,458</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,599</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,759</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,578</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(265</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from discontinued operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,873</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain on sale of CBR business</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,076</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,388</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income from discontinued operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,925</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The cash flows related to discontinued operations have not been segregated and are included in the consolidated statements of cash flows for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. For the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, capital expenditures related to the CBR business were </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Depreciation and amortization expense related to the CBR business for the same periods was </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$21.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Excluding the gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$87.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> recognized on the sale of the CBR business and the related transaction expenses of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> presented in the consolidated statements of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">year ended December 31, 2018</span>, there were no other significant operating or investing non-cash items related to the CBR business for any period presented. <div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of net income from discontinued operations for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:    </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,177</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs and expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,559</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,817</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,899</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,458</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,599</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,759</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,578</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(265</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from discontinued operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,873</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain on sale of CBR business</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,076</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,388</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income from discontinued operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,925</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 71217000 114177000 12559000 21817000 39899000 81782000 52458000 103599000 18759000 10578000 114000 -265000 18873000 10313000 87076000 0 2371000 4388000 103578000 5925000 1600000 4900000 8400000 21700000 87100000 14100000 REVENUE RECOGNITION<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Revenue</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about disaggregated revenue by product for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Makena</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120,859</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>320,311</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>385,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Feraheme</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167,947</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,001</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrarosa</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,417</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,816</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(238</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>368</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>741</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>309,985</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>471,898</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>493,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total gross product sales were offset by product sales allowances and accruals for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> as follows (in thousands):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>955,693</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>974,330</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>920,061</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for product sales allowances and accruals:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>530,645</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>387,540</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>310,588</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Governmental rebates</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,063</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,630</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>645,708</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>502,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>426,218</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>309,985</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>471,898</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>493,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the product revenue allowance and accrual activity for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Governmental</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at January 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>47,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>52,741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>100,341</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>314,537</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>428,506</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,949</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,661</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,288</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments/returns relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(253,545</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(61,569</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(315,114</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments/returns relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42,479</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(53,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(95,539</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>62,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>53,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>115,906</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>389,861</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,988</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496,849</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,330</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,903</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments/returns relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(333,694</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75,920</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(409,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments/returns relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(58,802</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(58,501</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(117,303</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>57,199</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>34,212</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>91,411</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provisions related to current period sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>521,916</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,926</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>622,842</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments related to prior period sales</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,137</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,911</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments/returns relating to current period sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(431,014</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(60,218</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(491,232</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments/returns relating to prior period sales</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(61,654</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(41,435</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(103,089</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>95,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>47,622</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>142,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded adjustments of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for Medicaid rebate claims received that related to prior period sales and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for contractual adjustments related to prior period sales. We concluded that these adjustments represented changes in estimate during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> due to higher Medicaid and payer utilization and subsequent rebate obligations than anticipated based on our historical experience.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration Revenue</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first quarter of 2019, in conjunction with the Perosphere transaction, we assumed responsibility for a clinical trial collaboration agreement with a pharmaceutical company. This agreement provided for milestone payments to us, provided we met certain clinical obligations in connection with our ciraparantag program. We also acquired </span><span style="font-family:inherit;font-size:10pt;"><span>$6.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of deferred revenue related to this agreement, which represented the fair value of our remaining performance obligations associated with upfront milestone payments received by Perosphere under this agreement prior to acquisition. We accounted for this agreement under ASC 606.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the fourth quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we entered into a termination and settlement agreement (the “Termination Agreement”) with the pharmaceutical company which provided for a </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> termination payment to us and stated that no party had any remaining performance obligations effective as of the termination date. The </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> termination payment was received during the fourth quarter of 2019. Under ASC 606, the Termination Agreement met the definition of a contract modification and was accounted for as a cumulative catch-up adjustment at the time of modification.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">year ended December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> termination payment and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of deferred revenue were recognized as collaboration revenue in our consolidated statements of operations.</span></div> <div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about disaggregated revenue by product for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Makena</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120,859</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>320,311</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>385,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Feraheme</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167,947</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,001</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrarosa</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,417</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,816</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(238</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>368</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>741</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>309,985</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>471,898</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>493,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total gross product sales were offset by product sales allowances and accruals for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> as follows (in thousands):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>955,693</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>974,330</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>920,061</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for product sales allowances and accruals:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>530,645</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>387,540</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>310,588</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Governmental rebates</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,063</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,630</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>645,708</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>502,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>426,218</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>309,985</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>471,898</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>493,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 120859000 320311000 385356000 167947000 135001000 105930000 21417000 16218000 1816000 -238000 368000 741000 309985000 471898000 493843000 955693000 974330000 920061000 530645000 387540000 310588000 115063000 114892000 115630000 645708000 502432000 426218000 309985000 471898000 493843000 <div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the product revenue allowance and accrual activity for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Governmental</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at January 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>47,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>52,741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>100,341</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>314,537</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>428,506</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,949</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,661</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,288</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments/returns relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(253,545</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(61,569</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(315,114</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments/returns relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42,479</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(53,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(95,539</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>62,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>53,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>115,906</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>389,861</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,988</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496,849</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,330</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,903</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments/returns relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(333,694</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75,920</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(409,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments/returns relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(58,802</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(58,501</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(117,303</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>57,199</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>34,212</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>91,411</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provisions related to current period sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>521,916</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,926</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>622,842</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments related to prior period sales</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,137</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,911</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments/returns relating to current period sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(431,014</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(60,218</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(491,232</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments/returns relating to prior period sales</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(61,654</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(41,435</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(103,089</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>95,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>47,622</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>142,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 47600000 52741000 100341000 314537000 113969000 428506000 -3949000 1661000 -2288000 253545000 61569000 315114000 42479000 53060000 95539000 62164000 53742000 115906000 389861000 106988000 496849000 -2330000 7903000 5573000 333694000 75920000 409614000 58802000 58501000 117303000 57199000 34212000 91411000 521916000 100926000 622842000 8774000 14137000 22911000 431014000 60218000 491232000 61654000 41435000 103089000 95221000 47622000 142843000 14100000 8800000 6400000 10000000.0 10000000.0 10000000.0 6400000 MARKETABLE SECURITIES <div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, our marketable securities consisted of securities classified as available-for-sale in accordance with accounting standards which provide guidance related to accounting and classification of certain investments in marketable securities.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of our marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Securities:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments:*</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,186</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,324</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury and government agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,436</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term investments:**</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,016</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,016</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,452</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>292</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Securities:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments:*</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,184</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(236</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,948</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury and government agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,647</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,613</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(270</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,556</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term investments:**</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(433</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury and government agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,742</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,710</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,772</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(465</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,359</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,598</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(735</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,915</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">* Represents marketable securities with a remaining maturity of less than one year.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">** Represents marketable securities with a remaining maturity of one to three years classified as short-term on our consolidated balance sheets.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Impairments and Unrealized Gains and Losses on Marketable Securities</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;">t recognize any other-than-temporary impairment losses in our consolidated statements of operations related to our marketable securities during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. We considered various factors, including the length of time that each security was in an unrealized loss position and our ability and intent to hold these securities until recovery of their amortized cost basis occurs. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have no material losses in an unrealized loss position for more than one year. Future events may occur, or additional information may become available, which may cause us to identify credit losses where we do not expect to receive cash flows sufficient to recover the entire amortized cost basis of a security and may necessitate the recording of future realized losses on securities in our portfolio. Significant losses in the estimated fair values of our marketable securities could have a material adverse effect on our earnings in future periods.</span></div> <div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of our marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Securities:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments:*</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,186</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,324</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury and government agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,436</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term investments:**</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,016</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,016</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,452</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>292</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Securities:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments:*</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,184</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(236</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,948</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury and government agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,647</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,613</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(270</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,556</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term investments:**</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(433</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury and government agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,742</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,710</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,772</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(465</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,359</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,598</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(735</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,915</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">* Represents marketable securities with a remaining maturity of less than one year.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">** Represents marketable securities with a remaining maturity of one to three years classified as short-term on our consolidated balance sheets.</span></div> 46186000 140000 2000 46324000 2750000 0 0 2750000 1500000 0 0 1500000 50436000 140000 2000 50574000 8016000 152000 0 8168000 8016000 152000 0 8168000 58452000 292000 2000 58742000 51184000 0 236000 50948000 7647000 0 34000 7613000 3995000 0 0 3995000 12000000 0 0 12000000 74826000 0 270000 74556000 62530000 52000 433000 62149000 2742000 0 32000 2710000 1500000 0 0 1500000 66772000 52000 465000 66359000 141598000 52000 735000 140915000 0 FAIR VALUE MEASUREMENTS <div style="line-height:120%;padding-bottom:10px;padding-left:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables present information about our assets and liabilities that we measure at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques utilized to determine such fair value as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at December 31, 2019 Using:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,732</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,732</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,492</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,492</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury and government agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72,474</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,732</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at December 31, 2018 Using:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,097</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,097</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury and government agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,995</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,995</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>212,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,568</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,915</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>359</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>359</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>359</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>359</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash equivalents</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our cash equivalents are classified as Level 1 assets under the fair value hierarchy as these assets have been valued using quoted market prices in active markets and do not have any restrictions on redemption. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, cash equivalents were comprised of funds in money market accounts.</span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketable securities</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our marketable securities are classified as Level 2 assets under the fair value hierarchy as these assets were primarily determined from independent pricing services, which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based upon other significant observable market transactions. At the end of each reporting period, we perform quantitative and qualitative analysis of prices received from third parties to determine whether prices are reasonable estimates of fair value. After completing our analysis, we did not adjust or override any fair value measurements provided by our pricing services as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. In addition, there were </span><span style="font-family:inherit;font-size:10pt;">no</span><span style="font-family:inherit;font-size:10pt;"> transfers or reclassifications of any securities between Level 1 and Level 2 during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingent consideration</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with GAAP, for asset acquisitions, we record contingent consideration for obligations we consider to be probable and estimable and these liabilities are not adjusted to fair value. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> contingent consideration was recorded in accrued expenses. </span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recorded contingent consideration related to the November 2014 acquisition of Lumara Health Inc. (“Lumara Health”) for our Makena product and related to our June 2013 license agreement for MuGard</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Mucoadhesive Oral Wound Rinse (the “MuGard License Agreement”) with Abeona Therapeutics, Inc. (“Abeona”), under which we acquired the U.S. commercial rights for the management of oral mucositis and stomatitis (the “MuGard Rights”).</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value measurements of contingent consideration obligations and the related intangible assets arising from business combinations are classified as Level 3 under the fair value hierarchy as they have been valued using unobservable inputs. These inputs include: (a) the estimated amount and timing of projected cash flows; (b) the probability of the achievement of the factors on which the contingency is based; and (c) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, we reduced the fair value of our contingent consideration liability by approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$49.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, primarily based on actual Makena net sales to date and our expectations for future performance, which indicated that achievement of future milestones is not probable. This adjustment was based on our estimates, which are reliant on a number of external factors as well as the exercise of judgment. </span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe the estimated fair values of the contingent payments associated with Lumara Health and the MuGard Rights are based on reasonable assumptions, however, our actual results may vary significantly from the estimated results.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate the fair value of our debt obligations by using quoted market prices obtained from third-party pricing services, which is classified as a Level 2 input. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the estimated fair value of the 2022 Convertible Notes was </span><span style="font-family:inherit;font-size:10pt;"><span>$274.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, which differed from its carrying value. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the estimated fair value of the 2022 Convertible Notes and the 2019 Convertible Notes was </span><span style="font-family:inherit;font-size:10pt;"><span>$294.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$20.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which differed from their carrying values. See Note R, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Debt,</span><span style="font-family:inherit;font-size:9pt;">”</span><span style="font-family:inherit;font-size:10pt;"> for additional information on our debt obligations.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nonrecurring Fair Value Measurements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we measured the Makena base technology, Makena auto-injector developed technology, Intrarosa developed technology and Vyleesi developed technology intangible assets at fair value based on indicators of impairment identified for the Makena, Intrarosa and Vyleesi products. The aggregate fair values of our intangible assets at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$23.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and we recorded total impairment charges of </span><span style="font-family:inherit;font-size:10pt;"><span>$232.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in our consolidated statements of operations for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The fair value measurement related to the Makena base technology intangible asset was recorded during the second quarter of 2019. The Makena auto-injector developed technology intangible asset was measured at fair value as of October 29, 2019 and the Intrarosa developed technology and Vyleesi developed technology intangible assets were measured at fair value as of December 31, 2019. See Note I, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets, Net</span><span style="font-family:inherit;font-size:10pt;">” for additional information regarding our intangible asset impairment assessments.</span></div> <div style="line-height:120%;padding-bottom:10px;padding-left:0px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables present information about our assets and liabilities that we measure at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques utilized to determine such fair value as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at December 31, 2019 Using:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,732</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,732</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,492</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,492</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury and government agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72,474</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,732</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at December 31, 2018 Using:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,097</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,097</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury and government agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,995</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,995</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>212,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,568</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,915</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>359</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>359</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>359</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>359</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 13732000 13732000 0 0 54492000 0 54492000 0 2750000 0 2750000 0 1500000 0 1500000 0 72474000 13732000 58742000 0 17000 0 0 17000 17000 0 0 17000 71568000 71568000 0 0 113097000 0 113097000 0 10323000 0 10323000 0 3995000 0 3995000 0 13500000 0 13500000 0 212483000 71568000 140915000 0 359000 0 0 359000 359000 0 0 359000 0 49600000 274800000 294800000 20900000 23600000 232300000 INVENTORIES <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our major classes of inventories were as follows as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,211</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,388</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,248</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,932</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,094</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,553</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,691</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded inventory write-downs of </span><span style="font-family:inherit;font-size:10pt;"><span>$19.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in conjunction with the impairments of the asset groups related to the Makena intramuscular (“IM”) products and the Makena auto-injector product.</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our major classes of inventories were as follows as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,211</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,388</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,248</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,932</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,094</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,553</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,691</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5211000 9388000 6248000 5932000 20094000 11371000 31553000 26691000 19800000 PROPERTY AND EQUIPMENT, NET <div style="line-height:120%;padding-bottom:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer equipment and software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,637</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,714</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,737</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,984</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory and production equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,570</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>656</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,492</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,732</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,116</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,521</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">During </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, depreciation expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span>, respectively. 1568000 1637000 1714000 1737000 4984000 2938000 6570000 6000000 656000 420000 15492000 12732000 11376000 5211000 4116000 7521000 2600000 1600000 1200000 GOODWILL AND INTANGIBLE ASSETS, NET <div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill </span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our </span><span style="font-family:inherit;font-size:10pt;"><span>$422.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> goodwill balance represents goodwill of the continuing business following the goodwill allocation performed in 2018 in connection with the CBR transaction discussed in Note C, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">“Discontinued Operations.” </span><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> accumulated impairment losses related to goodwill. </span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2019 Impairment Testing Results</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 31, 2019 (the “2019 measurement date”), we conducted our 2019 annual goodwill impairment test using a market approach to estimate the fair value of our reporting unit as of the 2019 measurement date. We considered our market capitalization, as adjusted for a control premium, to be one indicator of the fair value of our reporting unit. On October 31, 2019, our stock price closed at </span><span style="font-family:inherit;font-size:10pt;"><span>$9.71</span></span><span style="font-family:inherit;font-size:10pt;"> per share, resulting in a market capitalization of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$329 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was below the carrying amount of our reporting unit as of the 2019 measurement date, resulting in an implied control premium of </span><span style="font-family:inherit;font-size:10pt;"><span>6%</span></span><span style="font-family:inherit;font-size:10pt;">. During the fourth quarter of 2019, we obtained a control premium analysis that benchmarked average control premiums paid in prior merger and acquisition transactions among biotechnology and pharmaceutical companies. The analysis indicated that control premiums vary depending on facts and circumstances for each transaction. The range of control premiums observed was between </span><span style="font-family:inherit;font-size:10pt;"><span>37%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>84%</span></span><span style="font-family:inherit;font-size:10pt;">, with a median of </span><span style="font-family:inherit;font-size:10pt;"><span>65%</span></span><span style="font-family:inherit;font-size:10pt;">. Management believes that using this market approach of assessing reasonable control premiums provided a sufficient basis to assess whether the fair value of our reporting unit, including a range of reasonable control premiums, was above its carrying amount. Incorporating control premiums in this range to our October 31, 2019 market capitalization of </span><span style="font-family:inherit;font-size:10pt;"><span>$329 million</span></span><span style="font-family:inherit;font-size:10pt;"> resulted in a fair value which was at least </span><span style="font-family:inherit;font-size:10pt;"><span>29%</span></span><span style="font-family:inherit;font-size:10pt;"> greater (at the low end of the range) than the carrying amount of our net assets as of October 31, 2019. As a result of this review, we determined that there was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairment of our goodwill at October 31, 2019.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Between October 31, 2019 and December 31, 2019, in accordance with ASC 350, we evaluated business factors, including the business decision to divest Intrarosa and Vyleesi, to determine whether there were indicators that the fair value of our reporting unit was less than its carrying value. We determine that it was not more likely than not that the fair value of the reporting unit was less than its carrying value and accordingly, determined that there was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairment of goodwill at December 31, 2019. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on our assessment, we determined that there was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> goodwill impairment at October 31, 2019 or December 31, 2019. However, the future occurrence of events including, but are not limited to, an adverse change in current economic and market conditions, including a significant prolonged decline in market capitalization, a significant adverse change in legal factors, unexpected adverse business conditions and an adverse action or assessment by a regulator could indicate potential impairment and trigger an interim impairment assessment of goodwill. As a result of the significance of goodwill, our results of operations and financial position in a future period could be negatively impacted should an impairment test be triggered that results in an impairment of goodwill.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2018 Impairment Testing Results</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the second quarter of </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, in conjunction with the goodwill allocation required by the CBR transaction and in accordance with ASC 350, we performed a goodwill impairment test to assess whether there were indicators that its fair value was less than its carrying value. As a result of this evaluation, we determined that there was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairment of goodwill at June 30, 2018. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 31, 2018 (the “2018 measurement date”), we conducted our </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> annual goodwill impairment test using a market approach to estimate the fair value of our reporting unit as of the 2018 measurement date. We considered our market capitalization, as adjusted for a control premium, to be one indicator of the fair value of our reporting unit. On October 31, 2018, our stock price closed at </span><span style="font-family:inherit;font-size:10pt;"><span>$21.50</span></span><span style="font-family:inherit;font-size:10pt;"> per share, resulting in a market capitalization of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$742 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was below the carrying amount of our reporting unit as of the 2018 measurement date, resulting in an implied control premium of </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;">. In the days following our October 31, 2018 annual testing date, our stock price declined, largely in response to our November 1, 2018 earnings release and Company update. This decline resulted in a market capitalization of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$633 million</span></span><span style="font-family:inherit;font-size:10pt;"> on November 5, 2018, resulting in an implied control premium of </span><span style="font-family:inherit;font-size:10pt;"><span>20%</span></span><span style="font-family:inherit;font-size:10pt;">. During the third quarter of </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, we obtained an updated control premium analysis that benchmarked average control premiums paid in prior merger and acquisition transactions among biotechnology and pharmaceutical companies. The analysis indicated that control premiums vary depending on facts and circumstances for each transaction. The range of control premiums observed was between </span><span style="font-family:inherit;font-size:10pt;"><span>39%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>96%</span></span><span style="font-family:inherit;font-size:10pt;">, with a median of </span><span style="font-family:inherit;font-size:10pt;"><span>71%</span></span><span style="font-family:inherit;font-size:10pt;">. Management believes that using this market approach of assessing reasonable control premiums provided a sufficient basis to assess whether the fair value of our reporting unit, including a range of reasonable control premiums, was above its carrying amount. Incorporating control premiums in this range to our October 31, 2018 market capitalization of </span><span style="font-family:inherit;font-size:10pt;"><span>$742 million</span></span><span style="font-family:inherit;font-size:10pt;"> resulted in a fair value which was at least </span><span style="font-family:inherit;font-size:10pt;"><span>36%</span></span><span style="font-family:inherit;font-size:10pt;"> greater (at the low end of the range) than the carrying amount of our net assets as of October 31, 2018. As a result of this review, we determined that there was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairment of our goodwill at October 31, 2018.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Between October 31, 2018 and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, our stock price continued to fluctuate, with a median closing stock price of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.84</span></span><span style="font-family:inherit;font-size:10pt;"> per share for the period from November 1, 2018 through </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. The median closing stock price of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.84</span></span><span style="font-family:inherit;font-size:10pt;"> per share resulted in a market capitalization of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$617 million</span></span><span style="font-family:inherit;font-size:10pt;">, which as compared to the </span><span style="font-family:inherit;font-size:10pt;"><span>$747 million</span></span><span style="font-family:inherit;font-size:10pt;"> carrying amount of our reporting unit at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> resulted in an implied control premium of </span><span style="font-family:inherit;font-size:10pt;"><span>21%</span></span><span style="font-family:inherit;font-size:10pt;">. Incorporating the range of control premiums obtained from the control premium study used in our annual goodwill impairment test at October 31, 2018 to the calculated market capitalization of </span><span style="font-family:inherit;font-size:10pt;"><span>$617 million</span></span><span style="font-family:inherit;font-size:10pt;"> resulted in a fair value which was at least </span><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span><span style="font-family:inherit;font-size:10pt;"> greater (at the low end of the range) than the carrying amount of our net assets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Using the closing stock price of </span><span style="font-family:inherit;font-size:10pt;"><span>$15.19</span></span><span style="font-family:inherit;font-size:10pt;"> per share on </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> results in an implied control premium of </span><span style="font-family:inherit;font-size:10pt;"><span>41%</span></span><span style="font-family:inherit;font-size:10pt;">. This implied control premium is within the range of control premiums observed. As a result of this review, we determined that there was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairment of our goodwill between our annual goodwill impairment test date and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. In addition, we determined that there were no other indicators of impairment through </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> requiring further assessment.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Original Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life to Date Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life to Date Impairments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Original Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life to Date Accumulated Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life to Date Impairments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amortizable intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Makena base technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>797,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>400,496</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>396,604</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>797,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>400,495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>319,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>77,359</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Makena auto-injector developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>79,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15,782</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>55,426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,892</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>79,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,952</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>72,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Intrarosa developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>77,655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>16,798</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>56,881</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,976</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>77,655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>67,526</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Vyleesi developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>60,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>9,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>38,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11,752</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,013,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>442,340</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>547,895</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>23,620</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>953,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>417,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>319,246</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>217,033</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the second quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, Vyleesi received FDA approval, which triggered a </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment, which was capitalized as developed technology.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Late in the second quarter of 2019, we were notified that an additional manufacturing site for the Makena IM products, which relates to the Makena base technology intangible asset, received FDA approval. However, the approval was received later than expected and the extended period of the stock-out caused our authorized generic partner to lose additional customers and market share, resulting in no shipments of IM to our authorized generic partner during that quarter. As a result of this loss of market share, we deemed it probable as of the end of the second quarter of 2019 that we would terminate the Distribution and Supply Agreement with our authorized generic partner. We do not expect to generate any future revenues from shipments </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of the IM products. Accordingly, we eliminated the Makena IM products from our long-term revenue forecast during the second quarter of 2019. These business factors were considered indicators of impairment for the Makena base technology intangible asset during the second quarter of 2019. We determined that the fair value of the Makena base technology intangible asset was </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> at June 30, 2019, and as a result, we recorded an impairment charge for the full remaining value of the asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$77.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was recorded within a separate operating expense line item on our consolidated statements of operations. The Distribution and Supply Agreement with our authorized generic partner was terminated in August 2019 and we have not sold any Makena IM in the second half of 2019. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2019, we identified indicators of impairment for the Makena auto-injector developed technology, Intrarosa developed technology and Vyleesi developed technology intangible assets (each part of its own asset group) related to (i) the October 29, 2019 unfavorable FDA Advisory Committee recommendation for Makena as described in Note A, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Description of Business</span><span style="font-family:inherit;font-size:10pt;">”, and (ii) the December 2019 decision to divest Intrarosa and Vyleesi based on the strategic review that we conducted. We determined that the Intrarosa and Vyleesi asset groups did not meet the criteria to be classified as held for sale as of December 31, 2019 and as a result, assessed these assets for potential impairment under the held and used guidance. For each asset group, we estimated the sum of the undiscounted projected cash flows and found that the sum of the projected, probability-weighted undiscounted cash flows were less than the carrying value of each corresponding asset group. Therefore, we reassessed the fair value of each asset group using an income approach, a Level 3 measurement technique, which included probability weighting a range of potential outcomes as impacted by multiple significant and inter-related business factors. For all three asset groups, these significant assumptions included an estimated probability of a negative FDA action with respect to Makena and the expected timing of any such FDA action. In addition, for the Intrarosa and Vyleesi asset groups, management’s assessment also included assumptions regarding the probability of completing a sale of these assets and the expected timing of a sale, should one occur. We derived these estimates based on management’s judgment as informed by externally available information. We believe the assumptions we used to determine the estimated fair value of the asset groups are reasonable. Based on our consideration of these probability-weighted assumptions evaluated in the aggregate, we recorded impairment charges of </span><span style="font-family:inherit;font-size:10pt;"><span>$55.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$56.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$39.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to reduce the carrying values of the Makena auto-injector developed technology, Intrarosa developed technology and Vyleesi developed technology intangible assets to their respective estimated fair values. Total impairment charges of </span><span style="font-family:inherit;font-size:10pt;"><span>$155.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> were recorded within a separate operating expense line item in our consolidated statements of operations during the fourth quarter of 2019, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$151.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> were allocated to the intangible assets in each asset group. In addition, we reassessed and prospectively adjusted the estimated remaining useful lives of the Makena auto-injector developed technology, Intrarosa developed technology and Vyleesi developed technology intangible assets and other long-lived assets within each asset group. As such, we accelerated amortization of these intangible assets resulting in an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$7.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of expense recorded in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. As described in more detail above, our assessment was based on our estimates and assumptions, a number of which are based on external factors and the exercise of management judgment. Actual results may differ significantly from our estimates.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the weighted average estimated remaining amortization period for our finite-lived intangible assets was approximately </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> year. Total amortization expense for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, was </span><span style="font-family:inherit;font-size:10pt;"><span>$24.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$158.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$130.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Amortization expense is recorded in cost of product sales in our consolidated statements of operations. We expect amortization expense related to our finite-lived intangible assets to be </span><span style="font-family:inherit;font-size:10pt;"><span>$23.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended December 31, 2020.</span></div> 422500000 0 9.71 329000000 0.06 0.37 0.84 0.65 329000000 0.29 0 0 0 0 21.50 742000000 0.02 633000000 0.20 0.39 0.96 0.71 742000000 0.36 0 17.84 17.84 617000000 747000000 0.21 617000000 0.15 15.19 0.41 0 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Original Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life to Date Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life to Date Impairments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Original Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life to Date Accumulated Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life to Date Impairments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amortizable intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Makena base technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>797,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>400,496</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>396,604</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>797,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>400,495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>319,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>77,359</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Makena auto-injector developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>79,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15,782</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>55,426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,892</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>79,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,952</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>72,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Intrarosa developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>77,655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>16,798</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>56,881</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,976</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>77,655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>67,526</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Vyleesi developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>60,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>9,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>38,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11,752</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,013,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>442,340</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>547,895</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>23,620</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>953,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>417,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>319,246</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>217,033</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span> 797100000 400496000 396604000 0 797100000 400495000 319246000 77359000 79100000 15782000 55426000 7892000 79100000 6952000 0 72148000 77655000 16798000 56881000 3976000 77655000 10129000 0 67526000 60000000 9264000 38984000 11752000 0 0 0 0 1013855000 442340000 547895000 23620000 953855000 417576000 319246000 217033000 60000000.0 0 77400000 55400000 56900000 39000000.0 155000000.0 151300000 7100000 24800000 158400000 130400000 23600000 CURRENT AND LONG-TERM LIABILITIES <div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accrued Expenses</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial rebates, fees and returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124,730</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,618</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued manufacturing</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,364</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Salaries, bonuses, and other compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,693</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Professional, license, and other fees and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,960</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,539</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>867</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,067</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>797</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183,382</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134,635</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial rebates, fees and returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124,730</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,618</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued manufacturing</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,364</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Salaries, bonuses, and other compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,693</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Professional, license, and other fees and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,960</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,539</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>867</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,067</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>797</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183,382</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134,635</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 124730000 85618000 21364000 9282000 18693000 22482000 13392000 13960000 3539000 2226000 867000 1067000 797000 0 183382000 134635000 INCOME TAXES<div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31,</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, all of our profit or loss before income taxes was from U.S. operations. The income tax (benefit) expense consisted of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(630</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,136</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,358</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(451</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>333</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,520</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,546</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(172,238</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,443</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>404</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,103</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(183,041</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total income tax (benefit) expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,436</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(175,521</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The reconciliation of the statutory U.S. federal income tax rate to our effective income tax rate from continuing operations was as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory U.S. federal tax rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State taxes, net of federal benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of 2017 tax reform on deferred tax balance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other permanent items, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(67.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized an immaterial income tax benefit, representing an effective tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span><span style="font-family:inherit;font-size:10pt;">. The difference between the expected statutory federal tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span>21.0%</span></span><span style="font-family:inherit;font-size:10pt;"> and the effective tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, was primarily attributable to the valuation allowance established against our current period losses generated and the non-deductible IPR&amp;D expense related to the Perosphere acquisition.We have established a valuation allowance on our deferred tax assets other than refundable AMT credits to the extent that our existing taxable temporary differences would not be available as a source of income to realize the benefits of those deferred tax assets. The income tax benefit for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> primarily related to the offset of the recognition of the income tax expense recorded in other comprehensive loss associated with the increase in the value of available-for-sale securities that we carried at fair market value during the period, partially offset by state income taxes.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we recognized income tax expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$40.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> representing an effective tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span>(30.7)%</span></span><span style="font-family:inherit;font-size:10pt;">. The difference between the expected statutory federal tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span>21.0%</span></span><span style="font-family:inherit;font-size:10pt;"> and the </span><span style="font-family:inherit;font-size:10pt;"><span>(30.7)%</span></span><span style="font-family:inherit;font-size:10pt;"> effective tax rate for 2018 was primarily attributable to the establishment of a valuation allowance on net deferred tax assets other than refundable AMT credits, the impact of non-deductible stock compensation and other non-deductible expenses, partially offset by a benefit from contingent consideration associated with Lumara Health, state income taxes and orphan drug tax credits. The valuation allowance on our deferred tax assets, other than refundable AMT credits, increased during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> primarily because the deferred tax liabilities associated with the CBR business, which was reclassified to discontinued operations and sold during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, are no longer available as a source of income to realize the benefits of the net deferred tax assets. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">, we recognized an income tax benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$175.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> representing an effective tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span>45.9%</span></span><span style="font-family:inherit;font-size:10pt;">. The difference between the expected statutory federal tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span>35.0%</span></span><span style="font-family:inherit;font-size:10pt;"> and the </span><span style="font-family:inherit;font-size:10pt;"><span>45.9%</span></span><span style="font-family:inherit;font-size:10pt;"> effective tax rate for 2017 was primarily attributable to the impact of the 2017 federal tax reform legislation, as discussed below, contingent consideration associated with Lumara Health, federal research and orphan drug tax credits generated during the year, and the impact of state income taxes, partially offset by equity-based compensation expenses and an increase to our valuation allowance.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Tax Cuts and Jobs Act (the “2017 Tax Act”), was enacted. The 2017 Tax Act includes significant changes to the U.S. corporate income tax system, including a reduction of the federal corporate income tax rate from </span><span style="font-family:inherit;font-size:10pt;"><span>35.0%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>21.0%</span></span><span style="font-family:inherit;font-size:10pt;">, effective January 1, 2018. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which those temporary differences are expected to be recovered or settled. As a result of the reduction in the federal tax rate from </span><span style="font-family:inherit;font-size:10pt;"><span>35.0%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>21.0%</span></span><span style="font-family:inherit;font-size:10pt;">, we revalued our ending net deferred tax liabilities at December 31, 2017 and recognized a </span><span style="font-family:inherit;font-size:10pt;"><span>$17.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> tax benefit.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future enacted rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. The components of our deferred tax assets and liabilities were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,679</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,888</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credit carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital loss carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,659</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,746</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,318</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity-based compensation expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,106</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,931</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capitalized research &amp; development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,635</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,847</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,565</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserves</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,683</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,739</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,846</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,627</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(218,291</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(114,516</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(614</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt instruments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right of use asset</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,599</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(41</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The valuation allowance </span><span style="font-family:inherit;font-size:10pt;">increased</span><span style="font-family:inherit;font-size:10pt;"> by approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$103.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. We have established a valuation allowance on our deferred tax assets other than refundable AMT credits to the extent that our existing taxable temporary differences would not be available as a source of income to realize the benefits of those deferred tax assets. Our valuation allowance on our deferred tax assets, other than refundable AMT credits, increased during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, primarily due to our current period losses generated.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had federal and state NOL carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$332.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$184.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$123.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$16.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> federal and state NOL carryforwards, were acquired as part of the Lumara Health transaction, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$21.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$14.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> federal and state NOL carryforwards were acquired as part of the Perosphere transaction, respectively. The majority of the federal and state NOLs expire at various dates </span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">through </span><span style="font-family:inherit;font-size:10pt;">2039</span><span style="font-family:inherit;font-size:10pt;">. We have </span><span style="font-family:inherit;font-size:10pt;"><span>$127.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of federal NOLs generated after 2017 which will not expire. We have federal tax credits of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$26.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> to offset future tax liabilities of which </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> were acquired as part of the Lumara Health transaction and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of which were acquired as part of the Perosphere transaction. We have state tax credits of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to offset future tax liabilities of which </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> were acquired as part of the Perosphere transaction. These federal and state tax credits will expire periodically through </span><span style="font-family:inherit;font-size:10pt;">2039</span><span style="font-family:inherit;font-size:10pt;"> if not utilized. We have a capital loss carryforward of </span><span style="font-family:inherit;font-size:10pt;"><span>$90.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> from the sale of the CBR business that can only be used to offset future capital gains and expires in 2023. Our interest expense carryforward is </span><span style="font-family:inherit;font-size:10pt;"><span>$23.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, which may be carried forward indefinitely.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Utilization of our NOLs, interest expense carryforwards, and research and development (“R&amp;D”) credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section 382 of the Internal Revenue Code of 1986 (“Section 382”) as well as similar state provisions. These ownership changes may limit the amount of NOLs and interest expense carryforwards that can be utilized annually to offset future taxable income and may limit the amounts of R&amp;D credit carryforwards that can be utilized annually to offset taxes. In general, an ownership change as defined by Section 382 results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than </span><span style="font-family:inherit;font-size:10pt;">50%</span><span style="font-family:inherit;font-size:10pt;"> over a </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year period. Since our formation, we have raised capital through the issuance of capital stock on several occasions. These financings, combined with the purchasing shareholders’ subsequent disposition of those shares, could result in a change of control, as defined by Section 382. We conducted an analysis under Section 382 to determine if historical changes in ownership through </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, based upon publicly available information as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, would limit or otherwise restrict our ability to utilize these NOLs, interest expense, and R&amp;D credit carryforwards. As a result of this analysis, we do not believe there are any significant limitations on our ability to utilize these carryforwards. The NOLs and tax credits acquired from Lumara Health and Perosphere are subject to restrictions under Section 382. These restricted NOLs and credits may be utilized subject to an annual limitation. We identified ownership changes associated with the attributes acquired as part of the Lumara Health and Perosphere transactions and determined these attributes are subject to annual limitations. Future changes in ownership after </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> could affect the limitation in future years and any limitation may result in expiration of a portion of the NOL or R&amp;D credit carryforwards before utilization.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits represent uncertain tax positions for which reserves have been established. A reconciliation of our changes in unrecognized tax benefits is as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits at the beginning of the year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,180</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,020</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions based on tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>574</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions for tax positions from prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,173</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtractions for federal tax reform</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,296</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtractions for tax positions from prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(336</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits at the end of the year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,538</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,560</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amount of unrecognized tax benefits that would impact the effective tax rate if recognized is immaterial, as the majority of our uncertain tax positions relate to NOL and credit carryforwards, which, if recognized, are currently expected to require a full valuation allowance.</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our unrecognized tax benefits as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> increased by </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> as compared to </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> primarily due to tax reserves associated with NOLs and R&amp;D credit carryforwards acquired in connection with the Perosphere transaction.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our unrecognized tax benefits as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> increased by </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> as compared to December 31, 2017 primarily due to tax reserves established on R&amp;D tax credits.</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our unrecognized tax benefits as of December 31, 2017 decreased by </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> as compared to December 31, 2016 primarily due to the change in the federal tax rate, which reduced the future value of our federal NOLs and the corresponding value of the unrecognized tax benefits related to those NOLs. This decrease was partially offset by tax reserves established on R&amp;D tax credits.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have recorded minimal interest or penalties on unrecognized tax benefits since inception. We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We do not expect our unrecognized tax benefits to change significantly in the next </span><span style="font-family:inherit;font-size:10pt;">12 months</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span style="font-family:inherit;font-size:10pt;">The statute of limitations for assessment by the Internal Revenue Service (the “IRS”) and most state tax authorities is closed for tax years prior to December 31, 2016, although carryforward attributes that were generated prior to tax year </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> may still be adjusted upon examination by the IRS or state tax authorities if they either have been or will be used in a future period. We file income tax returns in the U.S. federal and various state jurisdictions. There are currently </span><span style="font-family:inherit;font-size:10pt;">no</span> federal or state audits in progress. The income tax (benefit) expense consisted of the following (in thousands):<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(630</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,136</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,358</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(451</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>333</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,520</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,546</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(172,238</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,443</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>404</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,103</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(183,041</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total income tax (benefit) expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,436</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(175,521</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -630000 -1136000 2162000 179000 1469000 5358000 -451000 333000 7520000 432000 43546000 -172238000 -28000 -3443000 -10803000 404000 40103000 -183041000 -47000 40436000 -175521000 <div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The reconciliation of the statutory U.S. federal income tax rate to our effective income tax rate from continuing operations was as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory U.S. federal tax rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State taxes, net of federal benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of 2017 tax reform on deferred tax balance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other permanent items, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(67.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.210 0.210 0.350 0.026 0.047 0.033 0 0 0.045 -0.004 -0.015 -0.008 0 0.071 0.044 -0.034 0 0 -0.004 -0.014 -0.005 -0.004 -0.062 -0.007 -0.198 -0.674 -0.008 0 0.006 0.001 0 -0.307 0.459 0.000 0.210 0.000 40400000 -0.307 0.210 -0.307 -175500000 0.459 0.350 0.459 0.350 0.210 0.350 0.210 -17100000 The components of our deferred tax assets and liabilities were as follows (in thousands):<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79,679</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,888</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credit carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital loss carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,659</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,746</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,318</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity-based compensation expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,106</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,931</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capitalized research &amp; development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,635</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,847</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,565</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserves</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,683</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,739</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,846</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,627</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(218,291</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(114,516</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(614</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt instruments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right of use asset</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,599</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(41</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 79679000 46888000 28641000 24290000 20659000 20896000 5746000 4318000 6106000 5931000 2347000 4635000 67847000 12565000 5721000 2683000 5739000 391000 0 4000 87000 10846000 6627000 218291000 114516000 0 614000 9195000 12489000 5599000 11000 41000 630000 1260000 103800000 332800000 184600000 123100000 16600000 21400000 14600000 127400000 26100000 2300000 2300000 2500000 1200000 90400000 23600000 A reconciliation of our changes in unrecognized tax benefits is as follows (in thousands):<div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits at the beginning of the year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,180</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,020</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions based on tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>574</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions for tax positions from prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,173</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtractions for federal tax reform</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,296</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtractions for tax positions from prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(336</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits at the end of the year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,538</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,560</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 11180000 10560000 13020000 521000 12000 574000 2173000 608000 340000 0 0 3296000 336000 0 78000 13538000 11180000 10560000 2400000 600000 2500000 ACCUMULATED OTHER<span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">COMPREHENSIVE LOSS </span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in the accumulated balances of other comprehensive loss associated with unrealized (losses) gains on securities during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,985</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,908</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,838</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>746</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(77</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(70</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,985</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,908</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in the accumulated balances of other comprehensive loss associated with unrealized (losses) gains on securities during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,985</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,908</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,838</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>746</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(77</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(70</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,985</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,908</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -3985000 -3908000 -3838000 746000 -77000 -70000 -3239000 -3985000 -3908000 EQUITY-BASED COMPENSATION <div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently maintain </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> equity compensation plans, namely our 2019 Equity Incentive Plan (the “2019 Plan”), which was approved by our stockholders at our 2019 annual meeting and replaced our Fourth Amended and Restated 2007 Equity Incentive Plan, as amended (the “2007 Plan”), the Lumara Health Inc. Amended and Restated 2013 Incentive Compensation Plan (the “Lumara Health 2013 Plan”) and our 2015 Employee Stock Purchase Plan (“2015 ESPP”). All outstanding stock options granted under each of our equity compensation plans other than our 2015 ESPP (discussed below) have an exercise price equal to the closing price of a share of our common stock on the grant date.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our 2019 Plan succeeded our 2007 Plan, which has expired and under which </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> further grants may be made. The number of shares available for future grants under the 2019 Plan consists of the sum of (i) the number of shares that remained available for issuance under the 2007 Plan as of the date of adoption of the 2019 Plan and (ii) an additional </span><span style="font-family:inherit;font-size:10pt;"><span>2,161,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares. All outstanding awards granted under the 2007 Plan will remain subject to the terms of the 2007 Plan. In addition, any shares subject to outstanding awards granted under the 2007 Plan that expire or terminate for any reason prior to exercise will be added to the total number of shares of our stock available for issuance under the 2019 Plan. The allotted number of shares available for issuance under the 2019 Plan was </span><span style="font-family:inherit;font-size:10pt;"><span>3,519,304</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and there were </span><span style="font-family:inherit;font-size:10pt;"><span>2,828,030</span></span><span style="font-family:inherit;font-size:10pt;"> shares remaining available for future issuance under the 2019 Plan. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, all outstanding options under both the 2019 Plan and 2007 Plan have a </span><span style="font-family:inherit;font-size:10pt;">ten</span><span style="font-family:inherit;font-size:10pt;">-year term.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2014, we assumed the Lumara Health 2013 Plan in connection with the acquisition of Lumara Health. The total number of shares issuable pursuant to awards under this plan as of the effective date of the acquisition and after taking into account any adjustments as a result of the acquisition, was </span><span style="font-family:inherit;font-size:10pt;"><span>200,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>9,817</span></span><span style="font-family:inherit;font-size:10pt;"> shares remaining available for issuance under the Lumara Health 2013 Plan, which are available for grants to certain employees, officers, directors, consultants, and advisers of AMAG and our subsidiaries who are newly-hired or who previously performed services for Lumara Health. All outstanding options under the Lumara Health 2013 Plan have a </span><span style="font-family:inherit;font-size:10pt;">ten</span><span style="font-family:inherit;font-size:10pt;">-year term.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The 2019 Plan, 2007 Plan and the Lumara Health 2013 Plan provide for the grant of stock options, RSUs, restricted stock, stock, stock appreciation rights and other equity interests in our company. We generally issue common stock from previously authorized but unissued shares to satisfy option exercises and RSU awards. The terms and conditions of each award are determined by our Board of Directors (the “Board”) or the Compensation Committee of our Board. The terms and conditions of each award assumed in the acquisition of Lumara Health were previously determined by Lumara Health prior to being assumed in connection with the acquisition, subject to applicable adjustments made in connection with such acquisition.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2015, our stockholders approved our 2015 ESPP, which authorizes the issuance of up to </span><span style="font-family:inherit;font-size:10pt;"><span>200,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock to eligible employees. In June 2018, at our annual meeting of stockholders, our stockholders approved an amendment to our 2015 ESPP to increase the maximum number of shares of our common stock that will be made available for sale thereunder by </span><span style="font-family:inherit;font-size:10pt;"><span>500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares. The terms of the 2015 ESPP permit eligible employees to purchase shares (subject to certain plan and tax limitations) in semi-annual offerings through payroll deductions of up to an annual maximum of </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> of the employee’s “compensation” as defined in the 2015 ESPP. Shares are purchased at a price equal to </span><span style="font-family:inherit;font-size:10pt;"><span>85%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value of our common stock on either the first or last business day of the offering period, whichever is lower. Plan periods consist of </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;">-month periods typically commencing June 1 and ending November 30 and commencing December 1 and ending May 31. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>445,713</span></span><span style="font-family:inherit;font-size:10pt;"> shares have been issued under our 2015 ESPP. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we also granted equity through inducement grants outside of our equity compensation plans to certain employees to induce them to accept employment with us (collectively, “Inducement Grants”). The options were granted at an exercise price equal to the fair market value of a share of our common stock on the respective grant dates and will be exercisable in </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;"> equal annual installments beginning on the first anniversary of the respective grant dates. The RSU grants will vest in </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> equal annual installments beginning on the first anniversary of the respective grant dates. The foregoing grants were made pursuant to inducement grants outside of our stockholder approved equity plans as permitted under the NASDAQ Stock Market listing rules. We assessed the terms of these awards and determined there was no possibility that we would have to settle these awards in cash and therefore, equity accounting was applied.</span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:35%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2007 Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2013 Lumara</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inducement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Plan</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,781,786</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124,450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>810,343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,716,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>479,212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>465,009</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,366</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,061,587</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,025</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,025</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired or terminated</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(659,304</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(194,545</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(890,324</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>472,412</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,585,466</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>131,775</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>696,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,885,817</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Stock Units</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes RSU activity during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:35%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2007 Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2013 Lumara</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inducement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Plan</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,041,141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,128,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,023,847</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,385</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,186,874</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(358,362</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,034</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44,909</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(404,305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired or terminated</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(299,321</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(331,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,407,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,223</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,579,437</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, March 2018 and February 2017, we granted RSUs under our 2007 Plan to certain members of our senior management covering a maximum of </span><span style="font-family:inherit;font-size:10pt;"><span>365,591</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>206,250</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>191,250</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively. These performance-based RSUs will vest, if at all, on February 24, 2022, March 1, 2021 and February 22, 2020, respectively, based on our total shareholder return (“TSR”) performance measured against the median TSR of a defined group of companies over a </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year period. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the maximum shares of common stock that may be issued under these awards was </span><span style="font-family:inherit;font-size:10pt;"><span>325,091</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>155,250</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>131,250</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The maximum aggregate total fair value of these RSUs at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which is being recognized as expense over a period of </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> from the date of grant, net of any estimated and actual forfeitures.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity-based compensation expense</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity-based compensation expense for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>871</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>884</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,844</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,533</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,818</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,614</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,187</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total equity-based compensation expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,533</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,949</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,296</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,188</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After-tax effect of equity-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,533</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,949</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,108</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the equity-based compensation expense presented in the table above, we incurred </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of equity-based compensation expense related to the restructuring activities during the first quarter of 2019, which is classified within restructuring expense on our consolidated statements of operations for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the weighted average assumptions we utilized for purposes of valuing grants of options to our employees and non-employee directors:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:23%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:12%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-Employee</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-Employee</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-Employee</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Employees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Directors</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Employees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Directors</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Employees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Directors</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rate (%)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.61</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility (%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected option term (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">none</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">none</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">none</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">none</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">none</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">none</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rates utilized are based upon published U.S. Treasury yields at the date of the grant for the expected option term. During </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, we estimated our expected stock price volatility by using the historical volatility of our own common stock price over the prior period equivalent to our expected option term, in order to better reflect expected future volatility. To compute the expected option term, we analyze historical exercise experience as well as expected stock option exercise patterns.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes details regarding stock options granted under our equity incentive plans for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Remaining Contractual Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value <br/>($ in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at beginning of year</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,716,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,061,587</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,025</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired and/or forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(890,324</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,885,817</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>776</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at end of year - vested and unvested expected to vest</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,799,575</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>701</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,242,727</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value of stock options granted during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$6.33</span></span><span style="font-family:inherit;font-size:10pt;">, $</span><span style="font-family:inherit;font-size:10pt;"><span>10.76</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$9.52</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. A total of </span><span style="font-family:inherit;font-size:10pt;"><span>728,758</span></span><span style="font-family:inherit;font-size:10pt;"> stock options vested during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. The aggregate intrinsic value of options exercised during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, excluding purchases made pursuant to our 2015 ESPP, measured as of the exercise date, was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The intrinsic value of a stock option is the amount by which the fair market value of the underlying stock on a specific date exceeds the exercise price of the common stock option.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes details regarding RSUs granted under our equity incentive plans for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Restricted Stock Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at beginning of year</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,128,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,186,874</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(404,305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(331,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,579,437</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at end of year and expected to vest</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,462,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value of RSUs granted during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$15.65</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$22.32</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$24.18</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The total fair value of RSUs that vested during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$9.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$12.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$12.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the amount of unrecorded equity-based compensation expense for both option and RSU awards, attributable to future periods was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$28.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. Of this amount, </span><span style="font-family:inherit;font-size:10pt;"><span>$11.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> was associated with stock options and is expected to be amortized on a straight-line basis to expense over a weighted average period of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>2.5</span></span><span style="font-family:inherit;font-size:10pt;"> years, </span><span style="font-family:inherit;font-size:10pt;"><span>$12.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> was associated with RSUs and is expected to be amortized on a straight-line basis to expense over a weighted average period of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span><span style="font-family:inherit;font-size:10pt;"> years, and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> was associated with performance-based RSUs and is expected to be amortized on a straight-line basis to expense over a weighted average period of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>1.5</span></span><span style="font-family:inherit;font-size:10pt;"> years. Such amounts will be amortized primarily to research and development or selling, general and administrative expense. These future estimates are subject to change based upon a variety of future events, which include, but are not limited to, changes in estimated forfeiture rates, employee turnover, and the issuance of new stock options and other equity-based awards.</span></div> 3 0 2161000 3519304 2828030 200000 9817 200000 500000 0.10 0.85 445713 0 2781786 124450 810343 3716579 479212 465009 37000 80366 1061587 0 2025 0 0 2025 6800 659304 29675 194545 890324 472412 2585466 131775 696164 3885817 0 1041141 2101 85293 1128535 132542 1023847 1100 29385 1186874 0 358362 1034 44909 404305 3800 299321 0 28546 331667 128742 1407305 2167 41223 1579437 365591 206250 191250 325091 155250 131250 4200000 2900000 2600000 P3Y <div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity-based compensation expense for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>871</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>884</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,844</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,533</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,818</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,614</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,187</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total equity-based compensation expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,533</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,949</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,296</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,188</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After-tax effect of equity-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,533</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,949</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,108</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 871000 802000 884000 2844000 2533000 3225000 14818000 16614000 16187000 18533000 19949000 20296000 0 0 6188000 18533000 19949000 14108000 700000 <div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the weighted average assumptions we utilized for purposes of valuing grants of options to our employees and non-employee directors:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:23%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:12%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-Employee</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-Employee</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-Employee</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Employees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Directors</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Employees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Directors</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Employees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Directors</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rate (%)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.61</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility (%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected option term (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">none</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">none</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">none</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">none</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">none</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">none</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.0212 0.0204 0.0275 0.0270 0.0186 0.0161 0.57 0.59 0.57 0.59 0.53 0.57 P5Y P4Y P5Y P4Y P5Y P4Y <div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes details regarding stock options granted under our equity incentive plans for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Remaining Contractual Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value <br/>($ in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at beginning of year</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,716,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,061,587</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,025</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired and/or forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(890,324</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,885,817</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>776</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at end of year - vested and unvested expected to vest</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,799,575</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>701</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,242,727</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:35%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2007 Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2013 Lumara</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inducement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Plan</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,781,786</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124,450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>810,343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,716,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>479,212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>465,009</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,366</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,061,587</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,025</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,025</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired or terminated</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(659,304</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(194,545</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(890,324</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>472,412</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,585,466</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>131,775</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>696,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,885,817</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3716579 24.81 P7Y3M18D 1061587 12.71 2025 14.56 890324 22.93 3885817 21.94 P6Y9M18D 776000 3799575 22.12 P6Y9M18D 701000 2242727 25.76 P5Y6M 116000 6.33 10.76 9.52 728758 0.0 600000 400000 <div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes details regarding RSUs granted under our equity incentive plans for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Restricted Stock Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at beginning of year</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,128,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,186,874</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(404,305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(331,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,579,437</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at end of year and expected to vest</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,462,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes RSU activity during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:35%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2007 Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2013 Lumara</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inducement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Plan</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,041,141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,128,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,023,847</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,385</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,186,874</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(358,362</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,034</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44,909</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(404,305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired or terminated</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(299,321</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(331,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,407,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,223</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,579,437</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1128535 23.42 1186874 15.65 404305 22.49 331667 19.71 1579437 18.60 1462952 18.88 15.65 22.32 24.18 9100000 12400000 12300000 28100000 11500000 P2Y6M 12300000 P1Y8M12D 4300000 P1Y6M EMPLOYEE SAVINGS PLAN <div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We provide a 401(k) Plan to our employees by which they may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code. Each employee may elect to defer a percentage of his or her salary up to a specified maximum. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> our 401(k) Plan provided, among other things, for a company contribution of </span><span style="font-family:inherit;font-size:10pt;"><span>4%</span></span><span style="font-family:inherit;font-size:10pt;"> of each employee’s combined salary and certain other compensation for the plan year. Contributions by us to the 401(k) Plan are not taxable to employees until withdrawn from the 401(k) Plan and contributions are deductible by us when made. The amount of our company contribution for the 401(k) Plan was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> 0.04 3700000 4000000.0 2300000 STOCKHOLDERS’ EQUITY <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">As of January 1, 2019, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$20.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> available under our previously approved program to repurchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in shares of our common stock. In March 2019, our Board authorized additional repurchases of shares in an amount up to </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> under this program. The repurchase program does not have an expiration date and may be suspended for periods or discontinued at any time. Under the program, we may purchase our stock from time to time at the discretion of management in the open market or in privately negotiated transactions. The number of shares repurchased and the timing of the purchases will depend on a number of factors, including share price, trading volume and general market conditions, along with working capital requirements, general business conditions and other factors. We may also from time to time establish a trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934 to facilitate purchases of our shares under this program. During </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we repurchased and retired </span><span style="font-family:inherit;font-size:10pt;"><span>1,074,800</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock under this repurchase program for </span><span style="font-family:inherit;font-size:10pt;"><span>$13.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. During </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, we did </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;">t repurchase shares of common stock under this program. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$26.8 million</span></span> remains available for the repurchase of shares under the program. 20500000 60000000.0 20000000.0 1074800 13700000 0 26800000 COMMITMENTS AND CONTINGENCIES <div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our long-term contractual obligations include commitments and estimated purchase obligations entered into in the normal course of business. These include commitments related to our facility and vehicle leases, purchases of inventory, debt obligations, and other purchase obligations.</span></div><div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Lease Obligations</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2019, we had operating leases for real estate, including our lease for use as our principal executive offices, vehicles and office equipment. As of January 1, 2019, we recorded operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and related ROU assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with our adoption of ASC 842. During the fourth quarter of 2019, we modified the operating lease for our principal executive offices to extend the term through July 2028. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$23.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and related ROU assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$23.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, our leases have remaining terms of </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>8.5 years</span></span><span style="font-family:inherit;font-size:10pt;">. The weighted average remaining lease term and discount rate for our operating leases was </span><span style="font-family:inherit;font-size:10pt;"><span>7.95 years</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>5.1%</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease costs for our operating leases were </span><span style="font-family:inherit;font-size:10pt;"><span>$5.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$5.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">years ended December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. Operating cash outflows for operating leases were </span><span style="font-family:inherit;font-size:10pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">year ended December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum payments under our non-cancelable operating leases as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Future Minimum Lease Payments</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December 31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,077</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December 31, 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December 31, 2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,734</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December 31, 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December 31, 2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,246</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,818</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,868</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Purchase Obligations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase obligations primarily represent minimum purchase commitments for inventory. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, our minimum purchase commitments totaled $</span><span style="font-family:inherit;font-size:10pt;"><span>105.9 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent Regulatory and Commercial Milestone Payments </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are required to make payments contingent on the achievement of certain regulatory and/or commercial milestones under the terms of our collaboration, license and other strategic agreements. Please refer to Note Q, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration, License and Other Strategic Agreements</span><span style="font-family:inherit;font-size:10pt;">” for additional details regarding these contingent payments.</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Employment Arrangements</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have entered into employment agreements or other arrangements with most of our executive officers and certain other employees, which provide for the continuation of salary and certain benefits and, in certain instances, the acceleration of the vesting of certain equity awards to such individuals in the event that the individual is terminated other than for cause, as defined in the applicable employment agreements or arrangements. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Indemnification Obligations</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As permitted under Delaware law, pursuant to our certificate of incorporation, by-laws and agreements with all of our current directors, executive officers, and certain of our employees, we are obligated to indemnify such individuals for certain events or occurrences while the officer, director or employee is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification obligations is not capped. Our director and officer insurance policy limits our initial exposure and our policy provides significant coverage. As a result, we believe the estimated fair value of these indemnification obligations is likely to be immaterial.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also a party to a number of other agreements entered into in the ordinary course of business, typically with business partners, contract manufacturers, clinical sites and customers, which contain typical provisions and which obligate us to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. Our aggregate maximum potential future liability under such indemnification provisions is uncertain. We have not incurred any expenses as a result of such indemnification provisions during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. Accordingly, we have determined that the estimated aggregate fair value of our potential liabilities under such indemnification provisions is not significant, and we have not recorded any liability related to such indemnification.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Proceedings</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss. We review these accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. For certain matters referenced below, the liability is not probable or the amount cannot be reasonably estimated and, therefore, accruals have not been made. In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, we will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, we will provide disclosure to that effect. We expense legal costs as they are incurred.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 6, 2019, we were served with a summons in a case filed in the U.S. District Court, Northern District of Ohio, captioned Civil Case in Saginaw Chippewa Indian Tribe v. Purdue Pharma et al (Case No. 1-19-op-45841). The complaint names K-V Pharmaceutical Company (“KV”) (Lumara Health’s predecessor company), certain of its successor entities, subsidiaries and affiliate entities as defendants, along with over </span><span style="font-family:inherit;font-size:10pt;"><span>forty</span></span><span style="font-family:inherit;font-size:10pt;"> other pharmaceutical companies. We acquired Lumara Health in November 2014, a year after KV emerged from bankruptcy protection, at which time it and its then-existing subsidiaries became our wholly-owned subsidiaries. The plaintiff in this action alleges that KV’s subsidiary, Ethex Corporation (as well as the other pharmaceutical companies named in the complaint), manufactured, promoted, sold, and distributed opioids, including a generic version of morphine. We are in discussions with the plaintiff’s counsel to dismiss all claims in the Chippewa case. At this time, based on available information, we are currently unable to predict the outcome or reasonably estimate the range of potential loss associated with this matter, if any.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 1, 2019, we were named as a defendant in a class action lawsuit filed in the United States District Court for the Western District of Missouri, captioned Barnes v. AMAG Pharmaceuticals, Inc., Case No. 3:19-cv-05088-RK (W.D. Mo.).  Subsequently, other plaintiffs represented by the same law firm have filed </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> similar class action lawsuits in other jurisdictions, captioned Gill v. AMAG Pharmaceuticals, Inc., Case No. 2:19-cv-02681-DDC-JPO (D. Kan., filed Nov. 4, 2019), Faughnan, et al. v. AMAG Pharmaceuticals, Inc., Case No. 3:19-cv-01394-FJS-ML (N.D.N.Y, filed Nov. 12, 2019), Zamifrova v. AMAG Pharmaceuticals, Inc., Case No. 2:20-cv-00152-JMV-SCM (D.N.J., filed Jan. 3, 2020) and Nelson v. AMAG Pharmaceuticals, Inc., Case No. 2:20-cv-00089-WBS-DMC (E.D. Cal., filed Jan. 13, 2020). The plaintiffs in these actions, on behalf of themselves and purported state-wide classes of similarly situated consumers, assert claims for violation of state consumer protection laws and unjust enrichment based on allegations that we and/or our predecessor companies made misrepresentations and omissions regarding the effectiveness of Makena in connection with the sale and marketing of that product from 2011 through the present. Because these cases are in the earliest stages, we are currently unable to predict the outcome or reasonably estimate the range of potential loss associated with this matter, if any.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 29, 2019, Lunar Representative, LLC (“Plaintiff”), on behalf of the former equityholders of Lumara Health Inc. (“Lumara”), filed a complaint against us in the Delaware Court of Chancery, captioned Lunar Representative, LLC v. AMAG Pharmaceuticals, Inc. (No. 2019-0688-JTL). On September 25, 2019, we filed a motion to dismiss the complaint. On January 9, </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020, Plaintiff filed an amended complaint. Plaintiff alleges that we did not exercise commercially reasonable efforts to market and sell the drug product Makena, and failed to achieve sales milestones for Makena, in breach of certain provisions of the September 28, 2014 Agreement and Plan of Merger between, among other parties, us and Lumara. On January 24, 2020, we filed a motion to dismiss the amended complaint. Plaintiff is seeking damages of </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, together with pre- and post-judgment interest, as well as attorneys’ fees and costs. At this time, based on available information, we are unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses. We believe this lawsuit is without merit and intend to vigorously defend against the allegations.  </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On or about April 6, 2016, we received Notice of a Lawsuit and Request to Waive Service of a Summons in a case entitled Plumbers’ Local Union No. 690 Health Plan v. Actavis Group et. al. (“Plumbers’ Union”), which was filed in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania and, after removal to federal court, is now pending in the United States District Court for the Eastern District of Pennsylvania (Civ. Action No. 16-65-AB). Thereafter, we were also made aware of a related complaint entitled Delaware Valley Health Care Coalition v. Actavis Group et. al. (“Delaware Valley”), which was filed with the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania District Court of Pennsylvania (Case ID: 160200806). The complaints name K-V Pharmaceutical Company (“KV”) (Lumara Health’s predecessor company), certain of its successor entities, subsidiaries and affiliate entities (the “Subsidiaries”), along with a number of other pharmaceutical companies. We acquired Lumara Health in November 2014, a year after KV emerged from bankruptcy protection, at which time it, along with its then existing subsidiaries, became our wholly-owned subsidiary. We have not been served with process or waived service of summons in either case. The actions are being brought alleging unfair and deceptive trade practices with regard to certain pricing practices that allegedly resulted in certain payers overpaying for certain of KV’s generic products. On July 21, 2016, the Plaintiff in the Plumbers’ Union case dismissed KV with prejudice to refiling and on October 6, 2016, all claims against the Subsidiaries were dismissed without prejudice. We are in discussions with Plaintiff’s counsel to similarly dismiss all claims in the Delaware Valley case. Because we have not been served with process in the Delaware Valley case, we are currently unable to predict the outcome or reasonably estimate the range of potential loss associated with this matter, if any.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 20, 2015, the Federal Trade Commission (the “FTC”) notified us that it is conducting an investigation into whether Lumara Health or its predecessor engaged in unfair methods of competition with respect to Makena or any hydroxyprogesterone caproate product. The FTC noted in its letter that the existence of the investigation does not indicate that the FTC has concluded that Lumara Health or its predecessor has violated the law and we believe that our contracts and practices comply with relevant law and policy, including the federal Drug Quality and Security Act (the “DQSA”), which was enacted in November 2013, and public statements from and enforcement actions by the FDA regarding its implementation of the DQSA. We have provided the FTC with a response providing a brief overview of the DQSA for context, which we believe was helpful, including: (a) how the statute outlined that large-scale compounding of products that are copies or near-copies of FDA-approved drugs (like Makena) is not in the interests of public safety; (b) our belief that the DQSA has had a significant impact on the compounding of hydroxyprogesterone caproate; and (c) how our contracts with former compounders allow those compounders to continue to serve physicians and patients with respect to supplying medically necessary alternative/altered forms of hydroxyprogesterone caproate. We believe we have fully cooperated with the FTC and we have had no further interactions with the FTC on this matter since we provided our response to the FTC in August 2015. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may periodically become subject to other legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which we are focused. Other than the above actions, we are not aware of any material claims against us as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div> 8500000 7600000 23900000 23300000 P8Y6M P7Y11M12D 0.051 5100000 5100000 3000000.0 5200000 <div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum payments under our non-cancelable operating leases as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Future Minimum Lease Payments</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December 31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,077</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December 31, 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December 31, 2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,734</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December 31, 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December 31, 2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,246</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,818</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,868</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4077000 3207000 3734000 3230000 3246000 12192000 29686000 5818000 23868000 105900000 40 4 50000000.0 COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS <div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2019, we were a party to the following collaboration, license or other strategic agreements:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Perosphere</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 16, 2019, we acquired Perosphere Pharmaceuticals Inc. (“Perosphere”) pursuant to the Agreement and Plan of Merger (the “Perosphere Agreement”), dated as of December 12, 2018 between AMAG and Perosphere. Pursuant to the Perosphere Agreement, in January 2019, we paid approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “Upfront Merger Consideration”). Of the Upfront Merger Consideration, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> was funded from our available cash and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> was deemed paid in connection with the cancellation of a convertible note in the principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> issued to us by Perosphere in October 2018. In addition to the Upfront Merger Consideration, we used available cash to repay </span><span style="font-family:inherit;font-size:10pt;"><span>$12.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Perosphere’s term loan indebtedness and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$6.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Perosphere’s other liabilities. We are also required to pay regulatory and sales milestone payments to Perosphere as described in more detail below. Further, we were </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a party to a clinical trial collaboration agreement with a pharmaceutical company, which we acquired through the Perosphere transaction, which provided for partial funding of the Phase 3 program for ciraparantag if certain clinical milestones were met. In December 2019, the clinical trial collaboration agreement with the pharmaceutical company was terminated as described in more detail in Note D, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</span><span style="font-family:inherit;font-size:10pt;">.”</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Substantially all of the fair value of the assets acquired in conjunction with the Perosphere transaction was concentrated in the IPR&amp;D asset. As a result, we accounted for this transaction as an asset acquisition under ASU No. 2017-01, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business </span><span style="font-family:inherit;font-size:10pt;">(“ASU 2017-01”). The acquired IPR&amp;D was charged to expense at acquisition, as it relates to a development stage compound with no alternative future use. A summary of the assets and liabilities acquired in exchange for cash consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$60.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> that was deemed paid in connection with the cancellation of the convertible note, described above,</span><span style="font-family:inherit;font-size:10pt;color:#ee2724;"> </span><span style="font-family:inherit;font-size:10pt;">is presented in the following table (in millions):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued severance liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Excluded from the table above are contingent payments associated with achievement of potential regulatory and sales milestones as described below, which were not deemed probable at the date of acquisition. The fair values of certain of the assets and liabilities acquired are classified as Level 3 estimates under the fair value hierarchy as they have been valued using unobservable inputs. These inputs include: (a) the estimated amount and timing of projected cash flows; (b) the probability of the achievement of key development and regulatory objectives; and (c) the risk-adjusted discount rate used to present value the probability-weighted cash flows. The fair values of the assets and liabilities acquired were initially valued and recorded based on various market factors, including an analysis of estimated sales using a discount rate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>34%</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under and subject to the terms and conditions set forth in the Perosphere Agreement, we are obligated to pay future contingent consideration of up to an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$365.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “Milestone Payments”), including (a) up to an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$140.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> that becomes payable upon the achievement of specified regulatory milestones for ciraparantag (the “Regulatory Milestone Payments”), including a </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment upon approval of ciraparantag by the European Medicines Agency and (b) up to an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$225.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> that becomes payable conditioned upon the achievement of specified sales milestones (the “Sales Milestone Payments”). If the final label approved for ciraparantag in the U.S. includes a boxed warning, the Regulatory Milestone Payments shall no longer be payable, and any previously paid Regulatory Milestone Payments shall be credited against </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of any future Milestone Payments that otherwise becomes payable. The first sales milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> will be payable upon annual net sales of ciraparantag of at least </span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Velo</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, we exercised our option to acquire the global rights to AMAG-423 pursuant to an option agreement entered into in July 2015 with Velo Bio, LLC (“Velo”), the terms of which were amended at the time of exercise. Under the terms of the agreement, we paid Velo an upfront option exercise fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$12.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and are obligated to pay Velo a </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment upon FDA approval of AMAG-423. In addition, we are obligated to pay sales milestone payments to Velo of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$240.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the aggregate, triggered at various annual net sales thresholds between </span><span style="font-family:inherit;font-size:10pt;"><span>$300.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$900.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and low-single digit royalties based on net sales. Further, we have assumed additional obligations under a previous agreement entered into by Velo with a third-party, including a </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment upon regulatory approval and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> following the first commercial sale of AMAG-423, payable in quarterly installments as a percentage of quarterly gross commercial sales until the obligation is met. We are also obligated to pay the third-party low-single digit royalties based on net sales. We accounted for this transaction as an asset acquisition under ASU 2017-01</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Prasco </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2017, we entered into a Distribution and Supply Agreement (the “Prasco Agreement”) with Prasco, LLC (“Prasco”), under which Prasco was granted an exclusive, non-sublicensable, nontransferable license to purchase, distribute and sell a generic version of Makena in the U.S. (the “Makena authorized generic”). In July 2018, Prasco launched the Makena authorized generic of both the single-dose and multi-dose IM injections and in August 2019, we and Prasco terminated the Prasco Agreement based on our determination that it was not commercially viable to continue the relationship. Under the Prasco Agreement, we were responsible for the manufacture and supply of the Makena authorized generic to be sold to Prasco at a predetermined supply price. Prasco was also required to pay us a certain percentage of the net distributable profits from the sale of the Makena authorized generic. We accounted for revenue recognized under the Prasco Agreement in accordance with ASC 606. Pursuant to the terms of the Prasco Agreement, in certain circumstances we have reimbursed Prasco as a result of our failure to supply a certain percentage of product ordered by Prasco in a prespecified timeframe. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we incurred </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of failure to supply penalties, the majority of which were incurred in the first quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Antares </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are party to a development and license agreement (the “Antares License Agreement”) with Antares Pharma, Inc. (“Antares”), which grants us an exclusive, worldwide, royalty-bearing license, with the right to sublicense, to certain intellectual property rights, including know-how, patents and trademarks, to develop, use, sell, offer for sale and import and export the Makena auto-injector. Under the terms of the Antares License Agreement, as amended in March 2018, we are responsible for the clinical development and preparation, submission and maintenance of all regulatory applications in each country where we desire to market and sell the Makena auto-injector, including the U.S. We are required to pay royalties to Antares on net sales of the Makena auto-injector until the Antares License Agreement is terminated (the “Antares Royalty Term”). The royalty rates range from high single digit to low double digits and are tiered based on levels of net sales of the Makena auto-injector and decrease after the expiration of licensed patents or where there are generic equivalents to the Makena auto-injector being sold in a particular country. In addition, we are required to pay Antares sales milestone payments upon the achievement of certain annual net sales. The Antares License Agreement terminates at the end of the Antares Royalty Term, but is subject to early termination by us for convenience and by either party upon an uncured breach by or bankruptcy of the other party. In March 2018, the Antares License Agreement was amended to, among other things, transfer the agreement to AMAG from our subsidiary, amend certain confidentiality provisions, and to provide for co-termination with the Antares Manufacturing Agreement (described below).</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also party to a Manufacturing Agreement with Antares (the “Antares Manufacturing Agreement”) that sets forth the terms and conditions pursuant to which Antares agreed to sell to us on an exclusive basis, and we agreed to purchase, the fully packaged Makena auto-injector for commercial distribution. Antares remains responsible for the manufacture and supply of the device components and assembly of the Makena auto-injector. We are responsible for the supply of the drug to be used in the assembly of the finished auto-injector product. The Antares Manufacturing Agreement terminates at the expiration or earlier termination of the Antares License Agreement, but is subject to early termination by us for certain supply failure situations, and by either party upon an uncured breach by or bankruptcy of the other party or our permanent cessation of commercialization of the Makena auto-injector for efficacy or safety reasons.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Endoceutics</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2017, we entered into the Endoceutics License Agreement with Endoceutics, Inc. (“Endoceutics”) to obtain an exclusive right to commercialize Intrarosa for the treatment of vulvar and vaginal atrophy (“VVA”) and FSD in the United States. We have agreed to use commercially reasonable efforts to market, promote and otherwise commercialize Intrarosa for the treatment of VVA. The transactions contemplated by the Endoceutics License Agreement closed on April 3, 2017. We accounted for the Endoceutics License Agreement as an asset acquisition under ASU 2017-01</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon the closing of the Endoceutics License Agreement, we made an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and issued </span><span style="font-family:inherit;font-size:10pt;"><span>600,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of unregistered common stock to Endoceutics, which had a value of </span><span style="font-family:inherit;font-size:10pt;"><span>$13.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, as measured on April 3, 2017, the date of closing. In addition, we paid Endoceutics </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the third quarter of 2017 upon the delivery by Endoceutics of Intrarosa launch quantities and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2018 following the first anniversary of the closing. In the second quarter of 2017, we recorded a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$83.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of consideration, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$77.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> was allocated to the Intrarosa developed technology intangible asset and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded as IPR&amp;D expense based on their relative fair values.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the Endoceutics License Agreement, we pay tiered royalties to Endoceutics equal to a percentage of net sales of Intrarosa in the U.S. ranging from mid-teens to mid twenty percent. Endoceutics is also eligible to receive certain sales </span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">milestone payments up to an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$895.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, including a first sales milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which would be triggered when Intrarosa annual net U.S. sales exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2017, we entered into an exclusive commercial supply agreement with Endoceutics pursuant to which Endoceutics, itself or through affiliates or contract manufacturers, agreed to manufacture and supply Intrarosa to us (the “Endoceutics Supply Agreement”) and is our exclusive supplier of Intrarosa in the U.S., subject to certain rights for us to manufacture and supply Intrarosa in the event of a cessation notice or supply failure (as such terms are defined in the Endoceutics Supply Agreement). The Endoceutics Supply Agreement will generally remain in effect until the termination of the Endoceutics License Agreement.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Endoceutics License Agreement expires on the date of expiration of all royalty obligations due thereunder unless earlier terminated in accordance with the Endoceutics License Agreement. </span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Palatin</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, we entered into a license agreement with Palatin Technologies, Inc. (“Palatin”) under which we acquired (a) an exclusive license in all countries of North America (the “Palatin Territory”), with the right to grant sub-licenses, to research, develop and commercialize the Vyleesi Products, (b) a worldwide non-exclusive license, with the right to grant sub-licenses, to manufacture the Vyleesi Products, and (c) a non-exclusive license in all countries outside the Palatin Territory, with the right to grant sub-licenses, to research and develop (but not commercialize) the Vyleesi Products (the “Palatin License Agreement”). The transaction closed in February 2017 and was accounted for as an asset acquisition under ASU 2017-01.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the Palatin License Agreement, in February 2017 we paid Palatin </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> as a one-time upfront payment and subject to agreed-upon deductions reimbursed Palatin approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for reasonable, documented, out-of-pocket expenses incurred by Palatin in connection with the development and regulatory activities necessary to submit the Vyleesi New Drug Application (“NDA”) in the U.S. The </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment made in February 2017 to Palatin was recorded as IPR&amp;D expense as the product candidate had not received regulatory approval. In June 2018, our NDA submission to the FDA for Vyleesi was accepted, which triggered a </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment, which we paid in the second quarter of 2018 and recorded as an IPR&amp;D expense in the first quarter of 2018 when acceptance was deemed probable. In June 2019, the FDA approval of Vyleesi triggered a </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment to Palatin, which we paid in July 2019 and recorded as a developed technology intangible asset in the second quarter of 2019.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the Palatin License Agreement requires us to make contingent payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$300.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of aggregate sales milestone payments upon the achievement of certain annual net sales milestones over the course of the license. The first sales milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> will be triggered when Vyleesi annual net sales exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. We are also obligated to pay Palatin tiered royalties on annual net sales of the Vyleesi Products, on a product-by-product basis, in the Palatin Territory ranging from the high-single digits to the low double-digits. After the expiration of the applicable royalties for any Vyleesi Product in a given country, the license for such Vyleesi Product in such country would become a fully paid-up, royalty-free, perpetual and irrevocable license. The Palatin License Agreement expires on the date of expiration of all royalty obligations due thereunder, unless earlier terminated in accordance with the Palatin License Agreement. </span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Abeona</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We acquired the U.S. commercial rights to MuGard, a prescription oral mucoadhesive, under a June 2013 license agreement with Abeona (the “MuGard Rights”). We ceased selling MuGard at the end of 2019.</span></div> 50000000.0 40000000.0 10000000.0 10000000.0 12000000.0 6200000 A summary of the assets and liabilities acquired in exchange for cash consideration of <span style="font-family:inherit;font-size:10pt;"><span>$60.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> that was deemed paid in connection with the cancellation of the convertible note, described above,</span><span style="font-family:inherit;font-size:10pt;color:#ee2724;"> </span><span style="font-family:inherit;font-size:10pt;">is presented in the following table (in millions):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued severance liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span> 60800000 10000000.0 2600000 800000 1400000 74900000 79700000 1700000 6400000 800000 8900000 0.34 365000000.0 140000000.0 40000000.0 225000000.0 0.50 20000000.0 100000000.0 12500000 30000000.0 240000000.0 300000000.0 900000000.0 5000000.0 10000000.0 3500000 50000000.0 600000 13500000 10000000.0 10000000.0 83500000 77700000 5800000 895000000.0 15000000.0 150000000.0 60000000.0 25000000.0 60000000.0 20000000.0 60000000.0 300000000.0 25000000.0 250000000.0 DEBT <div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our outstanding debt obligations as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022 Convertible Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,034</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>261,933</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 Convertible Notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,034</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>283,209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current maturities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,276</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt, net of current maturities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>261,933</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Convertible Notes</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The outstanding balances of our Convertible Notes as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consisted of the following (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2022 Convertible Notes</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability component:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>320,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: debt discount and issuance costs, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,966</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net carrying amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross equity component</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72,576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with accounting guidance for debt with conversion and other options, we separately account for the liability and equity components of our Convertible Notes by allocating the proceeds between the liability component and the embedded conversion option (the “Equity Component”) due to our ability to settle the Convertible Notes in cash, common stock or a combination of cash and common stock, at our option. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The allocation was performed in a manner that reflected our non-convertible debt borrowing rate for similar debt. The Equity Component of the Convertible Notes was recognized as a debt discount and represents the difference between the proceeds from the issuance of the Convertible Notes and the fair value of the liability of the Convertible Notes on their respective dates of issuance. The excess of the principal amount of the liability component over its carrying amount (the “Debt Discount”) is amortized to interest expense using the effective interest method over </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">. The Equity Component is not remeasured as long as it continues to meet the conditions for equity classification.</span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2022 Convertible Notes</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the second quarter of 2017, we issued </span><span style="font-family:inherit;font-size:10pt;"><span>$320.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of convertible senior notes due in 2022 and received net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$310.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> from the sale of the 2022 Convertible Notes, after deducting fees and expenses of </span><span style="font-family:inherit;font-size:10pt;"><span>$9.6 million</span></span><span style="font-family:inherit;font-size:10pt;">. The approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$9.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> of debt issuance costs primarily consisted of underwriting, legal and other professional fees, and allocated these costs to the liability and equity components based on the allocation of the proceeds. Of the total </span><span style="font-family:inherit;font-size:10pt;"><span>$9.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> of debt issuance costs, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> was allocated to the Equity Component and recorded as a reduction to additional paid-in capital and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> was allocated to the liability component and is now recorded as a reduction of the 2022 Convertible Notes in our consolidated balance sheet. The portion allocated to the liability component is amortized to interest expense using the effective interest method over </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The 2022 Convertible Notes are governed by the terms of an indenture between us, as issuer, and Wilmington Trust, National Association, as the trustee. The 2022 Convertible Notes are senior unsecured obligations and bear interest at a rate of </span><span style="font-family:inherit;font-size:10pt;"><span>3.25%</span></span><span style="font-family:inherit;font-size:10pt;"> per year, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2017. The 2022 Convertible Notes will mature on </span><span style="font-family:inherit;font-size:10pt;">June 1, 2022</span><span style="font-family:inherit;font-size:10pt;">, unless earlier repurchased or converted. Upon conversion of the 2022 Convertible Notes, such 2022 Convertible Notes will be convertible into, at our election, cash, shares of our common stock, or a combination thereof, at a conversion rate of </span><span style="font-family:inherit;font-size:10pt;">36.5464</span><span style="font-family:inherit;font-size:10pt;"> shares of common stock per </span><span style="font-family:inherit;font-size:10pt;">$1,000</span><span style="font-family:inherit;font-size:10pt;"> principal amount of the 2022 Convertible Notes, which corresponds to an initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$27.36</span></span><span style="font-family:inherit;font-size:10pt;"> per share of our common stock.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The conversion rate is subject to adjustment from time to time upon the occurrence of certain events, including, but not limited to, the issuance of stock dividends and payment of cash dividends. At any time prior to the close of business on the business day immediately preceding March 1, 2022, holders may convert their 2022 Convertible Notes at their option only under the following circumstances:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending September 30, 2017, if the last reported sale price of our common stock for at least </span><span style="font-family:inherit;font-size:10pt;"><span>20</span></span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during a period of </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to </span><span style="font-family:inherit;font-size:10pt;"><span>130%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price on each applicable trading day;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">during the </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> business day period after any </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period (the “measurement period”) in which the trading price per </span><span style="font-family:inherit;font-size:10pt;">$1,000</span><span style="font-family:inherit;font-size:10pt;"> principal amount of the 2022 Convertible Notes for each trading day of the measurement period was less than </span><span style="font-family:inherit;font-size:10pt;"><span>98%</span></span><span style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">upon the occurrence of specified corporate events.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On or after March 1, 2022, until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their 2022 Convertible Notes, in multiples of </span><span style="font-family:inherit;font-size:10pt;">$1,000</span><span style="font-family:inherit;font-size:10pt;"> principal amount, at the option of the holder regardless of the foregoing circumstances. The 2022 Convertible Notes were not convertible as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determined the expected life of the debt was equal to the </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year term on the 2022 Convertible Notes. The effective interest rate on the liability component was </span><span style="font-family:inherit;font-size:10pt;"><span>9.49%</span></span><span style="font-family:inherit;font-size:10pt;"> for the period from the date of issuance through </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the “if-converted value” did not exceed the remaining principal amount of the 2022 Convertible Notes.</span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2019 Convertible Notes</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2014, we issued </span><span style="font-family:inherit;font-size:10pt;"><span>$200.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of 2019 Convertible Notes. We received net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$193.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> from the sale of the 2019 Convertible Notes, after deducting fees and expenses of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. We used </span><span style="font-family:inherit;font-size:10pt;"><span>$14.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the net proceeds from the sale of the 2019 Convertible Notes to pay the cost of the convertible bond hedges, as described below (after such cost was partially offset by the proceeds to us from the sale of warrants in the warrant transactions described below). The 2019 Convertible Notes are senior unsecured obligations and bear interest at a rate of </span><span style="font-family:inherit;font-size:10pt;"><span>2.5%</span></span><span style="font-family:inherit;font-size:10pt;"> per year, payable semi-annually in arrears on February 15 and August 15 of each year. </span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2017, we entered into two privately negotiated transactions with certain investors to repurchase approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$178.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of the 2019 Convertible Notes for an aggregate repurchase price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$192.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, including accrued interest. Pursuant to ASC Topic 470,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Debt</span><span style="font-family:inherit;font-size:10pt;"> (“ASC 470”), we concluded that the 2017 repurchases of 2019 Convertible Notes should be accounted for as extinguishments and we recorded a net debt extinguishment loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the difference between the consideration paid, the fair value of the liability component and carrying values at the repurchase date. The remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$21.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of 2019 Convertible Notes matured on February 15, 2019 and were settled with cash.</span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Notes Interest Expense </span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth total interest expense recognized related to the 2022 Convertible Notes and 2019 Convertible Notes during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands): </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,961</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,412</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt discount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,414</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,071</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,752</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Convertible Bond Hedge and Warrant Transactions </span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2014 we entered into convertible bond hedge transactions and separate warrant transactions of our common stock underlying the aggregate principal amount of the 2019 Convertible Notes with certain financial institutions (the “call spread counterparties”). In connection with our 2017 repurchases of the 2019 Convertible Notes, as discussed above, we entered into agreements with the call spread counterparties to terminate a portion of the then existing convertible bond hedge transactions in an amount corresponding to the amount of such 2019 Convertible Notes repurchased and to terminate a portion of the then-existing warrant transactions. In February 2019, the 2019 Convertible Notes were settled with cash and the remaining bond hedge and warrant transactions expired.</span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2023 Senior Notes</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2015, in connection with the CBR acquisition, we completed a private placement of </span><span style="font-family:inherit;font-size:10pt;"><span>$500 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>7.875%</span></span><span style="font-family:inherit;font-size:10pt;"> Senior Notes due 2023 (the “2023 Senior Notes”). The 2023 Senior Notes were issued pursuant to an Indenture, dated as of August 17, 2015 (the “Indenture”), by and among us, certain of our subsidiaries acting as guarantors of the 2023 Senior Notes and Wilmington Trust, National Association, as trustee. In October 2017, we repurchased </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the 2023 Senior Notes in a privately negotiated transaction, resulting in a loss on extinguishment of debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. In September 2018, we repurchased the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$475.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the 2023 Senior Notes at a premium of </span><span style="font-family:inherit;font-size:10pt;"><span>$28.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> using the proceeds from the CBR sale, which resulted in a loss on extinguishment of debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$35.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, inclusive of the premium paid.</span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2015 Term Loan Facility</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2015, we entered into a credit agreement with a group of lenders, including Jefferies Finance LLC as administrative and collateral agent, that provided us with, among other things, a </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;">-year </span><span style="font-family:inherit;font-size:10pt;"><span>$350.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> term loan facility, </span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">under which we borrowed the full amount (the “2015 Term Loan Facility”). In May 2017, we repaid the remaining outstanding borrowings and accrued interest of the 2015 Term Loan Facility and, in accordance with ASC 470, recognized a </span><span style="font-family:inherit;font-size:10pt;"><span>$9.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss on debt extinguishment.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Future Payments</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future annual principal payments on our long-term debt as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> include </span><span style="font-family:inherit;font-size:10pt;"><span>$320.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> due during the year ended December 31, 2022.</span></div> <div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our outstanding debt obligations as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022 Convertible Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,034</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>261,933</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 Convertible Notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,034</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>283,209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current maturities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,276</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt, net of current maturities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>261,933</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 277034000 261933000 0 21276000 277034000 283209000 0 21276000 277034000 261933000 <div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The outstanding balances of our Convertible Notes as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consisted of the following (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2022 Convertible Notes</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability component:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>320,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: debt discount and issuance costs, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,966</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net carrying amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross equity component</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72,576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 320000000 42966000 277034000 72576000 P5Y 320000000.0 310400000 9600000 9600000 9600000 2200000 7400000 P5Y 0.0325 27.36 20 30 1.30 5 5 0.98 0.0949 200000000.0 193300000 6700000 14100000 0.025 178500000 192700000 100000 21400000 <div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth total interest expense recognized related to the 2022 Convertible Notes and 2019 Convertible Notes during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands): </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,961</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,412</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt discount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,414</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,071</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,752</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 10467000 10935000 8961000 1412000 1403000 1275000 13830000 13414000 11071000 25709000 25752000 21307000 500000000 0.07875 25000000.0 -1100000 475000000.0 28100000 -35900000 350000000.0 -9700000 320000000.0 RESTRUCTURING EXPENSES <div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, we completed a restructuring to combine our women’s health and maternal health sales forces into one integrated sales team. Approximately </span><span style="font-family:inherit;font-size:10pt;"><span>110</span></span><span style="font-family:inherit;font-size:10pt;"> employees were displaced through this workforce reduction. We recorded one-time restructuring charges of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> primarily related to severance and related benefits on our consolidated statement of operations for the </span><span style="font-family:inherit;font-size:10pt;">year ended December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. We expect the restructuring charges incurred to date under this program to be substantially paid in cash by the end of the first quarter of 2020. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table displays charges taken related to restructuring activities during the </span><span style="font-family:inherit;font-size:10pt;">year ended December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and a rollforward of the changes to the accrued balances as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Workforce reduction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Contract termination</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance accrued at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,034</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(229</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(157</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,623</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance accrued at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>797</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>797</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 110 7400000 <div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table displays charges taken related to restructuring activities during the </span><span style="font-family:inherit;font-size:10pt;">year ended December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and a rollforward of the changes to the accrued balances as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Workforce reduction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Contract termination</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance accrued at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,034</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,420</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(229</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(157</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,623</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance accrued at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>797</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>797</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 0 0 0 7034000 229000 157000 7420000 6237000 229000 157000 6623000 797000 0 0 797000 CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED <div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables provide unaudited consolidated quarterly financial data for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, which have been revised to correct for immaterial errors in prior periods as detailed below and further described in Note X, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">“Revision of Prior Period Financial Statements”</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>75,488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>77,767</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>83,808</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>89,483</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross profit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>57,011</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>53,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>62,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>46,162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating expenses </span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>175,024</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>169,662</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>81,050</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>240,329</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss from continuing operations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(122,400</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(121,169</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(23,940</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(200,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income (loss) from discontinued operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(122,400</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(121,169</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(23,940</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(200,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Basic and diluted earnings per share:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income (loss) from discontinued operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>116,867</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>145,663</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>121,646</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>87,871</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross profit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>52,955</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>68,887</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>75,157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>59,155</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating expenses </span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>104,239</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27,591</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>95,084</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>78,241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss from continuing operations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(58,994</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(26,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(65,282</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21,004</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income (loss) from discontinued operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,856</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,736</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>95,517</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net (loss) income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(55,138</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21,059</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30,235</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(22,535</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Basic and diluted earnings per share:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income (loss) from discontinued operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.04</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.88</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The sum of quarterly earnings per share totals differ from annual earnings per share totals due to rounding. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating expenses for the first quarter of 2019 include </span><span style="font-family:inherit;font-size:9pt;"><span>$74.9 million</span></span><span style="font-family:inherit;font-size:9pt;"> relating to IPR&amp;D acquired through the Perosphere acquisition and </span><span style="font-family:inherit;font-size:9pt;"><span>$7.4 million</span></span><span style="font-family:inherit;font-size:9pt;"> relating to the restructuring expenses for the consolidation of the women’s health and maternal health sales forces. Operating expenses for the second quarter of 2019 include </span><span style="font-family:inherit;font-size:9pt;"><span>$77.4 million</span></span><span style="font-family:inherit;font-size:9pt;"> of impairment charges relating to the Makena base technology intangible asset. Operating expenses for the fourth quarter of 2019 include </span><span style="font-family:inherit;font-size:9pt;"><span>$155.0 million</span></span><span style="font-family:inherit;font-size:9pt;"> of impairment charges relating to the Makena auto-injector, Intrarosa and Vyleesi asset groups.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating expenses for the second quarter of 2018 include the reversal of </span><span style="font-family:inherit;font-size:9pt;"><span>$49.8 million</span></span><span style="font-family:inherit;font-size:9pt;"> relating to the fair value of a contingent consideration liability that was no longer expected to be paid. </span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables present the effect of the revisions to our unaudited condensed consolidated statements of operations for the three months ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 to correct for immaterial errors in prior periods as further described in Note X, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">“Revision of Prior Period Financial Statements”</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share amounts):</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,729</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,413</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(342</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,634</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,804</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(316</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,488</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(342</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,767</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(137</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(137</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(120</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(120</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(122,084</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(316</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(122,400</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(120,827</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(342</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(121,169</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.54</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.55</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.57</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,107</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(323</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,784</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,378</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,154</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(323</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,808</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,707</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(224</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,483</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23,617</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(323</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23,940</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(199,928</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(224</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(200,152</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.70</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.71</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.89</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.90</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables present the effect of the revisions to our unaudited condensed consolidated statements of operations for the three months ended March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018 to correct for immaterial errors in prior periods as further described in Note X, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">“Revision of Prior Period Financial Statements”</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share amounts):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117,348</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116,828</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,219</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(591</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,628</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117,387</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(520</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116,867</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,254</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(591</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,663</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>376</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,624</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,556</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,943</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(54,242</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(896</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55,138</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20,081</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(978</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,059</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.59</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.02</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.61</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.03</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.61</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(592</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>121,646</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,047</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,796</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,238</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(592</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>121,646</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,122</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(251</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,871</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,352</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,550</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,839</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(604</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,235</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,277</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(258</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,535</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.64</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.65</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables provide unaudited consolidated quarterly financial data for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, which have been revised to correct for immaterial errors in prior periods as detailed below and further described in Note X, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">“Revision of Prior Period Financial Statements”</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>75,488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>77,767</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>83,808</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>89,483</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross profit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>57,011</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>53,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>62,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>46,162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating expenses </span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>175,024</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>169,662</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>81,050</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>240,329</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss from continuing operations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(122,400</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(121,169</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(23,940</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(200,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income (loss) from discontinued operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(122,400</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(121,169</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(23,940</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(200,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Basic and diluted earnings per share:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income (loss) from discontinued operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>116,867</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>145,663</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>121,646</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>87,871</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross profit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>52,955</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>68,887</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>75,157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>59,155</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating expenses </span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>104,239</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27,591</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>95,084</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>78,241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss from continuing operations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(58,994</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(26,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(65,282</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21,004</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income (loss) from discontinued operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,856</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,736</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>95,517</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net (loss) income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(55,138</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21,059</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30,235</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(22,535</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Basic and diluted earnings per share:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income (loss) from discontinued operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.04</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.88</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The sum of quarterly earnings per share totals differ from annual earnings per share totals due to rounding. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating expenses for the first quarter of 2019 include </span><span style="font-family:inherit;font-size:9pt;"><span>$74.9 million</span></span><span style="font-family:inherit;font-size:9pt;"> relating to IPR&amp;D acquired through the Perosphere acquisition and </span><span style="font-family:inherit;font-size:9pt;"><span>$7.4 million</span></span><span style="font-family:inherit;font-size:9pt;"> relating to the restructuring expenses for the consolidation of the women’s health and maternal health sales forces. Operating expenses for the second quarter of 2019 include </span><span style="font-family:inherit;font-size:9pt;"><span>$77.4 million</span></span><span style="font-family:inherit;font-size:9pt;"> of impairment charges relating to the Makena base technology intangible asset. Operating expenses for the fourth quarter of 2019 include </span><span style="font-family:inherit;font-size:9pt;"><span>$155.0 million</span></span><span style="font-family:inherit;font-size:9pt;"> of impairment charges relating to the Makena auto-injector, Intrarosa and Vyleesi asset groups.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup> </span></div><span style="font-family:inherit;font-size:9pt;">Operating expenses for the second quarter of 2018 include the reversal of </span><span style="font-family:inherit;font-size:9pt;"><span>$49.8 million</span></span> relating to the fair value of a contingent consideration liability that was no longer expected to be paid. 75488000 77767000 83808000 89483000 57011000 53477000 62703000 46162000 175024000 169662000 81050000 240329000 -122400000 -121169000 -23940000 -200152000 0 0 0 0 -122400000 -121169000 -23940000 -200152000 -3.55 -3.58 -0.71 -5.90 0 0 0 0 -3.55 -3.58 -0.71 -5.90 116867000 145663000 121646000 87871000 52955000 68887000 75157000 59155000 104239000 27591000 95084000 78241000 -58994000 -26795000 -65282000 -21004000 3856000 5736000 95517000 -1531000 -55138000 -21059000 30235000 -22535000 -1.72 -0.78 -1.89 -0.61 0.11 0.17 2.77 -0.04 -1.61 -0.61 0.88 -0.65 74900000 7400000 77400000 155000000.0 49800000 <div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables present the effect of the revisions to our unaudited condensed consolidated statements of operations for the three months ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 to correct for immaterial errors in prior periods as further described in Note X, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">“Revision of Prior Period Financial Statements”</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share amounts):</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,729</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,413</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(342</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,634</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,804</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(316</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,488</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(342</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,767</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(137</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(137</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(120</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(120</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(122,084</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(316</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(122,400</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(120,827</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(342</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(121,169</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.54</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.55</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.57</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,107</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(323</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,784</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,378</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,154</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(323</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,808</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,707</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(224</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,483</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23,617</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(323</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23,940</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(199,928</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(224</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(200,152</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.70</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.71</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.89</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.90</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables present the effect of the revisions to our unaudited condensed consolidated statements of operations for the three months ended March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018 to correct for immaterial errors in prior periods as further described in Note X, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">“Revision of Prior Period Financial Statements”</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share amounts):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117,348</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116,828</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,219</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(591</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,628</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117,387</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(520</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116,867</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,254</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(591</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,663</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>376</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,624</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,556</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,943</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(54,242</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(896</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55,138</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20,081</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(978</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,059</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.59</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.02</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.61</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.03</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.61</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adj</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(592</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>121,646</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,047</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,796</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,238</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(592</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>121,646</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,122</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(251</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,871</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,352</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,550</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,839</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(604</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,235</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,277</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(258</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,535</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.64</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.65</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effect of the corrections to our consolidated statements of operations for the years ended December 31, 2019, 2018 and 2017 are as follows (in thousands, except per share amounts): </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311,190</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,205</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>309,985</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>327,751</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,205</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>326,546</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss from continuing operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(466,456</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,205</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(467,661</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(466,456</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,205</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(467,661</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13.74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473,852</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,954</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>471,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>474,002</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,954</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>472,048</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,654</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>782</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,436</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss from continuing operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(169,339</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,736</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(172,075</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65,761</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,736</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68,497</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495,645</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>493,843</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495,769</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,802</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>493,967</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(175,254</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(267</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(175,521</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss from continuing operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(205,153</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,535</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(206,688</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(199,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(200,763</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 75729000 -316000 75413000 77976000 -342000 77634000 75804000 -316000 75488000 78109000 -342000 77767000 -137000 0 -137000 -120000 0 -120000 -122084000 -316000 -122400000 -120827000 -342000 -121169000 -3.54 -0.01 -3.55 -3.57 -0.01 -3.58 84107000 -323000 83784000 73378000 -224000 73154000 84131000 -323000 83808000 89707000 -224000 89483000 232000 0 232000 -21000 0 -21000 -23617000 -323000 -23940000 -199928000 -224000 -200152000 -0.70 -0.01 -0.71 -5.89 -0.01 -5.90 117348000 -520000 116828000 146219000 -591000 145628000 117387000 -520000 116867000 146254000 -591000 145663000 -8000000 376000 -7624000 52556000 387000 52943000 -54242000 -896000 -55138000 -20081000 -978000 -21059000 -1.59 -0.02 -1.61 -0.58 -0.03 -0.61 122238000 -592000 121646000 88047000 -251000 87796000 122238000 -592000 121646000 88122000 -251000 87871000 -2352000 12000 -2340000 -2550000 7000 -2543000 30839000 -604000 30235000 -22277000 -258000 -22535000 0.89 -0.01 0.88 -0.64 -0.01 -0.65 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VALUATION AND QUALIFYING ACCOUNTS (IN THOUSANDS) </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at Beginning of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions Charged to Reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at End of Period</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31, 2019:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable allowances</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>324,542</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(310,668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,417</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rebates, fees and returns reserves</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,868</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321,210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(283,653</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance for deferred tax assets </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,516</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>104,858</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>218,291</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31, 2018:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable allowances</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>229,509</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(232,026</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rebates, fees and returns reserves</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,846</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>272,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(294,891</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,868</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance for deferred tax assets </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,800</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,516</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31, 2017:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable allowances</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,533</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>168,945</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(166,418</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rebates, fees and returns reserves</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,809</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>257,273</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(244,236</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,846</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance for deferred tax assets </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,875</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(564</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">________________________</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts receivable allowances represent discounts and other chargebacks related to the provision of our product sales.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additions to rebates, fees and returns reserves are recorded as a reduction of revenues.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup> </span></div><span style="font-family:inherit;font-size:9pt;">As of </span><span style="font-family:inherit;font-size:9pt;">December 31, 2019</span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;">2018</span>, we have established a valuation allowance on our net deferred tax assets other than refundable AMT credits. At December 31, 2017, our valuation allowance related primarily to certain of our state NOL and credit carryforwards. <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at Beginning of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions Charged to Reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at End of Period</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31, 2019:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable allowances</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>324,542</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(310,668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,417</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rebates, fees and returns reserves</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,868</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321,210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(283,653</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance for deferred tax assets </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,516</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>104,858</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>218,291</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31, 2018:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable allowances</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>229,509</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(232,026</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rebates, fees and returns reserves</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,846</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>272,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(294,891</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,868</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance for deferred tax assets </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,800</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,516</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31, 2017:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable allowances</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,533</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>168,945</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(166,418</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rebates, fees and returns reserves</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,809</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>257,273</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(244,236</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,846</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance for deferred tax assets </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,875</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(564</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">________________________</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts receivable allowances represent discounts and other chargebacks related to the provision of our product sales.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additions to rebates, fees and returns reserves are recorded as a reduction of revenues.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup> </span></div><span style="font-family:inherit;font-size:9pt;">As of </span><span style="font-family:inherit;font-size:9pt;">December 31, 2019</span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;">2018</span>, we have established a valuation allowance on our net deferred tax assets other than refundable AMT credits. At December 31, 2017, our valuation allowance related primarily to certain of our state NOL and credit carryforwards. 9543000 324542000 310668000 23417000 81868000 321210000 283653000 119425000 114516000 104858000 1083000 218291000 12060000 229509000 232026000 9543000 103846000 272913000 294891000 81868000 4740000 109800000 24000 114516000 9533000 168945000 166418000 12060000 90809000 257273000 244236000 103846000 1429000 3875000 564000 4740000 RECENTLY ISSUED AND PROPOSED ACCOUNTING PRONOUNCEMENTS<div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by us as of the specified effective date.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;"> (“ASU 2016-13”). This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. We adopted ASU 2016-13 effective January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on our consolidated financial statements.</span></div> RECENTLY ISSUED AND PROPOSED ACCOUNTING PRONOUNCEMENTS<div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by us as of the specified effective date.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;"> (“ASU 2016-13”). This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. We adopted ASU 2016-13 effective January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on our consolidated financial statements.</span></div>RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS<div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;"> (“ASC 842”). This standard requires an entity to recognize on its balance sheet assets and liabilities associated with the rights and obligations created by leases with terms greater than twelve months. We adopted the standard effective January 1, 2019. We chose to apply the provisions of ASC 842 as of the effective date with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected to utilize the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also made accounting policy elections to not separate lease and non-lease components for our real estate lease and to not recognize leases with an initial term of twelve months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis on our condensed consolidated statements of income over the lease term.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In preparation for adoption of the standard, we implemented internal controls to enable the preparation of the related financial information. The adoption of this standard resulted in the recognition of operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and related ROU assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> on our condensed consolidated balance sheets as of January 1, 2019, but did not have an impact on our consolidated statements of operations.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 </span><span style="font-family:inherit;font-size:10pt;">(“ASU 2018-18”). This standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In </span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">addition, ASU 2018-18 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. We adopted ASU 2018-18 during the first quarter of 2019 and applied the provisions of this update retrospectively to all contracts that were not completed as of the date of our initial adoption of ASC 606. The adoption of ASU 2018-18 did not have a material impact on our financial position or results of operations.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. We adopted ASU 2016-09 during the first quarter of 2017 and will now record all excess tax benefits and deficiencies related to share-based compensation in our condensed consolidated statements of operations as discrete events in the interim reporting period in which the benefit or deficiency occurs. Such benefits and deficiencies will not be considered in the calculation of our annual estimated effective tax rate. Any excess tax benefits that were not previously recognized because the related tax deduction had not reduced current taxes payable (i.e. was not realized) are to be recorded using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings as of the beginning of the period in which the new guidance is adopted. We recorded a cumulative-effect adjustment to our accumulated deficit from previously unrecognized excess tax benefits of </span><span style="font-family:inherit;font-size:10pt;"><span>$21.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the first quarter of 2017. Lastly, we will continue to use the current method of estimated forfeitures each period rather than accounting for forfeitures as they occur.</span></div> RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS<div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;"> (“ASC 842”). This standard requires an entity to recognize on its balance sheet assets and liabilities associated with the rights and obligations created by leases with terms greater than twelve months. We adopted the standard effective January 1, 2019. We chose to apply the provisions of ASC 842 as of the effective date with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected to utilize the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also made accounting policy elections to not separate lease and non-lease components for our real estate lease and to not recognize leases with an initial term of twelve months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis on our condensed consolidated statements of income over the lease term.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In preparation for adoption of the standard, we implemented internal controls to enable the preparation of the related financial information. The adoption of this standard resulted in the recognition of operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and related ROU assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> on our condensed consolidated balance sheets as of January 1, 2019, but did not have an impact on our consolidated statements of operations.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 </span><span style="font-family:inherit;font-size:10pt;">(“ASU 2018-18”). This standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In </span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">addition, ASU 2018-18 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. We adopted ASU 2018-18 during the first quarter of 2019 and applied the provisions of this update retrospectively to all contracts that were not completed as of the date of our initial adoption of ASC 606. The adoption of ASU 2018-18 did not have a material impact on our financial position or results of operations.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. We adopted ASU 2016-09 during the first quarter of 2017 and will now record all excess tax benefits and deficiencies related to share-based compensation in our condensed consolidated statements of operations as discrete events in the interim reporting period in which the benefit or deficiency occurs. Such benefits and deficiencies will not be considered in the calculation of our annual estimated effective tax rate. Any excess tax benefits that were not previously recognized because the related tax deduction had not reduced current taxes payable (i.e. was not realized) are to be recorded using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings as of the beginning of the period in which the new guidance is adopted. We recorded a cumulative-effect adjustment to our accumulated deficit from previously unrecognized excess tax benefits of </span><span style="font-family:inherit;font-size:10pt;"><span>$21.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the first quarter of 2017. Lastly, we will continue to use the current method of estimated forfeitures each period rather than accounting for forfeitures as they occur.</span></div> 8500000 7600000 21600000 REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS<div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subsequent to the issuance of our Form 10-K for the year ended December 31, 2019, management identified certain individually immaterial errors aggregating to </span><span style="font-family:inherit;font-size:10pt;"><span>$6.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to governmental rebate accruals associated with Makena sales from 2016 through 2019. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From 2016 through 2019, we understated our GTN adjustments for governmental rebates and the related accrual for a certain state program. We concluded that the errors were not material to any prior annual or interim period; however, we determined that correcting the aggregate error would be material to the three and six months ended June 30, 2020. As a result, we have revised our historical financial statements to properly reflect GTN adjustments and the related accrual in the appropriate periods.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effect of the corrections to our consolidated balance sheet for the years ended December 31, 2019 and 2018 were as follows (in thousands): </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183,382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,008,898</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,303</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,015,201</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129,537</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,098</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134,635</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(542,442</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,098</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(547,540</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effect of the corrections to our consolidated statements of operations for the years ended December 31, 2019, 2018 and 2017 are as follows (in thousands, except per share amounts): </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311,190</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,205</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>309,985</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>327,751</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,205</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>326,546</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss from continuing operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(466,456</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,205</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(467,661</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(466,456</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,205</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(467,661</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13.74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473,852</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,954</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>471,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>474,002</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,954</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>472,048</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,654</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>782</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,436</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss from continuing operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(169,339</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,736</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(172,075</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65,761</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,736</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68,497</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495,645</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>493,843</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495,769</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,802</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>493,967</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(175,254</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(267</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(175,521</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss from continuing operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(205,153</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,535</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(206,688</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(199,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(200,763</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated statements of other comprehensive loss for the years ended December 31, 2019, 2018 and 2017 have been revised to include the changes to “net loss” summarized above.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated statements of stockholders’ equity for the years ended December 31, 2019, 2018 and 2017 have been revised to include the changes to “net loss” summarized above as well as an increase of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the beginning “accumulated deficit” as of January 1, 2017, representing the accumulated error through that date.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The impact on our consolidated statements of cash flows for the years ended December 31, 2019, 2018 and 2017, was limited to the offsetting corrections between “net loss” and changes in “accounts payable and accrued expenses” and “deferred income taxes” presented within “net cash used in operating activities” in each year, as summarized in the above tables.</span></div> -6300000 177079000 6303000 183382000 -1008898000 -6303000 -1015201000 129537000 5098000 134635000 -542442000 -5098000 -547540000 311190000 -1205000 309985000 327751000 -1205000 326546000 -47000 0 -47000 -466456000 -1205000 -467661000 -466456000 -1205000 -467661000 -13.71 -0.03 -13.74 473852000 -1954000 471898000 474002000 -1954000 472048000 39654000 782000 40436000 -169339000 -2736000 -172075000 -65761000 -2736000 -68497000 -1.91 -0.08 -1.99 495645000 -1802000 493843000 495769000 -1802000 493967000 -175254000 -267000 -175521000 -205153000 -1535000 -206688000 -199228000 -1535000 -200763000 -5.71 -0.04 -5.75 -800000 SUBSEQUENT EVENTS <span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(unaudited)</span><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the amendment of our financial statements, we have evaluated subsequent events through the date the financial statements were available to be reissued.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">May 2020 Restructuring</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2020, we completed a restructuring to reduce the size of our organization in conjunction with the planned divestiture of Intrarosa and Vyleesi and expected declines in our revenue due to the COVID-19 pandemic. Approximately </span><span style="font-family:inherit;font-size:10pt;"><span>110</span></span><span style="font-family:inherit;font-size:10pt;"> employees were displaced through this workforce reduction. We recorded a one-time restructuring charge of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> primarily related to severance and related benefits on our condensed consolidated statement of operations during the second quarter of 2020 and expect the restructuring charges incurred to date under this program to be substantially paid in cash by the end of the second quarter of 2021.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sale of Intrarosa</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 21, 2020, we sold our rights to commercialize and have manufactured Intrarosa in the United States to Millicent Pharma Limited (“Millicent”) pursuant to an Asset Purchase Agreement between the Company and Millicent, dated May 21, 2020. Under the terms of the Asset Purchase Agreement, we received an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$20.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash, subject to customary purchase price adjustments, including in connection with the transfer of certain inventory. We are eligible to receive up to </span><span style="font-family:inherit;font-size:10pt;"><span>$105.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in aggregate milestone payments upon the achievement of certain sales milestones, namely: (a) </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> the first time net sales during any consecutive </span><span style="font-family:inherit;font-size:10pt;"><span>twelve</span></span><span style="font-family:inherit;font-size:10pt;"> month period exceeds </span><span style="font-family:inherit;font-size:10pt;"><span>$65.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, (b) </span><span style="font-family:inherit;font-size:10pt;"><span>$35.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> the first time net sales during any consecutive </span><span style="font-family:inherit;font-size:10pt;"><span>twelve</span></span><span style="font-family:inherit;font-size:10pt;"> month period exceeds </span><span style="font-family:inherit;font-size:10pt;"><span>$115.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and (c) </span><span style="font-family:inherit;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> the first time net sales during any consecutive </span><span style="font-family:inherit;font-size:10pt;"><span>twelve</span></span><span style="font-family:inherit;font-size:10pt;"> month period exceeds </span><span style="font-family:inherit;font-size:10pt;"><span>$175.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. We recognized a Gain on Sale of Assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> on our condensed consolidated statements of operations for the three and six months ended June 30, 2020 related to this transaction. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cessation of the AMAG-423 Study</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2020, we decided to stop the AMAG-423 Phase 2b/3a study. This decision was based primarily on the independent Data Safety Monitoring Board’s (the “DSMB”) unanimous recommendation to stop the study following an interim analysis of the data collected to date in the study, which analysis we asked the DSMB to conduct due to extended and ongoing delays in enrollment of the trial (based primarily on the effect of COVID-19 on clinical trial research and the nature of the patient population). There were no safety concerns raised during this study and safety was not a contributing factor to our decision to terminate the study. We are currently focused on ensuring an appropriate closeout of the study in partnership with investigators and other relevant stakeholders. In connection with the cessation of the AMAG-423 Phase 2b/3a study, on August 6, 2020, we terminated our supply agreement (including termination of significant minimum purchase obligations) with our third party supplier in exchange for a one-time payment by us of </span><span style="font-family:inherit;font-size:10pt;"><span>$12.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and our grant to our third party supplier of a </span><span style="font-family:inherit;font-size:10pt;"><span>9</span></span><span style="font-family:inherit;font-size:10pt;">-month option (subject to extension under certain situations) to acquire the AMAG-423 program rights and assume our related obligations, including our obligations under the Velo Option Agreement.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">License to Develop and Commercialize ciraparantag in Europe, Australia and New Zealand</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2020, we entered into a License and Commercialization Agreement with Norgine B.V. (“Norgine”, and such agreement, the “Norgine Agreement”), pursuant to which we granted Norgine an exclusive license to develop and commercialize ciraparantag in certain countries in Europe, Australia and New Zealand. We received a </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment upon signing. In addition, pursuant to the terms and conditions of the Norgine Agreement (a) Norgine will pay us one-</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">third of the actual and reasonable out-of-pocket costs of the Phase 3 program, pursuant to a mutually agreed upon budget, (b) we are eligible to receive up to </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of certain regulatory milestones (of which we will pay </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the former equity holders of Perosphere pursuant to the terms of the Perosphere Agreement), (c) we are eligible to receive up to </span><span style="font-family:inherit;font-size:10pt;"><span>$190.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> contingent upon meeting certain sales milestones, and (d) Norgine will pay us tiered double-digit royalties on net sales in the licensed territory. We will be responsible for manufacturing and supplying Norgine with its requirements of clinical and commercial product pursuant to supply agreement(s) to be entered into by the parties.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Settlement</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 14, 2020, we entered into a Confidential Settlement Agreement and Release with a third-party manufacturer to resolve outstanding disputes. Pursuant to this agreement, we were paid a sum of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, and the parties exchanged mutual releases to resolve all disputes between them.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Termination of the Palatin Agreement</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2020, we entered into a termination agreement with Palatin detailing the terms and conditions for the termination of our rights and obligations to develop and commercialize Vyleesi under the Palatin License Agreement and for the transfer of full ownership of Vyleesi to Palatin (the “Termination Agreement”). In accordance with the terms of the Termination Agreement, we transferred and assigned to Palatin the regulatory approval for Vyleesi, inventory, certain third party contracts, intellectual property rights and regulatory files and commercial materials of AMAG related to Vyleesi in the AMAG Territory. In consideration for the early termination of the License Agreement, the assumption of certain liabilities by Palatin (including significant minimum purchase obligations), and in lieu of any future milestone payments, royalties and other payments by AMAG to Palatin contemplated by the Palatin License Agreement, we paid Palatin </span><span style="font-family:inherit;font-size:10pt;"><span>$12.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> following the termination, and we will pay an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> on March 31, 2021. In addition, we agreed to provide certain transitional services to Palatin for a period of time following the closing pursuant to a transition services agreement.</span></div> 110 8200000 20900000 105000000.0 25000000.0 12 65000000.0 35000000.0 12 115000000.0 45000000.0 12 175000000.0 14400000 12500000 P9M 30000000.0 70000000.0 40000000.0 190000000.0 17400000 12000000.0 4300000 XML 14 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Mar. 02, 2020
Jun. 28, 2019
Cover [Abstract]      
Document Type 10-K/A    
Document Annual Report true    
Document Period End Date Dec. 31, 2019    
Document Transition Report false    
Entity File Number 001-10865    
Entity Registrant Name AMAG PHARMACEUTICALS, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 04-2742593    
Entity Address, Address Line One 1100 Winter Street,    
Entity Address, City or Town Waltham,    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02451    
City Area Code 617    
Local Phone Number 498-3300    
Title of 12(b) Security Common Stock, par value $0.01 per sharePreferred Share Purchase Rights    
Trading Symbol AMAG    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 335.0
Entity Common Stock, Shares Outstanding (in shares)   34,265,738  
Entity Central Index Key 0000792977    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2019    
Document Fiscal Period Focus FY    
Amendment Flag true    
Amendment Description AMAG Pharmaceuticals, Inc (the “Company” or “we”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to amend and restate certain items in its Annual Report on Form 10-K for the year ended December 31, 2019, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 6, 2020 (the “Original 10-K”). The Company identified immaterial errors in its previously reported revenue over the impacted annual periods of 2016 through 2019 and, in connection therewith, the Company’s management identified a material weakness in our internal control over financial reporting (“ICFR”) related to ensuring the timely recognition of our gross-to-net adjustments for certain governmental rebates and the related accruals. Accordingly, this Amendment is being filed to amend Item 6, Selected Financial Data, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, Item 8, Financial Statements and Supplementary Data, and Item 9A, Controls and Procedures, of Part II of the Original 10-K and restate the financial statements and related notes to reflect the immaterial errors identified, Management’s Annual Report on Internal Control Over Financial Reporting, management’s assessment of the effectiveness of our disclosure controls and procedures and PwC’s Report of Independent Registered Public Accounting Firm on the Company’s internal control over financial reporting.    

XML 15 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 113,009 $ 253,256
Marketable securities 58,742 140,915
Accounts receivable, net 94,163 75,347
Inventories 31,553 26,691
Prepaid and other current assets 19,100 18,961
Note receivable 0 10,000
Total current assets 316,567 525,170
Property and equipment, net 4,116 7,521
Goodwill 422,513 422,513
Intangible assets, net 23,620 217,033
Operating lease right-of-use asset 23,286  
Deferred tax assets 630 1,260
Restricted cash 495 495
Other long-term assets 0 1,467
Total assets 791,227 1,175,459
Current liabilities:    
Accounts payable 27,021 14,487
Accrued expenses 183,382 134,635
Current portion of convertible notes, net 0 21,276
Current portion of operating lease liability 4,077  
Current portion of acquisition-related contingent consideration 17 144
Total current liabilities 214,497 170,542
Long-term liabilities:    
Convertible notes, net 277,034 261,933
Long-term operating lease liability 19,791  
Long-term acquisition-related contingent consideration 0 215
Other long-term liabilities 89 1,212
Total liabilities 511,411 433,902
Commitments and Contingencies (Note P)
Stockholders’ equity:    
Preferred stock, par value $0.01 per share, 2,000,000 shares authorized; none issued 0 0
Common stock, par value $0.01 per share, 117,500,000 shares authorized; 33,999,081 and 34,606,760 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively 339 346
Additional paid-in capital 1,297,917 1,292,736
Accumulated other comprehensive loss (3,239) (3,985)
Accumulated deficit (1,015,201) (547,540)
Total stockholders’ equity 279,816 741,557
Total liabilities and stockholders’ equity $ 791,227 $ 1,175,459
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 2,000,000 2,000,000
Preferred stock, shares issued 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 117,500,000 117,500,000
Common stock, shares issued 33,999,081 34,606,760
Common stock, shares outstanding 33,999,081 34,606,760
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenues:      
Revenues $ 326,546 $ 472,048 $ 493,967
Costs and expenses:      
Cost of product sales $ 107,193 $ 215,892 $ 161,349
Cost, Product and Service [Extensible List] us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember
Research and development expenses $ 64,853 $ 44,846 $ 75,017
Acquired in-process research and development 74,856 32,500 65,845
Selling, general and administrative expenses 286,600 227,810 178,151
Impairment of assets 232,336 0 319,246
Restructuring expenses 7,420 0 0
Total costs and expenses 773,258 521,048 799,608
Operating loss (446,712) (49,000) (305,641)
Other income (expense):      
Interest expense (25,709) (51,971) (68,382)
Loss on debt extinguishment 0 (35,922) (10,926)
Interest and dividend income 4,285 5,328 2,810
Other income (expense) 428 (74) (70)
Total other expense, net (20,996) (82,639) (76,568)
Loss from continuing operations before income taxes (467,708) (131,639) (382,209)
Income tax (benefit) expense (47) 40,436 (175,521)
Net loss from continuing operations (467,661) (172,075) (206,688)
Discontinued operations:      
Income from discontinued operations 0 18,873 10,313
Gain on sale of CBR business 0 87,076 0
Income tax expense 0 2,371 4,388
Net income from discontinued operations 0 103,578 5,925
Net loss $ (467,661) $ (68,497) $ (200,763)
Basic and diluted earnings per share:      
Loss from continuing operations (in dollars per share) $ (13.74) $ (5.00) $ (5.92)
Income from discontinued operations (in dollars per share) 0 3.01 0.17
Total (in dollars per share) $ (13.74) $ (1.99) $ (5.75)
Weighted average shares outstanding used to compute earnings per share (basic and diluted) (in shares) 34,030 34,394 34,907
Product sales, net      
Revenues:      
Revenues $ 309,985 $ 471,898 $ 493,843
Collaboration revenue      
Revenues:      
Revenues 16,400 0 0
Other revenues      
Revenues:      
Revenues $ 161 $ 150 $ 124
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Statement of Comprehensive Income [Abstract]      
Net loss $ (467,661) $ (68,497) $ (200,763)
Unrealized (losses) gains on marketable securities:      
Holding gains (losses) arising during period, net of tax 746 (77) (70)
Total comprehensive loss $ (466,915) $ (68,574) $ (200,833)
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2016   34,336,147          
Beginning balance at Dec. 31, 2016 $ 933,562 $ 343 $ 1,238,031 $ (3,838) $ (300,974) $ 21,558 $ 21,558
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Settlement of warrants 323   323        
Equity component of the 2022 Convertible Notes, net of issuance costs and taxes 43,236   43,236        
Equity component of debt repurchase (27,988)   (27,988)        
Shares issued in connection with Endoceutics License Agreement (in shares)   600,000          
Shares issued in connection with Endoceutics License Agreement 13,500 $ 6 13,494        
Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program (in shares)   (1,366,266)          
Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program (19,467) $ (14) (19,453)        
Issuance of common stock under employee stock purchase plan (in shares)   120,580          
Issuance of common stock under employee stock purchase plan 1,594 $ 1 1,593        
Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings (in shares)   392,651          
Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings (1,267) $ 5 (1,272)        
Non-cash equity based compensation 23,664   23,664        
Unrealized gains (losses) on securities, net of tax (70)     (70)      
Net loss (200,763)       (200,763)    
Ending balance (in shares) at Dec. 31, 2017   34,083,112          
Ending balance at Dec. 31, 2017 $ 787,882 $ 341 1,271,628 (3,908) (480,179) $ 1,136 $ 1,136
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201409Member            
Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program (in shares) 0            
Issuance of common stock under employee stock purchase plan (in shares)   59,872          
Issuance of common stock under employee stock purchase plan $ 918 $ 1 917        
Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings (in shares)   463,776          
Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings 279 $ 4 275        
Non-cash equity based compensation 19,916   19,916        
Unrealized gains (losses) on securities, net of tax (77)     (77)      
Net loss $ (68,497)       (68,497)    
Ending balance (in shares) at Dec. 31, 2018 34,606,760 34,606,760          
Ending balance at Dec. 31, 2018 $ 741,557 $ 346 1,292,736 (3,985) (547,540)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201409            
Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program (in shares) (1,074,800)            
Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program $ (13,700)            
Issuance of common stock under employee stock purchase plan (in shares)   185,937          
Issuance of common stock under employee stock purchase plan 1,506 $ 1 1,505        
Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings (in shares)   281,184          
Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings (1,800) $ 3 (1,803)        
Repurchase of common stock pursuant to the share repurchase program (in shares)   (1,074,800)          
Repurchase of common stock pursuant to the share repurchase program (13,730) $ (11) (13,719)        
Non-cash equity based compensation 19,198   19,198        
Unrealized gains (losses) on securities, net of tax 746     746      
Net loss $ (467,661)       (467,661)    
Ending balance (in shares) at Dec. 31, 2019 33,999,081 33,999,081          
Ending balance at Dec. 31, 2019 $ 279,816 $ 339 $ 1,297,917 $ (3,239) $ (1,015,201)    
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED STATEMENTS OF CASH FLOWS
$ in Thousands
 12 Months Ended
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Cash flows from operating activities:      
Net loss $ (467,661) $ (68,497) $ (200,763)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:      
Depreciation and amortization 27,324 172,223 155,538
Impairment of long-lived assets 232,336 0 319,246
Provision for bad debt expense 0 678 3,852
Amortization of premium/discount on purchased securities (95) 87 302
Write-down of inventory 19,767 5,176 0
(Gain) loss on disposal of fixed assets 0 (99) 265
Non-cash equity-based compensation expense 19,198 19,916 23,664
Non-cash IPR&D expense 18,029 0 945
Loss on debt extinguishment 0 35,922 10,926
Amortization of debt discount and debt issuance costs 15,242 15,658 14,395
(Gain) loss on sale of marketable securities, net (265) (1) 70
Change in fair value of contingent consideration (270) (49,607) (47,686)
Deferred income taxes 404 41,948 (178,688)
Non-cash lease expense 2,725 0 0
Gain on sale of the CBR business 0 (87,076) 0
Transaction costs 0 (14,111) 0
Changes in operating assets and liabilities:      
Accounts receivable, net (18,816) 16,995 (14,978)
Inventories (19,253) (454) (2,331)
Prepaid and other current assets (113) (6,097) (2,222)
Accounts payable and accrued expenses 53,952 (30,614) 18,636
Deferred revenues (6,400) 8,658 17,080
Payment of contingent consideration in excess of acquisition date fair value 0 0 (10,432)
Other assets and liabilities (1,800) 95 (1,223)
Net cash (used in) provided by operating activities (125,696) 60,800 106,596
Cash flows from investing activities:      
Proceeds from sales or maturities of marketable securities 98,321 85,342 294,957
Purchases of marketable securities (14,815) (89,956) (127,249)
Proceeds from the sale of the CBR business 0 519,303 0
Note receivable 0 (10,000) 0
Capital expenditures (2,544) (2,534) (8,988)
Net cash provided by investing activities 20,962 502,155 102,920
Cash flows from financing activities:      
Long-term debt principal payments 0 (475,000) (353,125)
Proceeds from 2022 Convertible Notes 0 0 320,000
Payments to repurchase 2019 Convertible Notes (21,417) 0 (191,730)
Payment of premium on debt extinguishment 0 (28,054) (625)
Proceeds to settle warrants 0 0 323
Payment of convertible debt issuance costs 0 0 (9,553)
Payment of contingent consideration (72) (119) (39,793)
Payments for repurchases of common stock (13,730) 0 (19,466)
Proceeds from the issuance of common stock under the ESPP 1,506 0 0
Proceeds from the exercise of common stock options 30 3,881 3,021
Payments of employee tax withholding related to equity-based compensation (1,830) (2,682) (2,696)
Net cash used in financing activities (35,513) (501,974) (293,644)
Net (decrease) increase in cash, cash equivalents and restricted cash (140,247) 60,981 (84,128)
Cash, cash equivalents and restricted cash at beginning of the year 253,751 192,770 276,898
Cash, cash equivalents and restricted cash at end of the year 113,504 253,751 192,770
Supplemental data of cash flow information:      
Cash (refunded) paid for taxes (202) 5,345 5,296
Cash paid for interest 10,667 48,757 56,959
Non-cash investing and financing activities:      
Right-of-use assets obtained in exchange for lease obligations 18,455    
Settlement of note receivable in connection with Perosphere acquisition 10,000 0 0
Fair value of common stock issued in connection with the acquisition of the Intrarosa intangible asset     13,500
Vyleesi Products      
Cash flows from investing activities:      
Acquisition of intangible asset (60,000) 0 0
Intrarosa      
Cash flows from investing activities:      
Acquisition of intangible asset 0 0 (55,800)
Endoceutics, Inc.      
Non-cash investing and financing activities:      
Fair value of common stock issued in connection with the acquisition of the Intrarosa intangible asset 0 0 12,555
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset $ 0 $ 0 $ 9,300
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.20.2
DESCRIPTION OF BUSINESS
 12 Months Ended
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
DESCRIPTION OF BUSINESS DESCRIPTION OF BUSINESS
AMAG Pharmaceuticals, Inc., a Delaware corporation, was founded in 1981. We are a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs by leveraging our development and commercial expertise to invest in and grow our pharmaceutical products across a range of therapeutic areas. Our currently marketed products support the health of patients in the areas of hematology and maternal and women’s health, including Feraheme® (ferumoxytol injection) for intravenous use, Makena® (hydroxyprogesterone caproate injection) auto-injector, Intrarosa® (prasterone) vaginal inserts and Vyleesi®(bremelanotide injection). In addition to our marketed products, our portfolio includes two product candidates, AMAG-423 (digoxin immune fab (ovine)), which is being studied for the treatment of severe preeclampsia, and ciraparantag, which is being studied as an anticoagulant reversal agent.

In March 2019, we announced topline results from the Progestin’s Role in Optimizing Neonatal Gestation clinical trial (“PROLONG” or “Trial 003”), a randomized, double-blinded, placebo-controlled clinical trial evaluating Makena in patients with a history of a prior spontaneous singleton preterm delivery. The PROLONG trial was conducted under the U.S. Food and Drug Administration’s (the “FDA”) “Subpart H” accelerated approval process. The approval of Makena was based primarily on the Meis trial (“Trial 002”), which was conducted by the Maternal-Fetal Medicine Units Network, sponsored by the National Institute of Child Health and Human Development. In contrast to the Meis trial, the PROLONG trial did not demonstrate a statistically significant difference between the treatment and placebo arms for the co-primary endpoints. On October 29, 2019, the Advisory Committee met to discuss the results of the PROLONG trial to inform the FDA’s regulatory decision for Makena. Following various presentations by experts and discussions at the meeting, the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee (the “Advisory Committee”) voted as follows: (a) in response to the question “Do the findings from Trial 003 verify the clinical benefits of Makena on neonatal outcomes?”, 16 members voted “No” and no members voted “Yes”; (b) in response to the question “Based on the findings from Trial 002 and Trial 003, is there substantial evidence of effectiveness of Makena in reducing the risk of recurrent preterm birth?”, 13 members voted “No” and three members voted “Yes”; and (c) in response to the question, “Should the FDA (A) pursue withdrawal of approval for Makena, (B) leave Makena on the market under accelerated approval and require a new confirmatory trial, or (C) leave Makena on the market without requiring a new confirmatory trial?”, nine members voted for (A), seven members voted for (B) and no members voted for (C). The FDA is not required to follow the recommendations of its Advisory Committees, but will take them into consideration in deciding what regulatory steps to take with respect to Makena. We are unable to predict the outcome or timing of any FDA action with respect to Makena.

In December 2019 we completed a review of our product portfolio and strategy. This strategic review resulted in our intention to divest Intrarosa® (prasterone) and Vyleesi® (bremelanotide), as announced in January 2020. We determined that these anticipated actions did not result in the related assets meeting the criteria to be recorded as held of sale at December 31, 2019.
We are subject to risks common to companies in the pharmaceutical industry including, but not limited to (as such risks pertain to our business) the impact of any action by the FDA with respect to Makena, including the potential of the removal of Makena’s approval, our ability to successfully divest Intrarosa and Vyleesi, our ability to successfully commercialize our products, intense competition, including from generic products; maintaining and defending the proprietary nature of our technology, including in the event that Sandoz launches a generic version of Feraheme in accordance with the 2018 settlement agreement; our dependence upon third-party manufacturers and our potential inability to obtain raw or other materials and impacts of supply shortages; our reliance on and the extent of reimbursement from third parties for the use of our products, including the impact of generic competitors, Makena’s high Medicaid reimbursement concentration; our ability to expand our product portfolio through business development transactions; the approval of our product candidates and our ability to commercialize such products, if approved; potential litigation, including securities and product liability suits; our ability to work effectively and collaboratively with our licensors and partners; our reliance on other third parties in our business, including to conduct our clinical trials and undertake our product and distribution; our ability to maintain, attract and retain key employees; our potential failure to comply with federal and state healthcare fraud and abuse laws, marketing disclosure laws, or other federal and state laws and regulations and potential civil or criminal penalties as a result thereof; uncertainties regarding reporting and payment obligations under government pricing programs; post-approval commitments for Feraheme; our ability to comply with data protection laws and regulations; the impact of disruptions to our information technology systems; our level of and ability to repay our indebtedness; our access to sufficient capital; the availability of net operating loss carryforwards and other tax assets; potential differences between actual future results and the estimates or assumptions used by us in preparation of our consolidated financial statements, including goodwill and intangible assets; the volatility of our stock price; the potential
fluctuation of our operating results; and provisions in our charter, by-laws and certain contracts that discourage an acquisition of our company.

Throughout this Annual Report on Form 10-K, AMAG Pharmaceuticals, Inc. and our consolidated subsidiaries are collectively referred to as “the Company,” “AMAG,” “we,” “us,” or “our.”
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“GAAP”) and include the accounts of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

As of June 30, 2018, our CBR business met the criteria to be classified as a discontinued operation. All historical operating results for CBR are reflected within discontinued operations in the consolidated statements of operations for the years ended December 31, 2018 and 2017. For additional information, see Note C, “Discontinued Operations.”

Use of Estimates and Assumptions

The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent liabilities. The most significant estimates and assumptions are used to determine amounts and values of, but are not limited to: revenue recognition related to product sales revenue; product sales allowances and accruals; allowance for doubtful accounts; marketable securities; inventory; acquisition date fair value and subsequent fair value estimates used to assess impairment of long-lived assets, including goodwill and other intangible assets; debt obligations; certain accrued liabilities, including clinical trial accruals; equity-based compensation expense, and income taxes, inclusive of valuation allowances. Actual results could differ materially from those estimates.

Revenue Recognition

Product revenues
On January 1, 2018, we adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”) applying the modified retrospective transition method to all contracts that were not completed as of January 1, 2018 as an adjustment of $1.1 million to the opening balance of stockholders’ equity at the beginning of 2018. The adjustment recorded was for incremental contract acquisition costs related to the CBR business. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for prior periods. There was no impact to our product revenue as a result of adoption.

Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:

a.Identify the contract(s) with a customer;
b.Identify the performance obligations in the contract;
c.Determine the transaction price;
d.Allocate the transaction price to the performance obligations in the contract; and
e.Recognize revenue when (or as) the performance obligations are satisfied.

We only apply the five step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, if the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Our major sources of revenue during the reporting periods were product revenues from Makena, Feraheme and Intrarosa. The adoption of ASC 606 in 2018 did not have an impact on the pattern or timing of recognition of our product revenue, as the majority of our product revenue continues to be recognized when the customer takes control of our product.

We receive payments from customers based upon contractual billing schedules; accounts receivable are recorded when the right to consideration becomes unconditional.

Performance Obligations

At contract inception, we assess the goods promised in our contracts with customers and identify a performance obligation for each promise to transfer to the customer a good (or bundle of goods) that is distinct. To identify the performance obligations, we consider all of the goods promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. We determined that the following distinct goods represent separate performance obligations:

•Supply of Makena product
•Supply of Feraheme product
•Supply of Intrarosa product
•Supply of Vyleesi product

We principally sell our products to wholesalers, specialty distributors, specialty pharmacies and other customers (collectively, “Customers”), who purchase products directly from us. Our Customers subsequently resell the products to healthcare providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payers that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products.

For the majority of our Customers, we transfer control at the point in time when the goods are delivered. In instances when we perform shipping and handling activities, these are considered fulfillment activities, and accordingly, the costs are accrued when the related revenue is recognized. Taxes collected from Customers and remitted to governmental authorities are excluded from revenues.

Variable Consideration
Under ASC 606, we are required to make estimates of the net sales price, including estimates of variable consideration (such as rebates, chargebacks, discounts, copay assistance and other deductions), and recognize the estimated amount as revenue, when we transfer control of the product to our customers. Variable consideration must be determined using either an “expected value” or a “most likely amount” method.

We record product revenues net of certain allowances and accruals in our consolidated statements of operations. Product sales allowances and accruals are primarily comprised of both direct and indirect fees, discounts and rebates and provisions for estimated product returns. Direct fees, discounts and rebates are contractual fees and price adjustments payable to Customers that purchase products directly from us. Indirect fees, discounts and rebates are contractual price adjustments payable to healthcare providers and organizations, such as certain physicians, clinics, hospitals, group purchasing organizations (“GPOs”), and dialysis organizations that typically do not purchase products directly from us but rather from wholesalers and specialty distributors. Consideration payable to a Customer, or other parties that purchase goods from a Customer, are considered to be a reduction of the transaction price, and therefore, of revenue.

Product sales allowances and accruals are based on definitive contractual agreements or legal requirements (such as laws and regulations to provide mandatory discounts for sales to government entities) related to the purchase and/or utilization of the product by these entities and are recorded in the same period that the related revenue is recognized. We use the expected value method for estimating variable consideration. We estimate product sales allowances and accruals using either historical, actual and/or other data, including estimated patient usage, applicable contractual rebate rates, contract performance by the benefit providers, other current contractual and statutory requirements, historical market data based upon experience of our products and other products similar to them, specific known market events and trends such as competitive pricing and new product introductions, current and forecasted Customer buying patterns and inventory levels, and the shelf life of our products. As part of this evaluation, we also review changes to federal and other legislation, changes to rebate contracts, changes in the level of discounts, and changes in product sales trends. Although allowances and accruals are recorded at the time of product sale, rebates are typically paid out in arrears, one to three months after the sale. 

The estimate of variable consideration, which is included in the transaction price, may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved in a future period. Estimating variable consideration and the related constraint requires the use of significant management judgment and actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. No amounts were constrained as of December 31, 2019.

Discounts

We typically offer a 2% prompt payment discount to certain customers as an incentive to remit payment in accordance with the stated terms of the invoice, generally between 30 to 60 days. Because we anticipate that those customers who are offered this discount will take advantage of the discount, 100% of the prompt payment discount at the time of sale is accrued for eligible customers, based on the gross amount of each invoice. We adjust the accrual quarterly to reflect actual experience.

Chargebacks

Chargeback reserves represent the estimated obligations resulting from the difference between the prices at which we sell our products to wholesalers and the sales price ultimately paid to wholesalers under fixed price contracts by third-party payers, including governmental agencies. The chargeback estimates are determined based on actual product sales data and forecasted customer buying patterns. Actual chargeback amounts are determined at the time of resale to the qualified healthcare provider, and we generally issue credits for such amounts within several weeks of receiving notification from the wholesaler. Estimated chargeback amounts are recorded at the time of sale and adjusted quarterly to reflect actual experience.

Distributor/Wholesaler and Group Purchasing Organization Fees

Fees under arrangements with distributors and wholesalers are usually based upon units of product purchased during the prior month or quarter and are usually paid by us within several weeks of the receipt of an invoice from the wholesaler or distributor. Fees under arrangements with GPOs are usually based upon member purchases during the prior quarter and are generally billed by the GPO within 30 days after period end. In accordance with ASC 606, since the consideration given to the Customer is not for a distinct good or service, the consideration is a reduction of the transaction price of the vendor’s products or services. We have included these fees in contractual adjustments in the table above. We generally pay such amounts within several weeks of the receipt of an invoice from the distributor, wholesaler or GPO. Accordingly, we accrue the estimated fee due at the time of sale, based on the contracted price invoiced to the Customer. We adjust the accrual quarterly to reflect actual experience.

Product Returns

Consistent with industry practice, we generally offer wholesalers, specialty distributors and other customers a limited right to return our products based on the product’s expiration date. The current shelf-lives or time between manufacture and expiration for products in our portfolio range from three to five years. Product returns are estimated based on the historical return patterns and known or expected changes in the marketplace. We track actual returns by individual production lots. Returns on lots eligible for credits under our returned goods policy are monitored and compared with historical return trends and rates. We expect that wholesalers and healthcare providers will not stock significant inventory due to the cost of the product, the expense to store our products, and/or that our products are readily available for distribution. We record an estimate of returns at the time of sale. If necessary, our estimated rate of returns may be adjusted for actual return experience as it becomes available and for known or expected changes in the marketplace. There were no material adjustments to our reserve for product returns during the years ended December 31, 2019, 2018 or 2017. To date, our product returns have been relatively limited; however, returns experience may change over time. We may be required to make future adjustments to our product returns estimate, which would result in a corresponding change to our net product sales in the period of adjustment and could be significant.

Sales Rebates

We contract with various private payer organizations, primarily pharmacy benefit managers, for the payment of rebates with respect to utilization of our products. We determine our estimates for rebates, if applicable, based on actual product sales data and our historical product claims experience. Rebate amounts generally are invoiced quarterly and are paid in arrears, and we expect to pay such amounts within several weeks of notification by the provider. We regularly assess our reserve balance and the rate at which we accrue for claims against product sales. If we determine in future periods that our actual rebate
experience is not indicative of expected claims, if actual claims experience changes, or if other factors affect estimated claims rates, we may be required to adjust our current accumulated reserve estimate, which would affect net product sales in the period of the adjustment and could be significant.

Governmental Rebates

Governmental rebates relate to our reimbursement arrangements with state Medicaid programs. We determine our estimates for Medicaid rebates, if applicable, based on actual product sales data and our historical product claims experience. In estimating these reserves, we provide for a Medicaid rebate associated with both those expected instances where Medicaid will act as the primary insurer as well as in those instances where we expect Medicaid will act as the secondary insurer. Rebate amounts generally are invoiced quarterly and are paid in arrears, and we expect to pay such amounts within several weeks of notification by the Medicaid or provider entity. We regularly assess our Medicaid reserve balance and the rate at which we accrue for claims against product sales. If we determine in future periods that our actual rebate experience is not indicative of expected claims, if actual claims experience changes, or if other factors affect estimated claims rates, we may be required to adjust our current Medicaid accumulated reserve estimate, which would affect net product sales in the period of the adjustment and could be significant.

Other Discounts
Other discounts which we offer include voluntary patient assistance programs, such as copay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug copayments required by payers. The calculation of the accrual for copay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with product that has been recognized as revenue.

Collaboration Revenues

When we enter into collaboration agreements, we assess whether the agreements fall within the scope of ASC Topic 808, Collaborative Arrangements (“ASC 808”) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606. However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the related underlying expense.

Cash and Cash Equivalents

Cash and cash equivalents consist principally of cash held in commercial bank accounts, money market funds and U.S. treasury securities having an original maturity of less than three months at the date of acquisition. We consider all highly liquid marketable securities with a maturity of three months or less as of the acquisition date to be cash equivalents. At December 31, 2019 and 2018, substantially all of our cash and cash equivalents were held in either commercial bank accounts or money market funds.

Concentrations and Significant Customer Information

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and cash equivalents, marketable securities, and accounts receivable. We currently hold our excess cash primarily in institutional money market funds, corporate debt securities, U.S. treasury and government agency securities and certificates of deposit. As of December 31, 2019, we did not have a material concentration in any single investment.

Our operations are located entirely within the U.S. We focus primarily on developing, manufacturing, and commercializing our products and product candidates. The following table sets forth customers who represented 10% or more of our total revenues for 2019, 2018 and 2017:
 
Years Ended December 31,
 
2019
 
2018
 
2017
McKesson Corporation
36%
 
26%
 
24%
AmerisourceBergen Drug Corporation
28%
 
27%
 
26%
Cardinal Health
13%
 
< 10%
 
< 10%

 
Our net accounts receivable primarily represent amounts due for products sold directly to wholesalers, distributors and specialty pharmacies. Accounts receivable for our products are recorded net of reserves for estimated chargeback obligations, prompt payment discounts and any allowance for doubtful accounts.
As part of our credit management policy, we perform ongoing credit evaluations of our customers, and we generally do not require collateral. If the financial condition of any of our significant product sales customers was to deteriorate and result in an impairment of its ability to make payments owed to us, an allowance for doubtful accounts may be required which could have a material effect on earnings in the period of any such adjustment. We did not experience any significant bad debts and have not established an allowance for doubtful accounts as of December 31, 2019 and 2018.
At December 31, 2019 and 2018, three customers accounted for 10% or more of our accounts receivable balance, representing approximately 85% and 73% in the aggregate of our total accounts receivable, respectively.
 
We are currently dependent on a single supplier for certain of our manufacturing processes, including Feraheme drug substance (produced in two separate facilities) and a single supplier for our Makena auto-injector product. We have been and may continue to be exposed to a significant loss of revenue from the sale of our products in the event that our suppliers and/or manufacturers are not able to fulfill demand for any reason.
Fair Value Measurements

We apply the provisions of ASC Topic 820, Fair Value Measurements (“ASC 820”) for our financial assets and liabilities that are re-measured and reported at fair value each reporting period and our nonfinancial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis, including property and equipment and identifiable intangible assets. Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, we consider the principal or most advantageous market in which it would transact and consider assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. Financial assets and liabilities are categorized within the valuation hierarchy based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•
Level 1- Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•
Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•
Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Marketable Securities

We account for and classify our marketable securities as either “available-for-sale,” “held-to-maturity,” or “trading debt securities,” in accordance with the accounting guidance related to the accounting and classification of certain investments in marketable securities. The determination of the appropriate classification by us is based primarily on management’s ability and intent to sell the debt security at the time of purchase. As of December 31, 2019 and 2018, all of our marketable securities were classified as available-for-sale.

Available-for-sale securities are those securities which we view as available for use in current operations, if needed. We generally classify our available-for-sale securities as short-term investments, even though the stated maturity date may be one year or more beyond the current balance sheet date. Available-for-sale marketable securities are stated at fair value with their
unrealized gains and losses included in accumulated other comprehensive income (loss) within the consolidated statements of stockholders’ equity, until such gains and losses are realized in other income (expense) within the consolidated statements of operations or until an unrealized loss is considered other-than-temporary.

We recognize other-than-temporary impairments of our marketable securities when there is a decline in fair value below the amortized cost basis and if (a) we have the intent to sell the security or (b) it is more likely than not that we will be required to sell the security prior to recovery of its amortized cost basis. If either of these conditions is met, we recognize the difference between the amortized cost basis of the security and its fair value at the impairment measurement date in our consolidated statements of operations. If neither of these conditions is met, we must perform additional analysis to evaluate whether the unrealized loss is associated with the creditworthiness of the issuer of the security rather than other factors, such as interest rates or market factors. If we determine from this analysis that we do not expect to receive cash flows sufficient to recover the entire amortized cost of the security, a credit loss exists, the impairment is considered other-than-temporary and is recognized in our consolidated statements of operations.

Inventory

Inventory is stated at the lower of cost or net realizable value, with approximate cost being determined on a first-in, first-out basis. Prior to initial approval from the FDA or other regulatory agencies, we expense costs relating to the production of inventory in the period incurred, unless we believe regulatory approval and subsequent commercialization of the product candidate is probable and we expect the future economic benefit from sales of the product to be realized, at which point we capitalize the costs as inventory. We assess any costs capitalized prior to regulatory approval each quarter for indicators of impairment, such as a reduced likelihood of approval. We expense costs associated with clinical trial material as research and development expense.

On a quarterly basis, we analyze our inventory levels to determine whether we have any obsolete, expired, or excess inventory. If any inventory is expected to expire prior to being sold, has a cost basis in excess of its net realizable value, is in excess of expected sales requirements as determined by internal sales forecasts, or fails to meet commercial sale specifications, the inventory is written-down through a charge to cost of product sales. The determination of whether inventory costs will be realizable requires estimates by management of future expected inventory requirements, based on sales forecasts. Once packaged, our products have a shelf-life ranging from three to five years. As a result of comparison to internal sales forecasts, we expect to fully realize the carrying value of our finished goods inventory. If actual market conditions are less favorable than those projected by management, inventory write-downs may be required. Charges for inventory write-downs are not reversed if it is later determined that the product is saleable.

Property and Equipment, Net

Property and equipment are recorded at cost and depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:
 
Useful Life
Computer equipment and software
5 Years
Furniture and fixtures
5 Years
Leasehold improvements
Lesser of Lease or Asset Life
Laboratory and production equipment
5 Years


Costs for capital assets not yet placed in service are capitalized on our balance sheets and will be depreciated in accordance with the above guidelines once placed into service. Costs for maintenance and repairs are expensed as incurred. Upon sale or other disposition of property and equipment, the cost and related depreciation are removed from the accounts and any resulting gain or loss is charged to our consolidated statements of operations. Assets classified as held for sale are no longer subject to depreciation and are recorded at the lower of carrying value or estimated net realizable value.

Intangible Assets

We amortize our intangible assets that have finite lives based on either the straight-line method, or if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be utilized.

If we acquire an asset or a group of assets that do not meet the definition of a business, the acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.

Impairment of Long-Lived Assets

We review our long-lived assets, which includes property and equipment and identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. To evaluate recoverability, management compares the projected undiscounted future cash flows associated with the asset or asset group, including proceeds from its eventual disposition over its estimated useful life against its carrying amount. If the undiscounted cash flows are not sufficient to recover the carrying value of the asset or asset group, the asset or asset group is considered impaired. The impairment loss, if any, is measured as the excess of the carrying amount of the asset or asset group over its estimated fair value, which is typically calculated utilizing a discounted cash flow (“DCF”) model following the same methodology as described in the following section.

Goodwill
We test goodwill at the reporting unit level for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that could indicate impairment and trigger an interim impairment assessment include, but are not limited to, an adverse change in current economic and market conditions, including a significant prolonged decline in market capitalization, a significant adverse change in legal factors, unexpected adverse business conditions, and an adverse action or assessment by a regulator. Our annual impairment test date is October 31. We have determined that we operate in a single operating segment and have a single reporting unit.
In performing our goodwill impairment tests, we utilize the approach prescribed under Accounting Standards Codification (“ASC”) 350, as amended by Accounting Standards Update (“ASU”) 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”), which requires that an entity perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value.
When we perform any goodwill impairment test, the estimated fair value of our reporting unit is determined using an income approach that utilizes a DCF model or a market approach, when appropriate, which assesses our market capitalization as adjusted for a control premium, or a combination thereof.
Under the market approach, when our carrying value exceeds our market capitalization, we consider a control premium for purposes of estimating the fair value of our reporting unit, as we believe that a market participant buyer would be required to pay a control premium for our business. The control premium utilized is based on control premiums observed in recent comparable market transactions. As described in the accounting guidance for evaluating long-lived assets for impairment, an entity’s fair value may include a control premium in addition to the quoted market price to determine the fair value of a single reporting unit entity, as an acquiring entity is often willing to pay more for equity securities that give it a controlling interest than an investor would pay for a number of equity securities representing less than a controlling interest. This accounting guidance also indicates that the quoted market price of an individual security need not be the sole measurement basis of the fair value of a single reporting unit. When our market capitalization exceeds our carrying value, we utilize our market capitalization as the indicator of fair value in our impairment test.
Under the income approach, the DCF model is based upon expected future after-tax operating cash flows of the reporting unit discounted to a present value using a risk-adjusted discount rate. Estimates of future cash flows require management to make significant assumptions concerning (i) future operating performance, including future sales, long-term growth rates, operating margins, variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows (ii) the probability of regulatory approvals, and (iii) future economic conditions, all of which may differ from actual future cash flows. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rate, which is intended to reflect the risks inherent in future cash flow projections, used in the DCF model, is based on estimates of the weighted average cost of capital (“WACC”) of market participants relative to our reporting unit. Financial and credit market volatility can directly impact certain inputs and assumptions used to develop the WACC. Any changes in these assumptions may affect our fair value estimate and the result of an impairment test. The discount rates and other inputs and assumptions are consistent with those that a market participant would use. In addition, in order to assess the reasonableness of the fair value of our reporting unit as calculated under the DCF model, we also compare the reporting unit’s fair value to our market capitalization and calculate an implied control premium (the excess sum of the reporting unit’s fair value over its market capitalization). We evaluate the implied control premium by comparing it to control premiums of recent comparable market transactions, as applicable.

Business Combinations and Asset Acquisitions

The purchase price allocation for business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values. Under ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business (“2017-01”), we first determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the single asset or group of assets, as applicable, is not a business.

We account for acquired businesses using the acquisition method of accounting, under which the total purchase price of an acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. Acquisition-related costs are expensed as incurred. Any excess of the consideration transferred over the estimated fair values of the identifiable net assets acquired is recorded as goodwill.

The purchase price allocations for business combinations are initially prepared on a preliminary basis and are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. Any adjustments to the purchase price allocations are made as soon as practicable but no later than one year from the acquisition date.

Acquired inventory is recorded at its fair value, which may require a step-up adjustment to recognize the inventory at its expected net realizable value. The inventory step-up is recorded to cost of product sales in our consolidated statements of operations when related inventory is sold, and we record step-up costs associated with clinical trial material as research and development expense.

Acquisition-Related Contingent Consideration

Contingent consideration arising from a business combination is included as part of the purchase price and is recognized at its estimated fair value as of the acquisition date. Subsequent to the acquisition date, we measure contingent consideration arrangements at fair value for each period until the contingency is resolved. These changes in fair value are recognized in selling, general and administrative expenses in our consolidated statements of operations. Changes in fair values reflect new information about the likelihood of the payment of the contingent consideration and the passage of time. For asset acquisitions, we record contingent consideration for obligations we consider to be probable and estimable and these liabilities are not adjusted to fair value.

Leases

Effective January 1, 2019, we adopted ASC Topic 842, Leases (“ASC 842”), and chose to apply the provisions of ASC 842 as of the effective date with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected to utilize the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also made accounting policy elections to not separate lease and non-lease components for our real estate lease and to not recognize leases with an initial term of twelve months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis on our consolidated statements of income over the lease term. We did not have any material short-term leases accounted for under this policy during the year ended December 31, 2019.
We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liability, and long-term operating lease liability on our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease.
ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Our incremental borrowing rate is determined based on an evaluation of our creditworthiness and the prevailing market rates for collateralized debt with maturity dates commensurate with the term of each lease. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option. Lease expense for operating leases is recognized on a straight-line basis over the lease term.
The lease payments used to determine our ROU assets may include lease incentives, stated rent increases, and escalation clauses linked to rates of inflation when determinable and are recognized in our ROU assets on our consolidated balance sheet. In addition, certain lease agreements contain lease and non-lease components. With the exception of our real estate leases, we separate lease payments for the identified assets from any non-lease payments included in the agreement. For our real estate leases, we account for the lease and non-lease components as a single lease component. Additionally, for vehicle and certain equipment leases, we apply a portfolio approach to effectively account for the related ROU assets and operating lease liabilities.

Restricted Cash

We classified $0.5 million of our cash as restricted cash, a non-current asset on the balance sheet, as of December 31, 2019 and 2018. This amount represented the security deposit delivered to the landlord of our Waltham, Massachusetts headquarters.

Research and Development Expenses

Research and development expenses include both external and internal expenses. External expenses primarily include costs of clinical trials and fees paid to contract research organizations (“CROs”), clinical supply and manufacturing expenses, regulatory filing fees, consulting and professional fees as well as other general costs related to the execution of research and development activities. Internal expenses primarily include compensation of employees engaged in research and development activities. Research and development expenses are expensed as incurred. Manufacturing costs are generally expensed as incurred until a product has received the necessary initial regulatory approval.

Patents

We expense all patent-related costs in selling, general and administrative expenses as incurred.

Advertising Costs

Advertising costs are expensed as incurred and included in selling, general and administrative expenses in our consolidated statements of operations. Advertising costs, including promotional expenses, costs related to digital marketing and print media advertising space were $53.3 million, $29.8 million and $9.1 million for the years ended December 31, 2019, 2018 and 2017, respectively.

Equity-Based Compensation

Equity-based compensation cost is generally measured at the estimated grant date fair value and recorded to expense over the requisite service period, which is generally the vesting period. Because equity-based compensation expense is based on awards ultimately expected to vest, we must make certain judgments about whether employees, officers, directors, consultants and advisers will complete the requisite service period, and reduce the compensation expense being recognized for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based upon historical experience and adjusted for unusual events such as corporate restructurings, which can result in higher than expected turnover and forfeitures. If factors change and we employ different assumptions in future periods, the compensation expense that we record in the future may differ significantly from what we have recorded in the current period.

We estimate the fair value of equity-based compensation involving stock options based on the Black-Scholes option pricing model. This model requires the input of several factors such as the expected option term, the expected risk-free interest rate over the expected option term, the expected volatility of our stock price over the expected option term and the expected dividend yield over the expected option term and are subject to various assumptions. The fair value of awards calculated using the Black-Scholes option pricing model is generally amortized on a straight-line basis over the requisite service period, and is recognized based on the proportionate amount of the requisite service period that has been rendered during each reporting period.

We estimate the fair value of our restricted stock units (“RSUs”) whose vesting is contingent upon market conditions, such as total shareholder return, using the Monte-Carlo simulation model. The fair value of RSUs where vesting is contingent upon market conditions is amortized based upon the estimated derived service period. The fair value of RSUs granted to our employees and directors whose vesting is dependent on future service is determined based upon the quoted closing market price per share on the date of grant, adjusted for estimated forfeitures.

We believe our valuation methodologies are appropriate for estimating the fair value of the equity awards we grant to our employees and directors. Our equity award valuations are estimates and may not be reflective of actual future results or amounts ultimately realized by recipients of these grants. These amounts are subject to future quarterly adjustments based upon a variety of factors, which include, but are not limited to, changes in estimated forfeiture rates and the issuance of new equity-based awards.

Income Taxes

We use the asset and liability method of accounting for deferred income taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A deferred tax asset is established for the expected future benefit of net operating loss (“NOL”) and credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance against net deferred tax assets is required if, based on available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Significant judgments, estimates and assumptions regarding future events, such as the amount, timing and character of income, deductions and tax credits, are required in the determination of our provision for income taxes and whether valuation allowances are required against deferred tax assets. In evaluating our ability to recover our deferred tax assets, we consider all available evidence, both positive and negative, including the existence of taxable temporary differences, our past operating results, the existence of cumulative income in the most recent fiscal years, changes in the business in which we operate and our forecast of future taxable income. In determining future taxable income, we are responsible for assumptions utilized including the amount of state and federal operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income. As of December 31, 2019, we have established a valuation allowance on our net deferred tax assets other than refundable alternative minimum tax (“AMT”) credits to the extent that our existing taxable temporary differences would not be available as a source of income to realize the benefits of those deferred tax assets.

We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position. We evaluate uncertain tax positions on a quarterly basis and adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could impact our income tax provision in future periods. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as a provision for income tax in our consolidated statement of operations.

Comprehensive Loss

Our comprehensive loss consists of net loss and other comprehensive loss. Other comprehensive loss includes changes in equity that are excluded from net loss, which for all periods presented in these consolidated financial statements related to unrealized holding gains and losses on available-for-sale marketable securities, net of tax.

Basic and Diluted Earnings per Share

We compute basic earnings per share by dividing earnings by the weighted average number of common shares outstanding during the relevant period. Diluted earnings per share is computed by dividing earnings by the diluted number of common shares outstanding during the period. Except where the result would be antidilutive, diluted earnings per common share would be computed assuming the impact of the conversion of the 3.25% convertible senior notes due in 2022 (the “2022 Convertible Notes”), the exercise of outstanding stock options and the vesting of RSUs.
We have a choice to settle the conversion obligation of our 2022 Convertible Notes (the “2022 Convertible Notes”) in cash, shares or any combination of the two. Our policy is to settle the principal balance of the 2022 Convertible Notes in cash. As such, we apply the treasury stock method to these securities and the dilution related to the conversion premium, if any, of the 2022 Convertible Notes is included in the calculation of diluted weighted-average shares outstanding to the extent the issuance is dilutive based on the average stock price during each reporting period being greater than the conversion price of the 2022 Convertible Notes.
The components of basic and diluted earnings per share for 2019, 2018 and 2017 were as follows (in thousands, except per share data):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Net loss from continuing operations
$
(467,661
)
 
$
(172,075
)
 
$
(206,688
)
Net income from discontinued operations
—

 
103,578

 
5,925

 
 

 
 

 
 

Weighted average common shares outstanding
34,030

 
34,394

 
34,907

Effect of dilutive securities:
 

 
 

 
 

Stock options and RSUs
—

 
—

 
—

Shares used in calculating dilutive net loss per share
34,030

 
34,394

 
34,907

 
 

 
 

 
 

Basic and diluted earnings per share:
 

 
 

 
 

Loss from continuing operations
$
(13.74
)
 
$
(5.00
)
 
$
(5.92
)
Income from discontinued operations
—

 
3.01

 
0.17

Total
$
(13.74
)
 
$
(1.99
)
 
$
(5.75
)

 
The following table sets forth the potential common shares issuable upon the exercise of outstanding options, the vesting of RSUs and the conversion of the Convertible Notes (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Options to purchase shares of common stock
3,976

 
3,797

 
3,531

Shares of common stock issuable upon the vesting of RSUs
1,579

 
1,129

 
1,070

Warrants
—

 
1,008

 
1,008

2022 Convertible Notes
11,695

 
11,695

 
11,695

2019 Convertible Notes
—

 
790

 
790

Shares of common stock under employee stock purchase plan
—

 
81

—
—

Total
17,250

 
18,500

 
18,094


 In connection with the issuance of the 2019 Convertible Notes, in February 2014, we entered into convertible bond hedges with certain financial institutions. The convertible bond hedges were not included for purposes of calculating the number of diluted shares outstanding, as their effect would be anti-dilutive. The convertible bond hedges and warrants expired in February 2019 in conjunction with the settlement of the 2019 Convertible Notes.

Business Segments
We have determined that we conduct our operations in one business segment: the manufacture, development and commercialization of products for use in treating various conditions, with a focus on maternal and women’s health and anemia management. Long-lived assets consist entirely of intangible assets, property and equipment and are located in the U.S. for all periods presented.  
Immaterial Revision of Prior Period Financial Information
Prior period amounts, specifically net product sales and accrued expenses have been revised to correct a prior period error related to gross-to-net (“GTN”) adjustments for governmental rebates and the related accrual for a certain state program. Refer to Note X, “Revision of Prior Period Financial Statements” for further detail.
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.20.2
DISCONTINUED OPERATIONS
 12 Months Ended
Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS DISCONTINUED OPERATIONS
On August 6, 2018, we completed the sale of our CBR business to GI Partners pursuant to the CBR Purchase Agreement. We determined that the sale of CBR represented a strategic shift that would have a major effect on our business and therefore met the criteria for classification as discontinued operations at June 30, 2018. All historical operating results for CBR were reflected within discontinued operations in the consolidated statements of operations for the years ended December 31, 2018 and 2017.
The following is a summary of net income from discontinued operations for the years ended December 31, 2018 and 2017:    
 
Years Ended December 31,
 
2018
 
2017
Service revenues, net
$
71,217

 
$
114,177

Costs and expenses:
 
 
 
Cost of services
12,559

 
21,817

Selling, general and administrative expenses
39,899

 
81,782

Total costs and expenses
52,458

 
103,599

Operating income
18,759

 
10,578

Other income (expense)
114

 
(265
)
Income from discontinued operations
18,873

 
10,313

Gain on sale of CBR business
87,076

 
—

Income tax expense
2,371

 
4,388

Net income from discontinued operations
$
103,578

 
$
5,925



The cash flows related to discontinued operations have not been segregated and are included in the consolidated statements of cash flows for the years ended December 31, 2018 and 2017. For the years ended December 31, 2018 and 2017, capital expenditures related to the CBR business were $1.6 million and $4.9 million, respectively. Depreciation and amortization expense related to the CBR business for the same periods was $8.4 million and $21.7 million, respectively. Excluding the gain of $87.1 million recognized on the sale of the CBR business and the related transaction expenses of $14.1 million presented in the consolidated statements of cash flows for the year ended December 31, 2018, there were no other significant operating or investing non-cash items related to the CBR business for any period presented.
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUE RECOGNITION
 12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION REVENUE RECOGNITION
Product Revenue

The following table provides information about disaggregated revenue by product for the years ended December 31, 2019, 2018 and 2017 (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Product sales, net
 
 
 
 
 
Makena
$
120,859

 
$
320,311

 
$
385,356

Feraheme
167,947

 
135,001

 
105,930

Intrarosa
21,417

 
16,218

 
1,816

Other
(238
)
 
368

 
741

Total
$
309,985

 
$
471,898

 
$
493,843


Total gross product sales were offset by product sales allowances and accruals for the years ended December 31, 2019, 2018 and 2017 as follows (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Gross product sales
$
955,693

 
$
974,330

 
$
920,061

Provision for product sales allowances and accruals:
 
 
 
 
 
Contractual adjustments
530,645

 
387,540

 
310,588

Governmental rebates
115,063

 
114,892

 
115,630

Total
645,708

 
502,432

 
426,218

Product sales, net
$
309,985

 
$
471,898

 
$
493,843



The following table summarizes the product revenue allowance and accrual activity for the years ended December 31, 2019, 2018 and 2017 (in thousands):
 
Contractual
 
Governmental
 
 
 
Adjustments
 
Rebates
 
Total
Balance at January 1, 2017
$
47,600

 
$
52,741

 
$
100,341

Current provisions relating to sales in current year
314,537

 
113,969

 
428,506

Adjustments relating to sales in prior years
(3,949
)
 
1,661

 
(2,288
)
Payments/returns relating to sales in current year
(253,545
)
 
(61,569
)
 
(315,114
)
Payments/returns relating to sales in prior years
(42,479
)
 
(53,060
)
 
(95,539
)
Balance at December 31, 2017
62,164

 
53,742

 
115,906

Current provisions relating to sales in current year
389,861

 
106,988

 
496,849

Adjustments relating to sales in prior years
(2,330
)
 
7,903

 
5,573

Payments/returns relating to sales in current year
(333,694
)
 
(75,920
)
 
(409,614
)
Payments/returns relating to sales in prior years
(58,802
)
 
(58,501
)
 
(117,303
)
Balance at December 31, 2018
57,199

 
34,212

 
91,411

Provisions related to current period sales
521,916

 
100,926

 
622,842

Adjustments related to prior period sales
8,774

 
14,137

 
22,911

Payments/returns relating to current period sales
(431,014
)
 
(60,218
)
 
(491,232
)
Payments/returns relating to prior period sales
(61,654
)
 
(41,435
)
 
(103,089
)
Balance at December 31, 2019
$
95,221

 
$
47,622

 
$
142,843



During the year ended December 31, 2019, we recorded adjustments of $14.1 million for Medicaid rebate claims received that related to prior period sales and $8.8 million for contractual adjustments related to prior period sales. We concluded that these adjustments represented changes in estimate during the year ended December 31, 2019 due to higher Medicaid and payer utilization and subsequent rebate obligations than anticipated based on our historical experience.

Collaboration Revenue

During the first quarter of 2019, in conjunction with the Perosphere transaction, we assumed responsibility for a clinical trial collaboration agreement with a pharmaceutical company. This agreement provided for milestone payments to us, provided we met certain clinical obligations in connection with our ciraparantag program. We also acquired $6.4 million of deferred revenue related to this agreement, which represented the fair value of our remaining performance obligations associated with upfront milestone payments received by Perosphere under this agreement prior to acquisition. We accounted for this agreement under ASC 606.

During the fourth quarter of 2019, we entered into a termination and settlement agreement (the “Termination Agreement”) with the pharmaceutical company which provided for a $10.0 million termination payment to us and stated that no party had any remaining performance obligations effective as of the termination date. The $10.0 million termination payment was received during the fourth quarter of 2019. Under ASC 606, the Termination Agreement met the definition of a contract modification and was accounted for as a cumulative catch-up adjustment at the time of modification.
During the year ended December 31, 2019, the $10.0 million termination payment and $6.4 million of deferred revenue were recognized as collaboration revenue in our consolidated statements of operations.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.20.2
MARKETABLE SECURITIES
 12 Months Ended
Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]  
MARKETABLE SECURITIES MARKETABLE SECURITIES
As of December 31, 2019 and 2018, our marketable securities consisted of securities classified as available-for-sale in accordance with accounting standards which provide guidance related to accounting and classification of certain investments in marketable securities.
The following is a summary of our marketable securities as of December 31, 2019 and 2018 (in thousands):
 
December 31, 2019
 
 
 
Gross
 
Gross
 
Estimated
 
Amortized
 
Unrealized
 
Unrealized
 
Fair
Description of Securities:
Cost
 
Gains
 
Losses
 
Value
Short-term investments:*
 
 
 
 
 
 
 
Corporate debt securities
$
46,186

 
$
140

 
$
(2
)
 
$
46,324

U.S. treasury and government agency securities
2,750

 
—

 
—

 
2,750

Certificates of deposit
1,500

 
—

 
—

 
1,500

Total short-term investments
50,436

 
140

 
(2
)
 
50,574

Long-term investments:**
 
 
 
 
 
 
 
Corporate debt securities
8,016

 
152

 
—

 
8,168

Total long-term investments
8,016

 
152

 
—

 
8,168

Total investments
$
58,452

 
$
292

 
$
(2
)
 
$
58,742

 
 
December 31, 2018
 
 
 
Gross
 
Gross
 
Estimated
 
Amortized
 
Unrealized
 
Unrealized
 
Fair
Description of Securities:
Cost
 
Gains
 
Losses
 
Value
Short-term investments:*
 
 
 
 
 
 
 
Corporate debt securities
$
51,184

 
$
—

 
$
(236
)
 
$
50,948

U.S. treasury and government agency securities
7,647

 
—

 
(34
)
 
7,613

Commercial paper
3,995

 
—

 
—

 
3,995

Certificates of deposit
12,000

 
—

 
—

 
12,000

Total short-term investments
74,826

 
—

 
(270
)
 
74,556

Long-term investments:**
 
 
 
 
 
 
 
Corporate debt securities
62,530

 
52

 
(433
)
 
62,149

U.S. treasury and government agency securities
2,742

 
—

 
(32
)
 
2,710

Certificates of deposit
1,500

 
—

 
—

 
1,500

Total long-term investments
66,772

 
52

 
(465
)
 
66,359

Total investments
$
141,598

 
$
52

 
$
(735
)
 
$
140,915



* Represents marketable securities with a remaining maturity of less than one year.
** Represents marketable securities with a remaining maturity of one to three years classified as short-term on our consolidated balance sheets.
 
Impairments and Unrealized Gains and Losses on Marketable Securities
We did not recognize any other-than-temporary impairment losses in our consolidated statements of operations related to our marketable securities during 2019, 2018 or 2017. We considered various factors, including the length of time that each security was in an unrealized loss position and our ability and intent to hold these securities until recovery of their amortized cost basis occurs. As of December 31, 2019, we have no material losses in an unrealized loss position for more than one year. Future events may occur, or additional information may become available, which may cause us to identify credit losses where we do not expect to receive cash flows sufficient to recover the entire amortized cost basis of a security and may necessitate the recording of future realized losses on securities in our portfolio. Significant losses in the estimated fair values of our marketable securities could have a material adverse effect on our earnings in future periods.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.20.2
FAIR VALUE MEASUREMENTS
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The following tables present information about our assets and liabilities that we measure at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques utilized to determine such fair value as of December 31, 2019 and 2018 (in thousands):
 
Fair Value Measurements at December 31, 2019 Using:
 
Total
 
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Cash equivalents
$
13,732

 
$
13,732

 
$
—

 
$
—

Corporate debt securities
54,492

 
—

 
54,492

 
—

U.S. treasury and government agency securities
2,750

 
—

 
2,750

 
—

Certificates of deposit
1,500

 
—

 
1,500

 
—

Total Assets
$
72,474

 
$
13,732

 
$
58,742

 
$
—

Liabilities:
 

 
 

 
 

 
 

Contingent consideration
17

 
—

 
—

 
17

Total Liabilities
$
17

 
$
—

 
$
—

 
$
17

 
Fair Value Measurements at December 31, 2018 Using:
 
Total
 
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Cash equivalents
$
71,568

 
$
71,568

 
$
—

 
$
—

Corporate debt securities
113,097

 
—

 
113,097

 
—

U.S. treasury and government agency securities
10,323

 
—

 
10,323

 
—

Commercial paper
3,995

 
—

 
3,995

 
—

Certificates of deposit
13,500

 
—

 
13,500

 
—

Total Assets
$
212,483

 
$
71,568

 
$
140,915

 
$
—

Liabilities:
 
 
 
 
 
 
 
Contingent consideration
359

 
—

 
—

 
359

Total Liabilities
$
359

 
$
—

 
$
—

 
$
359


Cash equivalents

Our cash equivalents are classified as Level 1 assets under the fair value hierarchy as these assets have been valued using quoted market prices in active markets and do not have any restrictions on redemption. As of December 31, 2019 and 2018, cash equivalents were comprised of funds in money market accounts.
Marketable securities
Our marketable securities are classified as Level 2 assets under the fair value hierarchy as these assets were primarily determined from independent pricing services, which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based upon other significant observable market transactions. At the end of each reporting period, we perform quantitative and qualitative analysis of prices received from third parties to determine whether prices are reasonable estimates of fair value. After completing our analysis, we did not adjust or override any fair value measurements provided by our pricing services as of December 31, 2019 or 2018. In addition, there were no transfers or reclassifications of any securities between Level 1 and Level 2 during 2019 or 2018.
Contingent consideration
In accordance with GAAP, for asset acquisitions, we record contingent consideration for obligations we consider to be probable and estimable and these liabilities are not adjusted to fair value. As of December 31, 2019 and December 31, 2018, no contingent consideration was recorded in accrued expenses.
We recorded contingent consideration related to the November 2014 acquisition of Lumara Health Inc. (“Lumara Health”) for our Makena product and related to our June 2013 license agreement for MuGard® Mucoadhesive Oral Wound Rinse (the “MuGard License Agreement”) with Abeona Therapeutics, Inc. (“Abeona”), under which we acquired the U.S. commercial rights for the management of oral mucositis and stomatitis (the “MuGard Rights”).
The fair value measurements of contingent consideration obligations and the related intangible assets arising from business combinations are classified as Level 3 under the fair value hierarchy as they have been valued using unobservable inputs. These inputs include: (a) the estimated amount and timing of projected cash flows; (b) the probability of the achievement of the factors on which the contingency is based; and (c) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement.
During 2018, we reduced the fair value of our contingent consideration liability by approximately $49.6 million, primarily based on actual Makena net sales to date and our expectations for future performance, which indicated that achievement of future milestones is not probable. This adjustment was based on our estimates, which are reliant on a number of external factors as well as the exercise of judgment.
We believe the estimated fair values of the contingent payments associated with Lumara Health and the MuGard Rights are based on reasonable assumptions, however, our actual results may vary significantly from the estimated results.
Debt

We estimate the fair value of our debt obligations by using quoted market prices obtained from third-party pricing services, which is classified as a Level 2 input. As of December 31, 2019, the estimated fair value of the 2022 Convertible Notes was $274.8 million, which differed from its carrying value. As of December 31, 2018, the estimated fair value of the 2022 Convertible Notes and the 2019 Convertible Notes was $294.8 million and $20.9 million, respectively, which differed from their carrying values. See Note R, “Debt,” for additional information on our debt obligations.

Nonrecurring Fair Value Measurements

During the year ended December 31, 2019, we measured the Makena base technology, Makena auto-injector developed technology, Intrarosa developed technology and Vyleesi developed technology intangible assets at fair value based on indicators of impairment identified for the Makena, Intrarosa and Vyleesi products. The aggregate fair values of our intangible assets at December 31, 2019 was $23.6 million and we recorded total impairment charges of $232.3 million in our consolidated statements of operations for the year ended December 31, 2019. The fair value measurement related to the Makena base technology intangible asset was recorded during the second quarter of 2019. The Makena auto-injector developed technology intangible asset was measured at fair value as of October 29, 2019 and the Intrarosa developed technology and Vyleesi developed technology intangible assets were measured at fair value as of December 31, 2019. See Note I, “Goodwill and Intangible Assets, Net” for additional information regarding our intangible asset impairment assessments.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.20.2
INVENTORIES
 12 Months Ended
Dec. 31, 2019
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES

Our major classes of inventories were as follows as of December 31, 2019 and 2018 (in thousands):
 
December 31,
 
2019
 
2018
Raw materials
$
5,211

 
$
9,388

Work in process
6,248

 
5,932

Finished goods
20,094

 
11,371

Total inventories
$
31,553

 
$
26,691



During the year ended December 31, 2019, we recorded inventory write-downs of $19.8 million in conjunction with the impairments of the asset groups related to the Makena intramuscular (“IM”) products and the Makena auto-injector product.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.20.2
PROPERTY AND EQUIPMENT, NET
 12 Months Ended
Dec. 31, 2019
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT, NET PROPERTY AND EQUIPMENT, NET
Property and equipment, net consisted of the following as of December 31, 2019 and 2018 (in thousands):
 
December 31,
 
2019
 
2018
Computer equipment and software
$
1,568

 
$
1,637

Furniture and fixtures
1,714

 
1,737

Leasehold improvements
4,984

 
2,938

Laboratory and production equipment
6,570

 
6,000

Construction in progress
656

 
420

 
15,492

 
12,732

Less: accumulated depreciation
(11,376
)
 
(5,211
)
Property and equipment, net
$
4,116

 
$
7,521



During 2019, 2018 and 2017, depreciation expense was $2.6 million, $1.6 million, and $1.2 million, respectively.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.20.2
GOODWILL AND INTANGIBLE ASSETS, NET
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS, NET GOODWILL AND INTANGIBLE ASSETS, NET
Goodwill
Our $422.5 million goodwill balance represents goodwill of the continuing business following the goodwill allocation performed in 2018 in connection with the CBR transaction discussed in Note C, “Discontinued Operations.” As of December 31, 2019, we had no accumulated impairment losses related to goodwill. 
2019 Impairment Testing Results
On October 31, 2019 (the “2019 measurement date”), we conducted our 2019 annual goodwill impairment test using a market approach to estimate the fair value of our reporting unit as of the 2019 measurement date. We considered our market capitalization, as adjusted for a control premium, to be one indicator of the fair value of our reporting unit. On October 31, 2019, our stock price closed at $9.71 per share, resulting in a market capitalization of approximately $329 million, which was below the carrying amount of our reporting unit as of the 2019 measurement date, resulting in an implied control premium of 6%. During the fourth quarter of 2019, we obtained a control premium analysis that benchmarked average control premiums paid in prior merger and acquisition transactions among biotechnology and pharmaceutical companies. The analysis indicated that control premiums vary depending on facts and circumstances for each transaction. The range of control premiums observed was between 37% and 84%, with a median of 65%. Management believes that using this market approach of assessing reasonable control premiums provided a sufficient basis to assess whether the fair value of our reporting unit, including a range of reasonable control premiums, was above its carrying amount. Incorporating control premiums in this range to our October 31, 2019 market capitalization of $329 million resulted in a fair value which was at least 29% greater (at the low end of the range) than the carrying amount of our net assets as of October 31, 2019. As a result of this review, we determined that there was no impairment of our goodwill at October 31, 2019.
Between October 31, 2019 and December 31, 2019, in accordance with ASC 350, we evaluated business factors, including the business decision to divest Intrarosa and Vyleesi, to determine whether there were indicators that the fair value of our reporting unit was less than its carrying value. We determine that it was not more likely than not that the fair value of the reporting unit was less than its carrying value and accordingly, determined that there was no impairment of goodwill at December 31, 2019.

Based on our assessment, we determined that there was no goodwill impairment at October 31, 2019 or December 31, 2019. However, the future occurrence of events including, but are not limited to, an adverse change in current economic and market conditions, including a significant prolonged decline in market capitalization, a significant adverse change in legal factors, unexpected adverse business conditions and an adverse action or assessment by a regulator could indicate potential impairment and trigger an interim impairment assessment of goodwill. As a result of the significance of goodwill, our results of operations and financial position in a future period could be negatively impacted should an impairment test be triggered that results in an impairment of goodwill.

2018 Impairment Testing Results

During the second quarter of 2018, in conjunction with the goodwill allocation required by the CBR transaction and in accordance with ASC 350, we performed a goodwill impairment test to assess whether there were indicators that its fair value was less than its carrying value. As a result of this evaluation, we determined that there was no impairment of goodwill at June 30, 2018.

On October 31, 2018 (the “2018 measurement date”), we conducted our 2018 annual goodwill impairment test using a market approach to estimate the fair value of our reporting unit as of the 2018 measurement date. We considered our market capitalization, as adjusted for a control premium, to be one indicator of the fair value of our reporting unit. On October 31, 2018, our stock price closed at $21.50 per share, resulting in a market capitalization of approximately $742 million, which was below the carrying amount of our reporting unit as of the 2018 measurement date, resulting in an implied control premium of 2%. In the days following our October 31, 2018 annual testing date, our stock price declined, largely in response to our November 1, 2018 earnings release and Company update. This decline resulted in a market capitalization of approximately $633 million on November 5, 2018, resulting in an implied control premium of 20%. During the third quarter of 2018, we obtained an updated control premium analysis that benchmarked average control premiums paid in prior merger and acquisition transactions among biotechnology and pharmaceutical companies. The analysis indicated that control premiums vary depending on facts and circumstances for each transaction. The range of control premiums observed was between 39% and 96%, with a median of 71%. Management believes that using this market approach of assessing reasonable control premiums provided a sufficient basis to assess whether the fair value of our reporting unit, including a range of reasonable control premiums, was above its carrying amount. Incorporating control premiums in this range to our October 31, 2018 market capitalization of $742 million resulted in a fair value which was at least 36% greater (at the low end of the range) than the carrying amount of our net assets as of October 31, 2018. As a result of this review, we determined that there was no impairment of our goodwill at October 31, 2018.
Between October 31, 2018 and December 31, 2018, our stock price continued to fluctuate, with a median closing stock price of $17.84 per share for the period from November 1, 2018 through December 31, 2018. The median closing stock price of $17.84 per share resulted in a market capitalization of approximately $617 million, which as compared to the $747 million carrying amount of our reporting unit at December 31, 2018 resulted in an implied control premium of 21%. Incorporating the range of control premiums obtained from the control premium study used in our annual goodwill impairment test at October 31, 2018 to the calculated market capitalization of $617 million resulted in a fair value which was at least 15% greater (at the low end of the range) than the carrying amount of our net assets as of December 31, 2018. Using the closing stock price of $15.19 per share on December 31, 2018 results in an implied control premium of 41%. This implied control premium is within the range of control premiums observed. As a result of this review, we determined that there was no impairment of our goodwill between our annual goodwill impairment test date and December 31, 2018. In addition, we determined that there were no other indicators of impairment through December 31, 2018 requiring further assessment.
Intangible Assets
 
December 31, 2019
 
December 31, 2018
 
Original Cost
 
Life to Date Accumulated Amortization
 
Life to Date Impairments
 
Net Book Value
 
Original Cost
 
Life to Date Accumulated Amortization
 
Life to Date Impairments
 
Net Book Value
Amortizable intangible assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Makena base technology
$
797,100

 
$
400,496

 
$
396,604

 
$
—

 
$
797,100

 
$
400,495

 
$
319,246

 
$
77,359

Makena auto-injector developed technology
79,100

 
15,782

 
55,426

 
7,892

 
79,100

 
6,952

 
—

 
72,148

Intrarosa developed technology
77,655

 
16,798

 
56,881

 
3,976

 
77,655

 
10,129

 
—

 
67,526

Vyleesi developed technology
60,000

 
9,264

 
38,984

 
11,752

 
—

 
—

 
—

 
—

Total intangible assets
$
1,013,855

 
$
442,340

 
$
547,895

 
$
23,620

 
$
953,855

 
$
417,576

 
$
319,246

 
$
217,033


During the second quarter of 2019, Vyleesi received FDA approval, which triggered a $60.0 million milestone payment, which was capitalized as developed technology.

Late in the second quarter of 2019, we were notified that an additional manufacturing site for the Makena IM products, which relates to the Makena base technology intangible asset, received FDA approval. However, the approval was received later than expected and the extended period of the stock-out caused our authorized generic partner to lose additional customers and market share, resulting in no shipments of IM to our authorized generic partner during that quarter. As a result of this loss of market share, we deemed it probable as of the end of the second quarter of 2019 that we would terminate the Distribution and Supply Agreement with our authorized generic partner. We do not expect to generate any future revenues from shipments
of the IM products. Accordingly, we eliminated the Makena IM products from our long-term revenue forecast during the second quarter of 2019. These business factors were considered indicators of impairment for the Makena base technology intangible asset during the second quarter of 2019. We determined that the fair value of the Makena base technology intangible asset was zero at June 30, 2019, and as a result, we recorded an impairment charge for the full remaining value of the asset of $77.4 million, which was recorded within a separate operating expense line item on our consolidated statements of operations. The Distribution and Supply Agreement with our authorized generic partner was terminated in August 2019 and we have not sold any Makena IM in the second half of 2019.

During the fourth quarter of 2019, we identified indicators of impairment for the Makena auto-injector developed technology, Intrarosa developed technology and Vyleesi developed technology intangible assets (each part of its own asset group) related to (i) the October 29, 2019 unfavorable FDA Advisory Committee recommendation for Makena as described in Note A, “Description of Business”, and (ii) the December 2019 decision to divest Intrarosa and Vyleesi based on the strategic review that we conducted. We determined that the Intrarosa and Vyleesi asset groups did not meet the criteria to be classified as held for sale as of December 31, 2019 and as a result, assessed these assets for potential impairment under the held and used guidance. For each asset group, we estimated the sum of the undiscounted projected cash flows and found that the sum of the projected, probability-weighted undiscounted cash flows were less than the carrying value of each corresponding asset group. Therefore, we reassessed the fair value of each asset group using an income approach, a Level 3 measurement technique, which included probability weighting a range of potential outcomes as impacted by multiple significant and inter-related business factors. For all three asset groups, these significant assumptions included an estimated probability of a negative FDA action with respect to Makena and the expected timing of any such FDA action. In addition, for the Intrarosa and Vyleesi asset groups, management’s assessment also included assumptions regarding the probability of completing a sale of these assets and the expected timing of a sale, should one occur. We derived these estimates based on management’s judgment as informed by externally available information. We believe the assumptions we used to determine the estimated fair value of the asset groups are reasonable. Based on our consideration of these probability-weighted assumptions evaluated in the aggregate, we recorded impairment charges of $55.4 million, $56.9 million and $39.0 million to reduce the carrying values of the Makena auto-injector developed technology, Intrarosa developed technology and Vyleesi developed technology intangible assets to their respective estimated fair values. Total impairment charges of $155.0 million were recorded within a separate operating expense line item in our consolidated statements of operations during the fourth quarter of 2019, of which $151.3 million were allocated to the intangible assets in each asset group. In addition, we reassessed and prospectively adjusted the estimated remaining useful lives of the Makena auto-injector developed technology, Intrarosa developed technology and Vyleesi developed technology intangible assets and other long-lived assets within each asset group. As such, we accelerated amortization of these intangible assets resulting in an additional $7.1 million of expense recorded in 2019. As described in more detail above, our assessment was based on our estimates and assumptions, a number of which are based on external factors and the exercise of management judgment. Actual results may differ significantly from our estimates.

As of December 31, 2019, the weighted average estimated remaining amortization period for our finite-lived intangible assets was approximately one year. Total amortization expense for 2019, 2018 and 2017, was $24.8 million, $158.4 million and $130.4 million, respectively. Amortization expense is recorded in cost of product sales in our consolidated statements of operations. We expect amortization expense related to our finite-lived intangible assets to be $23.6 million during the year ended December 31, 2020.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.20.2
CURRENT AND LONG-TERM LIABILITIES
 12 Months Ended
Dec. 31, 2019
Payables and Accruals [Abstract]  
CURRENT AND LONG-TERM LIABILITIES CURRENT AND LONG-TERM LIABILITIES
Accrued Expenses
Accrued expenses consisted of the following as of December 31, 2019 and 2018 (in thousands):
 
December 31,
 
2019
 
2018
Commercial rebates, fees and returns
$
124,730

 
$
85,618

Accrued manufacturing
21,364

 
9,282

Salaries, bonuses, and other compensation
18,693

 
22,482

Professional, license, and other fees and expenses
13,392

 
13,960

Accrued research and development
3,539

 
2,226

Interest expense
867

 
1,067

Restructuring expense
797

 
—

Total accrued expenses
$
183,382

 
$
134,635
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
For the years ended December 31, 2019, 2018, and 2017, all of our profit or loss before income taxes was from U.S. operations. The income tax (benefit) expense consisted of the following (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Current:
 
 
 
 
 
Federal
$
(630
)
 
$
(1,136
)
 
$
2,162

State
179

 
1,469

 
5,358

Total current
$
(451
)
 
$
333

 
$
7,520

Deferred:
 
 
 
 
 
Federal
$
432

 
$
43,546

 
$
(172,238
)
State
(28
)
 
(3,443
)
 
(10,803
)
Total deferred
$
404

 
$
40,103

 
$
(183,041
)
Total income tax (benefit) expense
$
(47
)
 
$
40,436

 
$
(175,521
)


The reconciliation of the statutory U.S. federal income tax rate to our effective income tax rate from continuing operations was as follows:
 
Years Ended December 31,
 
2019
 
2018
 
2017
Statutory U.S. federal tax rate
21.0
 %
 
21.0
 %
 
35.0
 %
State taxes, net of federal benefit
2.6

 
4.7

 
3.3

Impact of 2017 tax reform on deferred tax balance
—

 
—

 
4.5

Equity-based compensation expense
(0.4
)
 
(1.5
)
 
(0.8
)
Contingent consideration
—

 
7.1

 
4.4

In-process research and development
(3.4
)
 
—

 
—

Other permanent items, net
(0.4
)
 
(1.4
)
 
(0.5
)
Tax credits
0.4

 
6.2

 
0.7

Valuation allowance
(19.8
)
 
(67.4
)
 
(0.8
)
Other, net
—

 
0.6

 
0.1

Effective tax rate
—
 %
 
(30.7
)%
 
45.9
 %


For the year ended December 31, 2019, we recognized an immaterial income tax benefit, representing an effective tax rate of 0.0%. The difference between the expected statutory federal tax rate of 21.0% and the effective tax rate of 0.0% for the year ended December 31, 2019, was primarily attributable to the valuation allowance established against our current period losses generated and the non-deductible IPR&D expense related to the Perosphere acquisition.We have established a valuation allowance on our deferred tax assets other than refundable AMT credits to the extent that our existing taxable temporary differences would not be available as a source of income to realize the benefits of those deferred tax assets. The income tax benefit for the year ended December 31, 2019 primarily related to the offset of the recognition of the income tax expense recorded in other comprehensive loss associated with the increase in the value of available-for-sale securities that we carried at fair market value during the period, partially offset by state income taxes.
For the year ended December 31, 2018, we recognized income tax expense of $40.4 million representing an effective tax rate of (30.7)%. The difference between the expected statutory federal tax rate of 21.0% and the (30.7)% effective tax rate for 2018 was primarily attributable to the establishment of a valuation allowance on net deferred tax assets other than refundable AMT credits, the impact of non-deductible stock compensation and other non-deductible expenses, partially offset by a benefit from contingent consideration associated with Lumara Health, state income taxes and orphan drug tax credits. The valuation allowance on our deferred tax assets, other than refundable AMT credits, increased during the year ended December 31, 2018 primarily because the deferred tax liabilities associated with the CBR business, which was reclassified to discontinued operations and sold during the year ended December 31, 2018, are no longer available as a source of income to realize the benefits of the net deferred tax assets.

For the year ended December 31, 2017, we recognized an income tax benefit of $175.5 million representing an effective tax rate of 45.9%. The difference between the expected statutory federal tax rate of 35.0% and the 45.9% effective tax rate for 2017 was primarily attributable to the impact of the 2017 federal tax reform legislation, as discussed below, contingent consideration associated with Lumara Health, federal research and orphan drug tax credits generated during the year, and the impact of state income taxes, partially offset by equity-based compensation expenses and an increase to our valuation allowance.

On December 22, 2017, the Tax Cuts and Jobs Act (the “2017 Tax Act”), was enacted. The 2017 Tax Act includes significant changes to the U.S. corporate income tax system, including a reduction of the federal corporate income tax rate from 35.0% to 21.0%, effective January 1, 2018. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which those temporary differences are expected to be recovered or settled. As a result of the reduction in the federal tax rate from 35.0% to 21.0%, we revalued our ending net deferred tax liabilities at December 31, 2017 and recognized a $17.1 million tax benefit.

Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future enacted rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. The components of our deferred tax assets and liabilities were as follows (in thousands):
 
December 31,
 
2019
 
2018
Assets
 
 
 
Net operating loss carryforwards
$
79,679

 
$
46,888

Tax credit carryforwards
28,641

 
24,290

Capital loss carryforwards
20,659

 
20,896

Interest expense carryforwards
5,746

 
4,318

Equity-based compensation expense
6,106

 
5,931

Capitalized research & development
2,347

 
4,635

Intangible assets
67,847

 
12,565

Reserves
5,721

 
2,683

Lease liability
5,739

 
—

Property, plant and equipment
391

 
—

Contingent consideration
4

 
87

Other
10,846

 
6,627

Valuation allowance
(218,291
)
 
(114,516
)
Liabilities
 
 
 
Property, plant and equipment depreciation
—

 
(614
)
Debt instruments
(9,195
)
 
(12,489
)
Right of use asset
(5,599
)
 
—

Other
(11
)
 
(41
)
Net deferred tax assets
$
630

 
$
1,260



The valuation allowance increased by approximately $103.8 million for the year ended December 31, 2019. We have established a valuation allowance on our deferred tax assets other than refundable AMT credits to the extent that our existing taxable temporary differences would not be available as a source of income to realize the benefits of those deferred tax assets. Our valuation allowance on our deferred tax assets, other than refundable AMT credits, increased during the year ended December 31, 2019, primarily due to our current period losses generated.
At December 31, 2019, we had federal and state NOL carryforwards of approximately $332.8 million and $184.6 million, respectively, of which $123.1 million and $16.6 million federal and state NOL carryforwards, were acquired as part of the Lumara Health transaction, respectively, and $21.4 million and $14.6 million federal and state NOL carryforwards were acquired as part of the Perosphere transaction, respectively. The majority of the federal and state NOLs expire at various dates
through 2039. We have $127.4 million of federal NOLs generated after 2017 which will not expire. We have federal tax credits of approximately $26.1 million to offset future tax liabilities of which $2.3 million were acquired as part of the Lumara Health transaction and $2.3 million of which were acquired as part of the Perosphere transaction. We have state tax credits of $2.5 million to offset future tax liabilities of which $1.2 million were acquired as part of the Perosphere transaction. These federal and state tax credits will expire periodically through 2039 if not utilized. We have a capital loss carryforward of $90.4 million from the sale of the CBR business that can only be used to offset future capital gains and expires in 2023. Our interest expense carryforward is $23.6 million, which may be carried forward indefinitely.
Utilization of our NOLs, interest expense carryforwards, and research and development (“R&D”) credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section 382 of the Internal Revenue Code of 1986 (“Section 382”) as well as similar state provisions. These ownership changes may limit the amount of NOLs and interest expense carryforwards that can be utilized annually to offset future taxable income and may limit the amounts of R&D credit carryforwards that can be utilized annually to offset taxes. In general, an ownership change as defined by Section 382 results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. Since our formation, we have raised capital through the issuance of capital stock on several occasions. These financings, combined with the purchasing shareholders’ subsequent disposition of those shares, could result in a change of control, as defined by Section 382. We conducted an analysis under Section 382 to determine if historical changes in ownership through December 31, 2019, based upon publicly available information as of December 31, 2019, would limit or otherwise restrict our ability to utilize these NOLs, interest expense, and R&D credit carryforwards. As a result of this analysis, we do not believe there are any significant limitations on our ability to utilize these carryforwards. The NOLs and tax credits acquired from Lumara Health and Perosphere are subject to restrictions under Section 382. These restricted NOLs and credits may be utilized subject to an annual limitation. We identified ownership changes associated with the attributes acquired as part of the Lumara Health and Perosphere transactions and determined these attributes are subject to annual limitations. Future changes in ownership after December 31, 2019 could affect the limitation in future years and any limitation may result in expiration of a portion of the NOL or R&D credit carryforwards before utilization.
Unrecognized tax benefits represent uncertain tax positions for which reserves have been established. A reconciliation of our changes in unrecognized tax benefits is as follows (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Unrecognized tax benefits at the beginning of the year
$
11,180

 
$
10,560

 
$
13,020

Additions based on tax positions related to the current year
521

 
12

 
574

Additions for tax positions from prior years
2,173

 
608

 
340

Subtractions for federal tax reform
—

 
—

 
(3,296
)
Subtractions for tax positions from prior years
(336
)
 
—

 
(78
)
Unrecognized tax benefits at the end of the year
$
13,538

 
$
11,180

 
$
10,560


The amount of unrecognized tax benefits that would impact the effective tax rate if recognized is immaterial, as the majority of our uncertain tax positions relate to NOL and credit carryforwards, which, if recognized, are currently expected to require a full valuation allowance.

Our unrecognized tax benefits as of December 31, 2019 increased by $2.4 million as compared to December 31, 2018 primarily due to tax reserves associated with NOLs and R&D credit carryforwards acquired in connection with the Perosphere transaction.

Our unrecognized tax benefits as of December 31, 2018 increased by $0.6 million as compared to December 31, 2017 primarily due to tax reserves established on R&D tax credits.

Our unrecognized tax benefits as of December 31, 2017 decreased by $2.5 million as compared to December 31, 2016 primarily due to the change in the federal tax rate, which reduced the future value of our federal NOLs and the corresponding value of the unrecognized tax benefits related to those NOLs. This decrease was partially offset by tax reserves established on R&D tax credits.

We have recorded minimal interest or penalties on unrecognized tax benefits since inception. We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We do not expect our unrecognized tax benefits to change significantly in the next 12 months.
The statute of limitations for assessment by the Internal Revenue Service (the “IRS”) and most state tax authorities is closed for tax years prior to December 31, 2016, although carryforward attributes that were generated prior to tax year 2016 may still be adjusted upon examination by the IRS or state tax authorities if they either have been or will be used in a future period. We file income tax returns in the U.S. federal and various state jurisdictions. There are currently no federal or state audits in progress.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.20.2
ACCUMULATED OTHER COMPREHENSIVE LOSS
 12 Months Ended
Dec. 31, 2019
Equity [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE LOSS ACCUMULATED OTHER COMPREHENSIVE LOSS

The following table summarizes the changes in the accumulated balances of other comprehensive loss associated with unrealized (losses) gains on securities during 2019, 2018 and 2017 (in thousands):
 
December 31,
 
2019
 
2018
 
2017
Beginning balance
$
(3,985
)
 
$
(3,908
)
 
$
(3,838
)
Other comprehensive income (loss) before reclassifications
746

 
(77
)
 
(70
)
Ending balance
$
(3,239
)
 
$
(3,985
)
 
$
(3,908
)
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.20.2
EQUITY-BASED COMPENSATION
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
EQUITY-BASED COMPENSATION EQUITY-BASED COMPENSATION
We currently maintain three equity compensation plans, namely our 2019 Equity Incentive Plan (the “2019 Plan”), which was approved by our stockholders at our 2019 annual meeting and replaced our Fourth Amended and Restated 2007 Equity Incentive Plan, as amended (the “2007 Plan”), the Lumara Health Inc. Amended and Restated 2013 Incentive Compensation Plan (the “Lumara Health 2013 Plan”) and our 2015 Employee Stock Purchase Plan (“2015 ESPP”). All outstanding stock options granted under each of our equity compensation plans other than our 2015 ESPP (discussed below) have an exercise price equal to the closing price of a share of our common stock on the grant date.
Our 2019 Plan succeeded our 2007 Plan, which has expired and under which no further grants may be made. The number of shares available for future grants under the 2019 Plan consists of the sum of (i) the number of shares that remained available for issuance under the 2007 Plan as of the date of adoption of the 2019 Plan and (ii) an additional 2,161,000 shares. All outstanding awards granted under the 2007 Plan will remain subject to the terms of the 2007 Plan. In addition, any shares subject to outstanding awards granted under the 2007 Plan that expire or terminate for any reason prior to exercise will be added to the total number of shares of our stock available for issuance under the 2019 Plan. The allotted number of shares available for issuance under the 2019 Plan was 3,519,304 as of December 31, 2019 and there were 2,828,030 shares remaining available for future issuance under the 2019 Plan. As of December 31, 2019, all outstanding options under both the 2019 Plan and 2007 Plan have a ten-year term.
In November 2014, we assumed the Lumara Health 2013 Plan in connection with the acquisition of Lumara Health. The total number of shares issuable pursuant to awards under this plan as of the effective date of the acquisition and after taking into account any adjustments as a result of the acquisition, was 200,000 shares. As of December 31, 2019, there were 9,817 shares remaining available for issuance under the Lumara Health 2013 Plan, which are available for grants to certain employees, officers, directors, consultants, and advisers of AMAG and our subsidiaries who are newly-hired or who previously performed services for Lumara Health. All outstanding options under the Lumara Health 2013 Plan have a ten-year term.
The 2019 Plan, 2007 Plan and the Lumara Health 2013 Plan provide for the grant of stock options, RSUs, restricted stock, stock, stock appreciation rights and other equity interests in our company. We generally issue common stock from previously authorized but unissued shares to satisfy option exercises and RSU awards. The terms and conditions of each award are determined by our Board of Directors (the “Board”) or the Compensation Committee of our Board. The terms and conditions of each award assumed in the acquisition of Lumara Health were previously determined by Lumara Health prior to being assumed in connection with the acquisition, subject to applicable adjustments made in connection with such acquisition.

In May 2015, our stockholders approved our 2015 ESPP, which authorizes the issuance of up to 200,000 shares of our common stock to eligible employees. In June 2018, at our annual meeting of stockholders, our stockholders approved an amendment to our 2015 ESPP to increase the maximum number of shares of our common stock that will be made available for sale thereunder by 500,000 shares. The terms of the 2015 ESPP permit eligible employees to purchase shares (subject to certain plan and tax limitations) in semi-annual offerings through payroll deductions of up to an annual maximum of 10% of the employee’s “compensation” as defined in the 2015 ESPP. Shares are purchased at a price equal to 85% of the fair market value of our common stock on either the first or last business day of the offering period, whichever is lower. Plan periods consist of six-month periods typically commencing June 1 and ending November 30 and commencing December 1 and ending May 31. As of December 31, 2019, 445,713 shares have been issued under our 2015 ESPP.

During 2019, we also granted equity through inducement grants outside of our equity compensation plans to certain employees to induce them to accept employment with us (collectively, “Inducement Grants”). The options were granted at an exercise price equal to the fair market value of a share of our common stock on the respective grant dates and will be exercisable in four equal annual installments beginning on the first anniversary of the respective grant dates. The RSU grants will vest in three equal annual installments beginning on the first anniversary of the respective grant dates. The foregoing grants were made pursuant to inducement grants outside of our stockholder approved equity plans as permitted under the NASDAQ Stock Market listing rules. We assessed the terms of these awards and determined there was no possibility that we would have to settle these awards in cash and therefore, equity accounting was applied.
Stock Options
The following table summarizes stock option activity during 2019:
 
2019 Equity
 
2007 Equity
 
2013 Lumara
 
Inducement
 
 
 
Plan
 
Plan
 
Equity Plan
 
Grants
 
Total
Outstanding at December 31, 2018
—

 
2,781,786

 
124,450

 
810,343

 
3,716,579

Granted
479,212

 
465,009

 
37,000

 
80,366

 
1,061,587

Exercised
—

 
(2,025
)
 
—

 
—

 
(2,025
)
Expired or terminated
(6,800
)
 
(659,304
)
 
(29,675
)
 
(194,545
)
 
(890,324
)
Outstanding at December 31, 2019
472,412

 
2,585,466

 
131,775

 
696,164

 
3,885,817


 
Restricted Stock Units
The following table summarizes RSU activity during 2019:
 
2019 Equity
 
2007 Equity
 
2013 Lumara
 
Inducement
 
 
 
Plan
 
Plan
 
Equity Plan
 
Grants
 
Total
Outstanding at December 31, 2018
—

 
1,041,141

 
2,101

 
85,293

 
1,128,535

Granted
132,542

 
1,023,847

 
1,100

 
29,385

 
1,186,874

Vested
—

 
(358,362
)
 
(1,034
)
 
(44,909
)
 
(404,305
)
Expired or terminated
(3,800
)
 
(299,321
)
 
—

 
(28,546
)
 
(331,667
)
Outstanding at December 31, 2019
128,742

 
1,407,305

 
2,167

 
41,223

 
1,579,437


 
In February 2019, March 2018 and February 2017, we granted RSUs under our 2007 Plan to certain members of our senior management covering a maximum of 365,591, 206,250 and 191,250 shares of common stock, respectively. These performance-based RSUs will vest, if at all, on February 24, 2022, March 1, 2021 and February 22, 2020, respectively, based on our total shareholder return (“TSR”) performance measured against the median TSR of a defined group of companies over a three-year period. As of December 31, 2019, the maximum shares of common stock that may be issued under these awards was 325,091, 155,250 and 131,250, respectively. The maximum aggregate total fair value of these RSUs at December 31, 2019 was $4.2 million, $2.9 million and $2.6 million, respectively, which is being recognized as expense over a period of three years from the date of grant, net of any estimated and actual forfeitures.

Equity-based compensation expense
Equity-based compensation expense for 2019, 2018 and 2017 consisted of the following (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Cost of product sales
$
871

 
$
802

 
$
884

Research and development
2,844

 
2,533

 
3,225

Selling, general and administrative
14,818

 
16,614

 
16,187

Total equity-based compensation expense
18,533

 
19,949

 
20,296

Income tax effect
—

 
—

 
(6,188
)
After-tax effect of equity-based compensation expense
$
18,533

 
$
19,949

 
$
14,108


 
In addition to the equity-based compensation expense presented in the table above, we incurred $0.7 million of equity-based compensation expense related to the restructuring activities during the first quarter of 2019, which is classified within restructuring expense on our consolidated statements of operations for the year ended December 31, 2019.
The following table summarizes the weighted average assumptions we utilized for purposes of valuing grants of options to our employees and non-employee directors:
 
Years Ended December 31,
 
2019
 
2018
 
2017
 
 
 
Non-Employee
 
 
 
Non-Employee
 
 
 
Non-Employee
 
Employees
 
Directors
 
Employees
 
Directors
 
Employees
 
Directors
Risk free interest rate (%)
2.12
 
2.04
 
2.75
 
2.70
 
1.86
 
1.61
Expected volatility (%)
57
 
59
 
57
 
59
 
53
 
57
Expected option term (years)
5.0
 
4.0
 
5.0
 
4.0
 
5.0
 
4.0
Dividend yield
none
 
none
 
none
 
none
 
none
 
none


Risk free interest rates utilized are based upon published U.S. Treasury yields at the date of the grant for the expected option term. During 2019, 2018 and 2017, we estimated our expected stock price volatility by using the historical volatility of our own common stock price over the prior period equivalent to our expected option term, in order to better reflect expected future volatility. To compute the expected option term, we analyze historical exercise experience as well as expected stock option exercise patterns.

The following table summarizes details regarding stock options granted under our equity incentive plans for the year ended December 31, 2019:
 
December 31, 2019
 
Options
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term
 
Aggregate Intrinsic Value
($ in thousands)
Outstanding at beginning of year
3,716,579

 
$
24.81

 
7.3

 
$
—

Granted
1,061,587

 
12.71

 
—

 
—

Exercised
(2,025
)
 
14.56

 
—

 
—

Expired and/or forfeited
(890,324
)
 
22.93

 
—

 
—

Outstanding at end of year
3,885,817

 
$
21.94

 
6.8

 
$
776

Outstanding at end of year - vested and unvested expected to vest
3,799,575

 
$
22.12

 
6.8

 
$
701

Exercisable at end of year
2,242,727

 
$
25.76

 
5.5

 
$
116



The weighted average grant date fair value of stock options granted during 2019, 2018 and 2017 was $6.33, $10.76 and $9.52, respectively. A total of 728,758 stock options vested during 2019. The aggregate intrinsic value of options exercised during 2019, 2018 and 2017, excluding purchases made pursuant to our 2015 ESPP, measured as of the exercise date, was approximately $0.0 million, $0.6 million and $0.4 million, respectively. The intrinsic value of a stock option is the amount by which the fair market value of the underlying stock on a specific date exceeds the exercise price of the common stock option.

The following table summarizes details regarding RSUs granted under our equity incentive plans for the year ended December 31, 2019:
 
December 31, 2019
 
Restricted Stock Units
 
Weighted Average Grant Date Fair Value
Outstanding at beginning of year
1,128,535

 
$
23.42

Granted
1,186,874

 
15.65

Vested
(404,305
)
 
22.49

Forfeited
(331,667
)
 
19.71

Outstanding at end of year
1,579,437

 
$
18.60

Outstanding at end of year and expected to vest
1,462,952

 
$
18.88



The weighted average grant date fair value of RSUs granted during 2019, 2018 and 2017 was $15.65, $22.32 and $24.18, respectively. The total fair value of RSUs that vested during 2019, 2018 and 2017 was $9.1 million, $12.4 million and $12.3 million, respectively.

At December 31, 2019, the amount of unrecorded equity-based compensation expense for both option and RSU awards, attributable to future periods was approximately $28.1 million. Of this amount, $11.5 million was associated with stock options and is expected to be amortized on a straight-line basis to expense over a weighted average period of approximately 2.5 years, $12.3 million was associated with RSUs and is expected to be amortized on a straight-line basis to expense over a weighted average period of approximately 1.7 years, and $4.3 million was associated with performance-based RSUs and is expected to be amortized on a straight-line basis to expense over a weighted average period of approximately 1.5 years. Such amounts will be amortized primarily to research and development or selling, general and administrative expense. These future estimates are subject to change based upon a variety of future events, which include, but are not limited to, changes in estimated forfeiture rates, employee turnover, and the issuance of new stock options and other equity-based awards.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.20.2
EMPLOYEE SAVINGS PLAN
 12 Months Ended
Dec. 31, 2019
Retirement Benefits [Abstract]  
EMPLOYEE SAVINGS PLAN EMPLOYEE SAVINGS PLAN
We provide a 401(k) Plan to our employees by which they may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code. Each employee may elect to defer a percentage of his or her salary up to a specified maximum. As of December 31, 2019 our 401(k) Plan provided, among other things, for a company contribution of 4% of each employee’s combined salary and certain other compensation for the plan year. Contributions by us to the 401(k) Plan are not taxable to employees until withdrawn from the 401(k) Plan and contributions are deductible by us when made. The amount of our company contribution for the 401(k) Plan was $3.7 million, $4.0 million and $2.3 million for 2019, 2018 and 2017, respectively.
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.20.2
STOCKHOLDERS’ EQUITY
 12 Months Ended
Dec. 31, 2019
Equity [Abstract]  
STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY

As of January 1, 2019, we had $20.5 million available under our previously approved program to repurchase up to $60.0 million in shares of our common stock. In March 2019, our Board authorized additional repurchases of shares in an amount up to $20.0 million under this program. The repurchase program does not have an expiration date and may be suspended for periods or discontinued at any time. Under the program, we may purchase our stock from time to time at the discretion of management in the open market or in privately negotiated transactions. The number of shares repurchased and the timing of the purchases will depend on a number of factors, including share price, trading volume and general market conditions, along with working capital requirements, general business conditions and other factors. We may also from time to time establish a trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934 to facilitate purchases of our shares under this program. During 2019, we repurchased and retired 1,074,800 shares of common stock under this repurchase program for $13.7 million. During 2018, we did not repurchase shares of common stock under this program. As of December 31, 2019, $26.8 million remains available for the repurchase of shares under the program.
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.20.2
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Commitments
Our long-term contractual obligations include commitments and estimated purchase obligations entered into in the normal course of business. These include commitments related to our facility and vehicle leases, purchases of inventory, debt obligations, and other purchase obligations.
Operating Lease Obligations
During 2019, we had operating leases for real estate, including our lease for use as our principal executive offices, vehicles and office equipment. As of January 1, 2019, we recorded operating lease liabilities of $8.5 million and related ROU assets of $7.6 million in connection with our adoption of ASC 842. During the fourth quarter of 2019, we modified the operating lease for our principal executive offices to extend the term through July 2028. As of December 31, 2019, we had operating lease liabilities of $23.9 million and related ROU assets of $23.3 million. As of December 31, 2019, our leases have remaining terms of one to 8.5 years. The weighted average remaining lease term and discount rate for our operating leases was 7.95 years and 5.1% at December 31, 2019, respectively.

Lease costs for our operating leases were $5.1 million, $5.1 million and $3.0 million for the years ended December 31, 2019, 2018 and 2017, respectively. Operating cash outflows for operating leases were $5.2 million for the year ended December 31, 2019.

Future minimum payments under our non-cancelable operating leases as of December 31, 2019 are as follows (in thousands):
Period
 
Future Minimum Lease Payments
Year Ending December 31, 2020
 
$
4,077

Year Ending December 31, 2021
 
3,207

Year Ending December 31, 2022
 
3,734

Year Ending December 31, 2023
 
3,230

Year Ending December 31, 2024
 
3,246

Thereafter
 
12,192

Total
 
$
29,686

Less: Interest
 
$
5,818

Operating lease liability
 
$
23,868



Purchase Obligations

Purchase obligations primarily represent minimum purchase commitments for inventory. As of December 31, 2019, our minimum purchase commitments totaled $105.9 million.

Contingent Regulatory and Commercial Milestone Payments

We are required to make payments contingent on the achievement of certain regulatory and/or commercial milestones under the terms of our collaboration, license and other strategic agreements. Please refer to Note Q, “Collaboration, License and Other Strategic Agreements” for additional details regarding these contingent payments.
Employment Arrangements

We have entered into employment agreements or other arrangements with most of our executive officers and certain other employees, which provide for the continuation of salary and certain benefits and, in certain instances, the acceleration of the vesting of certain equity awards to such individuals in the event that the individual is terminated other than for cause, as defined in the applicable employment agreements or arrangements.

Indemnification Obligations

As permitted under Delaware law, pursuant to our certificate of incorporation, by-laws and agreements with all of our current directors, executive officers, and certain of our employees, we are obligated to indemnify such individuals for certain events or occurrences while the officer, director or employee is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification obligations is not capped. Our director and officer insurance policy limits our initial exposure and our policy provides significant coverage. As a result, we believe the estimated fair value of these indemnification obligations is likely to be immaterial.

We are also a party to a number of other agreements entered into in the ordinary course of business, typically with business partners, contract manufacturers, clinical sites and customers, which contain typical provisions and which obligate us to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. Our aggregate maximum potential future liability under such indemnification provisions is uncertain. We have not incurred any expenses as a result of such indemnification provisions during the years ended December 31, 2019, 2018 or 2017. Accordingly, we have determined that the estimated aggregate fair value of our potential liabilities under such indemnification provisions is not significant, and we have not recorded any liability related to such indemnification.

Contingencies

Legal Proceedings

We accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss. We review these accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. For certain matters referenced below, the liability is not probable or the amount cannot be reasonably estimated and, therefore, accruals have not been made. In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, we will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, we will provide disclosure to that effect. We expense legal costs as they are incurred.
On November 6, 2019, we were served with a summons in a case filed in the U.S. District Court, Northern District of Ohio, captioned Civil Case in Saginaw Chippewa Indian Tribe v. Purdue Pharma et al (Case No. 1-19-op-45841). The complaint names K-V Pharmaceutical Company (“KV”) (Lumara Health’s predecessor company), certain of its successor entities, subsidiaries and affiliate entities as defendants, along with over forty other pharmaceutical companies. We acquired Lumara Health in November 2014, a year after KV emerged from bankruptcy protection, at which time it and its then-existing subsidiaries became our wholly-owned subsidiaries. The plaintiff in this action alleges that KV’s subsidiary, Ethex Corporation (as well as the other pharmaceutical companies named in the complaint), manufactured, promoted, sold, and distributed opioids, including a generic version of morphine. We are in discussions with the plaintiff’s counsel to dismiss all claims in the Chippewa case. At this time, based on available information, we are currently unable to predict the outcome or reasonably estimate the range of potential loss associated with this matter, if any.

On November 1, 2019, we were named as a defendant in a class action lawsuit filed in the United States District Court for the Western District of Missouri, captioned Barnes v. AMAG Pharmaceuticals, Inc., Case No. 3:19-cv-05088-RK (W.D. Mo.).  Subsequently, other plaintiffs represented by the same law firm have filed four similar class action lawsuits in other jurisdictions, captioned Gill v. AMAG Pharmaceuticals, Inc., Case No. 2:19-cv-02681-DDC-JPO (D. Kan., filed Nov. 4, 2019), Faughnan, et al. v. AMAG Pharmaceuticals, Inc., Case No. 3:19-cv-01394-FJS-ML (N.D.N.Y, filed Nov. 12, 2019), Zamifrova v. AMAG Pharmaceuticals, Inc., Case No. 2:20-cv-00152-JMV-SCM (D.N.J., filed Jan. 3, 2020) and Nelson v. AMAG Pharmaceuticals, Inc., Case No. 2:20-cv-00089-WBS-DMC (E.D. Cal., filed Jan. 13, 2020). The plaintiffs in these actions, on behalf of themselves and purported state-wide classes of similarly situated consumers, assert claims for violation of state consumer protection laws and unjust enrichment based on allegations that we and/or our predecessor companies made misrepresentations and omissions regarding the effectiveness of Makena in connection with the sale and marketing of that product from 2011 through the present. Because these cases are in the earliest stages, we are currently unable to predict the outcome or reasonably estimate the range of potential loss associated with this matter, if any.

On August 29, 2019, Lunar Representative, LLC (“Plaintiff”), on behalf of the former equityholders of Lumara Health Inc. (“Lumara”), filed a complaint against us in the Delaware Court of Chancery, captioned Lunar Representative, LLC v. AMAG Pharmaceuticals, Inc. (No. 2019-0688-JTL). On September 25, 2019, we filed a motion to dismiss the complaint. On January 9,
2020, Plaintiff filed an amended complaint. Plaintiff alleges that we did not exercise commercially reasonable efforts to market and sell the drug product Makena, and failed to achieve sales milestones for Makena, in breach of certain provisions of the September 28, 2014 Agreement and Plan of Merger between, among other parties, us and Lumara. On January 24, 2020, we filed a motion to dismiss the amended complaint. Plaintiff is seeking damages of $50.0 million, together with pre- and post-judgment interest, as well as attorneys’ fees and costs. At this time, based on available information, we are unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses. We believe this lawsuit is without merit and intend to vigorously defend against the allegations.  

On or about April 6, 2016, we received Notice of a Lawsuit and Request to Waive Service of a Summons in a case entitled Plumbers’ Local Union No. 690 Health Plan v. Actavis Group et. al. (“Plumbers’ Union”), which was filed in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania and, after removal to federal court, is now pending in the United States District Court for the Eastern District of Pennsylvania (Civ. Action No. 16-65-AB). Thereafter, we were also made aware of a related complaint entitled Delaware Valley Health Care Coalition v. Actavis Group et. al. (“Delaware Valley”), which was filed with the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania District Court of Pennsylvania (Case ID: 160200806). The complaints name K-V Pharmaceutical Company (“KV”) (Lumara Health’s predecessor company), certain of its successor entities, subsidiaries and affiliate entities (the “Subsidiaries”), along with a number of other pharmaceutical companies. We acquired Lumara Health in November 2014, a year after KV emerged from bankruptcy protection, at which time it, along with its then existing subsidiaries, became our wholly-owned subsidiary. We have not been served with process or waived service of summons in either case. The actions are being brought alleging unfair and deceptive trade practices with regard to certain pricing practices that allegedly resulted in certain payers overpaying for certain of KV’s generic products. On July 21, 2016, the Plaintiff in the Plumbers’ Union case dismissed KV with prejudice to refiling and on October 6, 2016, all claims against the Subsidiaries were dismissed without prejudice. We are in discussions with Plaintiff’s counsel to similarly dismiss all claims in the Delaware Valley case. Because we have not been served with process in the Delaware Valley case, we are currently unable to predict the outcome or reasonably estimate the range of potential loss associated with this matter, if any.

On July 20, 2015, the Federal Trade Commission (the “FTC”) notified us that it is conducting an investigation into whether Lumara Health or its predecessor engaged in unfair methods of competition with respect to Makena or any hydroxyprogesterone caproate product. The FTC noted in its letter that the existence of the investigation does not indicate that the FTC has concluded that Lumara Health or its predecessor has violated the law and we believe that our contracts and practices comply with relevant law and policy, including the federal Drug Quality and Security Act (the “DQSA”), which was enacted in November 2013, and public statements from and enforcement actions by the FDA regarding its implementation of the DQSA. We have provided the FTC with a response providing a brief overview of the DQSA for context, which we believe was helpful, including: (a) how the statute outlined that large-scale compounding of products that are copies or near-copies of FDA-approved drugs (like Makena) is not in the interests of public safety; (b) our belief that the DQSA has had a significant impact on the compounding of hydroxyprogesterone caproate; and (c) how our contracts with former compounders allow those compounders to continue to serve physicians and patients with respect to supplying medically necessary alternative/altered forms of hydroxyprogesterone caproate. We believe we have fully cooperated with the FTC and we have had no further interactions with the FTC on this matter since we provided our response to the FTC in August 2015.
We may periodically become subject to other legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which we are focused. Other than the above actions, we are not aware of any material claims against us as of December 31, 2019 or 2018.
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.20.2
COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS
 12 Months Ended
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS
During 2019, we were a party to the following collaboration, license or other strategic agreements:
Perosphere

On January 16, 2019, we acquired Perosphere Pharmaceuticals Inc. (“Perosphere”) pursuant to the Agreement and Plan of Merger (the “Perosphere Agreement”), dated as of December 12, 2018 between AMAG and Perosphere. Pursuant to the Perosphere Agreement, in January 2019, we paid approximately $50.0 million (the “Upfront Merger Consideration”). Of the Upfront Merger Consideration, approximately $40.0 million was funded from our available cash and approximately $10.0 million was deemed paid in connection with the cancellation of a convertible note in the principal amount of $10.0 million issued to us by Perosphere in October 2018. In addition to the Upfront Merger Consideration, we used available cash to repay $12.0 million of Perosphere’s term loan indebtedness and approximately $6.2 million of Perosphere’s other liabilities. We are also required to pay regulatory and sales milestone payments to Perosphere as described in more detail below. Further, we were
a party to a clinical trial collaboration agreement with a pharmaceutical company, which we acquired through the Perosphere transaction, which provided for partial funding of the Phase 3 program for ciraparantag if certain clinical milestones were met. In December 2019, the clinical trial collaboration agreement with the pharmaceutical company was terminated as described in more detail in Note D, “Revenue Recognition.”

Substantially all of the fair value of the assets acquired in conjunction with the Perosphere transaction was concentrated in the IPR&D asset. As a result, we accounted for this transaction as an asset acquisition under ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”). The acquired IPR&D was charged to expense at acquisition, as it relates to a development stage compound with no alternative future use. A summary of the assets and liabilities acquired in exchange for cash consideration of $60.8 million and $10.0 million that was deemed paid in connection with the cancellation of the convertible note, described above, is presented in the following table (in millions):
Assets:
 
Cash
$
2.6

Operating lease right-of-use asset
0.8

Property and equipment
1.4

IPR&D
74.9

 
$
79.7

Liabilities:
 
Accrued severance liabilities
$
(1.7
)
Deferred revenue
(6.4
)
Operating lease liability
(0.8
)
 
$
(8.9
)


Excluded from the table above are contingent payments associated with achievement of potential regulatory and sales milestones as described below, which were not deemed probable at the date of acquisition. The fair values of certain of the assets and liabilities acquired are classified as Level 3 estimates under the fair value hierarchy as they have been valued using unobservable inputs. These inputs include: (a) the estimated amount and timing of projected cash flows; (b) the probability of the achievement of key development and regulatory objectives; and (c) the risk-adjusted discount rate used to present value the probability-weighted cash flows. The fair values of the assets and liabilities acquired were initially valued and recorded based on various market factors, including an analysis of estimated sales using a discount rate of approximately 34%.

Under and subject to the terms and conditions set forth in the Perosphere Agreement, we are obligated to pay future contingent consideration of up to an aggregate of $365.0 million (the “Milestone Payments”), including (a) up to an aggregate of $140.0 million that becomes payable upon the achievement of specified regulatory milestones for ciraparantag (the “Regulatory Milestone Payments”), including a $40.0 million milestone payment upon approval of ciraparantag by the European Medicines Agency and (b) up to an aggregate of $225.0 million that becomes payable conditioned upon the achievement of specified sales milestones (the “Sales Milestone Payments”). If the final label approved for ciraparantag in the U.S. includes a boxed warning, the Regulatory Milestone Payments shall no longer be payable, and any previously paid Regulatory Milestone Payments shall be credited against 50% of any future Milestone Payments that otherwise becomes payable. The first sales milestone payment of $20.0 million will be payable upon annual net sales of ciraparantag of at least $100.0 million.
Velo

In September 2018, we exercised our option to acquire the global rights to AMAG-423 pursuant to an option agreement entered into in July 2015 with Velo Bio, LLC (“Velo”), the terms of which were amended at the time of exercise. Under the terms of the agreement, we paid Velo an upfront option exercise fee of $12.5 million and are obligated to pay Velo a $30.0 million milestone payment upon FDA approval of AMAG-423. In addition, we are obligated to pay sales milestone payments to Velo of up to $240.0 million in the aggregate, triggered at various annual net sales thresholds between $300.0 million and $900.0 million and low-single digit royalties based on net sales. Further, we have assumed additional obligations under a previous agreement entered into by Velo with a third-party, including a $5.0 million milestone payment upon regulatory approval and $10.0 million following the first commercial sale of AMAG-423, payable in quarterly installments as a percentage of quarterly gross commercial sales until the obligation is met. We are also obligated to pay the third-party low-single digit royalties based on net sales. We accounted for this transaction as an asset acquisition under ASU 2017-01.
Prasco

In December 2017, we entered into a Distribution and Supply Agreement (the “Prasco Agreement”) with Prasco, LLC (“Prasco”), under which Prasco was granted an exclusive, non-sublicensable, nontransferable license to purchase, distribute and sell a generic version of Makena in the U.S. (the “Makena authorized generic”). In July 2018, Prasco launched the Makena authorized generic of both the single-dose and multi-dose IM injections and in August 2019, we and Prasco terminated the Prasco Agreement based on our determination that it was not commercially viable to continue the relationship. Under the Prasco Agreement, we were responsible for the manufacture and supply of the Makena authorized generic to be sold to Prasco at a predetermined supply price. Prasco was also required to pay us a certain percentage of the net distributable profits from the sale of the Makena authorized generic. We accounted for revenue recognized under the Prasco Agreement in accordance with ASC 606. Pursuant to the terms of the Prasco Agreement, in certain circumstances we have reimbursed Prasco as a result of our failure to supply a certain percentage of product ordered by Prasco in a prespecified timeframe. During the year ended December 31, 2019, we incurred $3.5 million of failure to supply penalties, the majority of which were incurred in the first quarter of 2019.
Antares

We are party to a development and license agreement (the “Antares License Agreement”) with Antares Pharma, Inc. (“Antares”), which grants us an exclusive, worldwide, royalty-bearing license, with the right to sublicense, to certain intellectual property rights, including know-how, patents and trademarks, to develop, use, sell, offer for sale and import and export the Makena auto-injector. Under the terms of the Antares License Agreement, as amended in March 2018, we are responsible for the clinical development and preparation, submission and maintenance of all regulatory applications in each country where we desire to market and sell the Makena auto-injector, including the U.S. We are required to pay royalties to Antares on net sales of the Makena auto-injector until the Antares License Agreement is terminated (the “Antares Royalty Term”). The royalty rates range from high single digit to low double digits and are tiered based on levels of net sales of the Makena auto-injector and decrease after the expiration of licensed patents or where there are generic equivalents to the Makena auto-injector being sold in a particular country. In addition, we are required to pay Antares sales milestone payments upon the achievement of certain annual net sales. The Antares License Agreement terminates at the end of the Antares Royalty Term, but is subject to early termination by us for convenience and by either party upon an uncured breach by or bankruptcy of the other party. In March 2018, the Antares License Agreement was amended to, among other things, transfer the agreement to AMAG from our subsidiary, amend certain confidentiality provisions, and to provide for co-termination with the Antares Manufacturing Agreement (described below).

We are also party to a Manufacturing Agreement with Antares (the “Antares Manufacturing Agreement”) that sets forth the terms and conditions pursuant to which Antares agreed to sell to us on an exclusive basis, and we agreed to purchase, the fully packaged Makena auto-injector for commercial distribution. Antares remains responsible for the manufacture and supply of the device components and assembly of the Makena auto-injector. We are responsible for the supply of the drug to be used in the assembly of the finished auto-injector product. The Antares Manufacturing Agreement terminates at the expiration or earlier termination of the Antares License Agreement, but is subject to early termination by us for certain supply failure situations, and by either party upon an uncured breach by or bankruptcy of the other party or our permanent cessation of commercialization of the Makena auto-injector for efficacy or safety reasons.

Endoceutics

In February 2017, we entered into the Endoceutics License Agreement with Endoceutics, Inc. (“Endoceutics”) to obtain an exclusive right to commercialize Intrarosa for the treatment of vulvar and vaginal atrophy (“VVA”) and FSD in the United States. We have agreed to use commercially reasonable efforts to market, promote and otherwise commercialize Intrarosa for the treatment of VVA. The transactions contemplated by the Endoceutics License Agreement closed on April 3, 2017. We accounted for the Endoceutics License Agreement as an asset acquisition under ASU 2017-01.
Upon the closing of the Endoceutics License Agreement, we made an upfront payment of $50.0 million and issued 600,000 shares of unregistered common stock to Endoceutics, which had a value of $13.5 million, as measured on April 3, 2017, the date of closing. In addition, we paid Endoceutics $10.0 million in the third quarter of 2017 upon the delivery by Endoceutics of Intrarosa launch quantities and $10.0 million in 2018 following the first anniversary of the closing. In the second quarter of 2017, we recorded a total of $83.5 million of consideration, of which $77.7 million was allocated to the Intrarosa developed technology intangible asset and $5.8 million was recorded as IPR&D expense based on their relative fair values.
Under the terms of the Endoceutics License Agreement, we pay tiered royalties to Endoceutics equal to a percentage of net sales of Intrarosa in the U.S. ranging from mid-teens to mid twenty percent. Endoceutics is also eligible to receive certain sales
milestone payments up to an aggregate of $895.0 million, including a first sales milestone payment of $15.0 million, which would be triggered when Intrarosa annual net U.S. sales exceed $150.0 million.

In April 2017, we entered into an exclusive commercial supply agreement with Endoceutics pursuant to which Endoceutics, itself or through affiliates or contract manufacturers, agreed to manufacture and supply Intrarosa to us (the “Endoceutics Supply Agreement”) and is our exclusive supplier of Intrarosa in the U.S., subject to certain rights for us to manufacture and supply Intrarosa in the event of a cessation notice or supply failure (as such terms are defined in the Endoceutics Supply Agreement). The Endoceutics Supply Agreement will generally remain in effect until the termination of the Endoceutics License Agreement.
The Endoceutics License Agreement expires on the date of expiration of all royalty obligations due thereunder unless earlier terminated in accordance with the Endoceutics License Agreement.
Palatin
In January 2017, we entered into a license agreement with Palatin Technologies, Inc. (“Palatin”) under which we acquired (a) an exclusive license in all countries of North America (the “Palatin Territory”), with the right to grant sub-licenses, to research, develop and commercialize the Vyleesi Products, (b) a worldwide non-exclusive license, with the right to grant sub-licenses, to manufacture the Vyleesi Products, and (c) a non-exclusive license in all countries outside the Palatin Territory, with the right to grant sub-licenses, to research and develop (but not commercialize) the Vyleesi Products (the “Palatin License Agreement”). The transaction closed in February 2017 and was accounted for as an asset acquisition under ASU 2017-01.
Under the terms of the Palatin License Agreement, in February 2017 we paid Palatin $60.0 million as a one-time upfront payment and subject to agreed-upon deductions reimbursed Palatin approximately $25.0 million for reasonable, documented, out-of-pocket expenses incurred by Palatin in connection with the development and regulatory activities necessary to submit the Vyleesi New Drug Application (“NDA”) in the U.S. The $60.0 million upfront payment made in February 2017 to Palatin was recorded as IPR&D expense as the product candidate had not received regulatory approval. In June 2018, our NDA submission to the FDA for Vyleesi was accepted, which triggered a $20.0 million milestone payment, which we paid in the second quarter of 2018 and recorded as an IPR&D expense in the first quarter of 2018 when acceptance was deemed probable. In June 2019, the FDA approval of Vyleesi triggered a $60.0 million milestone payment to Palatin, which we paid in July 2019 and recorded as a developed technology intangible asset in the second quarter of 2019.
In addition, the Palatin License Agreement requires us to make contingent payments of up to $300.0 million of aggregate sales milestone payments upon the achievement of certain annual net sales milestones over the course of the license. The first sales milestone payment of $25.0 million will be triggered when Vyleesi annual net sales exceed $250.0 million. We are also obligated to pay Palatin tiered royalties on annual net sales of the Vyleesi Products, on a product-by-product basis, in the Palatin Territory ranging from the high-single digits to the low double-digits. After the expiration of the applicable royalties for any Vyleesi Product in a given country, the license for such Vyleesi Product in such country would become a fully paid-up, royalty-free, perpetual and irrevocable license. The Palatin License Agreement expires on the date of expiration of all royalty obligations due thereunder, unless earlier terminated in accordance with the Palatin License Agreement.
Abeona
We acquired the U.S. commercial rights to MuGard, a prescription oral mucoadhesive, under a June 2013 license agreement with Abeona (the “MuGard Rights”). We ceased selling MuGard at the end of 2019.
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT
 12 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
DEBT DEBT

Our outstanding debt obligations as of December 31, 2019 and December 31, 2018 consisted of the following (in thousands):
 
December 31,
 
2019
 
2018
2022 Convertible Notes
$
277,034

 
$
261,933

2019 Convertible Notes
—

 
21,276

Total long-term debt
277,034

 
283,209

Less: current maturities
—

 
21,276

Long-term debt, net of current maturities
$
277,034

 
$
261,933


 
Convertible Notes
The outstanding balances of our Convertible Notes as of December 31, 2019 consisted of the following (in thousands):
 
 
2022 Convertible Notes
Liability component:
 
 

Principal
 
$
320,000

Less: debt discount and issuance costs, net
 
42,966

Net carrying amount
 
$
277,034

Gross equity component
 
$
72,576



In accordance with accounting guidance for debt with conversion and other options, we separately account for the liability and equity components of our Convertible Notes by allocating the proceeds between the liability component and the embedded conversion option (the “Equity Component”) due to our ability to settle the Convertible Notes in cash, common stock or a combination of cash and common stock, at our option. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The allocation was performed in a manner that reflected our non-convertible debt borrowing rate for similar debt. The Equity Component of the Convertible Notes was recognized as a debt discount and represents the difference between the proceeds from the issuance of the Convertible Notes and the fair value of the liability of the Convertible Notes on their respective dates of issuance. The excess of the principal amount of the liability component over its carrying amount (the “Debt Discount”) is amortized to interest expense using the effective interest method over five years. The Equity Component is not remeasured as long as it continues to meet the conditions for equity classification.
2022 Convertible Notes
In the second quarter of 2017, we issued $320.0 million aggregate principal amount of convertible senior notes due in 2022 and received net proceeds of $310.4 million from the sale of the 2022 Convertible Notes, after deducting fees and expenses of $9.6 million. The approximately $9.6 million of debt issuance costs primarily consisted of underwriting, legal and other professional fees, and allocated these costs to the liability and equity components based on the allocation of the proceeds. Of the total $9.6 million of debt issuance costs, $2.2 million was allocated to the Equity Component and recorded as a reduction to additional paid-in capital and $7.4 million was allocated to the liability component and is now recorded as a reduction of the 2022 Convertible Notes in our consolidated balance sheet. The portion allocated to the liability component is amortized to interest expense using the effective interest method over five years.
The 2022 Convertible Notes are governed by the terms of an indenture between us, as issuer, and Wilmington Trust, National Association, as the trustee. The 2022 Convertible Notes are senior unsecured obligations and bear interest at a rate of 3.25% per year, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2017. The 2022 Convertible Notes will mature on June 1, 2022, unless earlier repurchased or converted. Upon conversion of the 2022 Convertible Notes, such 2022 Convertible Notes will be convertible into, at our election, cash, shares of our common stock, or a combination thereof, at a conversion rate of 36.5464 shares of common stock per $1,000 principal amount of the 2022 Convertible Notes, which corresponds to an initial conversion price of approximately $27.36 per share of our common stock.
The conversion rate is subject to adjustment from time to time upon the occurrence of certain events, including, but not limited to, the issuance of stock dividends and payment of cash dividends. At any time prior to the close of business on the business day immediately preceding March 1, 2022, holders may convert their 2022 Convertible Notes at their option only under the following circumstances:
1)
during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending September 30, 2017, if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
2)
during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of the 2022 Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or
3)
upon the occurrence of specified corporate events.
On or after March 1, 2022, until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their 2022 Convertible Notes, in multiples of $1,000 principal amount, at the option of the holder regardless of the foregoing circumstances. The 2022 Convertible Notes were not convertible as of December 31, 2019.
We determined the expected life of the debt was equal to the five-year term on the 2022 Convertible Notes. The effective interest rate on the liability component was 9.49% for the period from the date of issuance through December 31, 2019. As of December 31, 2019, the “if-converted value” did not exceed the remaining principal amount of the 2022 Convertible Notes.
2019 Convertible Notes
In February 2014, we issued $200.0 million aggregate principal amount of 2019 Convertible Notes. We received net proceeds of $193.3 million from the sale of the 2019 Convertible Notes, after deducting fees and expenses of $6.7 million. We used $14.1 million of the net proceeds from the sale of the 2019 Convertible Notes to pay the cost of the convertible bond hedges, as described below (after such cost was partially offset by the proceeds to us from the sale of warrants in the warrant transactions described below). The 2019 Convertible Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on February 15 and August 15 of each year.
In 2017, we entered into two privately negotiated transactions with certain investors to repurchase approximately $178.5 million aggregate principal amount of the 2019 Convertible Notes for an aggregate repurchase price of approximately $192.7 million, including accrued interest. Pursuant to ASC Topic 470, Debt (“ASC 470”), we concluded that the 2017 repurchases of 2019 Convertible Notes should be accounted for as extinguishments and we recorded a net debt extinguishment loss of $0.1 million related to the difference between the consideration paid, the fair value of the liability component and carrying values at the repurchase date. The remaining $21.4 million of 2019 Convertible Notes matured on February 15, 2019 and were settled with cash.
Convertible Notes Interest Expense
The following table sets forth total interest expense recognized related to the 2022 Convertible Notes and 2019 Convertible Notes during 2019, 2018, and 2017 (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Contractual interest expense
$
10,467

 
$
10,935

 
$
8,961

Amortization of debt issuance costs
1,412

 
1,403

 
1,275

Amortization of debt discount
13,830

 
13,414

 
11,071

Total interest expense
$
25,709

 
$
25,752

 
$
21,307


Convertible Bond Hedge and Warrant Transactions
In February 2014 we entered into convertible bond hedge transactions and separate warrant transactions of our common stock underlying the aggregate principal amount of the 2019 Convertible Notes with certain financial institutions (the “call spread counterparties”). In connection with our 2017 repurchases of the 2019 Convertible Notes, as discussed above, we entered into agreements with the call spread counterparties to terminate a portion of the then existing convertible bond hedge transactions in an amount corresponding to the amount of such 2019 Convertible Notes repurchased and to terminate a portion of the then-existing warrant transactions. In February 2019, the 2019 Convertible Notes were settled with cash and the remaining bond hedge and warrant transactions expired.
2023 Senior Notes
In August 2015, in connection with the CBR acquisition, we completed a private placement of $500 million aggregate principal amount of 7.875% Senior Notes due 2023 (the “2023 Senior Notes”). The 2023 Senior Notes were issued pursuant to an Indenture, dated as of August 17, 2015 (the “Indenture”), by and among us, certain of our subsidiaries acting as guarantors of the 2023 Senior Notes and Wilmington Trust, National Association, as trustee. In October 2017, we repurchased $25.0 million of the 2023 Senior Notes in a privately negotiated transaction, resulting in a loss on extinguishment of debt of $1.1 million. In September 2018, we repurchased the remaining $475.0 million of the 2023 Senior Notes at a premium of $28.1 million using the proceeds from the CBR sale, which resulted in a loss on extinguishment of debt of $35.9 million, inclusive of the premium paid.
2015 Term Loan Facility
In August 2015, we entered into a credit agreement with a group of lenders, including Jefferies Finance LLC as administrative and collateral agent, that provided us with, among other things, a six-year $350.0 million term loan facility,
under which we borrowed the full amount (the “2015 Term Loan Facility”). In May 2017, we repaid the remaining outstanding borrowings and accrued interest of the 2015 Term Loan Facility and, in accordance with ASC 470, recognized a $9.7 million loss on debt extinguishment.
Future Payments
Future annual principal payments on our long-term debt as of December 31, 2019 include $320.0 million due during the year ended December 31, 2022.
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.20.2
RESTRUCTURING EXPENSES
 12 Months Ended
Dec. 31, 2019
Restructuring and Related Activities [Abstract]  
RESTRUCTURING EXPENSES RESTRUCTURING EXPENSES
In February 2019, we completed a restructuring to combine our women’s health and maternal health sales forces into one integrated sales team. Approximately 110 employees were displaced through this workforce reduction. We recorded one-time restructuring charges of $7.4 million primarily related to severance and related benefits on our consolidated statement of operations for the year ended December 31, 2019. We expect the restructuring charges incurred to date under this program to be substantially paid in cash by the end of the first quarter of 2020.
The following table displays charges taken related to restructuring activities during the year ended December 31, 2019 and a rollforward of the changes to the accrued balances as of December 31, 2019 (in thousands): 
 
Workforce reduction
 
Contract termination
 
Other
 
Total
Balance accrued at December 31, 2018
$
—

 
$
—

 
$
—

 
$
—

2019 restructuring charges
7,034

 
229

 
157

 
7,420

Payments
(6,237
)
 
(229
)
 
(157
)
 
(6,623
)
Balance accrued at December 31, 2019
$
797

 
$
—

 
$
—

 
$
797
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED
 12 Months Ended
Dec. 31, 2019
Condensed Financial Information Disclosure [Abstract]  
CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED
The following tables provide unaudited consolidated quarterly financial data for 2019 and 2018, which have been revised to correct for immaterial errors in prior periods as detailed below and further described in Note X, “Revision of Prior Period Financial Statements” (in thousands, except per share data):
 
March 31, 2019
 
June 30, 2019
 
September 30, 2019
 
December 31, 2019
Total revenues
$
75,488

 
$
77,767

 
$
83,808

 
$
89,483

Gross profit
57,011

 
53,477

 
62,703

 
46,162

Operating expenses (1)
175,024

 
169,662

 
81,050

 
240,329

Net loss from continuing operations
$
(122,400
)
 
$
(121,169
)
 
$
(23,940
)
 
$
(200,152
)
Net income (loss) from discontinued operations
$
—

 
$
—

 
$
—

 
$
—

Net loss
$
(122,400
)
 
$
(121,169
)
 
$
(23,940
)
 
$
(200,152
)
 
 
 
 
 
 
 
 
Basic and diluted earnings per share:
 
 
 
 
 
 
 
Loss from continuing operations
$
(3.55
)
 
$
(3.58
)
 
$
(0.71
)
 
$
(5.90
)
Income (loss) from discontinued operations
—

 
—

 
—

 
—

Total
$
(3.55
)
 
$
(3.58
)
 
$
(0.71
)
 
$
(5.90
)
 
March 31, 2018
 
June 30, 2018
 
September 30, 2018
 
December 31, 2018
Total revenues
$
116,867

 
$
145,663

 
$
121,646

 
$
87,871

Gross profit
52,955

 
68,887

 
75,157

 
59,155

Operating expenses (2)
104,239

 
27,591

 
95,084

 
78,241

Net loss from continuing operations
$
(58,994
)
 
$
(26,795
)
 
$
(65,282
)
 
$
(21,004
)
Net income (loss) from discontinued operations
$
3,856

 
$
5,736

 
$
95,517

 
$
(1,531
)
Net (loss) income
$
(55,138
)
 
$
(21,059
)
 
$
30,235

 
$
(22,535
)
 
 
 
 
 
 
 
 
Basic and diluted earnings per share:
 
 
 
 
 
 
 
Loss from continuing operations
$
(1.72
)
 
$
(0.78
)
 
$
(1.89
)
 
$
(0.61
)
Income (loss) from discontinued operations
0.11

 
0.17

 
2.77

 
(0.04
)
Total
$
(1.61
)
 
$
(0.61
)
 
$
0.88

 
$
(0.65
)
The sum of quarterly earnings per share totals differ from annual earnings per share totals due to rounding.

(1) 
Operating expenses for the first quarter of 2019 include $74.9 million relating to IPR&D acquired through the Perosphere acquisition and $7.4 million relating to the restructuring expenses for the consolidation of the women’s health and maternal health sales forces. Operating expenses for the second quarter of 2019 include $77.4 million of impairment charges relating to the Makena base technology intangible asset. Operating expenses for the fourth quarter of 2019 include $155.0 million of impairment charges relating to the Makena auto-injector, Intrarosa and Vyleesi asset groups.

(2) 
Operating expenses for the second quarter of 2018 include the reversal of $49.8 million relating to the fair value of a contingent consideration liability that was no longer expected to be paid.

The following tables present the effect of the revisions to our unaudited condensed consolidated statements of operations for the three months ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 to correct for immaterial errors in prior periods as further described in Note X, “Revision of Prior Period Financial Statements” (in thousands, except per share amounts):

 
Three Months Ended March 31, 2019
 
Three Months Ended June 30, 2019
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
75,729

 
$
(316
)
 
$
75,413

 
$
77,976

 
$
(342
)
 
$
77,634

Total revenues
75,804

 
(316
)
 
75,488

 
78,109

 
(342
)
 
77,767

Income tax (benefit) expense
(137
)
 
—

 
(137
)
 
(120
)
 
—

 
(120
)
Net loss
$
(122,084
)
 
$
(316
)
 
$
(122,400
)
 
$
(120,827
)
 
$
(342
)
 
$
(121,169
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
(3.54
)
 
$
(0.01
)
 
$
(3.55
)
 
$
(3.57
)
 
$
(0.01
)
 
$
(3.58
)

 
Three Months Ended September 30, 2019
 
Three Months Ended December 31, 2019
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
84,107

 
$
(323
)
 
$
83,784

 
$
73,378

 
$
(224
)
 
$
73,154

Total revenues
84,131

 
(323
)
 
83,808

 
89,707

 
(224
)
 
89,483

Income tax (benefit) expense
232

 
—

 
232

 
(21
)
 
—

 
(21
)
Net loss
$
(23,617
)
 
$
(323
)
 
$
(23,940
)
 
$
(199,928
)
 
$
(224
)
 
$
(200,152
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
(0.70
)
 
$
(0.01
)
 
$
(0.71
)
 
$
(5.89
)
 
$
(0.01
)
 
$
(5.90
)


The following tables present the effect of the revisions to our unaudited condensed consolidated statements of operations for the three months ended March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018 to correct for immaterial errors in prior periods as further described in Note X, “Revision of Prior Period Financial Statements” (in thousands, except per share amounts):

 
Three Months Ended March 31, 2018
 
Three Months Ended June 30, 2018
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
117,348

 
$
(520
)
 
$
116,828

 
$
146,219

 
$
(591
)
 
$
145,628

Total revenues
117,387

 
(520
)
 
116,867

 
146,254

 
(591
)
 
145,663

Income tax (benefit) expense
(8,000
)
 
376

 
(7,624
)
 
52,556

 
387

 
52,943

Net loss
$
(54,242
)
 
$
(896
)
 
$
(55,138
)
 
$
(20,081
)
 
$
(978
)
 
$
(21,059
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
(1.59
)
 
$
(0.02
)
 
$
(1.61
)
 
$
(0.58
)
 
$
(0.03
)
 
$
(0.61
)

 
Three Months Ended September 30, 2018
 
Three Months Ended December 31, 2018
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
122,238

 
$
(592
)
 
$
121,646

 
$
88,047

 
$
(251
)
 
$
87,796

Total revenues
122,238

 
(592
)
 
121,646

 
88,122

 
(251
)
 
87,871

Income tax (benefit) expense
(2,352
)
 
12

 
(2,340
)
 
(2,550
)
 
7

 
(2,543
)
Net loss
$
30,839

 
$
(604
)
 
$
30,235

 
$
(22,277
)
 
$
(258
)
 
$
(22,535
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
0.89

 
$
(0.01
)
 
$
0.88

 
$
(0.64
)
 
$
(0.01
)
 
$
(0.65
)
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.20.2
VALUATION AND QUALIFYING ACCOUNTS
 12 Months Ended
Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
VALUATION AND QUALIFYING ACCOUNTS
VALUATION AND QUALIFYING ACCOUNTS (IN THOUSANDS)
 
Balance at Beginning of Period
 
Additions (2)
 
Deductions Charged to Reserves
 
Balance at End of Period
Year ended December 31, 2019:
 
 
 
 
 
 
 
Accounts receivable allowances(1)
$
9,543

 
$
324,542

 
$
(310,668
)
 
$
23,417

Rebates, fees and returns reserves(2)
$
81,868

 
$
321,210

 
$
(283,653
)
 
$
119,425

Valuation allowance for deferred tax assets (3)
$
114,516

 
$
104,858

 
$
(1,083
)
 
$
218,291

Year ended December 31, 2018:
 
 
 
 
 
 
 
Accounts receivable allowances(1)
$
12,060

 
$
229,509

 
$
(232,026
)
 
$
9,543

Rebates, fees and returns reserves(2)
$
103,846

 
$
272,913

 
$
(294,891
)
 
$
81,868

Valuation allowance for deferred tax assets (3)
$
4,740

 
$
109,800

 
$
(24
)
 
$
114,516

Year ended December 31, 2017:
 
 
 
 
 
 
 
Accounts receivable allowances(1)
$
9,533

 
$
168,945

 
$
(166,418
)
 
$
12,060

Rebates, fees and returns reserves(2)
$
90,809

 
$
257,273

 
$
(244,236
)
 
$
103,846

Valuation allowance for deferred tax assets (3)
$
1,429

 
$
3,875

 
$
(564
)
 
$
4,740

________________________

(1) 
Accounts receivable allowances represent discounts and other chargebacks related to the provision of our product sales.

(2) 
Additions to rebates, fees and returns reserves are recorded as a reduction of revenues.

(3) 
As of December 31, 2019 and 2018, we have established a valuation allowance on our net deferred tax assets other than refundable AMT credits. At December 31, 2017, our valuation allowance related primarily to certain of our state NOL and credit carryforwards.
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.20.2
RECENTLY ISSUED AND PROPOSED ACCOUNTING PRONOUNCEMENTS
 12 Months Ended
Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]  
RECENTLY ISSUED AND PROPOSED ACCOUNTING PRONOUNCEMENTS RECENTLY ISSUED AND PROPOSED ACCOUNTING PRONOUNCEMENTS
From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by us as of the specified effective date.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. We adopted ASU 2016-13 effective January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on our consolidated financial statements.
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.20.2
RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS
 12 Months Ended
Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]  
RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASC 842”). This standard requires an entity to recognize on its balance sheet assets and liabilities associated with the rights and obligations created by leases with terms greater than twelve months. We adopted the standard effective January 1, 2019. We chose to apply the provisions of ASC 842 as of the effective date with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected to utilize the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also made accounting policy elections to not separate lease and non-lease components for our real estate lease and to not recognize leases with an initial term of twelve months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis on our condensed consolidated statements of income over the lease term.
In preparation for adoption of the standard, we implemented internal controls to enable the preparation of the related financial information. The adoption of this standard resulted in the recognition of operating lease liabilities of $8.5 million and related ROU assets of $7.6 million on our condensed consolidated balance sheets as of January 1, 2019, but did not have an impact on our consolidated statements of operations.
In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 (“ASU 2018-18”). This standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In
addition, ASU 2018-18 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. We adopted ASU 2018-18 during the first quarter of 2019 and applied the provisions of this update retrospectively to all contracts that were not completed as of the date of our initial adoption of ASC 606. The adoption of ASU 2018-18 did not have a material impact on our financial position or results of operations.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. We adopted ASU 2016-09 during the first quarter of 2017 and will now record all excess tax benefits and deficiencies related to share-based compensation in our condensed consolidated statements of operations as discrete events in the interim reporting period in which the benefit or deficiency occurs. Such benefits and deficiencies will not be considered in the calculation of our annual estimated effective tax rate. Any excess tax benefits that were not previously recognized because the related tax deduction had not reduced current taxes payable (i.e. was not realized) are to be recorded using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings as of the beginning of the period in which the new guidance is adopted. We recorded a cumulative-effect adjustment to our accumulated deficit from previously unrecognized excess tax benefits of $21.6 million during the first quarter of 2017. Lastly, we will continue to use the current method of estimated forfeitures each period rather than accounting for forfeitures as they occur.
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.20.2
REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS
 12 Months Ended
Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]  
REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS
Subsequent to the issuance of our Form 10-K for the year ended December 31, 2019, management identified certain individually immaterial errors aggregating to $6.3 million related to governmental rebate accruals associated with Makena sales from 2016 through 2019.

From 2016 through 2019, we understated our GTN adjustments for governmental rebates and the related accrual for a certain state program. We concluded that the errors were not material to any prior annual or interim period; however, we determined that correcting the aggregate error would be material to the three and six months ended June 30, 2020. As a result, we have revised our historical financial statements to properly reflect GTN adjustments and the related accrual in the appropriate periods.

The effect of the corrections to our consolidated balance sheet for the years ended December 31, 2019 and 2018 were as follows (in thousands):

 
December 31, 2019
 
As reported
 
Adjustment
 
As adjusted
Accrued expenses
177,079

 
6,303

 
183,382

Accumulated deficit
$
(1,008,898
)
 
$
(6,303
)
 
$
(1,015,201
)

 
December 31, 2018
 
As reported
 
Adjustment
 
As adjusted
Accrued expenses
129,537

 
5,098

 
134,635

Accumulated deficit
$
(542,442
)
 
$
(5,098
)
 
$
(547,540
)

The effect of the corrections to our consolidated statements of operations for the years ended December 31, 2019, 2018 and 2017 are as follows (in thousands, except per share amounts):

 
Year Ended December 31, 2019
 
As reported
 
Adjustment
 
As adjusted
Product sales, net
$
311,190

 
$
(1,205
)
 
$
309,985

Total revenues
327,751

 
(1,205
)
 
326,546

Income tax (benefit) expense
(47
)
 
—

 
(47
)
Net loss from continuing operations
(466,456
)
 
(1,205
)
 
(467,661
)
Net loss
$
(466,456
)
 
$
(1,205
)
 
$
(467,661
)
 
 
 
 
 
 
Basic and diluted net loss per share
$
(13.71
)
 
$
(0.03
)
 
$
(13.74
)

 
Year Ended December 31, 2018
 
As reported
 
Adjustment
 
As adjusted
Product sales, net
$
473,852

 
$
(1,954
)
 
$
471,898

Total revenues
474,002

 
(1,954
)
 
472,048

Income tax (benefit) expense
39,654

 
782

 
40,436

Net loss from continuing operations
(169,339
)
 
(2,736
)
 
(172,075
)
Net loss
$
(65,761
)
 
$
(2,736
)
 
$
(68,497
)
 
 
 
 
 
 
Basic and diluted net loss per share
$
(1.91
)
 
$
(0.08
)
 
$
(1.99
)

 
Year Ended December 31, 2017
 
As reported
 
Adjustment
 
As adjusted
Product sales, net
$
495,645

 
$
(1,802
)
 
$
493,843

Total revenues
495,769

 
(1,802
)
 
493,967

Income tax (benefit) expense
(175,254
)
 
(267
)
 
(175,521
)
Net loss from continuing operations
(205,153
)
 
(1,535
)
 
(206,688
)
Net loss
$
(199,228
)
 
$
(1,535
)
 
$
(200,763
)
 
 
 
 
 
 
Basic and diluted net loss per share
$
(5.71
)
 
$
(0.04
)
 
$
(5.75
)


The consolidated statements of other comprehensive loss for the years ended December 31, 2019, 2018 and 2017 have been revised to include the changes to “net loss” summarized above.

The consolidated statements of stockholders’ equity for the years ended December 31, 2019, 2018 and 2017 have been revised to include the changes to “net loss” summarized above as well as an increase of $0.8 million to the beginning “accumulated deficit” as of January 1, 2017, representing the accumulated error through that date.

The impact on our consolidated statements of cash flows for the years ended December 31, 2019, 2018 and 2017, was limited to the offsetting corrections between “net loss” and changes in “accounts payable and accrued expenses” and “deferred income taxes” presented within “net cash used in operating activities” in each year, as summarized in the above tables.
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.20.2
SUBSEQUENT EVENTS (unaudited)
 12 Months Ended
Dec. 31, 2019
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS (unaudited) SUBSEQUENT EVENTS (unaudited)
In connection with the amendment of our financial statements, we have evaluated subsequent events through the date the financial statements were available to be reissued.

May 2020 Restructuring

In May 2020, we completed a restructuring to reduce the size of our organization in conjunction with the planned divestiture of Intrarosa and Vyleesi and expected declines in our revenue due to the COVID-19 pandemic. Approximately 110 employees were displaced through this workforce reduction. We recorded a one-time restructuring charge of $8.2 million primarily related to severance and related benefits on our condensed consolidated statement of operations during the second quarter of 2020 and expect the restructuring charges incurred to date under this program to be substantially paid in cash by the end of the second quarter of 2021.

Sale of Intrarosa

On May 21, 2020, we sold our rights to commercialize and have manufactured Intrarosa in the United States to Millicent Pharma Limited (“Millicent”) pursuant to an Asset Purchase Agreement between the Company and Millicent, dated May 21, 2020. Under the terms of the Asset Purchase Agreement, we received an upfront payment of $20.9 million in cash, subject to customary purchase price adjustments, including in connection with the transfer of certain inventory. We are eligible to receive up to $105.0 million in aggregate milestone payments upon the achievement of certain sales milestones, namely: (a) $25.0 million the first time net sales during any consecutive twelve month period exceeds $65.0 million, (b) $35.0 million the first time net sales during any consecutive twelve month period exceeds $115.0 million and (c) $45.0 million the first time net sales during any consecutive twelve month period exceeds $175.0 million. We recognized a Gain on Sale of Assets of $14.4 million on our condensed consolidated statements of operations for the three and six months ended June 30, 2020 related to this transaction.

Cessation of the AMAG-423 Study

In July 2020, we decided to stop the AMAG-423 Phase 2b/3a study. This decision was based primarily on the independent Data Safety Monitoring Board’s (the “DSMB”) unanimous recommendation to stop the study following an interim analysis of the data collected to date in the study, which analysis we asked the DSMB to conduct due to extended and ongoing delays in enrollment of the trial (based primarily on the effect of COVID-19 on clinical trial research and the nature of the patient population). There were no safety concerns raised during this study and safety was not a contributing factor to our decision to terminate the study. We are currently focused on ensuring an appropriate closeout of the study in partnership with investigators and other relevant stakeholders. In connection with the cessation of the AMAG-423 Phase 2b/3a study, on August 6, 2020, we terminated our supply agreement (including termination of significant minimum purchase obligations) with our third party supplier in exchange for a one-time payment by us of $12.5 million and our grant to our third party supplier of a 9-month option (subject to extension under certain situations) to acquire the AMAG-423 program rights and assume our related obligations, including our obligations under the Velo Option Agreement.

License to Develop and Commercialize ciraparantag in Europe, Australia and New Zealand

In July 2020, we entered into a License and Commercialization Agreement with Norgine B.V. (“Norgine”, and such agreement, the “Norgine Agreement”), pursuant to which we granted Norgine an exclusive license to develop and commercialize ciraparantag in certain countries in Europe, Australia and New Zealand. We received a $30.0 million upfront payment upon signing. In addition, pursuant to the terms and conditions of the Norgine Agreement (a) Norgine will pay us one-
third of the actual and reasonable out-of-pocket costs of the Phase 3 program, pursuant to a mutually agreed upon budget, (b) we are eligible to receive up to $70.0 million upon the achievement of certain regulatory milestones (of which we will pay $40.0 million to the former equity holders of Perosphere pursuant to the terms of the Perosphere Agreement), (c) we are eligible to receive up to $190.0 million contingent upon meeting certain sales milestones, and (d) Norgine will pay us tiered double-digit royalties on net sales in the licensed territory. We will be responsible for manufacturing and supplying Norgine with its requirements of clinical and commercial product pursuant to supply agreement(s) to be entered into by the parties.

Settlement

On July 14, 2020, we entered into a Confidential Settlement Agreement and Release with a third-party manufacturer to resolve outstanding disputes. Pursuant to this agreement, we were paid a sum of $17.4 million, and the parties exchanged mutual releases to resolve all disputes between them.

Termination of the Palatin Agreement

In July 2020, we entered into a termination agreement with Palatin detailing the terms and conditions for the termination of our rights and obligations to develop and commercialize Vyleesi under the Palatin License Agreement and for the transfer of full ownership of Vyleesi to Palatin (the “Termination Agreement”). In accordance with the terms of the Termination Agreement, we transferred and assigned to Palatin the regulatory approval for Vyleesi, inventory, certain third party contracts, intellectual property rights and regulatory files and commercial materials of AMAG related to Vyleesi in the AMAG Territory. In consideration for the early termination of the License Agreement, the assumption of certain liabilities by Palatin (including significant minimum purchase obligations), and in lieu of any future milestone payments, royalties and other payments by AMAG to Palatin contemplated by the Palatin License Agreement, we paid Palatin $12.0 million following the termination, and we will pay an additional $4.3 million on March 31, 2021. In addition, we agreed to provide certain transitional services to Palatin for a period of time following the closing pursuant to a transition services agreement.
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“GAAP”) and include the accounts of our wholly-owned subsidiaries.
Principles of Consolidation All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates and Assumptions
Use of Estimates and Assumptions

The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent liabilities. The most significant estimates and assumptions are used to determine amounts and values of, but are not limited to: revenue recognition related to product sales revenue; product sales allowances and accruals; allowance for doubtful accounts; marketable securities; inventory; acquisition date fair value and subsequent fair value estimates used to assess impairment of long-lived assets, including goodwill and other intangible assets; debt obligations; certain accrued liabilities, including clinical trial accruals; equity-based compensation expense, and income taxes, inclusive of valuation allowances. Actual results could differ materially from those estimates.
Revenue Recognition
Revenue Recognition

Product revenues
On January 1, 2018, we adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”) applying the modified retrospective transition method to all contracts that were not completed as of January 1, 2018 as an adjustment of $1.1 million to the opening balance of stockholders’ equity at the beginning of 2018. The adjustment recorded was for incremental contract acquisition costs related to the CBR business. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for prior periods. There was no impact to our product revenue as a result of adoption.

Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:

a.Identify the contract(s) with a customer;
b.Identify the performance obligations in the contract;
c.Determine the transaction price;
d.Allocate the transaction price to the performance obligations in the contract; and
e.Recognize revenue when (or as) the performance obligations are satisfied.

We only apply the five step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, if the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Our major sources of revenue during the reporting periods were product revenues from Makena, Feraheme and Intrarosa. The adoption of ASC 606 in 2018 did not have an impact on the pattern or timing of recognition of our product revenue, as the majority of our product revenue continues to be recognized when the customer takes control of our product.

We receive payments from customers based upon contractual billing schedules; accounts receivable are recorded when the right to consideration becomes unconditional.

Performance Obligations

At contract inception, we assess the goods promised in our contracts with customers and identify a performance obligation for each promise to transfer to the customer a good (or bundle of goods) that is distinct. To identify the performance obligations, we consider all of the goods promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. We determined that the following distinct goods represent separate performance obligations:

•Supply of Makena product
•Supply of Feraheme product
•Supply of Intrarosa product
•Supply of Vyleesi product

We principally sell our products to wholesalers, specialty distributors, specialty pharmacies and other customers (collectively, “Customers”), who purchase products directly from us. Our Customers subsequently resell the products to healthcare providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payers that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products.

For the majority of our Customers, we transfer control at the point in time when the goods are delivered. In instances when we perform shipping and handling activities, these are considered fulfillment activities, and accordingly, the costs are accrued when the related revenue is recognized. Taxes collected from Customers and remitted to governmental authorities are excluded from revenues.

Variable Consideration
Under ASC 606, we are required to make estimates of the net sales price, including estimates of variable consideration (such as rebates, chargebacks, discounts, copay assistance and other deductions), and recognize the estimated amount as revenue, when we transfer control of the product to our customers. Variable consideration must be determined using either an “expected value” or a “most likely amount” method.

We record product revenues net of certain allowances and accruals in our consolidated statements of operations. Product sales allowances and accruals are primarily comprised of both direct and indirect fees, discounts and rebates and provisions for estimated product returns. Direct fees, discounts and rebates are contractual fees and price adjustments payable to Customers that purchase products directly from us. Indirect fees, discounts and rebates are contractual price adjustments payable to healthcare providers and organizations, such as certain physicians, clinics, hospitals, group purchasing organizations (“GPOs”), and dialysis organizations that typically do not purchase products directly from us but rather from wholesalers and specialty distributors. Consideration payable to a Customer, or other parties that purchase goods from a Customer, are considered to be a reduction of the transaction price, and therefore, of revenue.

Product sales allowances and accruals are based on definitive contractual agreements or legal requirements (such as laws and regulations to provide mandatory discounts for sales to government entities) related to the purchase and/or utilization of the product by these entities and are recorded in the same period that the related revenue is recognized. We use the expected value method for estimating variable consideration. We estimate product sales allowances and accruals using either historical, actual and/or other data, including estimated patient usage, applicable contractual rebate rates, contract performance by the benefit providers, other current contractual and statutory requirements, historical market data based upon experience of our products and other products similar to them, specific known market events and trends such as competitive pricing and new product introductions, current and forecasted Customer buying patterns and inventory levels, and the shelf life of our products. As part of this evaluation, we also review changes to federal and other legislation, changes to rebate contracts, changes in the level of discounts, and changes in product sales trends. Although allowances and accruals are recorded at the time of product sale, rebates are typically paid out in arrears, one to three months after the sale. 

The estimate of variable consideration, which is included in the transaction price, may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved in a future period. Estimating variable consideration and the related constraint requires the use of significant management judgment and actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. No amounts were constrained as of December 31, 2019.

Discounts

We typically offer a 2% prompt payment discount to certain customers as an incentive to remit payment in accordance with the stated terms of the invoice, generally between 30 to 60 days. Because we anticipate that those customers who are offered this discount will take advantage of the discount, 100% of the prompt payment discount at the time of sale is accrued for eligible customers, based on the gross amount of each invoice. We adjust the accrual quarterly to reflect actual experience.

Chargebacks

Chargeback reserves represent the estimated obligations resulting from the difference between the prices at which we sell our products to wholesalers and the sales price ultimately paid to wholesalers under fixed price contracts by third-party payers, including governmental agencies. The chargeback estimates are determined based on actual product sales data and forecasted customer buying patterns. Actual chargeback amounts are determined at the time of resale to the qualified healthcare provider, and we generally issue credits for such amounts within several weeks of receiving notification from the wholesaler. Estimated chargeback amounts are recorded at the time of sale and adjusted quarterly to reflect actual experience.

Distributor/Wholesaler and Group Purchasing Organization Fees

Fees under arrangements with distributors and wholesalers are usually based upon units of product purchased during the prior month or quarter and are usually paid by us within several weeks of the receipt of an invoice from the wholesaler or distributor. Fees under arrangements with GPOs are usually based upon member purchases during the prior quarter and are generally billed by the GPO within 30 days after period end. In accordance with ASC 606, since the consideration given to the Customer is not for a distinct good or service, the consideration is a reduction of the transaction price of the vendor’s products or services. We have included these fees in contractual adjustments in the table above. We generally pay such amounts within several weeks of the receipt of an invoice from the distributor, wholesaler or GPO. Accordingly, we accrue the estimated fee due at the time of sale, based on the contracted price invoiced to the Customer. We adjust the accrual quarterly to reflect actual experience.

Product Returns

Consistent with industry practice, we generally offer wholesalers, specialty distributors and other customers a limited right to return our products based on the product’s expiration date. The current shelf-lives or time between manufacture and expiration for products in our portfolio range from three to five years. Product returns are estimated based on the historical return patterns and known or expected changes in the marketplace. We track actual returns by individual production lots. Returns on lots eligible for credits under our returned goods policy are monitored and compared with historical return trends and rates. We expect that wholesalers and healthcare providers will not stock significant inventory due to the cost of the product, the expense to store our products, and/or that our products are readily available for distribution. We record an estimate of returns at the time of sale. If necessary, our estimated rate of returns may be adjusted for actual return experience as it becomes available and for known or expected changes in the marketplace. There were no material adjustments to our reserve for product returns during the years ended December 31, 2019, 2018 or 2017. To date, our product returns have been relatively limited; however, returns experience may change over time. We may be required to make future adjustments to our product returns estimate, which would result in a corresponding change to our net product sales in the period of adjustment and could be significant.

Sales Rebates

We contract with various private payer organizations, primarily pharmacy benefit managers, for the payment of rebates with respect to utilization of our products. We determine our estimates for rebates, if applicable, based on actual product sales data and our historical product claims experience. Rebate amounts generally are invoiced quarterly and are paid in arrears, and we expect to pay such amounts within several weeks of notification by the provider. We regularly assess our reserve balance and the rate at which we accrue for claims against product sales. If we determine in future periods that our actual rebate
experience is not indicative of expected claims, if actual claims experience changes, or if other factors affect estimated claims rates, we may be required to adjust our current accumulated reserve estimate, which would affect net product sales in the period of the adjustment and could be significant.

Governmental Rebates

Governmental rebates relate to our reimbursement arrangements with state Medicaid programs. We determine our estimates for Medicaid rebates, if applicable, based on actual product sales data and our historical product claims experience. In estimating these reserves, we provide for a Medicaid rebate associated with both those expected instances where Medicaid will act as the primary insurer as well as in those instances where we expect Medicaid will act as the secondary insurer. Rebate amounts generally are invoiced quarterly and are paid in arrears, and we expect to pay such amounts within several weeks of notification by the Medicaid or provider entity. We regularly assess our Medicaid reserve balance and the rate at which we accrue for claims against product sales. If we determine in future periods that our actual rebate experience is not indicative of expected claims, if actual claims experience changes, or if other factors affect estimated claims rates, we may be required to adjust our current Medicaid accumulated reserve estimate, which would affect net product sales in the period of the adjustment and could be significant.

Other Discounts
Other discounts which we offer include voluntary patient assistance programs, such as copay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug copayments required by payers. The calculation of the accrual for copay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with product that has been recognized as revenue.

Collaboration Revenues

When we enter into collaboration agreements, we assess whether the agreements fall within the scope of ASC Topic 808, Collaborative Arrangements (“ASC 808”) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606. However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the related underlying expense.
Cash and Cash Equivalents
Cash and Cash Equivalents

Cash and cash equivalents consist principally of cash held in commercial bank accounts, money market funds and U.S. treasury securities having an original maturity of less than three months at the date of acquisition. We consider all highly liquid marketable securities with a maturity of three months or less as of the acquisition date to be cash equivalents.
Concentrations and Significant Customer Information
We are currently dependent on a single supplier for certain of our manufacturing processes, including Feraheme drug substance (produced in two separate facilities) and a single supplier for our Makena auto-injector product. We have been and may continue to be exposed to a significant loss of revenue from the sale of our products in the event that our suppliers and/or manufacturers are not able to fulfill demand for any reason.
Our operations are located entirely within the U.S. We focus primarily on developing, manufacturing, and commercializing our products and product candidates.
Concentrations and Significant Customer Information

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and cash equivalents, marketable securities, and accounts receivable. We currently hold our excess cash primarily in institutional money market funds, corporate debt securities, U.S. treasury and government agency securities and certificates of deposit.
Our net accounts receivable primarily represent amounts due for products sold directly to wholesalers, distributors and specialty pharmacies. Accounts receivable for our products are recorded net of reserves for estimated chargeback obligations, prompt payment discounts and any allowance for doubtful accounts.
As part of our credit management policy, we perform ongoing credit evaluations of our customers, and we generally do not require collateral. If the financial condition of any of our significant product sales customers was to deteriorate and result in an impairment of its ability to make payments owed to us, an allowance for doubtful accounts may be required which could have a material effect on earnings in the period of any such adjustment.
Fair Value Measurements
Fair Value Measurements

We apply the provisions of ASC Topic 820, Fair Value Measurements (“ASC 820”) for our financial assets and liabilities that are re-measured and reported at fair value each reporting period and our nonfinancial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis, including property and equipment and identifiable intangible assets. Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, we consider the principal or most advantageous market in which it would transact and consider assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. Financial assets and liabilities are categorized within the valuation hierarchy based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•
Level 1- Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•
Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•
Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Marketable Securities
Marketable Securities

We account for and classify our marketable securities as either “available-for-sale,” “held-to-maturity,” or “trading debt securities,” in accordance with the accounting guidance related to the accounting and classification of certain investments in marketable securities. The determination of the appropriate classification by us is based primarily on management’s ability and intent to sell the debt security at the time of purchase. As of December 31, 2019 and 2018, all of our marketable securities were classified as available-for-sale.

Available-for-sale securities are those securities which we view as available for use in current operations, if needed. We generally classify our available-for-sale securities as short-term investments, even though the stated maturity date may be one year or more beyond the current balance sheet date. Available-for-sale marketable securities are stated at fair value with their
unrealized gains and losses included in accumulated other comprehensive income (loss) within the consolidated statements of stockholders’ equity, until such gains and losses are realized in other income (expense) within the consolidated statements of operations or until an unrealized loss is considered other-than-temporary.

We recognize other-than-temporary impairments of our marketable securities when there is a decline in fair value below the amortized cost basis and if (a) we have the intent to sell the security or (b) it is more likely than not that we will be required to sell the security prior to recovery of its amortized cost basis. If either of these conditions is met, we recognize the difference between the amortized cost basis of the security and its fair value at the impairment measurement date in our consolidated statements of operations. If neither of these conditions is met, we must perform additional analysis to evaluate whether the unrealized loss is associated with the creditworthiness of the issuer of the security rather than other factors, such as interest rates or market factors. If we determine from this analysis that we do not expect to receive cash flows sufficient to recover the entire amortized cost of the security, a credit loss exists, the impairment is considered other-than-temporary and is recognized in our consolidated statements of operations.
Inventory
Inventory

Inventory is stated at the lower of cost or net realizable value, with approximate cost being determined on a first-in, first-out basis. Prior to initial approval from the FDA or other regulatory agencies, we expense costs relating to the production of inventory in the period incurred, unless we believe regulatory approval and subsequent commercialization of the product candidate is probable and we expect the future economic benefit from sales of the product to be realized, at which point we capitalize the costs as inventory. We assess any costs capitalized prior to regulatory approval each quarter for indicators of impairment, such as a reduced likelihood of approval. We expense costs associated with clinical trial material as research and development expense.

On a quarterly basis, we analyze our inventory levels to determine whether we have any obsolete, expired, or excess inventory. If any inventory is expected to expire prior to being sold, has a cost basis in excess of its net realizable value, is in excess of expected sales requirements as determined by internal sales forecasts, or fails to meet commercial sale specifications, the inventory is written-down through a charge to cost of product sales. The determination of whether inventory costs will be realizable requires estimates by management of future expected inventory requirements, based on sales forecasts. Once packaged, our products have a shelf-life ranging from three to five years. As a result of comparison to internal sales forecasts, we expect to fully realize the carrying value of our finished goods inventory. If actual market conditions are less favorable than those projected by management, inventory write-downs may be required. Charges for inventory write-downs are not reversed if it is later determined that the product is saleable.
Property and Equipment, Net
Property and Equipment, Net

Property and equipment are recorded at cost and depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:
 
Useful Life
Computer equipment and software
5 Years
Furniture and fixtures
5 Years
Leasehold improvements
Lesser of Lease or Asset Life
Laboratory and production equipment
5 Years


Costs for capital assets not yet placed in service are capitalized on our balance sheets and will be depreciated in accordance with the above guidelines once placed into service. Costs for maintenance and repairs are expensed as incurred. Upon sale or other disposition of property and equipment, the cost and related depreciation are removed from the accounts and any resulting gain or loss is charged to our consolidated statements of operations. Assets classified as held for sale are no longer subject to depreciation and are recorded at the lower of carrying value or estimated net realizable value.
Intangible Assets
Intangible Assets

We amortize our intangible assets that have finite lives based on either the straight-line method, or if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be utilized.

If we acquire an asset or a group of assets that do not meet the definition of a business, the acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

We review our long-lived assets, which includes property and equipment and identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. To evaluate recoverability, management compares the projected undiscounted future cash flows associated with the asset or asset group, including proceeds from its eventual disposition over its estimated useful life against its carrying amount. If the undiscounted cash flows are not sufficient to recover the carrying value of the asset or asset group, the asset or asset group is considered impaired. The impairment loss, if any, is measured as the excess of the carrying amount of the asset or asset group over its estimated fair value, which is typically calculated utilizing a discounted cash flow (“DCF”) model following the same methodology as described in the following section.
Goodwill
Goodwill
We test goodwill at the reporting unit level for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that could indicate impairment and trigger an interim impairment assessment include, but are not limited to, an adverse change in current economic and market conditions, including a significant prolonged decline in market capitalization, a significant adverse change in legal factors, unexpected adverse business conditions, and an adverse action or assessment by a regulator. Our annual impairment test date is October 31. We have determined that we operate in a single operating segment and have a single reporting unit.
In performing our goodwill impairment tests, we utilize the approach prescribed under Accounting Standards Codification (“ASC”) 350, as amended by Accounting Standards Update (“ASU”) 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”), which requires that an entity perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value.
When we perform any goodwill impairment test, the estimated fair value of our reporting unit is determined using an income approach that utilizes a DCF model or a market approach, when appropriate, which assesses our market capitalization as adjusted for a control premium, or a combination thereof.
Under the market approach, when our carrying value exceeds our market capitalization, we consider a control premium for purposes of estimating the fair value of our reporting unit, as we believe that a market participant buyer would be required to pay a control premium for our business. The control premium utilized is based on control premiums observed in recent comparable market transactions. As described in the accounting guidance for evaluating long-lived assets for impairment, an entity’s fair value may include a control premium in addition to the quoted market price to determine the fair value of a single reporting unit entity, as an acquiring entity is often willing to pay more for equity securities that give it a controlling interest than an investor would pay for a number of equity securities representing less than a controlling interest. This accounting guidance also indicates that the quoted market price of an individual security need not be the sole measurement basis of the fair value of a single reporting unit. When our market capitalization exceeds our carrying value, we utilize our market capitalization as the indicator of fair value in our impairment test.
Under the income approach, the DCF model is based upon expected future after-tax operating cash flows of the reporting unit discounted to a present value using a risk-adjusted discount rate. Estimates of future cash flows require management to make significant assumptions concerning (i) future operating performance, including future sales, long-term growth rates, operating margins, variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows (ii) the probability of regulatory approvals, and (iii) future economic conditions, all of which may differ from actual future cash flows. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rate, which is intended to reflect the risks inherent in future cash flow projections, used in the DCF model, is based on estimates of the weighted average cost of capital (“WACC”) of market participants relative to our reporting unit. Financial and credit market volatility can directly impact certain inputs and assumptions used to develop the WACC. Any changes in these assumptions may affect our fair value estimate and the result of an impairment test. The discount rates and other inputs and assumptions are consistent with those that a market participant would use. In addition, in order to assess the reasonableness of the fair value of our reporting unit as calculated under the DCF model, we also compare the reporting unit’s fair value to our market capitalization and calculate an implied control premium (the excess sum of the reporting unit’s fair value over its market capitalization). We evaluate the implied control premium by comparing it to control premiums of recent comparable market transactions, as applicable.
Business Combinations, Asset Acquisitions and Acquisition-Related Contingent Consideration

Business Combinations and Asset Acquisitions

The purchase price allocation for business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values. Under ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business (“2017-01”), we first determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the single asset or group of assets, as applicable, is not a business.

We account for acquired businesses using the acquisition method of accounting, under which the total purchase price of an acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. Acquisition-related costs are expensed as incurred. Any excess of the consideration transferred over the estimated fair values of the identifiable net assets acquired is recorded as goodwill.

The purchase price allocations for business combinations are initially prepared on a preliminary basis and are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. Any adjustments to the purchase price allocations are made as soon as practicable but no later than one year from the acquisition date.

Acquired inventory is recorded at its fair value, which may require a step-up adjustment to recognize the inventory at its expected net realizable value. The inventory step-up is recorded to cost of product sales in our consolidated statements of operations when related inventory is sold, and we record step-up costs associated with clinical trial material as research and development expense.

Acquisition-Related Contingent Consideration

Contingent consideration arising from a business combination is included as part of the purchase price and is recognized at its estimated fair value as of the acquisition date. Subsequent to the acquisition date, we measure contingent consideration arrangements at fair value for each period until the contingency is resolved. These changes in fair value are recognized in selling, general and administrative expenses in our consolidated statements of operations. Changes in fair values reflect new information about the likelihood of the payment of the contingent consideration and the passage of time. For asset acquisitions, we record contingent consideration for obligations we consider to be probable and estimable and these liabilities are not adjusted to fair value.
Leases
Leases

Effective January 1, 2019, we adopted ASC Topic 842, Leases (“ASC 842”), and chose to apply the provisions of ASC 842 as of the effective date with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected to utilize the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also made accounting policy elections to not separate lease and non-lease components for our real estate lease and to not recognize leases with an initial term of twelve months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis on our consolidated statements of income over the lease term. We did not have any material short-term leases accounted for under this policy during the year ended December 31, 2019.
We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liability, and long-term operating lease liability on our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease.
ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Our incremental borrowing rate is determined based on an evaluation of our creditworthiness and the prevailing market rates for collateralized debt with maturity dates commensurate with the term of each lease. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option. Lease expense for operating leases is recognized on a straight-line basis over the lease term.
The lease payments used to determine our ROU assets may include lease incentives, stated rent increases, and escalation clauses linked to rates of inflation when determinable and are recognized in our ROU assets on our consolidated balance sheet. In addition, certain lease agreements contain lease and non-lease components. With the exception of our real estate leases, we separate lease payments for the identified assets from any non-lease payments included in the agreement. For our real estate leases, we account for the lease and non-lease components as a single lease component. Additionally, for vehicle and certain equipment leases, we apply a portfolio approach to effectively account for the related ROU assets and operating lease liabilities.
Restricted Cash
Restricted Cash

We classified $0.5 million of our cash as restricted cash, a non-current asset on the balance sheet, as of December 31, 2019 and 2018. This amount represented the security deposit delivered to the landlord of our Waltham, Massachusetts headquarters.
Research and Development Expenses
Research and Development Expenses

Research and development expenses include both external and internal expenses. External expenses primarily include costs of clinical trials and fees paid to contract research organizations (“CROs”), clinical supply and manufacturing expenses, regulatory filing fees, consulting and professional fees as well as other general costs related to the execution of research and development activities. Internal expenses primarily include compensation of employees engaged in research and development activities. Research and development expenses are expensed as incurred. Manufacturing costs are generally expensed as incurred until a product has received the necessary initial regulatory approval.
Patents
Patents

We expense all patent-related costs in selling, general and administrative expenses as incurred.
Advertising Costs
Advertising Costs

Advertising costs are expensed as incurred and included in selling, general and administrative expenses in our consolidated statements of operations.
Equity-Based Compensation
Equity-Based Compensation

Equity-based compensation cost is generally measured at the estimated grant date fair value and recorded to expense over the requisite service period, which is generally the vesting period. Because equity-based compensation expense is based on awards ultimately expected to vest, we must make certain judgments about whether employees, officers, directors, consultants and advisers will complete the requisite service period, and reduce the compensation expense being recognized for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based upon historical experience and adjusted for unusual events such as corporate restructurings, which can result in higher than expected turnover and forfeitures. If factors change and we employ different assumptions in future periods, the compensation expense that we record in the future may differ significantly from what we have recorded in the current period.

We estimate the fair value of equity-based compensation involving stock options based on the Black-Scholes option pricing model. This model requires the input of several factors such as the expected option term, the expected risk-free interest rate over the expected option term, the expected volatility of our stock price over the expected option term and the expected dividend yield over the expected option term and are subject to various assumptions. The fair value of awards calculated using the Black-Scholes option pricing model is generally amortized on a straight-line basis over the requisite service period, and is recognized based on the proportionate amount of the requisite service period that has been rendered during each reporting period.

We estimate the fair value of our restricted stock units (“RSUs”) whose vesting is contingent upon market conditions, such as total shareholder return, using the Monte-Carlo simulation model. The fair value of RSUs where vesting is contingent upon market conditions is amortized based upon the estimated derived service period. The fair value of RSUs granted to our employees and directors whose vesting is dependent on future service is determined based upon the quoted closing market price per share on the date of grant, adjusted for estimated forfeitures.

We believe our valuation methodologies are appropriate for estimating the fair value of the equity awards we grant to our employees and directors. Our equity award valuations are estimates and may not be reflective of actual future results or amounts ultimately realized by recipients of these grants. These amounts are subject to future quarterly adjustments based upon a variety of factors, which include, but are not limited to, changes in estimated forfeiture rates and the issuance of new equity-based awards.
Income Taxes
Income Taxes

We use the asset and liability method of accounting for deferred income taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A deferred tax asset is established for the expected future benefit of net operating loss (“NOL”) and credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance against net deferred tax assets is required if, based on available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Significant judgments, estimates and assumptions regarding future events, such as the amount, timing and character of income, deductions and tax credits, are required in the determination of our provision for income taxes and whether valuation allowances are required against deferred tax assets. In evaluating our ability to recover our deferred tax assets, we consider all available evidence, both positive and negative, including the existence of taxable temporary differences, our past operating results, the existence of cumulative income in the most recent fiscal years, changes in the business in which we operate and our forecast of future taxable income. In determining future taxable income, we are responsible for assumptions utilized including the amount of state and federal operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income. As of December 31, 2019, we have established a valuation allowance on our net deferred tax assets other than refundable alternative minimum tax (“AMT”) credits to the extent that our existing taxable temporary differences would not be available as a source of income to realize the benefits of those deferred tax assets.

We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position. We evaluate uncertain tax positions on a quarterly basis and adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could impact our income tax provision in future periods. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as a provision for income tax in our consolidated statement of operations.
Comprehensive Loss
Comprehensive Loss

Our comprehensive loss consists of net loss and other comprehensive loss. Other comprehensive loss includes changes in equity that are excluded from net loss, which for all periods presented in these consolidated financial statements related to unrealized holding gains and losses on available-for-sale marketable securities, net of tax.
Basic and Diluted Earnings per Share
Basic and Diluted Earnings per Share

We compute basic earnings per share by dividing earnings by the weighted average number of common shares outstanding during the relevant period. Diluted earnings per share is computed by dividing earnings by the diluted number of common shares outstanding during the period. Except where the result would be antidilutive, diluted earnings per common share would be computed assuming the impact of the conversion of the 3.25% convertible senior notes due in 2022 (the “2022 Convertible Notes”), the exercise of outstanding stock options and the vesting of RSUs.
We have a choice to settle the conversion obligation of our 2022 Convertible Notes (the “2022 Convertible Notes”) in cash, shares or any combination of the two. Our policy is to settle the principal balance of the 2022 Convertible Notes in cash. As such, we apply the treasury stock method to these securities and the dilution related to the conversion premium, if any, of the 2022 Convertible Notes is included in the calculation of diluted weighted-average shares outstanding to the extent the issuance is dilutive based on the average stock price during each reporting period being greater than the conversion price of the 2022 Convertible Notes.
Business Segments
Business Segments
We have determined that we conduct our operations in one business segment: the manufacture, development and commercialization of products for use in treating various conditions, with a focus on maternal and women’s health and anemia management. Long-lived assets consist entirely of intangible assets, property and equipment and are located in the U.S. for all periods presented.
Recently Issued and Proposed Accounting Pronouncements and Recently Adopted Accounting Pronouncements RECENTLY ISSUED AND PROPOSED ACCOUNTING PRONOUNCEMENTS
From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by us as of the specified effective date.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. We adopted ASU 2016-13 effective January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on our consolidated financial statements.
RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASC 842”). This standard requires an entity to recognize on its balance sheet assets and liabilities associated with the rights and obligations created by leases with terms greater than twelve months. We adopted the standard effective January 1, 2019. We chose to apply the provisions of ASC 842 as of the effective date with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected to utilize the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also made accounting policy elections to not separate lease and non-lease components for our real estate lease and to not recognize leases with an initial term of twelve months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis on our condensed consolidated statements of income over the lease term.
In preparation for adoption of the standard, we implemented internal controls to enable the preparation of the related financial information. The adoption of this standard resulted in the recognition of operating lease liabilities of $8.5 million and related ROU assets of $7.6 million on our condensed consolidated balance sheets as of January 1, 2019, but did not have an impact on our consolidated statements of operations.
In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 (“ASU 2018-18”). This standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In
addition, ASU 2018-18 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. We adopted ASU 2018-18 during the first quarter of 2019 and applied the provisions of this update retrospectively to all contracts that were not completed as of the date of our initial adoption of ASC 606. The adoption of ASU 2018-18 did not have a material impact on our financial position or results of operations.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. We adopted ASU 2016-09 during the first quarter of 2017 and will now record all excess tax benefits and deficiencies related to share-based compensation in our condensed consolidated statements of operations as discrete events in the interim reporting period in which the benefit or deficiency occurs. Such benefits and deficiencies will not be considered in the calculation of our annual estimated effective tax rate. Any excess tax benefits that were not previously recognized because the related tax deduction had not reduced current taxes payable (i.e. was not realized) are to be recorded using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings as of the beginning of the period in which the new guidance is adopted. We recorded a cumulative-effect adjustment to our accumulated deficit from previously unrecognized excess tax benefits of $21.6 million during the first quarter of 2017. Lastly, we will continue to use the current method of estimated forfeitures each period rather than accounting for forfeitures as they occur.
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Schedule of customers representing greater than 10% of revenues/accounts receivable balances The following table sets forth customers who represented 10% or more of our total revenues for 2019, 2018 and 2017:
 
Years Ended December 31,
 
2019
 
2018
 
2017
McKesson Corporation
36%
 
26%
 
24%
AmerisourceBergen Drug Corporation
28%
 
27%
 
26%
Cardinal Health
13%
 
< 10%
 
< 10%
Schedule of property and equipment estimated useful lives
Property and equipment are recorded at cost and depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:
 
Useful Life
Computer equipment and software
5 Years
Furniture and fixtures
5 Years
Leasehold improvements
Lesser of Lease or Asset Life
Laboratory and production equipment
5 Years

Property and equipment, net consisted of the following as of December 31, 2019 and 2018 (in thousands):
 
December 31,
 
2019
 
2018
Computer equipment and software
$
1,568

 
$
1,637

Furniture and fixtures
1,714

 
1,737

Leasehold improvements
4,984

 
2,938

Laboratory and production equipment
6,570

 
6,000

Construction in progress
656

 
420

 
15,492

 
12,732

Less: accumulated depreciation
(11,376
)
 
(5,211
)
Property and equipment, net
$
4,116

 
$
7,521
Schedule of components of basic and diluted net income (loss) per share
The components of basic and diluted earnings per share for 2019, 2018 and 2017 were as follows (in thousands, except per share data):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Net loss from continuing operations
$
(467,661
)
 
$
(172,075
)
 
$
(206,688
)
Net income from discontinued operations
—

 
103,578

 
5,925

 
 

 
 

 
 

Weighted average common shares outstanding
34,030

 
34,394

 
34,907

Effect of dilutive securities:
 

 
 

 
 

Stock options and RSUs
—

 
—

 
—

Shares used in calculating dilutive net loss per share
34,030

 
34,394

 
34,907

 
 

 
 

 
 

Basic and diluted earnings per share:
 

 
 

 
 

Loss from continuing operations
$
(13.74
)
 
$
(5.00
)
 
$
(5.92
)
Income from discontinued operations
—

 
3.01

 
0.17

Total
$
(13.74
)
 
$
(1.99
)
 
$
(5.75
)
Schedule of anti-dilutive securities from computation of diluted net (loss) income per share
The following table sets forth the potential common shares issuable upon the exercise of outstanding options, the vesting of RSUs and the conversion of the Convertible Notes (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Options to purchase shares of common stock
3,976

 
3,797

 
3,531

Shares of common stock issuable upon the vesting of RSUs
1,579

 
1,129

 
1,070

Warrants
—

 
1,008

 
1,008

2022 Convertible Notes
11,695

 
11,695

 
11,695

2019 Convertible Notes
—

 
790

 
790

Shares of common stock under employee stock purchase plan
—

 
81

—
—

Total
17,250

 
18,500

 
18,094
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.20.2
DISCONTINUED OPERATIONS (Tables)
 12 Months Ended
Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued operations held for sale
The following is a summary of net income from discontinued operations for the years ended December 31, 2018 and 2017:    
 
Years Ended December 31,
 
2018
 
2017
Service revenues, net
$
71,217

 
$
114,177

Costs and expenses:
 
 
 
Cost of services
12,559

 
21,817

Selling, general and administrative expenses
39,899

 
81,782

Total costs and expenses
52,458

 
103,599

Operating income
18,759

 
10,578

Other income (expense)
114

 
(265
)
Income from discontinued operations
18,873

 
10,313

Gain on sale of CBR business
87,076

 
—

Income tax expense
2,371

 
4,388

Net income from discontinued operations
$
103,578

 
$
5,925
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUE RECOGNITION (Tables)
 12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Disaggregated revenue
The following table provides information about disaggregated revenue by product for the years ended December 31, 2019, 2018 and 2017 (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Product sales, net
 
 
 
 
 
Makena
$
120,859

 
$
320,311

 
$
385,356

Feraheme
167,947

 
135,001

 
105,930

Intrarosa
21,417

 
16,218

 
1,816

Other
(238
)
 
368

 
741

Total
$
309,985

 
$
471,898

 
$
493,843


Total gross product sales were offset by product sales allowances and accruals for the years ended December 31, 2019, 2018 and 2017 as follows (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Gross product sales
$
955,693

 
$
974,330

 
$
920,061

Provision for product sales allowances and accruals:
 
 
 
 
 
Contractual adjustments
530,645

 
387,540

 
310,588

Governmental rebates
115,063

 
114,892

 
115,630

Total
645,708

 
502,432

 
426,218

Product sales, net
$
309,985

 
$
471,898

 
$
493,843
Product revenue allowance and accrual activity

The following table summarizes the product revenue allowance and accrual activity for the years ended December 31, 2019, 2018 and 2017 (in thousands):
 
Contractual
 
Governmental
 
 
 
Adjustments
 
Rebates
 
Total
Balance at January 1, 2017
$
47,600

 
$
52,741

 
$
100,341

Current provisions relating to sales in current year
314,537

 
113,969

 
428,506

Adjustments relating to sales in prior years
(3,949
)
 
1,661

 
(2,288
)
Payments/returns relating to sales in current year
(253,545
)
 
(61,569
)
 
(315,114
)
Payments/returns relating to sales in prior years
(42,479
)
 
(53,060
)
 
(95,539
)
Balance at December 31, 2017
62,164

 
53,742

 
115,906

Current provisions relating to sales in current year
389,861

 
106,988

 
496,849

Adjustments relating to sales in prior years
(2,330
)
 
7,903

 
5,573

Payments/returns relating to sales in current year
(333,694
)
 
(75,920
)
 
(409,614
)
Payments/returns relating to sales in prior years
(58,802
)
 
(58,501
)
 
(117,303
)
Balance at December 31, 2018
57,199

 
34,212

 
91,411

Provisions related to current period sales
521,916

 
100,926

 
622,842

Adjustments related to prior period sales
8,774

 
14,137

 
22,911

Payments/returns relating to current period sales
(431,014
)
 
(60,218
)
 
(491,232
)
Payments/returns relating to prior period sales
(61,654
)
 
(41,435
)
 
(103,089
)
Balance at December 31, 2019
$
95,221

 
$
47,622

 
$
142,843
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.20.2
MARKETABLE SECURITIES (Tables)
 12 Months Ended
Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]  
Summary of marketable securities
The following is a summary of our marketable securities as of December 31, 2019 and 2018 (in thousands):
 
December 31, 2019
 
 
 
Gross
 
Gross
 
Estimated
 
Amortized
 
Unrealized
 
Unrealized
 
Fair
Description of Securities:
Cost
 
Gains
 
Losses
 
Value
Short-term investments:*
 
 
 
 
 
 
 
Corporate debt securities
$
46,186

 
$
140

 
$
(2
)
 
$
46,324

U.S. treasury and government agency securities
2,750

 
—

 
—

 
2,750

Certificates of deposit
1,500

 
—

 
—

 
1,500

Total short-term investments
50,436

 
140

 
(2
)
 
50,574

Long-term investments:**
 
 
 
 
 
 
 
Corporate debt securities
8,016

 
152

 
—

 
8,168

Total long-term investments
8,016

 
152

 
—

 
8,168

Total investments
$
58,452

 
$
292

 
$
(2
)
 
$
58,742

 
 
December 31, 2018
 
 
 
Gross
 
Gross
 
Estimated
 
Amortized
 
Unrealized
 
Unrealized
 
Fair
Description of Securities:
Cost
 
Gains
 
Losses
 
Value
Short-term investments:*
 
 
 
 
 
 
 
Corporate debt securities
$
51,184

 
$
—

 
$
(236
)
 
$
50,948

U.S. treasury and government agency securities
7,647

 
—

 
(34
)
 
7,613

Commercial paper
3,995

 
—

 
—

 
3,995

Certificates of deposit
12,000

 
—

 
—

 
12,000

Total short-term investments
74,826

 
—

 
(270
)
 
74,556

Long-term investments:**
 
 
 
 
 
 
 
Corporate debt securities
62,530

 
52

 
(433
)
 
62,149

U.S. treasury and government agency securities
2,742

 
—

 
(32
)
 
2,710

Certificates of deposit
1,500

 
—

 
—

 
1,500

Total long-term investments
66,772

 
52

 
(465
)
 
66,359

Total investments
$
141,598

 
$
52

 
$
(735
)
 
$
140,915



* Represents marketable securities with a remaining maturity of less than one year.
** Represents marketable securities with a remaining maturity of one to three years classified as short-term on our consolidated balance sheets.
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.20.2
FAIR VALUE MEASUREMENTS (Tables)
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Schedule of assets and liabilities measured at fair value on a recurring basis
The following tables present information about our assets and liabilities that we measure at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques utilized to determine such fair value as of December 31, 2019 and 2018 (in thousands):
 
Fair Value Measurements at December 31, 2019 Using:
 
Total
 
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Cash equivalents
$
13,732

 
$
13,732

 
$
—

 
$
—

Corporate debt securities
54,492

 
—

 
54,492

 
—

U.S. treasury and government agency securities
2,750

 
—

 
2,750

 
—

Certificates of deposit
1,500

 
—

 
1,500

 
—

Total Assets
$
72,474

 
$
13,732

 
$
58,742

 
$
—

Liabilities:
 

 
 

 
 

 
 

Contingent consideration
17

 
—

 
—

 
17

Total Liabilities
$
17

 
$
—

 
$
—

 
$
17

 
Fair Value Measurements at December 31, 2018 Using:
 
Total
 
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Cash equivalents
$
71,568

 
$
71,568

 
$
—

 
$
—

Corporate debt securities
113,097

 
—

 
113,097

 
—

U.S. treasury and government agency securities
10,323

 
—

 
10,323

 
—

Commercial paper
3,995

 
—

 
3,995

 
—

Certificates of deposit
13,500

 
—

 
13,500

 
—

Total Assets
$
212,483

 
$
71,568

 
$
140,915

 
$
—

Liabilities:
 
 
 
 
 
 
 
Contingent consideration
359

 
—

 
—

 
359

Total Liabilities
$
359

 
$
—

 
$
—

 
$
359
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.20.2
INVENTORIES (Tables)
 12 Months Ended
Dec. 31, 2019
Inventory Disclosure [Abstract]  
Schedule of major classes of inventories

Our major classes of inventories were as follows as of December 31, 2019 and 2018 (in thousands):
 
December 31,
 
2019
 
2018
Raw materials
$
5,211

 
$
9,388

Work in process
6,248

 
5,932

Finished goods
20,094

 
11,371

Total inventories
$
31,553

 
$
26,691
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.20.2
PROPERTY AND EQUIPMENT, NET (Tables)
 12 Months Ended
Dec. 31, 2019
Property, Plant and Equipment [Abstract]  
Schedule of property equipment, net
Property and equipment are recorded at cost and depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:
 
Useful Life
Computer equipment and software
5 Years
Furniture and fixtures
5 Years
Leasehold improvements
Lesser of Lease or Asset Life
Laboratory and production equipment
5 Years

Property and equipment, net consisted of the following as of December 31, 2019 and 2018 (in thousands):
 
December 31,
 
2019
 
2018
Computer equipment and software
$
1,568

 
$
1,637

Furniture and fixtures
1,714

 
1,737

Leasehold improvements
4,984

 
2,938

Laboratory and production equipment
6,570

 
6,000

Construction in progress
656

 
420

 
15,492

 
12,732

Less: accumulated depreciation
(11,376
)
 
(5,211
)
Property and equipment, net
$
4,116

 
$
7,521
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.20.2
GOODWILL AND INTANGIBLE ASSETS, NET (Tables)
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of amortizable intangible assets
 
December 31, 2019
 
December 31, 2018
 
Original Cost
 
Life to Date Accumulated Amortization
 
Life to Date Impairments
 
Net Book Value
 
Original Cost
 
Life to Date Accumulated Amortization
 
Life to Date Impairments
 
Net Book Value
Amortizable intangible assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Makena base technology
$
797,100

 
$
400,496

 
$
396,604

 
$
—

 
$
797,100

 
$
400,495

 
$
319,246

 
$
77,359

Makena auto-injector developed technology
79,100

 
15,782

 
55,426

 
7,892

 
79,100

 
6,952

 
—

 
72,148

Intrarosa developed technology
77,655

 
16,798

 
56,881

 
3,976

 
77,655

 
10,129

 
—

 
67,526

Vyleesi developed technology
60,000

 
9,264

 
38,984

 
11,752

 
—

 
—

 
—

 
—

Total intangible assets
$
1,013,855

 
$
442,340

 
$
547,895

 
$
23,620

 
$
953,855

 
$
417,576

 
$
319,246

 
$
217,033
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.20.2
CURRENT AND LONG-TERM LIABILITIES (Tables)
 12 Months Ended
Dec. 31, 2019
Payables and Accruals [Abstract]  
Schedule of accrued expenses
Accrued expenses consisted of the following as of December 31, 2019 and 2018 (in thousands):
 
December 31,
 
2019
 
2018
Commercial rebates, fees and returns
$
124,730

 
$
85,618

Accrued manufacturing
21,364

 
9,282

Salaries, bonuses, and other compensation
18,693

 
22,482

Professional, license, and other fees and expenses
13,392

 
13,960

Accrued research and development
3,539

 
2,226

Interest expense
867

 
1,067

Restructuring expense
797

 
—

Total accrued expenses
$
183,382

 
$
134,635
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Schedule of income tax (benefit) expense The income tax (benefit) expense consisted of the following (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Current:
 
 
 
 
 
Federal
$
(630
)
 
$
(1,136
)
 
$
2,162

State
179

 
1,469

 
5,358

Total current
$
(451
)
 
$
333

 
$
7,520

Deferred:
 
 
 
 
 
Federal
$
432

 
$
43,546

 
$
(172,238
)
State
(28
)
 
(3,443
)
 
(10,803
)
Total deferred
$
404

 
$
40,103

 
$
(183,041
)
Total income tax (benefit) expense
$
(47
)
 
$
40,436

 
$
(175,521
)
Schedule of reconciliation of the statutory U.S. federal income tax rate to the entity's effective income tax rate
The reconciliation of the statutory U.S. federal income tax rate to our effective income tax rate from continuing operations was as follows:
 
Years Ended December 31,
 
2019
 
2018
 
2017
Statutory U.S. federal tax rate
21.0
 %
 
21.0
 %
 
35.0
 %
State taxes, net of federal benefit
2.6

 
4.7

 
3.3

Impact of 2017 tax reform on deferred tax balance
—

 
—

 
4.5

Equity-based compensation expense
(0.4
)
 
(1.5
)
 
(0.8
)
Contingent consideration
—

 
7.1

 
4.4

In-process research and development
(3.4
)
 
—

 
—

Other permanent items, net
(0.4
)
 
(1.4
)
 
(0.5
)
Tax credits
0.4

 
6.2

 
0.7

Valuation allowance
(19.8
)
 
(67.4
)
 
(0.8
)
Other, net
—

 
0.6

 
0.1

Effective tax rate
—
 %
 
(30.7
)%
 
45.9
 %
Schedule of components of the entity's deferred tax assets and liabilities The components of our deferred tax assets and liabilities were as follows (in thousands):
 
December 31,
 
2019
 
2018
Assets
 
 
 
Net operating loss carryforwards
$
79,679

 
$
46,888

Tax credit carryforwards
28,641

 
24,290

Capital loss carryforwards
20,659

 
20,896

Interest expense carryforwards
5,746

 
4,318

Equity-based compensation expense
6,106

 
5,931

Capitalized research & development
2,347

 
4,635

Intangible assets
67,847

 
12,565

Reserves
5,721

 
2,683

Lease liability
5,739

 
—

Property, plant and equipment
391

 
—

Contingent consideration
4

 
87

Other
10,846

 
6,627

Valuation allowance
(218,291
)
 
(114,516
)
Liabilities
 
 
 
Property, plant and equipment depreciation
—

 
(614
)
Debt instruments
(9,195
)
 
(12,489
)
Right of use asset
(5,599
)
 
—

Other
(11
)
 
(41
)
Net deferred tax assets
$
630

 
$
1,260
Summary of income tax contingencies A reconciliation of our changes in unrecognized tax benefits is as follows (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Unrecognized tax benefits at the beginning of the year
$
11,180

 
$
10,560

 
$
13,020

Additions based on tax positions related to the current year
521

 
12

 
574

Additions for tax positions from prior years
2,173

 
608

 
340

Subtractions for federal tax reform
—

 
—

 
(3,296
)
Subtractions for tax positions from prior years
(336
)
 
—

 
(78
)
Unrecognized tax benefits at the end of the year
$
13,538

 
$
11,180

 
$
10,560
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.20.2
ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)
 12 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Schedule of changes in accumulated other comprehensive loss associated with unrealized (losses) gains on securities

The following table summarizes the changes in the accumulated balances of other comprehensive loss associated with unrealized (losses) gains on securities during 2019, 2018 and 2017 (in thousands):
 
December 31,
 
2019
 
2018
 
2017
Beginning balance
$
(3,985
)
 
$
(3,908
)
 
$
(3,838
)
Other comprehensive income (loss) before reclassifications
746

 
(77
)
 
(70
)
Ending balance
$
(3,239
)
 
$
(3,985
)
 
$
(3,908
)
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.20.2
EQUITY-BASED COMPENSATION (Tables)
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Summary of details regarding stock options granted under equity incentive plans
The following table summarizes details regarding stock options granted under our equity incentive plans for the year ended December 31, 2019:
 
December 31, 2019
 
Options
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term
 
Aggregate Intrinsic Value
($ in thousands)
Outstanding at beginning of year
3,716,579

 
$
24.81

 
7.3

 
$
—

Granted
1,061,587

 
12.71

 
—

 
—

Exercised
(2,025
)
 
14.56

 
—

 
—

Expired and/or forfeited
(890,324
)
 
22.93

 
—

 
—

Outstanding at end of year
3,885,817

 
$
21.94

 
6.8

 
$
776

Outstanding at end of year - vested and unvested expected to vest
3,799,575

 
$
22.12

 
6.8

 
$
701

Exercisable at end of year
2,242,727

 
$
25.76

 
5.5

 
$
116


The following table summarizes stock option activity during 2019:
 
2019 Equity
 
2007 Equity
 
2013 Lumara
 
Inducement
 
 
 
Plan
 
Plan
 
Equity Plan
 
Grants
 
Total
Outstanding at December 31, 2018
—

 
2,781,786

 
124,450

 
810,343

 
3,716,579

Granted
479,212

 
465,009

 
37,000

 
80,366

 
1,061,587

Exercised
—

 
(2,025
)
 
—

 
—

 
(2,025
)
Expired or terminated
(6,800
)
 
(659,304
)
 
(29,675
)
 
(194,545
)
 
(890,324
)
Outstanding at December 31, 2019
472,412

 
2,585,466

 
131,775

 
696,164

 
3,885,817
Summary of details regarding restricted stock units granted under equity incentive plans

The following table summarizes details regarding RSUs granted under our equity incentive plans for the year ended December 31, 2019:
 
December 31, 2019
 
Restricted Stock Units
 
Weighted Average Grant Date Fair Value
Outstanding at beginning of year
1,128,535

 
$
23.42

Granted
1,186,874

 
15.65

Vested
(404,305
)
 
22.49

Forfeited
(331,667
)
 
19.71

Outstanding at end of year
1,579,437

 
$
18.60

Outstanding at end of year and expected to vest
1,462,952

 
$
18.88


The following table summarizes RSU activity during 2019:
 
2019 Equity
 
2007 Equity
 
2013 Lumara
 
Inducement
 
 
 
Plan
 
Plan
 
Equity Plan
 
Grants
 
Total
Outstanding at December 31, 2018
—

 
1,041,141

 
2,101

 
85,293

 
1,128,535

Granted
132,542

 
1,023,847

 
1,100

 
29,385

 
1,186,874

Vested
—

 
(358,362
)
 
(1,034
)
 
(44,909
)
 
(404,305
)
Expired or terminated
(3,800
)
 
(299,321
)
 
—

 
(28,546
)
 
(331,667
)
Outstanding at December 31, 2019
128,742

 
1,407,305

 
2,167

 
41,223

 
1,579,437
Schedule of equity-based compensation expense
Equity-based compensation expense for 2019, 2018 and 2017 consisted of the following (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Cost of product sales
$
871

 
$
802

 
$
884

Research and development
2,844

 
2,533

 
3,225

Selling, general and administrative
14,818

 
16,614

 
16,187

Total equity-based compensation expense
18,533

 
19,949

 
20,296

Income tax effect
—

 
—

 
(6,188
)
After-tax effect of equity-based compensation expense
$
18,533

 
$
19,949

 
$
14,108
Schedule of share-based payment award, stock options, valuation assumptions
The following table summarizes the weighted average assumptions we utilized for purposes of valuing grants of options to our employees and non-employee directors:
 
Years Ended December 31,
 
2019
 
2018
 
2017
 
 
 
Non-Employee
 
 
 
Non-Employee
 
 
 
Non-Employee
 
Employees
 
Directors
 
Employees
 
Directors
 
Employees
 
Directors
Risk free interest rate (%)
2.12
 
2.04
 
2.75
 
2.70
 
1.86
 
1.61
Expected volatility (%)
57
 
59
 
57
 
59
 
53
 
57
Expected option term (years)
5.0
 
4.0
 
5.0
 
4.0
 
5.0
 
4.0
Dividend yield
none
 
none
 
none
 
none
 
none
 
none
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.20.2
COMMITMENTS AND CONTINGENCIES (Tables)
 12 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Maturity schedule by fiscal year, operating leases
Future minimum payments under our non-cancelable operating leases as of December 31, 2019 are as follows (in thousands):
Period
 
Future Minimum Lease Payments
Year Ending December 31, 2020
 
$
4,077

Year Ending December 31, 2021
 
3,207

Year Ending December 31, 2022
 
3,734

Year Ending December 31, 2023
 
3,230

Year Ending December 31, 2024
 
3,246

Thereafter
 
12,192

Total
 
$
29,686

Less: Interest
 
$
5,818

Operating lease liability
 
$
23,868
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.20.2
COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS (Tables)
 12 Months Ended
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of assets acquired and liabilities assumed related to the asset acquisition A summary of the assets and liabilities acquired in exchange for cash consideration of $60.8 million and $10.0 million that was deemed paid in connection with the cancellation of the convertible note, described above, is presented in the following table (in millions):
Assets:
 
Cash
$
2.6

Operating lease right-of-use asset
0.8

Property and equipment
1.4

IPR&D
74.9

 
$
79.7

Liabilities:
 
Accrued severance liabilities
$
(1.7
)
Deferred revenue
(6.4
)
Operating lease liability
(0.8
)
 
$
(8.9
)
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT (Tables)
 12 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
Schedule of outstanding debt obligations

Our outstanding debt obligations as of December 31, 2019 and December 31, 2018 consisted of the following (in thousands):
 
December 31,
 
2019
 
2018
2022 Convertible Notes
$
277,034

 
$
261,933

2019 Convertible Notes
—

 
21,276

Total long-term debt
277,034

 
283,209

Less: current maturities
—

 
21,276

Long-term debt, net of current maturities
$
277,034

 
$
261,933
Schedule of outstanding convertible debt
The outstanding balances of our Convertible Notes as of December 31, 2019 consisted of the following (in thousands):
 
 
2022 Convertible Notes
Liability component:
 
 

Principal
 
$
320,000

Less: debt discount and issuance costs, net
 
42,966

Net carrying amount
 
$
277,034

Gross equity component
 
$
72,576
Schedule of total interest expense recognized related to the convertible notes
The following table sets forth total interest expense recognized related to the 2022 Convertible Notes and 2019 Convertible Notes during 2019, 2018, and 2017 (in thousands):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Contractual interest expense
$
10,467

 
$
10,935

 
$
8,961

Amortization of debt issuance costs
1,412

 
1,403

 
1,275

Amortization of debt discount
13,830

 
13,414

 
11,071

Total interest expense
$
25,709

 
$
25,752

 
$
21,307
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.20.2
RESTRUCTURING EXPENSES (Tables)
 12 Months Ended
Dec. 31, 2019
Restructuring and Related Activities [Abstract]  
Schedule of components of restructuring expenses and current liabilities
The following table displays charges taken related to restructuring activities during the year ended December 31, 2019 and a rollforward of the changes to the accrued balances as of December 31, 2019 (in thousands): 
 
Workforce reduction
 
Contract termination
 
Other
 
Total
Balance accrued at December 31, 2018
$
—

 
$
—

 
$
—

 
$
—

2019 restructuring charges
7,034

 
229

 
157

 
7,420

Payments
(6,237
)
 
(229
)
 
(157
)
 
(6,623
)
Balance accrued at December 31, 2019
$
797

 
$
—

 
$
—

 
$
797
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED (Tables)
 12 Months Ended
Dec. 31, 2019
Condensed Financial Information Disclosure [Abstract]  
Schedule of unaudited consolidated quartely financial data
The following tables provide unaudited consolidated quarterly financial data for 2019 and 2018, which have been revised to correct for immaterial errors in prior periods as detailed below and further described in Note X, “Revision of Prior Period Financial Statements” (in thousands, except per share data):
 
March 31, 2019
 
June 30, 2019
 
September 30, 2019
 
December 31, 2019
Total revenues
$
75,488

 
$
77,767

 
$
83,808

 
$
89,483

Gross profit
57,011

 
53,477

 
62,703

 
46,162

Operating expenses (1)
175,024

 
169,662

 
81,050

 
240,329

Net loss from continuing operations
$
(122,400
)
 
$
(121,169
)
 
$
(23,940
)
 
$
(200,152
)
Net income (loss) from discontinued operations
$
—

 
$
—

 
$
—

 
$
—

Net loss
$
(122,400
)
 
$
(121,169
)
 
$
(23,940
)
 
$
(200,152
)
 
 
 
 
 
 
 
 
Basic and diluted earnings per share:
 
 
 
 
 
 
 
Loss from continuing operations
$
(3.55
)
 
$
(3.58
)
 
$
(0.71
)
 
$
(5.90
)
Income (loss) from discontinued operations
—

 
—

 
—

 
—

Total
$
(3.55
)
 
$
(3.58
)
 
$
(0.71
)
 
$
(5.90
)
 
March 31, 2018
 
June 30, 2018
 
September 30, 2018
 
December 31, 2018
Total revenues
$
116,867

 
$
145,663

 
$
121,646

 
$
87,871

Gross profit
52,955

 
68,887

 
75,157

 
59,155

Operating expenses (2)
104,239

 
27,591

 
95,084

 
78,241

Net loss from continuing operations
$
(58,994
)
 
$
(26,795
)
 
$
(65,282
)
 
$
(21,004
)
Net income (loss) from discontinued operations
$
3,856

 
$
5,736

 
$
95,517

 
$
(1,531
)
Net (loss) income
$
(55,138
)
 
$
(21,059
)
 
$
30,235

 
$
(22,535
)
 
 
 
 
 
 
 
 
Basic and diluted earnings per share:
 
 
 
 
 
 
 
Loss from continuing operations
$
(1.72
)
 
$
(0.78
)
 
$
(1.89
)
 
$
(0.61
)
Income (loss) from discontinued operations
0.11

 
0.17

 
2.77

 
(0.04
)
Total
$
(1.61
)
 
$
(0.61
)
 
$
0.88

 
$
(0.65
)
The sum of quarterly earnings per share totals differ from annual earnings per share totals due to rounding.

(1) 
Operating expenses for the first quarter of 2019 include $74.9 million relating to IPR&D acquired through the Perosphere acquisition and $7.4 million relating to the restructuring expenses for the consolidation of the women’s health and maternal health sales forces. Operating expenses for the second quarter of 2019 include $77.4 million of impairment charges relating to the Makena base technology intangible asset. Operating expenses for the fourth quarter of 2019 include $155.0 million of impairment charges relating to the Makena auto-injector, Intrarosa and Vyleesi asset groups.

(2) 
Operating expenses for the second quarter of 2018 include the reversal of $49.8 million relating to the fair value of a contingent consideration liability that was no longer expected to be paid.
Schedule of effects of corrections and prior period adjustments
The following tables present the effect of the revisions to our unaudited condensed consolidated statements of operations for the three months ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 to correct for immaterial errors in prior periods as further described in Note X, “Revision of Prior Period Financial Statements” (in thousands, except per share amounts):

 
Three Months Ended March 31, 2019
 
Three Months Ended June 30, 2019
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
75,729

 
$
(316
)
 
$
75,413

 
$
77,976

 
$
(342
)
 
$
77,634

Total revenues
75,804

 
(316
)
 
75,488

 
78,109

 
(342
)
 
77,767

Income tax (benefit) expense
(137
)
 
—

 
(137
)
 
(120
)
 
—

 
(120
)
Net loss
$
(122,084
)
 
$
(316
)
 
$
(122,400
)
 
$
(120,827
)
 
$
(342
)
 
$
(121,169
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
(3.54
)
 
$
(0.01
)
 
$
(3.55
)
 
$
(3.57
)
 
$
(0.01
)
 
$
(3.58
)

 
Three Months Ended September 30, 2019
 
Three Months Ended December 31, 2019
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
84,107

 
$
(323
)
 
$
83,784

 
$
73,378

 
$
(224
)
 
$
73,154

Total revenues
84,131

 
(323
)
 
83,808

 
89,707

 
(224
)
 
89,483

Income tax (benefit) expense
232

 
—

 
232

 
(21
)
 
—

 
(21
)
Net loss
$
(23,617
)
 
$
(323
)
 
$
(23,940
)
 
$
(199,928
)
 
$
(224
)
 
$
(200,152
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
(0.70
)
 
$
(0.01
)
 
$
(0.71
)
 
$
(5.89
)
 
$
(0.01
)
 
$
(5.90
)


The following tables present the effect of the revisions to our unaudited condensed consolidated statements of operations for the three months ended March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018 to correct for immaterial errors in prior periods as further described in Note X, “Revision of Prior Period Financial Statements” (in thousands, except per share amounts):

 
Three Months Ended March 31, 2018
 
Three Months Ended June 30, 2018
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
117,348

 
$
(520
)
 
$
116,828

 
$
146,219

 
$
(591
)
 
$
145,628

Total revenues
117,387

 
(520
)
 
116,867

 
146,254

 
(591
)
 
145,663

Income tax (benefit) expense
(8,000
)
 
376

 
(7,624
)
 
52,556

 
387

 
52,943

Net loss
$
(54,242
)
 
$
(896
)
 
$
(55,138
)
 
$
(20,081
)
 
$
(978
)
 
$
(21,059
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
(1.59
)
 
$
(0.02
)
 
$
(1.61
)
 
$
(0.58
)
 
$
(0.03
)
 
$
(0.61
)

 
Three Months Ended September 30, 2018
 
Three Months Ended December 31, 2018
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
122,238

 
$
(592
)
 
$
121,646

 
$
88,047

 
$
(251
)
 
$
87,796

Total revenues
122,238

 
(592
)
 
121,646

 
88,122

 
(251
)
 
87,871

Income tax (benefit) expense
(2,352
)
 
12

 
(2,340
)
 
(2,550
)
 
7

 
(2,543
)
Net loss
$
30,839

 
$
(604
)
 
$
30,235

 
$
(22,277
)
 
$
(258
)
 
$
(22,535
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
0.89

 
$
(0.01
)
 
$
0.88

 
$
(0.64
)
 
$
(0.01
)
 
$
(0.65
)



The effect of the corrections to our consolidated statements of operations for the years ended December 31, 2019, 2018 and 2017 are as follows (in thousands, except per share amounts):

 
Year Ended December 31, 2019
 
As reported
 
Adjustment
 
As adjusted
Product sales, net
$
311,190

 
$
(1,205
)
 
$
309,985

Total revenues
327,751

 
(1,205
)
 
326,546

Income tax (benefit) expense
(47
)
 
—

 
(47
)
Net loss from continuing operations
(466,456
)
 
(1,205
)
 
(467,661
)
Net loss
$
(466,456
)
 
$
(1,205
)
 
$
(467,661
)
 
 
 
 
 
 
Basic and diluted net loss per share
$
(13.71
)
 
$
(0.03
)
 
$
(13.74
)

 
Year Ended December 31, 2018
 
As reported
 
Adjustment
 
As adjusted
Product sales, net
$
473,852

 
$
(1,954
)
 
$
471,898

Total revenues
474,002

 
(1,954
)
 
472,048

Income tax (benefit) expense
39,654

 
782

 
40,436

Net loss from continuing operations
(169,339
)
 
(2,736
)
 
(172,075
)
Net loss
$
(65,761
)
 
$
(2,736
)
 
$
(68,497
)
 
 
 
 
 
 
Basic and diluted net loss per share
$
(1.91
)
 
$
(0.08
)
 
$
(1.99
)

 
Year Ended December 31, 2017
 
As reported
 
Adjustment
 
As adjusted
Product sales, net
$
495,645

 
$
(1,802
)
 
$
493,843

Total revenues
495,769

 
(1,802
)
 
493,967

Income tax (benefit) expense
(175,254
)
 
(267
)
 
(175,521
)
Net loss from continuing operations
(205,153
)
 
(1,535
)
 
(206,688
)
Net loss
$
(199,228
)
 
$
(1,535
)
 
$
(200,763
)
 
 
 
 
 
 
Basic and diluted net loss per share
$
(5.71
)
 
$
(0.04
)
 
$
(5.75
)
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.20.2
VALUATION AND QUALIFYING ACCOUNTS (Tables)
 12 Months Ended
Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Schedule of valuation and qualifying accounts
 
Balance at Beginning of Period
 
Additions (2)
 
Deductions Charged to Reserves
 
Balance at End of Period
Year ended December 31, 2019:
 
 
 
 
 
 
 
Accounts receivable allowances(1)
$
9,543

 
$
324,542

 
$
(310,668
)
 
$
23,417

Rebates, fees and returns reserves(2)
$
81,868

 
$
321,210

 
$
(283,653
)
 
$
119,425

Valuation allowance for deferred tax assets (3)
$
114,516

 
$
104,858

 
$
(1,083
)
 
$
218,291

Year ended December 31, 2018:
 
 
 
 
 
 
 
Accounts receivable allowances(1)
$
12,060

 
$
229,509

 
$
(232,026
)
 
$
9,543

Rebates, fees and returns reserves(2)
$
103,846

 
$
272,913

 
$
(294,891
)
 
$
81,868

Valuation allowance for deferred tax assets (3)
$
4,740

 
$
109,800

 
$
(24
)
 
$
114,516

Year ended December 31, 2017:
 
 
 
 
 
 
 
Accounts receivable allowances(1)
$
9,533

 
$
168,945

 
$
(166,418
)
 
$
12,060

Rebates, fees and returns reserves(2)
$
90,809

 
$
257,273

 
$
(244,236
)
 
$
103,846

Valuation allowance for deferred tax assets (3)
$
1,429

 
$
3,875

 
$
(564
)
 
$
4,740

________________________

(1) 
Accounts receivable allowances represent discounts and other chargebacks related to the provision of our product sales.

(2) 
Additions to rebates, fees and returns reserves are recorded as a reduction of revenues.

(3) 
As of December 31, 2019 and 2018, we have established a valuation allowance on our net deferred tax assets other than refundable AMT credits. At December 31, 2017, our valuation allowance related primarily to certain of our state NOL and credit carryforwards.
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.20.2
REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Tables)
 12 Months Ended
Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]  
Schedule of effects of corrections and prior period adjustments
The following tables present the effect of the revisions to our unaudited condensed consolidated statements of operations for the three months ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 to correct for immaterial errors in prior periods as further described in Note X, “Revision of Prior Period Financial Statements” (in thousands, except per share amounts):

 
Three Months Ended March 31, 2019
 
Three Months Ended June 30, 2019
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
75,729

 
$
(316
)
 
$
75,413

 
$
77,976

 
$
(342
)
 
$
77,634

Total revenues
75,804

 
(316
)
 
75,488

 
78,109

 
(342
)
 
77,767

Income tax (benefit) expense
(137
)
 
—

 
(137
)
 
(120
)
 
—

 
(120
)
Net loss
$
(122,084
)
 
$
(316
)
 
$
(122,400
)
 
$
(120,827
)
 
$
(342
)
 
$
(121,169
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
(3.54
)
 
$
(0.01
)
 
$
(3.55
)
 
$
(3.57
)
 
$
(0.01
)
 
$
(3.58
)

 
Three Months Ended September 30, 2019
 
Three Months Ended December 31, 2019
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
84,107

 
$
(323
)
 
$
83,784

 
$
73,378

 
$
(224
)
 
$
73,154

Total revenues
84,131

 
(323
)
 
83,808

 
89,707

 
(224
)
 
89,483

Income tax (benefit) expense
232

 
—

 
232

 
(21
)
 
—

 
(21
)
Net loss
$
(23,617
)
 
$
(323
)
 
$
(23,940
)
 
$
(199,928
)
 
$
(224
)
 
$
(200,152
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
(0.70
)
 
$
(0.01
)
 
$
(0.71
)
 
$
(5.89
)
 
$
(0.01
)
 
$
(5.90
)


The following tables present the effect of the revisions to our unaudited condensed consolidated statements of operations for the three months ended March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018 to correct for immaterial errors in prior periods as further described in Note X, “Revision of Prior Period Financial Statements” (in thousands, except per share amounts):

 
Three Months Ended March 31, 2018
 
Three Months Ended June 30, 2018
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
117,348

 
$
(520
)
 
$
116,828

 
$
146,219

 
$
(591
)
 
$
145,628

Total revenues
117,387

 
(520
)
 
116,867

 
146,254

 
(591
)
 
145,663

Income tax (benefit) expense
(8,000
)
 
376

 
(7,624
)
 
52,556

 
387

 
52,943

Net loss
$
(54,242
)
 
$
(896
)
 
$
(55,138
)
 
$
(20,081
)
 
$
(978
)
 
$
(21,059
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
(1.59
)
 
$
(0.02
)
 
$
(1.61
)
 
$
(0.58
)
 
$
(0.03
)
 
$
(0.61
)

 
Three Months Ended September 30, 2018
 
Three Months Ended December 31, 2018
 
As reported
 
Adj
 
As adjusted
 
As reported
 
Adj
 
As adjusted
Product sales, net
$
122,238

 
$
(592
)
 
$
121,646

 
$
88,047

 
$
(251
)
 
$
87,796

Total revenues
122,238

 
(592
)
 
121,646

 
88,122

 
(251
)
 
87,871

Income tax (benefit) expense
(2,352
)
 
12

 
(2,340
)
 
(2,550
)
 
7

 
(2,543
)
Net loss
$
30,839

 
$
(604
)
 
$
30,235

 
$
(22,277
)
 
$
(258
)
 
$
(22,535
)
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per share
$
0.89

 
$
(0.01
)
 
$
0.88

 
$
(0.64
)
 
$
(0.01
)
 
$
(0.65
)



The effect of the corrections to our consolidated statements of operations for the years ended December 31, 2019, 2018 and 2017 are as follows (in thousands, except per share amounts):

 
Year Ended December 31, 2019
 
As reported
 
Adjustment
 
As adjusted
Product sales, net
$
311,190

 
$
(1,205
)
 
$
309,985

Total revenues
327,751

 
(1,205
)
 
326,546

Income tax (benefit) expense
(47
)
 
—

 
(47
)
Net loss from continuing operations
(466,456
)
 
(1,205
)
 
(467,661
)
Net loss
$
(466,456
)
 
$
(1,205
)
 
$
(467,661
)
 
 
 
 
 
 
Basic and diluted net loss per share
$
(13.71
)
 
$
(0.03
)
 
$
(13.74
)

 
Year Ended December 31, 2018
 
As reported
 
Adjustment
 
As adjusted
Product sales, net
$
473,852

 
$
(1,954
)
 
$
471,898

Total revenues
474,002

 
(1,954
)
 
472,048

Income tax (benefit) expense
39,654

 
782

 
40,436

Net loss from continuing operations
(169,339
)
 
(2,736
)
 
(172,075
)
Net loss
$
(65,761
)
 
$
(2,736
)
 
$
(68,497
)
 
 
 
 
 
 
Basic and diluted net loss per share
$
(1.91
)
 
$
(0.08
)
 
$
(1.99
)

 
Year Ended December 31, 2017
 
As reported
 
Adjustment
 
As adjusted
Product sales, net
$
495,645

 
$
(1,802
)
 
$
493,843

Total revenues
495,769

 
(1,802
)
 
493,967

Income tax (benefit) expense
(175,254
)
 
(267
)
 
(175,521
)
Net loss from continuing operations
(205,153
)
 
(1,535
)
 
(206,688
)
Net loss
$
(199,228
)
 
$
(1,535
)
 
$
(200,763
)
 
 
 
 
 
 
Basic and diluted net loss per share
$
(5.71
)
 
$
(0.04
)
 
$
(5.75
)
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.20.2
DESCRIPTION OF BUSINESS (Details)
 12 Months Ended
Dec. 31, 2019
product_candidate
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of product candidates 2
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2019
Jan. 01, 2018
Jan. 01, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]              
Cumulative effect of new accounting principle in period of adoption   $ 741,557 $ 787,882 $ 933,562 $ 279,816    
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201609Member us-gaap:AccountingStandardsUpdate201409 us-gaap:AccountingStandardsUpdate201409Member us-gaap:AccountingStandardsUpdate201609Member      
Cumulative Effect, Period of Adoption, Adjustment              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]              
Cumulative effect of new accounting principle in period of adoption     $ 1,136 $ 21,558   $ 1,100 $ 21,600
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition - Additional Information (Details)
 12 Months Ended
Dec. 31, 2019
Disaggregation of Revenue [Line Items]  
Discount percentage 2.00%
Percentage of discount accrued at time of sale 100.00%
GPO billing period 30 days
Minimum  
Disaggregation of Revenue [Line Items]  
Rebate payment term 1 year
Standard payment term 30 days
Product return term 3 years
Maximum  
Disaggregation of Revenue [Line Items]  
Rebate payment term 3 months
Standard payment term 60 days
Product return term 5 years
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customers Who Represent 10% or More of Total Revenues or Accounts Receivable Balances (Details) - facility
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenue from Contract with Customer | Customer Concentration Risk | McKesson Corporation      
Concentrations and Significant Customer Information      
Concentration risk, including less than and more than 10% (percent) 36.00% 26.00% 24.00%
Revenue from Contract with Customer | Customer Concentration Risk | AmerisourceBergen Drug Corporation      
Concentrations and Significant Customer Information      
Concentration risk, including less than and more than 10% (percent) 28.00% 27.00% 26.00%
Revenue from Contract with Customer | Customer Concentration Risk | Cardinal Health      
Concentrations and Significant Customer Information      
Concentration risk, including less than and more than 10% (percent) 13.00% 10.00% 10.00%
Accounts Receivable | Customer Concentration Risk | Three Customers      
Concentrations and Significant Customer Information      
Concentration risk, including less than and more than 10% (percent) 85.00%    
Accounts Receivable | Customer Concentration Risk | Two Customers      
Concentrations and Significant Customer Information      
Concentration risk, including less than and more than 10% (percent)   73.00%  
Feraheme      
Concentrations and Significant Customer Information      
Number of production facilities 2    
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventory (Details)
 12 Months Ended
Dec. 31, 2019
Minimum  
Inventory [Line Items]  
Shelf-life 3 years
Maximum  
Inventory [Line Items]  
Shelf-life 5 years
XML 71 R58.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment, Net (Details)
 12 Months Ended
Dec. 31, 2019
Computer equipment and software  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 5 years
Furniture and fixtures  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 5 years
Laboratory and production equipment  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 5 years
XML 72 R59.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Accounting Policies [Abstract]    
Restricted cash $ 495 $ 495
XML 73 R60.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Accounting Policies [Abstract]      
Advertising costs $ 53.3 $ 29.8 $ 9.1
XML 74 R61.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basic and Diluted Earnings per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Jun. 30, 2017
Feb. 28, 2014
Debt Instrument [Line Items]                          
Net loss from continuing operations $ (200,152) $ (23,940) $ (121,169) $ (122,400) $ (21,004) $ (65,282) $ (26,795) $ (58,994) $ (467,661) $ (172,075) $ (206,688)    
Net income from discontinued operations $ 0 $ 0 $ 0 $ 0 $ (1,531) $ 95,517 $ 5,736 $ 3,856 $ 0 $ 103,578 $ 5,925    
Weighted average common shares outstanding (in shares)                 34,030 34,394 34,907    
Effect of dilutive securities:                          
Stock options and RSUs (in shares)                 0 0 0    
Shares used in calculating dilutive net loss per share (in shares)                 34,030 34,394 34,907    
Basic and diluted earnings per share:                          
Loss from continuing operations (in dollars per share) $ (5.90) $ (0.71) $ (3.58) $ (3.55) $ (0.61) $ (1.89) $ (0.78) $ (1.72) $ (13.74) $ (5.00) $ (5.92)    
Income from discontinued operations (in dollars per share) 0 0 0 0 (0.04) 2.77 0.17 0.11 0 3.01 0.17    
Total (in dollars per share) $ (5.90) $ (0.71) $ (3.58) $ (3.55) $ (0.65) $ 0.88 $ (0.61) $ (1.61) $ (13.74) $ (1.99) $ (5.75)    
Convertible Debt | Convertible Notes Due 2019                          
Debt Instrument [Line Items]                          
Interest rate                         2.50%
Convertible Debt | 2022 Convertible Notes                          
Debt Instrument [Line Items]                          
Interest rate 3.25%               3.25%     3.25%  
XML 75 R62.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Anti-dilutive Securities excluded from Computation of Earnings per Share (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive securities (shares) 17,250 18,500 18,094
Options to purchase shares of common stock      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive securities (shares) 3,976 3,797 3,531
Shares of common stock issuable upon the vesting of RSUs      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive securities (shares) 1,579 1,129 1,070
Warrants      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive securities (shares) 0 1,008 1,008
Shares of common stock under employee stock purchase plan      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive securities (shares) 0 81 0
2022 Convertible Notes | Convertible Debt Securities      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive securities (shares) 11,695 11,695 11,695
2019 Convertible Notes | Convertible Debt Securities      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive securities (shares) 0 790 790
XML 76 R63.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Business Segments (Details)
 12 Months Ended
Dec. 31, 2019
business_segment
Accounting Policies [Abstract]  
Number of business segments 1
XML 77 R64.htm IDEA: XBRL DOCUMENT v3.20.2
DISCONTINUED OPERATIONS - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Gain on sale of CBR business $ 0 $ 87,076 $ 0
Transaction expenses $ 0 14,111 0
Discontinued Operations, Held-for-sale or Disposed of by Sale | CBR business      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Capital expenditures   1,600 4,900
Depreciation and amortization expense   8,400 21,700
Gain on sale of CBR business   87,076 $ 0
Transaction expenses   $ 14,100  
XML 78 R65.htm IDEA: XBRL DOCUMENT v3.20.2
DISCONTINUED OPERATIONS - Summary of Net Income (Loss) (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Costs and expenses:                      
Income from discontinued operations                 $ 0 $ 18,873 $ 10,313
Gain on sale of CBR business                 0 87,076 0
Income tax expense                 0 2,371 4,388
Net income from discontinued operations $ 0 $ 0 $ 0 $ 0 $ (1,531) $ 95,517 $ 5,736 $ 3,856 $ 0 103,578 5,925
CBR business | Discontinued Operations, Held-for-sale or Disposed of by Sale                      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                      
Service revenues, net                   71,217 114,177
Costs and expenses:                      
Cost of services                   12,559 21,817
Selling, general and administrative expenses                   39,899 81,782
Total costs and expenses                   52,458 103,599
Operating income                   18,759 10,578
Other income (expense)                   114 (265)
Income from discontinued operations                   18,873 10,313
Gain on sale of CBR business                   87,076 0
Income tax expense                   2,371 4,388
Net income from discontinued operations                   $ 103,578 $ 5,925
XML 79 R66.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUE RECOGNITION - Disaggregated Revenue By Major Products (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Disaggregation of Revenue [Line Items]                      
Revenues $ 89,483 $ 83,808 $ 77,767 $ 75,488 $ 87,871 $ 121,646 $ 145,663 $ 116,867 $ 326,546 $ 472,048 $ 493,967
Makena                      
Disaggregation of Revenue [Line Items]                      
Revenues                 120,859 320,311 385,356
Feraheme                      
Disaggregation of Revenue [Line Items]                      
Revenues                 167,947 135,001 105,930
Intrarosa                      
Disaggregation of Revenue [Line Items]                      
Revenues                 21,417 16,218 1,816
Other                      
Disaggregation of Revenue [Line Items]                      
Revenues                 (238) 368 741
Product sales, net                      
Disaggregation of Revenue [Line Items]                      
Revenues $ 73,154 $ 83,784 $ 77,634 $ 75,413 $ 87,796 $ 121,646 $ 145,628 $ 116,828 $ 309,985 $ 471,898 $ 493,843
XML 80 R67.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUE RECOGNITION - Total Gross Product (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Provision for product sales allowances and accruals:                      
Product sales, net $ 89,483 $ 83,808 $ 77,767 $ 75,488 $ 87,871 $ 121,646 $ 145,663 $ 116,867 $ 326,546 $ 472,048 $ 493,967
Product sales, net                      
Disaggregation of Revenue [Line Items]                      
Gross product sales                 955,693 974,330 920,061
Provision for product sales allowances and accruals:                      
Contractual adjustments                 530,645 387,540 310,588
Governmental rebates                 115,063 114,892 115,630
Total                 645,708 502,432 426,218
Product sales, net $ 73,154 $ 83,784 $ 77,634 $ 75,413 $ 87,796 $ 121,646 $ 145,628 $ 116,828 $ 309,985 $ 471,898 $ 493,843
XML 81 R68.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUE RECOGNITION - Product Revenue Allowance and Accrual Activity (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Contractual Adjustments      
Balance at Beginning of Period $ 57,199 $ 62,164 $ 47,600
Provisions related to current period sales 521,916 389,861 314,537
Adjustments related to prior period sales 8,774 (2,330) (3,949)
Payments/returns relating to current period sales (431,014) (333,694) (253,545)
Payments/returns relating to prior period sales (61,654) (58,802) (42,479)
Balance at End of Period 95,221 57,199 62,164
Governmental Rebates      
Balance at Beginning of Period 34,212 53,742 52,741
Provisions related to current period sales 100,926 106,988 113,969
Adjustments related to prior period sales 14,137 7,903 1,661
Payments/returns relating to current period sales (60,218) (75,920) (61,569)
Payments/returns relating to prior period sales (41,435) (58,501) (53,060)
Balance at End of Period 47,622 34,212 53,742
Revenue, Allowance [Roll Forward]      
Balance at Beginning of Period 91,411 115,906 100,341
Provisions related to current period sales 622,842 496,849 428,506
Adjustments related to prior period sales 22,911 5,573 (2,288)
Payments/returns relating to current period sales (491,232) (409,614) (315,114)
Payments/returns relating to prior period sales (103,089) (117,303) (95,539)
Balance at End of Period $ 142,843 $ 91,411 $ 115,906
XML 82 R69.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUE RECOGNITION - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Mar. 31, 2019
Revenue from Contract with Customer [Abstract]          
Adjustments related to prior period sales. Medicaid rebates   $ 14,137 $ 7,903 $ 1,661  
Adjustments related to prior period sales, contractual adjustments   $ 8,774 $ (2,330) $ (3,949)  
Deferred revenue         $ 6,400
Termination payment received $ 10,000        
XML 83 R70.htm IDEA: XBRL DOCUMENT v3.20.2
MARKETABLE SECURITIES (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Short-term investments:      
Amortized Cost, short-term investments $ 50,436,000 $ 74,826,000  
Gross Unrealized Gains, short-term investments 140,000 0  
Gross Unrealized Losses, short-term investments (2,000) (270,000)  
Estimated Fair Value, short-term investments 50,574,000 74,556,000  
Long-term investments:      
Amortized Cost, long-term investments 8,016,000 66,772,000  
Gross Unrealized Gains, long-term investments 152,000 52,000  
Gross Unrealized Losses, long-term investments 0 (465,000)  
Estimated Fair Value, long-term investments 8,168,000 66,359,000  
Total investments      
Amortized Cost, total 58,452,000 141,598,000  
Gross Unrealized Gains, total 292,000 52,000  
Gross Unrealized Losses, total (2,000) (735,000)  
Estimated Fair Value, total 58,742,000 140,915,000  
Other-than-temporary impairment losses 0 0 $ 0
Corporate debt securities      
Short-term investments:      
Amortized Cost, short-term investments 46,186,000 51,184,000  
Gross Unrealized Gains, short-term investments 140,000 0  
Gross Unrealized Losses, short-term investments (2,000) (236,000)  
Estimated Fair Value, short-term investments 46,324,000 50,948,000  
Long-term investments:      
Amortized Cost, long-term investments 8,016,000 62,530,000  
Gross Unrealized Gains, long-term investments 152,000 52,000  
Gross Unrealized Losses, long-term investments 0 (433,000)  
Estimated Fair Value, long-term investments 8,168,000 62,149,000  
U.S. treasury and government agency securities      
Short-term investments:      
Amortized Cost, short-term investments 2,750,000 7,647,000  
Gross Unrealized Gains, short-term investments 0 0  
Gross Unrealized Losses, short-term investments 0 (34,000)  
Estimated Fair Value, short-term investments 2,750,000 7,613,000  
Long-term investments:      
Amortized Cost, long-term investments   2,742,000  
Gross Unrealized Gains, long-term investments   0  
Gross Unrealized Losses, long-term investments   (32,000)  
Estimated Fair Value, long-term investments   2,710,000  
Commercial paper      
Short-term investments:      
Amortized Cost, short-term investments   3,995,000  
Gross Unrealized Gains, short-term investments   0  
Gross Unrealized Losses, short-term investments   0  
Estimated Fair Value, short-term investments   3,995,000  
Certificates of deposit      
Short-term investments:      
Amortized Cost, short-term investments 1,500,000 12,000,000  
Gross Unrealized Gains, short-term investments 0 0  
Gross Unrealized Losses, short-term investments 0 0  
Estimated Fair Value, short-term investments $ 1,500,000 12,000,000  
Long-term investments:      
Amortized Cost, long-term investments   1,500,000  
Gross Unrealized Gains, long-term investments   0  
Gross Unrealized Losses, long-term investments   0  
Estimated Fair Value, long-term investments   $ 1,500,000  
XML 84 R71.htm IDEA: XBRL DOCUMENT v3.20.2
FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair value, measurements, recurring - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Assets:    
Cash equivalents $ 13,732 $ 71,568
Total Assets 72,474 212,483
Liabilities:    
Total Liabilities 17 359
Other    
Liabilities:    
Contingent consideration 17 359
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Cash equivalents 13,732 71,568
Total Assets 13,732 71,568
Liabilities:    
Total Liabilities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other    
Liabilities:    
Contingent consideration 0 0
Significant Other Observable Inputs (Level 2)    
Assets:    
Cash equivalents 0 0
Total Assets 58,742 140,915
Liabilities:    
Total Liabilities 0 0
Significant Other Observable Inputs (Level 2) | Other    
Liabilities:    
Contingent consideration 0 0
Significant Unobservable Inputs (Level 3)    
Assets:    
Cash equivalents 0 0
Total Assets 0 0
Liabilities:    
Total Liabilities 17 359
Significant Unobservable Inputs (Level 3) | Other    
Liabilities:    
Contingent consideration 17 359
Corporate debt securities    
Assets:    
Available-for-sale securities 54,492 113,097
Corporate debt securities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Available-for-sale securities 0 0
Corporate debt securities | Significant Other Observable Inputs (Level 2)    
Assets:    
Available-for-sale securities 54,492 113,097
Corporate debt securities | Significant Unobservable Inputs (Level 3)    
Assets:    
Available-for-sale securities 0 0
U.S. treasury and government agency securities    
Assets:    
Available-for-sale securities 2,750 10,323
U.S. treasury and government agency securities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Available-for-sale securities 0 0
U.S. treasury and government agency securities | Significant Other Observable Inputs (Level 2)    
Assets:    
Available-for-sale securities 2,750 10,323
U.S. treasury and government agency securities | Significant Unobservable Inputs (Level 3)    
Assets:    
Available-for-sale securities 0 0
Commercial paper    
Assets:    
Available-for-sale securities   3,995
Commercial paper | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Available-for-sale securities   0
Commercial paper | Significant Other Observable Inputs (Level 2)    
Assets:    
Available-for-sale securities   3,995
Commercial paper | Significant Unobservable Inputs (Level 3)    
Assets:    
Available-for-sale securities   0
Certificates of deposit    
Assets:    
Available-for-sale securities 1,500 13,500
Certificates of deposit | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Available-for-sale securities 0 0
Certificates of deposit | Significant Other Observable Inputs (Level 2)    
Assets:    
Available-for-sale securities 1,500 13,500
Certificates of deposit | Significant Unobservable Inputs (Level 3)    
Assets:    
Available-for-sale securities $ 0 $ 0
XML 85 R72.htm IDEA: XBRL DOCUMENT v3.20.2
FAIR VALUE MEASUREMENTS - Contingent Consideration (Details) - USD ($)
 3 Months Ended 12 Months Ended
Jun. 30, 2018
Dec. 31, 2018
Dec. 31, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Accrued expenses   $ 134,635,000 $ 183,382,000
Endoceutics License Agreement      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Accrued expenses   0 $ 0
Contingent Consideration      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Adjustments to fair value of contingent consideration $ 49,800,000 $ 49,600,000  
XML 86 R73.htm IDEA: XBRL DOCUMENT v3.20.2
FAIR VALUE MEASUREMENTS - Debt (Details) - Convertible Debt - Significant Other Observable Inputs (Level 2) - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
2022 Convertible Notes    
Debt    
Fair value of debt $ 274.8 $ 294.8
2019 Convertible Notes    
Debt    
Fair value of debt   $ 20.9
XML 87 R74.htm IDEA: XBRL DOCUMENT v3.20.2
FAIR VALUE MEASUREMENTS - Nonrecurring Fair Value Measurements (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Fair Value Disclosures [Abstract]        
Fair value of intangible assets $ 23,600 $ 23,600    
Impairment of assets $ 155,000 $ 232,336 $ 0 $ 319,246
XML 88 R75.htm IDEA: XBRL DOCUMENT v3.20.2
INVENTORIES (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Inventory Disclosure [Abstract]      
Raw materials $ 5,211 $ 9,388  
Work in process 6,248 5,932  
Finished goods 20,094 11,371  
Total inventories 31,553 26,691  
Write-down of inventory $ 19,767 $ 5,176 $ 0
XML 89 R76.htm IDEA: XBRL DOCUMENT v3.20.2
PROPERTY AND EQUIPMENT, NET (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 15,492 $ 12,732  
Less: accumulated depreciation (11,376) (5,211)  
Property and equipment, net 4,116 7,521  
Depreciation expense 2,600 1,600 $ 1,200
Computer equipment and software      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 1,568 1,637  
Furniture and fixtures      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 1,714 1,737  
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 4,984 2,938  
Laboratory and production equipment      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 6,570 6,000  
Construction in progress      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 656 $ 420  
XML 90 R77.htm IDEA: XBRL DOCUMENT v3.20.2
GOODWILL AND INTANGIBLE ASSETS, NET - Goodwill - Narrative (Details)
 2 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 31, 2019
USD ($)
$ / shares
Dec. 31, 2018
USD ($)
$ / shares
Nov. 05, 2018
USD ($)
Oct. 31, 2018
USD ($)
$ / shares
Dec. 31, 2018
USD ($)
$ / shares
Dec. 31, 2019
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
$ / shares
Sep. 30, 2018
Goodwill [Line Items]                    
Goodwill   $ 422,513,000     $ 422,513,000 $ 422,513,000   $ 422,513,000 $ 422,513,000  
Accumulated impairment losses           0   0    
Share price (in dollars per share) | $ / shares $ 9.71 $ 15.19   $ 21.50 $ 15.19       $ 15.19  
Market capitalization $ 329,000,000   $ 633,000,000 $ 742,000,000 $ 617,000,000          
Fair value percentage below carrying amount, reporting unit 6.00% 41.00% 20.00% 2.00% 21.00%          
Fair value percentage above carrying amount, net assets 29.00% 15.00%   36.00%            
Goodwill, impairment $ 0     $ 0     $ 0 $ 0 $ 0  
Share price, median (in dollars per share) | $ / shares         $ 17.84          
Reporting unit, carrying amount   $ 747,000,000     $ 747,000,000       $ 747,000,000  
Impairment of intangible assets           $ 151,300,000        
Measurement Input, Control Premium                    
Goodwill [Line Items]                    
Reporting unit, measurement input, median           0.65   0.65   0.71
Measurement Input, Control Premium | Minimum                    
Goodwill [Line Items]                    
Reporting unit, measurement input           0.37   0.37   0.39
Measurement Input, Control Premium | Maximum                    
Goodwill [Line Items]                    
Reporting unit, measurement input           0.84   0.84   0.96
XML 91 R78.htm IDEA: XBRL DOCUMENT v3.20.2
GOODWILL AND INTANGIBLE ASSETS, NET - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]    
Life to Date Accumulated Amortization $ 442,340 $ 417,576
Total intangible assets    
Cost 1,013,855 953,855
Life to Date Accumulated Amortization 442,340 417,576
Impairments 547,895 319,246
Total 23,620 217,033
Makena | Developed technology rights    
Finite-Lived Intangible Assets [Line Items]    
Cost 797,100 797,100
Life to Date Accumulated Amortization 400,496 400,495
Impairments 396,604 319,246
Total 0 77,359
Total intangible assets    
Life to Date Accumulated Amortization 400,496 400,495
Makena auto-injector developed technology | Developed technology rights    
Finite-Lived Intangible Assets [Line Items]    
Cost 79,100 79,100
Life to Date Accumulated Amortization 15,782 6,952
Impairments 55,426 0
Total 7,892 72,148
Total intangible assets    
Life to Date Accumulated Amortization 15,782 6,952
Intrarosa | Developed technology rights    
Finite-Lived Intangible Assets [Line Items]    
Cost 77,655 77,655
Life to Date Accumulated Amortization 16,798 10,129
Impairments 56,881 0
Total 3,976 67,526
Total intangible assets    
Life to Date Accumulated Amortization 16,798 10,129
Vyleesi Products | Developed technology rights    
Finite-Lived Intangible Assets [Line Items]    
Cost 60,000 0
Life to Date Accumulated Amortization 9,264 0
Impairments 38,984 0
Total 11,752 0
Total intangible assets    
Life to Date Accumulated Amortization $ 9,264 $ 0
XML 92 R79.htm IDEA: XBRL DOCUMENT v3.20.2
GOODWILL AND INTANGIBLE ASSETS, NET - Intangible Assets - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2019
Jun. 30, 2019
Jun. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]            
Milestone payment accrued for FDA approval of Vyleesi   $ 60,000 $ 60,000      
Goodwill $ 422,513     $ 422,513 $ 422,513  
Impairment of intangible assets 151,300          
Impairment of assets 155,000     232,336 0 $ 319,246
Amortization of intangible assets       $ 24,800 158,400 $ 130,400
Expected useful life       1 year    
Expect amortization expense related to finite-lived intangible assets during the next 12 months 23,600     $ 23,600    
Developed technology rights            
Finite-Lived Intangible Assets [Line Items]            
Amortization of intangible assets       7,100    
Vyleesi Products | Developed technology rights            
Finite-Lived Intangible Assets [Line Items]            
Fair value of intangible asset 11,752     11,752 0  
Impairment of intangible assets 39,000          
Makena auto-injector developed technology | Developed technology rights            
Finite-Lived Intangible Assets [Line Items]            
Fair value of intangible asset 7,892     7,892 72,148  
Impairment of intangible assets 55,400          
Makena | Developed technology rights            
Finite-Lived Intangible Assets [Line Items]            
Fair value of intangible asset 0     0 77,359  
Impairment of intangible assets   $ 77,400 $ 77,400      
Intrarosa | Developed technology rights            
Finite-Lived Intangible Assets [Line Items]            
Fair value of intangible asset 3,976     $ 3,976 $ 67,526  
Impairment of intangible assets $ 56,900          
XML 93 R80.htm IDEA: XBRL DOCUMENT v3.20.2
CURRENT AND LONG-TERM LIABILITIES (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Accrued Expenses    
Commercial rebates, fees and returns $ 124,730 $ 85,618
Accrued manufacturing 21,364 9,282
Salaries, bonuses, and other compensation 18,693 22,482
Professional, license, and other fees and expenses 13,392 13,960
Accrued research and development 3,539 2,226
Interest expense 867 1,067
Restructuring expense 797 0
Total accrued expenses $ 183,382 $ 134,635
XML 94 R81.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES - Schedule of Income Tax Expense (Benefit) (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Current:                      
Federal                 $ (630) $ (1,136) $ 2,162
State                 179 1,469 5,358
Total current                 (451) 333 7,520
Deferred:                      
Federal                 432 43,546 (172,238)
State                 (28) (3,443) (10,803)
Total deferred                 404 40,103 (183,041)
Total income tax (benefit) expense $ (21) $ 232 $ (120) $ (137) $ (2,543) $ (2,340) $ 52,943 $ (7,624) $ (47) $ 40,436 $ (175,521)
XML 95 R82.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES - Income Tax Reconciliation (Details)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]      
Statutory U.S. federal tax rate 21.00% 21.00% 35.00%
State taxes, net of federal benefit 2.60% 4.70% 3.30%
Impact of 2017 tax reform on deferred tax balance 0.00% 0.00% 4.50%
Equity-based compensation expense (0.40%) (1.50%) (0.80%)
Contingent consideration 0.00% 7.10% 4.40%
In-process research and development (3.40%) 0.00% 0.00%
Other permanent items, net (0.40%) (1.40%) (0.50%)
Tax credits 0.40% 6.20% 0.70%
Valuation allowance (19.80%) (67.40%) (0.80%)
Other, net 0.00% 0.60% 0.10%
Effective tax rate 0.00% (30.70%) 45.90%
XML 96 R83.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Tax Credit Carryforward [Line Items]                      
Effective tax rate                 0.00% (30.70%) 45.90%
Statutory U.S. federal tax rate                 21.00% 21.00% 35.00%
Income tax (benefit) expense $ (21) $ 232 $ (120) $ (137) $ (2,543) $ (2,340) $ 52,943 $ (7,624) $ (47) $ 40,436 $ (175,521)
Tax cuts and jobs act, provisional tax benefit                     17,100
Increase in valuation allowance                 103,800    
Operating loss carryforwards, not subject to expiration 127,400               127,400    
Increase (decrease) in unrecognized tax benefits                 2,400 $ 600 $ 2,500
Domestic Tax Authority                      
Tax Credit Carryforward [Line Items]                      
Operating loss carryforwards 332,800               332,800    
Tax credit carryforward, amount 26,100               26,100    
Domestic Tax Authority | Lumara Health Inc.                      
Tax Credit Carryforward [Line Items]                      
Operating loss carryforwards 123,100               123,100    
Tax credit carryforward, amount 2,300               2,300    
State and Local Jurisdiction                      
Tax Credit Carryforward [Line Items]                      
Operating loss carryforwards 184,600               184,600    
Tax credit carryforward, amount 2,500               2,500    
State and Local Jurisdiction | Lumara Health Inc.                      
Tax Credit Carryforward [Line Items]                      
Operating loss carryforwards 16,600               16,600    
Capital Loss Carryforward | Discontinued Operations, Held-for-sale or Disposed of by Sale | CBR business                      
Tax Credit Carryforward [Line Items]                      
Tax credit carryforward, amount 90,400               90,400    
Interest Expense Carryforward                      
Tax Credit Carryforward [Line Items]                      
Tax credit carryforward, amount 23,600               23,600    
Perosphere Pharmaceuticals Inc. | Domestic Tax Authority                      
Tax Credit Carryforward [Line Items]                      
Operating loss carryforwards 21,400               21,400    
Tax credit carryforward, amount 2,300               2,300    
Perosphere Pharmaceuticals Inc. | State and Local Jurisdiction                      
Tax Credit Carryforward [Line Items]                      
Operating loss carryforwards 14,600               14,600    
Tax credit carryforward, amount $ 1,200               $ 1,200    
XML 97 R84.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES - Deferred Tax Components (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Assets    
Net operating loss carryforwards $ 79,679 $ 46,888
Tax credit carryforwards 28,641 24,290
Capital loss carryforwards 20,659 20,896
Interest expense carryforwards 5,746 4,318
Equity-based compensation expense 6,106 5,931
Capitalized research & development 2,347 4,635
Intangible assets 67,847 12,565
Reserves 5,721 2,683
Lease liability 5,739  
Property, plant and equipment 391 0
Contingent consideration 4 87
Other 10,846 6,627
Valuation allowance (218,291) (114,516)
Liabilities    
Property, plant and equipment depreciation 0 (614)
Debt instruments (9,195) (12,489)
Right of use asset (5,599)  
Other (11) (41)
Net deferred tax assets $ 630 $ 1,260
XML 98 R85.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES - Reconciliation of Uncertain Tax Positions (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Unrecognized tax benefits at the beginning of the year $ 11,180 $ 10,560 $ 13,020
Additions based on tax positions related to the current year 521 12 574
Additions for tax positions from prior years 2,173 608 340
Subtractions for federal tax reform 0 0 (3,296)
Subtractions for tax positions from prior years (336) 0 (78)
Unrecognized tax benefits at the end of the year $ 13,538 $ 11,180 $ 10,560
XML 99 R86.htm IDEA: XBRL DOCUMENT v3.20.2
ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
AOCI Attributable to Parent, Net of Tax      
Beginning balance $ 741,557 $ 787,882 $ 933,562
Other comprehensive income (loss) before reclassifications 746 (77) (70)
Ending balance 279,816 741,557 787,882
Accumulated Other Comprehensive Income (Loss)      
AOCI Attributable to Parent, Net of Tax      
Beginning balance (3,985) (3,908) (3,838)
Ending balance $ (3,239) $ (3,985) $ (3,908)
XML 100 R87.htm IDEA: XBRL DOCUMENT v3.20.2
EQUITY-BASED COMPENSATION - Narrative (Details)
$ / shares in Units, $ in Millions
 1 Months Ended 12 Months Ended
Feb. 28, 2019
shares
Jun. 30, 2018
shares
Mar. 31, 2018
shares
Feb. 28, 2017
shares
May 31, 2015
shares
Dec. 31, 2019
USD ($)
plan
$ / shares
shares
Dec. 31, 2018
USD ($)
$ / shares
Dec. 31, 2017
USD ($)
$ / shares
Nov. 30, 2014
shares
Equity compensation plans                  
Number of equity compensation plans | plan           3      
Options granted in period (in dollars per share) | $ / shares           $ 6.33 $ 10.76 $ 9.52  
Options vested in period (shares)           728,758      
Value of options exercised in period | $           $ 0.0 $ 0.6 $ 0.4  
Compensation cost not yet recognized | $           28.1      
Compensation cost not yet recognized, associated with stock options | $           $ 11.5      
RSUs                  
Equity compensation plans                  
Granted (shares)           1,186,874      
Compensation expense, period for recognition           1 year 8 months 12 days      
RSUs granted (in dollars per share) | $ / shares           $ 15.65 $ 22.32 $ 24.18  
Value of RSUs vested during period | $           $ 9.1 $ 12.4 $ 12.3  
Compensation cost not yet recognized | $           $ 12.3      
Performance Restricted Stock Units (RSUs)                  
Equity compensation plans                  
Compensation expense, period for recognition           1 year 6 months      
Compensation cost not yet recognized | $           $ 4.3      
Employee and Non Employee Director Stock Option                  
Equity compensation plans                  
Compensation expense, period for recognition           2 years 6 months      
2007 Equity Plan                  
Equity compensation plans                  
Remaining number of shares available for future grants (in shares)           0      
Offering period term           10 years      
2007 Equity Plan | RSUs                  
Equity compensation plans                  
Granted (shares)           1,023,847      
2007 Equity Plan | Performance Restricted Stock Units (RSUs)                  
Equity compensation plans                  
Granted (shares) 365,591   206,250 191,250          
Award vesting period           3 years      
Compensation expense, period for recognition           3 years      
2019 Equity Plan                  
Equity compensation plans                  
Remaining number of shares available for future grants (in shares)           2,828,030      
Additional common stock for issuance (shares)           2,161,000      
Shares authorized for issuance (in shares)           3,519,304      
Offering period term           10 years      
2019 Equity Plan | RSUs                  
Equity compensation plans                  
Granted (shares)           132,542      
2013 Lumara Equity Plan                  
Equity compensation plans                  
Remaining number of shares available for future grants (in shares)           9,817      
Shares authorized for issuance (in shares)                 200,000
Offering period term           10 years      
2013 Lumara Equity Plan | RSUs                  
Equity compensation plans                  
Granted (shares)           1,100      
2015 ESPP                  
Equity compensation plans                  
Additional common stock for issuance (shares)   500,000              
Shares authorized for issuance (in shares)         200,000        
Annual maximum percentage of employee compensation available for ESPP share purchases         10.00%        
Purchase price per share as a percentage of fair market value of common stock on the first or last day of the plan period         85.00%        
Stock offering period         6 years        
Shares issued (in shares)           445,713      
Inducement Grants | Employee Stock Option                  
Equity compensation plans                  
Award vesting period           4 years      
Inducement Grants | RSUs                  
Equity compensation plans                  
Granted (shares)           29,385      
Award vesting period           3 years      
February 2019 | 2007 Equity Plan | Performance Restricted Stock Units (RSUs)                  
Equity compensation plans                  
Granted (shares)           325,091      
Fair value, performance- based RSUs | $           $ 4.2      
XML 101 R88.htm IDEA: XBRL DOCUMENT v3.20.2
EQUITY-BASED COMPENSATION - Activity Related to Plans (Details) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Feb. 28, 2019
Mar. 31, 2018
Feb. 28, 2017
Dec. 31, 2019
Stock Options        
Beginning balance (shares)       3,716,579
Granted (shares)       1,061,587
Exercised (shares)       (2,025)
Expired or terminated (shares)       (890,324)
Ending balance (shares)       3,885,817
2019 Equity Plan        
Stock Options        
Beginning balance (shares)       0
Granted (shares)       479,212
Exercised (shares)       0
Expired or terminated (shares)       (6,800)
Ending balance (shares)       472,412
Restricted Stock Units        
Remaining number of shares available for future grants (in shares)       2,828,030
2007 Equity Plan        
Stock Options        
Beginning balance (shares)       2,781,786
Granted (shares)       465,009
Exercised (shares)       (2,025)
Expired or terminated (shares)       (659,304)
Ending balance (shares)       2,585,466
Restricted Stock Units        
Remaining number of shares available for future grants (in shares)       0
2013 Lumara Equity Plan        
Stock Options        
Beginning balance (shares)       124,450
Granted (shares)       37,000
Exercised (shares)       0
Expired or terminated (shares)       (29,675)
Ending balance (shares)       131,775
Restricted Stock Units        
Remaining number of shares available for future grants (in shares)       9,817
Inducement Grants        
Stock Options        
Beginning balance (shares)       810,343
Granted (shares)       80,366
Exercised (shares)       0
Expired or terminated (shares)       (194,545)
Ending balance (shares)       696,164
RSUs        
Restricted Stock Units        
Outstanding at beginning of year (shares)       1,128,535
Granted (shares)       1,186,874
Vested (shares)       (404,305)
Expired or terminated (in shares)       (331,667)
Outstanding at end of year (shares)       1,579,437
Compensation expense, period for recognition       1 year 8 months 12 days
RSUs | 2019 Equity Plan        
Restricted Stock Units        
Outstanding at beginning of year (shares)       0
Granted (shares)       132,542
Vested (shares)       0
Expired or terminated (in shares)       (3,800)
Outstanding at end of year (shares)       128,742
RSUs | 2007 Equity Plan        
Restricted Stock Units        
Outstanding at beginning of year (shares)       1,041,141
Granted (shares)       1,023,847
Vested (shares)       (358,362)
Expired or terminated (in shares)       (299,321)
Outstanding at end of year (shares)       1,407,305
RSUs | 2013 Lumara Equity Plan        
Restricted Stock Units        
Outstanding at beginning of year (shares)       2,101
Granted (shares)       1,100
Vested (shares)       (1,034)
Expired or terminated (in shares)       0
Outstanding at end of year (shares)       2,167
RSUs | Inducement Grants        
Restricted Stock Units        
Outstanding at beginning of year (shares)       85,293
Granted (shares)       29,385
Vested (shares)       (44,909)
Expired or terminated (in shares)       (28,546)
Outstanding at end of year (shares)       41,223
Award vesting period       3 years
Performance Restricted Stock Units (RSUs)        
Restricted Stock Units        
Compensation expense, period for recognition       1 year 6 months
Performance Restricted Stock Units (RSUs) | 2007 Equity Plan        
Restricted Stock Units        
Granted (shares) 365,591 206,250 191,250  
Award vesting period       3 years
Compensation expense, period for recognition       3 years
February 2019 | Performance Restricted Stock Units (RSUs) | 2007 Equity Plan        
Restricted Stock Units        
Granted (shares)       325,091
Fair value, performance- based RSUs       $ 4.2
March 2018 | Performance Restricted Stock Units (RSUs) | 2007 Equity Plan        
Restricted Stock Units        
Granted (shares)       155,250
Fair value, performance- based RSUs       $ 2.9
February 2017 | Performance Restricted Stock Units (RSUs) | 2007 Equity Plan        
Restricted Stock Units        
Remaining number of shares available for future grants (in shares)       131,250
Fair value, performance- based RSUs       $ 2.6
XML 102 R89.htm IDEA: XBRL DOCUMENT v3.20.2
EQUITY-BASED COMPENSATION - Equity-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Equity-based compensation expense        
Total equity-based compensation expense   $ 18,533 $ 19,949 $ 20,296
Income tax effect   0 0 (6,188)
After-tax effect of equity-based compensation expense   18,533 19,949 14,108
Cost of product sales        
Equity-based compensation expense        
Total equity-based compensation expense   871 802 884
Research and development        
Equity-based compensation expense        
Total equity-based compensation expense   2,844 2,533 3,225
Selling, general and administrative        
Equity-based compensation expense        
Total equity-based compensation expense   $ 14,818 $ 16,614 $ 16,187
Restructuring Charges        
Equity-based compensation expense        
Total equity-based compensation expense $ 700      
XML 103 R90.htm IDEA: XBRL DOCUMENT v3.20.2
EQUITY-BASED COMPENSATION - Weighted-Average Fair Value Assumptions, Stock Option Activity (Details)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Employee Stock Option      
Equity compensation plans      
Risk free interest rate (%) 2.12% 2.75% 1.86%
Expected volatility (%) 57.00% 57.00% 53.00%
Expected option term (years) 5 years 5 years 5 years
Dividend yield 0.00% 0.00% 0.00%
Non Employee Directors      
Equity compensation plans      
Risk free interest rate (%) 2.04% 2.70% 1.61%
Expected volatility (%) 59.00% 59.00% 57.00%
Expected option term (years) 4 years 4 years 4 years
Dividend yield 0.00% 0.00% 0.00%
XML 104 R91.htm IDEA: XBRL DOCUMENT v3.20.2
EQUITY-BASED COMPENSATION - Schedule of Stock-based Compensation (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Options    
Beginning balance (shares) 3,716,579  
Granted (shares) 1,061,587  
Exercised (shares) (2,025)  
Expired and/or forfeited (shares) (890,324)  
Ending balance (shares) 3,885,817 3,716,579
Outstanding at end of year - vested and unvested expected to vest (shares) 3,799,575  
Exercisable at end of year (shares) 2,242,727  
Weighted Average Exercise Price    
Beginning balance (in dollars per share) $ 24.81  
Granted (in dollars per share) 12.71  
Exercised (in dollars per share) 14.56  
Expired and/or forfeited (in dollars per share) 22.93  
Ending balance (in dollars per share) 21.94 $ 24.81
Outstanding at end of year - vested and unvested expected to vest (in dollars per share) 22.12  
Exercisable at end of year (in dollars per share) $ 25.76  
Stock Option Activity, Additional Disclosures    
Weighted Average Remaining Contractual Term, Outstanding 6 years 9 months 18 days 7 years 3 months 18 days
Weighted Average Remaining Contractual Term, Outstanding at end of year - vested and unvested expected to vest 6 years 9 months 18 days  
Weighted Average Remaining Contractual Term, Exercisable at end of year 5 years 6 months  
Aggregate Intrinsic Value, Outstanding at end of year $ 776  
Aggregate Intrinsic Value, Outstanding at end of year, vested and unvested expected to vest 701  
Aggregate Intrinsic Value, Exercisable at end of year $ 116  
XML 105 R92.htm IDEA: XBRL DOCUMENT v3.20.2
EQUITY-BASED COMPENSATION - Schedule of RSUs Granted (Details) - RSUs - $ / shares
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Restricted Stock Units      
Outstanding at beginning of year (shares) 1,128,535    
Granted (shares) 1,186,874    
Vested (shares) (404,305)    
Forfeited (shares) (331,667)    
Outstanding at end of year (shares) 1,579,437 1,128,535  
Outstanding at end of year and expected to vest (shares) 1,462,952    
Weighted Average Grant Date Fair Value      
Beginning balance (in dollars per share) $ 23.42    
Granted (in dollars per share) 15.65 $ 22.32 $ 24.18
Vested (in dollars per share) 22.49    
Forfeitures (in dollars per share) 19.71    
Ending balance (in dollars per share) 18.60 $ 23.42  
Outstanding at end of year and expected to vest (in dollars per share) $ 18.88    
XML 106 R93.htm IDEA: XBRL DOCUMENT v3.20.2
EMPLOYEE SAVINGS PLAN (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Retirement Benefits [Abstract]      
Employer matching contribution (percent) 4.00%    
Cost recognized $ 3.7 $ 4.0 $ 2.3
XML 107 R94.htm IDEA: XBRL DOCUMENT v3.20.2
STOCKHOLDERS’ EQUITY (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Mar. 31, 2019
Jan. 01, 2019
Jan. 31, 2016
Equity [Abstract]            
Share repurchase program, authorized amount (in shares)       $ 20,000,000.0   $ 60,000,000.0
Common stock repurchased and retired (in shares) 1,074,800 0        
Stock repurchased and retired during period, value $ 13,700,000   $ 19,467,000      
Available for repurchase of shares $ 26,800,000       $ 20,500,000  
XML 108 R95.htm IDEA: XBRL DOCUMENT v3.20.2
COMMITMENTS AND CONTINGENCIES - Narrative (Details)
$ in Thousands
 2 Months Ended 12 Months Ended
Nov. 06, 2019
defendant
Sep. 25, 2019
USD ($)
Jan. 13, 2020
lawsuit
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Jan. 01, 2019
USD ($)
Commitments              
Operating lease liability       $ 23,868      
Operating lease right-of-use asset       $ 23,286      
Weighted average operating lease remaining lease term       7 years 11 months 12 days      
Weighted average operating lease discount rate       5.10%      
Lease cost for operating leases       $ 5,100      
Lease cost for operating leases         $ 5,100 $ 3,000  
Operating cash outflows from operating leases       5,200      
Remaining minimum purchase commitments       $ 105,900      
Minimum              
Commitments              
Remaining operating lease term       1 year      
Maximum              
Commitments              
Remaining operating lease term       8 years 6 months      
Accounting Standards Update 2016-02              
Commitments              
Operating lease liability       $ 23,900     $ 8,500
Operating lease right-of-use asset             $ 7,600
Subsequent Event | Pending Litigation              
Commitments              
Number of class action lawsuits filed | lawsuit     4        
Civil Case In Saginaw Chippewa Indian Tribe V. Purdue Pharma Et Al | Pending Litigation              
Commitments              
Number of other pharmaceutical companies named as defendants | defendant 40            
Lunar Representative, LLC V. AMAG Pharmaceuticals, Inc. | Pending Litigation              
Commitments              
Damages sought by plaintiff   $ 50,000          
XML 109 R96.htm IDEA: XBRL DOCUMENT v3.20.2
COMMITMENTS AND CONTINGENCIES - Operating Leases, Fiscal Year Maturity Schedule (Details)
$ in Thousands
Dec. 31, 2019
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Year Ending December 31, 2020 $ 4,077
Year Ending December 31, 2021 3,207
Year Ending December 31, 2022 3,734
Year Ending December 31, 2023 3,230
Year Ending December 31, 2024 3,246
Thereafter 12,192
Total 29,686
Less: Interest 5,818
Operating lease liability $ 23,868
XML 110 R97.htm IDEA: XBRL DOCUMENT v3.20.2
COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 16, 2019
Apr. 03, 2017
Jan. 31, 2019
Sep. 30, 2018
Feb. 28, 2017
Jun. 30, 2018
Sep. 30, 2017
Jun. 30, 2017
Jun. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Collaborative Agreements                        
Payment for debt extinguishment                   $ 0 $ 28,054,000 $ 625,000
Shares issued in connection with Endoceutics License Agreement                       13,500,000
Velo Bio, LLC                        
Collaborative Agreements                        
Payments related to collaborative arrangement       $ 12,500,000                
Velo Bio, LLC | Regulatory Milestone Achievement                        
Collaborative Agreements                        
Milestone payments       5,000,000.0                
Velo Bio, LLC | Regulatory Milestone Achievement, U.S.Food and Drug Administration Approval                        
Collaborative Agreements                        
Milestone payments       30,000,000.0                
Velo Bio, LLC | Annual Sales Milestone Achievements                        
Collaborative Agreements                        
Milestone payments       240,000,000.0                
Velo Bio, LLC | Annual Sales Milestone Achievements | Minimum                        
Collaborative Agreements                        
Sales milestone targets       300,000,000.0                
Velo Bio, LLC | Annual Sales Milestone Achievements | Maximum                        
Collaborative Agreements                        
Sales milestone targets       900,000,000.0                
Velo Bio, LLC | Commercial Milestone Payments                        
Collaborative Agreements                        
Milestone payments       $ 10,000,000.0                
Endoceutics, Inc.                        
Collaborative Agreements                        
Consideration recorded               $ 83,500,000        
Payments related to collaborative arrangement   $ 50,000,000.0                    
Number of shares issued under arrangement   600,000                    
Shares issued in connection with Endoceutics License Agreement   $ 13,500,000               0 0 12,555,000
Future contingent payments (up to)                   0 $ 0 $ 9,300,000
IPR&D expense               5,800,000        
Palatin Technologies, Inc.                        
Collaborative Agreements                        
Payments related to collaborative arrangement         $ 60,000,000.0              
Out-of-pocket expenses (up to)         25,000,000.0              
Intrarosa | Endoceutics, Inc. | Developed technology rights                        
Collaborative Agreements                        
Finite-lived intangible assets               $ 77,700,000        
Intrarosa | Endoceutics, Inc. | Sales Milestones Achievement                        
Collaborative Agreements                        
Future contingent payments (up to)   895,000,000.0                    
Intrarosa | Endoceutics, Inc. | First Sales Milestone Achievement                        
Collaborative Agreements                        
Potential milestone payment, triggering event, sales   150,000,000.0                    
Future contingent payments (up to)   $ 15,000,000.0                    
Intrarosa | Endoceutics, Inc. | Delivery of Intrarosa Launch Quantities                        
Collaborative Agreements                        
Payments related to collaborative arrangement             $ 10,000,000.0          
Intrarosa | Endoceutics, Inc. | First Anniversary of Closing                        
Collaborative Agreements                        
Future contingent payments (up to)                   10,000,000.0    
Intrarosa | Endoceutics, Inc. | Tiered Royalties                        
Collaborative Agreements                        
Royalty percentage, maximum   25.00%                    
Vyleesi Products | Palatin Technologies, Inc. | First Sales Milestone Achievement                        
Collaborative Agreements                        
Potential milestone payment, triggering event, sales         250,000,000.0              
Future contingent payments (up to)         25,000,000.0              
Vyleesi Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, Acceptance by U.S.Food And Drug Administration of New Drug Application                        
Collaborative Agreements                        
Payments related to collaborative arrangement           $ 20,000,000.0     $ 60,000,000.0      
Vyleesi Products | Palatin Technologies, Inc. | Achievement of Certain Annual Sales Milestones Over Course of License Agreement                        
Collaborative Agreements                        
Future contingent payments (up to)         $ 300,000,000.0              
Perosphere Pharmaceuticals Inc.                        
Collaborative Agreements                        
Consideration recorded $ 50,000,000.0                      
Payments of asset acquisitions 40,000,000.0                      
Cancellation of convertible note 10,000,000.0                      
Other liabilities 6,200,000                      
Cash consideration $ 60,800,000                      
Discount rate 34.00%                      
Contingent consideration (up to)     $ 365,000,000.0                  
Perosphere Pharmaceuticals Inc. | Regulatory Milestone Achievement                        
Collaborative Agreements                        
Contingent consideration (up to)     $ 140,000,000.0                  
Credited percentage     50.00%                  
Perosphere Pharmaceuticals Inc. | Milestone Achievement, Approval By European Medicines Agency                        
Collaborative Agreements                        
Contingent consideration (up to)     $ 40,000,000.0                  
Perosphere Pharmaceuticals Inc. | Sales Milestones Achievement                        
Collaborative Agreements                        
Contingent consideration (up to)     225,000,000.0                  
Perosphere Pharmaceuticals Inc. | First Sales Milestone Achievement                        
Collaborative Agreements                        
Contingent consideration, milestone payment     20,000,000.0                  
Potential milestone payment, triggering event, sales     $ 100,000,000.0                  
Perosphere Convertible Note | Convertible Debt | Perosphere Pharmaceuticals Inc.                        
Collaborative Agreements                        
Principal amount of debt at time of issuance $ 10,000,000.0                      
Perosphere Term Loan | Line of Credit | Perosphere Pharmaceuticals Inc.                        
Collaborative Agreements                        
Payment for debt extinguishment $ 12,000,000.0                      
Failure To Supply A Certain Percentage Of Product | Prasco, LLC                        
Collaborative Agreements                        
Failure to supply, penalties                   $ 3,500,000    
XML 111 R98.htm IDEA: XBRL DOCUMENT v3.20.2
COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS - Assets Acquired and Liabilities Assumed Related to the Asset Acquisition (Details) - Perosphere Pharmaceuticals Inc. - USD ($)
$ in Millions
 3 Months Ended
Jan. 16, 2019
Mar. 31, 2019
Assets:    
Cash $ 2.6  
Operating lease right-of-use asset 0.8  
Property and equipment 1.4  
IPR&D 74.9 $ 74.9
Total Assets 79.7  
Liabilities:    
Accrued severance liabilities (1.7)  
Deferred revenue (6.4)  
Operating lease liability (0.8)  
Total Liabilities $ (8.9)  
XML 112 R99.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT - Schedule of Outstanding Debt Obligations (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Debt Instrument [Line Items]    
Net carrying amount $ 277,034 $ 283,209
Less: current maturities 0 21,276
Long-term debt, net of current maturities 277,034 261,933
Convertible Debt | 2022 Convertible Notes    
Debt Instrument [Line Items]    
Net carrying amount 277,034 261,933
Convertible Debt | 2019 Convertible Notes    
Debt Instrument [Line Items]    
Net carrying amount $ 0 $ 21,276
XML 113 R100.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT - Outstanding Convertible Note Balances (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Liability component:    
Net carrying amount $ 277,034 $ 283,209
2022 Convertible Notes | Convertible Debt    
Liability component:    
Principal 320,000  
Less: debt discount and issuance costs, net 42,966  
Net carrying amount 277,034 $ 261,933
Gross equity component $ 72,576  
XML 114 R101.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT - Convertible Notes (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 15, 2019
USD ($)
May 31, 2017
USD ($)
Feb. 28, 2014
USD ($)
Jun. 30, 2017
USD ($)
day
$ / shares
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Debt Instrument [Line Items]              
Net proceeds from issuance of convertible debt         $ 0 $ 0 $ 320,000,000
Payment of convertible debt issuance costs         0 0 9,553,000
Gain (loss) on debt extinguishment         0 (35,922,000) (10,926,000)
Repayments of convertible debt         $ 21,417,000 $ 0 $ 191,730,000
Convertible Debt              
Debt Instrument [Line Items]              
Period of amortization of debt discount to interest expense using effective interest method (years)         5 years    
2022 Convertible Notes | Convertible Debt              
Debt Instrument [Line Items]              
Period of amortization of debt discount to interest expense using effective interest method (years)       5 years      
Principal amount of debt at time of issuance       $ 320,000,000.0      
Net proceeds from issuance of convertible debt       310,400,000      
Payment of convertible debt issuance costs       9,600,000      
Debt issuance costs       9,600,000      
Debt issuance costs allocated to equity component       2,200,000      
Debt issuance costs allocated to the liability component       $ 7,400,000      
Interest rate       3.25% 3.25%    
Debt conversion ratio         0.0365464    
Initial conversion price of convertible notes into common stock (USD per share) | $ / shares       $ 27.36      
Debt term       5 years      
Effective interest rate         9.49%    
2019 Convertible Notes | Convertible Debt              
Debt Instrument [Line Items]              
Principal amount of debt at time of issuance     $ 200,000,000.0        
Net proceeds from issuance of convertible debt     193,300,000        
Debt issuance costs     $ 6,700,000        
Interest rate     2.50%        
Debt conversion ratio         0.0369079    
Proceeds used to pay the cost of the bond hedges (after such cost was partially offset by proceeds from the sale of warrants)     $ 14,100,000        
Repurchased amount   $ 178,500,000          
Repurchase price   192,700,000          
Gain (loss) on debt extinguishment   $ 100,000          
Repayments of convertible debt $ 21,400,000            
Debt Instrument, Conversion, Period One | 2022 Convertible Notes | Convertible Debt              
Debt Instrument [Line Items]              
Trading period | day       20      
Consecutive trading period | day       30      
Closing sales price of the entity's common stock that the conversion price must exceed or be equal in order for the notes to be convertible       130.00%      
Debt Instrument, Conversion, Period Two | 2022 Convertible Notes | Convertible Debt              
Debt Instrument [Line Items]              
Consecutive trading period | day       5      
Closing sales price of the entity's common stock that the conversion price must exceed or be equal in order for the notes to be convertible       98.00%      
Number of consecutive business days after any five consecutive trading day period during the note measurement period | day       5      
XML 115 R102.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT - Schedule of Total Interest Expense Recognized Related to the Convertible Notes (Details) - Convertible Debt - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Debt Instrument [Line Items]      
Contractual interest expense $ 10,467 $ 10,935 $ 8,961
Amortization of debt issuance costs 1,412 1,403 1,275
Amortization of debt discount 13,830 13,414 11,071
Total interest expense $ 25,709 $ 25,752 $ 21,307
XML 116 R103.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT - 2023 Senior Notes (Details) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 30, 2018
Oct. 31, 2017
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Aug. 31, 2015
Debt Instrument [Line Items]            
Loss on debt extinguishment     $ 0 $ 35,922,000 $ 10,926,000  
Payment of premium on debt extinguishment     $ 0 $ 28,054,000 $ 625,000  
Senior Notes | 2023 Senior Notes            
Debt Instrument [Line Items]            
Principal amount of debt at time of issuance           $ 500,000,000
Interest rate           7.875%
Repurchased amount $ 475,000,000.0 $ 25,000,000.0        
Loss on debt extinguishment 35,900,000 $ 1,100,000        
Payment of premium on debt extinguishment $ 28,100,000          
XML 117 R104.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT - 2015 Term Loan Facility (Details) - USD ($)
 1 Months Ended 12 Months Ended
May 31, 2017
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Aug. 31, 2015
Debt Instrument [Line Items]          
Loss on debt extinguishment   $ 0 $ 35,922,000 $ 10,926,000  
Line of Credit | 2015 Term Loan Facility          
Debt Instrument [Line Items]          
Maximum borrowing capacity         $ 350,000,000.0
Loss on debt extinguishment $ 9,700,000        
XML 118 R105.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT - Future Payments (Details)
$ in Millions
Dec. 31, 2019
USD ($)
Debt Disclosure [Abstract]  
Future annual principal payments on long-term debt due year ended December 31, 2022 $ 320.0
XML 119 R106.htm IDEA: XBRL DOCUMENT v3.20.2
RESTRUCTURING EXPENSES (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2019
employee
Mar. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Restructuring and Related Activities [Abstract]          
Employees displaced through workforce reduction | employee 110        
Restructuring expenses | $   $ 7,400 $ 7,420 $ 0 $ 0
XML 120 R107.htm IDEA: XBRL DOCUMENT v3.20.2
RESTRUCTURING EXPENSES - Components of Restructuring Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Restructuring Reserve [Roll Forward]        
Balance accrued at December 31, 2018 $ 0 $ 0    
Restructuring expenses 7,400 7,420 $ 0 $ 0
Payments   (6,623)    
Balance accrued at December 31, 2019   797 0  
Workforce reduction        
Restructuring Reserve [Roll Forward]        
Balance accrued at December 31, 2018 0 0    
Restructuring expenses   7,034    
Payments   (6,237)    
Balance accrued at December 31, 2019   797 0  
Contract termination        
Restructuring Reserve [Roll Forward]        
Balance accrued at December 31, 2018 0 0    
Restructuring expenses   229    
Payments   (229)    
Balance accrued at December 31, 2019   0 0  
Other        
Restructuring Reserve [Roll Forward]        
Balance accrued at December 31, 2018 $ 0 0    
Restructuring expenses   157    
Payments   (157)    
Balance accrued at December 31, 2019   $ 0 $ 0  
XML 121 R108.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED - Schedule of Unaudited Consolidated Quartely Financial Data (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 16, 2019
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Condensed Financial Information Disclosure [Abstract]                          
Total revenues   $ 89,483 $ 83,808 $ 77,767 $ 75,488 $ 87,871 $ 121,646 $ 145,663 $ 116,867   $ 326,546 $ 472,048 $ 493,967
Gross profit   46,162 62,703 53,477 57,011 59,155 75,157 68,887 52,955        
Operating expenses   240,329 81,050 169,662 175,024 78,241 95,084 27,591 104,239        
Net loss from continuing operations   (200,152) (23,940) (121,169) (122,400) (21,004) (65,282) (26,795) (58,994)   (467,661) (172,075) (206,688)
Net income (loss) from discontinued operations   0 0 0 0 (1,531) 95,517 5,736 3,856   0 103,578 5,925
Net loss   $ (200,152) $ (23,940) $ (121,169) $ (122,400) $ (22,535) $ 30,235 $ (21,059) $ (55,138)   $ (467,661) $ (68,497) $ (200,763)
Basic and diluted earnings per share:                          
Loss from continuing operations (in dollars per share)   $ (5.90) $ (0.71) $ (3.58) $ (3.55) $ (0.61) $ (1.89) $ (0.78) $ (1.72)   $ (13.74) $ (5.00) $ (5.92)
Income (loss) from discontinued operations (in dollars per share)   0 0 0 0 (0.04) 2.77 0.17 0.11   0 3.01 0.17
Total (in dollars per share)   $ (5.90) $ (0.71) $ (3.58) $ (3.55) $ (0.65) $ 0.88 $ (0.61) $ (1.61)   $ (13.74) $ (1.99) $ (5.75)
Condensed Financial Statements, Captions [Line Items]                          
Restructuring expenses         $ 7,400           $ 7,420 $ 0 $ 0
Impairment of intangible assets   $ 151,300                      
Makena                          
Condensed Financial Information Disclosure [Abstract]                          
Total revenues                     120,859 320,311 $ 385,356
Makena | Developed technology rights                          
Condensed Financial Statements, Captions [Line Items]                          
Impairment of intangible assets       $ 77,400           $ 77,400      
Makena Auto-Injector, Intrarosa And Vyleesi Products | Developed technology rights                          
Condensed Financial Statements, Captions [Line Items]                          
Impairment of intangible assets                     $ 155,000    
Contingent Consideration                          
Condensed Financial Statements, Captions [Line Items]                          
Adjustments to fair value of contingent consideration               $ 49,800       $ 49,600  
Perosphere Pharmaceuticals Inc.                          
Condensed Financial Statements, Captions [Line Items]                          
In process research and development acquired $ 74,900       $ 74,900                
XML 122 R109.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED - Schedule of Effects of Corrections and Prior Period Ajustments (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]                      
Revenues $ 89,483 $ 83,808 $ 77,767 $ 75,488 $ 87,871 $ 121,646 $ 145,663 $ 116,867 $ 326,546 $ 472,048 $ 493,967
Income tax (benefit) expense (21) 232 (120) (137) (2,543) (2,340) 52,943 (7,624) (47) 40,436 (175,521)
Net loss $ (200,152) $ (23,940) $ (121,169) $ (122,400) $ (22,535) $ 30,235 $ (21,059) $ (55,138) $ (467,661) $ (68,497) $ (200,763)
Basic and diluted net loss per share (in dollars per share) $ (5.90) $ (0.71) $ (3.58) $ (3.55) $ (0.65) $ 0.88 $ (0.61) $ (1.61) $ (13.74) $ (1.99) $ (5.75)
Product sales, net                      
Error Corrections and Prior Period Adjustments Restatement [Line Items]                      
Revenues $ 73,154 $ 83,784 $ 77,634 $ 75,413 $ 87,796 $ 121,646 $ 145,628 $ 116,828 $ 309,985 $ 471,898 $ 493,843
As reported                      
Error Corrections and Prior Period Adjustments Restatement [Line Items]                      
Revenues 89,707 84,131 78,109 75,804 88,122 122,238 146,254 117,387 327,751 474,002 495,769
Income tax (benefit) expense (21) 232 (120) (137) (2,550) (2,352) 52,556 (8,000) (47) 39,654 (175,254)
Net loss $ (199,928) $ (23,617) $ (120,827) $ (122,084) $ (22,277) $ 30,839 $ (20,081) $ (54,242) $ (466,456) $ (65,761) $ (199,228)
Basic and diluted net loss per share (in dollars per share) $ (5.89) $ (0.70) $ (3.57) $ (3.54) $ (0.64) $ 0.89 $ (0.58) $ (1.59) $ (13.71) $ (1.91) $ (5.71)
As reported | Product sales, net                      
Error Corrections and Prior Period Adjustments Restatement [Line Items]                      
Revenues $ 73,378 $ 84,107 $ 77,976 $ 75,729 $ 88,047 $ 122,238 $ 146,219 $ 117,348 $ 311,190 $ 473,852 $ 495,645
Adj                      
Error Corrections and Prior Period Adjustments Restatement [Line Items]                      
Revenues (224) (323) (342) (316) (251) (592) (591) (520) (1,205) (1,954) (1,802)
Income tax (benefit) expense 0 0 0 0 7 12 387 376 0 782 (267)
Net loss $ (224) $ (323) $ (342) $ (316) $ (258) $ (604) $ (978) $ (896) $ (1,205) $ (2,736) $ (1,535)
Basic and diluted net loss per share (in dollars per share) $ (0.01) $ (0.01) $ (0.01) $ (0.01) $ (0.01) $ (0.01) $ (0.03) $ (0.02) $ (0.03) $ (0.08) $ (0.04)
Adj | Product sales, net                      
Error Corrections and Prior Period Adjustments Restatement [Line Items]                      
Revenues $ (224) $ (323) $ (342) $ (316) $ (251) $ (592) $ (591) $ (520) $ (1,205) $ (1,954) $ (1,802)
XML 123 R110.htm IDEA: XBRL DOCUMENT v3.20.2
VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Accounts receivable allowances      
Valuation Allowance for Impairment of Recognized Servicing Assets [Roll Forward]      
Balance at Beginning of Period $ 9,543 $ 12,060 $ 9,533
Additions 324,542 229,509 168,945
Deductions Charged to Reserves (310,668) (232,026) (166,418)
Balance at End of Period 23,417 9,543 12,060
Rebates, fees and returns reserves      
Valuation Allowance for Impairment of Recognized Servicing Assets [Roll Forward]      
Balance at Beginning of Period 81,868 103,846 90,809
Additions 321,210 272,913 257,273
Deductions Charged to Reserves (283,653) (294,891) (244,236)
Balance at End of Period 119,425 81,868 103,846
Valuation allowance for deferred tax assets      
Valuation Allowance for Impairment of Recognized Servicing Assets [Roll Forward]      
Balance at Beginning of Period 114,516 4,740 1,429
Additions 104,858 109,800 3,875
Deductions Charged to Reserves (1,083) (24) (564)
Balance at End of Period $ 218,291 $ 114,516 $ 4,740
XML 124 R111.htm IDEA: XBRL DOCUMENT v3.20.2
RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2019
Jan. 01, 2019
Jan. 01, 2018
Jan. 01, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Operating lease liability         $ 23,868      
Operating lease right-of-use asset         23,286      
Cumulative effect of new accounting principle in period of adoption   $ 741,557 $ 787,882 $ 933,562 279,816      
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201609Member us-gaap:AccountingStandardsUpdate201409 us-gaap:AccountingStandardsUpdate201409Member us-gaap:AccountingStandardsUpdate201609Member        
Accounting Standards Update 2016-02                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Operating lease liability         $ 23,900 $ 8,500    
Operating lease right-of-use asset           $ 7,600    
Cumulative Effect, Period of Adoption, Adjustment                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Cumulative effect of new accounting principle in period of adoption     $ 1,136 $ 21,558     $ 1,100 $ 21,600
XML 125 R112.htm IDEA: XBRL DOCUMENT v3.20.2
REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Narrative (Details) - USD ($)
$ in Thousands
 48 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Jan. 01, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]      
Increase to accumulated deficit $ 1,015,201 $ 547,540  
Adjustment      
Error Corrections and Prior Period Adjustments Restatement [Line Items]      
Governmental rebates 6,300    
Increase to accumulated deficit $ 6,303 $ 5,098 $ 800
XML 126 R113.htm IDEA: XBRL DOCUMENT v3.20.2
REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Condensed Consolidated Balance Sheet (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Jan. 01, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]      
Accrued expenses $ 183,382 $ 134,635  
Accumulated deficit (1,015,201) (547,540)  
As reported      
Error Corrections and Prior Period Adjustments Restatement [Line Items]      
Accrued expenses 177,079 129,537  
Accumulated deficit (1,008,898) (542,442)  
Adjustment      
Error Corrections and Prior Period Adjustments Restatement [Line Items]      
Accrued expenses 6,303 5,098  
Accumulated deficit $ (6,303) $ (5,098) $ (800)
XML 127 R114.htm IDEA: XBRL DOCUMENT v3.20.2
REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Condensed Consolidated Statements of Operations (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]                      
Revenues $ 89,483 $ 83,808 $ 77,767 $ 75,488 $ 87,871 $ 121,646 $ 145,663 $ 116,867 $ 326,546 $ 472,048 $ 493,967
Income tax (benefit) expense (21) 232 (120) (137) (2,543) (2,340) 52,943 (7,624) (47) 40,436 (175,521)
Net loss from continuing operations (200,152) (23,940) (121,169) (122,400) (21,004) (65,282) (26,795) (58,994) (467,661) (172,075) (206,688)
Net loss $ (200,152) $ (23,940) $ (121,169) $ (122,400) $ (22,535) $ 30,235 $ (21,059) $ (55,138) $ (467,661) $ (68,497) $ (200,763)
Basic and diluted net loss per share (in dollars per share) $ (5.90) $ (0.71) $ (3.58) $ (3.55) $ (0.65) $ 0.88 $ (0.61) $ (1.61) $ (13.74) $ (1.99) $ (5.75)
As reported                      
Error Corrections and Prior Period Adjustments Restatement [Line Items]                      
Revenues $ 89,707 $ 84,131 $ 78,109 $ 75,804 $ 88,122 $ 122,238 $ 146,254 $ 117,387 $ 327,751 $ 474,002 $ 495,769
Income tax (benefit) expense (21) 232 (120) (137) (2,550) (2,352) 52,556 (8,000) (47) 39,654 (175,254)
Net loss from continuing operations                 (466,456) (169,339) (205,153)
Net loss $ (199,928) $ (23,617) $ (120,827) $ (122,084) $ (22,277) $ 30,839 $ (20,081) $ (54,242) $ (466,456) $ (65,761) $ (199,228)
Basic and diluted net loss per share (in dollars per share) $ (5.89) $ (0.70) $ (3.57) $ (3.54) $ (0.64) $ 0.89 $ (0.58) $ (1.59) $ (13.71) $ (1.91) $ (5.71)
Adjustment                      
Error Corrections and Prior Period Adjustments Restatement [Line Items]                      
Revenues $ (224) $ (323) $ (342) $ (316) $ (251) $ (592) $ (591) $ (520) $ (1,205) $ (1,954) $ (1,802)
Income tax (benefit) expense 0 0 0 0 7 12 387 376 0 782 (267)
Net loss from continuing operations                 (1,205) (2,736) (1,535)
Net loss $ (224) $ (323) $ (342) $ (316) $ (258) $ (604) $ (978) $ (896) $ (1,205) $ (2,736) $ (1,535)
Basic and diluted net loss per share (in dollars per share) $ (0.01) $ (0.01) $ (0.01) $ (0.01) $ (0.01) $ (0.01) $ (0.03) $ (0.02) $ (0.03) $ (0.08) $ (0.04)
Product sales, net                      
Error Corrections and Prior Period Adjustments Restatement [Line Items]                      
Revenues $ 73,154 $ 83,784 $ 77,634 $ 75,413 $ 87,796 $ 121,646 $ 145,628 $ 116,828 $ 309,985 $ 471,898 $ 493,843
Product sales, net | As reported                      
Error Corrections and Prior Period Adjustments Restatement [Line Items]                      
Revenues 73,378 84,107 77,976 75,729 88,047 122,238 146,219 117,348 311,190 473,852 495,645
Product sales, net | Adjustment                      
Error Corrections and Prior Period Adjustments Restatement [Line Items]                      
Revenues $ (224) $ (323) $ (342) $ (316) $ (251) $ (592) $ (591) $ (520) $ (1,205) $ (1,954) $ (1,802)
XML 128 R115.htm IDEA: XBRL DOCUMENT v3.20.2
SUBSEQUENT EVENTS (unaudited) (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 06, 2020
USD ($)
Jul. 14, 2020
USD ($)
May 21, 2020
USD ($)
month
Jul. 31, 2020
USD ($)
May 31, 2020
employee
Feb. 28, 2019
employee
Jun. 30, 2020
USD ($)
Mar. 31, 2019
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Subsequent Event [Line Items]                        
Employees displaced through workforce reduction | employee           110            
Restructuring charges               $ 7,400   $ 7,420 $ 0 $ 0
Subsequent Event                        
Subsequent Event [Line Items]                        
Employees displaced through workforce reduction | employee         110              
Restructuring charges             $ 8,200          
Agreement termination payment $ 12,500                      
Option period to third party supplier to acquire study 9 months                      
Settlement awarded to other party   $ 17,400                    
Intrarosa | Millicent Pharma Limited | Subsequent Event                        
Subsequent Event [Line Items]                        
Proceeds related to collaborative arrangement     $ 20,900                  
Gain on sale of assets             $ 14,400   $ 14,400      
Ciraparantag | Subsequent Event                        
Subsequent Event [Line Items]                        
Potential milestone proceeds from collaborative arrangement payable to equity holders       $ 40,000                
Ciraparantag | Norgine B.V. | Subsequent Event                        
Subsequent Event [Line Items]                        
Proceeds related to collaborative arrangement       $ 30,000                
Recovery of direct costs       33.00%                
Vyleesi Products | Palatin Technologies, Inc. | Subsequent Event                        
Subsequent Event [Line Items]                        
Early contract termination fees       $ 12,000                
Maximum | Intrarosa | Millicent Pharma Limited | Subsequent Event                        
Subsequent Event [Line Items]                        
Potential milestone proceeds from collaborative arrangement     105,000                  
First Time Net Sales During Threshold Period Exceeds $65 Million | Intrarosa | Millicent Pharma Limited | Subsequent Event                        
Subsequent Event [Line Items]                        
Potential milestone proceeds from collaborative arrangement     25,000                  
Potential milestone proceeds, triggering event, sales     $ 65,000                  
Consecutive period for sales to exceed threshold amount for potential milestone proceeds (in months) | month     12                  
First Time Net Sales During Threshold Period Exceeds $115 Million | Intrarosa | Millicent Pharma Limited | Subsequent Event                        
Subsequent Event [Line Items]                        
Potential milestone proceeds from collaborative arrangement     $ 35,000                  
Potential milestone proceeds, triggering event, sales     $ 115,000                  
Consecutive period for sales to exceed threshold amount for potential milestone proceeds (in months) | month     12                  
First Time Net Sales During Threshold Period Exceeds $175 Million | Intrarosa | Millicent Pharma Limited | Subsequent Event                        
Subsequent Event [Line Items]                        
Potential milestone proceeds from collaborative arrangement     $ 45,000                  
Potential milestone proceeds, triggering event, sales     $ 175,000                  
Consecutive period for sales to exceed threshold amount for potential milestone proceeds (in months) | month     12                  
Regulatory Milestone Achievement | Maximum | Ciraparantag | Norgine B.V. | Subsequent Event                        
Subsequent Event [Line Items]                        
Potential milestone proceeds from collaborative arrangement       70,000                
Sales Milestones Achievement | Maximum | Ciraparantag | Norgine B.V. | Subsequent Event                        
Subsequent Event [Line Items]                        
Potential milestone proceeds from collaborative arrangement       190,000                
Forecast | Vyleesi Products | Palatin Technologies, Inc. | Subsequent Event                        
Subsequent Event [Line Items]                        
Early contract termination fees       $ 4,300                
EXCEL 129 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�DSK&(>G7?XT(95K4L M"4;"!XM/"QN'Y6@3'<+:Q@CP'C9?'2F#1G+'KX+?^:946W$G=L#:5\6GMKMN M=1&\YD'#U*ZM0V)S&-(9F#20]%3':]UUO#*/DEU5A44\,PY#ZJQ*\H KV0,C MHL"&>"_$%-88&E 9&!XF*!FVKEF#L%[/*+\7@?@-(S_@J(NQ)-:TFH".XRO, MY&&O'I':VB$&VD@94+8/C3QH1@H"1",^_2C$0YO%Y8U"19[^-"S':X8NNF&! M3L;-]D;V%$E5J)*4=':SQRD7F;1+CC=2,H]V#D85P><;,7#"VRMV'$B M#<<]F!,TCEU2D2A/*I@+\='[H,D2D:',,.L=:)@KG@%^)=V-+OWXX8G:R[Y@ M87_N\^ T>##G\BVS2#2RKCY0;L",P[$:=\2FKXYB ^3=0L\QBM6NJBCE0\R, ML16I/Y#&W%5LU)'%AK^?4,;]L=G;-5=\Z!)LH&'LE04O-0/A--L\"M='L XI MKX!VR_:B!8I)-_AMK#<[)5/E3"E_(%]R;!@A://DQJOI4B4@2X(=2=/$8%^O MBS*/XNY93U,Q9G[GX! %A"4) K'F*-J%D8FRQ]A>7%K$ M'/$V B[1'7L#F2$NBU^Z" 9R[&9(2Z"9)J;\N5AR?@D]]-%284?@*8O'7Y"G M;#^H]S,R#').BBIIO(,4B$5?8\N1WHX-U/@X1^R!.Y 4B@@HOC2TD*(E":RU M(RI,V5 K-UQC[M&3>#5B#?).6!B]3H-3K0##!FF'Z/TI M*4%DS;K;EKV+?"BZ0/0(PRU>P52 =+H=';,H'IV??V'TEEGH3#@?L@:*"H@# M@/2,QG.20Y5<'E&Q(V]&WX5@Z)\.DS^38ZJ^<]3KF%K.-@#%]4-20LQF;TKAA+%>C"\I1'2VSR" M28X:KFK(F>3$Y!&.1Z_]9Z>&6W)CD\+C^_H,!>]!_&)Y(HIUG@#.53%;*+D@ M;)Y0G]GT\>:BS6;%)RE#$[VB.J%7Q!P2LZP-SYM%)UC6$R!4[ J-)Q],6,B MLKB'>TC$Y4/ V D0A5I93BA]J&]4V5L>Y$J3HH $G9XVFD,Y+ M- "(/9Z^'9:W<$-[SIUHE8',71"N90ZUO/GX:/F?.N:.!8T>+AP?;GHFP^2! M!W,@!4?#*GJX)\+O6?,3F0AJ*7O5)U(E>BX#2J.9,/H&Y%-,#(HZO@^D/U&. M11Z),2'CQPR^+":H!%>WI'2TZ V_5A?X1*K B0!#W!S5 M3V2BGCER>-E0/;W)_ZR 5&?,._8BLCXN)Z70[K@?@T-W10<63 M05XYMDD^IHPRRA&:J$FS+N!H"U*&8V9-):=%/49U :-4$V_<(GK*6@[AXTY= MAH(+]5S1QG*O#LGSLD:7?WE5^J94T-FHIPU9E&UFP48*9*:UP)E" '-L MD9EB##4[@9CQ47<@[FXQP3JGP(3Q0\RT2!L7[>T/8MZOG.;(B:PQ 3ACUQ)) M$M7;DE@\@)&>-U4:_+F0[$^80NH-,)L0%EU,\F1XVE3,028Y19\X]W91>8VXP2_HG.1X 5S#,C!DP MF.'-VY#9K$7-JG=N0E/^:$S<96K$^6'/AD*6Q7MZ]IVXJ#Z:!!$B6C3"NS%H MK)S-B6G$)46\)'7A$/VM[,] H:#I>FI!$MKRJM. ^L1MGKL4;5I)[IF0#&() MI_JU\1HO[FJVX(2&4>FHJBG]+F1RDT$6-0M3R=0;89VDL.I_I,M:GY_8)RF3 M]LY:2V:'B!JI?%'8#<8Z:'7.@[+TI[GAT5M%QS&6JV@P) /X_.4&$XHGB$$)OHH2JF*W7[H"(BV% SA/RC.?K!)T.>9+]:5K] MT5KN2K+9ETI1['E,'-?O5F,?V*]X;."04ZKXV2'H/<65-WVYNYW6XA/_8T3W MNK51*[82U)7#R=XF]:><;O#()4PQ>2E.453+4FAZ Q;V>5:#)F=?[;),KI%;*-J$6[5UT#/R.&:Y37)#\9;6JFC58S/LJDDR2 "5,QR0N/IB;RQ<">V@:*\4 <9+WLGI%!H)<5Q&6&849) [9 )[;P.TVL^B@I8R9#L\I&IG0,FWQM3'<4">UHUD0U(=/FI=RC<5D M9,E,@ZG321%TX23L"&KSX(^8JRZ0,40)G%\E'JPESG7BEIBQF7JX!FO;2^2W MRHI!D&F9?CD4>5D!(_/!*Y5!EZ=/OP K/D*!!SN-OY2 MX0=G?JG8VYGE\"/7Q7%;UTC+APB;5=E^BM4M"W1WN8.FZ*Q'=691[XH!="X0 M* =3B8Z<@P$.P/ ;WU(2$=X"IX4W7*I2MI,$$#YZ+1+!E-$+F4]"HDK^S4C10<3)K<"65(8J!>FUG@.N\-$XY!D=>I2T7Q M*FH/J&OVHS "TCCV'?)F/@04O6.0,B:[$J(2N4^)T=^(;7.'7\S?8$J_ MGQ19,3ZPC@A38[4WFVV?T8'(TR=GC>=Z 3^,TJ3C&'285-?O.]+)J36!W42. MYK@EDR-)@>4,^>F P*78CN#D^-J!5/2#]E&9\_.A2I\5V27G8@9L+F ^8!AL MTY!9Y%B!Y0(7T\L$Q;'6+.(U]N@--!R>SO41+8Z*/5\"+TI#);X&2TR8Z&+" M1?WOE$D\3?Z+IBW\02GGHC"FHBB]:XY,9Q5IF-$1Q2+L_1%F9R#"]S'S;NC8 M"Z ECNP?C>[2V)_EV^)?R;WZPPGW*HVFD3]7_P*H T>_%$1 4#_Y^HOB,?[W MY1?%!>S-HI9LAS]^"D._X4M;=H9[.W33B=#=,03TL 6I4UL6*)B.'B]$1 SN'# MEF)OMQ[H5*)6L-,,U_&$XM-R6,@6@]Y2J2M,*%U]N,/9_$[(@\:5 MKB5PK3/?HN[1Y77<*=J%$U$$*^]K8FS1/"6WZ4)651\M-4I+FF:SRUU0:GHR M=G2_00.F)LK>F[XK4J,B!89P#3L-/"+&HU:!^NTK;,+T-ZI<^)D4#;'?\1IC M PI3(96[#QZ?+T[.D/D.'I]'WX&".?,>.2$WTWRIB!T:>G>VXYEKX4G:[2MO M(H59C=/F!-'Z;KOVOWQ%0FB8^*Q'+:SGAD"@@%I,!=C!3@;6WY"][:/;0JK/ M.5W VOY*-+7#M#7*O',*8C$S)A-J280#0-^8XEPS%6(I;QU ?A["A5 M*97%I!FE+ [25Z,GAM@;FTR[=.&2&D(N+'414T9G/$1>2"_'836=.5D84K(L MQD1E8:_M<+R>6G>I;@@QSZ8-XN8VSA-0BN_6M;&@@WB>PBL"9UD(\AKNCW8Y M<>8S+GU(S;NV0)1HH!\T-<&TD#-(8V"&=WP;3A(S!=!NP*+]/74WX63[XZ5- MZAR59X :*[.]C-[@Z7B0G_U)?+"*=*H'-7!NI ME/F2CXN[K\E^MVZ%FJ50)CYH:?KDMK38:'93(BWPF3/,/.C(BT2B"A>8[OG) M']CSV![M-_EYDG8:,[I6B!36"R[/W$PQ_C9Z.<46+.RRCH@KK,]!RWT)4C<: MXN^33?LQ]QH2O7-3SX.H"G,.&, ]<62(#(K)-V!N1L\_3LH:S1!S0HT&FE+K9'23=C![>B94 M9<%YC 35/KA"*NG*%^'DWQ@GR8SR&02*%TZ5:X-T[XR]+"R(#D?%6Y++>]HI M891@X\(ZX6RC$I6\T>O1;<-21]]E"--K6R@[LT;7J'S.SDNX*!2A$M<+86BR9;+4/=XEQ,4#EO0.<[P&NV]+T@?+*1XSI2\1'$-+09.=V5<%$AR#9N)1_N2G$/> M-9HF S<4Y1V(2_RNFS"^,40<6K9L+5S(,/#!UH+3BF?HK08I_#^ND>5]ACGKG'#C7KWRFLBYTHJ/\U,8!U M<;]\@)1"EA&77!WQA,@. 3W5P^D@)&04AI1D&<>;9>L?]TD6'\\'YU9I&1Z6!?5'P)&.#'3Y63)'BK]12W%467KV:_?1A\XCCU-3Q+ F!-53:7/+ M+GJ \H@^>>_7J+'"PNLU=JYO!X-7;(R3/WMZ[9,S+3#HR-X^ I3[[,/ '8#L MC=].[UHD;-((_B!6Q 3M] D5_\BQU4CHN>0UD$*'WE6^:N(9:KU16"MYC@3C M'>M$L92,C.*U[\-PYMN%?$(]3^COK9(K]9M O,,IKS!U0[TAKUY>I'X:TD\" M=Z[%= M-R6B#-D7BO&/43#N;>"[*3\I3SSV%P,]1"-8H"R@D=TT,S[LKEZVK M.RSS#M8V'#';A"*&(;):[4F66*H(QLRT;N>KF-W+)GW9I*Y(IFO0*DFH14KH MXH96:&F7U(!%^9?TC@H)%NRKXQP&= GQB/18;3GK,2S(W:+%5]RKF'*ZT-6/ M((]XGNA8(MK(/Y#C^VTGWEJ9,]8GI'N=,IA)&^Z4!Q]N#9 OL>%U:=+XQ%=# MM;[ )'[G%,QI(X:\7;OR0Q5VY&5? 2DZ-'.HP 6OHXLQ00/NU^R7]I828^H; M,EUZ.D&=20LC+ O**"JMC.%.K<)>4;C,$^UT9%Q/.\2;7BYEUI*52EJP3@8; M^M-@+3GEW#L09@R<':J-)F+,JJQTV5"5F)4"<_#K'KN-M62EJ!L2X1=7QSVPM':BGKF!0PF^V5&?NW M! (=A_C?6H_M#^JQ712_P'G?GO#F3BJ."7>9#8']HOR+'(Y8S5-S;I_V#>:6 M/FS*]266Z9V1(BZMA&PUF[=A3K! ,>;$M7?6W_:!?_@)<>L2,&7$\^>^Y]"M MAVO<]E<2J7XU]B"/M5)O[3_CYQ!__@FT4T?Y#L#8@5D+R_@)(S.D.] Y L7 MY!:BM7_B1*E.%!DCD]-F=(%+(EB*!K$$4B<:WND!G5(*N0@W=HTF<=6Q:I39 MLY)F*'S 7LDO+QM2W-EO%-7<#,8IXUOB7%]]HND:1/ MS;*7]8UE\6$O;",I.K4/E*PA/&T^<) :0G224436U7#'_;B2?.\)>N1JSJT5$/)ZW66J? 3OC?F)PJ2I>N7 MMEAX^3/OE9&($WNGPC\>Q6.!E7:#0@ %E#8<0WZ7JCXKWU?C3DM:1*%V25X= MR^OL=ND#WS *4+Q3:5J.U28DW'XUMGW\@7RY"ZL$266Q1AU5=H^MYLP@:Y'[ M3&;SG#=@;G>3^&CEG/9&1,PAR*".D3%$A!G]>BS^UBY6K'BR8 1(G+04\V2R MS=M=B^)PVN@_!OOIDYWZ96+M,TI0:][<*8!,F M@VL."W38:B Z2MUX9I\KD ML#?M;0Z&6716^YFE[DU:9X'0)O9"*Q5S<(SQ_I>7KV*LG]]789+OMM)N,0M@ MH=F!-2 K%[N@I4<"OVH2B_/D_4Y8@X_.H/3")_L2,'P&>Z-(S'-"?ES_4;8M M-=:/'DSUZ,D/.'W .S!= 4^0YFU>3#J,R1A8DQJ?;10UU)B8G"&P2*\?>!73T;AUH=]LN!4PV01^EXT@6U^Z9Q%C._6>,<[9JDF1UKIH$^N(HBE% M-(TED$7[IKEG)/MKZVO6YU61D^YZ^9/'>^%>I-%5.+91'.K8V#/?;HVUGSA& M4AV$4 0XJP-=DK@\.+U5,,- DW!0?3MO8!LZ_0/O?#KR5?G M]#X-(&M*=@7HS4[T84_ 2E-\B%-@(NS9^9<+HZ>%XBQ1/ *$:]_N<^(1K/G@ MV^(]O2IA'5\2]BO>"!)\?-"H 69=7<]V\O>4.Q1[!V(>4"NUEM%73FH-X0$K M=TQABY.PIU1_)=#N/,$.PVAX[0E(>6@G14?CF[,S+0XZOI?MVZHU%JQV1% MFY-!0?)S6&' $[464D-E]W:%\Z2"^U(SYA+SJ!<PP2G[_% [AAV.0CO284I-5.D41G)D)J!TIW0-Q\VB! M+$TYJ47S2R$"^3![B=3Y6-6DD'2Q.>AJ0[+8ORG&)C&+0\THTEV[)L]NRN*] M=[H48:"G&8YE #EOR$3YC1R+O>T2CIGD'TH <<*I+:^:<%MFXHG%^NQ-55'M MTL8\V%/O;"@_&\7&&%NQ%UR&J,:@H)QI+3OA'8L8H$2QL\B,8X?4GKP+Z;W% MR8%OUM7ZB9G7#6=ZILE.H^HG*C H[OL'.FF";E5>&4>N^ 5S#\KA 1OL M&MOP<">"- U+.W#.I;15"SCZ\WLY:K9/)P9)$SLJB <0NL6QF^ M*8M)3][W_L'BB:XZ?)8P!VXG%8')*_I2SB)= MFA19QTM.;\*.7L "=XRZ[F'2"6V"'XA;TFV#PE7'[Y%.S4[2RU[;8Y9W=,6V MA^*)?<I,>U&8C;-GWF5MT96WD8 M?TUDYP:Q])4 XMZ[F\JON'%"VE!9K2Q;E,\?#B^>/_0!_JG@/^!Y\"]%8EZ6 M0_GB^0Y+&"\=ME<@L']W[]$]\RU2TW?W+AY]>_'XWD-X,@U_\7P/R/XS,TO0 M#-;PZ/GRFZ_N<6-+_6/H]C@E-I08NAU]W+H20($#X/=U!_)?_L %KKO^$VWO MQ7\ 4$L#!!0 ( +: +U&6+X![R00 ( + 9 >&PO=V]R:W-H965T M"\-,N QD&2KAB& M?:"ED\15$E62BI/^^MU1MN*@<]9V7VR)O'ONN5?=?*/T)Y,C6G@LB\J<]')K MZ^/AT,0YEL(,5(T5W:1*E\+2J\Z&IM8H$J=4%L-@-#H:ED)6O<7[N!69KGE@^%B7HL,[]!^J&\TO0T[E$266!FI M*M"8GO26_O'IA.6=P.\2-V;O&=B3M5*?^.4J.>F-F! 6&%M&$/3W@&=8% Q$ M-#YO,7N=25;=-I&3%2?ESFJZE:1G%^=7=V>KZ_NKZP\7Y["ZN;A=WE^MKN_F M0TO@+#*,MT"G+5!P ,@/X+VJ;&[@HDHP>0DP)%8=M6!'[31X%?$.-#>-+$Q%!6#2:PJE$+K@L#HDJ [FIE1 &76C6U@3^7:V,U ME=(8GSO#D_\?XAX!@5<&RR:A8X,A%*_)@@Q"KLB[0DK,V1R#G$%0* MJM%P=GH+Z\80NC%@%5Q>P8W0MD)MH&ZT:41E^9SU6/:FT7%.I0_+3"-22]H! M?$0J?HN::M)9$/:%&5;32'/"D#0)".!X6LQD#":7J6U5-JHI$LC% Y)$*?Y6 M&C!-J6.!.I:I=C0Y2V2 >E9IA!);<[&6Q$$*H%.("V&,3&4LVH8WD.RG7.VE MW,)O384P'K7Q&L"R*""7U&Z:U(N=;)61$X8:W#@#[-2&*/ TXK%"H!MI!9F$RS]A((2@=Q&0$V Y1KUKA$B%PAZ"&$ M]R2& 5PKRS)QU_9A&G@ M3:81^*.Q-R7Q59?^;0"II4)BX(^\:1C!B@MQ=_5F"_*6?8(WP=$4WL+5-\2= M,*-PS)AC?PR7] 'EHM]OH*[XH] ;A4?P\T]1X >_[-"M>-QY ($W#GV8>.,H M@NMO3'R_]9<XBJ51< C#M6ZE+*P1B3S2@,B< MCDL*M0H1*1JNE/]NA3W+W]T*[[Y/P2-CM>1B< %,I&VHT?<=WLV^+@>N\?O^ MX(@^PU2 /& (K3\9S+H#CZ=%C6[1*)X&1( &8"RWXX@#4BIMY9?V8)>ZUXSN MXF $)9.B+E5"3&BR]:/!Y"61P!^$!YE[J;OA:T(J-F ;I/E;*[%S;0+=V+?P!02P,$% @ MH O4584&ULK5AK;]LX%OTKA#=8 MN(#6UMM2)PF0IIEN%V@;I.T,%HO]0$NTS:DDNB25-//K]UQ2=N5N7LWN%YN2 M>!_GW .Z&VF<=AF,];+KO)Z;%[=ZE/CU5O&]F)2\U,W[9C$_/=[RM?@H[.?MI<;3?*^EEJWHC%0=TV)U,CF+7KY*:;Z;\)L4-V8T M9H1DJ=07>GA;GTQ"/O6IR+IB%%<./KH'.R-TF"X_%.^Z\..[ L MN1'GJOE=UG9S,BDFK!8KWC?V2MW\70QX,M)7J<:X7W;CYZ:+":MZ8U4[",.# M5G;^GW\;>!@)%.$] O$@$#N_O2'GY6MN^>FQ5C=,TVQHHX&#ZJ3AG.PH*!^M MQE<).7MZ=?';Q?O/%^SJXOS#F_=O/[W]\/YX;J&8/L^K0J MLQO#+KI:U(<*YO!H[U:\<^M5_*#&UZ*:L20*6!Q&Y0/ZDCW,Q.E+[H,IKD77 M"[;2JF7G\%4C'4"UW;!S1[+0[%]G2^/>__L!@^G>8.H,IO\;KS^MA%UJ5??P M?8?HTP:H5(/BDMV:6;YL!-MJ=2UK89CL?-FZ_%^B)EDM#5^OM5AS*VI4E5>R MO"49IQ<"S$+GK>#:,$'Q9(B&:)>@:!<1YOX*QKN:!@LVE1VD5&_PQKQXR?[I MI"_ND7:R3FZ'QO!&F(!UZ$+O^!?1<7;$HC@,BJS$*,$HB2(:%5F09#G[56B. M]B18E"^",EVP*,F",(Q8%&9!F83L+858*\-9' 4I+$5Y$,-J%!11SCX H6;3 M."G8"Y;D!5ND$?ND+&_(1E@&99%AE"XPO2QH5"9!D2;#G#44FSUCSG=V([1@ M:K4R@#"BTW_D%!_>530$9;RJ=,\;\TRRN1DB;I[-^YL[$!RQ,LN"O$QHM$B# M!#1B!.[#/*)(74O7BLGI)\%[N:\T/#%>_X%*0S^WAF5)&.1IAG N@BP-X6$8 M9$7!WJAKH3N: P$MEDA2PZ((H(1NR><_CF8P$UP2(L6!;&09K$+(U] MH._(K$=">T,>P_8+C;2W_Z=2&G-XP,_9B-"K@2O/ MR2O>>*\L^P?O>BRVS%M;..1!'E)DLSB@M$>AA2@OC,Y[K:'-MP\*M0'2!MV# M^%!#K.%=-'>GEJV6X,=S,X5L6J(6HR!' MKDWC("ZH-"_YK=,PU\+V^DG^3.,L04YED)[F49#EI'::(&>0/T]6>>!8AC1Q$>8IT!],^<4M0\SR>BS(HXN!./Z8I((6.P&D> MNBY&K )0G,2/L7J'5Y3_>>;4I2 E<341A5#5COPN2K)J^WMD&8"-^4(&3D,$0 M4ZH-[]8^L86QLB4(]1.9JK&8P(T-CA!B1 3!V?);O.JM;.2?PT8.;TV_-.)K M3RDTL*66C5R[";16<9IF926W#B*=6VH&6=5K6,&&5\-"P\0WPBR0!3.L,TV# M/:+V1G;;RU&L5U(;R[YB.;'P""$DUP/7&U3W1]_Y8Y;;4]/T2X$]QG9#VR+0 MWQGNOKN 6Q]95$/?>#F?;#<<& MMQ(@J'*SVRWO;F=8S:49S1YVQ+6S@>1 A%0GB%P?2)#?8Y>PGP8G6^P8*J$M M)X [G\8L>^"=&.$F>BNI^98#L>5K4KC6O'79A!V1PN;@:R\U+!SELW2?IB 3 M)TFA]6A//DI/>P &%&YDM3E(/A@ZI2O?/8;XX. MI+RJLX_G+ _SV4'J 0V\^R'W?(,A H@WV9$]A@<
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end XML 130 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 131 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 132 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 463 602 1 false 122 0 false 13 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.amagpharma.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.amagpharma.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.amagpharma.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.amagpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 1004000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101100 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://www.amagpharma.com/role/DescriptionOfBusiness DESCRIPTION OF BUSINESS Notes 8 false false R9.htm 2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.amagpharma.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 2103100 - Disclosure - DISCONTINUED OPERATIONS Sheet http://www.amagpharma.com/role/DiscontinuedOperations DISCONTINUED OPERATIONS Notes 10 false false R11.htm 2104100 - Disclosure - REVENUE RECOGNITION Sheet http://www.amagpharma.com/role/RevenueRecognition REVENUE RECOGNITION Notes 11 false false R12.htm 2105100 - Disclosure - MARKETABLE SECURITIES Sheet http://www.amagpharma.com/role/MarketableSecurities MARKETABLE SECURITIES Notes 12 false false R13.htm 2106100 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.amagpharma.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 13 false false R14.htm 2107100 - Disclosure - INVENTORIES Sheet http://www.amagpharma.com/role/Inventories INVENTORIES Notes 14 false false R15.htm 2108100 - Disclosure - PROPERTY AND EQUIPMENT, NET Sheet http://www.amagpharma.com/role/PropertyAndEquipmentNet PROPERTY AND EQUIPMENT, NET Notes 15 false false R16.htm 2109100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET Sheet http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNet GOODWILL AND INTANGIBLE ASSETS, NET Notes 16 false false R17.htm 2110100 - Disclosure - CURRENT AND LONG-TERM LIABILITIES Sheet http://www.amagpharma.com/role/CurrentAndLongTermLiabilities CURRENT AND LONG-TERM LIABILITIES Notes 17 false false R18.htm 2111100 - Disclosure - INCOME TAXES Sheet http://www.amagpharma.com/role/IncomeTaxes INCOME TAXES Notes 18 false false R19.htm 2112100 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS Sheet http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLoss ACCUMULATED OTHER COMPREHENSIVE LOSS Notes 19 false false R20.htm 2113100 - Disclosure - EQUITY-BASED COMPENSATION Sheet http://www.amagpharma.com/role/EquityBasedCompensation EQUITY-BASED COMPENSATION Notes 20 false false R21.htm 2114100 - Disclosure - EMPLOYEE SAVINGS PLAN Sheet http://www.amagpharma.com/role/EmployeeSavingsPlan EMPLOYEE SAVINGS PLAN Notes 21 false false R22.htm 2115100 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://www.amagpharma.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 22 false false R23.htm 2116100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.amagpharma.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 23 false false R24.htm 2117100 - Disclosure - COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS Sheet http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreements COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS Notes 24 false false R25.htm 2118100 - Disclosure - DEBT Sheet http://www.amagpharma.com/role/Debt DEBT Notes 25 false false R26.htm 2119100 - Disclosure - RESTRUCTURING EXPENSES Sheet http://www.amagpharma.com/role/RestructuringExpenses RESTRUCTURING EXPENSES Notes 26 false false R27.htm 2120100 - Disclosure - CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED Sheet http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnaudited CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED Notes 27 false false R28.htm 2121100 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS Sheet http://www.amagpharma.com/role/ValuationAndQualifyingAccounts VALUATION AND QUALIFYING ACCOUNTS Notes 28 false false R29.htm 2122100 - Disclosure - RECENTLY ISSUED AND PROPOSED ACCOUNTING PRONOUNCEMENTS Sheet http://www.amagpharma.com/role/RecentlyIssuedAndProposedAccountingPronouncements RECENTLY ISSUED AND PROPOSED ACCOUNTING PRONOUNCEMENTS Notes 29 false false R30.htm 2123100 - Disclosure - RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS Sheet http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncements RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS Notes 30 false false R31.htm 2124100 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS Sheet http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatements REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS Notes 31 false false R32.htm 2125100 - Disclosure - SUBSEQUENT EVENTS (unaudited) Sheet http://www.amagpharma.com/role/SubsequentEventsUnaudited SUBSEQUENT EVENTS (unaudited) Notes 32 false false R33.htm 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 33 false false R34.htm 2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.amagpharma.com/role/SummaryOfSignificantAccountingPolicies 34 false false R35.htm 2303301 - Disclosure - DISCONTINUED OPERATIONS (Tables) Sheet http://www.amagpharma.com/role/DiscontinuedOperationsTables DISCONTINUED OPERATIONS (Tables) Tables http://www.amagpharma.com/role/DiscontinuedOperations 35 false false R36.htm 2304301 - Disclosure - REVENUE RECOGNITION (Tables) Sheet http://www.amagpharma.com/role/RevenueRecognitionTables REVENUE RECOGNITION (Tables) Tables http://www.amagpharma.com/role/RevenueRecognition 36 false false R37.htm 2305301 - Disclosure - MARKETABLE SECURITIES (Tables) Sheet http://www.amagpharma.com/role/MarketableSecuritiesTables MARKETABLE SECURITIES (Tables) Tables http://www.amagpharma.com/role/MarketableSecurities 37 false false R38.htm 2306301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.amagpharma.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.amagpharma.com/role/FairValueMeasurements 38 false false R39.htm 2307301 - Disclosure - INVENTORIES (Tables) Sheet http://www.amagpharma.com/role/InventoriesTables INVENTORIES (Tables) Tables http://www.amagpharma.com/role/Inventories 39 false false R40.htm 2308301 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) Sheet http://www.amagpharma.com/role/PropertyAndEquipmentNetTables PROPERTY AND EQUIPMENT, NET (Tables) Tables http://www.amagpharma.com/role/PropertyAndEquipmentNet 40 false false R41.htm 2309301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET (Tables) Sheet http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetTables GOODWILL AND INTANGIBLE ASSETS, NET (Tables) Tables http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNet 41 false false R42.htm 2310301 - Disclosure - CURRENT AND LONG-TERM LIABILITIES (Tables) Sheet http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesTables CURRENT AND LONG-TERM LIABILITIES (Tables) Tables http://www.amagpharma.com/role/CurrentAndLongTermLiabilities 42 false false R43.htm 2311301 - Disclosure - INCOME TAXES (Tables) Sheet http://www.amagpharma.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://www.amagpharma.com/role/IncomeTaxes 43 false false R44.htm 2312301 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) Sheet http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLossTables ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) Tables http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLoss 44 false false R45.htm 2313301 - Disclosure - EQUITY-BASED COMPENSATION (Tables) Sheet http://www.amagpharma.com/role/EquityBasedCompensationTables EQUITY-BASED COMPENSATION (Tables) Tables http://www.amagpharma.com/role/EquityBasedCompensation 45 false false R46.htm 2316301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://www.amagpharma.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://www.amagpharma.com/role/CommitmentsAndContingencies 46 false false R47.htm 2317301 - Disclosure - COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS (Tables) Sheet http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsTables COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS (Tables) Tables http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreements 47 false false R48.htm 2318301 - Disclosure - DEBT (Tables) Sheet http://www.amagpharma.com/role/DebtTables DEBT (Tables) Tables http://www.amagpharma.com/role/Debt 48 false false R49.htm 2319301 - Disclosure - RESTRUCTURING EXPENSES (Tables) Sheet http://www.amagpharma.com/role/RestructuringExpensesTables RESTRUCTURING EXPENSES (Tables) Tables http://www.amagpharma.com/role/RestructuringExpenses 49 false false R50.htm 2320301 - Disclosure - CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED (Tables) Sheet http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedTables CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED (Tables) Tables http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnaudited 50 false false R51.htm 2321301 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS (Tables) Sheet http://www.amagpharma.com/role/ValuationAndQualifyingAccountsTables VALUATION AND QUALIFYING ACCOUNTS (Tables) Tables http://www.amagpharma.com/role/ValuationAndQualifyingAccounts 51 false false R52.htm 2324301 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Tables) Sheet http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsTables REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Tables) Tables http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatements 52 false false R53.htm 2401401 - Disclosure - DESCRIPTION OF BUSINESS (Details) Sheet http://www.amagpharma.com/role/DescriptionOfBusinessDetails DESCRIPTION OF BUSINESS (Details) Details http://www.amagpharma.com/role/DescriptionOfBusiness 53 false false R54.htm 2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details) Sheet http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details) Details 54 false false R55.htm 2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition - Additional Information (Details) Sheet http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition - Additional Information (Details) Details 55 false false R56.htm 2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customers Who Represent 10% or More of Total Revenues or Accounts Receivable Balances (Details) Sheet http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customers Who Represent 10% or More of Total Revenues or Accounts Receivable Balances (Details) Details 56 false false R57.htm 2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventory (Details) Sheet http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventory (Details) Details 57 false false R58.htm 2402407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment, Net (Details) Sheet http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment, Net (Details) Details 58 false false R59.htm 2402408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details) Sheet http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details) Details 59 false false R60.htm 2402409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) Sheet http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingCostsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) Details 60 false false R61.htm 2402410 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basic and Diluted Earnings per Share (Details) Sheet http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basic and Diluted Earnings per Share (Details) Details 61 false false R62.htm 2402411 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Anti-dilutive Securities excluded from Computation of Earnings per Share (Details) Sheet http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Anti-dilutive Securities excluded from Computation of Earnings per Share (Details) Details 62 false false R63.htm 2402412 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Business Segments (Details) Sheet http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBusinessSegmentsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Business Segments (Details) Details 63 false false R64.htm 2403402 - Disclosure - DISCONTINUED OPERATIONS - Narrative (Details) Sheet http://www.amagpharma.com/role/DiscontinuedOperationsNarrativeDetails DISCONTINUED OPERATIONS - Narrative (Details) Details 64 false false R65.htm 2403403 - Disclosure - DISCONTINUED OPERATIONS - Summary of Net Income (Loss) (Details) Sheet http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails DISCONTINUED OPERATIONS - Summary of Net Income (Loss) (Details) Details 65 false false R66.htm 2404402 - Disclosure - REVENUE RECOGNITION - Disaggregated Revenue By Major Products (Details) Sheet http://www.amagpharma.com/role/RevenueRecognitionDisaggregatedRevenueByMajorProductsDetails REVENUE RECOGNITION - Disaggregated Revenue By Major Products (Details) Details 66 false false R67.htm 2404403 - Disclosure - REVENUE RECOGNITION - Total Gross Product (Details) Sheet http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails REVENUE RECOGNITION - Total Gross Product (Details) Details 67 false false R68.htm 2404404 - Disclosure - REVENUE RECOGNITION - Product Revenue Allowance and Accrual Activity (Details) Sheet http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails REVENUE RECOGNITION - Product Revenue Allowance and Accrual Activity (Details) Details 68 false false R69.htm 2404405 - Disclosure - REVENUE RECOGNITION - Additional Information (Details) Sheet http://www.amagpharma.com/role/RevenueRecognitionAdditionalInformationDetails REVENUE RECOGNITION - Additional Information (Details) Details 69 false false R70.htm 2405402 - Disclosure - MARKETABLE SECURITIES (Details) Sheet http://www.amagpharma.com/role/MarketableSecuritiesDetails MARKETABLE SECURITIES (Details) Details http://www.amagpharma.com/role/MarketableSecuritiesTables 70 false false R71.htm 2406402 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 71 false false R72.htm 2406403 - Disclosure - FAIR VALUE MEASUREMENTS - Contingent Consideration (Details) Sheet http://www.amagpharma.com/role/FairValueMeasurementsContingentConsiderationDetails FAIR VALUE MEASUREMENTS - Contingent Consideration (Details) Details 72 false false R73.htm 2406404 - Disclosure - FAIR VALUE MEASUREMENTS - Debt (Details) Sheet http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails FAIR VALUE MEASUREMENTS - Debt (Details) Details 73 false false R74.htm 2406405 - Disclosure - FAIR VALUE MEASUREMENTS - Nonrecurring Fair Value Measurements (Details) Sheet http://www.amagpharma.com/role/FairValueMeasurementsNonrecurringFairValueMeasurementsDetails FAIR VALUE MEASUREMENTS - Nonrecurring Fair Value Measurements (Details) Details 74 false false R75.htm 2407402 - Disclosure - INVENTORIES (Details) Sheet http://www.amagpharma.com/role/InventoriesDetails INVENTORIES (Details) Details http://www.amagpharma.com/role/InventoriesTables 75 false false R76.htm 2408402 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details) Sheet http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails PROPERTY AND EQUIPMENT, NET (Details) Details http://www.amagpharma.com/role/PropertyAndEquipmentNetTables 76 false false R77.htm 2409402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET - Goodwill - Narrative (Details) Sheet http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails GOODWILL AND INTANGIBLE ASSETS, NET - Goodwill - Narrative (Details) Details 77 false false R78.htm 2409403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET - Schedule of Intangible Assets (Details) Sheet http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails GOODWILL AND INTANGIBLE ASSETS, NET - Schedule of Intangible Assets (Details) Details 78 false false R79.htm 2409404 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET - Intangible Assets - Narrative (Details) Sheet http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails GOODWILL AND INTANGIBLE ASSETS, NET - Intangible Assets - Narrative (Details) Details 79 false false R80.htm 2410402 - Disclosure - CURRENT AND LONG-TERM LIABILITIES (Details) Sheet http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails CURRENT AND LONG-TERM LIABILITIES (Details) Details http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesTables 80 false false R81.htm 2411402 - Disclosure - INCOME TAXES - Schedule of Income Tax Expense (Benefit) (Details) Sheet http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails INCOME TAXES - Schedule of Income Tax Expense (Benefit) (Details) Details 81 false false R82.htm 2411403 - Disclosure - INCOME TAXES - Income Tax Reconciliation (Details) Sheet http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails INCOME TAXES - Income Tax Reconciliation (Details) Details 82 false false R83.htm 2411404 - Disclosure - INCOME TAXES - Narrative (Details) Sheet http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails INCOME TAXES - Narrative (Details) Details 83 false false R84.htm 2411405 - Disclosure - INCOME TAXES - Deferred Tax Components (Details) Sheet http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails INCOME TAXES - Deferred Tax Components (Details) Details 84 false false R85.htm 2411406 - Disclosure - INCOME TAXES - Reconciliation of Uncertain Tax Positions (Details) Sheet http://www.amagpharma.com/role/IncomeTaxesReconciliationOfUncertainTaxPositionsDetails INCOME TAXES - Reconciliation of Uncertain Tax Positions (Details) Details 85 false false R86.htm 2412402 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) Sheet http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLossDetails ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) Details http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLossTables 86 false false R87.htm 2413402 - Disclosure - EQUITY-BASED COMPENSATION - Narrative (Details) Sheet http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails EQUITY-BASED COMPENSATION - Narrative (Details) Details 87 false false R88.htm 2413403 - Disclosure - EQUITY-BASED COMPENSATION - Activity Related to Plans (Details) Sheet http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails EQUITY-BASED COMPENSATION - Activity Related to Plans (Details) Details 88 false false R89.htm 2413404 - Disclosure - EQUITY-BASED COMPENSATION - Equity-Based Compensation Expense (Details) Sheet http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails EQUITY-BASED COMPENSATION - Equity-Based Compensation Expense (Details) Details 89 false false R90.htm 2413405 - Disclosure - EQUITY-BASED COMPENSATION - Weighted-Average Fair Value Assumptions, Stock Option Activity (Details) Sheet http://www.amagpharma.com/role/EquityBasedCompensationWeightedAverageFairValueAssumptionsStockOptionActivityDetails EQUITY-BASED COMPENSATION - Weighted-Average Fair Value Assumptions, Stock Option Activity (Details) Details 90 false false R91.htm 2413406 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Stock-based Compensation (Details) Sheet http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails EQUITY-BASED COMPENSATION - Schedule of Stock-based Compensation (Details) Details 91 false false R92.htm 2413407 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of RSUs Granted (Details) Sheet http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails EQUITY-BASED COMPENSATION - Schedule of RSUs Granted (Details) Details 92 false false R93.htm 2414401 - Disclosure - EMPLOYEE SAVINGS PLAN (Details) Sheet http://www.amagpharma.com/role/EmployeeSavingsPlanDetails EMPLOYEE SAVINGS PLAN (Details) Details http://www.amagpharma.com/role/EmployeeSavingsPlan 93 false false R94.htm 2415401 - Disclosure - STOCKHOLDERS??? EQUITY (Details) Sheet http://www.amagpharma.com/role/StockholdersEquityDetails STOCKHOLDERS??? EQUITY (Details) Details http://www.amagpharma.com/role/StockholdersEquity 94 false false R95.htm 2416402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) Sheet http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails COMMITMENTS AND CONTINGENCIES - Narrative (Details) Details 95 false false R96.htm 2416403 - Disclosure - COMMITMENTS AND CONTINGENCIES - Operating Leases, Fiscal Year Maturity Schedule (Details) Sheet http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails COMMITMENTS AND CONTINGENCIES - Operating Leases, Fiscal Year Maturity Schedule (Details) Details 96 false false R97.htm 2417402 - Disclosure - COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS (Details) Sheet http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS (Details) Details http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsTables 97 false false R98.htm 2417403 - Disclosure - COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS - Assets Acquired and Liabilities Assumed Related to the Asset Acquisition (Details) Sheet http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS - Assets Acquired and Liabilities Assumed Related to the Asset Acquisition (Details) Details 98 false false R99.htm 2418402 - Disclosure - DEBT - Schedule of Outstanding Debt Obligations (Details) Sheet http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails DEBT - Schedule of Outstanding Debt Obligations (Details) Details 99 false false R100.htm 2418403 - Disclosure - DEBT - Outstanding Convertible Note Balances (Details) Sheet http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails DEBT - Outstanding Convertible Note Balances (Details) Details 100 false false R101.htm 2418404 - Disclosure - DEBT - Convertible Notes (Details) Notes http://www.amagpharma.com/role/DebtConvertibleNotesDetails DEBT - Convertible Notes (Details) Details 101 false false R102.htm 2418405 - Disclosure - DEBT - Schedule of Total Interest Expense Recognized Related to the Convertible Notes (Details) Notes http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails DEBT - Schedule of Total Interest Expense Recognized Related to the Convertible Notes (Details) Details 102 false false R103.htm 2418406 - Disclosure - DEBT - 2023 Senior Notes (Details) Notes http://www.amagpharma.com/role/Debt2023SeniorNotesDetails DEBT - 2023 Senior Notes (Details) Details 103 false false R104.htm 2418407 - Disclosure - DEBT - 2015 Term Loan Facility (Details) Sheet http://www.amagpharma.com/role/Debt2015TermLoanFacilityDetails DEBT - 2015 Term Loan Facility (Details) Details 104 false false R105.htm 2418408 - Disclosure - DEBT - Future Payments (Details) Sheet http://www.amagpharma.com/role/DebtFuturePaymentsDetails DEBT - Future Payments (Details) Details 105 false false R106.htm 2419402 - Disclosure - RESTRUCTURING EXPENSES (Details) Sheet http://www.amagpharma.com/role/RestructuringExpensesDetails RESTRUCTURING EXPENSES (Details) Details http://www.amagpharma.com/role/RestructuringExpensesTables 106 false false R107.htm 2419403 - Disclosure - RESTRUCTURING EXPENSES - Components of Restructuring Expenses (Details) Sheet http://www.amagpharma.com/role/RestructuringExpensesComponentsOfRestructuringExpensesDetails RESTRUCTURING EXPENSES - Components of Restructuring Expenses (Details) Details 107 false false R108.htm 2420402 - Disclosure - CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED - Schedule of Unaudited Consolidated Quartely Financial Data (Details) Sheet http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED - Schedule of Unaudited Consolidated Quartely Financial Data (Details) Details 108 false false R109.htm 2420403 - Disclosure - CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED - Schedule of Effects of Corrections and Prior Period Ajustments (Details) Sheet http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED - Schedule of Effects of Corrections and Prior Period Ajustments (Details) Details 109 false false R110.htm 2421402 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS (Details) Sheet http://www.amagpharma.com/role/ValuationAndQualifyingAccountsDetails VALUATION AND QUALIFYING ACCOUNTS (Details) Details http://www.amagpharma.com/role/ValuationAndQualifyingAccountsTables 110 false false R111.htm 2423401 - Disclosure - RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS - Narrative (Details) Sheet http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncementsNarrativeDetails RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS - Narrative (Details) Details 111 false false R112.htm 2424402 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Narrative (Details) Sheet http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsNarrativeDetails REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Narrative (Details) Details 112 false false R113.htm 2424403 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Condensed Consolidated Balance Sheet (Details) Sheet http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedBalanceSheetDetails REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Condensed Consolidated Balance Sheet (Details) Details 113 false false R114.htm 2424404 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Condensed Consolidated Statements of Operations (Details) Sheet http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Condensed Consolidated Statements of Operations (Details) Details 114 false false R115.htm 2425401 - Disclosure - SUBSEQUENT EVENTS (unaudited) (Details) Sheet http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails SUBSEQUENT EVENTS (unaudited) (Details) Details http://www.amagpharma.com/role/SubsequentEventsUnaudited 115 false false All Reports Book All Reports a201910-ka.htm amag-20191231.xsd amag-20191231_cal.xml amag-20191231_def.xml amag-20191231_lab.xml amag-20191231_pre.xml ex2312019a.htm ex3112019a.htm ex3122019a.htm ex3212019a.htm ex3222019a.htm amag_rgba03.jpg http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 135 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a201910-ka.htm": { "axisCustom": 2, "axisStandard": 37, "contextCount": 463, "dts": { "calculationLink": { "local": [ "amag-20191231_cal.xml" ] }, "definitionLink": { "local": [ "amag-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "a201910-ka.htm" ] }, "labelLink": { "local": [ "amag-20191231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "amag-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "amag-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 867, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 45, "http://www.amagpharma.com/20191231": 6, "http://xbrl.sec.gov/dei/2020-01-31": 6, "total": 57 }, "keyCustom": 102, "keyStandard": 500, "memberCustom": 65, "memberStandard": 54, "nsprefix": "amag", "nsuri": "http://www.amagpharma.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.amagpharma.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - DISCONTINUED OPERATIONS", "role": "http://www.amagpharma.com/role/DiscontinuedOperations", "shortName": "DISCONTINUED OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418403 - Disclosure - DEBT - Outstanding Convertible Note Balances (Details)", "role": "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails", "shortName": "DEBT - Outstanding Convertible Note Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4_us-gaap_DebtInstrumentAxis_amag_ConvertibleNotesDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "-3", "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418404 - Disclosure - DEBT - Convertible Notes (Details)", "role": "http://www.amagpharma.com/role/DebtConvertibleNotesDetails", "shortName": "DEBT - Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418405 - Disclosure - DEBT - Schedule of Total Interest Expense Recognized Related to the Convertible Notes (Details)", "role": "http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails", "shortName": "DEBT - Schedule of Total Interest Expense Recognized Related to the Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418406 - Disclosure - DEBT - 2023 Senior Notes (Details)", "role": "http://www.amagpharma.com/role/Debt2023SeniorNotesDetails", "shortName": "DEBT - 2023 Senior Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "I2016Q4Aug31_us-gaap_DebtInstrumentAxis_amag_SeniorNotesDue2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418407 - Disclosure - DEBT - 2015 Term Loan Facility (Details)", "role": "http://www.amagpharma.com/role/Debt2015TermLoanFacilityDetails", "shortName": "DEBT - 2015 Term Loan Facility (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "I2016Q4Aug31_us-gaap_DebtInstrumentAxis_amag_TermLoanFacility2015Member_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember", "decimals": "INF", "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418408 - Disclosure - DEBT - Future Payments (Details)", "role": "http://www.amagpharma.com/role/DebtFuturePaymentsDetails", "shortName": "DEBT - Future Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "D2019Q1Feb1toFeb28", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "reportCount": 1, "unitRef": "employee", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419402 - Disclosure - RESTRUCTURING EXPENSES (Details)", "role": "http://www.amagpharma.com/role/RestructuringExpensesDetails", "shortName": "RESTRUCTURING EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R107": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419403 - Disclosure - RESTRUCTURING EXPENSES - Components of Restructuring Expenses (Details)", "role": "http://www.amagpharma.com/role/RestructuringExpensesComponentsOfRestructuringExpensesDetails", "shortName": "RESTRUCTURING EXPENSES - Components of Restructuring Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:PaymentsForRestructuring", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420402 - Disclosure - CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED - Schedule of Unaudited Consolidated Quartely Financial Data (Details)", "role": "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "shortName": "CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED - Schedule of Unaudited Consolidated Quartely Financial Data (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420403 - Disclosure - CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED - Schedule of Effects of Corrections and Prior Period Ajustments (Details)", "role": "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails", "shortName": "CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED - Schedule of Effects of Corrections and Prior Period Ajustments (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - REVENUE RECOGNITION", "role": "http://www.amagpharma.com/role/RevenueRecognition", "shortName": "REVENUE RECOGNITION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "amag:ScheduleOfValuationAndQualifyingAccountsTableTextBlock", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_amag_AllowanceForPromotions1Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421402 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS (Details)", "role": "http://www.amagpharma.com/role/ValuationAndQualifyingAccountsDetails", "shortName": "VALUATION AND QUALIFYING ACCOUNTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "amag:ScheduleOfValuationAndQualifyingAccountsTableTextBlock", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_amag_AllowanceForPromotions1Member", "decimals": "-3", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423401 - Disclosure - RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS - Narrative (Details)", "role": "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncementsNarrativeDetails", "shortName": "RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R112": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424402 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Narrative (Details)", "role": "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsNarrativeDetails", "shortName": "REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "D2019Q4Jan01-Dec31_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember", "decimals": "-5", "lang": null, "name": "amag:RevenueAdjustmentGovernmentalRebates", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424403 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Condensed Consolidated Balance Sheet (Details)", "role": "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedBalanceSheetDetails", "shortName": "REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Condensed Consolidated Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember", "decimals": "-3", "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424404 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Condensed Consolidated Statements of Operations (Details)", "role": "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails", "shortName": "REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS - Condensed Consolidated Statements of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember", "decimals": "-3", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "D2019Q1Feb1toFeb28", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "reportCount": 1, "unitRef": "employee", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425401 - Disclosure - SUBSEQUENT EVENTS (unaudited) (Details)", "role": "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails", "shortName": "SUBSEQUENT EVENTS (unaudited) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "D2020Q2May01-May31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "0", "lang": null, "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "reportCount": 1, "unique": true, "unitRef": "employee", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - MARKETABLE SECURITIES", "role": "http://www.amagpharma.com/role/MarketableSecurities", "shortName": "MARKETABLE SECURITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.amagpharma.com/role/FairValueMeasurements", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - INVENTORIES", "role": "http://www.amagpharma.com/role/Inventories", "shortName": "INVENTORIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - PROPERTY AND EQUIPMENT, NET", "role": "http://www.amagpharma.com/role/PropertyAndEquipmentNet", "shortName": "PROPERTY AND EQUIPMENT, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET", "role": "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNet", "shortName": "GOODWILL AND INTANGIBLE ASSETS, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - CURRENT AND LONG-TERM LIABILITIES", "role": "http://www.amagpharma.com/role/CurrentAndLongTermLiabilities", "shortName": "CURRENT AND LONG-TERM LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - INCOME TAXES", "role": "http://www.amagpharma.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS", "role": "http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLoss", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.amagpharma.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - EQUITY-BASED COMPENSATION", "role": "http://www.amagpharma.com/role/EquityBasedCompensation", "shortName": "EQUITY-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - EMPLOYEE SAVINGS PLAN", "role": "http://www.amagpharma.com/role/EmployeeSavingsPlan", "shortName": "EMPLOYEE SAVINGS PLAN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "role": "http://www.amagpharma.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.amagpharma.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS", "role": "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreements", "shortName": "COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - DEBT", "role": "http://www.amagpharma.com/role/Debt", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - RESTRUCTURING EXPENSES", "role": "http://www.amagpharma.com/role/RestructuringExpenses", "shortName": "RESTRUCTURING EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120100 - Disclosure - CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED", "role": "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnaudited", "shortName": "CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121100 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS", "role": "http://www.amagpharma.com/role/ValuationAndQualifyingAccounts", "shortName": "VALUATION AND QUALIFYING ACCOUNTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122100 - Disclosure - RECENTLY ISSUED AND PROPOSED ACCOUNTING PRONOUNCEMENTS", "role": "http://www.amagpharma.com/role/RecentlyIssuedAndProposedAccountingPronouncements", "shortName": "RECENTLY ISSUED AND PROPOSED ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.amagpharma.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123100 - Disclosure - RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS", "role": "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncements", "shortName": "RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124100 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS", "role": "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatements", "shortName": "REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125100 - Disclosure - SUBSEQUENT EVENTS (unaudited)", "role": "http://www.amagpharma.com/role/SubsequentEventsUnaudited", "shortName": "SUBSEQUENT EVENTS (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - DISCONTINUED OPERATIONS (Tables)", "role": "http://www.amagpharma.com/role/DiscontinuedOperationsTables", "shortName": "DISCONTINUED OPERATIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - REVENUE RECOGNITION (Tables)", "role": "http://www.amagpharma.com/role/RevenueRecognitionTables", "shortName": "REVENUE RECOGNITION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - MARKETABLE SECURITIES (Tables)", "role": "http://www.amagpharma.com/role/MarketableSecuritiesTables", "shortName": "MARKETABLE SECURITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.amagpharma.com/role/FairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - INVENTORIES (Tables)", "role": "http://www.amagpharma.com/role/InventoriesTables", "shortName": "INVENTORIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)", "role": "http://www.amagpharma.com/role/PropertyAndEquipmentNetTables", "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET (Tables)", "role": "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetTables", "shortName": "GOODWILL AND INTANGIBLE ASSETS, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - CURRENT AND LONG-TERM LIABILITIES (Tables)", "role": "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesTables", "shortName": "CURRENT AND LONG-TERM LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - INCOME TAXES (Tables)", "role": "http://www.amagpharma.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)", "role": "http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLossTables", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - EQUITY-BASED COMPENSATION (Tables)", "role": "http://www.amagpharma.com/role/EquityBasedCompensationTables", "shortName": "EQUITY-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://www.amagpharma.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317301 - Disclosure - COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS (Tables)", "role": "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsTables", "shortName": "COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318301 - Disclosure - DEBT (Tables)", "role": "http://www.amagpharma.com/role/DebtTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319301 - Disclosure - RESTRUCTURING EXPENSES (Tables)", "role": "http://www.amagpharma.com/role/RestructuringExpensesTables", "shortName": "RESTRUCTURING EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "role": "http://www.amagpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320301 - Disclosure - CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED (Tables)", "role": "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedTables", "shortName": "CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "amag:ScheduleOfValuationAndQualifyingAccountsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321301 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS (Tables)", "role": "http://www.amagpharma.com/role/ValuationAndQualifyingAccountsTables", "shortName": "VALUATION AND QUALIFYING ACCOUNTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "amag:ScheduleOfValuationAndQualifyingAccountsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324301 - Disclosure - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Tables)", "role": "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsTables", "shortName": "REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "amag:NumberOfProductCandidates", "reportCount": 1, "unique": true, "unitRef": "product_candidate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401401 - Disclosure - DESCRIPTION OF BUSINESS (Details)", "role": "http://www.amagpharma.com/role/DescriptionOfBusinessDetails", "shortName": "DESCRIPTION OF BUSINESS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "amag:NumberOfProductCandidates", "reportCount": 1, "unique": true, "unitRef": "product_candidate", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details)", "role": "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "amag:RevenueDiscountPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition - Additional Information (Details)", "role": "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "amag:RevenueDiscountPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD_srt_MajorCustomersAxis_amag_McKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customers Who Represent 10% or More of Total Revenues or Accounts Receivable Balances (Details)", "role": "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customers Who Represent 10% or More of Total Revenues or Accounts Receivable Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD_srt_MajorCustomersAxis_amag_McKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember", "decimals": null, "first": true, "lang": "en-US", "name": "amag:InventoryFinishedGoodsShelfLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventory (Details)", "role": "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember", "decimals": null, "first": true, "lang": "en-US", "name": "amag:InventoryFinishedGoodsShelfLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_amag_ComputerEquipmentAndSoftwareMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment, Net (Details)", "role": "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_amag_ComputerEquipmentAndSoftwareMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details)", "role": "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)", "role": "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingCostsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402410 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basic and Diluted Earnings per Share (Details)", "role": "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basic and Diluted Earnings per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402411 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Anti-dilutive Securities excluded from Computation of Earnings per Share (Details)", "role": "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Anti-dilutive Securities excluded from Computation of Earnings per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "business_segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402412 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Business Segments (Details)", "role": "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBusinessSegmentsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Business Segments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "business_segment", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainLossOnSaleOfBusiness", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - DISCONTINUED OPERATIONS - Narrative (Details)", "role": "http://www.amagpharma.com/role/DiscontinuedOperationsNarrativeDetails", "shortName": "DISCONTINUED OPERATIONS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2018Q4YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_amag_CBRBusinessMember", "decimals": "-5", "lang": null, "name": "us-gaap:CapitalExpenditureDiscontinuedOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - DISCONTINUED OPERATIONS - Summary of Net Income (Loss) (Details)", "role": "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails", "shortName": "DISCONTINUED OPERATIONS - Summary of Net Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2018Q4YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_amag_CBRBusinessMember", "decimals": "-3", "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - REVENUE RECOGNITION - Disaggregated Revenue By Major Products (Details)", "role": "http://www.amagpharma.com/role/RevenueRecognitionDisaggregatedRevenueByMajorProductsDetails", "shortName": "REVENUE RECOGNITION - Disaggregated Revenue By Major Products (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_amag_FerahemeMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - REVENUE RECOGNITION - Total Gross Product (Details)", "role": "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails", "shortName": "REVENUE RECOGNITION - Total Gross Product (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember", "decimals": "-3", "lang": null, "name": "amag:RevenuefromContractwithCustomerExcludingAssessedTaxGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "amag:RevenueFromContractFromCustomerAllowance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404404 - Disclosure - REVENUE RECOGNITION - Product Revenue Allowance and Accrual Activity (Details)", "role": "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails", "shortName": "REVENUE RECOGNITION - Product Revenue Allowance and Accrual Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2016Q4", "decimals": "-3", "lang": null, "name": "amag:RevenueFromContractFromCustomerAllowance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "amag:RevenueAdjustmentGovernmentalRebatesPriorPeriodSales", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404405 - Disclosure - REVENUE RECOGNITION - Additional Information (Details)", "role": "http://www.amagpharma.com/role/RevenueRecognitionAdditionalInformationDetails", "shortName": "REVENUE RECOGNITION - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q1", "decimals": "-5", "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - MARKETABLE SECURITIES (Details)", "role": "http://www.amagpharma.com/role/MarketableSecuritiesDetails", "shortName": "MARKETABLE SECURITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "role": "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - FAIR VALUE MEASUREMENTS - Contingent Consideration (Details)", "role": "http://www.amagpharma.com/role/FairValueMeasurementsContingentConsiderationDetails", "shortName": "FAIR VALUE MEASUREMENTS - Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4_us-gaap_ContingentConsiderationByTypeAxis_amag_EndoceuticsLicenseAgreementMember", "decimals": "INF", "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4_us-gaap_DebtInstrumentAxis_amag_ConvertibleNotesDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - FAIR VALUE MEASUREMENTS - Debt (Details)", "role": "http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails", "shortName": "FAIR VALUE MEASUREMENTS - Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4_us-gaap_DebtInstrumentAxis_amag_ConvertibleNotesDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406405 - Disclosure - FAIR VALUE MEASUREMENTS - Nonrecurring Fair Value Measurements (Details)", "role": "http://www.amagpharma.com/role/FairValueMeasurementsNonrecurringFairValueMeasurementsDetails", "shortName": "FAIR VALUE MEASUREMENTS - Nonrecurring Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - INVENTORIES (Details)", "role": "http://www.amagpharma.com/role/InventoriesDetails", "shortName": "INVENTORIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)", "role": "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails", "shortName": "PROPERTY AND EQUIPMENT, NET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET - Goodwill - Narrative (Details)", "role": "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS, NET - Goodwill - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "I2019Q4Oct31", "decimals": "INF", "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET - Schedule of Intangible Assets (Details)", "role": "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS, NET - Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "amag:AccruedMilestonePaymentCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET - Intangible Assets - Narrative (Details)", "role": "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS, NET - Intangible Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - DESCRIPTION OF BUSINESS", "role": "http://www.amagpharma.com/role/DescriptionOfBusiness", "shortName": "DESCRIPTION OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "amag:AccruedCommercialRebatesFeesAndReturnsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - CURRENT AND LONG-TERM LIABILITIES (Details)", "role": "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails", "shortName": "CURRENT AND LONG-TERM LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "amag:AccruedCommercialRebatesFeesAndReturnsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - INCOME TAXES - Schedule of Income Tax Expense (Benefit) (Details)", "role": "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails", "shortName": "INCOME TAXES - Schedule of Income Tax Expense (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - INCOME TAXES - Income Tax Reconciliation (Details)", "role": "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "shortName": "INCOME TAXES - Income Tax Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - INCOME TAXES - Narrative (Details)", "role": "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails", "shortName": "INCOME TAXES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2017Q4YTD", "decimals": "-5", "lang": null, "name": "amag:TaxCutsAndJobsActIncompleteAccountingProvisionalIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - INCOME TAXES - Deferred Tax Components (Details)", "role": "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails", "shortName": "INCOME TAXES - Deferred Tax Components (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - INCOME TAXES - Reconciliation of Uncertain Tax Positions (Details)", "role": "http://www.amagpharma.com/role/IncomeTaxesReconciliationOfUncertainTaxPositionsDetails", "shortName": "INCOME TAXES - Reconciliation of Uncertain Tax Positions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2016Q4", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)", "role": "http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLossDetails", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "amag:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - EQUITY-BASED COMPENSATION - Narrative (Details)", "role": "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails", "shortName": "EQUITY-BASED COMPENSATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "amag:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2018Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413403 - Disclosure - EQUITY-BASED COMPENSATION - Activity Related to Plans (Details)", "role": "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "shortName": "EQUITY-BASED COMPENSATION - Activity Related to Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2018Q4_us-gaap_PlanNameAxis_amag_EquityIncentivePlan2019Member", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413404 - Disclosure - EQUITY-BASED COMPENSATION - Equity-Based Compensation Expense (Details)", "role": "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails", "shortName": "EQUITY-BASED COMPENSATION - Equity-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - EQUITY-BASED COMPENSATION - Weighted-Average Fair Value Assumptions, Stock Option Activity (Details)", "role": "http://www.amagpharma.com/role/EquityBasedCompensationWeightedAverageFairValueAssumptionsStockOptionActivityDetails", "shortName": "EQUITY-BASED COMPENSATION - Weighted-Average Fair Value Assumptions, Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2018Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Stock-based Compensation (Details)", "role": "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails", "shortName": "EQUITY-BASED COMPENSATION - Schedule of Stock-based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413407 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of RSUs Granted (Details)", "role": "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails", "shortName": "EQUITY-BASED COMPENSATION - Schedule of RSUs Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "lang": null, "name": "amag:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414401 - Disclosure - EMPLOYEE SAVINGS PLAN (Details)", "role": "http://www.amagpharma.com/role/EmployeeSavingsPlanDetails", "shortName": "EMPLOYEE SAVINGS PLAN (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415401 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details)", "role": "http://www.amagpharma.com/role/StockholdersEquityDetails", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "role": "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - COMMITMENTS AND CONTINGENCIES - Operating Leases, Fiscal Year Maturity Schedule (Details)", "role": "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Operating Leases, Fiscal Year Maturity Schedule (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsOfDebtExtinguishmentCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417402 - Disclosure - COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS (Details)", "role": "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "shortName": "COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "D2018Q3Sep01-Sep30_srt_CounterpartyNameAxis_amag_VeloBioLLCMember", "decimals": "-5", "lang": null, "name": "amag:PaymentsRelatedToCollaborativeArrangement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "D2019Q1Jan16_amag_AssetAcquisitionAxis_amag_PerospherePharmaceuticalsInc.Member", "decimals": "-5", "first": true, "lang": null, "name": "amag:AssetAcquisitionCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417403 - Disclosure - COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS - Assets Acquired and Liabilities Assumed Related to the Asset Acquisition (Details)", "role": "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails", "shortName": "COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS - Assets Acquired and Liabilities Assumed Related to the Asset Acquisition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "D2019Q1Jan16_amag_AssetAcquisitionAxis_amag_PerospherePharmaceuticalsInc.Member", "decimals": "-5", "first": true, "lang": null, "name": "amag:AssetAcquisitionCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418402 - Disclosure - DEBT - Schedule of Outstanding Debt Obligations (Details)", "role": "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "shortName": "DEBT - Schedule of Outstanding Debt Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a201910-ka.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 122, "tag": { "amag_AccruedCommercialRebatesFeesAndReturnsCurrent": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for commercial rebates, fees and returns. Used to reflect the current portion of liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Commercial Rebates, Fees And Returns, Current", "terseLabel": "Commercial rebates, fees and returns" } } }, "localname": "AccruedCommercialRebatesFeesAndReturnsCurrent", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "amag_AccruedManufacturingCostsCurrent": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Manufacturing Costs, Current", "label": "Accrued Manufacturing Costs, Current", "terseLabel": "Accrued manufacturing" } } }, "localname": "AccruedManufacturingCostsCurrent", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "amag_AccruedMilestonePaymentCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Milestone Payment, Current", "label": "Accrued Milestone Payment, Current", "terseLabel": "Milestone payment accrued for FDA approval of Vyleesi" } } }, "localname": "AccruedMilestonePaymentCurrent", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "amag_AccruedProfessionalLicenseandOtherFeesandExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional, license, and other fees and expenses. Used to reflect the current portion of liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional License and Other Fees and Expenses, Current", "terseLabel": "Professional, license, and other fees and expenses" } } }, "localname": "AccruedProfessionalLicenseandOtherFeesandExpensesCurrent", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "amag_AchievementOfCertainAnnualSalesMilestonesOverCourseOfLicenseAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Achievement Of Certain Annual Sales Milestones Over Course Of License Agreement [Member]", "label": "Achievement Of Certain Annual Sales Milestones Over Course Of License Agreement [Member]", "terseLabel": "Achievement of Certain Annual Sales Milestones Over Course of License Agreement" } } }, "localname": "AchievementOfCertainAnnualSalesMilestonesOverCourseOfLicenseAgreementMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtDebtIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Adjustments To Additional Paid In Capital, Equity Component Of Convertible Debt, Debt Issuance Costs", "label": "Adjustments To Additional Paid In Capital, Equity Component Of Convertible Debt, Debt Issuance Costs", "terseLabel": "Debt issuance costs allocated to equity component" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtDebtIssuanceCosts", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "amag_AdjustmentsToDebtInstrumentCarryingAmountLiabilityComponentOfConvertibleDebtDebtIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Adjustments To Debt Instrument Carrying Amount, Liability Component Of Convertible Debt, Debt Issuance Costs", "label": "Adjustments To Debt Instrument Carrying Amount, Liability Component Of Convertible Debt, Debt Issuance Costs", "terseLabel": "Debt issuance costs allocated to the liability component" } } }, "localname": "AdjustmentsToDebtInstrumentCarryingAmountLiabilityComponentOfConvertibleDebtDebtIssuanceCosts", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "amag_AllowanceForPromotions1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Allowance For Promotions1 [Member]", "label": "Allowance For Promotions1 [Member]", "terseLabel": "Accounts receivable allowances" } } }, "localname": "AllowanceForPromotions1Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/ValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "amag_AllowanceForSalesReturns1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Allowance For Sales Returns1 [Member]", "label": "Allowance For Sales Returns1 [Member]", "terseLabel": "Rebates, fees and returns reserves" } } }, "localname": "AllowanceForSalesReturns1Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/ValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "amag_AmerisourceBergenDrugCorporationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents AmerisourceBergen Drug Corporation, a major customer of the entity.", "label": "Amerisource Bergen Drug Corporation [Member]", "terseLabel": "AmerisourceBergen Drug Corporation" } } }, "localname": "AmerisourceBergenDrugCorporationMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "domainItemType" }, "amag_AnnualSalesMilestoneAchievementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Annual Sales Milestone Achievements [Member]", "label": "Annual Sales Milestone Achievements [Member]", "terseLabel": "Annual Sales Milestone Achievements" } } }, "localname": "AnnualSalesMilestoneAchievementsMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Assets", "label": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Assets", "totalLabel": "Total Assets" } } }, "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails", "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "amag_AssetAcquisitionCash": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails": { "order": 1.0, "parentTag": "amag_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Cash", "label": "Asset Acquisition, Cash", "terseLabel": "Cash" } } }, "localname": "AssetAcquisitionCash", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionConsiderationTransferredCancellationOfLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Cancellation Of Liabilities", "label": "Asset Acquisition, Consideration Transferred, Cancellation Of Liabilities", "terseLabel": "Cancellation of convertible note" } } }, "localname": "AssetAcquisitionConsiderationTransferredCancellationOfLiabilities", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionConsiderationTransferredGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Gross", "label": "Asset Acquisition, Consideration Transferred, Gross", "terseLabel": "Cash consideration" } } }, "localname": "AssetAcquisitionConsiderationTransferredGross", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionConsiderationTransferredNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Net", "label": "Asset Acquisition, Consideration Transferred, Net", "terseLabel": "Consideration recorded" } } }, "localname": "AssetAcquisitionConsiderationTransferredNet", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Value, High", "label": "Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Value, High", "terseLabel": "Contingent consideration (up to)" } } }, "localname": "AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionContingentConsiderationLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Contingent Consideration, Liability", "label": "Asset Acquisition, Contingent Consideration, Liability", "terseLabel": "Contingent consideration accrued for the acquisition of the Intrarosa intangible asset", "verboseLabel": "Future contingent payments (up to)" } } }, "localname": "AssetAcquisitionContingentConsiderationLiability", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionContingentConsiderationMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Contingent Consideration, Milestone Payment", "label": "Asset Acquisition, Contingent Consideration, Milestone Payment", "terseLabel": "Contingent consideration, milestone payment" } } }, "localname": "AssetAcquisitionContingentConsiderationMilestonePayment", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionContingentConsiderationTermsCreditedPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Contingent Consideration Terms, Credited Percentage", "label": "Asset Acquisition, Contingent Consideration Terms, Credited Percentage", "terseLabel": "Credited percentage" } } }, "localname": "AssetAcquisitionContingentConsiderationTermsCreditedPercentage", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "percentItemType" }, "amag_AssetAcquisitionContingentConsiderationTermsRoyaltyPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Contingent Consideration Terms, Royalty Percentage", "label": "Asset Acquisition, Contingent Consideration Terms, Royalty Percentage", "terseLabel": "Royalty percentage, maximum" } } }, "localname": "AssetAcquisitionContingentConsiderationTermsRoyaltyPercentage", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "percentItemType" }, "amag_AssetAcquisitionDeferredRevenue": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails": { "order": 2.0, "parentTag": "amag_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Deferred Revenue", "label": "Asset Acquisition, Deferred Revenue", "negatedTerseLabel": "Deferred revenue" } } }, "localname": "AssetAcquisitionDeferredRevenue", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionDiscountRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Discount Rate", "label": "Asset Acquisition, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "AssetAcquisitionDiscountRate", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "percentItemType" }, "amag_AssetAcquisitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Asset Acquisition [Axis]", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails", "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_AssetAcquisitionEarlyContractTerminationFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Early Contract Termination Fees", "label": "Asset Acquisition, Early Contract Termination Fees", "terseLabel": "Early contract termination fees" } } }, "localname": "AssetAcquisitionEarlyContractTerminationFees", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionOperatingLeaseObligation": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails": { "order": 3.0, "parentTag": "amag_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Operating Lease Obligation", "label": "Asset Acquisition, Operating Lease Obligation", "negatedTerseLabel": "Operating lease liability" } } }, "localname": "AssetAcquisitionOperatingLeaseObligation", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionPotentialMilestonePaymentTriggeringEventThresholdAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Potential Milestone Payment, Triggering Event, Threshold Amount", "label": "Asset Acquisition, Potential Milestone Payment, Triggering Event, Threshold Amount", "terseLabel": "Potential milestone payment, triggering event, sales" } } }, "localname": "AssetAcquisitionPotentialMilestonePaymentTriggeringEventThresholdAmount", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets [Abstract]", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails" ], "xbrltype": "stringItemType" }, "amag_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibles": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Indefinite-Lived Intangibles", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Indefinite-Lived Intangibles", "terseLabel": "IPR&D expense" } } }, "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibles", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangibles", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangibles", "verboseLabel": "Finite-lived intangible assets" } } }, "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities", "negatedTotalLabel": "Total Liabilities" } } }, "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities [Abstract]", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails" ], "xbrltype": "stringItemType" }, "amag_AssetAcquisitionSeverance": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails": { "order": 1.0, "parentTag": "amag_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Severance", "label": "Asset Acquisition, Severance", "negatedTerseLabel": "Accrued severance liabilities" } } }, "localname": "AssetAcquisitionSeverance", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "amag_AssetAcquisitionsLiabilitiesOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisitions, Liabilities, Other", "label": "Asset Acquisitions, Liabilities, Other", "terseLabel": "Other liabilities" } } }, "localname": "AssetAcquisitionsLiabilitiesOther", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "amag_CBRBusinessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CBR Business [Member]", "label": "CBR Business [Member]", "terseLabel": "CBR business" } } }, "localname": "CBRBusinessMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsNarrativeDetails", "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails", "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_CardinalHealthInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cardinal Health, Inc. [Member]", "label": "Cardinal Health, Inc. [Member]", "terseLabel": "Cardinal Health" } } }, "localname": "CardinalHealthInc.Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "domainItemType" }, "amag_CiraparantagMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ciraparantag [Member]", "label": "Ciraparantag [Member]", "terseLabel": "Ciraparantag" } } }, "localname": "CiraparantagMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "amag_CivilCaseInSaginawChippewaIndianTribeV.PurduePharmaEtAlMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Civil Case In Saginaw Chippewa Indian Tribe V. Purdue Pharma Et Al [Member]", "label": "Civil Case In Saginaw Chippewa Indian Tribe V. Purdue Pharma Et Al [Member]", "terseLabel": "Civil Case In Saginaw Chippewa Indian Tribe V. Purdue Pharma Et Al" } } }, "localname": "CivilCaseInSaginawChippewaIndianTribeV.PurduePharmaEtAlMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_CollaborativeArrangementPotentialMilestoneProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Potential Milestone Proceeds", "label": "Collaborative Arrangement, Potential Milestone Proceeds", "terseLabel": "Potential milestone proceeds from collaborative arrangement" } } }, "localname": "CollaborativeArrangementPotentialMilestoneProceeds", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "amag_CollaborativeArrangementPotentialMilestoneProceedsPayableToEquityHolders": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Potential Milestone Proceeds, Payable To Equity Holders", "label": "Collaborative Arrangement, Potential Milestone Proceeds, Payable To Equity Holders", "terseLabel": "Potential milestone proceeds from collaborative arrangement payable to equity holders" } } }, "localname": "CollaborativeArrangementPotentialMilestoneProceedsPayableToEquityHolders", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "amag_CollaborativeArrangementPotentialMilestoneProceedsTriggeringEventThresholdAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Potential Milestone Proceeds, Triggering Event, Threshold Amount", "label": "Collaborative Arrangement, Potential Milestone Proceeds, Triggering Event, Threshold Amount", "terseLabel": "Potential milestone proceeds, triggering event, sales" } } }, "localname": "CollaborativeArrangementPotentialMilestoneProceedsTriggeringEventThresholdAmount", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "amag_CollaborativeArrangementPotentialMilestoneProceedsTriggeringEventThresholdPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Potential Milestone Proceeds, Triggering Event, Threshold Period", "label": "Collaborative Arrangement, Potential Milestone Proceeds, Triggering Event, Threshold Period", "terseLabel": "Consecutive period for sales to exceed threshold amount for potential milestone proceeds (in months)" } } }, "localname": "CollaborativeArrangementPotentialMilestoneProceedsTriggeringEventThresholdPeriod", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "integerItemType" }, "amag_CollaborativeArrangementRecoveryOfDirectCostsPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Recovery Of Direct Costs, Percentage", "label": "Collaborative Arrangement, Recovery Of Direct Costs, Percentage", "terseLabel": "Recovery of direct costs" } } }, "localname": "CollaborativeArrangementRecoveryOfDirectCostsPercentage", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "percentItemType" }, "amag_CommercialMilestonePaymentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commercial Milestone Payments [Member]", "label": "Commercial Milestone Payments [Member]", "terseLabel": "Commercial Milestone Payments" } } }, "localname": "CommercialMilestonePaymentsMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Computer Equipment and Software [Member]", "label": "Computer Equipment And Software [Member]", "terseLabel": "Computer equipment and software" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "amag_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent Consideration [Member]", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent Consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "amag_ContractWithCustomerRefundLiabilityTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Refund Liability, Term", "label": "Contract With Customer, Refund Liability, Term", "terseLabel": "Product return term" } } }, "localname": "ContractWithCustomerRefundLiabilityTerm", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "amag_ConvertibleNotesDue2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible Notes due 2019 [Member]", "label": "Convertible Notes Due 2019 [Member]", "terseLabel": "2019 Convertible Notes", "verboseLabel": "Convertible Notes Due 2019" } } }, "localname": "ConvertibleNotesDue2019Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails", "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "amag_ConvertibleNotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible Notes due 2022 [Member]", "label": "Convertible Notes Due 2022 [Member]", "terseLabel": "2022 Convertible Notes" } } }, "localname": "ConvertibleNotesDue2022Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails", "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails", "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "amag_DebtInstrumentConversionPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Conversion, Period [Axis]", "label": "Debt Instrument, Conversion, Period [Axis]", "terseLabel": "Debt Instrument, Conversion, Period [Axis]" } } }, "localname": "DebtInstrumentConversionPeriodAxis", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "amag_DebtInstrumentConversionPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Debt Instrument, Conversion, Period [Axis]", "label": "Debt Instrument, Conversion, Period [Domain]", "terseLabel": "Debt Instrument, Conversion, Period [Domain]" } } }, "localname": "DebtInstrumentConversionPeriodDomain", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "amag_DebtInstrumentConversionPeriodOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Conversion, Period One [Member]", "label": "Debt Instrument, Conversion, Period One [Member]", "terseLabel": "Debt Instrument, Conversion, Period One" } } }, "localname": "DebtInstrumentConversionPeriodOneMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "amag_DebtInstrumentConversionPeriodTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Conversion, Period Two [Member]", "label": "Debt Instrument, Conversion, Period Two [Member]", "terseLabel": "Debt Instrument, Conversion, Period Two" } } }, "localname": "DebtInstrumentConversionPeriodTwoMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "amag_DebtInstrumentConvertibleThresholdBusinessDays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Convertible, Threshold Business Days", "label": "Debt Instrument, Convertible, Threshold Business Days", "terseLabel": "Number of consecutive business days after any five consecutive trading day period during the note measurement period" } } }, "localname": "DebtInstrumentConvertibleThresholdBusinessDays", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "integerItemType" }, "amag_DebtSecuritiesAvailableForSaleMaturityAllocatedandSingleMaturityDateRollingWithinOneYearGrossUnrealizedGain": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/MarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Within One Year, Gross Unrealized Gain", "label": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Within One Year, Gross Unrealized Gain", "terseLabel": "Gross Unrealized Gains, short-term investments" } } }, "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedandSingleMaturityDateRollingWithinOneYearGrossUnrealizedGain", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "amag_DebtSecuritiesAvailableForSaleMaturityAllocatedandSingleMaturityDateRollingWithinOneYearGrossUnrealizedLoss": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/MarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Within One Year, Gross Unrealized Loss", "label": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Within One Year, Gross Unrealized Loss", "negatedLabel": "Gross Unrealized Losses, short-term investments" } } }, "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedandSingleMaturityDateRollingWithinOneYearGrossUnrealizedLoss", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "amag_DebtSecuritiesAvailableForSaleMaturityAllocatedandSingleMaturityDateRollingYearTwoThroughThreeAmortizedCostBasis": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/MarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Amortized Cost Basis", "label": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Amortized Cost Basis", "totalLabel": "Amortized Cost, long-term investments" } } }, "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedandSingleMaturityDateRollingYearTwoThroughThreeAmortizedCostBasis", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "amag_DebtSecuritiesAvailableForSaleMaturityAllocatedandSingleMaturityDateRollingYearTwoThroughThreeFairValue": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/MarketableSecuritiesDetails": { "order": 3.0, "parentTag": "amag_DebtSecuritiesAvailableForSaleMaturityAllocatedandSingleMaturityDateRollingYearTwoThroughThreeAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Fair Value", "label": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Fair Value", "terseLabel": "Estimated Fair Value, long-term investments" } } }, "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedandSingleMaturityDateRollingYearTwoThroughThreeFairValue", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "amag_DebtSecuritiesAvailableForSaleMaturityAllocatedandSingleMaturityDateRollingYearTwoThroughThreeGrossUnrealizedGain": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/MarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Gross Unrealized Gain", "label": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Gross Unrealized Gain", "terseLabel": "Gross Unrealized Gains, long-term investments" } } }, "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedandSingleMaturityDateRollingYearTwoThroughThreeGrossUnrealizedGain", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "amag_DebtSecuritiesAvailableForSaleMaturityAllocatedandSingleMaturityDateRollingYearTwoThroughThreeGrossUnrealizedLoss": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/MarketableSecuritiesDetails": { "order": 2.0, "parentTag": "amag_DebtSecuritiesAvailableForSaleMaturityAllocatedandSingleMaturityDateRollingYearTwoThroughThreeAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Gross Unrealized Loss", "label": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year Two Through Three, Gross Unrealized Loss", "negatedLabel": "Gross Unrealized Losses, long-term investments" } } }, "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedandSingleMaturityDateRollingYearTwoThroughThreeGrossUnrealizedLoss", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "amag_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Deferred Expense, Capitalized Research And Development Costs", "label": "Deferred Tax Assets, Deferred Expense, Capitalized Research And Development Costs", "terseLabel": "Capitalized research & development" } } }, "localname": "DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "amag_DeferredTaxAssetsOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 15.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Operating Lease Liability", "label": "Deferred Tax Assets, Operating Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiability", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "amag_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 17.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset", "label": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset", "negatedTerseLabel": "Right of use asset" } } }, "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "amag_DeliveryOfIntrarosaLaunchQuantitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Delivery Of Intrarosa Launch Quantities [Member]", "label": "Delivery Of Intrarosa Launch Quantities [Member]", "terseLabel": "Delivery of Intrarosa Launch Quantities" } } }, "localname": "DeliveryOfIntrarosaLaunchQuantitiesMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense)", "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense)", "terseLabel": "Other income (expense)" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "amag_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseContingentConsiderationPercent": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Contingent Consideration, Percent", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Contingent Consideration, Percent", "terseLabel": "Contingent consideration" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseContingentConsiderationPercent", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "amag_EmployeeAndNonEmployeeDirectorStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee And Non Employee Director Stock Option [Member]", "label": "Employee And Non Employee Director Stock Option [Member]", "terseLabel": "Employee and Non Employee Director Stock Option" } } }, "localname": "EmployeeAndNonEmployeeDirectorStockOptionMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_EmployeeStockPurchasePlan2015Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee Stock Purchase Plan 2015 [Member]", "label": "Employee Stock Purchase Plan 2015 [Member]", "terseLabel": "2015 ESPP" } } }, "localname": "EmployeeStockPurchasePlan2015Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_EndoceuticsInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Endoceutics, Inc. [Member]", "label": "Endoceutics, Inc. [Member]", "terseLabel": "Endoceutics, Inc." } } }, "localname": "EndoceuticsInc.Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "amag_EndoceuticsLicenseAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Endoceutics License Agreement [Member]", "label": "Endoceutics License Agreement [Member]", "terseLabel": "Endoceutics License Agreement" } } }, "localname": "EndoceuticsLicenseAgreementMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "amag_EquityIncentivePlan2007Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This element represents the 2007 Equity Incentive Plan also referred as the 2007 Plan.", "label": "Equity Incentive Plan 2007 [Member]", "verboseLabel": "2007 Equity Plan" } } }, "localname": "EquityIncentivePlan2007Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_EquityIncentivePlan2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Incentive Plan 2019 [Member]", "label": "Equity Incentive Plan 2019 [Member]", "terseLabel": "2019 Equity Plan" } } }, "localname": "EquityIncentivePlan2019Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_FailureToSupplyACertainPercentageOfProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Failure To Supply A Certain Percentage Of Product [Member]", "label": "Failure To Supply A Certain Percentage Of Product [Member]", "terseLabel": "Failure To Supply A Certain Percentage Of Product" } } }, "localname": "FailureToSupplyACertainPercentageOfProductMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_February2017Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "February 2017 [Member]", "label": "February 2017 [Member]", "terseLabel": "February 2017" } } }, "localname": "February2017Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails" ], "xbrltype": "domainItemType" }, "amag_February2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "February 2019", "label": "February 2019 [Member]", "terseLabel": "February 2019" } } }, "localname": "February2019Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_FerahemeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Feraheme [Member]", "label": "Feraheme [Member]", "terseLabel": "Feraheme" } } }, "localname": "FerahemeMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionDisaggregatedRevenueByMajorProductsDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "domainItemType" }, "amag_FiniteLivedIntangibleAssetsAccumulatedImpairmentLoss": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated impairment loss for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Impairment Loss", "terseLabel": "Impairments" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedImpairmentLoss", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "amag_FirstAnniversaryOfClosingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First Anniversary Of Closing [Member]", "label": "First Anniversary Of Closing [Member]", "terseLabel": "First Anniversary of Closing" } } }, "localname": "FirstAnniversaryOfClosingMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_FirstSalesMilestoneAchievementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First Sales Milestone Achievement [Member]", "label": "First Sales Milestone Achievement [Member]", "terseLabel": "First Sales Milestone Achievement" } } }, "localname": "FirstSalesMilestoneAchievementMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_FirstTimeNetSalesDuringThresholdPeriodExceeds115MillionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First Time Net Sales During Threshold Period Exceeds $115 Million [Member]", "label": "First Time Net Sales During Threshold Period Exceeds $115 Million [Member]", "terseLabel": "First Time Net Sales During Threshold Period Exceeds $115 Million" } } }, "localname": "FirstTimeNetSalesDuringThresholdPeriodExceeds115MillionMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "amag_FirstTimeNetSalesDuringThresholdPeriodExceeds175MillionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First Time Net Sales During Threshold Period Exceeds $175 Million [Member]", "label": "First Time Net Sales During Threshold Period Exceeds $175 Million [Member]", "terseLabel": "First Time Net Sales During Threshold Period Exceeds $175 Million" } } }, "localname": "FirstTimeNetSalesDuringThresholdPeriodExceeds175MillionMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "amag_FirstTimeNetSalesDuringThresholdPeriodExceeds65MillionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First Time Net Sales During Threshold Period Exceeds $65 Million [Member]", "label": "First Time Net Sales During Threshold Period Exceeds $65 Million [Member]", "terseLabel": "First Time Net Sales During Threshold Period Exceeds $65 Million" } } }, "localname": "FirstTimeNetSalesDuringThresholdPeriodExceeds65MillionMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "amag_GroupPurchasingOrganizationBillingPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Group Purchasing Organization, Billing Period", "label": "Group Purchasing Organization, Billing Period", "terseLabel": "GPO billing period" } } }, "localname": "GroupPurchasingOrganizationBillingPeriod", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "amag_IncreaseDecreaseInTransactionCosts": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Transaction Costs", "label": "Increase (Decrease) In Transaction Costs", "negatedTerseLabel": "Transaction costs", "terseLabel": "Transaction expenses" } } }, "localname": "IncreaseDecreaseInTransactionCosts", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/DiscontinuedOperationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "amag_InducementGrantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the other equity compensation grants such as inducement grants used for certain employees to induce them to accept employment with the company.", "label": "Inducement Grants [Member]", "terseLabel": "Inducement Grants" } } }, "localname": "InducementGrantsMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairmentLoss": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Intangible Assets, Net (Excluding Goodwill), Accumulated Impairment Loss", "label": "Intangible Assets, Net (Excluding Goodwill), Accumulated Impairment Loss", "totalLabel": "Impairments" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAccumulatedImpairmentLoss", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "amag_InterestExpenseCarryforwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Expense Carryforward [Member]", "label": "Interest Expense Carryforward [Member]", "terseLabel": "Interest Expense Carryforward" } } }, "localname": "InterestExpenseCarryforwardMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_IntrarosaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intrarosa [Member]", "label": "Intrarosa [Member]", "terseLabel": "Intrarosa" } } }, "localname": "IntrarosaMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "http://www.amagpharma.com/role/RevenueRecognitionDisaggregatedRevenueByMajorProductsDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "amag_InventoryFinishedGoodsShelfLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inventory, Finished Goods, Shelf Life", "label": "Inventory, Finished Goods, Shelf Life", "terseLabel": "Shelf-life" } } }, "localname": "InventoryFinishedGoodsShelfLife", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" ], "xbrltype": "durationItemType" }, "amag_LumaraHealth2013PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information relating to the Lumara Health 2013 Plan.", "label": "Lumara Health 2013 Plan [Member]", "verboseLabel": "2013 Lumara Equity Plan" } } }, "localname": "LumaraHealth2013PlanMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_LumaraHealthInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lumara Health Inc. [Member]", "label": "Lumara Health Inc. [Member]", "terseLabel": "Lumara Health Inc." } } }, "localname": "LumaraHealthInc.Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_LunarRepresentativeLLCV.AMAGPharmaceuticalsInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lunar Representative, LLC V. AMAG Pharmaceuticals, Inc. [Member]", "label": "Lunar Representative, LLC V. AMAG Pharmaceuticals, Inc. [Member]", "terseLabel": "Lunar Representative, LLC V. AMAG Pharmaceuticals, Inc." } } }, "localname": "LunarRepresentativeLLCV.AMAGPharmaceuticalsInc.Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_MakenaAutoInjectorIntrarosaAndVyleesiProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Makena Auto-Injector, Intrarosa And Vyleesi Products [Member]", "label": "Makena Auto-Injector, Intrarosa And Vyleesi Products [Member]", "terseLabel": "Makena Auto-Injector, Intrarosa And Vyleesi Products" } } }, "localname": "MakenaAutoInjectorIntrarosaAndVyleesiProductsMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails" ], "xbrltype": "domainItemType" }, "amag_MakenaAutoInjectorMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Makena Auto-Injector [Member]", "label": "Makena Auto-Injector [Member]", "terseLabel": "Makena auto-injector developed technology" } } }, "localname": "MakenaAutoInjectorMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "amag_MakenaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Makena", "label": "Makena [Member]", "terseLabel": "Makena" } } }, "localname": "MakenaMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "http://www.amagpharma.com/role/RevenueRecognitionDisaggregatedRevenueByMajorProductsDetails" ], "xbrltype": "domainItemType" }, "amag_March2018Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "March 2018 [Member]", "label": "March 2018 [Member]", "terseLabel": "March 2018" } } }, "localname": "March2018Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails" ], "xbrltype": "domainItemType" }, "amag_MarketCapitalization": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Market Capitalization", "label": "Market Capitalization", "terseLabel": "Market capitalization" } } }, "localname": "MarketCapitalization", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "amag_McKessonCorporationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents McKesson Corporation.", "label": "McKesson Corporation [Member]", "terseLabel": "McKesson Corporation" } } }, "localname": "McKessonCorporationMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "domainItemType" }, "amag_MilestoneAchievementApprovalByEuropeanMedicinesAgencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Milestone Achievement, Approval By European Medicines Agency [Member]", "label": "Milestone Achievement, Approval By European Medicines Agency [Member]", "terseLabel": "Milestone Achievement, Approval By European Medicines Agency" } } }, "localname": "MilestoneAchievementApprovalByEuropeanMedicinesAgencyMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_MillicentPharmaLimitedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Millicent Pharma Limited [Member]", "label": "Millicent Pharma Limited [Member]", "terseLabel": "Millicent Pharma Limited" } } }, "localname": "MillicentPharmaLimitedMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "amag_MugardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to the Mugard product line.", "label": "Mugard [Member]", "terseLabel": "Other" } } }, "localname": "MugardMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.amagpharma.com/role/RevenueRecognitionDisaggregatedRevenueByMajorProductsDetails" ], "xbrltype": "domainItemType" }, "amag_NetAssetsPercentageOfFairValueInExcessOfCarryingAmount": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net Assets, Percentage Of Fair Value In Excess Of Carrying Amount", "label": "Net Assets, Percentage Of Fair Value In Excess Of Carrying Amount", "terseLabel": "Fair value percentage above carrying amount, net assets" } } }, "localname": "NetAssetsPercentageOfFairValueInExcessOfCarryingAmount", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "percentItemType" }, "amag_NonEmployeeDirectorStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non Employee Director Stock Option [Member]", "label": "Non Employee Director Stock Option [Member]", "terseLabel": "Non Employee Directors" } } }, "localname": "NonEmployeeDirectorStockOptionMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationWeightedAverageFairValueAssumptionsStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "amag_NoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Non-cash Lease Expense", "label": "Non-cash Lease Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "NoncashLeaseExpense", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "amag_NoncashResearchAndDevelopmentInProcessExpense": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Noncash Research and Development in Process Expense", "label": "Noncash Research And Development In Process Expense", "terseLabel": "Non-cash IPR&D expense" } } }, "localname": "NoncashResearchAndDevelopmentInProcessExpense", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "amag_NoncashorPartNoncashAcquisitionReceivableSettled": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Noncash or Part Noncash Acquisition, Receivable Settled", "label": "Noncash or Part Noncash Acquisition, Receivable Settled", "terseLabel": "Settlement of note receivable in connection with Perosphere acquisition" } } }, "localname": "NoncashorPartNoncashAcquisitionReceivableSettled", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "amag_NorgineB.V.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Norgine B.V. [Member]", "label": "Norgine B.V. [Member]", "terseLabel": "Norgine B.V." } } }, "localname": "NorgineB.V.Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "amag_NumberOfProductCandidates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Product Candidates", "label": "Number Of Product Candidates", "terseLabel": "Number of product candidates" } } }, "localname": "NumberOfProductCandidates", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/DescriptionOfBusinessDetails" ], "xbrltype": "integerItemType" }, "amag_NumberOfProductionFacilities": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Production Facilities", "label": "Number Of Production Facilities", "terseLabel": "Number of production facilities" } } }, "localname": "NumberOfProductionFacilities", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "integerItemType" }, "amag_OptionAgreementContingentConsiderationLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Option Agreement, Contingent Consideration, Liability", "label": "Option Agreement, Contingent Consideration, Liability", "terseLabel": "Milestone payments" } } }, "localname": "OptionAgreementContingentConsiderationLiability", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "amag_OptionAgreementPotentialSalesMilestonePaymentTriggeringEventThresholdAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Option Agreement, Potential Sales Milestone Payment, Triggering Event, Threshold Amount", "label": "Option Agreement, Potential Sales Milestone Payment, Triggering Event, Threshold Amount", "terseLabel": "Sales milestone targets" } } }, "localname": "OptionAgreementPotentialSalesMilestonePaymentTriggeringEventThresholdAmount", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "amag_PalatinTechnologiesInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Palatin Technologies, Inc. [Member]", "label": "Palatin Technologies, Inc. [Member]", "terseLabel": "Palatin Technologies, Inc." } } }, "localname": "PalatinTechnologiesInc.Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "amag_PatentCostPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Patent Cost Policy [Policy Text Block]", "label": "Patent Cost Policy [Policy Text Block]", "terseLabel": "Patents" } } }, "localname": "PatentCostPolicyPolicyTextBlock", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "amag_PaymentsForAssetAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments For Asset Acquisitions", "label": "Payments For Asset Acquisitions", "terseLabel": "Payments of asset acquisitions" } } }, "localname": "PaymentsForAssetAcquisitions", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "amag_PaymentsRelatedToCollaborativeArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments Related to Collaborative Arrangement", "label": "Payments Related To Collaborative Arrangement", "verboseLabel": "Payments related to collaborative arrangement" } } }, "localname": "PaymentsRelatedToCollaborativeArrangement", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "amag_PerformanceRestrictedStockUnitsRSUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance Restricted Stock Units (RSUs) [Member]", "label": "Performance Restricted Stock Units (RSUs) [Member]", "terseLabel": "Performance Restricted Stock Units (RSUs)" } } }, "localname": "PerformanceRestrictedStockUnitsRSUsMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_PerosphereConvertibleNoteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Perosphere Convertible Note [Member]", "label": "Perosphere Convertible Note [Member]", "terseLabel": "Perosphere Convertible Note" } } }, "localname": "PerosphereConvertibleNoteMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_PerospherePharmaceuticalsInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Perosphere Pharmaceuticals Inc. [Member]", "label": "Perosphere Pharmaceuticals Inc. [Member]", "terseLabel": "Perosphere Pharmaceuticals Inc." } } }, "localname": "PerospherePharmaceuticalsInc.Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails", "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "amag_PerosphereTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Perosphere Term Loan [Member]", "label": "Perosphere Term Loan [Member]", "terseLabel": "Perosphere Term Loan" } } }, "localname": "PerosphereTermLoanMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_PrascoLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prasco, LLC [Member]", "label": "Prasco, LLC [Member]", "terseLabel": "Prasco, LLC" } } }, "localname": "PrascoLLCMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_ProceedsFromTerminationOfBondHedgeAndWarrants": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from Termination of Bond Hedge and Warrants", "label": "Proceeds From Termination Of Bond Hedge And Warrants", "terseLabel": "Proceeds to settle warrants" } } }, "localname": "ProceedsFromTerminationOfBondHedgeAndWarrants", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "amag_ProceedsRelatedToCollaborativeArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Proceeds Related To Collaborative Arrangement", "label": "Proceeds Related To Collaborative Arrangement", "terseLabel": "Proceeds related to collaborative arrangement" } } }, "localname": "ProceedsRelatedToCollaborativeArrangement", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "amag_ProvisionForProductSalesAllowancesAndAccruals": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails": { "order": 2.0, "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Provision For Product Sales Allowances And Accruals", "label": "Provision For Product Sales Allowances And Accruals", "totalLabel": "Total" } } }, "localname": "ProvisionForProductSalesAllowancesAndAccruals", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails" ], "xbrltype": "monetaryItemType" }, "amag_ProvisionForProductSalesAllowancesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Provision For Product Sales Allowances And Accruals", "label": "Provision For Product Sales Allowances And Accruals [Abstract]", "terseLabel": "Provision for product sales allowances and accruals:" } } }, "localname": "ProvisionForProductSalesAllowancesAndAccrualsAbstract", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails" ], "xbrltype": "stringItemType" }, "amag_PurchaseCommitmentOptionToThirdPartyToAcquireStudyPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase Commitment, Option To Third Party To Acquire Study, Period", "label": "Purchase Commitment, Option To Third Party To Acquire Study, Period", "terseLabel": "Option period to third party supplier to acquire study" } } }, "localname": "PurchaseCommitmentOptionToThirdPartyToAcquireStudyPeriod", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "durationItemType" }, "amag_PurchaseCommitmentTerminationPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Purchase Commitment, Termination Payment", "label": "Purchase Commitment, Termination Payment", "terseLabel": "Agreement termination payment" } } }, "localname": "PurchaseCommitmentTerminationPayment", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "amag_RebatePaymentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rebate, Payment Term", "label": "Rebate, Payment Term", "terseLabel": "Rebate payment term" } } }, "localname": "RebatePaymentTerm", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "amag_RegulatoryMilestoneAchievementAcceptanceByU.S.FoodAndDrugAdministrationOfNewDrugApplicationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regulatory Milestone Achievement, Acceptance By U.S.Food And Drug Administration Of New Drug Application [Member]", "label": "Regulatory Milestone Achievement, Acceptance By U.S.Food And Drug Administration Of New Drug Application [Member]", "terseLabel": "Regulatory Milestone Achievement, Acceptance by U.S.Food And Drug Administration of New Drug Application" } } }, "localname": "RegulatoryMilestoneAchievementAcceptanceByU.S.FoodAndDrugAdministrationOfNewDrugApplicationMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_RegulatoryMilestoneAchievementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regulatory Milestone Achievement [Member]", "label": "Regulatory Milestone Achievement [Member]", "terseLabel": "Regulatory Milestone Achievement" } } }, "localname": "RegulatoryMilestoneAchievementMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "amag_RegulatoryMilestoneAchievementU.S.FoodAndDrugAdministrationApprovalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regulatory Milestone Achievement, Acceptance By U.S.Food And Drug Administration Approval [Member]", "label": "Regulatory Milestone Achievement, U.S. Food And Drug Administration Approval [Member]", "terseLabel": "Regulatory Milestone Achievement, U.S.Food and Drug Administration Approval" } } }, "localname": "RegulatoryMilestoneAchievementU.S.FoodAndDrugAdministrationApprovalMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_ReportingUnitCarryingAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Reporting Unit, Carrying Amount", "label": "Reporting Unit, Carrying Amount", "terseLabel": "Reporting unit, carrying amount" } } }, "localname": "ReportingUnitCarryingAmount", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "amag_ReportingUnitMeasurementInput": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reporting Unit, Measurement Input", "label": "Reporting Unit, Measurement Input", "terseLabel": "Reporting unit, measurement input" } } }, "localname": "ReportingUnitMeasurementInput", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "decimalItemType" }, "amag_ReportingUnitMeasurementInputMedian": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reporting Unit, Measurement Input, Median", "label": "Reporting Unit, Measurement Input, Median", "terseLabel": "Reporting unit, measurement input, median" } } }, "localname": "ReportingUnitMeasurementInputMedian", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "decimalItemType" }, "amag_ReportingUnitPercentageOfFairValueBelowCarryingAmount": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reporting Unit, Percentage Of Fair Value Below Carrying Amount", "label": "Reporting Unit, Percentage Of Fair Value Below Carrying Amount", "terseLabel": "Fair value percentage below carrying amount, reporting unit" } } }, "localname": "ReportingUnitPercentageOfFairValueBelowCarryingAmount", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "percentItemType" }, "amag_ResearchAndDevelopmentPayableCurrent": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research and Development Payable, Current", "label": "Research And Development Payable, Current", "terseLabel": "Accrued research and development" } } }, "localname": "ResearchAndDevelopmentPayableCurrent", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenueAdjustmentGovernmentalRebates": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails": { "order": 2.0, "parentTag": "amag_ProvisionForProductSalesAllowancesAndAccruals", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Revenue Adjustment, Governmental Rebates", "label": "Revenue Adjustment, Governmental Rebates", "negatedLabel": "Governmental rebates", "terseLabel": "Governmental rebates" } } }, "localname": "RevenueAdjustmentGovernmentalRebates", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenueAdjustmentGovernmentalRebatesAllowance": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": 2.0, "parentTag": "amag_RevenueAllowance", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue Adjustment, Governmental Rebates, Allowance", "label": "Revenue Adjustment, Governmental Rebates, Allowance", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance at Beginning of Period" } } }, "localname": "RevenueAdjustmentGovernmentalRebatesAllowance", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenueAdjustmentGovernmentalRebatesAllowanceRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue Adjustment, Governmental Rebates, Allowance [Roll Forward]", "label": "Revenue Adjustment, Governmental Rebates, Allowance [Roll Forward]", "terseLabel": "Governmental Rebates" } } }, "localname": "RevenueAdjustmentGovernmentalRebatesAllowanceRollForward", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "stringItemType" }, "amag_RevenueAdjustmentGovernmentalRebatesCurrentPeriodSales": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": 2.0, "parentTag": "amag_RevenueAdjustmentsCurrentPeriodSales", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Revenue Adjustment, Governmental Rebates, Current Period Sales", "label": "Revenue Adjustment, Governmental Rebates, Current Period Sales", "terseLabel": "Provisions related to current period sales" } } }, "localname": "RevenueAdjustmentGovernmentalRebatesCurrentPeriodSales", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenueAdjustmentGovernmentalRebatesPaymentsAndReturnsCurrentPeriodSales": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": 2.0, "parentTag": "amag_RevenuePaymentsandReturnsCurrentPeriodSales", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue Adjustment, Governmental Rebates, Payments And Returns, Current Period Sales", "label": "Revenue Adjustment, Governmental Rebates, Payments And Returns, Current Period Sales", "negatedTerseLabel": "Payments/returns relating to current period sales" } } }, "localname": "RevenueAdjustmentGovernmentalRebatesPaymentsAndReturnsCurrentPeriodSales", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenueAdjustmentGovernmentalRebatesPaymentsAndReturnsPriorPeriodSales": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": 2.0, "parentTag": "amag_RevenuePaymentsandReturnsPriorPeriodSales", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue Adjustment, Governmental Rebates, Payments And Returns, Prior Period Sales", "label": "Revenue Adjustment, Governmental Rebates, Payments And Returns, Prior Period Sales", "negatedTerseLabel": "Payments/returns relating to prior period sales" } } }, "localname": "RevenueAdjustmentGovernmentalRebatesPaymentsAndReturnsPriorPeriodSales", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenueAdjustmentGovernmentalRebatesPriorPeriodSales": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": 2.0, "parentTag": "amag_RevenueAdjustmentPriorPeriodSales", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Revenue Adjustment, Governmental Rebates, Prior Period Sales", "label": "Revenue Adjustment, Governmental Rebates, Prior Period Sales", "terseLabel": "Adjustments related to prior period sales", "verboseLabel": "Adjustments related to prior period sales. Medicaid rebates" } } }, "localname": "RevenueAdjustmentGovernmentalRebatesPriorPeriodSales", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionAdditionalInformationDetails", "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenueAdjustmentPriorPeriodSales": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Revenue Adjustment, Prior Period Sales", "label": "Revenue Adjustment, Prior Period Sales", "totalLabel": "Adjustments related to prior period sales" } } }, "localname": "RevenueAdjustmentPriorPeriodSales", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenueAdjustmentsCurrentPeriodSales": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Revenue Adjustments, Current Period Sales", "label": "Revenue Adjustments, Current Period Sales", "totalLabel": "Provisions related to current period sales" } } }, "localname": "RevenueAdjustmentsCurrentPeriodSales", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenueAllowance": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue, Allowance", "label": "Revenue, Allowance", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance at Beginning of Period" } } }, "localname": "RevenueAllowance", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenueAllowanceRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue, Allowance [Roll Forward]", "label": "Revenue, Allowance [Roll Forward]", "terseLabel": "Revenue, Allowance [Roll Forward]" } } }, "localname": "RevenueAllowanceRollForward", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "stringItemType" }, "amag_RevenueDiscountPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue Discount Percentage", "label": "Revenue Discount Percentage", "terseLabel": "Discount percentage" } } }, "localname": "RevenueDiscountPercentage", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "amag_RevenueDiscountPercentageAccruedAtTimeOfSale": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue Discount, Percentage Accrued At Time Of Sale", "label": "Revenue Discount, Percentage Accrued At Time Of Sale", "terseLabel": "Percentage of discount accrued at time of sale" } } }, "localname": "RevenueDiscountPercentageAccruedAtTimeOfSale", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "amag_RevenueFromContractFromCustomerAllowance": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": 1.0, "parentTag": "amag_RevenueAllowance", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue From Contract From Customer, Allowance", "label": "Revenue From Contract From Customer, Allowance", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance at Beginning of Period" } } }, "localname": "RevenueFromContractFromCustomerAllowance", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenueFromContractFromCustomerAllowanceRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue From Contract From Customer, Allowance [Roll Forward]", "label": "Revenue From Contract From Customer, Allowance [Roll Forward]", "terseLabel": "Contractual Adjustments" } } }, "localname": "RevenueFromContractFromCustomerAllowanceRollForward", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "stringItemType" }, "amag_RevenueFromContractWithCustomerContractualAdjustments": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails": { "order": 1.0, "parentTag": "amag_ProvisionForProductSalesAllowancesAndAccruals", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Revenue From Contract With Customer, Contractual Adjustments", "label": "Revenue From Contract With Customer, Contractual Adjustments", "terseLabel": "Contractual adjustments" } } }, "localname": "RevenueFromContractWithCustomerContractualAdjustments", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenueFromContractWithCustomerPaymentsAndReturnsCurrentPeriodSales": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": 1.0, "parentTag": "amag_RevenuePaymentsandReturnsCurrentPeriodSales", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue From Contract With Customer, Payments And Returns, Current Period Sales", "label": "Revenue From Contract With Customer, Payments And Returns, Current Period Sales", "negatedTerseLabel": "Payments/returns relating to current period sales" } } }, "localname": "RevenueFromContractWithCustomerPaymentsAndReturnsCurrentPeriodSales", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenueFromContractWithCustomerPaymentsAndReturnsPriorPeriodSales": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": 1.0, "parentTag": "amag_RevenuePaymentsandReturnsPriorPeriodSales", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue From Contract With Customer, Payments And Returns, Prior Period Sales", "label": "Revenue From Contract With Customer, Payments And Returns, Prior Period Sales", "negatedTerseLabel": "Payments/returns relating to prior period sales" } } }, "localname": "RevenueFromContractWithCustomerPaymentsAndReturnsPriorPeriodSales", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenuePaymentsandReturnsCurrentPeriodSales": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue, Payments and Returns, Current Period Sales", "label": "Revenue, Payments and Returns, Current Period Sales", "negatedTotalLabel": "Payments/returns relating to current period sales" } } }, "localname": "RevenuePaymentsandReturnsCurrentPeriodSales", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenuePaymentsandReturnsPriorPeriodSales": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue, Payments and Returns, Prior Period Sales", "label": "Revenue, Payments and Returns, Prior Period Sales", "negatedTotalLabel": "Payments/returns relating to prior period sales" } } }, "localname": "RevenuePaymentsandReturnsPriorPeriodSales", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenueStandardPaymentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue, Standard Payment Term", "label": "Revenue, Standard Payment Term", "terseLabel": "Standard payment term" } } }, "localname": "RevenueStandardPaymentTerm", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "amag_RevenuefromContractwithCustomerContractualAdjustmentsCurrentPeriodSales": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": 1.0, "parentTag": "amag_RevenueAdjustmentsCurrentPeriodSales", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Revenue from Contract with Customer, Contractual Adjustments, Current Period Sales", "label": "Revenue from Contract with Customer, Contractual Adjustments, Current Period Sales", "terseLabel": "Provisions related to current period sales" } } }, "localname": "RevenuefromContractwithCustomerContractualAdjustmentsCurrentPeriodSales", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenuefromContractwithCustomerContractualAdjustmentsPriorPeriodSales": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails": { "order": 1.0, "parentTag": "amag_RevenueAdjustmentPriorPeriodSales", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Revenue from Contract with Customer, Contractual Adjustments, Prior Period Sales", "label": "Revenue from Contract with Customer, Contractual Adjustments, Prior Period Sales", "terseLabel": "Adjustments related to prior period sales", "verboseLabel": "Adjustments related to prior period sales, contractual adjustments" } } }, "localname": "RevenuefromContractwithCustomerContractualAdjustmentsPriorPeriodSales", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionAdditionalInformationDetails", "http://www.amagpharma.com/role/RevenueRecognitionProductRevenueAllowanceAndAccrualActivityDetails" ], "xbrltype": "monetaryItemType" }, "amag_RevenuefromContractwithCustomerExcludingAssessedTaxGross": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails": { "order": 1.0, "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue from Contract with Customer, Excluding Assessed Tax, Gross", "label": "Revenue from Contract with Customer, Excluding Assessed Tax, Gross", "terseLabel": "Gross product sales" } } }, "localname": "RevenuefromContractwithCustomerExcludingAssessedTaxGross", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails" ], "xbrltype": "monetaryItemType" }, "amag_SalesMilestonesAchievementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales Milestones Achievement [Member]", "label": "Sales Milestones Achievement [Member]", "terseLabel": "Sales Milestones Achievement" } } }, "localname": "SalesMilestonesAchievementMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "amag_ScheduleOfAssetAcquisitionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Schedule Of Asset Acquisitions [Table]", "label": "Schedule Of Asset Acquisitions [Line Items]", "terseLabel": "Schedule Of Asset Acquisitions [Line Items]" } } }, "localname": "ScheduleOfAssetAcquisitionsLineItems", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails" ], "xbrltype": "stringItemType" }, "amag_ScheduleOfAssetAcquisitionsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Asset Acquisitions [Table]", "label": "Schedule Of Asset Acquisitions [Table]", "terseLabel": "Schedule Of Asset Acquisitions [Table]" } } }, "localname": "ScheduleOfAssetAcquisitionsTable", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails" ], "xbrltype": "stringItemType" }, "amag_ScheduleOfValuationAndQualifyingAccountsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Valuation and Qualifying Accounts [Table Text Block]", "label": "Schedule Of Valuation And Qualifying Accounts [Table Text Block]", "terseLabel": "Schedule of valuation and qualifying accounts" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsTableTextBlock", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/ValuationAndQualifyingAccountsTables" ], "xbrltype": "textBlockItemType" }, "amag_SeniorNotesDue2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes Due 2023 [Member]", "label": "Senior Notes Due 2023 [Member]", "terseLabel": "2023 Senior Notes" } } }, "localname": "SeniorNotesDue2023Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/Debt2023SeniorNotesDetails" ], "xbrltype": "domainItemType" }, "amag_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEmployeeCompensationMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the maximum percentage of an employee's compensation that can be deducted and used to purchase shares under an Employee Stock Purchase Plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Employee Compensation Maximum", "terseLabel": "Annual maximum percentage of employee compensation available for ESPP share purchases" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfEmployeeCompensationMaximum", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "amag_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Number", "terseLabel": "Outstanding at end of year and expected to vest (shares)" } } }, "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails" ], "xbrltype": "sharesItemType" }, "amag_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Outstanding at end of year and expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails" ], "xbrltype": "perShareItemType" }, "amag_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfPlans": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation Arrangements By Share-Based Payment Award, Number Of Plans", "label": "Share-Based Compensation Arrangements By Share-Based Payment Award, Number Of Plans", "terseLabel": "Number of equity compensation plans" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfPlans", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "amag_SharePriceMedian": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Price, Median", "label": "Share Price, Median", "terseLabel": "Share price, median (in dollars per share)" } } }, "localname": "SharePriceMedian", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "perShareItemType" }, "amag_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOfferingPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Offering Period", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Offering Period", "terseLabel": "Stock offering period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardStockOfferingPeriod", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "amag_TaxCutsAndJobsActIncompleteAccountingProvisionalIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts And Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)", "label": "Tax Cuts And Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)", "negatedLabel": "Tax cuts and jobs act, provisional tax benefit" } } }, "localname": "TaxCutsAndJobsActIncompleteAccountingProvisionalIncomeTaxExpenseBenefit", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "amag_TermLoanFacility2015Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information relating to the 2015 Term Loan Facility.", "label": "Term Loan Facility 2015 [Member]", "terseLabel": "2015 Term Loan Facility" } } }, "localname": "TermLoanFacility2015Member", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/Debt2015TermLoanFacilityDetails" ], "xbrltype": "domainItemType" }, "amag_ThreeCustomersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Three Customers [Member]", "label": "Three Customers [Member]", "terseLabel": "Three Customers" } } }, "localname": "ThreeCustomersMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "domainItemType" }, "amag_TieredRoyaltiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tiered Royalties [Member]", "label": "Tiered Royalties [Member]", "terseLabel": "Tiered Royalties" } } }, "localname": "TieredRoyaltiesMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_TwoCustomersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Customers [Member]", "label": "Two Customers [Member]", "terseLabel": "Two Customers" } } }, "localname": "TwoCustomersMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "domainItemType" }, "amag_UnrecognizedTaxBenefitsDecreaseResultingFromTaxCutsAndJobsAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized Tax Benefits, Decrease Resulting From Tax Cuts And Jobs Act", "label": "Unrecognized Tax Benefits, Decrease Resulting From Tax Cuts And Jobs Act", "negatedTerseLabel": "Subtractions for federal tax reform" } } }, "localname": "UnrecognizedTaxBenefitsDecreaseResultingFromTaxCutsAndJobsAct", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesReconciliationOfUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "amag_VeloBioLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Velo Bio, LLC [Member]", "label": "Velo Bio, LLC [Member]", "terseLabel": "Velo Bio, LLC" } } }, "localname": "VeloBioLLCMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "amag_VyleesiProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vyleesi Products [Member]", "label": "Vyleesi Products [Member]", "terseLabel": "Vyleesi Products" } } }, "localname": "VyleesiProductsMember", "nsuri": "http://www.amagpharma.com/20191231", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description", "terseLabel": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r698", "r699", "r700" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r701" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r702" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r702" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r702" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r703" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r702" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r702" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r702" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r702" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r696" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r697" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Financial Information Disclosure [Abstract]" } } }, "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract", "nsuri": "http://fasb.org/srt/2020-01-31", "xbrltype": "stringItemType" }, "srt_CondensedFinancialStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Condensed Financial Statements, Captions [Line Items]", "terseLabel": "Condensed Financial Statements, Captions [Line Items]" } } }, "localname": "CondensedFinancialStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r83", "r145", "r707" ], "lang": { "en-US": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r162", "r173", "r257", "r458", "r459", "r460", "r500", "r501" ], "lang": { "en-US": { "role": { "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncementsNarrativeDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r162", "r173", "r257", "r458", "r459", "r460", "r500", "r501" ], "lang": { "en-US": { "role": { "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncementsNarrativeDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r162", "r173", "r257", "r458", "r459", "r460", "r500", "r501" ], "lang": { "en-US": { "role": { "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncementsNarrativeDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r238", "r384", "r389", "r674" ], "lang": { "en-US": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r412", "r415", "r599", "r600", "r601", "r602", "r603", "r604", "r623", "r672", "r675" ], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r412", "r415", "r599", "r600", "r601", "r602", "r603", "r604", "r623", "r672", "r675" ], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r238", "r384", "r389", "r674" ], "lang": { "en-US": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r236", "r384", "r387", "r624", "r671", "r673" ], "lang": { "en-US": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails", "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "http://www.amagpharma.com/role/RevenueRecognitionDisaggregatedRevenueByMajorProductsDetails", "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r236", "r384", "r387", "r624", "r671", "r673" ], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails", "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "http://www.amagpharma.com/role/RevenueRecognitionDisaggregatedRevenueByMajorProductsDetails", "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r401", "r412", "r415", "r599", "r600", "r601", "r602", "r603", "r604", "r623", "r672", "r675" ], "lang": { "en-US": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r401", "r412", "r415", "r599", "r600", "r601", "r602", "r603", "r604", "r623", "r672", "r675" ], "lang": { "en-US": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r158", "r159", "r160", "r161", "r165", "r166", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r193", "r260", "r261", "r462", "r501", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687" ], "lang": { "en-US": { "role": { "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Axis]", "terseLabel": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedBalanceSheetDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r158", "r159", "r160", "r161", "r165", "r166", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r193", "r260", "r261", "r462", "r501", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687" ], "lang": { "en-US": { "role": { "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Domain]", "terseLabel": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedBalanceSheetDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": { "auth_ref": [ "r171", "r172", "r175", "r176", "r178", "r179" ], "lang": { "en-US": { "role": { "documentation": "Cumulative increase (decrease) to previously issued financial statements for correction of error.", "label": "Revision of Prior Period, Error Correction, Adjustment [Member]", "terseLabel": "Adjustment", "verboseLabel": "Adj" } } }, "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedBalanceSheetDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r413", "r704" ], "lang": { "en-US": { "role": { "documentation": "Information reported for future period.", "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r158", "r160", "r161", "r165", "r166", "r171", "r172", "r173", "r175", "r176", "r178", "r179", "r193", "r260", "r261", "r462", "r501", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687" ], "lang": { "en-US": { "role": { "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Previously Reported [Member]", "terseLabel": "As reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedBalanceSheetDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r413" ], "lang": { "en-US": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedFinancialStatementsTable": { "auth_ref": [ "r147", "r531", "r705", "r708", "r709", "r710" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.", "label": "Condensed Financial Statements [Table]", "terseLabel": "Condensed Financial Statements [Table]" } } }, "localname": "ScheduleOfCondensedFinancialStatementsTable", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r156", "r706" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "VALUATION AND QUALIFYING ACCOUNTS" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ValuationAndQualifyingAccounts" ], "xbrltype": "textBlockItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r328", "r413", "r591" ], "lang": { "en-US": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2020-01-31", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r156", "r706" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsTextBlock": { "auth_ref": [ "r177", "r182" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.", "label": "Accounting Changes and Error Corrections [Text Block]", "terseLabel": "REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS" } } }, "localname": "AccountingChangesAndErrorCorrectionsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatements" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r576" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r165", "r166", "r167", "r169", "r254", "r255", "r256", "r257", "r260", "r261", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r500", "r501", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687" ], "lang": { "en-US": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible List]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncementsNarrativeDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "CURRENT AND LONG-TERM LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CurrentAndLongTermLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r65" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r27", "r45", "r239", "r240" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r135" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedTerseLabel": "Amortization of premium/discount on purchased securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r70" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets", "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails", "http://www.amagpharma.com/role/FairValueMeasurementsContingentConsiderationDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r63", "r305" ], "calculation": { "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r48", "r85", "r86", "r87", "r660", "r683", "r687" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r562", "r563", "r564", "r565", "r566", "r568" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r84", "r87", "r88", "r158", "r159", "r161", "r539", "r678", "r679" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLossDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r46" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r158", "r159", "r161", "r458", "r459", "r460" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r165", "r166", "r167", "r169", "r254", "r255", "r256", "r257", "r260", "r261", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r498", "r499", "r500", "r501", "r626", "r627", "r628", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687" ], "lang": { "en-US": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": { "auth_ref": [ "r344" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt", "terseLabel": "Equity component of the 2022 Convertible Notes, net of issuance costs and taxes" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments", "negatedTerseLabel": "Equity component of debt repurchase" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r417", "r419", "r465", "r466" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Non-cash equity based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r343", "r356", "r362" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Settlement of warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r468" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r469" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising costs" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r419", "r450", "r464" ], "calculation": { "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total equity-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, after Tax", "totalLabel": "After-tax effect of equity-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r111", "r134", "r571" ], "calculation": { "http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails": { "order": 3.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r103", "r134", "r573" ], "calculation": { "http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r134", "r573" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount and debt issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r134", "r288", "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive securities (shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r134", "r301" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment of assets", "verboseLabel": "Impairment of long-lived assets" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/FairValueMeasurementsNonrecurringFairValueMeasurementsDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r143", "r219", "r228", "r234", "r253", "r535", "r541", "r560", "r637", "r657" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r29", "r30", "r82", "r143", "r253", "r535", "r541", "r560" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r543" ], "calculation": { "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total Assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r248" ], "calculation": { "http://www.amagpharma.com/role/MarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "totalLabel": "Gross Unrealized Gains, total" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r249" ], "calculation": { "http://www.amagpharma.com/role/MarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTotalLabel": "Gross Unrealized Losses, total" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r246", "r268" ], "calculation": { "http://www.amagpharma.com/role/MarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost, total" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/MarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost", "totalLabel": "Amortized Cost, short-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/MarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value", "terseLabel": "Estimated Fair Value, short-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r242", "r247", "r268", "r642" ], "calculation": { "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Available-for-sale securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r244", "r268" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.amagpharma.com/role/MarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Marketable securities", "totalLabel": "Estimated Fair Value, total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets", "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r421", "r452" ], "lang": { "en-US": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]", "terseLabel": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]", "terseLabel": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r421", "r452" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails", "http://www.amagpharma.com/role/EquityBasedCompensationWeightedAverageFairValueAssumptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r411", "r414" ], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r411", "r414", "r518", "r519" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r133", "r526" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r522", "r523", "r525" ], "calculation": { "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_NonfinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r522", "r524" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Current portion of acquisition-related contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r522", "r524" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Long-term acquisition-related contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r140", "r517" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations, Asset Acquisitions and Acquisition-Related Contingent Consideration" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpenditureDiscontinuedOperations": { "auth_ref": [ "r17" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of capital expenditure attributable to discontinued operations.", "label": "Capital Expenditure, Discontinued Operations", "terseLabel": "Capital expenditures" } } }, "localname": "CapitalExpenditureDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLossCarryforwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year.", "label": "Capital Loss Carryforward [Member]", "terseLabel": "Capital Loss Carryforward" } } }, "localname": "CapitalLossCarryforwardMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r25", "r60", "r136" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r35", "r137", "r140" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r35", "r137", "r140", "r635" ], "lang": { "en-US": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r129", "r136", "r139" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the year", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r129", "r561" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r653" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r527", "r528", "r530" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Agreements" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r339" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r402", "r551" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r76", "r327", "r643", "r664" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (Note P)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r324", "r325", "r326", "r336" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r158", "r159" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r44", "r356" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r44" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.01 per share, 117,500,000 shares authorized; 33,999,081 and 34,606,760 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": { "auth_ref": [ "r399", "r400", "r416" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]", "terseLabel": "EMPLOYEE SAVINGS PLAN" } } }, "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EmployeeSavingsPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r90", "r92", "r93", "r101", "r647", "r668" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r100", "r114", "r646", "r667" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r206", "r207", "r238", "r557", "r558" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r206", "r207", "r238", "r557", "r558", "r689" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r206", "r207", "r238", "r557", "r558", "r689" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r201", "r655" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations and Significant Customer Information" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "verboseLabel": "Concentrations and Significant Customer Information" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r206", "r207", "r238", "r557", "r558" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "verboseLabel": "Concentration risk, including less than and more than 10% (percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r204", "r206", "r207", "r208", "r557", "r559" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r206", "r207", "r238", "r557", "r558" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r140", "r537" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.amagpharma.com/role/FairValueMeasurementsContingentConsiderationDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.amagpharma.com/role/FairValueMeasurementsContingentConsiderationDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractTerminationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Contract Termination [Member]", "terseLabel": "Contract termination" } } }, "localname": "ContractTerminationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RestructuringExpensesComponentsOfRestructuringExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r364", "r365", "r385" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract": { "auth_ref": [ "r366" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract", "terseLabel": "Termination payment received" } } }, "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails", "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails", "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails", "http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r74" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Convertible notes, net" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r402" ], "lang": { "en-US": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]", "terseLabel": "Convertible Debt Securities" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Schedule of outstanding convertible debt" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r402", "r409", "r688" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r107", "r624" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of product sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of product sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r104" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r144", "r494", "r507" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r144", "r494", "r507", "r509" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r144", "r494", "r507" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r205", "r238" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r39", "r40", "r41", "r638", "r639", "r656" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/Debt2015TermLoanFacilityDetails", "http://www.amagpharma.com/role/Debt2023SeniorNotesDetails", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails", "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails", "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r41", "r346", "r639", "r656" ], "calculation": { "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Principal" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r345" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Gross equity component" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r350" ], "lang": { "en-US": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Initial conversion price of convertible notes into common stock (USD per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r73", "r357", "r358", "r360" ], "lang": { "en-US": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Debt conversion ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period", "terseLabel": "Period of amortization of debt discount to interest expense using effective interest method (years)" } } }, "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Consecutive trading period" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Closing sales price of the entity's common stock that the conversion price must exceed or be equal in order for the notes to be convertible" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Trading period" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r572", "r574" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount of debt at time of issuance" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/Debt2023SeniorNotesDetails", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r554" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "verboseLabel": "Fair value of debt" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r72", "r351", "r572" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "verboseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r72" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/Debt2023SeniorNotesDetails", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/Debt2015TermLoanFacilityDetails", "http://www.amagpharma.com/role/Debt2023SeniorNotesDetails", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails", "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails", "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r74" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/Debt2015TermLoanFacilityDetails", "http://www.amagpharma.com/role/Debt2023SeniorNotesDetails", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails", "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails", "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value amount of debt instrument that was repurchased.", "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Repurchase price" } } }, "localname": "DebtInstrumentRepurchaseAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of the original debt instrument that was repurchased.", "label": "Debt Instrument, Repurchased Face Amount", "terseLabel": "Repurchased amount" } } }, "localname": "DebtInstrumentRepurchasedFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/Debt2023SeniorNotesDetails", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r74", "r146", "r357", "r359", "r360", "r361", "r571", "r572", "r574", "r654" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/Debt2015TermLoanFacilityDetails", "http://www.amagpharma.com/role/Debt2023SeniorNotesDetails", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails", "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails", "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "verboseLabel": "Debt term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/Debt2015TermLoanFacilityDetails", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r347", "r573" ], "calculation": { "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Less: debt discount and issuance costs, net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Summary of marketable securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r144", "r495", "r507" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r64", "r573" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r474", "r475" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r134", "r144", "r495", "r507", "r508", "r509" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r135" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r144", "r495", "r507" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetInterestCarryforward": { "auth_ref": [ "r492" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.", "label": "Deferred Tax Asset, Interest Carryforward", "terseLabel": "Interest expense carryforwards" } } }, "localname": "DeferredTaxAssetInterestCarryforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "auth_ref": [ "r492", "r493" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.", "label": "Deferred Tax Assets, Capital Loss Carryforwards", "terseLabel": "Capital loss carryforwards" } } }, "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 14.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Assets" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r487" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r492", "r493" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "Operating loss carryforwards, not subject to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r492", "r493" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 16.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Deferred Tax Assets, Property, Plant and Equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r490", "r492", "r493" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r492", "r493" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 13.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Equity-based compensation expense" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": { "auth_ref": [ "r492", "r493" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies", "terseLabel": "Contingent consideration" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": { "auth_ref": [ "r492", "r493" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves", "terseLabel": "Reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r486" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": { "auth_ref": [ "r492", "r493" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 11.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.", "label": "Deferred Tax Liabilities, Financing Arrangements", "negatedTerseLabel": "Debt instruments" } } }, "localname": "DeferredTaxLiabilitiesFinancingArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r492", "r493" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 12.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedTerseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r492", "r493" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails": { "order": 10.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedTerseLabel": "Property, plant and equipment depreciation" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesDeferredTaxComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r410" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Cost recognized" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EmployeeSavingsPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer matching contribution (percent)" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EmployeeSavingsPlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r134", "r303" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": { "auth_ref": [ "r17", "r134" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.", "label": "Depreciation and Amortization, Discontinued Operations", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortizationDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r134", "r217" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.", "label": "Description of New Accounting Pronouncements Not yet Adopted [Text Block]", "terseLabel": "RECENTLY ISSUED AND PROPOSED ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "DescriptionOfNewAccountingPronouncementsNotYetAdopted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RecentlyIssuedAndProposedAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r521" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology rights", "verboseLabel": "Developed technology rights" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionDisaggregatedRevenueByMajorProductsDetails", "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r384", "r387", "r388", "r389", "r390", "r391", "r392", "r393" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionDisaggregatedRevenueByMajorProductsDetails", "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r384" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregated revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r467" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "EQUITY-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r4", "r5", "r6", "r7", "r8", "r15", "r98", "r665" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 }, "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "terseLabel": "Income from discontinued operations", "totalLabel": "Income from discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax": { "auth_ref": [ "r4", "r6", "r8" ], "calculation": { "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.", "label": "Discontinued Operation, Provision for Loss (Gain) on Disposal, before Income Tax", "totalLabel": "Total costs and expenses" } } }, "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "auth_ref": [ "r5", "r6", "r7", "r8", "r15", "r20", "r476", "r506", "r513" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "terseLabel": "Income tax expense" } } }, "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]", "terseLabel": "Discontinued operations:" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember": { "auth_ref": [ "r1", "r2", "r3" ], "lang": { "en-US": { "role": { "documentation": "Component or group of components classified as held-for-sale or disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]", "terseLabel": "Discontinued Operations, Held-for-sale or Disposed of by Sale" } } }, "localname": "DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsNarrativeDetails", "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails", "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsNarrativeDetails", "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails", "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsNarrativeDetails", "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails", "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r16", "r23" ], "calculation": { "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of services" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "auth_ref": [ "r16" ], "calculation": { "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "auth_ref": [ "r16" ], "calculation": { "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "terseLabel": "Operating income" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "auth_ref": [ "r16", "r23" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Service revenues, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r24", "r311" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "DISCONTINUED OPERATIONS" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r411", "r414" ], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsNarrativeDetails", "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails", "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic and diluted earnings per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r189" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted net loss per share (in dollars per share)", "totalLabel": "Total (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails", "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "verboseLabel": "Basic and diluted earnings per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r140", "r191", "r192" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Earnings per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r477" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r477", "r510" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory U.S. federal tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r477", "r510" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r477", "r510" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Impact of 2017 tax reform on deferred tax balance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r477", "r510" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "terseLabel": "Other permanent items, net" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "auth_ref": [ "r477", "r510" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 10.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent", "terseLabel": "In-process research and development" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r477", "r510" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent", "terseLabel": "Equity-based compensation expense" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent", "terseLabel": "Other, net" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r477", "r510" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r477", "r510" ], "calculation": { "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "negatedLabel": "Tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r70" ], "calculation": { "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Salaries, bonuses, and other compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Equity-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r451" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Compensation cost not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r451" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Compensation expense, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r451" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Fair value, performance- based RSUs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r451" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Compensation cost not yet recognized, associated with stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r450" ], "calculation": { "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "negatedLabel": "Income tax effect" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Workforce reduction" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RestructuringExpensesComponentsOfRestructuringExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Shares of common stock under employee stock purchase plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r448" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Options to purchase shares of common stock", "verboseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails", "http://www.amagpharma.com/role/EquityBasedCompensationWeightedAverageFairValueAssumptionsStockOptionActivityDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Laboratory and production equipment", "verboseLabel": "Laboratory and production equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r158", "r159", "r161", "r166", "r176", "r179", "r197", "r257", "r356", "r362", "r458", "r459", "r460", "r500", "r501", "r562", "r563", "r564", "r565", "r566", "r568", "r678", "r679", "r680" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLossDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedBalanceSheetDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair value of assets and liabilities measured on a recurring basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r543", "r544", "r545", "r552" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Debt" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r543", "r555", "r556" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r544", "r596", "r597", "r598" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r551", "r552" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r543", "r544", "r547", "r548", "r553" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r551" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r402", "r403", "r408", "r409", "r544", "r596" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r402", "r403", "r408", "r409", "r544", "r597" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r544", "r598" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r549" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r549", "r552" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r550" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Adjustments to fair value of contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r596", "r597", "r598" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r551", "r553" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair value, measurements, recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r250", "r251", "r262", "r264", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]", "terseLabel": "Assets:" } } }, "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Expected useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r295" ], "calculation": { "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 }, "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetailsCalc2": { "order": 3.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Life to Date Accumulated Amortization", "verboseLabel": "Life to Date Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r297" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "verboseLabel": "Expect amortization expense related to finite-lived intangible assets during the next 12 months" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r289", "r291", "r295", "r298", "r625", "r632" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": { "auth_ref": [ "r543" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-lived Intangible Assets, Fair Value Disclosure", "terseLabel": "Fair value of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsNonrecurringFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r295", "r632" ], "calculation": { "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r289", "r294" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r295", "r625" ], "calculation": { "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Fair value of intangible asset", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r290" ], "calculation": { "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails": { "order": 2.0, "parentTag": "amag_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures", "verboseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r134", "r302", "r307" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "negatedLabel": "(Gain) loss on disposal of fixed assets" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "auth_ref": [ "r134" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.", "label": "Gain (Loss) on Disposition of Intangible Assets", "terseLabel": "Gain on sale of assets" } } }, "localname": "GainLossOnDispositionOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r134", "r540" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "negatedTerseLabel": "Gain on sale of the CBR business", "terseLabel": "Gain on sale of CBR business" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/DiscontinuedOperationsNarrativeDetails", "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r134", "r353", "r354" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on debt extinguishment", "negatedTerseLabel": "Loss on debt extinguishment", "terseLabel": "Loss on debt extinguishment", "verboseLabel": "Gain (loss) on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/Debt2015TermLoanFacilityDetails", "http://www.amagpharma.com/role/Debt2023SeniorNotesDetails", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r278", "r280", "r636" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND INTANGIBLE ASSETS, NET" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r140", "r284" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r140", "r292" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r281", "r283" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Accumulated impairment losses" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r134", "r279", "r282", "r285" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill, impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r105", "r143", "r219", "r227", "r230", "r233", "r235", "r253", "r560" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r134", "r299" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r106", "r135", "r171", "r172", "r173", "r174", "r188", "r190", "r532" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net loss from continuing operations", "totalLabel": "Net loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r97", "r219", "r227", "r230", "r233", "r235", "r633", "r644", "r649", "r669" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss from continuing operations before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasicAndDiluted", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share", "terseLabel": "Loss from continuing operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r4", "r5", "r6", "r7", "r8", "r15", "r20", "r533" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net income from discontinued operations", "totalLabel": "Net income from discontinued operations", "verboseLabel": "Net income (loss) from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasicAndDiluted", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share", "terseLabel": "Income from discontinued operations (in dollars per share)", "verboseLabel": "Income (loss) from discontinued operations (in dollars per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r411", "r414" ], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsNarrativeDetails", "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails", "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsNarrativeDetails", "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r0", "r9", "r10", "r11", "r12", "r13", "r14", "r18", "r21", "r22", "r23", "r309", "r310" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsNarrativeDetails", "http://www.amagpharma.com/role/DiscontinuedOperationsSummaryOfNetIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r479" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r478", "r484", "r489", "r505", "r511", "r514", "r515", "r516" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r144", "r178", "r179", "r218", "r476", "r506", "r512", "r670" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 }, "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "totalLabel": "Total income tax (benefit) expense", "verboseLabel": "Income tax (benefit) expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails", "http://www.amagpharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseBenefitDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r94", "r140", "r472", "r473", "r484", "r485", "r488", "r496", "r692" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r138" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash (refunded) paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r133" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r133" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r133" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenues" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r133" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r133" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedTerseLabel": "Other assets and liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r133" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r185", "r186", "r187", "r190" ], "calculation": { "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Stock options and RSUs (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails": { "order": 4.0, "parentTag": "amag_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.", "label": "Indefinite-lived Intangible Assets Acquired", "terseLabel": "In process research and development acquired", "verboseLabel": "IPR&D" } } }, "localname": "IndefinitelivedIntangibleAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails", "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Cost" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r287", "r293" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Total" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]", "terseLabel": "Total intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r96", "r216", "r570", "r573", "r648" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r111", "r352" ], "calculation": { "http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "totalLabel": "Total interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r113" ], "calculation": { "http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Contractual interest expense" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Schedule of total interest expense recognized related to the convertible notes" } } }, "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r126", "r130", "r138" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r32", "r33", "r70" ], "calculation": { "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Interest expense" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r52", "r276" ], "calculation": { "http://www.amagpharma.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r26", "r80" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.amagpharma.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets", "http://www.amagpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r34", "r81", "r140", "r194", "r273", "r275", "r277" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r54", "r276" ], "calculation": { "http://www.amagpharma.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r53", "r276" ], "calculation": { "http://www.amagpharma.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r274" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Write-down of inventory" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r109" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Interest and dividend income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments [Abstract]", "terseLabel": "Total investments" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r252", "r634", "r652", "r690" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "MARKETABLE SECURITIES" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/MarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r586", "r588" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease cost for operating leases" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r580" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r587" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Maturity schedule by fiscal year, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r587" ], "calculation": { "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r587" ], "calculation": { "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r587" ], "calculation": { "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Year Ending December 31, 2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r587" ], "calculation": { "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "Year Ending December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r587" ], "calculation": { "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Year Ending December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r587" ], "calculation": { "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Year Ending December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r587" ], "calculation": { "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Year Ending December 31, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r587" ], "calculation": { "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r581" ], "lang": { "en-US": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining operating lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r69", "r143", "r229", "r253", "r536", "r541", "r542", "r560" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r51", "r143", "r253", "r560", "r641", "r662" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r71", "r143", "r253", "r536", "r541", "r542", "r560" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r67" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/Debt2015TermLoanFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/Debt2015TermLoanFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Settlement awarded to other party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r41", "r348", "r639", "r658" ], "calculation": { "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Net carrying amount" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails", "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Long-term Debt, Unclassified [Abstract]", "terseLabel": "Liability component:" } } }, "localname": "LongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r68" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of convertible notes, net", "verboseLabel": "Less: current maturities" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets", "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r148", "r340" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "Future annual principal payments on long-term debt due year ended December 31, 2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtFuturePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r74" ], "calculation": { "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of current maturities" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Long-term Investments [Abstract]", "terseLabel": "Long-term investments:" } } }, "localname": "LongTermInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r74" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/Debt2015TermLoanFacilityDetails", "http://www.amagpharma.com/role/Debt2023SeniorNotesDetails", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails", "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails", "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails", "http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r74", "r341" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/Debt2015TermLoanFacilityDetails", "http://www.amagpharma.com/role/Debt2023SeniorNotesDetails", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails", "http://www.amagpharma.com/role/DebtOutstandingConvertibleNoteBalancesDetails", "http://www.amagpharma.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "http://www.amagpharma.com/role/DebtScheduleOfTotalInterestExpenseRecognizedRelatedToConvertibleNotesDetails", "http://www.amagpharma.com/role/FairValueMeasurementsDebtDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r327", "r328", "r329", "r331", "r332", "r333", "r335", "r337", "r338" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Commitments" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r327", "r328", "r329", "r331", "r332", "r333", "r335", "r337", "r338" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r327", "r330", "r334" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Damages sought by plaintiff" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyLossInPeriod": { "auth_ref": [ "r327" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.", "label": "Loss Contingency, Loss in Period", "terseLabel": "Failure to supply, penalties" } } }, "localname": "LossContingencyLossInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r327", "r328", "r329", "r331", "r332", "r333", "r335", "r337", "r338" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Number of class action lawsuits filed" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNumberOfDefendants": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of defendants named in a legal action.", "label": "Loss Contingency, Number of Defendants", "terseLabel": "Number of other pharmaceutical companies named as defendants" } } }, "localname": "LossContingencyNumberOfDefendants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MarketableSecuritiesGainLoss": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Gain (Loss)", "negatedLabel": "(Gain) loss on sale of marketable securities, net" } } }, "localname": "MarketableSecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r651" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputControlPremiumMember": { "auth_ref": [ "r546" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using amount above fair value that investor seeking to acquire control of entity will pay.", "label": "Measurement Input, Control Premium [Member]", "terseLabel": "Measurement Input, Control Premium" } } }, "localname": "MeasurementInputControlPremiumMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r546" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "Valuation Allowance for Impairment of Recognized Servicing Assets [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r198", "r212" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "DESCRIPTION OF BUSINESS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r129" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r129" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r129", "r131", "r135" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r23", "r89", "r91", "r99", "r135", "r143", "r165", "r171", "r172", "r173", "r174", "r178", "r179", "r188", "r219", "r227", "r230", "r233", "r235", "r253", "r560", "r645", "r666" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.amagpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails", "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r163", "r164", "r167", "r168", "r180", "r181", "r182", "r258", "r259", "r394", "r395", "r396", "r397", "r461", "r502", "r503", "r504", "r629", "r630", "r631", "r682", "r683", "r684", "r685", "r687" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "verboseLabel": "RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncementsNarrativeDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r162", "r165", "r166", "r167", "r169", "r170", "r173", "r193", "r254", "r255", "r256", "r257", "r260", "r261", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r498", "r499", "r500", "r501", "r626", "r627", "r628", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncementsNarrativeDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued and Proposed Accounting Pronouncements and Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonfinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.", "label": "Nonfinancial Liabilities Fair Value Disclosure", "totalLabel": "Total Liabilities" } } }, "localname": "NonfinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r110" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAndLoansReceivableGrossCurrent": { "auth_ref": [ "r27", "r28", "r78", "r240" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allowance for credit loss, of financing receivable, classified as current.", "label": "Financing Receivable, before Allowance for Credit Loss, Current", "terseLabel": "Note receivable" } } }, "localname": "NotesAndLoansReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of business segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBusinessSegmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r87", "r95" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r219", "r227", "r230", "r233", "r235" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r578" ], "calculation": { "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.amagpharma.com/role/CommitmentsAndContingenciesOperatingLeasesFiscalYearMaturityScheduleDetails", "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r578" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r578" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r579", "r582" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash outflows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r577" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.amagpharma.com/role/ConsolidatedBalanceSheets", "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r585", "r588" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average operating lease discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r584", "r588" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average operating lease remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r575" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases, Rent Expense, Net", "terseLabel": "Lease cost for operating leases" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r490" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r64" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "terseLabel": "Out-of-pocket expenses (up to)" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r533", "r534", "r538" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Holding gains (losses) arising during period, net of tax", "verboseLabel": "Unrealized gains (losses) on securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Unrealized (losses) gains on marketable securities:" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r75" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r112" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestructuringMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring and related activities classified as other.", "label": "Other Restructuring [Member]", "terseLabel": "Other" } } }, "localname": "OtherRestructuringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RestructuringExpensesComponentsOfRestructuringExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.", "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings", "terseLabel": "Other-than-temporary impairment losses" } } }, "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r123" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedLabel": "Payment of contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": { "auth_ref": [ "r127" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Operating Activities", "negatedTerseLabel": "Payment of contingent consideration in excess of acquisition date fair value" } } }, "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForHedgeFinancingActivities": { "auth_ref": [ "r125", "r132" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.", "label": "Payments for Hedge, Financing Activities", "verboseLabel": "Proceeds used to pay the cost of the bond hedges (after such cost was partially offset by proceeds from the sale of warrants)" } } }, "localname": "PaymentsForHedgeFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r120" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Payments for repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r128", "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RestructuringExpensesComponentsOfRestructuringExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r124" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "negatedTerseLabel": "Payment of premium on debt extinguishment", "terseLabel": "Payment of premium on debt extinguishment", "verboseLabel": "Payment for debt extinguishment" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/Debt2023SeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r122" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Payment of convertible debt issuance costs", "terseLabel": "Payment of convertible debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r120" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Payments of employee tax withholding related to equity-based compensation" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r117" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Acquisition of intangible asset" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r243" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireNotesReceivable": { "auth_ref": [ "r116" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Payments to Acquire Notes Receivable", "negatedTerseLabel": "Note receivable" } } }, "localname": "PaymentsToAcquireNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r117" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r421", "r452" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r43" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, par value $0.01 per share, 2,000,000 shares authorized; none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r29", "r58", "r59" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r119" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from 2022 Convertible Notes", "verboseLabel": "Net proceeds from issuance of convertible debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r115" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from the sale of the CBR business" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sales or maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r118", "r453" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the exercise of common stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r118" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from the issuance of common stock under the ESPP" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]", "terseLabel": "Other revenues" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product sales, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/RevenueRecognitionDisaggregatedRevenueByMajorProductsDetails", "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails": { "order": 3.0, "parentTag": "amag_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Additions", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentAdditions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsAssetsAcquiredAndLiabilitiesAssumedRelatedToAssetAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r63", "r306" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r311", "r693", "r694", "r695" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT, NET" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/PropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r62", "r304" ], "calculation": { "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r36", "r37", "r306", "r663" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets", "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r61", "r140", "r306", "r693", "r694" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r36", "r306" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property equipment, net", "verboseLabel": "Schedule of property and equipment estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/PropertyAndEquipmentNetTables", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r36", "r304" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r102", "r263" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "auth_ref": [ "r42", "r640", "r659" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Remaining minimum purchase commitments" } } }, "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r196" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesReconciliationOfUncertainTaxPositionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r121" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of Convertible Debt", "negatedTerseLabel": "Payments to repurchase 2019 Convertible Notes", "terseLabel": "Repayments of convertible debt" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/DebtConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfMediumTermNotes": { "auth_ref": [ "r121" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.", "label": "Repayments of Medium-term Notes", "negatedLabel": "Long-term debt principal payments" } } }, "localname": "RepaymentsOfMediumTermNotes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r470" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r140", "r470" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Acquired in-process research and development" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r31", "r38", "r139", "r691" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs", "verboseLabel": "Shares of common stock issuable upon the vesting of RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "RESTRUCTURING EXPENSES" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RestructuringExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of positions eliminated during the period as a result of restructuring activities.", "label": "Restructuring and Related Cost, Number of Positions Eliminated", "terseLabel": "Employees displaced through workforce reduction" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RestructuringExpensesDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "integerItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r134", "r312", "r317", "r321" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring expenses", "verboseLabel": "Restructuring charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/RestructuringExpensesComponentsOfRestructuringExpensesDetails", "http://www.amagpharma.com/role/RestructuringExpensesDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesMember": { "auth_ref": [ "r314", "r317", "r322" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.", "label": "Restructuring Charges [Member]", "terseLabel": "Restructuring Charges" } } }, "localname": "RestructuringChargesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RestructuringExpensesComponentsOfRestructuringExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RestructuringExpensesComponentsOfRestructuringExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r313", "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance accrued at December 31, 2019", "periodStartLabel": "Balance accrued at December 31, 2018" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RestructuringExpensesComponentsOfRestructuringExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveCurrent": { "auth_ref": [ "r312", "r320" ], "calculation": { "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Current", "terseLabel": "Restructuring expense" } } }, "localname": "RestructuringReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RestructuringExpensesComponentsOfRestructuringExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r47", "r362", "r462", "r661", "r682", "r687" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Increase to accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedBalanceSheetDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r158", "r159", "r161", "r166", "r176", "r179", "r257", "r458", "r459", "r460", "r500", "r501", "r678", "r680" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r214", "r215", "r226", "r231", "r232", "r236", "r237", "r238", "r383", "r384", "r624" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues", "totalLabel": "Product sales, net", "verboseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails", "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfUnauditedConsolidatedQuartelyFinancialDataDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/RevenueRecognitionDisaggregatedRevenueByMajorProductsDetails", "http://www.amagpharma.com/role/RevenueRecognitionTotalGrossProductDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r206", "r238" ], "lang": { "en-US": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue from Contract with Customer" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesCustomersWhoRepresent10OrMoreOfTotalRevenuesOrAccountsReceivableBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r141", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r398" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r386", "r398" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE RECOGNITION" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r583", "r588" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Product revenue allowance and accrual activity" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CurrentAndLongTermLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r87", "r567", "r568" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of changes in accumulated other comprehensive loss associated with unrealized (losses) gains on securities" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of anti-dilutive securities from computation of diluted net (loss) income per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r529" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r496" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of income tax (benefit) expense" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of outstanding debt obligations" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r487" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of components of the entity's deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r0", "r9", "r10", "r11", "r12", "r13", "r14", "r18", "r21", "r22", "r23", "r309", "r310" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Discontinued operations held for sale" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/DiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of components of basic and diluted net income (loss) per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of the statutory U.S. federal income tax rate to the entity's effective income tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r419", "r449", "r464" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r419", "r449", "r464" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of equity-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "auth_ref": [ "r160", "r171", "r172", "r175", "r176", "r178", "r179", "r193" ], "lang": { "en-US": { "role": { "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.", "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]", "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedScheduleOfEffectsOfCorrectionsAndPriorPeriodAjustmentsDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedBalanceSheetDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsCondensedConsolidatedStatementsOfOperationsDetails", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "auth_ref": [ "r177", "r178", "r179" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.", "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "terseLabel": "Schedule of effects of corrections and prior period adjustments" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedTables", "http://www.amagpharma.com/role/RevisionOfPriorPeriodFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r543", "r544" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r289", "r294", "r625" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetIntangibleAssetsNarrativeDetails", "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r289", "r294" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of amortizable intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r284", "r286" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r34", "r55", "r56", "r57" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of major classes of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r63", "r306" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/PropertyAndEquipmentNetDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of unaudited consolidated quartely financial data" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedQuarterlyFinancialDataUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r520" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "verboseLabel": "Summary of assets acquired and liabilities assumed related to the asset acquisition" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r315", "r316", "r319" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RestructuringExpensesComponentsOfRestructuringExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r313", "r320" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of components of restructuring expenses and current liabilities" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RestructuringExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r421", "r452" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails", "http://www.amagpharma.com/role/EquityBasedCompensationWeightedAverageFairValueAssumptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r427" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of details regarding restricted stock units granted under equity incentive plans" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r427", "r437", "r440" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of details regarding stock options granted under equity incentive plans" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of share-based payment award, stock options, valuation assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r483", "r497" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Summary of income tax contingencies" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r204", "r206", "r207", "r208", "r557", "r559" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedule of customers representing greater than 10% of revenues/accounts receivable balances" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r140", "r220", "r221", "r222", "r223", "r224", "r225", "r237" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Business Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r108" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/Debt2023SeniorNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Collaboration revenue" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r133" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Non-cash equity-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r422" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r431" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Expired or terminated (in shares)", "negatedTerseLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeitures (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r434" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r434" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)", "verboseLabel": "RSUs granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r433" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at end of year (shares)", "periodStartLabel": "Outstanding at beginning of year (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Stock Units", "verboseLabel": "Restricted Stock Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r433" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "verboseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r435" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r439" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Value of RSUs vested during period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r435" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r446" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationWeightedAverageFairValueAssumptionsStockOptionActivityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r445" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility (%)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationWeightedAverageFairValueAssumptionsStockOptionActivityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r447" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate (%)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationWeightedAverageFairValueAssumptionsStockOptionActivityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Equity compensation plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails", "http://www.amagpharma.com/role/EquityBasedCompensationWeightedAverageFairValueAssumptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional common stock for issuance (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r424" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r452" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Remaining number of shares available for future grants (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Stock Option Activity, Additional Disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r439" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Value of options exercised in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r432" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Expired and/or forfeited (shares)", "negatedTerseLabel": "Expired or terminated (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r432" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired and/or forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r438" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Options granted in period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r452" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding at end of year" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r429", "r452" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (shares)", "periodStartLabel": "Beginning balance (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options", "verboseLabel": "Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r428" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r442" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable at end of year" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r442" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Exercisable at end of year (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r442" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of year (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r440" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding at end of year, vested and unvested expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r441" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Outstanding at end of year - vested and unvested expected to vest (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r441" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Outstanding at end of year - vested and unvested expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r418", "r425" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfRsusGrantedDetails", "http://www.amagpharma.com/role/EquityBasedCompensationWeightedAverageFairValueAssumptionsStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r140", "r421", "r426" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Equity-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/GoodwillAndIntangibleAssetsNetGoodwillNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Offering period term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r444", "r463" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected option term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationWeightedAverageFairValueAssumptionsStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r441" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r442" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable at end of year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r441" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding at end of year - vested and unvested expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Options vested in period (shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price per share as a percentage of fair market value of common stock on the first or last day of the plan period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Short-term Investments [Abstract]", "terseLabel": "Short-term investments:" } } }, "localname": "ShortTermInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r77", "r158", "r159", "r161", "r166", "r176", "r179", "r197", "r257", "r356", "r362", "r458", "r459", "r460", "r500", "r501", "r562", "r563", "r564", "r565", "r566", "r568", "r678", "r679", "r680" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLossDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r158", "r159", "r161", "r197", "r624" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r43", "r44", "r356", "r362" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)", "verboseLabel": "Shares issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.amagpharma.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Shares issued in connection with Endoceutics License Agreement (in shares)", "verboseLabel": "Number of shares issued under arrangement" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r43", "r44", "r356", "r362" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r43", "r44", "r356", "r362", "r430" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/EquityBasedCompensationActivityRelatedToPlansDetails", "http://www.amagpharma.com/role/EquityBasedCompensationScheduleOfStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r43", "r44", "r356", "r362" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Value, Purchase of Assets", "terseLabel": "Shares issued in connection with Endoceutics License Agreement", "verboseLabel": "Fair value of common stock issued in connection with the acquisition of the Intrarosa intangible asset" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CollaborationLicenseAndOtherStrategicAgreementsDetails", "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows", "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r43", "r44", "r362", "r420", "r438" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Share repurchase program, authorized amount (in shares)" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Available for repurchase of shares" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r43", "r44", "r356", "r362" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Stock Repurchased and Retired During Period, Shares", "negatedTerseLabel": "Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program (in shares)", "verboseLabel": "Common stock repurchased and retired (in shares)" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.amagpharma.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r43", "r44", "r356", "r362" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program", "verboseLabel": "Stock repurchased and retired during period, value" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.amagpharma.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r43", "r44", "r356", "r362" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Repurchase of common stock pursuant to the share repurchase program (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r43", "r44", "r356", "r362" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchase of common stock pursuant to the share repurchase program" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r44", "r49", "r50", "r143", "r241", "r253", "r560" ], "calculation": { "http://www.amagpharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Cumulative effect of new accounting principle in period of adoption", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/AccumulatedOthercomprehensiveLossDetails", "http://www.amagpharma.com/role/ConsolidatedBalanceSheets", "http://www.amagpharma.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncementsNarrativeDetails", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r142", "r362", "r363" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r569", "r590" ], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r569", "r590" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r569", "r590" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r569", "r590" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.amagpharma.com/role/SubsequentEventsUnauditedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r589", "r592" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS (unaudited)" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SubsequentEventsUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental data of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r490" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward, amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r491" ], "lang": { "en-US": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Tax Credit Carryforward [Line Items]", "terseLabel": "Tax Credit Carryforward [Line Items]" } } }, "localname": "TaxCreditCarryforwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r491" ], "lang": { "en-US": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCreditCarryforwardTable": { "auth_ref": [ "r491" ], "lang": { "en-US": { "role": { "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Tax Credit Carryforward [Table]", "terseLabel": "Tax Credit Carryforward [Table]" } } }, "localname": "TaxCreditCarryforwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r250", "r251", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r165", "r166", "r167", "r169", "r254", "r255", "r256", "r257", "r260", "r261", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r498", "r499", "r500", "r501", "r626", "r627", "r628", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687" ], "lang": { "en-US": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.amagpharma.com/role/RecentlyAdoptedAccountingPronouncementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Indicates type of cost from product sold and service rendered.", "label": "Cost, Product and Service [Extensible List]", "terseLabel": "Cost, Product and Service [Extensible List]" } } }, "localname": "TypeOfCostGoodOrServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "extensibleListItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/RestructuringExpensesComponentsOfRestructuringExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r402", "r650", "r688" ], "lang": { "en-US": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "U.S. treasury and government agency securities" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.amagpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r471", "r480" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits at the end of the year", "periodStartLabel": "Unrecognized tax benefits at the beginning of the year" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesReconciliationOfUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r481" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Subtractions for tax positions from prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesReconciliationOfUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r482" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions based on tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesReconciliationOfUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r481" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions for tax positions from prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesReconciliationOfUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "auth_ref": [ "r480" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.", "label": "Unrecognized Tax Benefits, Period Increase (Decrease)", "terseLabel": "Increase (decrease) in unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r199", "r200", "r202", "r203", "r209", "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates and Assumptions" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r487" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]", "terseLabel": "Valuation allowance for deferred tax assets" } } }, "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r149", "r154" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance at Beginning of Period" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r152" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Additions" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r153" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedTerseLabel": "Deductions Charged to Reserves" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r149", "r150", "r151", "r153", "r154" ], "lang": { "en-US": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r149", "r150", "r151", "r153", "r154" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r184", "r190" ], "calculation": { "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Shares used in calculating dilutive net loss per share (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r183", "r190" ], "calculation": { "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding (in shares)", "verboseLabel": "Weighted average shares outstanding used to compute earnings per share (basic and diluted) (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amagpharma.com/role/ConsolidatedStatementsOfOperations", "http://www.amagpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 13 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(ee)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3581-108585" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(ColumnA))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r24": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=SL6284422-111562" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r300": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(c))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r336": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r355": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r363": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r398": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r399": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r416": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r467": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r516": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5283-111683" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r592": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r634": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803" }, "r652": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r696": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r697": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r698": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r699": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r701": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r702": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r703": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r704": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03" }, "r705": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "a", "Publisher": "SEC", "Section": "12", "Subsection": "04" }, "r706": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r707": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r708": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "c", "Publisher": "SEC", "Section": "5", "Subparagraph": "Schedule I", "Subsection": "04" }, "r709": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "c", "Publisher": "SEC", "Section": "7", "Subparagraph": "Schedule II", "Subsection": "05" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "9", "Subsection": "06" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a),(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 136 0000792977-20-000090-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000792977-20-000090-xbrl.zip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Μ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�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

D=[X&G]OF2IQ VMS&GF\AU/Z;M^ M[.O0E(OICHISW-EIMI_X3;R6Y'-REK"S.9\2#\='"@QC7&L?3.'Y:&(3B45W M443*![W@'"XIIZ79PDEN;IP]328MBAS/[].--:K&T<.Z:&+\#\$-0]; .V-7 M&U4B%=!V'; />4-8I73_E+7//W[3A^#KM^E&]F+/_ MT6Z:Y2W&W=@N#F+5L*YT"_.#\L)\@837 !XMN7T(B9E !70:!?VA O#W0)3D M^?%,>(LF">R'@4QL=;PQZ_O3Z^E6//MIX?-*;9P",*H,&.LWZ733J*BMZDW? M,]:-PM^=]X4*M%TDW(OT30\<]**,C>56"*F<2!(+\\)J?(F6K4)<976JD,@ MBXSN>7\/L=LQB-?MIL7K]W?R(@\M'VJW+CXHXGE\[F=UALRG5.'GW0NGK+H4XN2]^EL+G9FR+9JE7V:@!ZNA^ ,U&'A+>E'A:IJ"]U)I\,M5,3 M7!I?SN0,EV\FH.U>:_/90C&>_>3M!X$ZI&)Y"XSB#7"Q,A M;&& (B[@/,VR0?#99EL M\L)H\Y[0&H!X]R<[< ZB:B/IT1Y?$YA 2S#1YP0G*N"%"^C0>B4 IO/5N#=_L$!-:,TD22%@1TFDNGBL MX.%]/X[!X$07O/NNRH]"&SX<3_@'KP\*$8\JVCKYMV( 8UHPKE+G:QTJTOU>3 MIS[Y65?%9,M/)03N?*]6&_^>*2XPGF_:?0!O<:;<:%&.3U?H4HK]=4.VN^RC M!Q7PL&@KBD37R#$BB=YJ0)Y>1Z%B#&=Z@($P+QJF3':]R08[8>?;%/0ASRX) MY99^N.C^47TE6/[!9^YK'.^6/OH#0TBZBX$ZG11!]%A5T58LV'14"!I=_W/: M*[';/W'BWU=;!QASZUL()'>$!N21F$,6!)! N.O.5=%;+K*0RZSCWDH75,RN M*^[;"7]?2WO%8%#6#?\P_M&7N=EBO@/,8>;KT^;OUHDJ<75?F9YJ_NEXY/B0 ME<6S_S4+8R+D!_K'\3;"GGB;!$1HFM\X;N=,DYBK@16%9BR]DM>8_X5(LMKW M$Z:/R!4UOS&Y'5&OL:27%=7^L=1T"=R:!HP%79638IJ_%^O.?+>/[8WELX:< MD/59#8_XN;I"#A]&4Q69BQJLCWU?/O7+E%T**;YQ5DM#7'VX1]BP[( M<4W>@1:X5,@UMFNDE^8Q,-1E?#L^QUD$,8>WJ*F7>>F'Q^&J-NPLK=4$+Y)7(GT"/NZ'0-FXF]'@ MH1=F_!+'*_Q[FEWU,@Z11T)-K_[-HKLM0.ATEV8M9E-,<+*NJ9[=M5!+[N6[ M/#&_PX2)D;SWOY(=(!,9C%@GO(TE.2\2L5>4,WHM+TE ^ MN=E[<$DD"^VL?!!,SJ9U1BC$=PBP%] M;.FNF5UQV60@'BFC_[@:HP87X7T7,ZWF,?=P7&7\;;5'S2Y&*078/AN.(5&2 MT(N!;E[6W?-+QUQVB0!.Y75:@M0FZJ)VJ62PI45"UW,/&+Z?G\.!)C MFF4]SN!Y_8$0KAC&"3V^>UP(VBU-V1/.VJ]??V-71!2!H)ZL,S'X:H"Q3*&5 M9#:M&AU=!9T:':BS:8YS"-UF0(*?L%!E?A:ZWF4X5E'LM8F6N6"YSC^(K[1^ M*3[;,(]OQ.(S%^.2[LJ6^Z:*OJG-/<.S&:+RQB5?S6%547,0F MO4Y\:\PO4EVCK55$$52W*C=0AN(%"29-3.2O,.ZZKG"[864U)S>^ 7R17-R^ MT$$.OP?_ZP>:>W_&R_.G1++*?WE.F0==3;Z4/++$/O]T7DQ[=]:ZZE*B9V*B MRC]D-(7;-[H+>4/ERLRZOV1!D6HV(62@*6&(CF^R:\TB?5=CEEV=9BO^&442 M1(_;&N&+D&;RU:ZV.OG<4ILGBQ?JM5MV$BB7XMJWP]NP2!$ 8QB2G+,;Z!PJ; M Z>2PURDUIPO,'B&_,K7Y_OJ+2V5&YA3\I..<5^FNT."-4RC3?'9]RJ_!=,[ M8K5-3Q-BK$S%H23M\0/3S?M)N;(_ZX!W28\(^L6^X91+8$RCI_O5.8BOS<,K MWVH;$X;[RDWW=P$F F[]YK['K,#M-UAB![#"O6N>V_>J&YM98O/]#VL&?ZI M E7%5][!LDCOM*4+^E6<0=.L1ZRLJX,+7Q_>\>P3-4HHV,DS.753S/^5MGU)"])KNW[@*3OVA<;NSI3RYY:6R(QC'[?9QGD3HR)M_!20+ MS+8<"PKVXA$VKA_VCO5\D.Z*G[KQ9W*Z:_\]?^ ?F=M! :WB VA7($$X*;P- M'O:1$())KXF28V)UK@MM;+_YV_L8%9%@>QAG R,JV1@$7+1Q3_T=WIGN@?< MZ4I?=46FEEOZ'QGU33_&G(60/R$090K-5UQHL,TEV6,A'8ASSCN+UD]:\]W< M*_,G[E2HIMS^Z"31GB!Z.9G#@(YQ:2/JPHSX7'_Y?;\,ADWOU6$]:4,3 \,0 M@YCDV%?5574CS#5J8B-V;8VZN M'3N+2>&]7$<& 4NO.;I>CO]2X224X-Y@CK>/A%O-59@("0?MUR9ULJ9=]:_@ MSS/0GPM[I-S$^N,JMO&B>#>J)I]?UNFKQ!%)N],6=R/;,'XX,2IZ-<3'=4CO M]T.CY,(]#\.27S\MZN97_=RWW;&/M_ !!+HL7_?G\0*C_ >2*%CU++?GKXXH MT5T6VS&_FQ*8O?E\ M9E9F:K;=/HGN68>6X>95Z/2 MDAA3_F$P\0EQ4MN/08Q=FFS^476Y!8#V+YG M(/@+W X<-G<;"]D!X@;TQV1UP<]^C,N-(<&U/]]U\6S#H0UN@XG'8>-/XB=# M_?-V[+$V[E,,"VP1RA)0@==S\^H)4PWA%]?4^'Z]1[PP!PA70P?S43)2&)@\ MEVB&KOR:7M#@@_6I E%M'3!.-CK)<6WG_@8!R ^3(Q=1A&%"!.]<@HX) ;BD M:]C.>275I>=AULW*NNN2[6_XBH1O,28Y&O8P,+ >:7SP#DB'MTZY':W$3#G, MKN08#CB)]B7'=7-DNWL+%!RS?NNM'TNNZBZ'V9Q5Z6\2,_Z6$&.43?]/=7V4 MGMZ4/ 5C5,#AFH3X#'=#ATX=[US'H3%=(?:#1RE8MX:]?*C%I^OE+1RW\B$R MWUY$+?#Z?3*]3E2EM*.Q SZ4R[B\5K)4QWU\0=96V<.=E"G>4\>:J3YKU66 MH2T=*O7B!L1UT(;7";,+011%M"]R>1?^DH[9_EFP+Y*?_U:KD^)6GZK!*I++ M6KXQ$S<%KYS6X"L2B7]"[RW6QI_)\#$P%I9$-'')N(M%[OS$,/$XJS#@&**+ M91_>ZN*;>/RVOF:*^17IVH4;YSO%MU+%YQ:Y8QUKG9][\RAPM+IJ"8U\VZWT ML3R6SC6,GQM7#E]@V&%:W(O.D&H8/MH+I?!A==,;O]3JS*H>< ^YJ^V'_U)Y M>>]5(\NX&O$Q21\WE3#%WU:+9^^\+);2\DRL=.EG3VN^4-,TRWN/ M+1TK&*@-/5DEOB@VZNTZYM*OJZZP8E4@TB%0W.2V.6DL=I"34*X*>5]S>C63 M-U-E1\& ]Y\A%BK@:>(:UP X!=F*AB%DSX1 =#G,.H ?YM@)/$M(;KTRYZ:+ MN+?Y-.FE]L#/>C(QBFP-^^9X\!)HWL])4^EEM]_;>P\N,K"_A M-U+)TB@V9F7^.XWQ]U)2[9@M!!1A[N++>-\4],S6/P1TW=2,@M M/Z43V]G)W!=&5^N??@@31*NP/:6:VB;#H)R5S?QGS?/NJ%FFV7#+';:V;%/N;CVS%Z?A= M]XVN2DN-E=Q2'7&R\'=ZNAC-07@"QJV%>E\!&H4/_!A9@/H-9XJU<3"4\:AN M/Y(K4.5@37=]7L2@G:4GK2N+=]E%)M+M'R^FM 50 2'SU^2 5S?-78K_(8], MM,X^]HO3I^P?'2KQ%)U!.E,!RJ;35$#-0#.$8-9T%L+L\D,V=3S,WLDKUG/< M)#P%[(D,A"_8$XH.B%WWCR?OT#?H?I$,TV.:!5/0X'YTB++JP@D6[Z',!Y[4 MF?M.[#A$^Z*]3X5'>3MY@P8E5QDBJY [L\_+:TZ507<@.TQ[02",D4O1.]"E MMYN$_V^++W=Y1H+CA!E^-(COLHSO\U2NKC6Y:W7-^ZUSP,S^(_??LRXO5BGGW M[WMD;O#OU82Z#^=?,:VS?%=U?5[=Z7B&M?7I_,VW\ML3,Y[M.;CSRKJ ^N-7 M+S<^,U]WL6'U_(>!<=WQ=^6D/E0]_+/(9)7^_9 MJ^SM)G[INGSM_K=O4I;'^0E\ *2L+J("9'\OWQF\ZWO"UOUOJZY%;RC\GW157TOX]8X(8 M8]^52*85*I,;&)[MK/^1XM]^_POSCO\,!Y<^_\\@NZCK#[_\X9_QUU;5;P[^ ML?2;\MV?V/_<**=?/T%OL?_&=BFS_]3UH]IG?W5 M/^O_-:[\S_! \#^#PK?-[XBP:/'?^%/_&5Y(S?_'*/^)'VC/V_WI\3?S#\R3 M_W%^T2NQ6Y*_0[OW'N'5_7KDM$Q7R^K<2JY)_,K*S>>C?C.ZBP3&K_Q@Q\[; M>M#+(JNPJ:C\J6>\Z]Y)%AN%\J(V+.K2?LO#!)V19SMCKG;Y1'(3?V&\P!^' MOY/VR9]^_#;[GTJ1UMHWIU;,FGI)2:.(:56G0X 5 P-3E_:#BO=ZAY)6!E7, M"IP[>[M)\-9+>]?-79]:[[R<7VWV9J-ZPD'QYS:ROZS^K@'M%D7S.WJ(=FG\ M9PC_M/\7V_+_# WN?YIOG=_-CV[R8O007=2/'%&VV.SYDG\S^%OF!__F?8:W M7VV3TCO]FCLS9?NDZ)//!78REK-.O%F>V''.R/BH2/CJB2F1.<9#(S,3(P,3EA+FAT;>U8ZV_B.!#_W/X5 MLU37NY4:\N(1((M$>?30M;2BK'KWT22&6!OLR#:EO;_^Q@EAH:U6V[M6]V'W M \$>S_,WXYE ^&%PW9_]=3.$1*]2N/E\?CGN0\6R[3N_;]N#V0!^GUU=0JWJ MN#"3A"NFF> DM>WAI *51.NL;=N;S::Z\:M"+NW9U#:J:G8JA*+56,>5[G%H M2-WCHS"A),;OH_"#9<% 1.L5Y1HB28FF,:P5XTNXBZGZ BY8UHZS+[)'R9:) M!L_Q'+@3\@N[)R6'9CJEW>%#PN9,AW:Q16/VUEHX%_%C-XS9/2C]F-)/E87@ MVEJ0%4L?VS.VH@HF= -3L2*\DY\I]C=MNTZF.\9[E.R&!#A9H:P:>9X[:+F] M\UHPK(^:C5:S>7[N^"H3QA$KV3"+?;@JSF)VW ZGE]U0]MPO8'/$::3RG=QNG\]N1U.9G ]@O%D,+P9X@.WT^'%^'8V MG X'9?7V^OWKSY/9>'(!H_'TZOMC^\]>5[IW%/"$SA\A$ER9VM8"=$*!\4C( M3$ABK@_@N:0+9.21.2* MR"@!=-?TBC.@#Q'--"R$S&&FBP6-#*R+?"OI/5,&\9BI:*T4RF,^)D)3^+/, MG4FE2%FA?<$XX1$C*=;%+D?&<\.Y(AK+_U"7H2N*.F+(B"1+2;+$6+\BG"QS M^5\5]#A?H\II$0>Z,S;W"/LLMCZNI4A!W*/BTR -JM%U#^:WVG)[[7D30EQM\2U&_B6"2)W5-.59XJ M5L(1[ML"_F<\Z-@^Y.]UZ4YBHHX62Z5MG+RC JLR;U-8' MA*5S *N'$.UCMK_?CM1]4OX*D%->3E4YA0^'CDO]N/P_P/A>X_4$L#!!0 ( +: +U'_EX4<:@@ M /\] . 97@S,3$R,#$Y82YH=&WM6VUOVS@2_MS^"JZ++E+ CJPX+XWC M!G =]R[8;1ND613WD1:IB @E:DG*CN_7WPPI.W+L;.Q=YU*G+E#'XML,J7EF MGAG)G5_.OO:N_G/1)XE-);GXX^/OYSU2:P3!]U8O",ZNSLB_KS[_3O9WFR&Y MTC0SP@J541D$_2\U4DNLS=M!,!J-=D>M7:6O@ZO+ )?:#Z12AN\RRVJGKSO8 M=/KZ52?AE,'?5YU?&@URIJ(BY9DED>;4WPV9N3U![F'G:H22C*2*W(=GV/:F'YK6U0*:ZSMCMGWR R M!K>GO?\^O_WG>KK+D9-@\:86[X>PN'E5XK?K53KT>*^K@ M#RT"/;C^_YQ:KW]Y=?[IO->].O_ZY=O&'IGD\2);7EF%\SKY%BEKR=DN^3SF MVM1)Q+45\9C8A-KVLRHW#TU+!Y*#AE+FE#'P=Q]JS9J[-CF-)M=+^"DR+\R" M,,LFDT>"V<3?:71)EF%G^25P0V>&#_'0(BK+$[ JKZWDN'0K2O](HLA*%%,X.![) L&:P+,*O9> M!X@*+<\9L)$ M4ID"YF',U4IZV.1:19Q!LR$[@!+& 78>"OW;**'9-2=="&>7A>2F9)PM6E+. M\&"'>X7" U9M\XT"L];,XQ<%$@R"%5A[F*%R?T=RO$!R#)+Q).ZC'\8AJVYO M$7T/T<>'SX'HB1]9^<#HNQ\?TF?%9M>,.&:Y4&&2ZSHL91XM=9%6&@T(6(CE.RBG>K$)2 M) 2P+:?$'6.&&9Y_5],&^#;@.!!B-LSG;!NC-QS1@XU#]-)1;0[8R\?#I?$- M/F$H&,*6&I4Y4Z,&((]I+&*9:C;!%2!=T(&0PHZ1("\2BU[&0="ARSN(F:&5 M--@1CMMR0WFA^ 02/8]D,'+B!Q" M_!;*&P[E: .@W!]26;@(AG;.XQBR33$$"S4+LL8I'5\B(OO+Q8FD0RY,A&AJ M?+HZ4(5]6(-E. .=CN:8B\>/%YO(8)+E.V?$_4F /B>X^!9\FPT^M@'@._-V M/8\/+/Z6&9_K60C"%:(GLET5185&%%2HY8)54V4LM.,35EC+P!&1/PM@IK#T MS@-38H SQ+5[HTO%(P"9JUMC2=L]M/%ZO?-:)=1,>3A&1 =_SAQ5<.=1AO$Q MD>*&R[*(?6]\_1\?T=HA/UM\/IPK/J_I@?#SNX7-*H$=O.02F'M.RB8^I7X7 MWS#<5G%]%^H0F2OP][F<>*H=A;S8*FVFE-DUP))I*JSE_"_(Q$ !*<=^)D _ MM\@.H!]BMT%N '\Q.Y^X+/YG(4!]YYZ*+'+E[G=KK6/]--#=L(B^";6NKH2< M$!84 $TLM&(--Q(<@%12XFG-:<3I#7)#*L89P4P< 0#,A;"QE?1$!^+$S\E0+SL7$-*ORMMQK+3TU,"0.#Z#GMK\S3W5/=^Y:BU&QXUCUK3C[$SZMSPJ\-$Z^>J?'#R8<3^%1CL7_L46*N<5651EFJF)+/#,Q,C(P,3EA+FAT;>U;[W/:1A/^G/P55S+I.#-@ 08[!N(9;)/W];1- M/"YMIA\/Z63=^*13[TY@^M=W]TZ ,+)C6AR7F,P$H_NY>]IG]]F5Z/UP_OEL M^,?E@$0F%N3RM].?+\Y(I>9Y7P[./.]\>$[^/_SE9]+:KS?(4-%$<\-E0H7G M#3Y52"4R)NUXWF0RV9\<[$MU[0VO/%RJY0DI-=L/3% Y>=W#II/7KWH1HP'\ M?=7[H58CY]+/8I88XBM�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end

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